IAPO7Rec'd PCT 31 OCT 2007

١

			formation unless it displays a valid OMB control
TF	RANSMITTAL LETTER TO		ATTORNEY'S DOCKET NUMBER 0020-5610PUS1
co	DESIGNATED/ELECTED NCERNING A SUBMISSIC		U.S. APHLICATIONINO (MONTA 8 37 C
	ATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
	PCT/JP2006/310571 F INVENTION	26 May 2006	26 May 2005
PHARM	ACEUTICAL COMPOSITION		
	ANT(S) FOR DO/EO/US ki FUJIHARA		
Applicar	t herewith submits to the United Stat	es Designated/Elected Office (DO/EC	//US) the following items and other information
1. x	This is a FIRST submission of items	concerning a submission under 35 U	I.S.C. 371.
2.	This is a SECOND or SUBSEQUEN	IT submission of items concerning a s	submission under 35 U.S.C. 371.
3. 🗙	This is an express request to begin include items (5), (6), (9) and (21) in	national examination procedures (35 idicated below:	U.S.C. 371(f)). The submission must
4.	The US has been elected (Article 31	I).	
5. X	A copy of the International Application	on as filed (35 U.S.C. 371 (c)(2))	
а.[is attached hereto (required onl	y if not communicated by the Internati	onal Bureau).
b.[x has been communicated by the	International Bureau.	
c.[is not required, as the application	on was filed in the United States Rece	iving Office (RO/US).
6. 🗶	An English language translation of t	he International Application as filed (3	5 U.S.C. 371(c)(2)).
a.[x is attached hereto.		
b.[has been previously submitted	under 35 U.S.C. 154(d)(4).	
7. X	Amendments to the claims of the Inf	ernational Application under PCT Arti	de 19 (35 U.S.C. 371(c)(3))
a.	are attached hereto (required or	nly if not communicated by the Interna	itional Bureau).
b.[have been communicated by the	e International Bureau.	
c .[have not been made; however,	the time limit for making such amendr	ments has NOT expired.
d.[x have not been made and will no	t be made.	
8.	An English language translation of the	he amendments to the claims under P	PCT Article 19 (35 U.S.C. 371(c)(3)).
9. x	An oath or declaration of the invento	or(s) (35 U.S.C. 371(c)(4)).	
10.	An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).	he annexes of the International Prelim	inary Examination Report under PCT
	s 11 to 20 below concern docum	.,	
11. x	An Information Disclosure Statem	ent under 37 CFR 1.97 and 1.98.	
12. X	An assignment document for record	ing. A separate cover sheet in compli	ance with 37 CFR 3.28 and 3.31 is include
3. x	A preliminary amendment.		
14.	An Application Data Sheet under 3	7 CFR 1.76.	
15.	A substitute specification.		
6.	A power of attorney and/or change	of address letter.	
7.	A computer-readable form of the se	equence listing in accordance with P	CT Rule 13ter.2 and 37 CFR 1.821 – 1.8
	A second copy of the published Inte	ernational Application under 35 U.S.	C. 154(d)(4).
18.	recoord copy of the published that		

ia i i iù

Ģ

Į

IPDAS/BSKB MB 0651-0021 COMMERCE ontrol number.

• Under the Paper	work Reduction Act o	f 1995, no persons a		Approved Patent and Trademark	/. 09-200 for use th Office; U.	7)updated 10/0 rough 03/31/20 .S. DEPARTME	4/07 by IPDAS/BSK 007. OMB 0651-002 ENT OF COMMERC
	DN 10. (jfkrom, fee		INTERNATIONAL APPLICA PCT/JP200	TION NO.		NEY'S DOCKET	NUMBER
20. X Other	r items or informa		Receipt Postcard; /308 (2 sheets); PCT/IE /ts)	3/304; PCT/ISA/237	(4 shee	ets); PCT/ISA	V210; Drawings
The fo	llowing fees have	e been submitte	d		CAL	ULATIONS	PTO USE ONLY
21. x Bas	ic national fee (3	37 CFR 1.492(a))))	\$310	\$	310.00	
If the written op	IPEA/US indicates a	A/US or the interna all claims satisfy pro	ational preliminary examinal ovisions of PCT Article 33(1)-(4)\$0	\$	210.00	
If the written op IPEA/US Search fee (37 International Se previous	indicates all claims CFR 1.445(a)(2)) ha brail Searching Auth earch Report prepare by communicated to	or the international satisfy provisions of as been paid on the ority	preliminary examination rep of PCT Article 33(1)-(4) international application to than the US and provided to	\$0 the USPTO as an \$100 the Office or \$410	\$	410.00	
	TOTAL OF 21, 22	? and 23 =			\$	930.00	
seque	nce listing in compli uter program listing	ance with 37 CFR in an electronic me	d in paper over 100 sheets 1.821(c) or (e) or in an elect dium) (37 CFR 1.492(j)). paper or fraction thereof.				
Total Sheets	Extra Sheets		additional 50 or fraction ip to a whole number)	RATE			
57 100-	/50 -			~ \$260.00	6		

Total Sheets	Extra Sh	neets		h additional 50 or fraction I up to a whole number)			RATE				
57 - 100 =		/50 =				x \$	260.00	\$			
				e, examination fee, or the e (37 CFR 1.492(h)).	e oath	or decla	aration	\$			·
CLAIMS	S	NUM	BER FILED	NUMBER EXTRA		R/	ATE				
Total clair	ms	2	4 - 20 =	4	×	x	\$50		200.0	0	
Independent	claims		5 - 3 =	2	×	x	\$210		420.0	0	
MULTIPLE DEP	ENDENT	CLAIM(S) (if applicable)		+	+	\$370				
				TOTAL OF A	BOV	E CALC	CULATIONS =	\$	1,550.0	0	
Applican	it claims sr	nall entity	/ status. See 37 (CFR 1.27. Fees above ar	re red	luced by	1 1/2.				
							SUBTOTAL =	\$	1,550.0	0	
Processing fee of claimed priority of	of \$130.00 date (37 Cl	for furnis FR 1.492	hing the English ti (i)).	ranslation later than 30 m	nonths	s from th	ne earliest	\$			• <u>•••••</u>
					тот	AL NAT	IONAL FEE =	\$		1	1,550.00
				1.21(h)). The assignment 40.00 per property	t mus	t be acc	ompanied +	\$			40.00
								\$			
				TO	TAL	FEES EI	NCLOSED =	\$			
									unt to be ided:	\$	
								Amo char	unt to be ged	\$	1,590.00

.

1

¥

.

••

•

÷

11/919678

PTO-1390 (Rev.	09-2007)updated	10/04/07	by IPDAS/BSK

• •	, (PTO-1390 (Rev. 09-2007)updated 10/04/07 by IPDAS/BSKB Approved for use through 03/31/2007. OMB 0651-0021 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co	
-	a. A check in the amount of \$ to cover the abo	P17 Rec'd PCT/PTO 31 OCT 2007
	b. X Please charge my Deposit Account No. 02-2448 in the am	ount of \$ 1,590.00 to cover the above fees.
ч •	c. X The Commissioner is hereby authorized to charge any additional fees Account No. 02-2448	which may be required, or credit any overpayment to Deposit
•	d. Fees are to be charged to a credit card. WARNING: Information on the not be included on this form. Provide credit card information and an	
	ADVISORY: If filing by EFS-Web, do NOT attach the PTO-2038 for be advised that this is not recommended and by doing so your cree protect your information, it is recommended paying fees online by	edit card information may be displayed via PAIR. To
	NOTE: Where an appropriate time limit under 37 CFR 1.495 has not bee filed and granted to restore the International Application to pending sta	
	SEND ALL CORRESPONDENCE TO:	SIGMATURE #32,868
		- Sar Mark J. Nuell
		NAMÉ
	CUSTOMER NUMBER: 02292	36,623
		REGISTRATION NUMBER
	October 31, 2007 /scp	

IAPO7Rec'd PCT 31 OCT 2007

١

			formation unless it displays a valid OMB control
TF	RANSMITTAL LETTER TO		ATTORNEY'S DOCKET NUMBER 0020-5610PUS1
co	DESIGNATED/ELECTED NCERNING A SUBMISSIC		U.S. APHLICATIONINO (MONTA 8 37 C
	ATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
	PCT/JP2006/310571 F INVENTION	26 May 2006	26 May 2005
PHARM	ACEUTICAL COMPOSITION		
	ANT(S) FOR DO/EO/US ki FUJIHARA		
Applicar	t herewith submits to the United Stat	es Designated/Elected Office (DO/EC	//US) the following items and other information
1. x	This is a FIRST submission of items	concerning a submission under 35 U	I.S.C. 371.
2.	This is a SECOND or SUBSEQUEN	IT submission of items concerning a s	submission under 35 U.S.C. 371.
3. 🗙	This is an express request to begin include items (5), (6), (9) and (21) in	national examination procedures (35 idicated below:	U.S.C. 371(f)). The submission must
4.	The US has been elected (Article 31	I).	
5. X	A copy of the International Application	on as filed (35 U.S.C. 371 (c)(2))	
а.[is attached hereto (required onl	y if not communicated by the Internati	onal Bureau).
b.[x has been communicated by the	International Bureau.	
c.[is not required, as the application	on was filed in the United States Rece	iving Office (RO/US).
6. 🗶	An English language translation of t	he International Application as filed (3	5 U.S.C. 371(c)(2)).
a.[x is attached hereto.		
b.[has been previously submitted	under 35 U.S.C. 154(d)(4).	
7. X	Amendments to the claims of the Inf	ernational Application under PCT Arti	de 19 (35 U.S.C. 371(c)(3))
a.	are attached hereto (required or	nly if not communicated by the Interna	itional Bureau).
b.[have been communicated by the	e International Bureau.	
c .[have not been made; however,	the time limit for making such amendr	ments has NOT expired.
d.[x have not been made and will no	t be made.	
8.	An English language translation of the	he amendments to the claims under P	PCT Article 19 (35 U.S.C. 371(c)(3)).
9. x	An oath or declaration of the invento	or(s) (35 U.S.C. 371(c)(4)).	
10.	An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).	he annexes of the International Prelim	inary Examination Report under PCT
	s 11 to 20 below concern docum	.,	
11. x	An Information Disclosure Statem	ent under 37 CFR 1.97 and 1.98.	
12. X	An assignment document for record	ing. A separate cover sheet in compli	ance with 37 CFR 3.28 and 3.31 is include
3. x	A preliminary amendment.		
14.	An Application Data Sheet under 3	7 CFR 1.76.	
15.	A substitute specification.		
6.	A power of attorney and/or change	of address letter.	
7.	A computer-readable form of the se	equence listing in accordance with P	CT Rule 13ter.2 and 37 CFR 1.821 – 1.8
	A second copy of the published Inte	ernational Application under 35 U.S.	C. 154(d)(4).
18.	recoord copy of the published that		

ia i i iù

Ģ

J

IPDAS/BSKB MB 0651-0021 COMMERCE ontrol number.

• Under the Paper	work Reduction Act o	f 1995. no persons a		Approved f Patent and Trademark (09-2007 or use the Office; U.	')updated 10/0 rough 03/31/20 S. DEPARTME	4/07 by IPDAS/BSK 007. OMB 0651-002 ENT OF COMMERC
	NO. (KRON Tee		INTERNATIONAL APPLICAT PCT/JP200	FION NO.	1	NEY'S DOCKET 0020-56	NUMBER
20. X Other	items or informa		Receipt Postcard; /308 (2 sheets); PCT/IE ts)	3/304; PCT/ISA/237	(4 shee	ts); PCT/ISA	/210; Drawings
The fol	llowing fees have	e been submitte	d		CALC	ULATIONS	PTO USE ONLY
21. x Basi	ic national fee (3	37 CFR 1.492(a))	\$310	\$	310.00	
If the written opi	IPEA/US indicates a	A/US or the interna all claims satisfy pro	tional preliminary examinat ovisions of PCT Article 33(1)-(4)\$0	\$	210.00	
If the written opi IPEA/US Search fee (37 (International Se previous)	indicates all claims CFR 1.445(a)(2)) ha bral Searching Auth arch Report prepare y communicated to	or the international satisfy provisions of as been paid on the ority ed by an ISA other t the US by the IB	preliminary examination rep of PCT Article 33(1)-(4) international application to than the US and provided to	\$0 the USPTO as an \$100 the Office or \$410	\$	410.00	
	TOTAL OF 21, 22	2 and 23 =			\$	930.00	
seque compu	nce listing in compli iter program listing	ance with 37 CFR 1	d in paper over 100 sheets 1.821(c) or (e) or in an elect dium) (37 CFR 1.492(j)). paper or fraction thereof.				
Total Sheets	Extra Sheets		additional 50 or fraction p to a whole number)	RATE			
1	1	1		1	1		

									_		
Total Sh	neets	Extra S	heets		h additional 50 or fraction I up to a whole number)			RATE			
57 ·	- 100 =		/50 =				x	\$260.00	\$		
Surcharg	ge of \$1: date of	30 for furn commenc	ishing an ement of	y of the search fe the national stage	e, examination fee, or the e (37 CFR 1.492(h)).	e oath d	or dec	aration	\$		
	CLAIMS	5	NUN	BER FILED	NUMBER EXTRA	1	R	ATE			
т	Total clair	ms	2	4 - 20 =	4	×	x	\$50	200.	00	
Indep	pendent	claims		5 - 3 =	2	x	x	\$210	420.	00	
MULTIP	PLE DEP	ENDENT	CLAIM(S) (if applicable)	•	+	+	\$370			
					TOTAL OF A	BOVE	CAL	CULATIONS =	\$ 1,550.	00	
	Applican	t claims s	mall entity	status. See 37 (CFR 1.27. Fees above a	re redu	iced b	y ½.			
								SUBTOTAL =	\$ 1,550.	00	
		f \$130.00 late (37 C			ranslation later than 30 m	nonths	from t	he earliest	\$	1	
						τοτα	L NA	TIONAL FEE =	\$	1	,550.00
					1.21(h)). The assignmen 40.00 per property	t must	be acc	companied +	\$		40.00
									\$		
					то	TAL F	EES E	NCLOSED =	\$		
									Amount to be refunded:	\$	
									Amount to be charged	\$	1,590.00
										1	

.

4

¥

.

••

•

÷

11/919678

PTO-1390 (Rev. 0	09-2007)updated	10/04/07 b	y IPDAS/BSK
	,		,

· ·	•	PTO-1390 (Rev. 09-2007)updated 10/04/07 by IPDAS/BSKB Approved for use through 03/31/2007. OMB 0651-0021
		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co	
-	a. A check in the amount of \$ to cover the abo	P17 Rec'd PCT/PTO 31 OCT 2007
	b. X Please charge my Deposit Account No. 02-2448 in the am	nount of \$ 1,590.00 to cover the above fees.
ч ч	c. X The Commissioner is hereby authorized to charge any additional fees Account No. 02-2448	s which may be required, or credit any overpayment to Deposit
•	d. Fees are to be charged to a credit card. WARNING: Information on t not be included on this form. Provide credit card information and a	
	ADVISORY: If filing by EFS-Web, do NOT attach the PTO-2038 for be advised that this is not recommended and by doing so your cro protect your information, it is recommended paying fees online by	orm as a PDF along with your EFS-Web submission. Please edit card information may be displayed via PAIR. To
	NOTE: Where an appropriate time limit under 37 CFR 1.495 has not bee filed and granted to restore the International Application to pending sta	
		\square
	SEND ALL CORRESPONDENCE TO:	SIGNATURE #32,868
		- Sar Mark J. Nuell
		NAME
	CUSTOMER NUMBER: 02292	
		36,623 REGISTRATION NUMBER
	October 31, 2007	
	/scp	

TT/9196/8 IAP05Rec'd PGT 31 OCT 2007

Docket No.: 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

International Application No.: PCT/JP2006/310571

Application No.: NEW

Filed: October 31, 2007

Art Unit: N/A

Examiner: Not Yet Assigned

For: PHARMACEUTICAL COMPOSITION

PRELIMINARY AMENDMENT

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

э

1 1

÷

1

INTRODUCTORY COMMENTS

The following preliminary amendments and remarks are respectfully submitted in connection with the above-identified application.

This amendment includes:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.


Remarks/Arguments begin on page 6 of this paper.

.

AMENDMENTS TO THE CLAIMS

1. (Original) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-

bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder.

2. (Original) An oral preparation which is prepared by granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

3. (Original) An oral preparation which is prepared by granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble polymer binder.

4. (Currently Amended) The oral preparation of any one of claims 1 to 3<u>claim 1</u> wherein the water-soluble excipient is mannitol or lactose.

5. (Original) A method of granulation of a powder mixture which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

2

6. (Original) A method of granulation of a powder mixture which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by using a solution or dispersion of lurasidone and a water-soluble polymer binder.

7. (Original) The method of granulation of claim 5 wherein the water-soluble excipient is mannitol or lactose.

8. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

9. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt).

11. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

12. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Currently Amended) The oral preparation of any one of claims 1-to 4claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein a content of lurasidone per tablet is 40 to 120 mg.

DRN//scp

Application No.: NEW

15. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the water-soluble excipient is mannitol or lactose and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

16. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the water-soluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

18. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

19. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

20. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

4

•

21. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Currently Amended) The oral preparation of any one of claims 1 to $4\underline{\text{claim 1}}$ wherein an average particle size of lurasidone is 0.1 to 8 μ m. 23. (Currently Amended) The oral preparation of any one of claims 1 to $4\underline{\text{claim 1}}$ wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Currently Amended) The oral preparation of any one of claims 1 to 4<u>claim 1</u> wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to 40% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

â

REMARKS

The claims have been amended to remove the multiple dependencies listed therein. Claims 1-24 are pending in this application.

CONCLUSION

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Mark J. Nuell (Reg. No. 36,623) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37.C.F.R. §§1.16 or 1.14; particularly, extension of time fees.

Dated: October 31, 2007

Respectfully submitted,

#32 868 By Mark J. Nuell

Registration No.: 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive Suite 260 San Diego, California 92130 (858) 792-8855 Attorney for Applicant

TT/919678 IAP05Rec'd PGT 31 OCT 2007

Docket No.: 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

Application No.: NEW

Filed: October 31, 2007

Confirmation No.: N/A

For: PHARMACEUTICAL COMPOSITION

Examiner: Not Yet Assigned

Art Unit: N/A

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

A summary/abstract translation of the non-English language references BA and BB is enclosed. Reference AA corresponds to reference BA. The references can be found cited in the International Search Report.

Birch, Stewart, Kolasch & Birch, LLP

Application No.: NEW

TT/919678 IAP05Rec'd PCT 31 OCT 2007 Docket No.: 0020-5610PUST

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: October 31, 2007

Respectfully submitted,

1 #32 <u>868</u> Βv - Mark J. Nuell

Registration No.: 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive Suite 260 San Diego, California 92130 (858) 792-8855 Attorney for Applicant

Attachment(s)

TT/919678 IAP05Rec'd PGT 31 OCT 2007

Used in Lieu of PTO/SB/08A/B (Based on PTO 10-07 version)

Su	bstitute for form 1449/PTC)		Complete if Known			
				Application Number	NEW		
- 11	NFORMATIO	N DIS	SCLOSURE	Filing Date	October 31, 2007		
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Kazuyuki FUJIHARA		
				Art Unit	N/A		
	(Use as many s	sheets as	necessary)	Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	0020-5610PUS1		

	U.S. PATENT DOCUMENTS								
Examiner	0.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where				
Initials*	Cite No. ¹	Number-Kind Code ² (<i>il known</i>)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear				
	AA*	US-2004/0028741-A1	02-12-2004	Fujihara					

		FORE	GN PATENT D	OCUMENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages Or Relevant Figures Appear	T6
	BA	WO-02/24166-A1	03-28-2002			ABS
	BB	WO-2004/078173-A1	09-16-2004			ABS
	BC	JP-8-325146-A	12-10-1996			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 90.04. * Ener Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent document, such the wol-tetter code (WIPO Standard ST.3). * For Japanese patent symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date	
Pimb Stought Kolosch & Pimb LLP	Considered	DRN//scn

Birch, Stewart, Kolasch & Birch, LLP

TT/919678 APO5Rec'd PGT 31 OCT 2007

DESCRIPTION

1

PHARMACEUTICAL COMPOSITION

5 TECHNICAL FIELD [0001]

The present invention relates to an oral preparation with a good disintegration which comprises as an active ingredient N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-

(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone). More particularly, the present invention relates to a preparation for oral administration, particularly a tablet, comprising lurasidone as an active ingredient, which has an equivalent dissolution profile of the active ingredient even though contents of the active 15 ingredient therein are varied.

BACKGROUND ART

[0002]

Patent Document 1 discloses that a compound such as lurasidone can be orally administered and an oral preparation can be prepared by blending an active ingredient with a conventional carrier, excipient, binder, stabilizer and the like, but there is no disclosure of an oral preparation which shows a rapid dissolution and has an equivalent dissolution profile of the active ingredient even though contents of the active ingredient therein are varied in the wide range, particularly an oral preparation with increased contents of the active ingredient which has a similar dissolution profile to that of multiple tablets with a lower content of the active ingredient per tablet. [0003]

30

For the purpose of securing the bioequivalence when

pharmaceutical preparations with different contents of the active ingredient were administered so as to be the same dose to each other, a guideline has been issued, i.e., "Guideline for Bioequivalence Studies of Oral Solid Dosage Forms with Different Content" (Notification No. 64 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, promulgated on February 14, 2000) by which it has been required that pharmaceutical preparations with different contents should have an equivalent dissolution profile in each test solution such as buffers of pH1.2, 3.0 to 5.0 and 6.8 (which correspond to the pH values of stomach, intestine and oral cavity, respectively), water, and

[0004]

saline.

5

10

15

20

25

30

Patent Document 2 discloses an oral preparation comprising lurasidone as an active ingredient, which shows a rapid dissolution and has an equivalent dissolution profile even though contents of the active ingredient therein are varied, particularly an oral preparation with increased contents of the active ingredient which has an equivalent dissolution profile to that of multiple tablets with a lower content of the active ingredient per tablet and can release a slightly water-soluble active ingredient therefrom at a desired concentration.

[0005]

Patent Document 2 further discloses an oral preparation, particularly a tablet, which shows a rapid dissolution of the active ingredient even though contents of the active ingredient therein are varied in the range of several mg to several tens of mg (e.g. in the range of 5 mg to 20 mg or in the range of 5 mg to 40 mg), and further has an equivalent dissolution profile in the same componential ratio. An oral preparation has been frequently required to be a preparation with higher contents of the active ingredient in order to get higher clinical effects, or a preparation which has an equivalent dissolution profile to

that of multiple tablets and can release the active ingredient therefrom at a desired concentration in wider ranges of contents in order to adjust clinical effects depending on conditions of patients. The art disclosed in Patent Document 2 may provide an oral preparation which has an equivalent dissolution profile in the range of 5 mg to 40 mg of lurasidone per tablet, as shown in Figure 1. However, as shown in Figure 2, when the content of the active ingredient per tablet was increased to double, i.e., 80 mg tablet, it could not have an equivalent dissolution profile. Hence, it remains in a state of administering multiple tablets at one time or using a tablet having a big size which is difficult to administer. Therefore, for such a slightly water-soluble active ingredient as lurasidone, it has been difficult to provide an oral preparation having an equivalent dissolution profile even in high content or in wider ranges of contents of the active ingredient.

15 [0006]

ç

5

10

20

In Patent Document 2, a water-soluble polymer binder includes starch, but there is no description about a pregelatinized starch therein. The pregelatinized starch is known to remarkably improve a disintegration and a dissolution of a pharmaceutical composition as described, for example, in Patent Document 3, but it is often used, typically, in 10% or less of contents as also described in Non-patent Document 1.

[0007]

Patent Document 1: JP2800953 25 Patent Document 2: WO2002/024166 Patent Document 3: JP2000-26292 Non-patent Document 1: Handbook of Pharmaceutical Excipients, 2nd edition, 491, 1994, The Pharmaceutical Press

30 DISCLOSURE OF INVENTION

PROBLEMS TO BE RESOLVED BY THE INVENTION [0008]

The present invention is directed to provide an oral preparation comprising lurasidone as an active ingredient which shows a rapid dissolution and has an equivalent dissolution profile even though contents of the active ingredient therein are varied in the wide range, particularly an oral preparation with increased contents of the active ingredient which has a similar dissolution profile to that of multiple tablets with a lower content of the active ingredient per tablet and can release the active ingredient therefrom at a desired concentration. [0009]

4

The present invention is directed to provide a preparation for oral administration which comprises as an active ingredient N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-

(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (hereinafter referred to as lurasidone), which has an equivalent dissolution profile of the active ingredient even though contents of the active ingredient therein are varied.

MEANS OF SOLVING THE PROBLEMS

20 [0010]

Ę

5

10

15

The present inventors have intensively studied in order to solve the above problems and found to solve said problems by means of the following methods.

[0011]


The present invention includes the following embodiments:

[0012]

(1) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-

2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):

30



5

10

15

20

25

a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder.

(2) An oral preparation which is prepared by granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

(3) An oral preparation which is prepared by granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble polymer binder.

(4) The oral preparation of any one of (1) to (3) wherein the watersoluble excipient is mannitol or lactose.

(5) A method of granulation of a powder mixture which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a watersoluble polymer binder.

(6) A method of granulation of a powder mixture which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by using a solution or dispersion of lurasidone and a water-soluble polymer binder.

(7) The method of granulation of (5) wherein the water-soluble excipient is mannitol or lactose.

(8) The oral preparation of any one of (1) to (4) wherein the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

(9) The oral preparation of any one of (1) to (4) wherein the

pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

(10) The oral preparation of any one of (1) to (4) wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt).

5

(11) The oral preparation of any one of (1) to (4) wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

(12) The oral preparation of any one of (1) to (4) wherein a content of lurasidone per tablet is 10 to 160 mg.

(13) The oral preparation of any one of (1) to (4) wherein a content of lurasidone per tablet is 20 to 120 mg.

(14) The oral preparation of any one of (1) to (4) wherein a content of lurasidone per tablet is 40 to 120 mg.

(15) The oral preparation of any one of (1) to (4) wherein the watersoluble excipient is mannitol or lactose and the pregelatinized starch is

5 incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

(16) The oral preparation of any one of (1) to (4) wherein the watersoluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

20 (17) The oral preparation of any one of (1) to (4) wherein the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

(18) The oral preparation of any one of (1) to (4) wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

(19) The oral preparation of any one of (1) to (4) wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is

6

15

30

incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

7

5

-

(20) The oral preparation of any one of (1) to (4) wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

The oral preparation of any one of (1) to (4) wherein a (21)pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

10 The oral preparation of any one of (1) to (4) wherein an average (22)particle size of lurasidone is 0.1 to 8 µm.

The oral preparation of any one of (1) to (4) wherein the (23)pregelatinized starch contains water soluble matter of 30% or less.

(24)The oral preparation of any one of (1) to (4) wherein the water-15 soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to 40% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

EFFECTS OF INVENTION

20 [0013]

> It has been confirmed in the art disclosed in Patent Document 2 that a pharmaceutical preparation with low contents of lurasidone up to 40 mg per tablet could provide an oral preparation having an equivalent dissolution profile. However, a pharmaceutical preparation with higher

> contents of lurasidone could not have an equivalent dissolution profile. Therefore, double amounts or more of the preparation with low contents

> present invention which comprises a pregelatinized starch can provide

25

30

lurasidone, which imposed increased burdens on the patient, and hence an improvement thereon has been required. The preparation of the

an oral preparation with higher contents of lurasidone which imposes less of burdens on a patient. Additionally, the present invention can provide an oral preparation with high contents of lurasidone, and a preparation for oral administration which has an equivalent dissolution profile even though contents of lurasidone therein are varied. Moreover, the preparations are excellent for a long-term conservation.

BEST MODE FOR CARRYING OUT THE INVENTION [0014]

N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) refers to a compound of the following formula:

[0015]

15

20

25

5

10

(see, for example, JP2800953). Lurasidone is known to exhibit a psychotropic effect, and it is useful as a therapeutic agent for schizophrenia, etc. Said compound is incorporated into the preparation, for example, in the range of 10 to 50% by weight, preferably in the range of 20 to 45% by weight, particularly in the range of 20 to 45% by weight of a tablet. Additionally, the compound is preferably finely milled, for example, 90% by volume or more of particles have 27 μ m or less of particle size, and average particle size in a volume ratio (i.e. 50% by volume particle size) includes, for example, in the range of 0.1 to 8 μ m, preferably in the range of 1 to 4 μ m. The contents of lurasidone are 10 to 160 mg, preferably 20 to

120 mg, more preferably 40 to 120 mg per tablet. [0016]

"pregelatinized starch" refers to those prepared The bv pregelatinizing various kinds of starch (e.g. corn starch, potato starch, wheat starch, rice starch, tapioca starch, etc.), and may include 5 pregelatinized starch or partly pregelatinized starch described in Japanese Pharmaceutical Excipients. The pregelatinized starch has a pregelatinizing ratio, for example, in the range of 50 to 100%, preferably in the range of 50 to 95%, more preferably in the range of 80 to 95%. Additionally, the pregelatinized starch contains water soluble matter of, for example, 40% or less, more preferably 30% or less. Such a pregelatinized starch is typically used in a powder which average particle size is in the range of 1 to 1000 μ m, preferably in the range of 1 to 500 µm, more preferably in the range of 10 to 100 µm. Α 15 commercially available pregelatinized starch suitable for the present invention includes, for example, partly pregelatinized starch such as PCS (brand name, manufactured by Asahi Kasei Corporation) or Starch 1500 (brand name, manufactured by Colorcon, Inc.), etc. Among the above pregelatinized starch, partly pregelatinized starch such as PCS (brand name, manufactured by Asahi Kasei Corporation) is preferably used. A pregelatinizing ratio of partly pregelatinized starch is preferably in the range of 50 to 95%, more preferably in the range of 80 to 95%. The pregelatinized starch used in the present invention is in the range of 10% to 50%, preferably in the range of 10% to 40%, particularly in 25 the range of 20% to 30% by weight of the preparation.

[0017]

The "water-soluble excipient" includes, for example, mannitol, lactose, saccharose, sorbitol, D-sorbitol, erythritol, xylitol, etc. More preferable one includes mannitol and lactose. Further preferable one may include mannitol. Also, said water-soluble excipient may be used

10

alone, or two or more thereof may be used together. The water-soluble excipient is incorporated in an amount of, for example, the range of 30 to 80% by weight, preferably the range of 40 to 60% by weight on the basis of the total weight of a tablet. The average particle size of mannitol is, for example, in the range of 10 to 200 μ m.

[0018]

5

20

30

The "water-soluble polymer binder" includes, for example, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, etc. More preferable one

includes hydroxypropylcellulose, hydroxypropyl methylcellulose,
 polyvinylpyrrolidone or polyvinyl alcohol. Said water-soluble polymer
 binder may be used alone, or two or more thereof may be used together.
 The water-soluble polymer binder is incorporated in an amount of, for
 example, the range of 0.5 to 10% by weight, preferably the range of 1 to
 5% by weight on the basis of the total weight of a tablet.

The oral preparation in the form of a pharmaceutical composition of the present invention refers to a pharmaceutical preparation which is formulated into tablet, capsule, granule or fine granule. Said preparation may be formulated by a conventional method into tablet, capsule, granule or fine granule by using water-soluble excipient as well as water-insoluble excipient, binder, disintegrant, lubricant, etc. The following agents may be added thereto.

[0019]

The "water-insoluble excipient" includes, for example, corn starch, 25 crystalline cellulose, etc. Said water-insoluble excipient may be used alone, or two or more thereof may be used together. [0020]

The "disintegrant" includes, for example, corn starch, crystalline cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium, crospovidone, etc. Said disintegrant may be used alone, or two or more thereof may be used together. The disintegrant is used in an amount of, for example, the range of 0 to 10% by weight, preferably the range of 0.5 to 5% by weight on the basis of the total weight of a tablet.

[0021]

The "lubricant" includes, for example, magnesium stearate, talc, polyethylene glycol, silica, hydrogenated vegetable oil, etc. [0022]

The oral preparation of the present invention may be prepared according to a conventional method depending on a desired dosage form. (1) Preparation of an aqueous solution of water-soluble polymer binder:

A water-soluble polymer binder is dissolved in purified water. The amount of the water-soluble polymer binder is, for example, in the range of 1 to 20% by weight, preferably in the range of 2 to 8% by weight of purified water.

(2) Preparation of granule comprising lurasidone:

To a fluid bed granulator are charged excipient including 20 lurasidone, mannitol and partly pregelatinized starch, and disintegrant, and thereto is sprayed the water-soluble polymer binder prepared in the above process (1) to be granulated. [0023]

The apparatus for granulation includes, for example, one classified into fluid bed granulation, high share granulation, roto fluid bed granulation, etc., but it is not limited thereto.

(3) Drying of granule:

The above-obtained granule is dried either under reduced pressure or atmospheric pressure. The drying is carried out so that the loss on dry measured by infrared moisture meter is, for example, within

3

.÷

5

10

3% by weight, preferably 1 to 2% by weight.

(4) Blending of lubricant:

To the granule dried in the above (3) is added lubricant to be mixed. For mixing, for example, a blending machine classified into diffusion mixers [Tumble] is used. Specifically, tumble blender, V blenders, double cone, bin tumble, etc. are used, but it is not limited thereto.

(5) Compression:

The above mixture is compressed to give a tablet.

10 [0024]

÷

5

15

30

The apparatus for compression includes, for example, one classified into tablet press, etc. The compression hardness is selected, for example, from the range of 30 to 200N.

(6) Film-coating is optionally carried out:

The above-obtained tablet may be optionally subjected to filmcoating, if necessary. The apparatus for coating includes, for example, one classified into a coating pan. Preferable one includes one classified by perforated coating system.

[0025]

20 The coating agent includes, for example, a mixture of base material (e.g. hydroxypropyl methylcellulose, hydropropylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, etc.) and plasticizer (e.g. polyethylene glycol, propylene glycol, triacetin, triethyl citrate, glycerin, glycerin fatty acid ester, polyethylene glycol, etc.). If necessary, an additive such as titanium oxide may be also added therein. After film-coating, carnauba wax, etc. may be also added as polishing agent therein.

(7) Drying:

The above-obtained tablet is dried. The drying is carried out either under reduced pressure or atmospheric pressure so that the loss

on dry measured by infrared moisture meter is, for example, within 3% by weight, preferably 1 to 2% by weight. [0026]

Examples of the present invention are illustrated below. Said examples are intended to exemplify the present invention but not to limit the present invention thereto.

EXAMPLES

Example 1

10 [0027]

15

30

÷

A. A film-coated tablet comprising 80 mg of lurasidone (Example 1)

Granules, uncoated tablets and FC tablets comprising the following components are sequentially prepared. The charging amounts shown in parentheses in the following description are an example for preparing the formulation shown in Example 1.

According to the preparation method, other examples may be also prepared in principle, provided that the charging amounts are needed to be changed depending on formulations.

[0028]

20 B. Preparation method

(1) Preparation of binding solution (5% aqueous hydroxypropyl methylcellulose solution):

Hydroxypropyl methylcellulose (32 g) as water-soluble polymer binder was dissolved in purified water (608 g) to give binding solution.

25 (2) Granulation:

Lurasidone (320 g), mannitol (576 g), partly pregelatinized starch (320 g) and croscarmellose sodium (16 g) were charged to a fluid bed granulator (Multiplex MP-01/manufactured by Powrex Corporation), and the mixture was granulated by spray granulation under the following conditions using the binding solution prepared in the above (1) to give granule powder. To the obtained granule powder was added magnesium stearate to give a granule for compression having a formulation (b) after mixing (40 rpm, 5 minutes). Magnesium stearate was mixed in amounts calculated from a formulation on the basis of yields of granule powder.

Conditions for granulation

Temperature for supplying air: 60°C

Airflow: 50 to 65 m^3/hr

Spray speed: 13 g/min

10

30

5

.7

Spray pressure: 0.12MPa

Gun position: the middle stand

Diameter of spray nozzle: 1.2 mm

(3) Compression:

The granule for compression prepared in the above (2) was compressed by HT-AP12SS-II (manufactured by Hata Iron Works Co., Ltd.) to give a tablet.

> Pestle size: φ10 mm 14R Thickness: 4.20 to 4.30 mm Compression pressure: 10 KN

20 (4) Coating:

The uncoated tablet prepared in the above (3) were coated by using High Coater HCT30N (manufactured by Freund Industrial Co., Ltd.) under the following conditions so as to control amounts of the coat to 5 mg, and thereto was added carnauba wax after coating to give a

film-coated tablet.

FC conditions

Temperature for supplying air: 80°C Airflow: 0.6 m³/min

Rotation rate of pan: 25 rpm

Spray pressure: 0.15MPa

Liquid flow rate: 5 g/min

The preparation obtained in the above method was evaluated a quality thereof according to the following methods, and the present invention has been achieved on the basis of the knowledge obtained therein.

[0029]

5

C. Quality evaluation

(1) Dissolution test

A manufactured preparation was subjected to the dissolution test 10 according to the Japanese Pharmacopoeia, Dissolution test, Method 2. Measuring conditions are shown below.

> Test solution: Diluted McIlvaine buffer, pH4.0 Rotation rate of paddle: 50 rpm Test fluid: 900 ml

15 (2) Similarity of dissolution profiles

A similarity factor f2 shown in Scale-Up and Past-Approval Changes for Intermediate Release Products (SUPAC-IR) was used as an indicative for evaluating a similarity of dissolution profiles. The f2 value is calculated by the following equation. It was determined that each 20 manufactured preparation had a similar dissolution profile in case that the f2 value calculated from dissolution ratio of each preparation by SUPAC-IR was in the range of 50≤f2≤100. Dissolution ratios at three time points such as 15 min, 30 min and 45 min after starting the test were used for a calculation of the f2 value.

f2= 50 •
$$LOG\left[\frac{100}{\sqrt{1 + \frac{\sum_{i=1}^{n} (Ti - Ri)^{2}}{n}}}\right]$$

Par Pharm., Inc. Exhibit 1015 Page 030 Ti and Ri are the percent dissolved at each point.

n is the number of points to be compared.

(3) Size distribution

Ŧ

5

A size distribution of lurasidone was measured according to a dry-spray method by Laser Diffraction Particle Size Analyzer (SLAD-3000/Shimadzu Corporation). Measuring conditions are shown below.

Amounts of sample: 2 g Air pressure: 0.4MPa or more Turntable rotation speed: 2 Parameter setting

Environmental setting

Monitoring average:

monitoring average:	16	measuring optimum range	1500	
	10	(Max):	1000	
Dark measuring average:	2	(Min):	700	
Light intensity	2000	(CH-1) baud	rate 9600	
display Max:	2000	(bps):	9000	
Previous blank:	reading	Blank measurable Max:	300	
Printer: monochrome		Blank measurable	20	
		variation range:	20	

Refractive parameter Standard refraction:

1.70-0.20i

64

Measuring conditions setting

Measuring	g average

e: 1 Measuring interval (sec): 1

Average:	

Measured absorbance	0.1
range (Max):	
(Min):	0.05
Trigger mode:	OFF
Dry threshold:	300

	Dry permissible Min:	300
	Max:	2500
	Granule range	0.1
	for evaluation (Min):	0.1
	Granule range	2000
	for evaluation (Max):	2000
5	Start position of sensor usage:	1
F		

Measuring optimum range

[0031]

17

<Test 1>

÷

5

10

Examples 2 and З, tablets comprising specific In 1, pharmaceutical compositions comprising water-soluble excipient comprising 20 mg, 40 mg and 80 mg, respectively, of lurasidone per tablet, partly pregelatinized starch and water-soluble polymer binder were manufactured. In Comparative experiments 1 and 2, tablets comprising 40 mg and 80 mg, respectively, of lurasidone per tablet were manufactured on the basis of the formulation disclosed in Patent Document 2.

The manufactured preparations were subjected to the dissolution tests under conditions shown in (d) and (e), and similarities of dissolution profiles were evaluated. Additionally, preproductions in Comparative experiments 1 and 2 were shown in Test 8.

Results were shown in Tables 4 and 5. Temporal dissolution 15 ratios in (d) were shown in Figures 2 and 3.

[0032]

(a) Formulations of granule powders

[0033]

Table 1

20

Unit: mg

Component	E	xample N	Compar. Ex. No.		
Component	1	2	3	1	2
Lurasidone	80	40	20	40	80
Mannitol	144	72	36	188	148
Partly pregelatinized starch	80	40	20	-	-
Croscarmellose sodium	4	2	1	16	16
Hydroxypropyl methylcellulose	8	4	2	10	10

[0034]

(b) Formulations of granules for compression/uncoated tablets[0035]

Par Pharm., Inc. Exhibit 1015 Page 032

Table 2

÷

Unit: mg

Component	E	Example No	Compar. Ex. No.		
Component	1	1	1	1	2
Granules in the above (a)	316	158	79	254	254
Lactose	-	-	-	62	62
Magnesium stearate	. 4	2	1	4	4

[0036]

(c) Formulations of FC tablets

[0037]

5

10

20

Table 3

Unit: mg

Component	E	xample No	Compar.Ex.No.		
Component	1	2	3	1	2
Uncoated tablets in the above (b)	320	160	80	320	320
Hydroxypropyl methylcellulose	3.25	1.95	1.3	2.6	2.6
Titanium oxide	1	0.6	0.4	0.8	0.8
Polyethylene glycol 6000	0.75	0.45	0.3	0.6	0.6
Carnauba wax	0.01	0.006	0.004	0.01	0.01
(0000)	•			-	

[0038]

(d) Dissolution test in the system comprising 80 mg of lurasidone in each vessel

Each film-coated tablet comprising 80 mg, 40 mg or 20 mg of lurasidone in the system comprising 80 mg of lurasidone in each vessel was subjected to the dissolution test, and a similarity of each dissolution profile was evaluated by f2 value.

15 [0039]

As evidenced by Table 4, f2 values in Examples 2 and 3 showed similarities to Example 1, but f2 value in Comparative experiment 2 did not show a similarity to Comparative experiment 1. In other words, as evidenced by Table 4 and Figure 3, in Examples 1 to 3, f2 values which represented similarities of dissolution profiles were in the range of $50 \le f_2 \le 100$, and preparations which showed similarities of dissolution profiles without depending on contents in tablets (unit strength) even in preparations with different contents were obtained. On the other hand, as evidenced by Table 4 and Figure 2, dissolution of the formulation disclosed in Patent Document 2 in Comparative experiment 2 was

5 disclosed in Patent Document 2 in Comparative experiment 2 was apparently slower than that of two tablets of preparations in Comparative experiment 1, and a similarity of dissolution profile was not shown as detailed in Test 8.

[0040]

10 Table 4

Similarity factor	E	xample N	Compar.Ex. No.		
Similarity factor	1	2	3	1	2
f2	-	88	97	-	37

[0041]

(e) Dissolution test in the system comprising 40 mg of lurasidone in each vessel

15

÷

Each film-coated tablet comprising 40 mg or 20 mg of lurasidone in the system comprising 40 mg of lurasidone in each vessel was subjected to the dissolution test, and a similarity of each dissolution profile was evaluated by using f2 values in the similar manner. [0042]

20

As evidenced by Table 5, f2 values in Example 3 and Comparative experiment 1 showed similarities to Example 2. In other words, f2 values were in the range of $50 \le f2 \le 100$ even in the system comprising 40 mg of lurasidone in each vessel, and similarities of dissolution profiles were shown without depending on contents in tablets (unit strength). [0043]

25 Table 5

Similarity factor	Examı	ole No.	Compar. Ex. No.		
	2	3	1		
f2	-	88	97		

[0044]

<Test 2>

5

10

÷

Preparations comprising a pharmaceutical composition comprising water-soluble excipient and water-soluble polymer binder and partly pregelatinized starch were prepared in Examples 1 and 4. Preparations comprising a pharmaceutical composition comprising water-soluble excipient and water-soluble polymer binder and corn starch which was non-pregelatinized starch were prepared in Comparative experiments 3, 4 and 5. Each preparation was subjected to the dissolution test, and a similarity of each dissolution profile was evaluated by f2 value. Results were shown in Table 9.

(a) Formulations of granule powders

[0045]

Table 6

[0046]

Component	Example No.		Compar. Ex. No.			
Component	1	4	3	4	5	
Lurasidone	80	80	80	80	80	
Mannitol	144	176	108	108	-	
Lactose	-	-	-	-	108	
Partly pregelatinized starch	80	40		-	-	
Corn starch	-	-	40	40	40	
Croscarmellose sodium	4	8	16	16	16	
Hydroxypropyl methylcellulose	8	12	10	10	10	

15

(b) Formulations of granules for compression/uncoated tablets [0047]

Unit: mg

Table 7

÷

Unit: mg

Component	Exam	ole No.	Comparative Example No.			
	1	4	3	4	5	
Granules in the above (a)	316	316	254	254	254	
Mannitol	-		62	-	-	
Magnesium stearate	4	4	4	4	4	

[0048]

(c) Formulations of FC tablets

5 [0049]

Table 8

Unit: mg

Comment	Examp	ole No.	Comparative Example No.			
Component	1	4	3	4	5	
Uncoated tablets in the above (b)	320	320	320	258	258	
Hydroxypropyl methylcellulose	3.25	-	2.6	2.6	2.6	
Titanium oxide	1	-	0.8	0.8	0.8	
Polyethylene glycol 6000	0.75	-	0.6	0.6	0.6	

[0050]

(d) Dissolution test

10

As evidenced by Table 9, Example 4 showed a similarity to Example 1, but f2 values in Comparative experiments 3, 4 and 5 did not show similarities to Example 1. In other words, preparations containing corn starch in Comparative experiments 3, 4 and 5 showed different dissolution profiles and slow dissolutions compared to preparations

- 15 containing partly pregelatinized starch in Examples 1 and 4.
 - [0051]

Table 9

Similarity factor	Exam	ole No.	Comparative Ex. No.			
	1	4	3	4	5	
f2	-	67	44	29	26	

[0052]

<Test 3>

2

5

Effects of blending quantities of partly pregelatinized starch in Examples 4, 5, 6 and 7 on dissolutions were evaluated. Results were shown in Table 13.

(a) Formulations of granule powders

[0053]

Table 10

Unit: mg

Component	Example No.						
Component	1	4	5	6	7		
Lurasidone	80	80	80	80	80		
Mannitol	144	176	116	136	156		
Partly pregelatinized starch	80	40	100	80	60		
Croscarmellose sodium	4	8	8	8	8		
Hydroxypropyl methylcellulose	8	12	12	12	12		

[0054]

(b) Formulations of granules for compression/uncoated tablets

10 [0055]

Table 11

Unit: mg

Component		Example No.						
Component	1	4	5	6	7			
Granules in the above (a)	316	316	316	316	316			
Magnesium stearate	4	4	4	4	4			

[0056]

(c) Formulations of FC tablets

[0057]

Table	12	

					Unit: mg			
Component	Example No.							
Component	1	4	5	6	7			
Uncoated tablets in the above (b)	320	320	320	320	320			
Hydroxypropyl methylcellulose	3.25	-	-	-	-			
Titanium oxide	1	-	-	-	-			
Polyethylene glycol 6000	0.75	-	-	-	-			
Carnauba wax	0.01	-	-	-	· -			

[0058]

(d) Dissolution test

5

15

20

As evidenced by Table 13, f2 values in Examples 4, 5, 6 and 7 showed similarities to Example 1. In other words, a preparation comprising a pharmaceutical composition comprising 10% wt/wt or more of partly pregelatinized starch in preparation components showed a rapid dissolution and a similar dissolution profile.

[0059]

10 Table 13

Similarity factor	Example No.						Example No.					
Similarity factor	1	4	5	6	7							
f2	-	67	60	62	81							

[0060]

<Test 4>

In Comparative experiment 6, a tablet was tried to be prepared with containing water-soluble excipient and partly pregelatinized starch but without water-soluble polymer binder. However, in a compression step, components could not be compressed due to capping and sticking, and no similar dissolution profile or even tablet was obtained. In Examples 8, 9, 10 and 11, preparations comprising pharmaceutical compositions with different blending quantities of water-soluble excipient and partly pregelatinized starch and water-soluble polymer binder were prepared. Results were shown in Table 17. (a) Formulations of granule powders

Formulations of FC tablets

[0061]

2

Table 14

Unit: mg

Commonant		Exa	Compar.Ex.No.			
Component	1	8	9	10	11	6
Lurasidone	80	80	80	80	80	80
Mannitol	144	136	138	140	142	148
Partly pregelatinized starch	80	80	80	80	80	80
Croscarmellose sodium	4	8	8	8	8	8
Hydroxypropyl methylcellulose	8	12	10	8	6	-

[0062]

5

(b) Formulations of granules for compression/uncoated tablets [0063]

Table 15

						Unit: mg
Component		Ex	Compar. Ex. No.			
Component	1	8	9 [·]	10	11	6
Granules in the above (a)	316	316	316	316	316	316
Magnesium stearate	4	4	4	4	4	4

[0064]

10

[0065]

(c)

Table 16

Unit: mg

Component		Exa	Compar.Ex. No.			
	1	8	9	10	11	6
Uncoated tablets in the above (b)	320	320	320	320	320	320
Hydroxypropyl methylcellulose	3.25	-	-	-	-	-
Titanium oxide	1	-	-	-	-	-
Polyethylene glycol 6000	0.75	-	-	-	-	-
Carnauba wax	0.01	-	-	-	-	-

[0066]

(d) Dissolution test

As evidenced by Table 17, f2 values in Examples 8, 9, 10 and 11 showed similarities to Example 1. In other words, preparations comprising pharmaceutical compositions comprising water-soluble polymer binder in the range of 1.8% wt/wt to 3.8% wt/wt showed rapid dissolutions and similar dissolution profiles.

[0067]

Table 17

Similarity factor	Example No.						
Similarity factor	1	8	9	10	11		
f2	-	77	81	73	73		

[0068]

<Test 5>

10

5

7

In Example 12, a preparation comprising a pharmaceutical composition comprising water-soluble polymer binder and partly pregelatinized starch was prepared by using lactose as water-soluble excipient. Results were shown in Table 21.

(a) Formulations of granule powders

15 [0069]

Table 18

			Unit: mg		
Component	Example No.				
Component	1	6	12		
Lurasidone	80	80	80		
Mannitol	144	136	-		
Lactose	-	-	136		
Partly pregelatinized starch	80	80	80		
Croscarmellose sodium	4	8	8		
Hydroxypropyl methylcellulose	8	12	12		

[0070]

(b) Formulations of granules for compression/uncoated tablets [0071]

Table 19

÷

Unit: mg						
Component	Example No.					
Component	1	6	12			
Granules in the above (a)	316	316	316			
Magnesium stearate	4	4	4			

[0072]

(c) Formulations of FC tablets

[0073]

5 Table 20

			OIIIt. Ing			
Component	Example No.					
Component	1	6	12			
Uncoated tablets in the above (b)	320	320	320			
Hydroxypropyl methylcellulose	3.25	-	-			
Titanium oxide	1	- ·	-			
Polyethylene glycol 6000	0.75	-	· –			
Carnauba wax	0.01	-	-			

[0074]

(d) Dissolution test

As evidenced by Table 21, f2 values in Examples 6 and 12 showed similarities to Example 1. In other words, preparations containing mannitol and lactose as water-soluble excipient showed rapid dissolutions and similar dissolution profiles.

[0075]

10

15

Table 21

Similarity factor	E	xample N	D.
Similarity factor	1	6	12
f2	-	62	66

[0076] <Test 6>

In Examples 4, 13, 14 and 15, preparations comprising a specific pharmaceutical composition comprising water-soluble excipient and

water-soluble polymer binder and partly pregelatinized starch were prepared by using lurasidone bulk powders with different size distribution. Results were shown in Table 25.

(a) Size distribution of lurasidone bulk powders

D50 % (50% particle size) represents a particle size at a point where an integrated distribution calculated on the basis of volume is 50%, and D90 % (90% particle size) represents a particle size at a point where an integrated distribution calculated on the basis of volume is 90% (under sieving).

10 [0077]

5

ç

Table 22

Unit: mg Example No. Size distribution 4 13 14 15 D10 % 0.5 0.9 1.0 1.5 Particle size D50 % 5.9 7.6 13.9 1.6 D90 % 4.7 17.5 26.9 58.3

[0078]

(b) Formulations of granules for compression/uncoated tablets [0079]

15 Table 23

				Unit: mg
Component		Examp	ole No.	
Component	4	13	14	15
Lurasidone	80	80	80	80
Mannitol	176	144	144	144
Partly pregelatinized starch	40	80	80	80
Croscarmellose sodium	8	4	4	4
Hydroxypropyl methylcellulose	12	8	8	8
Magnesium stearate	4	4	4	4

[0080]

(c) Formulations of FC tablets

[0081]

Par Pharm., Inc. Exhibit 1015 Page 042

Ta	ble	24	

Unit: mg

Commonsent		Example No.			
Component	4	13	14	15	
Uncoated tablets in the above (b)	320	320	320	320	
Hydroxypropyl methylcellulose	-	3.25	3.25	3.25	
Titanium oxide	-	1	1	1	
Polyethylene glycol 6000	-	0.75	0.75	0.75	
Carnauba wax	-	0.01	0.01	0.01	

[0082]

(d) Dissolution test

5

As evidenced by Table 25, f2 values in Examples 13, 14 and 15 showed similarities to Example 4. In other words, it was found that preparations prepared by using lurasidone bulk powders wherein 50% particle size is in the range of 1 to 8 μ m and 90% particle size is 27 μ m or less in size distribution showed similar dissolution profiles.

10 [0083]

Table 25

Similarity factor	Example No.			
	4	13	14	15
ŕ2	-	56	56	46

[0084]

<Test 7>

Preparations wherein contents of lurasidone per tablet were 10 15 mg and 40 mg were manufactured by using the art disclosed in Patent Document 2, and were subjected to examination if they could provide preparations for oral administration with equivalent dissolution profiles in the range of 10 mg to 40 mg of lurasidone contents per tablet as disclosed in the document 2. Results were shown in Figure 1.

20 [0085]

As evidenced by Figure 1, dissolution profiles of preparations with different contents of lurasidone obtained by the art disclosed in Patent Document 2 were shown by f2 values, and tablets with 10 mg and 40 mg of lurasidone per tablet could provide preparations for oral administration with equivalent dissolution profiles as described in Patent Document 2.

(a) Formulations of granules

[0086]

÷

5

Table 26

	
Unit:	mol
Ome.	1115

	the second se	¥
Component	10 mg tablet	40 mg tablet
Lurasidone	10	40
Mannitol	47	188
Croscarmellose sodium	4	16
Hydroxypropyl methylcellulose	2.5	10

(b) Formulations of uncoated tablets

[0087]

10 Table 27

		Unit: mg
Component	10 mg tablet	40 mg tablet
Granules in (a)	63.5	254
Lactose	15.5	62
Magnesium stearate	1	4

(c) Formulations of FC tablets

[0088]

Table 28

		Unit: mg
Component	10 mg tablet	40 mg tablet
Uncoated tablets in the above (b)	80	320
Hydroxypropyl methylcellulose	1.3	2.6
Titanium oxide	0.4	0.8
Polyethylene glycol 6000	0.3	0.6
Carnauba wax	0.006	0.01

[0089]

15 <Test 8>

29

It could be confirmed that a preparation with up to 40 mg of lurasidone per tablet could provide an oral preparation with equivalent dissolution profile in the art disclosed in Patent Document 2. A preparation wherein contents of lurasidone were 80 mg per tablet without containing partly pregelatinized starch was manufactured herein according to the art disclosed in Patent Document 2. The preparation was prepared by doubling a content ratio of the active ingredient so that a tablet weight thereof was the same as 40 mg tablet, in order to avoid an increased strain on a patient associated with growth of tablets in size. Results of Comparative experiments 1 and 2 were shown in Table 4 and Figure 2.

[0090]

4

5

10

15

As evidenced by Table 4 and Figure 2, 80 mg tablet with double content ratios of lurasidone without containing pregelatinized starch could not show equivalent dissolution to two tablets of 40 mg tablet as shown by f2 values in the art disclosed in Patent Document 2.

- (a) Formulations of granules
- [0091]

Table 29

·		Unit: mg
Component	40 mg tablet	80 mg tablet
Lurasidone	40	80
Mannitol	188	148
Croscarmellose sodium	16	16
Hydroxypropyl methylcellulose	10	10

20.

(b) Formulations of uncoated tablets

[0092]

-- .

Table 30

4

-		Unit: mg
Component	40 mg tablet	80 mg tablet
Granules in (a)	254	254
Lactose	62	62
Magnesium stearate	4	4

(c) Formulations of FC tablets

[0093]

Table 31

		Unit: mg
	40 mg tablet	80 mg tablet
Uncoated tablets in the above (b)	320	320
Hydroxypropyl methylcellulose	2.6	2.6
Titanium oxide	0.8	0.8
Polyethylene glycol 6000	0.6	0.6
Carnauba wax	0.01	0.01

5 [0094]

<Test 9>

Dissolutions of three kinds of preparations with different contents manufactured in Examples 1 to 3 of Test 1 were evaluated. Results were shown in Figure 3.

10

As evidenced by Figure 3, it was confirmed that preparations of the present invention which contained in the range of 20 mg to 80 mg of lurasidone per tablet showed equivalent dissolutions without depending on tablet contents (unit strength).

(a) Formulations of granule powders

15 [0095]

Table 32

			Unit: mg
Component	80 mg tablet	40 mg tablet	20 mg tablet
Lurasidone	80	40	20
Mannitol	144	72	36
Partly pregelatinized starch	80	40	20
Croscarmellose sodium	4	2	1
Hydroxypropyl methylcellulose	8	4	2

(b) Formulations of granules for compression/uncoated tablets

[0096]

Table 33

			Unit: mg
Component	80 mg tablet	40 mg tablet	20 mg tablet
Granules in the above (a)	316	158	79
Lactose	-		-
Magnesium stearate	4	2	1

5

4

(c) Formulations of FC tablets

[0097]

Table 34

			Unit: mg
Component	80 mg tablet	40 mg tablet	20 mg tablet
Uncoated tablets in the above (b)	320	160	80
Hydroxypropyl methylcellulose	3.25	1.95	1.3
Titanium oxide	1	0.6	0.4
Polyethylene glycol 6000	0.75	0.45	0.3
Carnauba wax	0.01	0.006	0.004

[0098]

10 <Test 10>

Lurasidone 120 mg tablet preparations wherein each tablet weight was equal were prepared according to the art disclosed in the present invention as well as Patent Document 2, and dissolution profile of each preparation was evaluated. (a) Experimental method

Lurasidone 120 mg tablet preparations were manufactured according to the preparation method of the present invention as well as Preparation method 2 in Patent Document 2 (described hereinafter) (Table 35). These manufactured preparations were subjected to the dissolution test on partly changed conditions described in C. Quality evaluation (1) dissolution test in the Example in the present specification.

The dissolution test was carried out by changing pH4.0 to pH3.8 10 in pH of the test solution diluted McIlvaine buffer.

[0099]

.

5

(b) Preparation method of the present invention

To a fluid bed granulator (Flow Coater FLF-30/manufactured by Freund Industrial Co., Ltd.) were charged lurasidone (8000 g), D-15 mannitol (14200 g), partly pregelatinized starch (8000 g) and croscarmellose sodium (400 g), and thereto was sprayed 5% hydroxypropyl methylcellulose solution previously prepared to be granulated on conditions that intake temperature was 80°C, intake airflow was 7 m^3 /min, spray liquid flow rate was 200 mL/min and 20 atomizing airflow was 200 L/min. The obtained granule was dried in the granulator on conditions that drying temperature was 80°C and drying time was 10 minutes, and it was confirmed by a halogen moisture analyzer that the loss on dry was within 2%. The obtained granule was sized by using a sizing machine (Fiore F-0 type). Then, the 25 sized granule (18000 g) and magnesium stearate (228 g) were blended together by using a blending machine (container size 110 L) on conditions that rotation rate was 20 rpm and blending time was 5 Finally, the obtained mixture was compressed at a minutes. compressing pressure of 12.5 kN by using a compression apparatus 30 (HT-AP12SS-II/manufactured by Hata Iron Works Co., Ltd.) to prepare

a lurasidone 120 mg uncoated tablet.

[0100]

,

(c) Preparation method 2 in Patent Document 2

To a fluid bed granulator (Multiplex MP-01/manufactured by 5 Powrex Corporation) were charged lurasidone (160 g), D-mannitol (296 g) and croscarmellose sodium (32 g), and thereto was sprayed 5% hydroxypropyl methylcellulose solution previously prepared to be granulated on conditions that temperature for supplying air was 60°C and granulating time was 45 minutes. The obtained granule was dried 10 in the granulator on conditions that drying temperature was 80°C and drying time was 5 minutes, and it was confirmed by a halogen moisture analyzer that the loss on dry was within 1%. Then, the obtained granule (254 g) and lactose (62 g) were blended together by using a blending machine (manufactured by Tsutsui Rikagaku Kikai Co., Ltd.) 15 on conditions that rotation rate was 40 rpm and blending time was 30 After that, the resulting mixture (316 g) and magnesium minutes. stearate (4 g) were blended together by using a blending machine

- (manufactured by Tsutsui Rikagaku Kikai Co., Ltd.) on conditions that rotation rate was 40 rpm and blending time was 5 minutes. Finally, the
 obtained mixture was compressed at a compressing pressure of 12.5 kN by using a compression apparatus (HT-AP12SS-II/manufactured by Hata Iron Works Co., Ltd.) to prepare a lurasidone 120 mg uncoated tablet.
 - [0101]
- 25 (d) Results

Components of the manufactured preparations and results of the dissolution tests were shown below. [0102]

Table	35
-------	----

•

Components of tablets

Formulations	034-15-120-1000	RP-03323-120-1000
1 ormulations	(Disclosure of the present application)	(Disclosure of Patent Document 2)
Lurasidone	120	120
Mannitol	213	222
Partly pregelatinized starch	120	-
Croscarmellose sodium	6	24
Tablettose 70	-	93
Hydroxypropyl methylcellulose	15	15
Magnesium stearate	6	6
Total	480	480
Dissolution profile		
Time (min)	Dissoluti	on rate (%)
10	83	54
15	91	66 [`]
30	95	80
45	96	84
f2 value	-	37

As a result, it was confirmed that lurasidone 120 mg tablet 5 manufactured according to the disclosure of the present application showed more rapid dissolution compared to lurasidone 120 mg tablet manufactured according to the disclosure of Patent Document 2. [0103]

<Test 11>

10

15

Applied content ranges of drug substance of the present invention were evaluated on the basis of dissolution profiles of preparations.

(a) Experimental method

Lurasidone 80 mg tablets were manufactured according to the preparation method of the present invention (Table 36). These manufactured preparations were subjected to the dissolution test on conditions described in C. Quality evaluation (1) dissolution test in the Example in the present specification. [0104]

1

(b) Preparation method

To a fluid bed granulator (Multiplex MP-01/manufactured by Powrex Corporation) were charged lurasidone, D-mannitol, partly pregelatinized starch and croscarmellose sodium, and thereto was sprayed 5% hydroxypropyl methylcellulose solution previously prepared to be granulated on conditions that temperature for supplying air was 60°C and granulating time was 45 minutes or 60 minutes. The obtained granule was dried in the granulator on conditions that drying temperature was 80°C and drying time was 5 minutes, and it was confirmed by a halogen moisture analyzer that the loss on dry was within 2%. Then, the obtained granule and magnesium stearate were blended together by using a blending machine (manufactured by Tsutsui Rikagaku Kikai Co., Ltd.) on conditions that rotation rate was

15 40 rpm and blending time was 5 minutes. Finally, the obtained mixture was compressed at a compressing pressure of 10 kN by using a compression apparatus (HT-AP12SS-II/manufactured by Hata Iron Works Co., Ltd.) to prepare a lurasidone 80 mg uncoated tablet.

[0105]

20 (c) Results

Components of manufactured preparations and results of dissolution tests were shown below. [0106]

Tuble 66				
Formulations	034-15-80-1000	RP-03320	RP-03321	RP-03322
Lurasidone	80	80	80	80
Mannitol	142	104	67	30
Partly pregelatinized starch	80	80	80	80
Croscarmellose sodium	4	4	4	4
Hydroxyproplyl methylcellulose	10	8	6	4
Magnesium stearate	4	4	3	2
Total	320	280	240	200

Table 36

Ť

Dissolution profile

Time (min)	Dissolution ratio (%)			
10	85	73	71	68
15	89	80	80	81
30	93	88	88	89
45	94	90	91	91
f2 value	-	60	60	63

As a result, it could be confirmed that similar dissolution profiles were shown by components of preparations wherein lurasidone was contained in the range of 25 to 40%.

5 [0107]

<Test 12>

Dissolution profiles of preparations were evaluated for the watersoluble polymer binders of the present invention.

- (a) Experimental method
- 10

Lurasidone 80 mg tablet was manufactured according to the preparation method of the present invention (Table 37). These manufactured preparations were subjected to the dissolution test on conditions described in C. Quality evaluation (1) dissolution test in Example in the present specification.

15 [0108]

(b) Preparation method

37

To a fluid bed granulator (Multiplex MP-01/manufactured by Powrex Corporation) were charged lurasidone (160 g), D-mannitol (284 g), partly pregelatinized starch (160 g) and croscarmellose sodium (8 g), and thereto was sprayed 5% water-soluble polymer binder solution previously prepared to be granulated on conditions that temperature for 5 supplying air was 60°C and granulating time was 45 minutes. The obtained granule was dried in the granulator on conditions that drying temperature was 80°C and drying time was 5 minutes, and it was confirmed by a halogen moisture analyzer that the loss on dry was 10 within 2%. Then, the obtained granule and magnesium stearate were blended together by using a blending machine (manufactured by Tsutsui Rikagaku Kikai Co., Ltd.) on conditions that rotation rate was 40 rpm and blending time was 5 minutes. Finally, the obtained mixture was compressed at a compressing pressure of 10 kN by using a compression apparatus (HT-AP12SS-II/manufactured by Hata Iron 15 Works Co., Ltd.) to prepare a lurasidone 80 mg uncoated tablet. [0109]

(c) Results

Components of manufactured preparations and results of 20 dissolution tests were shown below.

[0110]

7

â

Par Pharm., Inc. Exhibit 1015 Page 053

Та	ble	37
10	DIC	01

9

Formulations	034-15-80-1000	RP-03326	RP-03327	RP-03328
Lurasidone	80	80	80	80
Mannitol	142	142	142	142
Partly pregelatinized starch	80	80	80	80
Croscarmellose sodium	4	4	4	4
Hydroxyproplyl methylcellulose	10	-	-	-
Polyvinylalcohol	-	10	-	-
Polyvinylpyrrolidone	-	-	10	-
Hydroxypropylcellulose	-	-	-	10
Magnesium stearate	4	4	4	4
Total	320	320	320	320

Dissolution profile

Time (min)	Dissolution ratio (%)			
10	83	59	78	80
15	91	76	82	87
30	95	94	88	91
45	96	96	90	92
f2 value	-	53	56	69

As a result, it was confirmed that preparations using as watersoluble polymer binder polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose met the standard of "C. Quality evaluation (2) Similarity of dissolution profiles" in the present specification (similar dissolution profiles).

[0111]

<Test 13>

10

5

Dissolution profiles of lurasidone 20, 40, 80 and 120 mg FC tablets prepared according to the art disclosed in the present invention were evaluated.

(a) Experimental method

Lurasidone 20, 40, 80 and 120 mg FC tablets were manufactured according to the preparation method of the present invention (Table 38).

[0112]

9

2

(b) Preparation method

To a fluid bed granulator (Flow Coater FLF-30/manufactured by Freund Industrial Co., Ltd.) were charged lurasidone (8000 g), D-5 mannitol (14200 g), partly pregelatinized starch (8000 g) and croscarmellose sodium (400 g), and thereto was sprayed 5% aqueous hydroxypropyl methylcellulose solution previously prepared to be granulated on conditions that intake temperature was 80°C, intake airflow was 7 m³/min, spray liquid flow rate was 200 mL/min and 10 atomizing airflow was 200 L/min. After spraying, the obtained granule was dried on conditions that drying temperature was 80°C and drying time was 10 minutes, and it was confirmed by a halogen moisture analyzer that the loss on dry was within 2%. The obtained granule were sized by using a sizing machine (Fiore F-0 powders 15 type/manufactured by Tokuju Corporation). Then, the sized granule powders (18000 g) and magnesium stearate (228 g) were blended together by using a blending machine (container size 110 L/manufactured by Furukawa Altec Co., Ltd.) on conditions that rotation rate was 20 rpm and blending time was 5 minutes. The 20 obtained powder mixtures were compressed at a compressing pressure of about 10 kN by using a compression apparatus (CLEANPRESS Correct 12HUK/manufactured by Kikusui Seisakusho Ltd. for a lurasidone 20, 40 or 80 uncoated tablet, HT-AP12SS-II/manufactured by Hata Iron Works Co., Ltd. for a lurasidone 120 mg uncoated tablet) 25 to prepare a lurasidone 20, 40, 80 or 120 mg uncoated tablet. Then, an uncoated tablet was coated on conditions that temperature for supplying air was 80°C, airflow was 0.6 m³/min, rotation rate of pan was 25 rpm, spray pressure was 0.15MPa and liquid flow rate was 5 g/min to give a lurasidone 20, 40, 80 or 120 mg FC tablet. 30 [0113]

> Par Pharm., Inc. Exhibit 1015 Page 055

(c) Dissolution test

Manufactured preparations were subjected to the dissolution test according to the Japanese Pharmacopoeia, Dissolution test, Method 2. Measuring conditions are shown below.

Components of manufactured preparations and results of

Test solution: Diluted McIlvaine buffer, pH3.8 and 4.0 Paddle rotation: 50 rpm Test fluid: 900 ml

[0114]

(d) Results

dissolution tests were shown below.

10

5

Ŷ

[0115]

Par Pharm., Inc. Exhibit 1015 Page 056

Table 38

÷.,

Q.

â

Components of tablets

Prod	uct name	Lurasidone 20 mg FC tablet	Lurasidone 40 mg FC tablet	Lurasidone 80 mg FC tablet	Lurasidone 120 mg FC tablet
L	ot No.	034-15-20	034-15-40	034-15-80	034-15-120
Formulation	Lurasidone	20 mg	40 mg	80 mg	120 mg
	mannitol	35.5 mg	71 mg	142 mg	216mg
	Partly pregelatinized starch	20 mg	40 mg	80 mg	120 mg
	Croscarmellose sodium	1 mg	2 mg	4 mg	6 mg
	Hydroxypropyl methylcellulose	2.5 mg	5 mg	10 mg	15 mg
	Magnesium stearate	1 mg	2 mg	4 mg	6 mg
	Subtotal	80 mg	160 mg	320 mg	480 mg
	Hydroxypropyl methylcellulose	1.001 mg	1.690 mg	2.730 mg	1.100 mg
	Titanium oxide	0.308 mg	0.520 mg	0.840 mg	0.825 mg
	Macrogol 6000	0.231 mg	0.390 mg	0.630 mg	5.500 ⁻ mg
	Carnauba wax	0.01 mg	0.01 mg	0.01 mg	0.01 mg
	Total	81.55 mg	162.61 mg	324.21 mg	485.51 mg

Dissolution profile

Time (min)		Dissolution ratio (%)			
10	80	77	77	77	
15	91	90	88	92	
30	100	98	93	96	
45	101	100	94	97	
pH of test fluid	4.0	4.0	4.0	3.8	

As a result, it was confirmed that lurasidone 20, 40, 80 and 120 mg FC tablets manufactured according to the disclosure of the present application showed rapid dissolutions.

[0116]

5

<Test 13>

Similarities of dissolution profiles were evaluated for 1 tablet of 40 mg FC tablet/2 tablets of 20 mg FC tablet, 1 tablet of 80 mg FC tablet/2

tablets of 40 mg FC tablet/4 tablets of 20 mg FC tablet, 1 tablet of 120 mg FC tablet/3 tablets of 40 mg FC tablet/6 tablets of 20 mg FC tablet.

(a) Experimental method

5 Preparation method and test method were abbreviated because 5 they were similar to dissolution profiles in Test 12.

[0117]

(b) Results

Dissolution profiles of manufactured preparations and similarities thereof were shown below.

10 [0118]

Table 39

Tablet		40 mg tablet	20 mg tablet	80 mg tablet	40 mg tablet	20 mg tablet		120 mg tablet	40 mg tablet	20 mg tablet	
Number of tablets		1 tablet	2 tablets	1 tablet	2 tablets	4 tablets	_	1 tablet	3 tablets	6 tablets	
		Dissoluti	on ratio (%)	Dissolution ratio (%)				Dissolution ratio (%)			
	10	77	79	77	78	75	77		90	83	
Time	15	90	90	88	86	84		92	94	90	
(min)	30	98	98	93	91	90		96	97	94	
	45	100	100	94	93	92		97	98	95	
f2 value			100	_	85	74		-	88	83	

As a result, it was confirmed that all preparations met the standard of "C. Quality evaluation (2) Similarity of dissolution profiles" in the present specification.

15

INDUSTRIAL APPLICABILITY

[0119]

The present invention allows to provide a preparation for oral administration with a good disintegration which comprises as an active ingredient N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-

20

ingredient N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone), which has an equivalent dissolution profile of the active ingredient even though contents of the

17/919678 APO5Rec'd PGT 31 OCT 2007

44

active ingredient therein are varied.

BRIEF DESCRIPTION OF DRAWINGS

[0120]

5

Figure 1 shows a comparison of dissolution profiles in preparations with different contents of lurasidone. Preparations wherein contents of lurasidone per tablet manufactured according to the art disclosed in Patent Document 2 were 10 mg (4 tablets) and 40 mg (1 tablet) were measured in dissolution profiles.

Figure 2 shows a comparison of dissolution profiles in preparations with different contents of lurasidone. Preparations wherein contents of lurasidone per tablet manufactured according to the art disclosed in Patent Document 2 were 40 mg (2 tablets) and 80 mg (1 tablet) were measured in dissolution profiles.

15

10


Figure 3 shows a comparison of dissolution profiles in preparations with different contents of lurasidone. Preparations wherein contents of lurasidone per tablet manufactured according to the present invention were 20 mg (4 tablets), 40 mg (2 tablets) and 80 mg (1 tablet) were measured in dissolution profiles.

CLAIMS

1. An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of

the formula (1):

polymer binder.



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder.

10

5

3

2. An oral preparation which is prepared by granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

3. An oral preparation which is prepared by granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble

15

25

4. The oral preparation of any one of claims 1 to 3 wherein the water-soluble excipient is mannitol or lactose.

5. A method of granulation of a powder mixture which comprises
20 granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

6. A method of granulation of a powder mixture which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by using a solution or dispersion of lurasidone and a water-soluble polymer binder. Ŷ

5

7. The method of granulation of claim 5 wherein the water-soluble excipient is mannitol or lactose.

8. The oral preparation of any one of claims 1 to 4 wherein the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

9. The oral preparation of any one of claims 1 to 4 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10. The oral preparation of any one of claims 1 to 4 wherein a contentof lurasidone in the preparation is 20 to 45% (wt/wt).

11. The oral preparation of any one of claims 1 to 4 wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

12. The oral preparation of any one of claims 1 to 4 wherein a content of lurasidone per tablet is 10 to 160 mg.

15 13. The oral preparation of any one of claims 1 to 4 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. The oral preparation of any one of claims 1 to 4 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. The oral preparation of any one of claims 1 to 4 wherein the water-soluble excipient is mannitol or lactose and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

16. The oral preparation of any one of claims 1 to 4 wherein the water-soluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17. The oral preparation of any one of claims 1 to 4 wherein the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

30

20

25

18. The oral preparation of any one of claims 1 to 4 wherein the

water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

- 5 19. The oral preparation of any one of claims 1 to 4 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).
- 10 20. The oral preparation of any one of claims 1 to 4 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.
- 15 21. The oral preparation of any one of claims 1 to 4 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. The oral preparation of any one of claims 1 to 4 wherein an average particle size of lurasidone is 0.1 to 8 μ m.

23. The oral preparation of any one of claims 1 to 4 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. The oral preparation of any one of claims 1 to 4 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to

25

20

3

40% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

47

ABSTRACT

\$

٦,

÷

.

A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-5 (2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is 10 varied.

Par Pharm., Inc. Exhibit 1015 Page 063

PLEASE NOTE: YOU MUST COMPLETE THE FOLLOWING

IAP05Rec'd PGT 31 OCT 2007 Attorney Docket No. TT/919678

0020-5610PUS1

BIRCH, STEWART, KOLASCH & BIRCH, LLP

P.O. Box 747 • Falls Church, Virginia 22040-0747 Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT AND DESIGN APPLICATIONS

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACEUTICAL	COMPOSITION

Fill in Appropriate

Insert Priority Information: (if appropriate

Insert Title:

for Information -For Use Without Specification Attached

th above and/or the following:	
The specification was filed on	as
United States Application Number	زز
and amended on	(if applicable) and/or
the specification was filed on <u>May 26, 2006</u>	as PCT
International Application Number <u>PCT/JP2006/310571</u>	; and was
amended on	(if applicable)

the specification of which is attached hereto. If not attached hereto, the application is identified by the attorney docket number as set

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56. I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application, filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows. I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: Prior Foreign Application(s)

Prior Foreign Application(s) Priority Claimed

	0 11	• •		,	
=)	<u>2005–153508</u> (Number)	Japan (Country)	May 26, 2005 (Month/Day/Year Filed)	X Yes	□ No
	(Number)	(Country)	(Month/Day/Year Filed)	□ Yes	□ No
	(Number)	(Country)	(Month/Day/Year Filed)	□ Yes	□ No
	(Number)	(Country)	(Month/Day/Year Filed)	□ Yes	□ No

I hereby claim the benefit under Title 35, United States Code, \$119(e) of any United States provisional applications(s) listed below.

Insert Provisional Application(s): (if any)	(Application Number)		(Filing Date)			
	(Application Number)		(Filing Date)			
	All Foreign Applications, if any the Filing Date of This Applicat		ate Filed More than 12 Months (6 Months for Designs) Prior to			
	Country	Application Number	Date of Filing (Month/Day/Year)			
Insert Requested Information: (if appropriate)						
	continuation-in-part applicatio disclosed in the prior United St Code. \$112. Lacknowledge th	n(s) listed below and, insofar as the ates and/or PCT application in the ma e duty to disclose information which ich became available between the fi	of any United States and/or PCT application(s), including for subject matter of each of the claims of this application is no anner provided by the first paragraph of Title 35, United States is material to the patentability as defined in Title 37, Code of ling date of the prior application and the national or PCI			
Insert Prior U.S.						
Application(s): (if any)	(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)			
Page 1 of 2	(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)			

Page 1 of 2 (Rev. 05/2004)

(Filing Date)

(Status - patented, pending, abandoned)

 $\begin{array}{c} & \text{Attorney Docket No.} \\ 0020-5610PUSI \\ \hline \\ \text{otherwise} \\ \text{otherwise}$

Send Correspondence to:

CUSTOMER NO. 02292 (BIRCH, STEWART, KOLASCH & BIRCH, LLP) Facsimile: (703) 205-8050 Telephone: (703) 205-8000 .

PLEASE NOTE: YOU MUST COMPLETE THE FOLLOWING: T

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. ぼる


Full Name of First or Sole Inventor:	GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	5	DATE*	1			
Full Name of First or Sole Inventor. Intert Name of Intert Date This Document is Signed	Kazuyuki FUJIHARA	x Kaguyuki Fujiha	ra	2007. Sep. 13.	22 6			
Insert Residence	Residence (City, State & Country)	· · · · · · · · · · · · · · · · · · ·	CITIZENSHI	p	1			
Insert Citizenship \rightarrow	Ibaraki-shi, Osaka-fu, Japa	Japan						
Insert Post Office Address →	MAILING ADDRESS (Complete Street Address							
	c/o Dainippon Sumitomo Phan Ibaraki-shi, Osaka 567-0878	ma CO., Ltd., $3-45$, 3 Japan	Kurakaki	ucni 1-cnome,				
Full Name of Second Inventor, if any: see above	GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE		DATE*				
	Residence (City, State & Country)		CITIZENSHI					
	MAILING ADDRESS (Complete Street Address	including City, State & Country)						
Full Name of Third Inventor, if any:	GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE		DATE*	4			
see above								
	Residence (City, State & Country)		CITIZENSHI	P				
	MAILING ADDRESS (Complete Street Address including City, State & Country)							
Full Name of Fourth Inventor, if any: see above	GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE		DATE*				
	Residence (City, State & Country)	• <u>• • • • • • • • • • • • • • • • • • </u>	CITIZENSHI	P	1			
	MAILING ADDRESS (Complete Street Address including City, State & Country)							
Full Name of Fifth Inventor, if any:	GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	•	DATE*	4			
see above								
	Residence (City, State & Country)		CITIZENSHI	P				
	MAILING ADDRESS (Complete Street Address							
Full Name of Sixth Inventor, if any: see above	GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE		DATE*				
	Residence (City, State & Country)	CITIZENSHI						
	MAILING ADDRESS (Complete Street Address	including City, State & Country)	L					

Page 2 of 2 (Rev. 05/2004)

*DATE OF SIGNATURE

Docket No.: 0020-5610PUS1 App No.: NEW Docket Inventor: Kazuyuki FUJIHARA Title: PHARMACEUTICAL COMPOSITION Sheet 1 of 3 NEW SHEET


Figure 1




App No.: NEW	Docket No.: 0020-5610PUS1
Inventor: Kazuyuki FUJIHARA Title: PHARMACEUTICAL COM	POSITION
NEW SHEET	Sheet 2 of 3

Figure 2

æ





ţ

(19)日本国特許庁(JP)

í - 4

.

=

.

(12) 公開特許公報(A)

(11)特許出願公開番号

特開平8-325146

(43)公開日 平成8年(1996)12月10日

(51) Int.Cl.6		識別記号	庁内整理番号	ΓI						技術表示箇所
A 6 1 K	31/415 9/20	AED		A 6	1 K	31/415 9/20		AE	D D	
	0,20					0,20			E	
	31/645	ABN				31/645		AB	N	
	45/00					45/00				
			審査請求	未請求	請求	項の数4	OL	(全を	3 頁)	最終頁に続く
(21)出願番号		特願平7-127786		(71)	出願人	00000	1029			
						協和醗酵工業株式会社				
(22)出顧日		平成7年(1995)5月	東京都千代田区大手町1丁目6番1号						目6番1号	
				(72)	発明者	釬 上野	靖彦			
						静岡県	1.三島市	佐野見明	骨台2	- 1 - 2
				(72)	発明者	新正田	友章			
						静岡県	三島市	加茂 8	- 16	
				(72)	発明者	予藤	直浩			
					静		争岡県沼津市大岡2763-2			

(54)【発明の名称】 医薬組成物

(57)【要約】

【目的】 高含量の薬物を含有する製剤において、打錠 しやすく溶出性および生体への吸収性に優れた小型化さ れた錠剤を開発する。 【構成】 微粒子化した薬物成分および界面活性剤また

は有機酸塩からなる核と部分アルファ化デンプンとを含有することを特徴とする医薬組成物。

【特許請求の範囲】

2

【請求項1】 微粒子化した薬物活性成分および界面活 性剤または有機酸塩からなる核と部分アルファ化デンプ ンとを含有することを特徴とする医薬組成物。

1

【請求項2】 有機酸塩がクエン酸三ナトリウム、コハ ク酸ニナトリウム、酢酸ナトリウム、酢酸カリウムおよ びグルタミン酸ナトリウムからなる群から選ばれる請求 項1記載の組成物。

【請求項3】 薬物活性成分が、バルプロ酸またはその 塩、マクロライド系抗生物質、スルホアミド系経口血糖 10 降下剤、非ステロイド性抗炎症剤、サルファ剤およびト ロンボキサンA2 拮抗剤からなる群から選ばれる請求項 1または2記載の組成物。

【請求項4】 トロンボキサンA2 拮抗剤が11-〔2 - (5, 6-ジメチルー1-ベンゾイミダゾリル)エチ リデン)-6,11-ジヒドロジベンソ [b, e] オキ セピン-2-カルポン酸またはその塩である請求項3記 載の組成物。

【発明の詳細な説明】

[0001]

【産業上の利用分野】本発明は崩壊性、溶出性並びに吸 収性の改善された経口投与用製剤に関する。

[0002]

【従来の技術】固形製剤、特に汎用される錠剤中の薬物 活性成分を効率良く消化管から吸収させバイオアベイラ ビリティーを高めることは製剤学上の課題の一つであ る。一錠中に大量の薬物活性成分を含有する製剤は、崩 壊時間が長く、溶出率が低下し、そのためパイオアベイ ラビリティーの低下を生じることが知られている。かか るパイオアペイラビリティーの低下を防止するために錠 30 剤径の拡大が図られたが服用しにくいという問題があ る.

【0003】 製剤学的にパイオアベイラビリティーの低 下を防止する方法としては、薬物活性成分を1. 有機溶 媒に溶解しゼラチンカプセルに充填した軟カプセル剤と する方法、2. 高分子と共に溶媒に溶解し速やかに乾燥 して固体分散体とするか、または高分子と共に溶融して 固体分散体とする方法、3. 有機溶媒に溶解した後、多 孔性物質に微粒子状に吸着させて表面積を増大する方 法、4. 高分子の添加剤と共に混合粉砕し非晶質とする 40 方法、5. 薬物活性成分を単独あるいは添加剤と共に粉 砕し微粒子化する方法、6.界面活性剤を製剤基剤に混 合する方法等があげられるが、1~4の方法は高含量化 が難しい等の問題がある。

【0004】5の微粒子化法においては、薬物活性成分 のみを微粒子化した製剤(特開平5-97670号公 報)や、糖あるいは糖アルコールと共に混合粉砕し超微 粒子化する方法(特開平3-66613号公報)が知ら れている。また、6の界面活性剤を製剤基剤に混合する ことにより薬物の製剤からの放出が促進される方法が知 50 物活性成分を微粒子化すればよい。微粒子の径は30μ

られている (ドラック デベロップメント アンド イ ンダストリアル ファーマシー, 16巻, 10号, 17 17頁, 1990年; 同, 12巻, 6号, 851頁, 1 986年)。

2

[0005]

【発明が解決しようとする課題】薬物微粒子の直径を小 さくするほどバイオアベイラビリティーが向上するが、 薬物活性成分単独では直径数 µ m程度にしか粉砕でき ず、それ以上の超微粒子を得るのは不可能である。糖あ

るいは糖アルコールとの混合粉砕ではサプミクロン程度 の粉砕が可能であるが、糖あるいは糖アルコールが医薬 品原末の5~10倍程度必要であり、小型で薬物活性成 分が高含量の製剤を得るのは難しい。また、界面活性剤 を製剤基剤に混合する方法は、薬物の製剤からの放出は 促進されるが打錠時にステイッキングが生じるため、製 剤方法として好ましくない。

【0006】本発明の目的は、打錠しやすく溶出性およ び生体への吸収性に優れた小型化された錠剤を提供する ことにある。

20 [0007]

> 【課題を解決するための手段】本発明は、微粒子化した 薬物活性成分および界面活性剤または有機酸塩からなる 核と部分アルファ化デンプンとを含有することを特徴と する医薬組成物に関する。本発明においては、微粒子化 した薬物活性成分を造粒して得た顆粒に界面活性剤また は有機酸塩を噴霧して核顆粒を形成させた後、部分アル ファ化デンプン等の基剤と混合して打錠するため、打錠 障害が生じることなく溶出性に優れた医薬組成物が提供 される。

- 【0008】本発明において薬物活性成分としては、錠 剤として使用されるものであればいずれでもよいが、錠 剤中の含有量が多い薬物活性成分に適用するのが好まし い。例えばパルプロ酸またはその塩、アセチルスピラマ イシン等のマクロライド系抗生物質、グリブソール等の スルホアミド系経口血糖降下剤、ケトフェニルプタゾン 等の非ステロイド性抗炎症剤、スルファメトピラジン等 のサルファ剤、レポドパ、酢酸メドロキシプロゲストロ ン、11-〔2-(5, 6-ジメチル-1-ペンゾイミ ダゾリル) エチリデン) -6, 11-ジヒドロジベンゾ
- [b, e] オキセピン-2-カルボン酸またはその塩 (特開平2-91041)等のトロンポキサンA2 拮抗 剤があげられる。これら化合物の塩としては、ナトリウ ム塩、カリウム塩等の金属塩があげられる。本医薬組成 物1錠中の薬物活性成分の含有量は通常1~80重量% 程度でよいが、好ましくは30~80重量%、より好ま しくは30~60重量%である。

【0009】薬物活性成分の微粒子化は、どのような方 法を用いてもよいが、ジェット粉砕法、ハンマーミル法 等により通常の高速攪拌粉砕機、衝撃粉砕機を用いて薬 m以下、好ましくは10μm以下である。

- -

.

【0010】本発明において用いられる界面活性剤は、 経口製剤で許容される界面活性剤ならいかなるものでも よいが、ポリソルペート80、ポリオキシエチレン硬化 ヒマシ油60、ショ糖脂肪酸エステル類、ラウリル硫酸 ナトリウム等があげられ、好ましくはラウリル硫酸ナト リウムがあげられる。本発明で用いられる界面活性剤の 添加量は、薬物活性成分に対して1~2重量%程度が好 ましい。添加量が1重量%未満では効果がなく、2重量 %を越えると硬度が低下し、摩損・かけの原因となる。 【0011】本発明において用いられる有機酸塩は、経 ロ製剤で許容される有機酸塩ならいずれでもよいが、好 ましくは、クエン酸三ナトリウム、コハク酸二ナトリウ ム、酢酸ナトリウム、酢酸カリウム、グルタミン酸ナト リウムなどがあげられ、好ましくはクエン酸三ナトリウ ムが用いられる。本発明で用いられる有機酸塩の添加量 は、薬物活性成分に対して0.5~4重量%、好ましく は2~4重量%である。添加量が0.5重量%未満では 効果が無く、4重量%を越えるとスティッキングなどの 打錠障害の原因となる。

3

【0012】本発明で用いられる部分アルファ化デンプ ンは、トウモロコシデンプンを水と共に加熱して、でん ぷん粒を破壊することなくアルファ化したものを急速に 乾燥したものであればいかなるものでもよく、市販のP CS(旭化成工業株式会社製)、スターチ1500(日 本カラコン株式会社製)等があげられる。部分アルファ 化デンプンは、薬物活性成分に対して通常1~40重量 %程度、好ましくは20~30重量%加える。

【0013】本発明の医薬組成物は通常錠剤である。

【0014】以下に、本発明の医薬組成物の製造方法を 30 説明する。薬物活性成分をジェット粉砕法、ハンマーミ ル法等により微粒子化した後、結合剤を加えて攪拌造粒 法あるいは流動層造粒法等の一般的な造粒法により核顆 粒を調製し、ついで界面活性剤を2.5~5.0W/V %溶解した水溶液あるいは1.25~10.0W/V% の有機酸塩を含有した水溶液を流動層造粒機により該顆 粒に噴霧した後、部分アルファ化デンプンおよび製剤上 常用される添加剤と混合し打錠、成型する(医薬品の開 発,第11巻製剤の単位操作と機械,1989年広川書 店刊)ことにより、本発明の医薬組成物が得られる。

【0015】結合剤としては、ヒドロキシプロピルセル ロース、ヒドロキシプロピルメチルセルロース、ポリピ ニルアルコール、プルランなどが挙げられる。結合剤の 添加量は薬物活性成分に対して1~3重量%、より好ま しくは2~3重量%である。

【0016】 製剤上常用される添加剤としては、通常用 いられる賦形剤、崩壊剤、滑沢剤等の中から主薬の安定 性をそこなわず、かつ錠剤特性に影響を与えないもので あればよく、例えば賦形剤としては乳糖、馬鈴薯デンプ ン、トウモロコシデンプン、結晶セルロース、白糖、マ 50 L という)〕3mgを用いて撹拌造粒法により造粒し核

ンニトール、炭酸カルシウム、リン酸カルシウム等があ げられる。崩壊剤としては、カルボキシメチルセルロー ス、カルボキシメチルセルロースカルシウム、低置換度 ヒドロキシプロピルセルロース、デンプングリコール酸 ナトリウム、ポリビニルポリプラスドン、クロスカルメ ロースナトリウム等があげられる。滑沢剤としては、ス テアリン酸、ステアリン酸マグネシウム、タルク、軽質 無水ケイ酸、コロイド状シリカ等があげられ、これらの 添加剤を単独あるいは組み合わせて用いてもよい。

4

10 【0017】 賦形剤の添加量は、薬物活性成分に対して 通常0~70%、好ましくは0~30%であり、崩壊剤 の添加量は、薬物活性成分に対して1~50重量%、好 ましくは25~30重量%である。滑沢剤の添加畳は、 薬物活性成分に対して0.5~3 重量%、好ましくは1 ~2重量%である。

【0018】本発明の錠剤には必要に応じて通常の剤皮 を施してフィルムコーティング錠や糖衣錠、腸溶性フィ ルムコーティング錠とすることができる。フィルムコー ティング剤皮の成分としては、水溶性高分子のヒドロキ

シプロピルメチルセルロース、ヒドロキシプロピルセル 20 ロース、胃溶性高分子のメタアクリル酸メチル・メタア クリル酸プチル・メタアクリル酸ジメチル・アミノエチ ル共重合体〔オイラギッド(以下、 Eudragit という) E100: ロームファーマ社製(以下、Rohm Pharma とい う))、ポリビニルアセタールジエチルアミノアセテー ト(AEA; 三共株式会社製) 、腸溶性髙分子のメタアクリ ル酸・アクリル酸エチル共重合体(Eudragit L100-55; R ohm Pharma)、メタアクリル酸・メタアクリル酸メチル 共重合体(Eudragit L100, S100; Rohm Pharma)、ヒドロ

キシプロピルメチルセルロースアセテートサクシネー ト、ヒドロキシプロプルメチルセルロースフタレート、 カルボキシメチルエチルセルロース、不溶性高分子とし てエチルセルロース、アクリル酸エチル・メタアクリル 酸メチル・メタアクリル酸塩化トリメチル・アンモニウ ムエチル共重合体(Eudragit RS; Rohm Pharma) 等があ げられる。糖衣成分としては、白糖、炭酸カルシウム、 ゼラチン等が挙げられる。

【0019】以下に実施例を挙げて本発明をさらに詳細 に説明する。なお、これらの実施例は本発明を限定する ものではない。

40

【実施例】

【0021】実施例1(組成物1)

ジェット粉砕法により微粒化したソジウム(E)-11 - 〔2-(5,6-ジメチル-1-ペンゾイミダゾリ ル) エチリデン) -6, 11-ジヒドロジベンゾ [b, e]オキセピン-2-カルポキシレートモノハイドレー ト(以下、化合物Aという)100mgをヒドロキシプ ロビルセルロース〔日本曹達株式会社製、(以下、IPC-

^[0020]

.

. .

2

顆粒を調製した。得られた核顆粒にラウリル硫酸ナトリ ウム〔日光ケミカルズ株式会社製(以下、SLS とい う) 〕溶液を流動層コーティング装置を用いて、SLS が 化合物Aに対し1重量%(以下、単に%で表す)になる ように噴霧した。ついで得られた該顆粒に部分アルファ 化デンプン〔旭化成工業株式会社製、(以下、PCS とい う))28.3mg、低置換度ヒドロキシプロピルセル ロース〔信越化学工業株式会社製、(以下、L-IPC とい う)) 27.0mg、ポリビニルポリプラスドンXL-10 〔GAFケミカル社製(以下、PVPP XL-10という)〕1 8.0mg、軽質無水ケイ酸〔フロイント産業製(以 下、アドソリダー101 という)) 0. 9mg、ステアリ ン酸マグネシウム〔堺化学株式会社製、(以下、Mg-St という)〕1.8mgを添加し、常法により打錠して組 成物1 (錠剤)を得た。なお得られた錠剤の直径は8m mであった。

5

【0022】実施例2(組成物2)

ジェット粉砕法により微粒化した化合物A100mgを ポリビニルアルコール (日本合成化学工業株式会社製 (以下、PVAという)) 3.0mgを用いて撹拌造粒法 20 により造粒し核顆粒を調製した。この核顆粒に化合物A に対しSLS 2%となるように流動層コーティング装置を 用いてSLS 溶液を噴霧した。ついでPCSを27.3m gにする以外は実施例1と同様の方法で添加剤を加え組 成物2(錠剤)を得た。

【0023】実施例3(組成物3)

SLS が化合物Aに対し1%となるように流動層コーティング装置を用いてSLS溶液を核顆粒に噴霧し、PCSを28.3mgにする以外は実施例2と同様の方法で組成物3(錠剤)を得た。

【0024】実施例4(組成物4)

実施例1と同様の方法で化合物AをIDC-L を用いて攪拌 造粒法で造粒し核顆粒を調製した後、得られた核顆粒に クエン酸三ナトリウムが化合物Aに対して4%となるよ うに流動層コーテイング装置を用いてクエン酸三ナトリ ウム溶液を噴霧し、PCSを25.3mgにする以外は 実施例1と同様の方法により錠剤を製造し組成物4(錠 剤)を得た。

【0025】実施例5(組成物5)

クエン酸三ナトリウムを化合物Aに対し2%となるよう に流動層コーティング装置を用いて噴霧し、PCSを2 7.3mgにする以外は実施例4と同様の方法により組 成物5(錠剤)を得た。

【0026】実施例6(組成物6)

クエン酸三ナトリウムを化合物Aに対し1%となるよう に流動層コーティング装置を用いて噴霧し、PCSを2 8.3mgにする以外は実施例4と同様の方法により組 成物6(錠剤)を得た。

【0027】実施例7(組成物7)

クエン酸三ナトリウムを化合物Aに対し0.5%となる 50

特開平8-325146

ように流動層コーティング装置を用いて噴霧し、PCS を28.8mgにする以外は実施例4と同様の方法によ り組成物7(錠剤)を得た。

б

【0028】実施例8(組成物8)

(4)

クエン酸三ナトリウムの代わりコハク酸ニナトリウムを 用いる以外は実施例4と同様の方法により組成物8(錠 剤)を得た。

【0029】実施例9(組成物9)

クエン酸三ナトリウムの代わり酢酸ナトリウムを用いる 10 以外は実施例4と同様の方法により組成物9(錠剤)を 得た。 【0030】実施例10(組成物10)

クエン酸三ナトリウムの代わり酢酸カリウムを用いる以 外は実施例4と同様の方法により組成物10の錠剤を得 た。

【0031】実施例11(組成物11)

クエン酸三ナトリウムの代わりグルタミン酸ナトリウム を用いる以外は実施例4と同様の方法により組成物11 (錠剤)を得た。

0 【0032】実施例12(組成物12)

実施例4で得た錠剤にあらかじめ調製したヒドロキシプ ロピルメチルセルロース、酸化チタン、マクロゴール60 00からなるコーティング液をハイコータHC-48(フロイン ト産業製)を用いてコーティングし、フィルムコーティ ング錠を得た。

【0033】実施例13(組成物13)

SLS が微粒化した化合物Aに対し4重量%となるように 流動層コーティング装置を用いてSLS 溶液を噴霧し、P CSを25.3mgにする以外は実施例3と同様の方法 30 にて組成物13(錠剤)を得た。

【0034】実施例14(組成物14) SLS が微粒化した化合物Aに対し0.5重量%となるように流動層コーティング装置を用いてSLS 溶液を噴霧 し、PCSを28.8mgにする以外は実施例3と同様 の方法にて組成物14(錠剤)を得た。 【0035】参考例1(組成物a) 微粒化した化合物A100mgをIPC-L 2mgを用いて 撹拌造粒法により造粒したのち直打用乳糖〔太陽化学社

製;タプレトース(以下、Tablettoseという))21. 3mg、HPC-L 36mg、PVPP XL-1018mg、アドソ

リダー101 0.9mg、Mg-St 1.8mgを添加し常法 により打錠して、部分アルファ化デンプンおよび界面活 性剤または有機酸の塩を添加せずに調合した組成物 a (錠剤)を得た。得られた錠剤の直径は8mmであっ た。

【0036】参考例2(組成物b) 微粒化した化合物A100mgをIPC-L 3mgを用いて 撹拌造粒法により造粒したのちPCS 29.3mg、IPC-L 27mg、PVPP XL-10 18mg、アドソリダー101 0.9mg、Mg-St 1.8mgを添加し常法により打

40

Par Pharm., Inc. Exhibit 1015 Page 072

特開平8-325146

7 錠して、界面活性剤または有機酸の塩を添加せずに調合 した組成物b(錠剤)を得た。

【0037】参考例3(組成物c)

ŝ

組成物bを実施例12と同じ方法で被服して組成物c (被覆剤)を得た。

【0038】参考例4(組成物d)

化合物Aおよび化合物Aに対し4%となるようにクエン 酸三ナトリウムを粉末のまま混合する以外は、実施例1 で用いられている添加剤を添加した後打錠し組成物d (錠剤) を得た。

【0039】実施例および参考例で得られた各製剤につ いて崩壊性、化合物Aの溶出性および吸収性について比 較した結果を以下に説明する。

【0040】試験例1

*実施例1で得られた組成物1、参考例1で得られた組成 物aおよび参考例2で得られた組成物bの崩壊試験およ び硬度の測定に関する比較試験を行った。また、組成物 1と組成物bに関しては溶出試験の比較試験を行った。 崩壊試験は日本薬局方第12改正一般試験法崩壊試験法に 従い試験液として精製水を用いた。硬度は、錠剤破壊強 度測定器(富山産業株式会社製)を用いて測定した。溶 出試験は日本薬局方第12改正一般試験法溶出試験法第2 法に準じ、パドル回転数を100回転とし、試験液として

8

10 精製水〔日本薬局方指定〕を用いた。 【0041】崩壊試験及び硬度測定の結果を第1表に、 溶出試験の結果を図1に示す。

[0042]

【表1】

第1表

試験項目乀組成物	組成物1	組成物 a	組成物b
硬度試験の測定硬度(Kgf)	6.3	8.5	8.2
崩壊試験の測定崩壊時間 (分)	11.0	14.6	18.4

【0043】第1表によれば、組成物1は組成物aおよ び組成物 b よりも早い崩壊時間を示した。また、図1に よれば組成物1は界面活性剤を加えない組成物 b よりも 高い溶出効果を示した。

【0044】試験例2

※13、14で得られた組成物13、14に関して崩壊試 験および硬度の測定を試験例1に準じて行った。

【0045】崩壊試験及び硬度測定の結果を第2表に示 す。

実施例2、3で各々得られた組成物2、3および実施例※ 第2表

試験項目乀組成物	組成物2	組成物3	組成物13	組成物14
硬度試験の 測定硬度(Kgf)	4.5	5.5	2.9	6.2
崩壊試験の 測定崩壊時間 (分)	10.9	13.5	7.2	16.2

【0047】試験例3

【0048】崩壊試験及び硬度測定の結果を第3表に、

実施例4~11で各々得られた組成物4~11および参 考例2で得られた有機酸塩を加えない組成物 b に関して 崩壊試験、硬度の測定および溶出試験の比較を試験例1 40 に準じて行った。

溶出試験の結果を図2および図3に示す。

[0049]【表3】

^[0046] 【表2】

ę.,

10

第3表

	試験項目	
組成物	硬度試験の 測定硬度 (Kgf)	崩壊試験の測定 崩壊時間(分) 精製水
4	6.8	3.0
5	7.3	5.7
6	7.2	5.6
7	6. l	9.8
8	7.4	6.0
9	7.3	4.6
10	6.9	7.9
1 1	7.1	6.9
b	7.1	17.3

【0050】第3表によれば各実施例組成物の水におけ る崩壊時間は、組成物りよりも短かった。また図2およ び図3によれば各実施例組成物の溶出率はいずれも組成 物りよりも高かった。

9

*づつ水20mlと共に投与した。経時的に採血し、血漿中 の化合物Aの濃度をIFLC法により測定した。 【0052】化合物Aの血漿中濃度推移を図4に薬動力 学的パラメータ(血漿中濃度下面積、最高血漿中濃度) を第4表に示した。

【0051】試験例4

•

. .

.

実施例12で得られた組成物12と参考例3で得られた 組成物cについてビーグル犬を用いて化合物Aの吸収性 を比較した。ビーグル犬を1群5頭とし、各製剤を1錠*30

【表4】

[0053]

第	4	表
---	---	---

	血漿中濃度下面積 (ng×h/ml)	最高血漿中濃度 (ng/ml)
組成物12	771.7	476.8
組成物 c	325.1	173.4

【0054】図4によれば、クエン酸ナトリウムを添加 した組成物12は、組成物cよりも体内の吸収が良く、 血液中の貯留時間も長かった。また、第4表によれば、 組成物12は血漿中濃度下面積(AUC0-8h)および最 高血漿中濃度(Cmax)も高かった。

【0055】試験例5

実施例12で得られた組成物12と参考例3で得られた 組成物cについて、試験例1に示した方法により溶出試 験をおこなった。結果を図5に示す。図5によれば、組 成物12のほうが溶出効果が高いことが示された。

40 【0056】試験例6

実施例4で得られた組成物4と参考例4で得られた組成 物dについて、試験例1と同様の条件で崩壊試験および 硬度測定を行った。結果を第5表に示す。

[0057]

÷

2

12

組成物8~11と組成物bの溶出試験での比

【図4】 組成物12と組成物 c の化合物 A の血漿中濃

・・・・・組成物b

→●●● ・・・・・組成物8

-×— ・・・・・組成物 9

--■-- ・・・・・組成物11

第5表

試験項目乀組成物	組成物4	組成物 d
硬度(Kgf)	6.8	7.8
崩壞時間(分)	3.0	8.2

較

【図3】

【符号の説明】

度変化の比較

【0058】第5表によれば、組成物4および組成物d の硬度に差は無いものの、組成物4では崩壊時間が大幅 に増加していた。さらに、組成物4および組成物dの打 錠性を比較したところ、組成物dは打錠性が悪く打錠時 10 にステイッキングを認めた。

11

[0059]

【発明の効果】本発明により、高含量の薬物を含有する にもかかわらず、打錠しやすく、溶出性および生体への 吸収性に優れた小型化された製剤を得ることができる。 【図面の簡単な説明】

【図1】 組成物1と組成物bの溶出試験での比較 【符号の説明】

→●→ ・・・・・・組成物1

—〇— ・・・・・組成物b

【図2】 組成物4~7と組成物bの溶出試験での比較 【符号の説明】


ー×ー ・・・・・組成物4 ●- ・・・・・組成物 5 -□- ・・・・・組成物6

--■---・・・・・・組成物7


【符号の説明】 →●→ ・・・・・組成物12 20 — · · · · · · · 組成物c 【図5】 組成物12と組成物cの化合物Aの溶出試験

での比較 【符号の説明】

● ・・・・・組成物12 -〇-- ・・・・・組成物 c



[図2]





é


(8)











フロントページの続き

(51) Int. Cl. 6	識別記号	庁内整理番号	FΙ		技術表示箇所
A61K 47/12			A 6 1 K	47/12	E
47/16				47/16	E
47/36				47/36	В

PATENT COOPERATION TREATY

To:

知韵財産

From the INTERNATIONAL BUREAU

PCT

FIRST NOTICE INFORMING THE APPLICANT OF
THE COMMUNICATION OF THE INTERNATIONAL
APPLICATION (TO DESIGNATED OFFICES WHICH
DO NOT APPLY THE 30 MONTH TIME LIMIT
UNDER ARTICLE 22(1))

(PCT Rule 47.1(c))

ISOBE, Yutaka Intellectual Property (Kasugade), Dainippon Sumitomo Pharma Co., Ltd. 1-98, Kasugadenaka 3-chome Konohana-ku, Osaka-shi, Osaka 5540022 JAPON 19, 1, 11

Date of mailing (day/month/year)

28 December 2006 (28.12.20	106)		
Applicant's or agent's file reference 2006012WO1	見み物 いしょうん		IMPORTANT NOTICE
International application No. PCT/JP2006/310571	International filing da 26 May 200	te (day/month/year) 6 (26.05.2006)	Priority date (<i>day/month/year</i>) 26 May 2005 (26.05.2005)
Applicant	Dainippon Sumitomo	Pharma Co., Ltd. et a	al

- ATTENTION: For any designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002 (30 months from 1. the priority date), does apply, please see Form PCT/IB/308(Second and Supplementary Notice) (to be issued promptly after the expiration of 28 months from the priority date).
- 2. Notice is hereby given that the following designated Office(s), for which the time limit under Article 22(1), as in force from 1 April 2002, does not apply, has/have requested that the communication of the international application, as provided for in Article 20, be effected under Rule 93bis.1. The International Bureau has effected that communication on the date indicated below: 30 November 2006 (30.11.2006)

CH

ſ

In accordance with Rule 47.1(c-bis)(i), those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

3. The following designated Offices, for which the time limit under Article 22(1), as in force from 1 April 2002, does not apply, have not requested, as at the time of mailing of the present notice, that the communication of the international application be effected under Rule 93bis.1 :

LU, SE, TZ, UG, ZM

In accordance with Rule 47.1(c-bis)(ii), those Offices accept the present notice as conclusive evidence that the Contracting State for which that Office acts as a designated Office does not require the furnishing, under Article 22, by the applicant of a copy of the international application.

4. TIME LIMITS for entry into the national phase

For the designated Office(s) listed above, and unless a demand for international preliminary examination has been filed before the expiration of 19 months from the priority date (see Article 39(1)), the applicable time limit for entering the national phase will, subject to what is said in the following paragraph, be 20 MONTHS from the priority date.

In practice, time limits other than the 20-month time limit will continue to apply, for various periods of time, in respect of certain of the designated Offices listed above. For regular updates on the applicable time limits (20 or 21 months, or other time limit), Office by Office, refer to the PCT Gazette, the PCT Newsletter and the PCT Applicant's Guide, Volume II, National Chapters, all available from WIPO's Internet site, at http://www.wipo.int/pct/en/index.html.

It is the applicant's sole responsibility to monitor all these time limits.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

e-mail: pt08@wipo.int

Masashi Honda

Facsimile No. +41 22 338 82 70

Form PCT/IB/308(First Notice) (January 2004)

0669490362-=AOYAMA

PATENT COOPERATION TREATY

WO 2006/126681 PCT/JP2006/310571

From the INTERNATIONAL BUREAU

PCT		To:		
SECOND AND SUPPLEMENTARY INFORMING THE APPLICANT C COMMUNICATION OF THE INTERN APPLICATION (TO DESIGNATED WHICH APPLY THE 30 MONTH LIMIT UNDER ARTICLE 22(OF THE IATIONAL OFFICES TIME	ISOBE, Yutaka Intellectual Property (Co., Ltd. 1-98, Kasugadenaka Konohana-ku, Osaka 5540022 JAPON	-shi, Osaka	
(PCT Rule 47.1(c))			1 9.10 5	
Date of mailing (day/montil/year) 27 September 2007 (27.09.2007)			知的財產額	
Applicant's or agent's file reference 2006012WO1 原系ポルズどの	しいとうた	N	APORTANT NOTICE	
International application No. 1 PCT/JP2006/310571	nternational filing dat 26 May 2000	e (day/montlvyear) 6 (26.05.2006)	Priority date (day/month/year) 26 May 2005 (26.05.2005)	
Applicant Da	inippon Sumitomo	Pharma Co., Ltd. et al		
1. ATTENTION: For any designated Office(s), the priority date), does not apply, please see F				
 Notice is hereby given that the following desi does apply, has/have requested that the com- Rule 93bis.1. The International Bureau has eff 30 November 2006 (30.11.2006) 	munication of the int	emational application, as p	rovided for in Article 20, be effected under	
AU, AZ, BY, CN, CO, DZ, EP, HU, KO	G, KP, K <mark>R,</mark> MD, MK	, MZ, NA, NG, PG, RU, S	SY, TM, US	
In accordance with Rule 47.1(c-bis)(i), those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).				
3. The following designated Offices, for which the time limit under Article 22(1), as in force from 1 April 2002, does apply, have not requested, as at the time of mailing of the present notice, that the communication of the international application be effected under Rule 93bis.1:				
AE, AG, AL, AM, AP, AT, BA, BB, BG, BR, BW, BZ, CA, CR, CU, CZ, DE, DK, DM, EA, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KM, KN, KZ, LC, LK, LR, LS, LT, LV, LY, MA, MG, MN, MW, MX, NI, NO, NZ, OA, OM, PH, PL, PT, RO, SC, SD, SG, SK, SL, SM, TJ, TN, TR, TT, UA, UZ, VC, VN, YU, ZA, ZM, ZW				
accordance with Rule 47.1(c-bis)(ii), those Offices accept the present notice as conclusive evidence that the Contracting State for which that Office acts as a designated Office does not require the furnishing, under Article 22, by the applicant of a copy of the international application.				
4. TIME LIMITS for entry into the national p	ohase			
For the designated or elected Office(s) listed above, the applicable time limit for entering the national phase will, subject to what is said in the following paragraph, be 30 MONTHS from the priority date.			ational phase will, subject to what is said in	
In practice, time limits other than the 30-month time limit will continue to apply, for various periods of time, in respect of certain of the designated or elected Office(s) listed above. For regular updates on the applicable time limits (30 or 31 months, or other time limit), Office by Office, refer to the PCT Gazette, the PCT Newsletter and the PCT Applicant's Guide, Volume II. National Chapters, all available from WIPO's Internet site, at http://www.wipo.int/pct/cn/index.html.				
It is the applicant's sole responsibility to monitor all these time limits.				
		Authorized officer		
The International Bureau of WI 34, chemin des Colombettes			Masashi Honda	
1211 Geneva 20, Switzerland			IVIASASHI NUHUA	
Facsimile No. +41 22 338 82 70		e-mail: pt08.pct@wipo.	int	

,

Form PCT/IB/308(Second and Supplementary Notice) (January 2004)

PATENT COOPERATION TREATY

РСТ	From the INTERNATIONAL BUREAU
РСТ	To:
NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT	ISOBE, Yutaka Intellectual Property (Kasugade), Dainippon Sumitomo Pharma Co., Ltd. 1-98, Kasugadenaka 3-chome Konohana-ku, Osaka-shi, Osaka
(PCT Administrative Instructions, Section 411)	5540022 JAPON 18.8.28 知的財産部
16 August 2006 (16.08.2006)	
Applicant's or agent's file reference 2006012WO1 原業品報日成的 ルレナナム	IMPORTANT NOTIFICATION
International application No. PCT/JP2006/310571	International filing date (day/month/year) 26 May 2006 (26.05.2006)
Not yet published	Priority date (<i>day/month/year</i>) 26 May 2005 (26.05.2005)
Applicant Dainippon Sumitomo Ph	arma Co., Ltd. et al
 all earlier application(s) whose priority is claimed. Unless otherwi asterisk appearing next to a date of receipt, the priority document in compliance with Rule 17.1(a) or (b). 2. (If applicable) The letters "NR" appearing in the right-hand columnation of the priority document must be submitted by the International B priority document must be submitted by the applicant to the received by the priority document within the applicable time limit un 17.1(c) which provides that no designated Office may disregat opportunity, upon entry into the national phase, to furnish the priority after the time limit prescribed in Rule 17.1(a) or the request to receiving Office after the applicable time limit under Rule 17.1(a) or (b), the International Bureau wy Offices, for their consideration. In case such a copy is not accept 	Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the eiving Office or the International Bureau, but the applicant fails to ider that Rule, the attention of the applicant is directed to Rule ard the priority claim concerned before giving the applicant an riority document within a time limit which is reasonable under the and the right-hand column, denotes a priority document submitted ance with Rule 17.1(a) or (b) (the priority document was received by prepare and transmit the priority document was not furnished in ill nevertheless transmit a copy of the document to the designated ted by the designated Office as the priority document, Rule 17.1(c)
into the national phase, to furnish the priority document within a t <u>Priority date</u> <u>Priority application No.</u>	Country or regional Office Date of receipt
26 May 2005 (26.05.2005) 2005-153508	or PCT receiving Office of priority document JP 06 July 2006 (06.07.2006)
34, chemin des Colombettes	Authorized officer Macashi Honda
34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Masashi Honda Facsimile No. +41 22 338 70 10 Telephone No. +41 22 338 82 54

特許協力条約

.

.

.

1

1

2

Writhen Opinion

発信人 日本国特許庁(国際調査機関)		
代理人		
五十部 穣	受信	
様	(文信)	λ.
	18.8.18	
あて名	知的財産部人	
〒554-0022		国際調査機関の見解 (法施行規則第40条の2)
日本国大阪府大阪市此花区春日出中3丁目1番98 号 大日本住友製薬株式会社 知的財産部(春日出)		[PCT規則43の2.1]
		
	発送日	
	(日.月.年)	15.08.2006
出願人又は代理人 の 類記号 2006012₩01	今後の手続	きについては、下記2を参照すること。
国際出願番号		優先日
	5. 2006	(日.月.年) 26.05.2005
国際特許分類 (IPC) Int.Cl. A61K31/496 (2006.01), A6 (2006.01), A61K47/38 (20)	1 K9/20 (2006.01) 06.01), <i>C07D417/</i>	, A61K47/10 (2006.01), A61K47/26 12 (2006.01)
出願人(氏名又は名称)		
大日本住友製薬株式会社		
<u> </u>		
 この見解書は次の内容を含む。 		
■ 第1欄 見解の基礎		
□ 第Ⅱ欄 優先権		
□ 第Ⅲ欄 新規性、進歩性又は産業上の利用可	能性についての見解	の不作成
□ 第Ⅳ欄 発明の単一性の欠如	•	
☑ 第V欄 PCT規則 43 の 2.1(a)(i)に規定	トる新規性、進歩性	又は産業上の利用可能性についての見解、
	トる新規性、進歩性	又は産業上の利用可能性についての見解、
☑ 第V欄 PCT規則 43 の 2.1(a)(i)に規定	トる新規性、進歩性	又は産業上の利用可能性についての見解、
 第V欄 PCT規則 43 の 2.1(a)(i)に規定 それを裏付けるための文献及び説明 	↑る新規性、進歩性	又は産業上の利用可能性についての見解、
 第V欄 PCT規則 43 の 2.1(a)(i)に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 	↑る新規性、進歩性	又は産業上の利用可能性についての見解、
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出願の不備 第VI欄 国際出願に対する意見 	↑る新規性、進歩性	又は産業上の利用可能性についての見解、
 ▶ 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 ● 第VI欄 ある種の引用文献 ● 第VI欄 国際出願の不備 ● 第VI欄 国際出願に対する意見 2. 今後の手続き 		
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出願の不備 第VI欄 国際出願に対する意見 	调査機関とは異なる	国際予備審査機関を選択し、かつ、その国
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出願の不備 第VI欄 国際出願に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 	週査機関とは異なる \て国際調査機関の	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出顧の不備 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出顧人がこの国際 際予備審査機関が PCT規則 66.1 の 2(b) の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この 	周査機関とは異なる いて国際調査機関の 見解書は国際予備署	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出顧の不備 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関が PCT規則 66.1 の 2(b) の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とお 	周査機関とは異なる 、て国際調査機関の 見解書は国際予備報 、なされる場合、様表	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出顧の不備 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出顧人がこの国際 際予備審査機関が PCT規則 66.1 の 2(b) の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この 	周査機関とは異なる 、て国際調査機関の 見解書は国際予備署 、なされる場合、様式 る期限が経過するま	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出顧の不備 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出顧人がこの国際 際予備審査機関がPCT規則 66.1 の 2(b)の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ ら3月又は優先日から22月のうちいずれか遅く満了す 	周査機関とは異なる 、て国際調査機関の 見解書は国際予備署 、なされる場合、様式 る期限が経過するま	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出顧の不備 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出顧人がこの国際 際予備審査機関がPCT規則 66.1 の 2(b)の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ ら3月又は優先日から22月のうちいずれか遅く満了す 	周査機関とは異なる 、て国際調査機関の ・見解書は国際予備署 、なされる場合、様式 る期限が経過するま ・	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 ▶ 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 ■ 第VI欄 ある種の引用文献 ■ 第VI欄 国際出顧の不備 ■ 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関がPCT規則 66.1 の 2(b) の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ ら3月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる さらなる選択肢は、様式PCT/ISA/220を参照す 	周査機関とは異なる 、て国際調査機関の ・見解書は国際予備署 ・なされる場合、様式 る期限が経過するま ・ ること。	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出顧の不備 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関が PCT規則 66.1 の 2(b) の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ ら3月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる 	周査機関とは異なる 、て国際調査機関の ・見解書は国際予備署 ・なされる場合、様式 る期限が経過するま ・ ること。	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 ▶ 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 ■ 第VI欄 ある種の引用文献 ■ 第VI欄 国際出顧の不備 ■ 第VI欄 国際出顧に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関がPCT規則 66.1 の 2(b) の規定に基づい さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ ら3月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる さらなる選択肢は、様式PCT/ISA/220を参照す 	周査機関とは異なる 、て国際調査機関の ・見解書は国際予備署 ・なされる場合、様式 る期限が経過するま ・ ること。	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 ✓ 第V欄 PCT規則 43 の 2.1 (a) (i) に規定 それを裏付けるための文献及び説明 「第VI欄 ある種の引用文献 「第VI欄 国際出願の不備 「第VI欄 国際出願の不備 「第VI欄 国際出願に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関が PCT規則 66.1 の 2(b)の規定に基づし さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書と ら3月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる さらなる選択肢は、様式PCT/ISA/220を参照す 3. さらなる詳細は、様式PCT/ISA/220の備考を参 見解書を作成した日 	周査機関とは異なる 、て国際調査機関の ・見解書は国際予備署 ・なされる場合、様式 る期限が経過するま ・ ること。	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 ● 第V欄 PCT規則 43 の 2.1 (a) (i) に規定で それを裏付けるための文献及び説明 ● 第VI欄 ある種の引用文献 ● 第VI欄 国際出願の不備 ● 第VI欄 国際出願の不備 ● 第VI欄 国際出願に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関がPCT規則 66.1 の 2(b)の規定に基づし さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ ら3月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる さらなる選択肢は、様式PCT/ISA/220を参照す 3. さらなる詳細は、様式PCT/ISA/220の備考を参 ○ 	周査機関とは異なる 、て国際調査機関の ・見解書は国際予備署 ・なされる場合、様式 る期限が経過するま ・ ること。	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か
 ✓ 第V欄 PCT規則 43 の 2.1(a)(i)に規定で それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出願の不備 第VI欄 国際出願に対する意見 2. 今後の手続き 国際予備審査他関がPCT規則 66.1 の 2(b)の規定に基づし さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ 63月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる さらなる選択肢は、様式PCT/ISA/220を参照す 3. さらなる詳細は、様式PCT/ISA/220の備考を表 見解書を作成した日 07.08.2006 	周査機関とは異なる へて国際調査機関の 2見解書は国際予備署 なされる場合、様式 る期限が経過するま 。 ること。 :照すること。	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か でに、出願人は国際予備審査機関に、適当
 ✓ 第V欄 PCT規則 43 の 2.1(a)(i)に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出願の不備 第VI欄 国際出願に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関がPCT規則 66.1 の 2(b)の規定に基づし さない旨を国際事務局に通知していた場合を除いて、この この見解費が上記のように国際予備審査機関の見解費と2 ら3月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる さらなる選択肢は、様式PCT/ISA/220を参照す さらなる詳細は、様式PCT/ISA/220の備考を参 見解書を作成した日 	 周査機関とは異なる、 マ国際調査機関の 見解書は国際予備報 なされる場合、様式る期限が経過するま。 ること。 照すること。 特許庁審査官(権) 	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か でに、出願人は国際予備審査機関に、適当 限のある職員) 4C 3755
 ✓ 第V欄 PCT規則 43 の 2.1(a)(i)に規定 それを裏付けるための文献及び説明 第VI欄 ある種の引用文献 第VI欄 国際出願の不備 第VI欄 国際出願に対する意見 2. 今後の手続き 国際予備審査の請求がされた場合は、出願人がこの国際 際予備審査機関が PCT規則 66.1 の 2(b)の規定に基づし さない旨を国際事務局に通知していた場合を除いて、この この見解書が上記のように国際予備審査機関の見解書とみ ら3月又は優先日から22月のうちいずれか遅く満了す な場合は補正書とともに、答弁書を提出することができる さらなる選択肢は、様式PCT/ISA/220を参照す 3. さらなる詳細は、様式PCT/ISA/220の備考を参 見解書を作成した日 07.08.2006 	周査機関とは異なる 、て国際調査機関の ・見解書は国際予備署 なされる場合、様式 る期限が経過するま ・ ること。 照すること。 特許庁審査官(権 八原 由美	国際予備審査機関を選択し、かつ、その国 見解書を国際予備審査機関の見解書とみな 審査機関の最初の見解書とみなされる。 式PCT/ISA/220を送付した日か でに、出願人は国際予備審査機関に、適当 限のある職員) 4C 3755

様式PCT/ISA/237(表紙)(2005年4月)

	際調査機	と関の見解書	国際出願番号 PCT/JP200	06/310571
第1欄 見解の基礎				
 ☑ 出願時の言語 □ 出願時の言語 (PCT規則) 	による国 から国際 12.3(a)]	調査のための言語である &び23.1(b))	語に翻訳された、この国際	
2. この国際田願で開 以下に基づき見角			可欠なヌクレオチド又はアミノ酸配列に関し	
a.タイプ		配列表	•	
		配列表に関連するテーブル		
b. フォーマット	Г	紙形式	· · ·	
		電子形式		
c.提出時期		出願時の国際出願に含まれて	いたもの	
		この国際出願と共に電子形式	により提出されたもの	
		出願後に、調査のために、こ	の国際調査機関に提出されたもの	
た配列が出解	時に提出	した配列と同一である旨、又	出した場合に、出願後に提出した配列若し。 は、出願時の開示を超える事項を含まない	
た配列が出願 あった。 4.補足意見:	時に提出	3した配列と同一である旨、又	は、出願時の開示を超える事項を含まない	
あった。	時に提出	3した配列と同一である旨、又		
あった。	師時に提出	1した配列と同一である旨、又		
あった。	師時に提出	出した配列と同一である旨、又		
あった。	師時に提出	1した配列と同一である旨、又		
あった。	師時に提出	1した配列と同一である旨、又		
あった。	師時に提出	1した配列と同一である旨、又	は、出願時の開示を超える事項を含まない	
あった。	(時に提出	1した配列と同一である旨、又	は、出願時の開示を超える事項を含まない	≦の陳述 費の提出が
あった。	(時に提出	1した配列と同一である旨、又	は、出願時の開示を超える事項を含まない	≦の陳述 費の提出が

様式PCT/ISA/237(第I欄)(2005年4月)

.

,

1. EN 新規性(N) 請求の範囲 請求の範囲 1-24 「請求の範囲 1001 「請求の範囲 2002.02.03.28 文献1には、水難溶性の有効成分の言葉の、 2004.09.16 ○	それを裏付る文献及び説明	-				
請求の範囲 1-24 22. 文献及び説明 国際調査報告 見解は、国際調査報告で引用された以下の各文献の記載に基づいて示された。 文献 1: W0 2002/024166 A1 (住友製薬株式会社) 2002.03.28 文献 2: W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲 1~24 に対して 文献 1: には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 職され、A) 10~40mg のルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている (実施例参照)。 文献 2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80 重量%、部分アルファ化デンプンを1~30 重力 乳糖を20~95 重量%およびとドロキシプロビルセルロースを0.1~5 重量%含有 ことを特徴とする錠剤が記載され、a) 40mg の化合物(I-1)、b) 83mg の乳糖、c) 30 のとドロキシブロビルセルロース、d) 22.5mg の部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優加た溶出性を示す が開示されている (請求項3、実施例7、及び、図1参照)。	見解					
進歩性(IS) 請求の範囲 1-24	新規性(N)		1-24			
請求の範囲 産業上の利用可能性(IA) 請求の範囲 請求の範囲 1-24 請求の範囲 1-24 22. 文献及び説明 国際調査報告 見解は、国際調査報告で引用された以下の各文献の記載に基づいて示された。 文献1:W0 2002/024166 A1 (住友製薬株式会社) 2002.03.28 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲 1~2 4 に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mg のルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重引< 乳糖を20~95重量%およびヒドロキシプロビルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mg の化合物(I-1)、b) 83mg の乳糖、c) 3 のヒドロキシプロビルセルロース、d) 22.5mg の部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。		間水の範囲				
 産業上の利用可能性(IA) 舗求の範囲 	進歩性(IS)					
 請求の範囲 2. 文献及び既明 国際調査報告 見解は、国際調査報告で引用された以下の各文献の記載に基づいて示された。 文献1:W0 2002/024166 A1 (住友製薬株式会社) 2002.03.28 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mg のルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80 重量%、部分アルファ化デンプンを1~30 重封 乳糖を20~95 重量%およびヒドロキシプロピルセルロースを0.1~5 重量%含有 ことを特徴とする錠剤が記載され、a) 40mg の化合物(I-1)、b) 83mg の乳糖、c) 3: のヒドロキシプロピルセルロース、d) 22.5mg の部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。 		6月3767 申记[21]				
 2. x献及び既明 国際調査報告 見解は、国際調査報告で引用された以下の各文献の記載に基づいて示された。 文献1:W0 2002/024166 A1 (住友製薬株式会社) 2002.03.28 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 ○請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mgのルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重封 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mgの化合物(I-1)、b) 83mgの乳糖、c) 3の にドロキシプロピルセルロース、d) 22.5mgの部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。 	産業上の利用可能性(IA)		1-24			
国際調査報告 見解は、国際調査報告で引用された以下の各文献の記載に基づいて示された。 文献1:W0 2002/024166 A1 (住友製薬株式会社) 2002.03.28 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mgのルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重封 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mgの化合物(I-1)、b) 83mgの乳糖、c) 3 のヒドロキシプロピルセルロース、d) 22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。			·· <u> </u>	· · · · · · · · · · · · · · · · · · ·		
 見解は、国際調査報告で引用された以下の各文献の記載に基づいて示された。 文献1:W0 2002/024166 A1 (住友製薬株式会社) 2002.03.28 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mg のルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重封 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mg の化合物(I-1)、b) 83mg の乳糖、c) 3 のヒドロキシプロピルセルロース、d) 22.5mg の部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。 	?. 文献及び説明					
 文献1:W0 2002/024166 A1 (住友製薬株式会社) 2002.03.28 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mgのルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mgの化合物(I-1)、b) 83mgの乳糖、c) 3 のヒドロキシプロピルセルロース、d) 22.5mgの部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。 					». <u> </u>	
 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mgのルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重す 乳糖を20~95重量%およびとドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mgの化合物(I-1)、b) 83mgの乳糖、c) 3 のヒドロキシプロピルセルロース、d) 22.5mgの部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。 	見解は、国際調査報告	で引用され	こ以下の各文献	の記載に基	づいて示され	いた。
 文献2:W0 2004/078173 A1 (塩野義製薬株式会社) 2004.09.16 〇請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mgのルラシドン、B) マンニトール又は乳糖、及び、C) 水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重す 乳糖を20~95重量%およびとドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mgの化合物(I-1)、b) 83mgの乳糖、c) 3 のヒドロキシプロピルセルロース、d) 22.5mgの部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。 	文献1・₩0 2002/02414	56 A1 (住友	製薬株式会社)	2002 03 28	۲	
 ○請求の範囲1~24に対して 文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A)10~40mgのルラシドン、B)マンニトール又は乳糖、及び、C)水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重す 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c)3 のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。 	~m(1 . #0 2002/02410					
文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A)10~40mgのルラシドン、B)マンニトール又は乳糖、及び、C)水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c)3 のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	文献 2・WO 2004/07813	73 A1 (恆野	盖匙亚株式会社			
文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A)10~40mgのルラシドン、B)マンニトール又は乳糖、及び、C)水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c)3 のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	文献 2:WO 2004/07817	73 A1(塩野	義製薬株式会社	.) 2004.09.	10	
文献1には、水難溶性の有効成分の含量を増大した場合に低含量の製剤の複数 同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A)10~40mgのルラシドン、B)マンニトール又は乳糖、及び、C)水溶 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c)3 のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	文献 2:WO 2004/0781	73 A1(塩野	義製薬株式会社	.) 2004.09.	10	
同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度に放出し得る経口製剤 載され、A) 10~40mgのルラシドン、B) マンニトール又は乳糖、及び、C) 水落 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mgの化合物(I-1)、b) 83mgの乳糖、c) 5 のヒドロキシプロピルセルロース、d) 22.5mgの部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。			義製薬株式会社	.) 2004.09.	10	
載され、A) 10~40mg のルラシドン、B) マンニトール又は乳糖、及び、C) 水落 分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a) 40mg の化合物(I-1)、b) 83mg の乳糖、c) 3 のヒドロキシプロピルセルロース、d) 22.5mg の部分アルファ化デンプン、及び 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	○請求の範囲1~24	に対して		:		の複数
分子結合剤を含有する経口製剤が開示されている(実施例参照)。 文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c) のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	○請求の範囲1~24 文献1には、水難溶性	に対して 生の有効成分	の含量を増大し	た場合に低	気全量の製剤	
文献2には、錠剤全量に対し、式(I)で示される化合物もしくは製薬上許容さ 塩またはそれらの溶媒和物を3~80重量%、部分アルファ化デンプンを1~30重 乳糖を20~95重量%およびヒドロキシプロピルセルロースを0.1~5重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c) のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 	に対して 生の有効成分 、水難溶性の	の含量を増大し 有効成分を所望	った場合に低 望の濃度に方	5含量の製剤 女出し得る経	口製斉
塩またはそれらの溶媒和物を3~80 重量%、部分アルファ化デンプンを1~30 重 乳糖を20~95 重量%およびヒドロキシプロピルセルロースを0.1~5 重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c) のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mg 0 	に対して 生の有効成分 、水難溶性の のルラシドン	の含量を増大し 有効成分を所望 、B) マンニト	った場合に低 望の濃度にあ ール又は乳	5含量の製剤 女出し得る経 糖、及び、0	口製剤
塩またはそれらの溶媒和物を3~80 重量%、部分アルファ化デンプンを1~30 重1 乳糖を20~95 重量%およびヒドロキシプロピルセルロースを0.1~5 重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c)3 のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mg 0 	に対して 生の有効成分 、水難溶性の のルラシドン	の含量を増大し 有効成分を所望 、B) マンニト	った場合に低 望の濃度にあ ール又は乳	5含量の製剤 女出し得る経 糖、及び、0	口製剤
乳糖を20~95 重量%およびヒドロキシプロピルセルロースを0.1~5 重量%含有 ことを特徴とする錠剤が記載され、a)40mgの化合物(I-1)、b)83mgの乳糖、c): のヒドロキシプロピルセルロース、d)22.5mgの部分アルファ化デンプン、及び 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mg の 分子結合剤を含有する 	に対して 生の有効成分 、水難溶性の のルラシドン 経口製剤が	の含量を増大し 有効成分を所望 、B)マンニト 開示されている	ンた場合に低 望の濃度に方 ール又は乳 (実施例参	5含量の製剤 女出し得る経 糖、及び、C 照)。	口製剤
ことを特徴とする錠剤が記載され、a) 40mg の化合物(I-1)、b) 83mg の乳糖、c) 3 のヒドロキシプロピルセルロース、d) 22.5mg の部分アルファ化デンプン、及ひ 1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mg の 分子結合剤を含有する 文献2には、錠剤全 	に対して 生の有効成分 、水難溶性の のルラシドン 経口製剤が 量に対し、	の含量を増大し 有効成分を所望 、B)マンニト 開示されている 式(I)で示される	レた場合に低 望の濃度にあ ール又は乳 (実施例参 5化合物もし	5 全量の製剤 女出し得る経 糖、及び、C 照)。 	ロ製剤) 水溶 許容さ
のヒドロキシプロピルセルロース、d) 22.5mgの部分アルファ化デンプン、及ひ 1.5mgのステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mgの 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 	に対して 生の有効成分 、水難溶性の りルラシドン 経口製剤が 量に対し、 和物を3~8	の含量を増大し 有効成分を所留 (、B) マンニト 開示されている 気(I)で示される)重量%、部分ア	ンた場合に低 望の濃度に カール又は乳 (実施例参 ら化合物もし ルファ化デ	気含量の製剤 対出し得る経 糖、及び、C 照)。 、くは製薬上 ジンプンを 1~	ロ製剤)水溶 許容さ ~30重1
1.5mg のステアリン酸マグネシウムを含有する経口製剤が優れた溶出性を示す が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mg の 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95重量%素 	に対して 生の有効成分 、水難溶性の のルラシドン 経口製剤が 量に対し、 和物を3~8 らよびヒドロ	の含量を増大し 有効成分を所望 、B) マンニト 開示されている (I)で示される)重量%、部分ア キシプロピルセ	した場合に低 望の濃度にあ ール又施例参 の化合物もし ルファースを	5 全量の製剤 女出し得る経 糖、及び、C 照)。 、くは製薬上 、ンプンを1~ ・0.1~5重量	ロ製剤)水溶 許容さ ~30重 、%含有
が開示されている(請求項3、実施例7、及び、図1参照)。	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mgの 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95重量%ま ことを特徴とする錠剤 	に対して 生の有効成分 、水難溶性の のルラシドン 経口製剤が 量に対し、 和物を3~8 ふよびヒドロ が記載され	の含量を増大し 有効成分を所望 (、B) マンニト 開示されている 式(I)で示される)重量%、部分ア キシプロピルセ a) 40mg の化合	レた場合に低 望の濃度に カール又は乳 (実施例参 ひとつァ化デ ルロースを 物(I-1)、b	 (3合量の製剤) (3合量の製剤) (4つし得る経糖、及び、0 (5点製薬上) (1~5重量) (3mgの乳料) 	口製剤) 水溶 () 水溶 () () () () () () () () () () () () () (
	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mg の 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95 重量%ま ことを特徴とする錠剤 のヒドロキシプロピル 	に対して 生の有効成分 、水フシンドン のルフ製剤がし、 に物などに し、 を るいで れ 、 で の た の の た の の が の の が の の の の の の の の の	の含量を増大し 有効成分を所望 、B) マンニト 開示されている 式(I)で示される 気(I)で示される まシプロピルセ a) 40mg の化合 d) 22.5mg の音	した場合に低 のルよう のルス施 のルス施 の た で の の に た の の に た の の ル に た で の ル に の の ル に た の の ル に の の ル に の の い に の の い に の の い に の の い に の の の い に の の い に の の の い に の の い に の の い に の の い に の い の い	会量の製剤 数出し得るる 糖、及び、C 照)。 シインン、C シンプン5 第 シンプンプン	ロ 製 水 容 1 30 重 有 、 ひ ひ
(以下、続葉に約	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mg の 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95 重量%ま ことを特徴とする錠剤 のヒドロキシプロピル 	に対して 生の有効成分 、水フシンドン のルフ製剤がし、 に物などに し、 を るいで れ 、 で の た の の た の の が の の が の の の の の の の の の	の含量を増大し 有効成分を所望 、B) マンニト 開示されている 式(I)で示される 気(I)で示される まシプロピルセ a) 40mg の化合 d) 22.5mg の音	した場合に低 のルよう のルス施 のルス施 の た で の の に た の の に た の の ル に た で の ル に の の ル に た の の ル に の の ル に の の い に の の い に の の い に の の い に の の の い に の の い に の の の い に の の い に の の い に の の い に の い の い	会量の製剤 数出し得るる 糖、及び、C 照)。 シインン、C シンプン5 第 シンプンプン	ロ 製水 容 重 そ 、 ひ で 、 ひ で 、 ひ で 、 ひ で 、 ひ で 、 ひ で 、 の で 、 の 、 、 の 、 の 、 の 、 、 の 、 の 、 の 、 の 、 の 、 の 、 の 、 、 、 、 、 の 、 、 、 、 、 、 、 、 、 、 、 、 、
(以下、続葉に約	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mgの 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95重量%ま ことを特徴とする錠剤 のヒドロキシプロピル 5mgのステアリン酸 	に対して 生の有効成分 、水戸シドン のルラシドン 経口製剤が 量和物でし、 お お 記 む レース で ネシウ	の含量を増大し 有効成分を所望 (、B) マンニト 県示されている 気(I)で示される も、部分ア キシプロピルセ a) 40mg の化合 d) 22.5mg の部 ムを含有する紹	レた場合に低 望のル 夏のル した した し た 場合に が の し た 場合に が の し い た 場合に が の し い と の し い と で の し い と で の し い と の し の に の し の に の の で の に の の で の の で の に の の で の の で の の に て う の い て 、 物 の し い ら の し い に う の し い に う の し い ら の い い ろ の い い ち に う の い い ら の い い ら の い い ら の い い ら の ら い い ろ の の い い ろ の の の の の の の の の の の の	会量の製剤 数出し得るる 糖、及び、C 照)。 シインン、C シンプン5 第 シンプンプン	ロ 製水 容 重 そ 、 ひ で 、 ひ で 、 ひ で 、 ひ で 、 ひ で 、 ひ で 、 の で 、 の 、 、 の 、 の 、 の 、 、 の 、 の 、 の 、 の 、 の 、 の 、 の 、 、 、 、 、 の 、 、 、 、 、 、 、 、 、 、 、 、 、
	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mgの 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95重量%ま ことを特徴とする錠剤 のヒドロキシプロピル 5mgのステアリン酸 	に対して 生の有効成分 、水戸シドン のルラシドン 経口製剤が 量和物でし、 お お 記 む レース で ネシウ	の含量を増大し 有効成分を所望 (、B) マンニト 県示されている 気(I)で示される も、部分ア キシプロピルセ a) 40mg の化合 d) 22.5mg の部 ムを含有する紹	レた場合に低 望のル 夏のル した した し た 場合に が の し た 場合に が の し い た 場合に が の し い と の し い と で の し い と で の し い と の し の に の し の に の の で の に の の で の の で の に の の で の の で の の に て う の い て 、 物 の し い ら の し い に う の し い に う の し い ら の い い ろ の い い ち に う の い い ら の い い ら の い い ら の い い ら の ら い い ろ の の い い ろ の の の の の の の の の の の の	気含量の製剤 数出し得る、 の 数 た な 、 の 製 を 1~ シ い し 、 の 製 を 1~ し 、 の 製 を い 、 の の 乳 素 の の 乳 た 溶 二 い た っ の 乳 れ た っ の 乳 れ た っ の 乳 れ た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の の 、 し た っ の い た っ 、 い し い っ の の 、 の 、 の 、 し っ い た っ 、 、 の 、 の し た っ 、 の し っ し っ の の し っ し っ の の し っ し っ の っ し っ し っ っ の っ し っ っ の の っ し っ っ の っ し っ っ っ っ の っ っ っ の っ し っ っ っ っ っ つ っ つ っ つ っ つ っ つ こ っ う っ っ っ っ っ っ っ う っ う っ う っ う っ う	ロ い 許 30 含 に 入 で 本 、 を 、 を 、 で も 、 で 、 、 で 、 で 、 で 、 、 で 、 、 で 、 、 で 、 、 、 、 、 、 、 、 、 、 、 、 、
	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mgの 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95重量%ま ことを特徴とする錠剤 のヒドロキシプロピル 5mgのステアリン酸 	に対して 生の有効成分 、水戸シドン のルラシドン 経口製剤が 量和物でし、 お お 記 む レース で ネシウ	の含量を増大し 有効成分を所望 (、B) マンニト 県示されている 気(I)で示される も、部分ア キシプロピルセ a) 40mg の化合 d) 22.5mg の部 ムを含有する紹	レた場合に低 望のル 夏のル した した し た 場合に が の し た 場合に が の し い た 場合に が の し い と の し い と で の し い と で の し い と の し の に の し の に の の で の に の の で の の で の に の の で の の で の の に て う の い て 、 物 の し い ら の し い に う の し い に う の し い ら の い い ろ の い い ち に う の い い ら の い い ら の い い ら の い い ら の ら い い ろ の の い い ろ の の の の の の の の の の の の	気含量の製剤 数出し得る、 の 数 た な 、 の 製 を 1~ シ い し 、 の 製 を 1~ し 、 の 製 を い 、 の の 乳 素 の の 乳 た 溶 二 い た っ の 乳 れ た っ の 乳 れ た っ の 乳 れ た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の の 、 し た っ の い た っ 、 い し い っ の の 、 の 、 の 、 し っ い た っ 、 、 の 、 の し た っ 、 の し っ し っ の の し っ し っ の の し っ し っ の っ し っ し っ っ の っ し っ っ の の っ し っ っ の っ し っ っ っ っ の っ っ っ の っ し っ っ っ っ っ つ っ つ っ つ っ つ っ つ こ っ う っ っ っ っ っ っ っ う っ う っ う っ う っ う	ロ い 許 30 含 に 入 で 本 、 を 、 を 、 で も 、 で 、 、 で 、 で 、 で 、 、 で 、 、 で 、 、 で 、 、 、 、 、 、 、 、 、 、 、 、 、
	 ○請求の範囲1~24 文献1には、水難溶性 同様の溶出挙動を示し 載され、A)10~40mgの 分子結合剤を含有する 文献2には、錠剤全 塩またはそれらの溶媒 乳糖を20~95重量%ま ことを特徴とする錠剤 のヒドロキシプロピル 5mgのステアリン酸 	に対して 生の有効成分 、水戸シドン のルラシドン 経口製剤が 量和物でし、 お お 記 む レース で ネシウ	の含量を増大し 有効成分を所望 (、B) マンニト 県示されている 気(I)で示される も、部分ア キシプロピルセ a) 40mg の化合 d) 22.5mg の部 ムを含有する紹	レた場合に低 望のル 夏のル した した し た 場合に が の し た 場合に が の し い た 場合に が の し い と の し い と で の し い と で の し い と の し の に の し の に の の で の に の の で の の で の に の の で の の で の の に て う の い て 、 物 の し い ら の し い に う の し い に う の し い ら の い い ろ の い い ち に う の い い ら の い い ら の い い ら の い い ら の ら い い ろ の の い い ろ の の の の の の の の の の の の	気含量の製剤 数出し得る、 の 数 た な 、 の 製 を 1~ シ い し 、 の 製 を 1~ し 、 の 製 を い 、 の の 乳 素 の の 乳 た 溶 二 い た っ の 乳 れ た っ の 乳 れ た っ の 乳 れ た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の 乳 た っ の の 、 し た っ の い た っ 、 い し い っ の の 、 の 、 の 、 し っ い た っ 、 、 の 、 の し た っ 、 の し っ し っ の の し っ し っ の の し っ し っ の っ し っ し っ っ の っ し っ っ の の っ し っ っ の っ し っ っ っ っ の っ っ っ の っ し っ っ っ っ っ つ っ つ っ つ っ つ っ つ こ っ う っ っ っ っ っ っ っ う っ う っ う っ う っ う	ロ 製 水 容 重 有 、 を 示 す

v

.

الد

国際調査機関の見解書

国際出願番号 PCT/JP2006/310571

補充欄

11

í

いずれかの欄の大きさが足りない場合

第 V.2 欄の続き

本国際出願の上記請求の範囲に記載のものにおいては、ルラシドンの含量を増大し た場合に低含量の製剤の複数錠と同様の溶出挙動を示し、ルラシドンを所望の濃度に 放出し得る経口製剤を提供すべく、アルファ化デンプンを添加するものであるが、文 献1及び2のいずれにもこの点について開示も示唆もされていない。

よって、請求の範囲1~24に記載のものは、文献1及び2に対して、新規性及び 進歩性を有する。

様式PCT/ISA/237(補充欄)(2005年4月)

PATENT APPLICATION SERIAL NO.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <u>FEE RECORD SHEET</u>

11/05/2007	GFREY1	00000090	022448	11919678
01 FC:1631 02 FC:1633 03 FC:1642 04 FC:1615 05 FC:1614		310.00 DA 210.00 DA 410.00 DA 200.00 DA 420.00 DA		

PTO-1556 (5/87)

*U.S. Government Printing Office: 2002- 489-267/69033

Par Pharm., Inc. Exhibit 1015 Page 084

(12) 特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関 国際事務局



PCT

日本語

日本語

Л

A61K 47/26 (2006.01)

A61K 47/38 (2006.01)

C07D 417/12 (2006.01)

2006年5月26日(26.05.2006)

2005年5月26日(26.05.2005)

PCT/JP2006/310571

(43) 国際公開日 2006 年11 月30 日 (30.11.2006)

(51) 国際特許分類:

(21) 国際出願番号:

(25) 国際出願の言語:

(26) 国際公開の言語:

特願2005-153508

(30) 優先権データ:

(22) 国際出願日:

A61K 31/496 (2006.01)

A61K 9/20 (2006.01)

A61K 47/10 (2006.01)



(10) 国際公開番号 WO 2006/126681 A1

Ltd.) [JP/JP]; 〒5418524 大阪府大阪市中央区道修町 2 丁目 6 番 8 号 Osaka (JP).

(72) 発明者;および


- (75) 発明者/出願人 (米国についてのみ): 富士原 和之 (FUJIHARA, Kazuyuki) [JP/JP]; 〒5670878 大阪府茨 木市蔵垣内 1 丁目 3 番 4 5 号 大日本住友製薬株式 会社内 Osaka (JP).
- (74) 代理人:五十部 穰 (ISOBE, Yutaka); 〒5540022 大阪 府大阪市此花区春日出中3丁目1番98号 大日本 住友製薬株式会社知的財産部(春日出) Osaka,外 (JP).
- (81) 指定国 (表示のない限り、全ての種類の国内保護が 可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU,

/続葉有/

(54) Title: PHARMACEUTICAL COMPOSITION

(71) 出願人(米国を除く全ての指定国について): 大日本

住友製薬株式会社 (Dainippon Sumitomo Pharma Co.,



(57) Abstract: A preparation administration for oral comprising: a pregelatinized starch N-[4-[4-(1,2-bencomprising zisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.

[続葉有]

ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) 指定国 (表示のない限り、全ての種類の広域保護が可能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


添付公開書類: — 国際調査報告書

のガイダンスノート」を参照。

2文字コード及び他の略語については、定期発行される 各PCTガゼットの巻頭に掲載されている「コードと略語

(57) 要約:

式(1)



で表されるN-[4-[4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニル]-(2R, 3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシクロ[2,2,1] ヘプタンジ カルボキシイミド・塩酸塩(ルラシドン)を有効成分とするアルファ化デンプン類、水溶性賦形剤 、水溶性高分子結合剤を含有する経口製剤において、有効成分の含量が変動しても、同等の 溶出挙動を示す経口投与用製剤を提供する。

明 細 書

1

医薬品組成物

技術分野

[0001] 本発明は、N-[4-[4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニ ル]-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシク ロ[2,2,1]ヘプタンジカルボキシイミド・塩酸塩(ルラシドン)を有効成分とする崩壊性 が良好な経口製剤に関する。詳しくはルラシドンを有効成分とする経口製剤におい て、有効成分の含量が変動しても、同等の溶出挙動を示す経口投与用製剤、特に 錠剤に関する。

背景技術

- [0002] 特許文献1には、ルラシドン等の化合物について、経口的に投与することができるこ と、また通常の担体・賦形剤・結合剤・安定剤等と有効成分とを配合することにより製 造できることの記載はあるが、該有効成分の含量が広い範囲で異なっても速溶解性 を示し、かつ、同等の溶出挙動を示す経口用の製剤、とくに有効成分の含量を増大 した場合に低含量の製剤の複数錠と同様の溶出挙動を示す経口製剤に関する記載 はない。
- [0003] 含量が異なる製剤を同一用量服用したときの生物学的同等性を保証することを目 的として医薬審第64号(平成12年2月14日公布)にて『含量が異なる経口固形製剤 の生物学的同等性試験ガイドライン』が示され、含量が異なる製剤において、胃、腸 および口腔内の各pH値に対応するpH1.2、3.0~5.0および6.8の緩衝液、水、生 理食塩水などの各試験液で同等の溶出挙動を示すことが求められるようになった。
- [0004] ルラシドンを有効成分とする薬剤について、該有効成分の含量が異なっても速溶 解性を示し、かつ、同等の溶出挙動を示す経口製剤、とくに有効成分の含量を増大 した場合に低含量の製剤の複数錠と同様の溶出挙動を示し、水難溶性の有効成分 を所望の濃度に放出し得る経口製剤については特許文献2に開示されている。
- [0005] 特許文献2には有効成分の含量が数mg~数十mgの範囲、例えば5mg~20mg または5mg~40mgの範囲、で変動しても、速溶解性を示し、かつ、同一組成比にお

いて同等の溶出挙動を示す経口製剤、特に錠剤が開示されている。経口製剤にお いては、より高い臨床効果を得るためにさらに高い含量の製剤、又は患者の症状に 応じて臨床効果を調節するためにより広い含量範囲で、複数錠と同様の挙動を示し 、有効成分を所望の濃度に放出し得る製剤が必要とされる場合が多い。特許文献2 の開示技術では図1に示すようにルラシドンが1錠あたり5mgから40mgまでは同等 の溶出挙動を示す経口製剤を提供することができる。しかしながら、図2に示すように 、製剤中の有効成分の含有率を2倍にすることにより一錠中の有効成分の含有量を 増やした場合、80mg錠では同等の溶出挙動を示すことができなかった。従って、複 数錠を一度に服用するか、服用に困難な大きさの錠剤にせざるを得ない状況であっ た。よって、水難溶性の有効成分であるルラシドンについては、高含量の経口製剤あ るいはさらに広い範囲で溶出挙動が同等な経口製剤の提供は困難であった。

- [0006] また、特許文献2には水溶性高分子結合剤としてデンプンが挙げられているが、ア ルファ化デンプンについての記載はない。アルファ化デンプンは、例えば、特許文献 3に記載されているように、医薬品組成物の崩壊性及び溶出性が顕著に改善するこ とが知られているが、非特許文献1の中でも記述されるように通常、10%以下の含有 量で用いられることが多い。
- [0007] 特許文献1:特許第2800953
 特許文献2:WO2002/024166
 特許文献3:特開2000-26292
 非特許文献1:Handbook of Pharmaceutical Excipients, 2nd edition, 491, 1994, The Pharmaceutical Press
 発明の開示


発明が解決しようとする課題

- [0008] 本発明の目的は、ルラシドンを有効成分とし、該有効成分の含量が広い範囲で異 なっても速溶解性を示し、かつ、同等の溶出挙動を示す経口用の製剤、とくに有効 成分の含量を増大した場合に低含量の製剤の複数錠と同様の溶出挙動を示し、有 効成分を所望の濃度に放出し得る経口製剤を提供することにある。
- [0009] N-[4-[4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニル]-(2R,

3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシクロ[2,2,1] ヘプタンジカルボキシイミド・塩酸塩(以下、ルラシドン)を有効成分とする経口製剤に おいて、有効成分の含量が変動しても、同等の溶出挙動を示す経口投与用製剤の 提供することを目的とする。

課題を解決するための手段

- [0010] 本発明者らは、前記課題を解決するために鋭意検討したところ、以下の手段により 当該課題を解決することを見いだすに至った。
- [0011] すなわち、本発明は、以下の通りである。
 - (1)式(1)
- [0012]



で表されるN-[4-[4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニル]-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシクロ[2,2,1]ヘプタンジカルボキシイミド・塩酸塩(ルラシドン)、アルファ化デンプン類、水 溶性賦形剤、水溶性高分子結合剤を含有する経口製剤。

(2)ルラシドン、アルファ化デンプン類及び水溶性賦形剤を含む混合末を、水溶性 高分子結合剤を溶解した溶液を用いて造粒した経口製剤。

(3)アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン及び水溶 性高分子結合剤を溶解又は分散した液により、造粒した経口製剤。

(4)水溶性賦形剤がマンニトールもしくは乳糖である(1)~(3)いずれか記載の経口 製剤。

(5)ルラシドン、アルファ化デンプン類及び水溶性賦形剤を含む混合末を、水溶性 高分子結合剤を溶解した溶液を用いることにより造粒する方法。

(6)アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン及び水溶性高分子結合剤を溶解又は分散した液を用いることにより造粒する方法。

(7)水溶性賦形剤がマンニトールもしくは乳糖である(5)記載の造粒方法。

(8)アルファ化デンプン類の配合量が製剤重量に対して10~50%(wt/wt)である

(1)から(4)いずれか記載の経口製剤。

(9)アルファ化デンプン類の配合量が製剤重量に対して20~30%(wt/wt)である (1)から(4)いずれか記載の経口製剤。

(10) 製剤中のルラシドン含有量が、20~45% (wt/wt) である(1)から(4) いずれ か記載の経口製剤。

(11) 製剤中のルラシドン含有量が、25~40% (wt/wt) である(1)から(4) いずれ か記載の経口製剤。

(12)ルラシドンの1錠中の含量が、10~160mgである(1)から(4)いずれか記載の 経口製剤。

(13) ルラシドンの1錠中の含量が、20~120mgである(1)から(4) いずれか記載の 経口製剤。

(14) ルラシドンの1錠中の含量が、40~120mgである(1)から(4) いずれか記載の 経口製剤。

(15)水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合 量が製剤重量に対して10~50%(wt/wt)である(1)から(4)いずれか記載の経口 製剤。

(16)水溶性賦形剤がマンニトールもしくは乳糖であり、製剤中のルラシドン含有量が 25~40%(wt/wt)である(1)から(4)いずれか記載の経口製剤。

(17)アルファ化デンプン類の配合量が製剤重量に対して10~50%(wt/wt)であ り、製剤中のルラシドン含有量が25~40%(wt/wt)である(1)から(4)いずれか記 載の経口製剤。

(18)水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合 量が製剤重量に対して10~50%(wt/wt)であり、製剤中のルラシドン含有量が25 ~40%(wt/wt)である(1)から(4)いずれか記載の経口製剤。

(19)水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合 量が製剤重量に対して20~30%(wt/wt)であり、製剤中のルラシドン含有量が25 ~40%(wt/wt)である(1)から(4)いずれか記載の経口製剤。 (20)水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合 量が製剤重量に対して20~30%(wt/wt)であり、ルラシドンの1錠中の含量が40 ~120mgである(1)から(4)いずれか記載の経口製剤。

(21)アルファ化デンプン類のアルファ化率が50~95%である(1)から(4)いずれか 記載の経口製剤。

(22) ルラシドンの平均粒子径が0.1~8 µ mである(1)から(4) いずれか記載の経 口製剤。

(23)アルファ化デンプン類中の水可溶分が、30%以下である(1)から(4)いずれか 記載の経口製剤

(24)水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合量が製剤重量に対して20~30%(wt/wt)であり、製剤中のルラシドン含有量が25~40%(wt/wt)であり、ルラシドンの1錠中の含量が20~120 mg である(1)から(4)いずれか記載の経口製剤。

発明の効果

[0013] 特許文献2の開示技術では、1錠中にルラシドンを40mgまでしか含有しない低含 有量製剤では溶出挙動をそろえた経口製剤を提供できることが確認できている。しか し、より高含有量のルラシドンを含む製剤においては、溶出挙動をそろえることができ なかった。そのためルラシドンの高投与量が必要な患者においては倍量以上の低含 量製剤を服用することになり、患者への負担が大きくなるため改善が求められていた 。アルファ化デンプン類を含むことを特徴とする本発明製剤により、ルラシドンをより 高含有量含む、患者への負担が少ない経口製剤の提供が可能となった。さらに、本 発明により、ルラシドンを高含有量含む経口製剤の提供が、またルラシドンの含量が 変動しても同等の溶出挙動を示す経口投与用製剤を提供することが可能となった。 また、長期保存性にも優れている。

発明を実施するための最良の形態

 [0014] N-[4-[4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニル]-(2R, 3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシクロ[2,2,1]
 ヘプタンジカルボキシイミド・塩酸塩(ルラシドン)は下記式:

6

 $\begin{bmatrix} 0015 \end{bmatrix} \xrightarrow{H}_{H} \xrightarrow{H}_{O} \xrightarrow{N}_{H} \xrightarrow{H}_{H} \xrightarrow{N}_{H} \xrightarrow{N} \xrightarrow{N}_{H} \xrightarrow{N} \xrightarrow{N}_{H} \xrightarrow{N}_{H} \xrightarrow{N} \xrightarrow{N}_{H} \xrightarrow{N}$

で示される化合物である(特許第2800953号参照)。ルラシドンは向精神病作用を持っことが知られており、統合失調症等の治療薬として有効である。本化合物の配合量としては、錠剤全重量に基づいて、例えば、10~50重量%の範囲、好ましくは20~45重量%の範囲、好ましくは20~45重量%の範囲、時に好ましくは20~45重量%の範囲から選択される。更に、微粉砕されていることが好ましく、例えば体積比90%以上の粒子が27 μ m以下であり、体積比による平均粒子径(50%粒子径)としては例えば、0.1~8 μ mの範囲が挙げられる。好ましくは、1~4 μ mの範囲が挙げられる。1錠中に含まれるルラシドンの含量としては、10-160mg、好ましくは20-120mg、さらに好ましくは40-120mg が挙げられる。

[0016] 「アルファ化デンプン類」とは例えばトウモロコシデンプン、バレイショデンプン、コム ギデンプン、コメデンプン、タピオカデンプン等各種デンプン類をアルファ化したもの であり、このようなものとしては例えば医薬品添加物規格にあるアルファ化デンプン(英語名: Pregelatinized Starch) 又は部分アルファ化デンプン(英語名: Partly Pregela tinized Starch)等を挙げることができる。アルファ化デンプン類のアルファ化率は、例 えば50~100%、好ましくは50~95%、さらに好ましくは80~95%である。更に、 アルファ化デンプン類中の水可溶分は、例えば40%以下、より好ましくは30%以下 である。これらアルファ化デンプン類は、通常、平均粒径が1~1000 µm、好ましく は1~500 µm、さらに好ましくは10~100 µmの粉末が用いられる。本発明に適す る市販のアルファ化デンプン類としては、例えばPCS(商品名、旭化成工業株式会 社製)若しくはスターチ1500(商品名、カラコン)等の部分アルファ化デンプンが挙げ られる。上記アルファ化デンプン類の中でも部分アルファ化デンプン、例えばPCS(商品名、旭化成工業株式会社製)が好ましく用いられる。部分アルファ化デンプンの アルファ化率は、好ましくは50~95%、さらに好ましくは80~95%である。本発明に おいて用いられるアルファ化デンプン類は、製剤重量に対して10%以上50%以下

であり、好ましくは10%以上40%以下であり、特に好ましくは、20%以上30%以下 である。

- [0017] 「水溶性賦形剤」としては、例えばマンニトール、乳糖、白糖、ソルビトール、D-ソ ルビトール、エリスリトール、キシリトール等が挙げられる。より好ましいものとしてはマ ンニトール及び乳糖が挙げられる。さらに好ましくはマンニトールを挙げることができ る。また、該水溶性賦形剤は、1種または同時に2種以上を使用することができる。水 溶性賦形剤の配合量としては、錠剤全重量に基づいて、例えば、30~80重量%の 範囲、好ましくは40~60重量%の範囲から選択される。また、マンニトールの平均粒 子径としては、例えば10~200 μ mの範囲が挙げられる。
- [0018] 「水溶性高分子結合剤」としては、例えば、ヒドロキシプロピルセルロース、ヒドロキシ プロピルメチルセルロース、ポリビニルピロリドン、ポリビニルアルコール等が挙げられ る。より好ましいものとしては、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチル セルロース、ポリビニルピロリドン、ポリビニルアルコールが挙げられる。該水溶性高 分子結合剤は、これらの1種または同時に2種類以上を用いることができる。水溶性 高分子結合剤の配合量としては錠剤全重量に基づいて、例えば、0.5~10重量% の範囲、好ましくは1~5重量%の範囲から選択される。

本発明の医薬品組成物から成る経口製剤は、錠剤、カプセル剤、顆粒剤、細粒剤に 製剤化されるものをいう。慣用手段によって、水溶性賦形剤に加えて非水溶性賦形 剤、結合剤、崩壊剤、滑沢剤、等を使用して、錠剤、カプセル剤、顆粒剤、細粒剤に 製剤化されるものであってもよい。また、以下のものを加えることもできる。

- [0019] 「非水溶性賦形剤」としては、例えばコーンスターチ、結晶セルロース等が挙げられる。また、1種または同時に2種以上を使用することができる。
- [0020] 「崩壊剤」としては、例えば、コーンスターチ、結晶セルロース、低置換度ヒドロキシ プロピルセルロース、カルメロース、カルメロースカルシウム、カルメロースナトリウム、 クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、クロスポピドン等が 挙げられる。該崩壊剤は、1種または同時に2種以上を使用することができる。崩壊剤 の配合量としては、錠剤全重量に基づいて、例えば、0~10重量%の範囲、好ましく は0.5~5重量%の範囲が挙げられる。

- [0021] 「滑沢剤」としては、例えばステアリン酸マグネシウム、タルク、ポリエチレングリコー ル、シリカ、硬化植物油等が挙げられる。
- [0022] 本発明の経口製剤の調製は、所望の剤形により異なるが、常法にしたがって所望 の剤形にすることができる。

(1)水溶性高分子結合剤の水溶液の調製:

水溶性高分子結合剤を精製水に溶解する。水溶性高分子結合剤の量としては、精 製水の量に対し、例えば1~20重量%の範囲、好ましくは2~8重量%の範囲から選 択される。

(2)ルラシドン含有造粒物の調製:

ルラシドン、マンニトール、部分アルファ化デンプンを含む賦形剤および崩壊剤を 仕込んだ流動層造粒機に、上記(1)の工程で調製された水溶性高分子結合剤を散 布しながら造粒する。

[0023] 造粒装置としては、例えば、流動層造粒(Fluid Bed Granulation)、高速攪拌造粒(Hi gh share granulation)、転動型流動層造粒(Roto Fluid Bed Granulation)等に分類される造粒装置が挙げられる。但し、これらに限定されるものではない。

(3) 造粒物の乾燥:

上記造粒物を、減圧または常圧にて乾燥する。この乾燥は、赤外線水分計にて測 定される乾燥減量値が、例えば、3重量%以内、好ましくは1~2重量%以内になるよ うに行う。

(4) 滑沢剤の配合:

上記(3)で乾燥した造粒物に滑沢剤を加えて混合する。混合は、例えば、攪拌ミキ サー[タンブル](Diffusion mixers [Tumble])に分類される混合機が用いられる。具体的 には、タンブラーブレンダー(Tumble Blender)、Vブレンダー(V Blenders)、ダブルコ ーン(Double Cone)、ビンタンブラー(Bin Tumble)等が挙げられる。但し、これらに限定 されるものではない。

(5)打錠:

上記混合物を打錠して錠剤を調製する。

[0024] 打錠装置としては、例えば、錠剤プレス(Tablet Press)に分類される打錠機等が挙 げられる。打錠硬度としては、例えば30~200N範囲から選択される。 (6)所望によりフィルムコーティングを施す:

上記錠剤には、必要に応じてフィルムコーティングしてもよい。コーティング装置としては、例えばコーティングパンに分類される装置が挙げられる。好ましくは、通気式コ ーティングシステム(Perforated Coating System)で分類される装置が挙げられる。

[0025] コーティング剤としては、例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシプ ロピルセルロース、ポリビニルピロリドン、ポリビニルアルコール等の基剤と、例えば、 ポリエチレングリコール、プロピレングリコール、トリアセチン、クエン酸トリエチル、グリ セリン、グリセリン脂肪酸エステル、ポリエチレングリコール等の可塑剤を組み合わせ たものが挙げられる。また、必要に応じて、酸化チタン等の添加剤を加え調製するこ ともできる。また、フィルムコーティング後に、光沢化剤としてカルナバロウ等を加える こともできる。

(7)乾燥:

上記のようにして得られた錠剤を乾燥する。乾燥は減圧または常圧で行い、赤外線 水分計にて測定される乾燥減量値が、例えば、3重量%以内、好ましくは1~2重量 %以内になるように行う。

[0026] 以下に本発明の実施例を挙げるが、本実施例は本発明を説明するためのものであって、本発明をなんら限定するものではない。

実施例1

[0027] A. ルラシドンを80mg含有するフィルムコート錠(実施例1)

下記組成からなる顆粒、裸錠およびFC錠を順次調製する。尚、説明文中の括弧内 に示す仕込み量は実施例1に示す処方の製剤を調製するための一例を示すもので ある。

原則としてこの製造方法に準じれば、その他に示す実施例についても調製できる。 但し、仕込み量は処方に基づき変更する必要がある。

[0028] B. 製造方法

⁽¹⁾結合液の調製(5% ビドロキシプロピルメチルセルロース水溶液):

水溶性高分子結合剤のヒドロキシプロピルメチルセルロース(32g)を精製水(608g) に溶解し、これを結合液とした。

(2)造粒:

ルラシドン(320g)、マンニトール(576g)、部分アルファ化デンプン(320g)、クロス カルメロースナトリウム(16g)を流動層造粒機(マルチプレックスMP-01/パウレック 製)に仕込み、上記(1)で調製した結合液を用いて、下記条件でスプレー造粒し造粒 末を得た。得られた造粒末にステアリン酸マグネシウムを加えて混合後(40rpm、5分)に、処方(b)を有する打錠用顆粒を得た。尚、ステアリン酸マグネシウムの仕込み量 は造粒末の収量に基づき処方から算出される量を混合した。

造粒条件

給気温度:60℃

風量:50-65m³/hr

スプレー速度:13g/分

スプレーノズル径:1.2mm

スプレー圧力:0.12MPa

ガン位置:中段

(3)打錠:

上記(2)で調製した打錠用顆粒をHT-AP12SS-II(畑鉄工所)を用いて錠剤を成形した。

杵サイズ: ϕ 10mm14R

厚み:4.20~4.30mm

打錠圧縮圧力:10KN

(4)コーティング:

上記(3)で調製した裸錠をハイコーターHCT30N(フロイント産業)で皮膜量が5mg になるように下記条件でコーティングを行い、コーティング後にカルナバロウを添加し フィルムコート錠を得た。

FC条件

給気温度 :80℃

11

風量 :0.6m³/分

パン回転数:25rpm

スプレー圧:0.15MPa

液速 :5g/分

上述の方法により得られた製剤は以下の方法により品質を評価し、そこで得られた知見をもとに本発明を見出すに至った。

[0029] C. 品質評価

(1)溶出試験

日本薬局方溶出試験法第2法に従い、試作した製剤の溶出試験を実施した。以下 に測定条件を示す。

試験溶液:希釈マックイルベイン緩衝液(diluted McIlvaine buffer、pH4.0)

パドル回転数:50rpm

試験液:900ml

(2)溶出プロファイルの類似性

溶出プロファイルの類似性を評価するための指標としてScale-Up and Past-Approv al Changes for Intermediate Release Products(SUPAC-IR)に示される類似因子f2を 用いた。f2は以下の式により算出される。SUPAC-IRにより各製剤の溶出率から算出 されるf2値が50 \leq f2 \leq 100の範囲にある場合、試作した各製剤は類似の溶出プロフ ァイルであると判定した。また、f2値の算出に当っては試験開始後15分、30分および 45分の3ポイントの時点での溶出率を用いた。

٦

[0030]

f2= 50 • LOG
$$\left[\frac{100}{\sqrt{1+\frac{\sum_{i=1}^{n} (T_i - R_i)^2}{n}}}\right]$$

Г

Ti and Ri are the percent dissolved at each point.

n is the number of points to be compared.

(3) 粒度分布

12

レーザー回折粒度分布測定装置(SLAD-3000/島津製作所)の乾式噴射法にてル ラシドンの粒度分布を測定した。以下に測定条件を示す。

試料量:2g エアーE: 0.4MPa以上 ターンテーブル回転スピード:2 パラメータ設定 環境設定 測定最適範囲(最大) : 1500 モニター平均回数:16 : 700 暗測定平均回数 :2 (最小) (CH-1) ボーレート(bps):9600 光強度表示最大值:2000 前回のブランク値 : 読み込み ブランク測定許容最大値:300 プリンター:モノクロ ブランク測定許容変動範囲:20 屈折率パラメーター 標準屈折率: 1.70-0.20i 測定条件設定 測定回数:1 乾式許容最小值:300 測定間隔(秒):1 最大值:2500 平均回数:64 評価対象粒子範囲(最小値):0.1 測定吸光度範囲(最大値):0.1 評価対象粒子範囲(最大値):2000 (最小値):0.05 センサ使用開始位置:1 トリガーモード:OFF 乾式しきい:300

[0031] <試験1>

実施例1、2,3で、1錠中にルラシドンを20mg、40mgおよび80mg含有する水溶 性賦形剤、部分アルファ化デンプンおよび水溶性高分子結合剤から成る特定の医 薬品組成物を含む錠剤を試作した。また、比較例1、2で、特許文献2の開示処方に 基づき1錠中にルラシドンを40mgおよび80mg含有する錠剤を試作した。

試作した製剤を(d)および(e)に示す条件で溶出試験を実施し、溶出プロファイルの類似性を評価した。なお、比較例1、2の試作については試験8にて示した。

結果は、表4,5に示した。なお、(d)については経時的な溶出率についても図2,3 で示した。

[0032] (a) 造粒末の処方

[0033] [表1]

				単位:m	g
成分	実施例番	号		比較例番号	
	1	2	3	1	2
ルラシドン	80	4 0	20	4 0	8 0
マンニトール	$1\ 4\ 4$	72	36	188	148
部分アルファ化デンプン	8.0	$4 \ 0$	20		—
クロスカルメロースナトリウム	4	2	1	16	16
ヒドロキシプロピルメチルセルロース	8	4	2	10	10

- [0034] (b) 打錠用顆粒/裸錠の処方
- [0035] [表2]

				単位:m	g
成分	実施例番	号	比較例番号		
	1	1	1	1	2
上記(a)の顆粒	316	158	79	254	254
乳糖	-	—	—	62	62
ステアリン酸マグネシム	4	2	1	4	4

- [0036] (c)FC錠の処方
- [0037] [表3]

				単位: m g		
成分	実施例番号			比較例番号		
	1	2	3	1	2	
 上記(b)の裸錠	320	160	80	320	320	
ヒドロキシプロピル	3.25	1.95	1.3	2.6	2.6	
メチルセルロース						
酸化チタン	1	0.6	0.4	0.8	0.8	
ポリエチレングリ	0.75	0.45	0.3	0.6	0.6	
コール6000						
カルナバロウ	0.01	0.006	0.004	0.01	0.01	

[0038] (d)1ベッセル当りルラシドンが80mgとなる系での溶出試験

1ベッセル当りルラシドンが80mgとなる系でルラシドンを80mg、40mgおよび20mg を含有する各フィルムコート錠の溶出試験を実施し、それぞれの溶出プロファイルの 類似性をf2値により評価した。

[0039] 表4から明らかなように、実施例2,3のf2値は実施例1に対する類似性を示したが、 比較例2のf2値は比較例1に対する類似性を示さなかった。即ち、表4,図3から明ら かなように、実施例1乃至3は溶出プロファイルの類似性を示すf2値が50≤f2≤10 0の範囲となり、含量の異なる製剤においても、錠剤の含量(力価)に依存することな く溶出プロファイルの類似性を示す製剤が得られた。一方、表4,図2から明らかによ うに、詳細を試験8に記載したが、特許文献2開示処方の比較例2は比較例1からな る製剤2錠の溶出よりも明らかに遅く、溶出プロファイルの類似性は示さなかった。

[0040] [表4]

Γ	類似因子	実施例番号			比較例番号	
		1	2	3	1	2
	f 2	_	88	97	_	37

[0041] (e)1ベッセル当りルラシドンが40mgとなる系での溶出試験

1ベッセル当りルラシドンが40mgとなる系でルラシドンを40mgおよび20mgを含有 する各フィルムコート錠の溶出試験を実施し、それぞれの溶出プロファイルの類似性 を同様にf2値を用いて評価した。

- [0042] 表5から明らかなように、実施例3,比較例1のf2値は実施例2に対する類似性を示 した。即ち、1ベッセル当りルラシドンが40mgである系においても、f2値は50≦f2≦ 100の範囲となり、錠剤の含量(力価)に依存することなく溶出プロファイルの類似性 が示された。
- [0043] [表5]

類似因子	実施例番号		実施例番号		比較例番号
	2	3	1		
f 2	_	88	97		

[0044] <試験2>

実施例1および4で、水溶性賦形剤と水溶性高分子結合剤および部分アルファ化 デンプンから成る医薬品組成物を含む製剤を調製した。また、比較例3,4および5で、 、水溶性賦形剤と水溶性高分子結合剤およびアルファ化していないデンプンである コーンスターチから成る医薬品組成物を含む製剤を調製した。各製剤の溶出試験を 実施し、溶出プロファイルの類似性をf2値により評価した。結果は、表9に示した。 (a) 造粒末の処方

[0045] [表6]

単位	:	m	g	

成分	実施例番号		比較例番号		
	1	4	3	4	5
ルラシドン	80	80	80	80	80
マンニトール	$1 \ 4 \ 4$	176	108	108	-
乳糖	-	—	—	_	108
部分アルファ化デンプン	80	4 0	—	_	_
コーンスターチ	-	—	4 0	40	4 0
クロスカルメロースナトリウム	4	8	16	16	16
ヒドロキシプロピルメチルセルロース	8	1 2	10	10	10

[0046] (b) 打錠用顆粒/裸錠の処方

[0047] [表7]

				単位:m	g
成分	実施例番	号	比較例番号		
	1	4	3	4	5
上記(a)の顆粒	316	316	254	254	254
マンニトール	—	—	62	_	—
ステアリン酸マグネシム	4	4	4	4	4

- [0048] (c)FC錠の処方
- [0049] [表8]

			単位	江:mg	
成分	実施例番号	比較例番号			
	1	4	3	4	5
上記(b)の裸錠	320	320	320	258	258
ヒドロキシプロピルメチルセルロース	3. 25	-	2.6	2.6	2.6
酸化チタン	1	-	0.8	0.8	0.8
ポリエチレングリコール6000	0.75	—	0.6	0.6	0.6

[0050] (d)溶出試験

表9から明らかなように、実施例4は実施例1に対する類似性を示したが、比較例3、4、5のf2値は実施例1に対して類似性を示さなかった。即ち、比較例3,4および5のコーンスターチを含む製剤は、実施例1および4の部分アルファ化デンプンを含む 製剤と比較して、溶出プロファイルが異なり、溶出の遅い製剤であった。

[0051] [表9]

類似因子	実施例番号		比較例番号		
	1	4	3	4	5
f 2	_	67	44	29	26

PCT/JP2006/310571

[0052] <試験3>

実施例4,5,6,7で、部分アルファ化デンプンの配合量の溶出性に及ぼす影響を 評価した。結果は表13に示した。

(a) 造粒末の処方

[0053] [表10]

単位:mg

成分	実施例番号						
	1	4	5	6	7		
ルラシドン	80	80	80	80	80		
マンニトール	$1 \ 4 \ 4$	176	116	136	156		
部分アルファ化デンプン	80	40	100	80	60		
クロスカルメロースナトリウム	4	8	8	8	8		
ヒドロキシプロピルメチルセルロ	8	12	12	12	12		
<u>ース</u>							

[0054] (b) 打錠用顆粒/裸錠の処方

[0055] [表11]

単位 : m g

成分	実施例番号					
	1	4	5	6	7	
上記(a)の顆粒	316	316	316	316	316	
ステアリン酸マグネシム	4	4	4	4	4	

[0056] (c)FC錠の処方

[0057] [表12]

単位:mg

成分	実施例番号	実施例番号					
	1	4	5	6	7		
上記(b)の裸錠	320	32	320	320	320		
		0					
ヒドロキシプロピルメチルセルロース	3.25	—	—	-	—		
酸化チタン	1	—	—	—	_		
ポリエチレングリコール6000	0.75	-	-	-	_		
カルナバロウ	0.01	—	—	-	—		

[0058] (d)溶出試験

表13から明らかなように、実施例4、5、6、7のf2値は実施例1に対する類似性を示した。即ち、部分アルファ化デンプンを製剤組成中の10%wt/wt以上含有する医薬

品組成物から成る製剤は、速溶解性を示し、かつ、類似の溶出プロファイルを示した

[0059] [表13]

0

類似因子	実施例番号					
	1	4	5	6	7	
f 2	-	67	60	62	81	

[0060] <試験4>

比較例6で、水溶性賦形剤と部分アルファ化デンプンを含むが、水溶性高分子結 合剤を含まない錠剤の製剤化を試みたが、打錠工程において、キャッピングとスティ ッキングが発生し打錠できず、類似の溶出プロファイルを得るどころか錠剤すら得ら れなかった。実施例8,9,10および11で、水溶性賦形剤および部分アルファ化デン プンと水溶性高分子結合剤の配合量の異なる医薬品組成物を含む製剤を調製した 。結果は、表17に示した。

(a) 造粒末の処方

[0061] [表14]

単位:mg

成分	実施例番号 比較例					例番号
	1	8	9	1 0	11	6
ルラシドン	80	80	80	80	80	80
マンニトール	$1 \ 4 \ 4$	136	138	140	$1\ 4\ 2$	148
部分アルファ化デンプン	80	80	80	80	80	80
クロスカルメロース	4	8	8	8	8	8
ナトリウム						
ヒドロキシプロピル	8	1 2	10	8	6	-
メチルセルロース						

[0062] (b) 打錠用顆粒/裸錠の処方

[0063] [表15]

					単位:r	n g
成分	実施例番	号	比較例番号			
	1	8	9	10	11	6
上記(a)の顆粒	316	316	316	316	316	316
ステアリン酸マグネシム	4	4	4	4	4	4

[0064] (c)FC錠の処方

[0065] [表16]

						単位:
						m g
成分	実施例番号					比較例
						番号
	1	8	9	10	11	6
上記(b)の裸錠	320	320	320	320	320	320
ヒドロキシプロピル	3.25	-	-	-	-	—
メチルセルロース						
酸化チタン	1	—	—	-	-	_
ポリエチレングリコール	0.75	—	—	-	—	_
6000						
カルナバロウ	0.01	-	-	-	-	-

[0066] (d)溶出試験

表17から明らかなように、実施例8,9、10、11のf2値は実施例1に対する類似性 を示した。即ち、水溶性高分子結合剤を1.8 %wt/wtから3.8%wt/wtの範囲にお いて含有する医薬品組成物から成る製剤は、速溶解性を示し、かつ、類似の溶出プ ロファイルを示した。

[0067] [表17]

類似因子	実施例番号						
	1	8	9	1 0	1 1		
f 2	—	77	8 1	73	73		

[0068] <試験5>

実施例12で、水溶性賦形剤として乳糖を用い、水溶性高分子結合剤および部分 アルファ化デンプンから成る医薬品組成物を含む製剤を調製した。結果は、表21に 示した。

(a) 造粒末の処方

[0069] [表18]

単位	:	m	g	
----	---	---	---	--

		· · ·=	0
成分	実施例番号	17	
	1	6	12
ルラシドン	80	80	80
マンニトール	144	136	—
乳糖	_	_	136
部分アルファ化デンプン	80	80	80
クロスカルメロースナトリウム	4	8	8
ヒドロキシプロピルメチルセルロース	8	12	12

19

- [0070] (b) 打錠用顆粒/裸錠の処方
- [0071] [表19]

		単位	: mg
成分	実施例番号		
	1	6	12
上記(a)の顆粒	316	316	316
ステアリン酸マグネシム	4	4	4

[0072] (c)FC錠の処方

[0073] [表20]

単位:mg

成分	実施例番号		
	1	6	1 2
上記(b)の裸錠	320	320	320
ヒドロキシプロピルメチルセルロース	3.25	—	-
酸化チタン	1	—	—
ポリエチレングリコール6000	0.75	—	—
カルナバロウ	0.01	_	_

[0074] (d)溶出試験

表21から明らかなように、実施例6および12のf2値は実施例1に対する類似性を 示した。即ち、水溶性賦形剤としてマンニトールおよび乳糖にて速溶解性を示し、か つ、類似の溶出プロファイルを示した。

[0075] [表21]

類似因子	実施例番号		
	1	6	12
f 2	-	62	66

[0076] <試験6>

実施例4,13,14および15で、粒度分布の異なるルラシドン原末を用いて、水溶 性賦形剤と水溶性高分子結合剤および部分アルファ化デンプンから成る特定の医 薬品組成物を含む製剤を調製した。結果は、表25に示した。

(a) ルラシドン原末の粒度分布

D50%(50%粒子径)とは体積基準により算出される積算分布が50%となるポイントでの粒子径を示し、D90%(90%粒子径)とは、体積基準により算出される積算分布

が90%(ふるい下)となるポイントでの粒子径を表す。

[0077] [表22]

単位:mg

粒度分布		実施例番号			
		4	13	14	15
粒子径	D10 %	0.5	0.9	1.0	1.5
	D50 %	1.6	5.9	7.6	13.9
	D90 %	4.7	17.5	26.9	58.3

[0078] (b) 打錠用顆粒/裸錠の処方

[0079] [表23]

単位:mg 成分 実施例番号 4 13 $1 \ 4$ $1 \, 5$ ルラシドン 8 0 8 0 8 0 8 0 マンニトール 1 7 6 $1 \ 4 \ 4$ $1 \ 4 \ 4$ $1 \ 4 \ 4$ 部分アルファ化デンプン 4 08 0 8 0 8 0 クロスカルメロースナトリウム 8 4 4 $\mathbf{4}$ ヒドロキシプロピル 1 2 8 8 8 メチルセルロース ステアリン酸マグネシウム 4 4 4 4

[0080] (c)FC錠の処方

[0081] [表24]

			単位	: mg
成分	実施例番号			
	4	13	14	1 5
上記(b)の裸錠	320	320	320	320
ヒドロキシプロピル	-	3.25	3.25	3.25
メチルセルロース				
酸化チタン	-	1	1	1
ポリエチレングリコール	—	0.75	0.75	0.75
6000				
カルナバロウ	-	0.01	0.01	0.01

[0082] (d)溶出試験

表25から明らかなように、実施例13,14、15のf2値は実施例4に対する類似性を示した。即ち、50%粒子径が1~8 μ mの範囲、90%粒子径が27 μ m以下の粒度分布のルラシドン原末を用いて調製した製剤で類似の溶出プロファイルが得られるこ

21

とを見出した。

[0083] [表25]

類似因子	実施例番号			
	4	1 3	14	15
f 2	-	56	56	46

[0084] <試験7>

特許文献2の開示技術を用いて1錠中のルラシドンの含有量が10mgと40mgとなる製剤を試作し、開示文献2の通り、1錠中のルラシドン含量が10mgから40mgまでは同等の溶出挙動を示す経口製剤を提供できるかどうか検証した。結果は、図1に示した。

[0085] 図1から明らかなように、特許文献2の開示技術により得られるルラシドンを異なる含 有量を有する製剤の溶出プロファイルは、f2の値から明らかなように、1錠中にルラシ ドンを10mg含有する錠剤と40mg含有する製剤は、特許文献2のとおり同等の溶出 挙動を示す経口製剤を提供できた。

(a)顆粒の処方

[0086] [表26]

		単位:mg
成分	10mg錠	40mg錠
ルラシドン	1 0	4 0
マンニトール	47	188
クロスカルメロースナトリウム	4	16
ヒドロキシプロピルメチルセルロース	2.5	10

(b)裸錠の処方

[0087] [表27]

c		単位:mg
成分	10mg錠	40mg錠
(a)の顆粒	63.5	254
乳糖	15.5	6 2
ステアリン酸マグネシウム	1	4

(c)FC錠の処方

[0088] [表28]

114 A.F.

	<u>1</u>	单位: m g
成分	10mg錠	4 0 m g 錠
上記(b)の裸錠	80	320
ヒドロキシプロピルメチルセルロース	1.3	2.6
酸化チタン	0.4	0.8
ポリエチレングリコール6000	0.3	0.6
カルナバロウ	0.006	0.01

[0089] <試験8>

特許文献2の開示技術では1錠中にルラシドンを40mgまで含有する製剤では同等 の溶出挙動を示す経口製剤を提供できることを確認できた。ここでは、特許文献2の 開示技術を用いて、部分アルファー化デンプンを含まない1錠中のルラシドン含有量 が80mgとなる製剤を試作した。錠剤の大型化は患者への負担を大きくするため、40 mg錠と同じ錠剤重量となるように、有効成分の含有率を2倍にすることにより製した。 比較例1および2の結果は表4および図2に示した。

(a)顆粒の処方

[0091] [表29]

		単位 : m g
成分	40mg錠	80mg錠
ルラシドン	4 0	80
マンニトール	188	148
クロスカルメロースナトリウム	16	16
ヒドロキシプロピルメチルセルロース	10	10

(b)裸錠の処方

[0092] [表30]

		単位 : m g
成分	40mg錠	80mg錠
(a)の顆粒	254	254
乳糖	62	62
ステアリン酸マグネシウム	4	4

^[0090] 表4および図2から明らかなように、特許文献2の開示技術では、f2の値から明らか なように、ルラシドンの含有率を2倍にしたアルファ化デンプンを含まない80mg錠で は40mg錠2錠と同等の溶出性を示すことはできなかった。

23

(c)FC錠の処方

[0093] [表31]

		単位: m g
成分	4 0 m g 錠	80mg錠
上記(b)の裸錠	320	320
ヒドロキシプロピルメチルセルロース	2.6	2.6
酸化チタン	0.8	0.8
ポリエチレングリコール6000	0.6	0.6
カルナバロウ	0.01	0.01

[0094] <試験9>

試験1の実施例1~3にて試作した含量の異なる3種類の製剤の溶出性を評価した。結果は、図3に示した。 図3から明らかなように、本発明により1錠中にルラシドンを20mgから80mgを含有 する製剤においても、錠剤の含量(力価)に依存しない同等の溶出性が確認された。

(a) 造粒末の処方

[0095] [表32]

			単位:mg
成分	80mg錠	40mg錠	20mg錠
ルラシドン	80	4 0	20
マンニトール	144	72	36
部分アルファ化	80	4 0	20
デンプン			
クロスカルメロース	4	2	1
ナトリウム			
ヒドロキシプロピル	8	4	2
メチルセルロース			

(b) 打錠用顆粒/裸錠の処方

[0096] [表33]

成分	80mg錠	40mg錠	2 0 m g 錠
上記(a)の顆粒	316	158	79
乳糖	—	—	_
ステアリン酸マグネシウム	4	2	1

(c)FC錠の処方

226 644

[0097] [表34]

			里位:mg
成分	80mg錠	4 0 m g 錠	20mg錠
上記(b)の裸錠	320	160	80
ヒドロキシプロピルメチルセルロース	3.25	1.95	1.3
酸化チタン	1	0.6	0.4
ポリエチレングリコール6000	0.75	0.45	0.3
カルナバロウ	0.01	0.006	0.004

[0098] <試験10>

本願発明の開示技術並びに特許文献2の開示技術を用いて、錠剤重量がそれぞ れ等しいルラシドン 120mg錠を作製し、両製剤の溶出挙動を評価した。

(a)実験方法

本願発明の製造方法ならびに特許文献2の製造方法2(以下に記載)に基づいてル ラシドン 120mg錠製剤を試作した(表35)。これら試作した製剤について本願明細書 実施例のC.品質評価(1)溶出試験に記載の条件を一部変更して溶出試験を実施し た。

溶出試験は、試験溶液である希釈マックイルベイン緩衝液のpHをpH4.0からpH3.8 に変更して実施した。

[0099] (b)本願発明の製造方法

ルラシドン 8000g、D-マンニトール 14200g、部分 α 化デンプン 8000g、クロスカルメロ ースナトリウム 400gを、流動層造粒機(フローコーター FLF-30/フロイント産業)に 仕込み、あらかじめ調製しておいた5% ヒドロキシプロピルメチルセルロース溶液を散 布しながら、吸気温度80℃、吸気風量 7 m³/min、スプレー液速度200mL/min、アトマ イズエアー流量 200L/minという条件で造粒した。得られた造粒物を造粒機内で、乾 燥温度80℃、乾燥時間10分という条件で乾燥し、乾燥減量値が2%以内となっている ことをハロゲン水分計で確認した。得られた造粒物は整粒機(フィオーレF-0型)を用 いて整粒した。次に得られた整粒物18000gとステアリン酸マグネシウム 228gを、混合 機(コンテナーサイズ110 L)を用いて回転数20rpm、混合時間5分という条件で混合 した。最後に得られたこの混合物を、打錠機(HT-AP12SS-II/畑鉄工所)を用いて 打錠圧12.5kNで打錠してルラシドン 120mg錠裸錠を作製した。 [0100] (c)特許文献2の製造方法2

ルラシドン 160g、D-マンニトール 296g、クロスカルメロースナトリウム 32gを、流動層 造粒機(マルチプレックスMP-01/パウレック)に仕込み、あらかじめ調製しておいた5 % ヒドロキシプロピルメチルセルロース溶液を散布しながら、給気温度60℃、造粒時 間45分という条件で造粒した。得られた造粒物を造粒機内で、乾燥温度80℃、乾燥 時間5分という条件で乾燥し、乾燥減量値が1%以内となっていることをハロゲン水分 計で確認した。次に得られた造粒物254gと乳糖62gを、混合機(筒井理化学器械)を 用いて回転数40rpm、混合時間30分という条件で混合した。その後、得られた混合物 316gとステアリン酸マグネシウム 4gを、混合機(筒井理化学器械)を用いて回転数40r pm、混合時間5分という条件で混合した。最後に得られたこの混合物を、打錠機(HT -AP12SS-II/畑鉄工所)を用いて打錠圧12.5kNで打錠してルラシドン 120mg錠裸錠 を作製した。

[0101] (d)実験結果

試作した製剤の組成と溶出試験の結果を以下に示す。

[0102] [表35]

処方	034-15-120-1000	RP-03323-120-1000
	(本出顧の開	(特許文献2の開示技
	示技術)	術)
ルラシドン	120	120
マンニトール	213	222
部分α化デンプン	120	—
クロスカルメロースナトリウム	6	24
タブレトース70	-	93
ヒドロキシプロピル	1 5	1 5
メチルセルロース	15	15
ステアリン酸マグネシウム	6	6
合計	480	480
溶出举動		
時間(分)	溶出率(%)	
10	83	54
15	91	6 6
30	95	80
45	96	84
f2值		37

錠剤の組成

この結果、特許文献2の開示技術を基に試作したルラシドン 120mg錠と比較して、 本出願の開示技術を基に試作したルラシドン 120mg錠が速溶解性を示すことが確認 された。

[0103] <試験11>

本願発明の原薬含量の適用範囲について、製剤の溶出挙動を基に評価した。 (a)実験方法

本願発明の製造方法に基づいてルラシドン 80mg錠を試作した(表36)。これら試 作した製剤について本願明細書実施例のC.品質評価(1)溶出試験に記載の条件で 溶出試験を実施した。

[0104] (b)製造方法

ルラシドン、D-マンニトール、部分 α 化デンプン、クロスカルメロースナトリウムを、流 動層造粒機(マルチプレックスMP-01/パウレック)に仕込み、あらかじめ調製してお いた5% ヒドロキシプロピルメチルセルロース溶液を散布しながら、給気温度60℃、造 粒時間45分あるいは60分という条件で造粒した。得られた造粒物を造粒機内で、乾 燥温度80℃、乾燥時間5分という条件で乾燥し、乾燥減量値が2%以内となっているこ とをハロゲン水分計で確認した。次に得られた造粒物とステアリン酸マグネシウムを、 混合機(筒井理化学器械)を用いて回転数40rpm、混合時間5分という条件で混合し た。最後に得られたこの混合物を、打錠機(HT-AP12SS-II/畑鉄工所)を用いて打 錠圧10kNで打錠してルラシドン 80mg錠裸錠を作製した。

[0105] (c)実験結果

試作した製剤の組成と溶出試験の結果を以下に示した。

[0106] [表36]

処方	034-15-80- 1000	RP-03320	RP-03321	RP-03322
ルラシドン	80	80	80	80
マンニトール	142	$1 \ 0 \ 4$	67	30
部分α化デンプン	80	80	80	80
クロスカルメロースナトリウム	4	4	4	4
ヒドロキシプロピル	10	8	6	4
メチルセルロース	10	0	0	4
_ ステアリン酸マグネシウム	4	4	3	2
合計	320	280	240	200
溶出举動				
時間(分)	溶出率(%)			
1 0	85	73	71	68
1 5	89	80	80	81
3 0	93	88	88	89
4 5	94	90	91	91
f 2值	_	60	60	63

この結果、ルラシドンの製剤中の含有量としては25~40%の範囲で類似の溶出プロファイルを示す製剤組成であることが確認できた。

[0107] <試験12>

本願発明の水溶性高分子結合剤について、製剤の溶出挙動を評価した。

(a)実験方法

本願発明の製造方法に基づいてルラシドン 80mg錠を試作した(表37)。これら試 作した製剤について本願明細書実施例のC.品質評価(1)溶出試験に記載の条件で 溶出試験を実施した。

[0108] (b)製造方法

ルラシドン 160 g、D-マンニトール 284 g、部分 α 化デンプン160 g、クロスカルメロー スナトリウム 8 gを、流動層造粒機(マルチプレックスMP-01/パウレック)に仕込み、 あらかじめ調製しておいた5% 水溶性高分子結合剤溶液を散布しながら、給気温度6 0℃、造粒時間45分という条件で造粒した。得られた造粒物を造粒機内で、乾燥温度 80℃、乾燥時間5分という条件で乾燥し、乾燥減量値が2%以内となっていることをハロ ゲン水分計で確認した。次に得られた造粒物とステアリン酸マグネシウムを、混合機(筒井理化学器械)を用いて回転数40rpm、混合時間5分という条件で混合した。最後 に得られたこの混合物を、打錠機(HT-AP12SS-II/畑鉄工所)を用いて打錠圧10kN で打錠してルラシドン 80mg錠裸錠を作製した。

> Par Pharm., Inc. Exhibit 1015 Page 113

28

[0109] (c)実験結果

試作した製剤の組成と溶出試験の結果を以下に示す。

[0110] [表37]

錠剤の組成

処方	034 - 15 - 80 - 1000	RP-03326	RP-03327	RP-03328
ルラシドン	80	8 0	80	80
マンニトール	142	$1 \ 4 \ 2$	142	$1 \ 4 \ 2$
部分α化デンプン	80	80	80	80
クロスカルメロー スナトリウム	4	4	4	4
ヒドロキシプロピル メチルセルロース	1 0	_	—	_
ポリビニルアルコール	—	1 0	—	—
ポリビニルピロリドン	—	_	10	—
ヒドロキシプロピル				10
セルロース	_		_	10
ステアリン酸 マグネシウム	4	4	4	4
合計	320	320	320	320
時間(分)	溶出率(%)			
1 0	83	59	78	80
1 5	91	76	82	87
3 0	95	94	88	91
4 5	96	96	90	92
f 2值	-	53	56	69

この結果、水溶性高分子結合剤にポリビニルアルコール、ポリビニルピロリドン、ヒド ロキシプロピルセルロースを用いた製剤においても、本明細書P.6「C. 品質評価(2) 溶出プロファイルの類似性」の基準を満たす製剤(類似の溶出プロファイル)となるこ とを確認した。

[0111] <試験13>

本願発明の開示技術を用いて作製したルラシドン 20、40、80、120 mg錠FC錠の溶 出挙動を評価した。

(a)実験方法

本願発明の製造方法に基づいてルラシドン 20、40、80、120 mg錠FC錠を試作した (表38)。 [0112] (b)製造方法

ルラシドン 8000g、D-マンニトール 14200g、部分 α 化デンプン 8000g、クロスカルメロ ースナトリウム 400gを、流動層造粒機(フローコーター FLF-30/フロイント産業)に 仕込み、あらかじめ調製しておいた5% ヒドロキシプロピルメチルセルロース水溶液を 散布しながら、吸気温度80℃、吸気風量 7 m³/min、スプレー液速度200 mL/min、ア トマイズエアー流量 200 L/minという条件で造粒した。スプレー終了後、乾燥温度80 ℃、乾燥時間10分という条件で乾燥し、乾燥減量値が2%以内となっていることをハロ ゲン水分計で確認した。得られた造粒末は整粒機(フィオーレF-0型/徳寿工作所) を用いて整粒した。次に得られた整粒末18000gとステアリン酸マグネシウム 228gを、 混合機(コンテナーサイズ110 L/古河アルテック)を用いて回転数20rpm、混合時間 5分という条件で混合した。得られたこの混合末を、打錠機(ルラシドン 20、40、80錠 裸錠についてはCLEANPRESS Correct 12HUK/菊水製作所、ルラシドン 120mg錠 裸錠についてはHT-AP12SS-II/畑鉄工所)を用いて打錠圧約10kNで打錠してルラ シドン 20、40、80、120mg錠裸錠を作製した。次に、給気温度80℃、風量0.6m³/min 、パン回転数25rpm、スプレー圧0.15MPa、液速5g/minという条件で裸錠をコーティン グしてルラシドン 20、40、80、120mg錠FC錠を得た。

[0113] (c)溶出試験

日本薬局方溶出試験法第2法に従い、試作した製剤の溶出試験を実施した。以下 に測定条件を示す。

試験溶液:希釈マックイルベイン緩衝液(diluted McIlvaine buffer、pH3.8および4.0)

パドル回転数:50rpm

試験液:900ml

[0114] (d)実験結果

試作した製剤の組成と溶出試験の結果を以下に示した。

[0115] [表38]

錠剤の組成						
		ルラシドン	ルラシドン	ルラシドン	ルラシドン	
品名		20mg 錠	40mg 錠	80mg 錠	120mg 錠	
		FC 錠	FC 錠	FC 錠	FC 錠	
	Lot No.	034-15-20	034-15-40	034-15-80	034-15-120	
	ルラシドン	20mg	40m g	80 m g	120m g	
	マンニトール	35.5mg	71mg	142mg	216m g	
	部分α化デンプン	20mg	40m g	80 m g	120m g	
	クロスカルメ	1 mg	2 m g	4 mg	6mg	
処方	ロースナトリウム	Ting			ome	
	ヒドロキシプロピル	2.5mg	5 m g	10mg	15mg	
	メチルセルロース					
	ステアリン酸	1 mg	2mg	4 m g	6mg	
	マグネシウム					
	小 計	80mg	160mg	320mg	480mg	
	ヒドロキシプロピル メチルセルロース	1.001mg	1.690mg	2.730mg	1.100mg	
	酸化チタン	0.308mg	0.520mg	0.840mg	0.825mg	
	マクロゴール 6000	0.231mg	0.390mg	0.630mg	5.500mg	
	カルナウバロウ	0.01mg	0.01 mg	0.01mg	0.01mg	
	合計	81.55mg	162.61mg	324.21mg	485.51mg	
		溶出	挙動			
	時間(分) 溶出率(%)					
	10	80	77	77	77	
	15	91	90	88	92	
	30	100	98	93	96	
	45	101	100	94	97	
	試験液のpH	4.0	4.0	4.0	8.8	

この結果、本出願の開示技術を基に試作したルラシドン 20,40,80,120mg錠FC錠が 速溶解性を示すことが確認された。

[0116] <試験13>

40 mg錠FC錠1錠/20 mg錠FC錠2錠、80 mg錠FC錠1錠/40 mg錠FC錠2錠/20 mg錠FC錠4錠、120 mg錠FC錠1錠/40 mg錠FC錠3錠/20 mg錠FC錠6錠の溶出挙動の類似性を評価した。

(a)実験方法

製造方法、試験方法は、試験12の溶出挙動」と同様なので省略した。

[0117] (b)実験結果

試作した製剤の溶出挙動とその類似性を以下に示した。

[0118] [表39]

錠	剤	40mg 錠	20mg 錠	80mg 錠	40mg 錠	20mg 錠	120mg 錠	40mg 錠	20mg 錠
錠剤数		1 錠	2 錠	1 錠	2 錠	4 錠	1 錠	3 錠	6錠
		溶出	率(%)		溶出率(%)	•	\$	容出 率 (%)	
	10	77	79	77	78	75	77	90	83
時間	15	90	90	88	86	84	92	94	90
(分)	30	98	98	93	91	90	96	97	94
	45	100	100	94	93	92	97	98	95
f2	値	-	100	-	85	74	-	88	83

この結果、すべての製剤において本明細書P.6「C. 品質評価(2)溶出プロファイルの 類似性」の基準を満たすことが確認された。

産業上の利用可能性


[0119] 本発明によりN-[4-[4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジ ニル]-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシ クロ[2,2,1]へプタンジカルボキシイミド・塩酸塩(ルラシドン)を有効成分とする崩壊 性が良好な経口製剤において、有効成分の含量が変動しても、同等の溶出挙動を 示す経口投与用製剤を提供することが可能となった。

図面の簡単な説明

[0120] [図1]図1はルラシドンを異なる含有量を有する製剤の溶出プロファイルの比較を示したものである。特許文献2の開示技術を用いて試作した1錠中のルラシドンの含有量が10mg(4錠)と40mg(1錠)の製剤について溶出プロファイルを測定した。
[図2]図2は、ルラシドンを異なる含有量を有する製剤の溶出プロファイルの比較を示したものである。特許文献2の開示技術を用いて試作した1錠中のルラシドンの含有量が40mg(2錠)と80mg(1錠)の製剤について溶出プロファイルを測定した。
[図3]図3は、ルラシドンを異なる含有量を有する製剤の溶出プロファイルの比較を示したものである。本発明の技術を用いて試作した1錠中のルラシドンの含有量が20mg(4錠)、40mg(2錠)と80mg(1錠)の製剤について溶出プロファイルを測定した。

請求の範囲

[1] 式(1)



で表されるN-[4-[4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニル]-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシクロ[2,2,1]ヘプタンジカルボキシイミド・塩酸塩(ルラシドン)、アルファ化デンプン類、水 溶性賦形剤、水溶性高分子結合剤を含有する経口製剤。


- [2] ルラシドン、アルファ化デンプン類及び水溶性賦形剤を含む混合末を、水溶性高分子結合剤を溶解した溶液を用いて造粒した経口製剤。
- [3] アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン及び水溶性高 分子結合剤を溶解又は分散した液により、造粒した経口製剤。
- [4] 水溶性賦形剤がマンニトールもしくは乳糖である請求項1~3いずれか記載の経口 製剤。
- [5] ルラシドン、アルファ化デンプン類及び水溶性賦形剤を含む混合末を、水溶性高分子結合剤を溶解した溶液を用いることにより造粒する方法。
- [6] アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン及び水溶性高 分子結合剤を溶解又は分散した液を用いることにより造粒する方法。
- [7] 水溶性賦形剤がマンニトールもしくは乳糖である請求項5記載の造粒方法。
- [8] アルファ化デンプン類の配合量が製剤重量に対して10~50%(wt/wt)である請 求項1~4いずれか記載の経口製剤。
- [9] アルファ化デンプン類の配合量が製剤重量に対して20~30%(wt/wt)である請 求項1~4いずれか記載の経口製剤。
- [10] 製剤中のルラシドン含有量が、20~45%(wt/wt)である請求項1~4いずれか記載の経口製剤。
- [11] 製剤中のルラシドン含有量が、25~40%(wt/wt)である(1)から(4)いずれか記

載の経口製剤。

- [12] ルラシドンの1錠中の含量が、10~160mgである請求項1~4いずれか記載の経口 製剤。
- [13] ルラシドンの1錠中の含量が、20~120mgである請求項1~4いずれか記載の経口 製剤。
- [14] ルラシドンの1錠中の含量が、40~120mgである請求項1~4いずれか記載の経口 製剤。
- [15] 水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合量が 製剤重量に対して10~50%(wt/wt)である請求項1~4いずれか記載の経口製 剤。
- [16] 水溶性賦形剤がマンニトールもしくは乳糖であり、製剤中のルラシドン含有量が25~ 40%(wt/wt)である請求項1~4いずれか記載の経口製剤。
- [17] アルファ化デンプン類の配合量が製剤重量に対して10~50%(wt/wt)であり、製剤中のルラシドン含有量が25~40%(wt/wt)である請求項1~4いずれか記載の経口製剤。
- [18] 水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合量が 製剤重量に対して10~50%(wt/wt)であり、製剤中のルラシドン含有量が25~4 0%(wt/wt)である請求項1~4いずれか記載の経口製剤。
- [19] 水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合量が 製剤重量に対して20~30%(wt/wt)であり、製剤中のルラシドン含有量が25~4 0%(wt/wt)である請求項1~4いずれか記載の経口製剤。
- [20] 水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合量が 製剤重量に対して20~30%(wt/wt)であり、ルラシドンの1錠中の含量が40~12 Omgである請求項1~4いずれか記載の経口製剤。
- [21] アルファ化デンプン類のアルファ化率が50~95%である請求項1~4いずれか記載 の経口製剤。
- [22] ルラシドンの平均粒子径が0.1~8µmである請求項1~4いずれか記載の経口製 剤。

- [23] アルファ化デンプン類中の水可溶分が、30%以下である請求項1~4いずれか記載 の経口製剤
- [24] 水溶性賦形剤がマンニトールもしくは乳糖であり、アルファ化デンプン類の配合量が
 製剤重量に対して20~30%(wt/wt)であり、製剤中のルラシドン含有量が25~4
 0%(wt/wt)であり、ルラシドンの1錠中の含量が20~120 mg である請求項1~4
 いずれか記載の経口製剤。


Par Pharm., Inc. Exhibit 1015 Page 120 [図1]



Par Pharm., Inc. Exhibit 1015 Page 121


2/3

[図2]



3/3

[図3]



- f2=88 (80 錠に対して 40mg 錠 2 錠)
- f2=97 (80 錠に対して 20mg 錠 4 錠)

	INTERNATIONAL SEARCH REPORT	ſ	International applica	ition No.	
			PCT/JP20	06/310571	
A61K31/49	CATION OF SUBJECT MATTER D6(2006.01), A61K9/20(2006.01), , A61K47/38(2006.01), C07D417/		:006.01), A6 :	1K47/26	
According to Inte	ernational Patent Classification (IPC) or to both national	al classification and IP	PC		
B. FIELDS SE	ARCHED				
Minimum docun A61K9/20,	nentation searched (classification system followed by cl A61K31/496, A61K47/10, A61K47	assification symbols) /26, A61K47/	38, C07D417,	/12	
Jitsuyo		ent that such documen tsuyo Shinan T oroku Jitsuyo S	'oroku Koho 1	fields searched .996-2006 .994-2006	
	pase consulted during the international search (name of RY (STN), CA (STN)	data base and, where	practicable, search te	rms used)	
C. DOCUMEN	VTS CONSIDERED TO BE RELEVANT		T		
Category*	Citation of document, with indication, where ap			Relevant to claim No.	
A	A WO 2002/024166 A1 (Sumitomo Pharmaceuticals 1-24 Co., Ltd.), 28 March, 2002 (28.03.02), 1 Full text; particularly, examples & AU 200186237 A & EP 1327440 A1 & US 2004/0028741 A1				
A	A WO 2004/078173 A1 (Shionogi & Co., Ltd.), 1-24 16 September, 2004 (16.09.04), Full text; particularly, Claim 3; example 7; Fig. 1 & TW 200423972 A				
A	JP 08-325146 A (Kyowa Hakko 10 December, 1996 (10.12.96) Full text (Family: none)		Ltd.),	1-24	
Further do	ocuments are listed in the continuation of Box C.	See patent far	nily annex.		
 "A" document de be of particu "E" earlier applie date "L" document w cited to esta special reaso "O" document re 	gories of cited documents: fining the general state of the art which is not considered to lar relevance cation or patent but published on or after the international filing which may throw doubts on priority claim(s) or which is blish the publication date of another citation or other in (as specified) ferring to an oral disclosure, use, exhibition or other means iblished prior to the international filing date but later than the claimed	 "T" later document pudate and not in conthe principle or the document of particonsidered novel step when the doc "Y" document of particonsidered to import document of particonsidered to import document with on being obvious to a step when the document of be step when the document of be	bblished after the internat nflict with the application eory underlying the inver cular relevance; the clair l or cannot be considere aument is taken alone cular relevance; the clain volve an inventive step	ntion ned invention cannot be d to involve an inventive ned invention cannot be when the document is uments, such combination	
	al completion of the international search ust, 2006 (07.08.06)		he international search st, 2006 (15		
Japane	ng address of the ISA/ se Patent Office	Authorized officer			
Facsimile No. Form PCT/ISA/21	0 (second sheet) (April 2005)	Telephone No.			

	国際調査報告	国際出願番号 PCT/JP200	6/310571		
Int.Cl. A	属する分野の分類(国際特許分類(IPC)) <i>61K31/496</i> (2006.01), <i>A61K9/20</i> (2006.01), <i>A</i> 2006.01), <i>C07D417/12</i> (2006.01)	61K47/10 (2006.01), A61K47/26 (2006.	01), A61K47/38		
調査を行った最	fった分野 ∂小限資料(国際特許分類(IPC)) 61K 9/20, A61K 31/496, A61K 47/10, A61K 47	/26, A61K 47/38, C07D 417/12			
日本国実用 日本国公開 日本国実用	▶の資料で調査を行った分野に含まれるもの 新案公報 1 9 2 2 − 1 9 9 6 年 実用新案公報 1 9 7 1 − 2 0 0 6 年 新案登録公報 1 9 9 6 − 2 0 0 6 年 実用新案公報 1 9 9 4 − 2 0 0 6 年				
	引した電子データベース(データベースの名称、 STN),CA(STN)	調査に使用した用語)			
C. 関連する 引用文献の カテゴリー *	らと認められる文献 引用文献名 及び一部の箇所が関連する	ときは、その関連する箇所の表示	関連する 請求の範囲の番号		
А	WO 2002/024166 A1 (住友製薬株式会 全文、特に、実施例参照 & AU 200 US 2004/0028741 A1		1-24		
А	W0 2004/078173 A1 (塩野義製薬株式 全文、特に、請求項3、実施例7、	· · ·	1-24		
C欄の続き	きにも文献が列挙されている。	パテントファミリーに関する別	川紙を参照。		
 * 引用文献のカテゴリー の日の後に公表された文献 「A」特に関連のある文献ではなく、一般的技術水準を示す もの 「E」国際出願日前の出願または特許であるが、国際出願日 以後に公表されたもの 「L」優先権主張に疑義を提起する文献又は他の文献の発行 日若しくは他の特別な理由を確立するために引用す る文献(理由を付す) 「O」口頭による開示、使用、展示等に言及する文献 「P」国際出願日前で、かつ優先権の主張の基礎となる出願 の日の後に公表された文献 「T」国際出願日又は優先日後に公表された文献であって 出願と矛盾するものではなく、発明の原理又は理論 の理解のために引用するもの 「X」特に関連のある文献であって、当該文献のみで発明 の新規性又は進歩性がないと考えられるもの 「Y」特に関連のある文献であって、当該文献と他の1以 上の文献との、当業者にとって自明である組合せに よって進歩性がないと考えられるもの 「&」同一パテントファミリー文献 					
国際調査を完了	了した日 07.08.2006	国際調査報告の発送日 15.0	8.2006		
日本国	D名称及びあて先 国特許庁(ISA/JP) 郵便番号100-8915 郡千代田区霞が関三丁目4番3号	特許庁審査官(権限のある職員) 八原 由美子 電話番号 03-3581-1101	4C 3755 内線 3452		

様式PCT/ISA/210(第2ページ)(2005年4月)

	国際調査報告	国際出願番号 PCT/JP2006/31057		
C(続き).	関連すると認められる文献			
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するとき	は、その関連する箇所の表示	関連する 請求の範囲の番号	
А	<u>引用文献名 & 05</u> 一部の箇所が関連するとき JP 08-325146 A (協和醗酵工業株式会社) 全文参照, (ファミリーなし)		請求の範囲の番号 1-24	

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/JP2006/310571

International filing date: 26 May 2006 (26.05.2006)

Document type:	Certified copy of priority document				
Document details:	Country/Office: Number: Filing date:	JP 2005-153508 26 May 2005 (26.05.2005)			

Date of receipt at the International Bureau: 06 July 2006 (06.07.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

日本国特許庁 JAPAN PATENT OFFICE


別紙添付の書類に記載されている事項は下記の出願書類に記載されている事項と同一であることを証明する。

This is to certify that the annexed is a true copy of the following application as filed with this Office.

出願年月日 Date of Application:	2005年 5月26日
出 願 番 号 Application Number:	特願2005-153508
パリ条約による外国への出願 に用いる優先権の主張の基礎 となる出願の国コードと出願 番号 The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is	JP2005-153508
出 願 人 Applicant(s):	大日本住友製薬株式会社

2006年 6月21日


特許庁長官 Commissioner, Japan Patent Office





【書類名】	特許願
【整理番号】	1 3 3 3 4 8
【あて先】	特許庁長官殿
【国際特許分類】	A 6 1 K 3 1 / 4 9 5
【発明者】	
【住所又は居所】	大阪府茨木市藏垣内1丁目3番45号 住友製薬株式会社内
【氏名】	富士原 和之
【特許出願人】	
【識別番号】	0 0 0 1 8 3 3 7 0
【氏名又は名称】	住友製薬株式会社
【代理人】	
【識別番号】	100121588
【弁理士】	
【氏名又は名称】	五十部 穣
【電話番号】	$0\ 6\ -\ 6\ 4\ 6\ 6\ -\ 5\ 2\ 1\ 4$
【手数料の表示】	
【予納台帳番号】	056546
【納付金額】	16.000円
【提出物件の目録】	
【物件名】	特許請求の範囲
【物件名】	明細書
【物件名】	図 面 1
【物件名】	要約書
【包括委任状番号】	0 2 0 5 8 7 6

【書類名】特許請求の範囲 【請求項1】 式(1)



で表されるN-[4-(4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニ ル)-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2 ,3-ビシクロ(2,2,1)へプタンジカルボキシイミド・塩酸塩(ルラシドン・塩酸塩)、アルファ化デンプン類、水溶性賦形剤、水溶性高分子結合剤を含有する経口製剤。 【請求項2】

ルラシドン・塩酸塩、アルファ化デンプン類及び水溶性賦形剤を含む混合末を、水溶性高 分子結合剤を溶解した溶液を用いて造粒した経口製剤。

【請求項3】

アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン・塩酸塩及び水溶性 高分子結合剤を溶解又は分散した液により、造粒した経口製剤。

【請求項4】

水溶性賦形剤がマンニトールもしくは乳糖である請求項1~3いずれか記載の経口製剤。 【請求項5】

ルラシドン・塩酸塩、アルファ化デンプン類及び水溶性賦形剤を含む混合末を、水溶性高 分子結合剤を溶解した溶液を用いることにより造粒する方法。

【請求項6】

アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン・塩酸塩及び水溶性 高分子結合剤を溶解又は分散した液を用いることにより造粒する方法。

【請求項7】

水溶性賦形剤がマンニトールもしくは乳糖である請求項5記載の造粒方法。

【請求項8】

アルファ化デンプン類の配合量が製剤重量に対して $10 \sim 50\%$ (wt/wt)である請 求項1から4記載の経口製剤。

【請求項9】

アルファ化デンブン類の配合量が製剤重量に対して20~30%(wt/wt)である請 求項1から4記載の経口製剤。

【請求項10】

製剤中のルラシドン・塩酸塩含有量が、20~40%(wt/wt)である請求項1から 4いずれか記載の経口製剤。

【請求項11】

ルラシドン・塩酸塩の1錠中の含量が、10~120mgである請求項1から4いずれか記載の経口製剤。

【請求項12】

アルファ化デンプン類のアルファ化率が50~95%である請求項1から4いずれか記載 の経口製剤。

【請求項13】

ルラシドン・塩酸塩の平均粒子径が0.1~8μmである請求項1から4いずれか記載の 経口製剤。

【請求項14】

アルファ化デンプン類中の水可溶分が、20%以下である請求項1から4いずれか記載の

経口製剤

【書類名】明細書

【発明の名称】医薬品組成物

【技術分野】

 $\begin{bmatrix} 0 & 0 & 0 & 1 \end{bmatrix}$

本発明は、N-[4-(4-(1,2-ベンズイソチアゾール-3-イル)-1-ビペラジ ニル)-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシクロ(2,2,1) ヘブタンジカルボキシイミド・塩酸塩(ルラシドン・塩酸 塩)を有効成分とする崩壊性が良好な経口製剤に関する。詳しくはルラシドン・塩酸塩を 有効成分とする経口製剤において、有効成分の含量が変動しても、同等の溶出挙動を示す 経口投与用製剤、特に錠剤に関する。

【背景技術】

 $\begin{bmatrix} 0 & 0 & 0 & 2 \end{bmatrix}$

特許文献1には、ルラシドン・塩酸塩等の化合物について、経口的に投与することがで きること、また通常の担体・賦形剤・結合剤・安定剤等と有効成分とを配合することによ り製造できることの記載はあるが、該有効成分の含量が広い範囲で異なっても速溶解性を 示し、かつ、同等の溶出挙動を示す経口用の製剤、とくに有効成分の含量を増大した場合 に低含量の製剤の複数錠と同様の溶出挙動を示す経口製剤に関する記載はない。

 $\begin{bmatrix} 0 & 0 & 0 & 3 \end{bmatrix}$

含量が異なる製剤を同一用量服用したときの生物学的同等性を保証することを目的として医薬審第64号(平成12年2月14日公布)にて『含量が異なる経口固形製剤の生物学的同等性試験ガイドライン』が示され、含量が異なる製剤において、胃、腸および口腔内の各pH値に対応するpH1.2、3.0~5.0および6.8の緩衝液、水、生理食塩水などの各試験液で同等の溶出挙動を示すことが求められるようになった。

[0004]

ルラシドン・塩酸塩を有効成分とする薬剤について、該有効成分の含量が異なっても速 溶解性を示し、かつ、同等の溶出挙動を示す経口製剤、とくに有効成分の含量を増大した 場合に低含量の製剤の複数錠と同様の溶出挙動を示し、水難溶性の有効成分を所望の濃度 に放出し得る経口製剤については特許文献2に開示されている。

[0005]

特許文献2には有効成分の含量が数mg~数十mgの範囲、例之は5mg~20mgまたは5mg~40mgの範囲、で変動しても、速溶解性を示し、かつ、同一組成比において同等の溶出挙動を示す経口製剤、特に錠剤が開示されている。経口製剤においては、より高い臨床効果を得るためにさらに高い含量の製剤、又は患者の症状に応じて臨床効果を 調節するためにより広い含量範囲で、複数錠と同様の挙動を示し、有効成分を所望の濃度 に放出し得る製剤が必要とされる場合が多い。特許文献2の開示技術では図1に示すよう にルラシドン・塩酸塩が1錠あたり5mgから40mgまでは同等の溶出挙動を示す経口 製剤を提供することができる。しかしながら、図2に示すように、製剤中の有効成分の含 有率を2倍にすることにより一錠中の有効成分の含有量を増やした場合、80mg錠では 同等の溶出挙動を示すことができなかった。従って、複数錠を一度に服用するか、服用に 困難な大きさの錠剤にせざるを得ない状況であった。よって、水難溶性の有効成分である ルラシドン・塩酸塩については、高含量の経口製剤あるいはさらに広い範囲で溶出挙動が 同等な経口製剤の提供は困難であった。

[0006]

また、特許文献2には水溶性高分子結合剤としてデンプンが挙げられているが、アルフ ア化デンプンについての記載はない。アルファ化デンプンは、例えば、特許文献3に記載 されているように、医薬品組成物の崩壊性及び溶出性が顕著に改善することが知られてい るが、医薬品に採用されることは必ずしも多くはない。崩壊剤として使用される場合、非 特許文献1の中でも記述されるように通常、10%以下の含有量で用いられることが多い

【0007】

【特許文献1】特許第2800953 【特許文献2】WO2002/024166 【特許文献3】特開2000−26292 【非特許文献1】Handbook of Pharmaceutical Excipients, 2nd edition, 491, 199 4, The Pharmaceutical Press

【発明の開示】

【発明が解決しようとする課題】

【0008】

本発明の目的は、ルラシドン・塩酸塩を有効成分とし、該有効成分の含量が広い範囲で 異なっても速溶解性を示し、かつ、同等の溶出挙動を示す経口用の製剤、とくに有効成分 の含量を増大した場合に低含量の製剤の複数錠と同様の溶出挙動を示し、有効成分を所望 の濃度に放出し得る経口製剤を提供することにある。

【 0 0 0 9 】

N-[4-(4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニル)-(2R,3R)-2,3-テトラメチレンーブチル]-(1'R,2'S,3'R,4'S)-2,3-ビシクロ(2,2,1)、プタンジカルボキシイミド・塩酸塩(以下、ルラシドン・塩酸塩)を有効成分とする経口製剤において、有効成分の含量が変動しても、同等の溶出挙動を示す経口投与用製剤の提供することを目的とする。

【課題を解決するための手段】


 $\begin{bmatrix} 0 & 0 & 1 & 0 \end{bmatrix}$

本発明者らは、前記課題を解決するために鋭意検討したところ、以下の手段により当該 課題を解決することを見いだすに至った。

 $\begin{bmatrix} 0 & 0 & 1 & 1 \end{bmatrix}$

すなわち、本発明は、以下の通りである。

- (1) 式(1)
 - $\begin{bmatrix} 0 & 0 & 1 & 2 \end{bmatrix}$
 - 【化1】



で表されるN-[4-(4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニ ル)-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2, 3-ビシクロ(2,2,1) ヘプタンジカルボキシイミド・塩酸塩(ルラシドン・塩酸塩)、アルファ化デンプン類、水溶性賦形剤、水溶性高分子結合剤を含有する経口製剤。

(2) ルラシドン・塩酸塩、アルファ化デンブン類及び水溶性賦形剤を含む混合末を、水 溶性高分子結合剤を溶解した溶液を用いて造粒した経口製剤。

(3) アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン・塩酸塩及び 水溶性高分子結合剤を溶解又は分散した液により、造粒した経口製剤。

(4) 水溶性賦形剤がマンニトールもしくは乳糖である(1)~(3)いずれか記載の経 口製剤。

(5) ルラシドン・塩酸塩、アルファ化デンプン類及び水溶性賦形剤を含む混合末を、水 溶性高分子結合剤を溶解した溶液を用いることにより造粒する方法。

(6) アルファ化デンプン類及び水溶性賦形剤を含む混合末を、ルラシドン・塩酸塩及び 水溶性高分子結合剤を溶解又は分散した液を用いることにより造粒する方法。

(7)水溶性賦形剤がマンニトールもしくは乳糖である(5)記載の造粒方法。

(8) アルファ化デンプン類の配合量が製剤重量に対して10~50%(wt/wt)で ある(1)から(4)いずれか記載の経口製剤。 (9) アルファ化デンプン類の配合量が製剤重量に対して20~30%(wt/wt)で ある(1)から(4)いずれか記載の経口製剤。

(10) 製剤中のルラシドン・塩酸塩含有量が、20~40%(wt/wt)である(1)から(4) いずれか記載の経口製剤。

(11) ルラシドン・塩酸塩の1錠中の含量が、10~120mgである(1)から(4) いずれか記載の経口製剤。

(12) アルファ化デンブン類のアルファ化率が50~95%である(1)から(4)い ずれか記載の経口製剤。

(13) ルラシドン・塩酸塩の平均粒子径が0.1~8µmである(1)から(4)いず れか記載の経口製剤。

(14) アルファ化デンブン類中の水可溶分が、20%以下である(1)から(4)いず れか記載の経口製剤

【発明の効果】

[0013]

本発明によりルラシドン・塩酸塩を有効成分とする崩壊性が良好な経口製剤において、 ルラシドン・塩酸塩を高含有量含む経口製剤の提供が、また有効成分の含量が変動しても 同等の溶出挙動を示す経口投与用製剤を提供することが可能となった。また、配合変化を 起こさず、長期保存性にも優れている。


【発明を実施するための最良の形態】

 $\begin{bmatrix} 0 & 0 & 1 & 4 \end{bmatrix}$

N-[4-(4-(1,2-ベンズイソチアゾール-3-イル)-1-ビベラジニル)-(2R,3R)-2,3-テトラメチレンーブチル]-(1'R,2'S,3'R,4'S)-2,3-ビ シクロ(2,2,1)へプタンジカルボキシイミド・塩酸塩(ルラシドン・塩酸塩)は下記 式:

 $\begin{bmatrix} 0 & 0 & 1 & 5 \end{bmatrix}$

【化2】



で示される化合物である(特許第2800953号参照)。ルラシドン・塩酸塩は向精神病 作用を持つことが知られており、統合失調症等の治療薬として有効である。本化合物の配 合量としては、錠剤全重量に基づいて、例えば、10~50重量%の範囲、好ましくは2 0~40重量%の範囲から選択される。更に、微粉砕されていることが好ましく、例えば 体積比90%以上の粒子が27 μ m以下であり、体積比による平均粒子径としては例えば、0.1~8 μ mの範囲が挙げられる。好ましくは、1~6 μ mの範囲が挙げられる。1 錠中に含まれるルラシドン・塩酸塩の含量としては、10-120mg、好ましくは20 -80mgが挙げられる。

 $\begin{bmatrix} 0 & 0 & 1 & 6 \end{bmatrix}$

「アルファ化デンプン類」とは例えばトウモロコシデンプン、バレイショデンプン、コムギデンプン、コメデンプン、タピオカデンプン等各種デンプン類をアルファ化したものであり、このようなものとしては例えば医薬品添加物規格にあるアルファ化デンプン(英語名:Partly Pregelatinized Starch)又は部分アルファ化デンプン(英語名:Partly Pregelatinized Starch)等を挙げることができる。アルファ化デンプン類のアルファ化率は、例えば50~100%、好ましくは50~95%、さらに好ましくは80~95%である。更に、アルファ化デンプン類中の水可溶分は、例えば20%以下、より好ましくは5%以下である。これらアルファ化デンプン類は、通常、平均粒径が1~1000µm、好ましくは1~500µm、さらに好ましくは10~100µmの粉末が用いられる。本発明に

適する市販のアルファ化デンプン類としては、例えばPCS(商品名、旭化成工業株式会 社製)又はスターチ1500(商品名、カラコン)等の部分アルファ化デンプンが挙げら れる。上記アルファ化デンプン類の中でも部分アルファ化デンプン、例えばPCS(商品 名、旭化成工業株式会社製)が好ましく用いられる。部分アルファ化デンプンのアルファ 化率は、好ましくは50~95%、さらに好ましくは80~95%である。本発明におい て用いられるアルファ化デンプン類は、製剤重量に対して10%以上50%以下であり、 好ましくは10%以上30%以下であり、特に好ましくは、20%以上30%以下である

 $\begin{bmatrix} 0 & 0 & 1 & 7 \end{bmatrix}$

「水溶性賦形剤」としては、例えばマンニトール、乳糖、白糖、ソルビトール、D-ソ ルビトール、エリスリトール、キシリトール等が挙げられる。より好ましいものとしては マンニトール及び乳糖が挙げられる。さらに好ましくはマンニトールを挙げることができ る。また、該水溶性賦形剤は、1種または同時に2種以上を使用することができる。水溶 性賦形剤の配合量としては、錠剤全重量に基づいて、例えば、30~80重量%の範囲、 好ましくは40~60重量%の範囲から選択される。また、マンニトールの平均粒子径と しては、例えば10~200μmの範囲が挙げられる。

 $\begin{bmatrix} 0 & 0 & 1 & 8 \end{bmatrix}$

「水溶性高分子結合剤」としては、例えば、ヒドロキシブロビルセルロース、ヒドロキ シブロビルメチルセルロース、ボリビニルピロリドン、ボリビニルアルコール等が挙げら れる。より好ましいものとしては、ヒドロキシプロピルセルロース、ヒドロキシプロピル メチルセルロース、ボリビニルピロリドン、ボリビニルアルコールが挙げられる。該水溶 性高分子結合剤は、これらの1種または同時に2種類以上を用いることができる。水溶性 高分子結合剤の配合量としては錠剤全重量に基づいて、例えば、0.5~10重量%の範 囲、好ましくは1~5重量%の範囲から選択される。

本発明の医薬品組成物から成る経口製剤は、錠剤、カプセル剤、顆粒剤、細粒剤に製剤化 されるものをいう。慣用手段によって、水溶性賦形剤に加えて非水溶性賦形剤、結合剤、 崩壊剤、滑沢剤、等を使用して、錠剤、カプセル剤、顆粒剤、細粒剤に製剤化されるもの であってもよい。また、以下のものを加えることもできる。

 $\begin{bmatrix} 0 & 0 & 1 & 9 \end{bmatrix}$

「非水溶性賦形剤」としては、例えばコーンスターチ、結晶セルロース等が挙げられる。 また、1種または同時に2種以上を使用することができる。

「崩壊剤」としては、例えば、コーンスターチ、結晶セルロース、低置換度ヒドロキシ ブロビルセルロース、カルメロース、カルメロースカルシウム、カルメロースナトリウム 、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、クロスボビド ン等が挙げられる。該崩壊剤は、1種または同時に2種以上を使用することができる。該 崩壊剤の平均粒子径としては、例えば、5~75µmの範囲のものが挙げられ、好ましく は5~75µmの範囲の平均粒子径を有し、75µmを越える粒子が全体の5%以下であ ることが望ましい。崩壊剤の配合量としては、錠剤全重量に基づいて、例えば、0~10 重量%の範囲、好ましくは0.5~5重量%の範囲が挙げられる。

 $\begin{bmatrix} 0 & 0 & 2 & 1 \end{bmatrix}$

[0 0 2 2]

本発明の経口製剤の調製は、所望の剤形により異なるが、常法にしたがって所望の剤形にすることができる。

(1)水溶性高分子結合剤の水溶液の調製:

水溶性高分子結合剤を精製水に溶解する。その際の温度としては、例えば、20℃から 90℃の範囲から選択され、好ましくは、20℃から70℃の範囲から選択される。水溶 性高分子結合剤の量としては、精製水の量に対し、例えば1~20重量%の範囲、好まし くは2~8重量%の範囲から選択される。

(2) ルラシドン・塩酸塩含有造粒物の調製:

ルラシドン・塩酸塩、マンニトール、部分アルファ化デンプンを含む賦形剤および崩壊 剤を仕込んだ流動層造粒機に、上記(1)の工程で調製された水溶性高分子結合剤を散布し ながら造粒する。

【0023】

造粒装置としては、例えば、流動層造粒(Fluid Bed Granulation)、高速攪拌造粒(High share granulation)、転動型流動層造粒(Roto Fluid Bed Granulation)等に分類される 造粒装置が挙げられる。但し、これらに限定されるものではない。

(3)造粒物の乾燥:

上記造粒物を、減圧または常圧にて乾燥する。この乾燥は、赤外線水分計にて測定され る乾燥減量値が、例えば、3重量%以内、好ましくは1~2重量%以内になるように行う

(4) 滑沢剤の配合:

上記(3)で乾燥した造粒物に滑沢剤を加えて混合する。混合は、例えば、攪拌ミキサー [タンブル](Diffusion mixers [Tumble])に分類される混合機が用いられる。具体的には 、タンブラーブレンダー(Tumble Blender)、Vブレンダー(V Blenders)、ダブルコーン(D ouble Cone)、ビンタンブラー(Bin Tumble)等が挙げられる。但し、これらに限定される ものではない。

(5)打錠:

上記混合物を打錠して錠剤を調製する。

[0 0 2 4]

打錠装置としては、例えば、錠剤プレス(Tablet Press)に分類される打錠機等が挙げられる。打錠硬度としては、例えば30~200N範囲から選択される。

(6)所望によりフィルムコーティングを施す:

上記錠剤には、必要に応じてフィルムコーティングしてもよい。コーティング装置としては、例えばコーティングバンに分類される装置が挙げられる。好ましくは、通気式コーティングシステム (Perforated Coating System)で分類される装置が挙げられる。

 $\begin{bmatrix} 0 & 0 & 2 & 5 \end{bmatrix}$

コーティング剤としては、例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシ プロピルセルロース、ボリビニルピロリドン、ボリビニルアルコール等の基剤と、例えば 、ポリエチレングリコール、プロピレングリコール、トリアセチン、クエン酸トリエチル 、グリセリン、グリセリン脂肪酸エステル、ポリエチレングリコール等の可塑剤を組み合 わせたものが挙げられる。また、必要に応じて、酸化チタン等の添加剤を加え調製するこ ともできる。また、フィルムコーティング後に、光沢化剤としてカルナバロウ等を加える こともできる。

(7)乾燥:

上記のようにして得られた錠剤を乾燥する。乾燥は減圧または常圧で行い、赤外線水分 計にて測定される乾燥減量値が、例えば、3重量%以内、好ましくは1~2重量%以内に なるように行う。

 $\begin{bmatrix} 0 & 0 & 2 & 6 \end{bmatrix}$

以下に本発明の実施例を挙げるが、本実施例は本発明を説明するためのものであって、 本発明をなんら限定するものではない。

【実施例1】

【0027】

A. ルラシドン・塩酸塩を80mg含有するフィルムコート錠(実施例1)

下記組成からなる顆粒、裸錠およびFC錠を順次調製する。尚、説明文中の括弧内に示 す仕込み量は実施例1に示す処方の製剤を調製するための一例を示すものである。

原則としてこの製造方法に準じれば、その他に示す実施例についても調製できる。但し、

仕込み量は処方に基づき変更する必要がある。

【0028】

B. 製造方法

(1)結合液の調製(5% ヒドロキシプロピルメチルセルロース水溶液):

水溶性高分子結合剤のヒドロキシプロピルメチルセルロース(32g)を精製水(640g)に溶解し、これを結合液とした。

(2)造粒:

ルラシドン・塩酸塩(320g)、マンニトール(576g)、部分アルファ化デンプン (320g)、クロスカルメロースナトリウム(16g)を流動層造粒機(マルチブレック スMP-01/バウレック製)に仕込み、上記(1)で調製した結合液を用いて、下記条件 でスプレー造粒し造粒末を得た。得られた造粒末にステアリン酸マグネシウムを加えて混 合後(40rpm、5分)に、処方(b)を有する打錠用顆粒を得た。尚、ステアリン酸マグ ネシウムの仕込み量は造粒末の収量に基づき処方から算出される量を混合した。 造粒条件

給気温度:60℃ 風量:50-65m³/hr スプレー速度:13g/分 スプレーノズル径:1.2mm スプレー圧力:0.12MP a

ガン位置:中段

(3)打錠:

上記(2)で調製した打錠用顆粒をHT-AP12SS-II(畑鉄工所)を用いて錠剤を成形した。

- 杵サイズ:φ10mm14R
- 厚み:4.20~4.30mm
- 打錠圧縮圧力:10KN
- (4)コーティング:

上記(3)で調製した裸錠をハイコーターHCT30N(フロイント産業)で皮膜量が5m gになるように下記条件でコーティングを行い、コーティング後にカルナバロウを添加し フィルムコート錠を得た。

FC条件

給気温度 :80℃

- 風量 : 0 . 6 m³∕分
- パン回転数:25rpm
- スプレーE: 0.15MP a
- 液速 :5g/分

上述の方法により得られた製剤は以下の方法により品質を評価し、そこで得られた知見を もとに本発明を見出すに至った。

- [0029]
- C. 品質評価
- (1)溶出試験

日本薬局方溶出試験法第2法に従い、試作した製剤の溶出試験を実施した。以下に測定 条件を示す。

|試験溶液:希釈マックイルベイン緩衝液(diluted Mcllvaine buffer、pH4.0)

パドル回転数:50rpm

試験液: 900ml

(2) 溶出プロファイルの類似性

溶出プロファイルの類似性を評価するための指標としてScale-Up and Past-Approval (hanges for Intermediate Release Products(SUPAC-IR)に示される類似因子12を用いた。 12は以下の式により算出される。SUPAC-IRにより各製剤の溶出率から算出される12値が50 \leq 12 \leq 100の範囲にある場合、試作した各製剤は類似の溶出プロファイルであると判 定した。また、12値の算出に当っては試験開始後15分、30分および45分の3ポイントの時点での溶出率を用いた。

【0030】 【数1】

$$f2= so \cdot Loo G\left[\frac{100}{\sqrt{1 + \frac{\sum_{i=1}^{n} (Ti - Ri)^{2}}{n}}}\right]$$

Ti and Ri are the percent dissolved at each point.
n is the number of points to be compared.

(3)粒度分布

レーザー回折粒度分布測定装置(SLAD-3000/島津製作所)の乾式噴射法にてルラシドン・塩酸塩の粒度分布を測定した。以下に測定条件を示す。

試料量:2g

エアーE: 0.4MPa以上 ターンテーブル回転スピード:2 パラメータ設定 環境設定 モニター平均回数:16 測定最適範囲(最大) : 1500 : 700 暗測定平均回数 :2 (最小) 光強度表示最大值:2000 (CH-1) $\pi - \nu - \gamma$ (bps) : 9600 前回のブランク値:読み込み ブランク測定許容最大値 : 300 プリンター:モノクロ ブランク測定許容変動範囲:20 屈折率パラメーター 標準屈折率: 1.70-0.20i 測定条件設定 測定回数:1 乾式許容最小值:300 測定間隔(秒):1 最大值:2500 平均回数:64 評価対象粒子範囲(最小値):0.1 測定吸光度範囲(最大値):0.1 評価対象粒子範囲(最大値):2000 (最小値):0.05 センサ使用開始位置:1 トリガーモード:OFF 乾式しきい:300 $\begin{bmatrix} 0 & 0 & 3 & 1 \end{bmatrix}$

<試験1>

実施例1、2,3で、1錠中にルラシドン・塩酸塩を20mg、40mgおよび80m g含有する水溶性賦形剤、部分アルファ化デンプンおよび水溶性高分子結合剤から成る特 定の医薬品組成物を含む錠剤を試作した。また、比較例1、2で、特許文献2の開示処方 に基づき1錠中にルラシドン・塩酸塩を40mgおよび80mg含有する錠剤を試作した

試作した製剤を(d)および(e)に示す条件で溶出試験を実施し、溶出プロファイルの類似性を評価した。なお、比較例1、2の試作については試験8にて示した。 結果は、表4,5に示した。なお、(d)については経時的な溶出率についても図2, 3で示した。

[0032]

(a) 造粒末の処方

【0033】

【表1】

	単位:mg				
成分	実施例番	実施例番号			号
	1	2	3	1	2
ルラシドン・塩酸塩	80	40	20	40	80
マンニトール	144	72	36	188	148
部分アルファ化デンプン	80	40	20	_	_
クロスカルメロースナトリウム	4	2	1	16	16
ヒドロキシプロピルメチルセルロース	8	4	2	10	10

 $\begin{bmatrix} 0 & 0 & 3 & 4 \end{bmatrix}$

(b) 打錠用顆粒/裸錠の処方

[0035]

【表2】

				単位:m	ιg
成分	実施例番	号	比較例番号		
	1	1	1	1	2
上記(a)の顆粒	316	158	79	254	254
乳糖	-	-	-	62	62
ステアリン酸マグネシム	4	2	1	4	4

 $\begin{bmatrix} 0 & 0 & 3 & 6 \end{bmatrix}$

(c) F C 錠の処方

 $\begin{bmatrix} 0 & 0 & 3 & 7 \end{bmatrix}$

【表3】

				単位:m	g
成分	実施例番	号	比較例番号		
	1	2	3	1	2
上記(b)の裸錠	320	160	80	320	320
ヒドロキシプロピルメチルセルロース	3.25	1.95	1.3	2.6	2.6
酸化チタン	1	0.6	0.4	0.8	0.8
ポリエチレングリコール6000	0.75	0.45	0.3	0.6	0.6
カルナバロウ	0.01	0.006	0.004	0.01	0.01

[0038]

(d) 1 ベッセル当りルラシドン・塩酸塩が80mgとなる系での溶出試験

1 ベッセル当りルラシドン・塩酸塩が80mgとなる系でルラシドン・塩酸塩を80mg 、40mgおよび20mgを含有する各フィルムコート錠の溶出試験を実施し、それぞれ の溶出プロファイルの類似性をf2値により評価した。

【0039】

表4から明らかなように、実施例2,3のf2値は実施例1に対する類似性を示したが、 比較例2のf2値は比較例1に対する類似性を示さなかった。即ち、表4,図3から明ら かなように、実施例1乃至3は溶出プロファイルの類似性を示すf2値が50≤f2≤1 00の範囲となり、含量の異なる製剤においても、錠剤の含量(力価)に依存することな く溶出プロファイルの類似性を示す製剤が得られた。一方、表4,図2から明らかによう に、詳細を試験8に記載したが、特許文献2開示処方の比較例2は比較例1からなる製剤 2錠の溶出よりも明らかに遅く、溶出プロファイルの類似性は示さなかった。

 $\begin{bmatrix} 0 & 0 & 4 & 0 \end{bmatrix}$

【表4】

類似因子	実施例番号			比較例番号	
	1	2	3	1	2
f 2	—	88	97	_	37

 $\begin{bmatrix} 0 & 0 & 4 & 1 \end{bmatrix}$

(e) 1 ベッセル当りルラシドン・塩酸塩が40mgとなる系での溶出試験

1 ベッセル当りルラシドン・塩酸塩が40mgとなる系でルラシドン・塩酸塩を40m gおよび20mgを含有する各フィルムコート錠の溶出試験を実施し、それぞれの溶出プ ロファイルの類似性を同様にf2値を用いて評価した。

 $\begin{bmatrix} 0 & 0 & 4 & 2 \end{bmatrix}$

表 5 から明らかなように、実施例 3,比較例 1 の f 2 値は実施例 2 に対する類似性を示した。即ち、1 ベッセル当りルラシドン・塩酸塩が40 mgである系においても、f 2 値は50 \leq f 2 \leq 100 の範囲となり、錠剤の含量(力価)に依存することなく溶出プロファイルの類似性が示された。

[0043]

【表5】

類似因子	実施例番号		比較例番号
	2	3	1
f 2	_	88	97

 $\begin{bmatrix} 0 & 0 & 4 & 4 \end{bmatrix}$

<試験2>

実施例1および4で、水溶性賦形剤と水溶性高分子結合剤および部分アルファ化デンプンから成る医薬品組成物を含む製剤を調製した。また、比較例3,4および5で、水溶性 賦形剤と水溶性高分子結合剤およびアルファ化していないデンプンであるコーンスターチ から成る医薬品組成物を含む製剤を調製した。各製剤の溶出試験を実施し、溶出プロファ イルの類似性をf2値により評価した。結果は、表9に示した。

(a) 造粒末の処方

 $[0\ 0\ 4\ 5]$

【表 6 】

			単位	位:mg	
成分	実施例番	号	比較例番号		
	1	4	3	4	5
ルラシドン・塩酸塩	80	80	80	80	80
マンニトール	144	176	108	108	-
乳糖	-	-	-	-	108
部分アルファ化デンプン	80	40	-	-	-
コーンスターチ	-	-	40	40	40
クロスカルメロースナトリウム	4	8	16	16	16
ヒドロキシプロピルメチルセルロース	8	12	10	10	10

[0046]

(b) 打錠用顆粒/裸錠の処方

 $\begin{bmatrix} 0 & 0 & 4 & 7 \end{bmatrix}$

【表7】

				単位:m	g	
成分	実施例番	号	比較例番号			
	1	4	3	4	5	
上記(a)の顆粒	316	316	254	254	254	
マンニトール	-	-	62	-	_	
ステアリン酸マグネシム	4	4	4	4	4	

[0048]

(c) F C 錠の処方

[0049]

【表8】

			単位	Ż∶mg		
成分	実施例番号		実施例番号 比較例番号		号	
	1	4	3	4	5	
上記(b)の裸錠	320	320	320	258	258	
ヒドロキシプロピルメチルセルロース	3.25	-	2.6	2.6	2.6	
酸化チタン	1	-	0.8	0.8	0.8	
ポリエチレングリコール6000	0.75	-	0.6	0.6	0.6	

[0050]

(d) 溶出試驗

表9から明らかなように、実施例4は実施例1に対する類似性を示したが、比較例3、 4、5のf2値は実施例1に対して類似性を示さなかった。即ち、比較例3,4および5 のコーンスターチを含む製剤は、実施例1および4の部分アルファ化デンプンを含む製剤 と比較して、溶出プロファイルが異なり、溶出の遅い製剤であった。

[0051]

【表 9 】

類似因子	実施例番号		比較例番号		
	1	4	3	4	5
f 2	-	67	4 4	29	26

[0052]

<試験3>

実施例4,5,6,7で、部分アルファ化デンプンの配合量の溶出性に及ぼす影響を評価した。結果は表13に示した。

(a) 造粒末の処方

[0053]

【表10】

単位:mg

成分	実施例番号						
	1	4	5	6	7		
ルラシドン・塩酸塩	80	80	80	80	80		
マンニトール	144	176	116	136	156		
部分アルファ化デンプン	80	40	100	80	60		
クロスカルメロースナトリウム	4	8	8	8	8		
ヒドロキシプロピルメチルセルロース	8	12	12	12	12		

【0054】

(b) 打錠用顆粒/裸錠の処方

【0055】

【表11】

単位:m g					
成分	実施例番号				
	1	4	5	6	7
上記(a)の顆粒	316	316	316	316	316
ステアリン酸マグネシム	4	4	4	4	4

【0056】

(c) F C 錠の処方

[0057]

【表12】

単位:mg

成分	実施例番号						
	1	4	5	6	7		
上記(b)の裸錠	320	320	320	320	320		
ヒドロキシプロピルメチルセルロース	3.25	-	-	_	-		
酸化チタン	1	_	-	_	-		
ポリエチレングリコール6000	0.75	-	-	-	-		
カルナバロウ	0.01	-	_	_	-		

[0058]

(d) 溶出試驗

表13から明らかなように、実施例4、5、6、7のf2値は実施例1に対する類似性 を示した。即ち、部分アルファ化デンプンを製剤組成中の10%wt/wt以上含有する医薬 品組成物から成る製剤は、速溶解性を示し、かつ、類似の溶出プロファイルを示した。

- [0059]
- 【表13】

類似因子	実施例番号					
	1	4	5	6	7	
f 2	—	67	60	62	81	

【0060】

<試験4>

比較例6で、水溶性賦形剤と部分アルファ化デンブンを含むが、水溶性高分子結合剤を 含まない錠剤の製剤化を試みたが、打錠工程において、キャッピングとスティッキングが 発生し打錠できず、類似の溶出プロファイルを得るどころか錠剤すら得られなかった。実 施例8,9,10および11で、水溶性賦形剤および部分アルファ化デンプンと水溶性高 分子結合剤の配合量の異なる医薬品組成物を含む製剤を調製した。結果は、表17に示し た。

(a) 造粒末の処方

 $\begin{bmatrix} 0 & 0 & 6 & 1 \end{bmatrix}$

【表14】

単位:mg

成分	実施例番	実施例番号				比較例番号		
	1	8	9	10	11	6		
ルラシドン・塩酸塩	80	80	80	80	80	80		
マンニトール	144	136	138	140	142	148		
部分アルファ化デンプン	80	80	80	80	80	80		
クロスカルメロースナトリウム	4	8	8	8	8	8		
ヒドロキシプロピルメチルセルロース	8	12	10	8	6	-		

[0062]

(b) 打錠用顆粒/裸錠の処方

[0063]

【表 1 5】

						単位:m g
成分	実施例	番号	比較例番号			
	1	8	9	10	11	6
上記(a)の顆粒	316	316	316	316	316	316
ステアリン酸マグネシム	4	4	4	4	4	4

 $\begin{bmatrix} 0 & 0 & 6 & 4 \end{bmatrix}$

(c) F C 錠の処方

[0065]

【表16】

単位:mg

成分	実施例	番号	比較例番号			
	1	8	9	10	11	6
上記(b)の裸錠	320	320	320	320	320	320
ヒドロキシプロピルメチルセルロース	3.25	-	-	-	-	-
酸化チタン	1	-	-	-	-	-
ポリエチレングリコール6000	0.75	-	-	-	-	-
カルナバロウ	0.01	-	-	-	_	-

【0066】

(d) 溶出試験

表17から明らかなように、実施例8,9、10、11のf2値は実施例1に対する類 似性を示した。即ち、水溶性高分子結合剤を1.8%wt/wtから3.8%wt/wtの範囲に おいて含有する医薬品組成物から成る製剤は、速溶解性を示し、かつ、類似の溶出プロフ ァイルを示した。

 $\begin{bmatrix} 0 & 0 & 6 & 7 \end{bmatrix}$

【表17】

類似因子	実施例番号						
	1	8	9	10	11		
f 2	—	77	81	73	73		

【0068】

<試験5>

実施例12で、水溶性賦形剤として乳糖を用い、水溶性高分子結合剤および部分カルフ アー化デンプンから成る医薬品組成物を含む製剤を調製した。結果は、表21に示した。 (a) 造粒末の処方

【0069】 【表18】

	単位:mg					
成分	実施例番号					
	1	6	12			
ルラシドン・塩酸塩	80	80	80			
マンニトール	144	136	-			
乳糖	-	-	136			
部分アルファ化デンプン	80	80	80			
クロスカルメロースナトリウム	4	8	8			
ヒドロキシプロピルメチルセルロース	8	12	12			

 $\begin{bmatrix} 0 & 0 & 7 & 0 \end{bmatrix}$

(b) 打錠用顆粒/裸錠の処方

 $\begin{bmatrix} 0 & 0 & 7 & 1 \end{bmatrix}$

【表19】

単位 : m g

成分	実施例番号				
	1	6	12		
上記(a)の顆粒	316	316	316		
ステアリン酸マグネシム	4	4	4		

[0072]

(c) F C 錠の処方

 $\begin{bmatrix} 0 & 0 & 7 & 3 \end{bmatrix}$

【表20】

単位:mg

成分	実施例番号			
	1	6	12	
上記(b)の裸錠	320	320	320	
ヒドロキシプロピルメチルセルロース	3.25	-	-	
酸化チタン	1	-	-	
ポリエチレングリコール6000	0.75	-	-	
カルナバロウ	0.01	-	-	

【0074】

(d) 溶出試驗

表21から明らかなように、実施例6および12のf2値は実施例1に対する類似性を示した。即ち、水溶性賦形剤としてマンニトールおよび乳糖にて速溶解性を示し、かつ、 類似の溶出プロファイルを示した。

[0075]

類似因子	実施例番号		
	1	6	12
f 2	—	62	66

【0076】

<試験6>

実施例4,13,14および15で、粒度分布の異なるルラシドン・塩酸塩原末を用い て、水溶性賦形剤と水溶性高分子結合剤および部分アルファ化デンプンから成る特定の医 薬品組成物を含む製剤を調製した。結果は、表25に示した。

(a) ルラシドン・塩酸塩原末の粒度分布

D50%(50%粒子径)とは体積基準により算出される積算分布が50%となるポイントでの粒子径を示し、D90%(90%粒子径)とは、体積基準により算出される積算分布が90%(ふるい下)となるポイントでの粒子径を表す。

 $\begin{bmatrix} 0 & 0 & 7 & 7 \end{bmatrix}$

【表22】

単位:mg

粒度分布		実施例番号			
		4	13	14	15
粒子径	D10 %	0.5	0.9	1.0	1.5
	D50 %	1.6	5.9	7.6	13.9
	D90 %	4.7	17.5	26.9	58.3

[0078]

(b) 打錠用顆粒/裸錠の処方

 $\begin{bmatrix} 0 & 0 & 7 & 9 \end{bmatrix}$

【表23】

単位:mg

成分	実施例番号	実施例番号		
	4	13	14	15
ルラシドン・塩酸塩	80	80	80	80
マンニトール	176	144	144	144
部分アルファ化デンプン	40	80	80	80
クロスカルメロースナトリウム	8	4	4	4
ヒドロキシプロピルメチルセルロース	12	8	8	8
ステアリン酸マグネシウム	4	4	4	4

[0080]

(c) F C 錠の処方

[0081]

【表24】

単位:mg

成分	実施例番号	実施例番号		
	4	13	14	15
上記(b)の裸錠	320	320	320	320
ヒドロキシプロピルメチルセルロース	-	3.25	3.25	3.25
酸化チタン	-	1	1	1
ポリエチレングリコール6000	-	0.75	0.75	0.75
カルナバロウ	-	0.01	0.01	0.01

[0082]

(d) 溶出試験

表25から明らかなように、実施例13,14、15のf2値は実施例4に対する類似 性を示した。即ち、50%粒子径が1~8μmの範囲、90%粒子径が27μm以下の粒 度分布のルラシドン・塩酸塩原末を用いて調製した製剤で類似の溶出プロファイルが得ら れることを見出した。

[0083]

【表25】

類似因子	実施例番号			
	4	13	14	15
f 2	—	56	56	4 6

[0084]

<試験7>

特許文献2の開示技術を用いて1錠中のルラシドン・塩酸塩の含有量が10mgと40 mgとなる製剤を試作し、開示文献2の通り、1錠中のルラシドン・塩酸塩含量が10m gから40mgまでは同等の溶出挙動を示す経口製剤を提供できるかどうか検証した。結 果は、図1に示した。

【0085】

図1から明らかなように、特許文献2の開示技術により得られるルラシドン・塩酸塩を 異なる含有量を有する製剤の溶出プロファイルは、f2の値から明らかなように、1錠中 にルラシドン・塩酸塩を10mg含有する錠剤と40mg含有する製剤は、特許文献2の とおり同等の溶出挙動を示す経口製剤を提供できた。

(a)顆粒の処方

単位	:	m	g
----	---	---	---

成分	10mg錠	40mg錠
ルラシドン・塩酸塩	10	40
マンニトール	47	188
クロスカルメロースナトリウム	4	16
ヒドロキシプロピルメチルセルロース	2.5	10

【0086】

(b) 裸錠の処方

с		単位:mg
成分	10mg錠	40mg錠
(a)の顆粒	63.5	254
マンニトール	15.5	62
ステアリン酸マグネシウム	1	4

[0087]

(c) F C 錠の処方

		単位:mg
成分	10mg錠	40mg錠
上記(b)の裸錠	80	320
ヒドロキシプロピルメチルセルロース	1.3	2.6
酸化チタン	0.4	0.8
ポリエチレングリコール6000	0.3	0.6
カルナバロウ	0.006	0.01

[0088]

<試験8>

特許文献2の開示技術では1錠中にルラシドン・塩酸塩を40mgまで含有する製剤で は同等の溶出挙動を示す経口製剤を提供できることを確認できた。ここでは、特許文献2 の開示技術を用いて、部分アルファー化デンプンを含まない1錠中のルラシドン・塩酸塩 含有量が80mgとなる製剤を試作した。錠剤の大型化は患者への負担を大きくするため 、40mg錠と同じ錠剤重量となるように、有効成分の含有率を2倍にすることにより製 した。比較例1および2の結果は表4および図2に示した。 【0089】

表4および図2から明らかなように、特許文献2の開示技術では、f2の値から明らか なように、ルラシドン・塩酸塩の含有率を2倍にしたアルファ化デンプンを含まない80 mg錠では40mg錠2錠と同等の溶出性を示すことはできなかった。 (a)顆粒の処方

		単位:mg
成分	40mg錠	80mg錠
ルラシドン・塩酸塩	40	80
マンニトール	188	148
クロスカルメロースナトリウム	16	16
ヒドロキシプロピルメチルセルロース	10	10

 $\begin{bmatrix} 0 & 0 & 9 & 0 \end{bmatrix}$

(b)裸錠の処方

		単位:mg
成分	40mg錠	80mg錠
(a)の顆粒	254	254
マンニトール	62	62
ステアリン酸マグネシウム	4	4

 $\begin{bmatrix} 0 & 0 & 9 & 1 \end{bmatrix}$

(c) F C 錠の処方

		単位:mg
成分	40mg錠	80mg錠
上記(b)の裸錠	320	320
ヒドロキシプロピルメチルセルロース	2.6	2.6
酸化チタン	0.8	0.8
ポリエチレングリコール6000	0.6	0.6
カルナバロウ	0.01	0.01

【0092】

<試験9>

試験1の実施例1~3にて試作した含量の異なる3種類の製剤の溶出性を評価した。結果は、図3に示した。

図3から明らかなように、本発明により1錠中にルラシドン・塩酸塩を20mgから80mgを含有する製剤においても、錠剤の含量(力価)に依存しない同等の溶出性が確認された。

(a) 造粒末の処方

[0093]

【表26】

			単位 : m g
成分	80mg錠	40mg錠	20mg錠
ルラシドン・塩酸塩	80	40	20
マンニトール	144	72	36
部分アルファ化デンプン	80	40	20
クロスカルメロースナトリウム	4	2	1
ヒドロキシプロピルメチルセルロース	8	4	2

 $\begin{bmatrix} 0 & 0 & 9 & 4 \end{bmatrix}$

			単位:mg
成分	80mg錠	40mg錠	20mg錠
上記(a)の顆粒	316	158	79
乳糖	-	-	-
ステアリン酸マグネシム	4	2	1

[0095]

(c)FC錠の処方

			単位:mg
成分	80mg錠	40mg錠	20mg錠
上記(b)の裸錠	320	160	80
ヒドロキシプロピルメチルセルロース	3.25	1.95	1.3
酸化チタン	1	0.6	0.4
ポリエチレングリコール6000	0.75	0.45	0.3
カルナバロウ	0.01	0.006	0.004

【産業上の利用可能性】

【0096】

本発明によりN-[4-(4-(1,2-ベンズイソチアゾール-3-イル)-1-ビペラ ジニル)-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S) -2,3-ビシクロ(2,2,1) ヘプタンジカルボキシイミド・塩酸塩(ルラシドン・塩 酸塩)を有効成分とする崩壊性が良好な経口製剤において、有効成分の含量が変動しても 、同等の溶出挙動を示す経口投与用製剤を提供することが可能となった。

【図面の簡単な説明】


 $\begin{bmatrix} 0 & 0 & 9 & 7 \end{bmatrix}$

【図1】図1はルラシドン・塩酸塩を異なる含有量を有する製剤の溶出プロファイルの比較を示したものである。特許文献2の開示技術を用いて試作した1錠中のルラシドン・塩酸塩の含有量が10mg(4錠)と40mg(1錠)の製剤について溶出プロファイルを測定した。

【図2】図2は、ルラシドン・塩酸塩を異なる含有量を有する製剤の溶出プロファイ ルの比較を示したものである。特許文献2の開示技術を用いて試作した1錠中のルラ シドン・塩酸塩の含有量が40mg(2錠)と80mg(1錠)の製剤について溶出 プロファイルを測定した。


【図3】図3は、ルラシドン・塩酸塩を異なる含有量を有する製剤の溶出プロファイ ルの比較を示したものである。本発明の技術を用いて試作した1錠中のルラシドン・ 塩酸塩の含有量が20mg(4錠)、40mg(2錠)と80mg(1錠)の製剤に ついて溶出プロファイルを測定した。


【書類名】図面 【図1】




→ 10mg錠(4錠) → 40mg錠







【図3】



で表されるN-[4-(4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニ ル)-(2R,3R)-2,3-テトラメチレン-ブチル]-(1'R,2'S,3'R,4'S)-2 ,3-ビシクロ(2,2,1)へプタンジカルボキシイミド・塩酸塩(ルラシドン・塩酸塩) を有効成分とする経口製剤において、有効成分の含量が変動しても、同等の溶出挙動を 示す経口投与用製剤の提供。

【解決手段】 アルファ化デンプン類を含むことを特徴とする、ルラシドン・塩酸塩 と水溶性賦形剤、水溶性高分子結合剤を含有する経口製剤は、経口投与された場合に、消 化管内での有効成分の溶出性に優れ、かつ有効成分の含量が異なる製剤間で同等の溶出挙 動を示すことができ、個々の患者に応じて最も適した薬剤の選択を可能にし、臨床上極め て有用である。

【選択図】なし

【書類名】	出願人名義変更届(一般承継)
【提出日】	平成17年10月26日
【あて先】	特許庁長官殿
【事件の表示】	
【出願番号】	特願2005-153508
【承継人】	
【識別番号】	0 0 0 0 2 9 1 2
【氏名又は名称】	大日本住友製薬株式会社
【代表者】	宮武 健次郎
【電話番号】	$0\ 6\ -\ 6\ 4\ 6\ 6\ -\ 5\ 2\ 1\ 4$
【提出物件の目録】	
【物件名】	権利の承継を証明する書面]
【援用の表示】	なお、当該書面は、平成17年10月19日付提出の平成10年
	特許願第547927号の特許出願人名義変更届(一般承継)に
	添付した履歴事項全部証明書を援用し、省略する。

000183370 19900809 新規登録

大阪府大阪市中央区道修町2丁目2番8号 住友製薬株式会社 000002912 19900808 新規登録

大阪府大阪市中央区道修町2丁目6番8号 大日本製薬株式会社 000002912 20051003 名称変更

大阪府大阪市中央区道修町2丁目6番8号 大日本住友製薬株式会社

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875								Docket Number 9,678		ing Date 31/2007	To be Maile
	AF	PPLICATION	AS FILE	D – PART I						OTH	IER THAN
			(Column	1) (SMA		ENTITY	OR	SMA	LL ENTITY	
	FOR	MBER EXTRA	RATE ((\$)	FEE (\$)		RATE (\$)	FEE (\$)			
	BASIC FEE (37 CFR 1.16(a), (b), c	or (c))	N/A		N/A	N/A				N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), c	or (m))	N/A		N/A	N/A				N/A	
	EXAMINATION FE (37 CFR 1.16(o), (p), o	E	N/A		N/A	N/A				N/A	
	TAL CLAIMS CFR 1.16(i))		mir	nus 20 = *		X \$	=		OR	X \$ =	
	EPENDENT CLAIM CFR 1.16(h))	S	m	inus 3 = *		X \$	=			X \$ =	
	APPLICATION SIZE (37 CFR 1.16(s)) MULTIPLE DEPEN the difference in colu	FEE is \$ add 35 U	250 (\$125 itional 50 J.S.C. 41(RESENT (3	677	for each hthereof. See	ТОТА	L			TOTAL	
	APPI	(Column 1)	S AMENE	DED – PART II (Column 2)	(Column 3)	SN	ЛАL	L ENTITY	OR		R THAN LL ENTITY
	10/31/2007	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE ((\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAI FEE (\$)
	Total (37 CFR 1.16(i))	* 23	Minus	** 24	= 0	X \$	=		OR	X \$50=	0
	Independent (37 CFR 1.16(h))	* 5	Minus	***5	= 0	X \$	=		OR	X \$210=	0
	Application Si	ze Fee (37 CFR	1.16(s))								
	FIRST PRESEN	TATION OF MULT	IPLE DEPEN	DENT CLAIM (37 CFF	R 1.16(j))				OR		
						TOTAL ADD'L FEE			OR	TOTAL ADD'L FEE	0
		(Column 1)		(Column 2)	(Column 3)						
		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE ((\$)	additional Fee (\$)		RATE (\$)	ADDITIONA FEE (\$)
	Total (37 CFR 1.16(i))	*	Minus	**	=	X \$	=		OR	X \$ =	
AMENDMEN	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$	=		OR	X \$ =	
	Application Si	ize Fee (37 CFR	1.16(s))								
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))								OR		
	FIRST PRESEN					TOTAL	_		1	TOTAL	
	FIRST PRESEN					ADD'L FEE			OR	ADD'L FEE	

The ingrest value Previously Paid For (Fourier Integretient) is the ingrest number value in the appropriate box in contine 1. This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/06 (07-06) Approved for use through 1/31/2007. OMB 0651-0032

Docket No.: 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

Application No.: 11/919,678

Filed: October 31, 2007

For: PHARMACEUTICAL COMPOSITION

Confirmation No.: 6965

Art Unit: N/A

Examiner: Not Yet Assigned

LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant wishes to advise the United States Patent and Trademark Office that the references cited in the International Search Report were previously filed on October 31, 2007.

As evidence of Applicant's previous submission of the references cited in the International Search Report in connection with the present application, Applicant encloses a copy of the postcard indicating receipt of the references cited in the International Search Report by the United States Patent and Trademark Office and payment of the appropriate fees by the Applicant.

However, we provide herewith a courtesy copy of the references filed on October 31, 2007.

Birch, Stewart, Kolasch & Birch, LLP

DRN/awl

Application No.: 11/919,678

Docket No.: 0020-5610PUS1

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Dated: March 14, 2008

Respectfully submitted,

By m/N _____ Mark J. Nuell

Registration No.: 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive Suite 260 San Diego, California 92130 (858) 792-8855 Attorney for Applicant

Attachments: Copy of Postcard Receipt SB-08 Copy of references submitted October 31, 2007

DRN/awl

Inventor: Kazuyuki FUJIHARA

Atty Docket No.: 6020-5610PUS1

Application No.: NEW TIMe: PHARMACEUTICAL COMPOSITION

Documents Filed:

PCT/IB/308 (2 streets), PCT/IEX304, PCT/ISA/237 (4 sheets), PCT//SA/218 Drawings (3 streets) Erg*sh language translation of the International application (45 pages)

Oath or declaration of the inventor(s)

Assignment (Z pages)

Transmittal Letter to the United States Designated-Elected Office (3 pages)

First Preliminary Amendment (6 pages)

Edormation Disclosure Statement (2 pages) IAPO7Rec'd PCT 3 1 OCT 2007

Via:

Sender's Initials: DRN//scp Filing Date: October 31, 2007

\$ 1919678 Recordation Form Cover Sheet (1 page)

IDS (Citation) by Applicant (4 Reficiences) (1 page)

Charge \$1.590.00 to deposit account 02-2448



Due Date: October 31, 2007 Date: October 31, 2007

Inventor: Kazuyuki FUJIHARA

Application No.: NEW PHARMACEUTICAL COMPOSITION Title:

Atty Docket No 0020-5610PUS1



Filing Date: October 31, 2007

Documents Filed: 1

- PCT/B/303 (2 sheets), PCT/B/304: PCT/SA/237 (4 sheets) PCT/SA/210, Dxtwings (3 sheets) English language translation of the International
- application (48 pages) Oath or declaration of the inventor(s)

- Assignment (2 pages)

- Transmittal Letter to the United States Designated-Elected Office (3 pages)
- First Preliminary Amendment (6 pages)
- Information Disclosure Statement (2 pages)

Via:

Sender's Initials: DRN//scp -Recordation Form Cover Sheet (1 page)

-IOS (Citation) by Applicant (4 References) (1 page)



Due Date: October 31, 2007 Date: October 31, 2007

Used in Lieu of PTO/SB/08A/B (Based on PTO 01-08 version)

S	ubstitute for form 1449/PTO	n de ser de la délition		Complete if Known		
				Application Number	11/919,678-Conf. #6965	
	NFORMATION	N DI	SCLOSURE	Filing Date	October 31, 2007	
	STATEMENT I	BY /	APPLICANT	First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	N/A	
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	0020-5610PUS1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

Examiner Initials*	Cite No.'	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Тę
	BA	WO 02/24166 A1	03-28-02			Abs
	BB	WO 2004/078173 A1	10-12-1990			Abs
	BC	JP-08-325146	12-10-1996	······		Abs
		ļ				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Petent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	CA	Handbook of Pharmaceutical Excipients, 2 nd edition, Vol. 491, The Pharmaceutical Press, 1994					

	and the second	
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Inventor: Kazuyuki FUJIHARA

PCTASA010; Drawings (3 sheats) Engish language translation of the international

First Preliminary Amendment (6 pages) Information Disclosure Statement (2 pages)

application (48 pages) Oath or declaration of the inventor(s)

Assignment (2 pages)

Via:

Sender's Initials:

THE: PHARMACEUTICAL COMPOSITION

PCT/IB/308 (2 sheets); PCT/IB/304; PCT/ISA/297 (4 sheets);

Transmittal Letter to the Unifed States Designated-Elected Office (3 pages)

IAPO7Rec'd PCT 31 OCT 2007

Application No.: NEW

Documents Filed:

Atty Docket No.: 0020-5610PUS1

Filing Date: October 31, 2007

W 1 /919678

Recordation Form Cover Sheet (1 page) IDS (Citation) by Applicant (4 References) (1 page)

Charge \$1.590.00 to deposit account 02-2448



Due Date: October 31, 2007 Date: October 31, 2007

Inventor: Kazuyuki FUJIHARA

Application No.: NEW Title: PHARMACEUTICAL COMPOSITION

DRN//scp

Documents Filed; PCT/IB/303 (2 sheets); PCT/IB/304; PCT/IS/A/237 (4 sheets); PCT/IS/A/210; Drawings (3 sheets);

- _ English language translation of the International application (48 pages)
- Oath or declaration of the inventor(s)
- Assignment (2 pages).
- -Transmittal Letter to the United States Designated-Elected Office (3 pages)
- ~ First Preliminary Amendment (6 pages)
- -Information Disclosure Statement (2 pages)

Via:

Sender's Initials: **DRN//scp** Atty Docket No: 0020-5610PUS1

Filing Date: October 31, 2007

- Recordation Form Cover Sheet (1 page)

-IOS (Citation) by Applicant (4 References) (1 page)

Charge \$1 590.00 to deposit account 02-2448



Due Date: October 31, 2007 Date: October 31, 2007

Docket No.: 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

Application No.: 11/919,678

Filed: October 31, 2007

Confirmation No.: 6965

Examiner: Not Yet Assigned

Art Unit: N/A

For: PHARMACEUTICAL COMPOSITION

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. <u>COPIES</u>

a. Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.

b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

Birch, Stewart, Kolasch & Birch, LLP

c. <u>REFERENCES PREVIOUSLY CITED OR SUBMITTED</u> - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

III. <u>CONCISE EXPLANATION OF THE RELEVANCE</u>

(check at least one box)

a. <u>DOCUMENTS IN THE ENGLISH LANGUAGE</u> – Some or all of the patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

b. <u>DOCUMENTS NOT IN THE ENGLISH LANGUAGE</u> - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: An English language abstract is provided for JP 2000-26292 A; US 5,532,372 corresponds to JP 28900953.

c. <u>ENGLISH LANGUAGE SEARCH REPORT</u> - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. <u>OTHER</u> - The following additional information is provided for the Examiner's consideration. **Cite Nos. AA, CA and CB are cited in the Specification at page 3.**

IV. <u>FEES</u> (check one box)

a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

2

C. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (*This section is not to be used with RCE's.*)

d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

 \Box e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

 \bigtriangleup f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached. or

See the statement below. No fee is required.

 V. <u>STATEMENT UNDER 37 C.F.R. § 1.97(e)</u> (check <u>only</u> one box) The undersigned hereby states that:

a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. <u>PAYMENT OF FEES</u> (check one box)

The required fee is listed on the attached Fee Transmittal.

 \boxtimes No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is

Application No.: 11/919,678

requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: MAR 1 4 2008

Respectfully submitted,

By m/N and Mark J. Nuell

Mark J. (Nuell Registration No.: 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive Suite 260 San Diego, California 92130 (858) 792-8855 Attorney for Applicant

5)

Used in Lieu of PTO/SB/08A/B (Based on PTO 01-08 version)

	Substitute for form 1449/PT	C		Complete if Known		
				Application Number	11/919,678-Conf. #6965	
	INFORMATIC	N DISC	LOSURE	Filing Date	October 31, 2007	
	STATEMENT	BY AP	PLICANT	First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	N/A	
	(Use as many	sheets as nec	essary)	Examiner Name	Not Yet Assigned	
Shee	et 1	of	1	Attorney Docket Number	0020-5610PUS1	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA*	US-5,532,372-A	07-02-1996	Saji et al.			

		FOREI	GN PATENT D	DCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Τ ⁶
	BA	JP-2000-26292-A	01-25-2000			Abs
	BB	JP-08-325146 A	10-12-1990			Abs
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the regin of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials	Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Handbook of Pharmaceutical Excipients, 2 nd edition, Vol. 491, The Pharmaceutical Press, 1994	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Docket No.: 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

Application No.: 11/919,678

Filed: October 31, 2007

Confirmation No.: 6965

Art Unit: Not yet Assigned

For: PHARMACEUTICAL COMPOSITION

Examiner: Not yet Assigned

<u>LETTER</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Subsequent to the filing of the above-identified application on October 31, 2007, attached hereto is an English translation of the International Preliminary Report on Patentability and Written Opinion of the International Searching Authority (Forms PCT/IB/326, PCT/IB/338, PCT/IB/373, PCT/ISA/237) that should be made of record in the present application.

DRN/kpc

Birch, Stewart, Kolasch & Birch, LLP

Application No.: 11/919,678

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or to credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Dated: MAR 1 4 2008

Respectfully submitted,

By_MANes Mark J. Nuell

Registration No.: 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive, Suite 260 San Diego, California 92130 858 792-8855 Attorney for Applicants

Electronic Acl	knowledgement Receipt
EFS ID:	3007308
Application Number:	11919678
International Application Number:	
Confirmation Number:	6965
Title of Invention:	Pharmaceutica compostion
First Named Inventor/Applicant Name:	Kazuyuki Fujihara
Customer Number:	2292
Filer:	Mark Jay Nuell/Kathleen Cassin
Filer Authorized By:	Mark Jay Nuell
Attorney Docket Number:	0020-5610PUS1
Receipt Date:	17-MAR-2008
Filing Date:	
Time Stamp:	12:14:25
Application Type:	U.S. National Stage under 35 USC 371

Payment information:


Submitted with Payment no						
File Listir	ng:					
Document Number	Document Description		File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed		2008031LETTER.pdf			4
				939b24bc4c80401178e93aa38f296153 1c9ced22	110	4
Warnings:						
Information						

This is not an l	JSPTO supplied IDS fillable form					
			78870			
2	Miscellaneous Incoming Letter	20080314Postcard.pdf	9125093a0ae2001d885fcc6b2ebfcd5a 90693b9a	no	1	
Warnings:						
Information:		Γ				
3	Foreign Reference	20080314JP8325146.pdf	951605	no	9	
Ũ	i oloigii Holoronoo		a794ec5a03ab23573112eaadc27dd2fd 30cb1598	110	0	
Warnings:						
Information:						
4	Foreign Reference	WO0224166.pdf	4354431	no	19	
4	roleigh neierence	W00224100.pui	d9e71fcc7b1a3c3288f80f55c4d479a5d 019d04f	ΠΟ	49	
Warnings:						
Information:						
		N/00001070170	1913456			
5	Foreign Reference	WO2004078173.pdf	10ba907d7eea888dfaab6f8bd650adbd d55413bd	no	23	
Warnings:						
Information:						
	Information Disclosure Statement		514743			
6	(IDS) Filed	20080314IDS.pdf	aec00aff93600b064ced9b88219e23e0 5904b73e	no	6	
Warnings:			· · · · · ·			
Information:						
This is not an l	JSPTO supplied IDS fillable form					
			1157851			
7	Foreign Reference	20080314JP2000026282.pdf	3867ee452242329fcd87ccf1c745defe1 0855a54	no	11	
Warnings:		I	11	I		
Information:						
		20080314PregelatinizedStar	531503			
8	NPL Documents	ch.pdf	18b1100d5669682ba230cbcf7d9e8f220 c07572c		3	
Warnings:		l				
Information:						
	Information Disclosure Statement		95195			
9	Letter	20080314LetterWO.pdf	fdac3df7ca9f345809482ca5118c938b5 7b64ed5	no	2	
Warnings:		<u> </u>				
Information:						

10	Miscellaneous Incoming Letter	20080314TransofWO.pdf	475204 4453725581214d69a1a010c614efad7b 71a1514a	no	5		
Warnings:							
Information	:	Total Files Size (in bytes)	: 103	357754			
characterize similar to a <u>New Applica</u> If a new app 37 CFR 1.53 shown on th	wledgement Receipt evidences re- ed by the applicant, and including Post Card, as described in MPEP <u>ations Under 35 U.S.C. 111</u> plication is being filed and the app 5(b)-(d) and MPEP 506), a Filing Re his Acknowledgement Receipt will age of an International Application	page counts, where applie 503. lication includes the neces ceipt (37 CFR 1.54) will be establish the filing date of	able. It serves as e sary components fo issued in due cours	vidence of or a filing c	receipt date (see		
National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.							

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



Par Pharm., Inc. Exhibit 1015 Page 171

-				ENDEN			2	ERIAL NO	lan	9679	1	FILING D	АТЕ	. ġ
		·.		ATION					71	161	<u> </u>	L		
		(FOR US	E WITH	FORM	PTO-875)) ,	ľ	APPLICAN	T(S)					ŝ.
			÷			C	LAIMS	5						
1			AF	FER	AF	FER,		I	· · · · ·		AF	FER	ÅF	TER
	AS F	ILED		NDMENT	2 MAME	NDMENT			ASF	ILED		NDMENT	2 *4 AME	NDMENT
	IND.	DEP.	IND.	DEP.	IND.	DEP.		1	IND.	DEP.	IND.	DEP.	IND.	DEP
1	T						1	51						
2			T				L L	52						ļ
3							ŀ	53			· · ·			ļ
4 5		3			·		┣	<u>54</u> 55						
5	4						ł	56						<u> </u>
7.	l	1		1		· · ·]	ł	57			[
8		Q	·				Ē	58						[
9		%]		59			ļ			
10		9		├ ┛		<u> </u> I	-	60 61						
11 12			÷			<u>├</u>	ŀ	61	<u> </u>		}			
13	• •	12					ł	63					· · · ·	<u> </u>
14		K	· · · · · · · · · · · · · · · · · · ·				Ī	64		·				
15		<u> </u>					1	65			· ·· -·			
16 17		<u>G</u>		 		<u> </u>]	. }	<u> 66 </u> 67		·				
18		12-1			· · · · ·	<u>├</u> {	·	68						· [
19		Øø		1			· · F	69						
20		0					. [70						
21		8		<i> </i>			ł	7 <u>1</u> 72]	·····		·
2 <u>2</u> 23		6	~~~~~			<u> </u>	F	$\frac{72}{73}$						
24		8					ł	74				[·	
25						•		75						ļ
26 27		·····				 		76 77			}	}		·
28						<u> </u>	ł	78						
29			•				ŀ	79						
30							. [80						
31			·			<u>_</u>	ļ.	81			·	 		
32 33							ł	82 83					i-	
34							ŀ	84.						<u> </u>
35							. [85						
36							l f	86			ļ			· · · · ·
37 38							- -	-87				 	··	ļ
19					,		ŀ	<u>88</u> 89			·			
10							t		· · · · · · · · · · · · · · · · · · ·			<u> </u>	Contraction of the second	4
1			·				É É	91 '					9 - 19 - 19 - 19 - 19 - 19 - 19 - 19 -	ŧ
$\frac{2}{2}$							L	92						····· · · · · · · · · · · · · · · · ·
3	υ, 						ŀ	93				<u> </u>		
4		ł				·	ŀ	<u>94</u> 95				 	·	<u> </u>
6							. F	<u>95</u> 96						
7				·			F	97				 		
8		21					F	98						
9	- C. "						E	99			•			
<u>(0</u> -1								100		·			·	
TAL D.	51	1	51				Г	TOTAL IND.		J	• •			1
FAL		.		_ ▼]	▼.	ļ.	TOTAL				1 🔻		I ▼ .
. d	21	🦇	19	4		4		DEP.		🔶 - I		4		4
AL	ATT	C BERNELL	. 11. 1	STATISTICS CONTRACTOR		THE REAL PROPERTY.	- F	TOTAL						200000

Par Pharm., Inc. Exhibit 1015 Page 172

9. 1

s.

·	INTERNATIONAL APPL JP06/310571
PPLICATION FILED BY: 20 MOS.,	OR 30 MOS., X SCREENED BY
NTERNATIONAL APPLICATION P	APERS IN THE APPLICATION FILE:
International application	409 annexes to IPER
Article 19 amendments	PCT/ISA/210 (Search report)
Priority Document(s) No. Request Form PCT/RO/101	Search report References
PCT/IB/302	Other Papers filed
CT/IB/304	WIPO PUBLICATION
PCT/IB/306	PUBLICATION NO. WO OF 1 AUS
PCT/IB/308 PCT/IB/331	PUBLICATION DATE 30 10 -06
OTHER PCT/IB/ <u>277</u>	PUBLICATION LANG., THE HATES
PCT/IPEA/409 also 416	U.S. onlyRequested
↓ .	
ECEIVED FROM THE APPLICANT National application basic fee paid	: (other than checked above) V Preliminary Amendment(s) Bet OCT 200 7
Express Processing Requested	second submission
Translation of the International Applicatio	In X Information Disclosure Statement DC 1 2007
_`Used the IB copy of the IA _ Description	second submission 3-1-1-18
Claims	Absignment Forward to Assignment Branch
Drawings 3	Substitute Specification
Foreign Language in drawing Article 19 Amendments	Small Entity Statement
_Amendment used in application	type Cath/Declaration (date submiles OCT 2007
_ Article 34 Amendment	Not executed
_Amendment used in application	X Executed
DNA 1194 transaction done	Power of Attorney Change of Address
A LAT MAIDAGUUNI UVIC	Change of Address

 Date complete 35 USC 371 requirements met
 3 1 OCT 200.9

 DATE NOTICE COMPLETED

 DO/EO 903
 Notice of Acceptance

 DO/EO 905
 Notice of Missing Requirements

 DO/BO 917
 Notice of A defective oath or declaration

 DO/EO 916
 Notice of defective response

 DO/BO 913
 Notice of defective translation

÷ .

DO/BO 909 Notification of Abandonment

UNITED STATES PATENT A	and Trademark Office	United States Address: COMMIS P.O. Box 1	SPatent and Tra SSIONER FOR PA 450 a, Virginia 22313-1450	TENTS
U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT		ATTY	. DOCKET NO.
11/919,678	Kazuyuki Fujihara		0020	-5610PUS1
2292		INTER	NATIONAL APP	LICATION NO.
BIRCH STEWART KOLASCH & BIRCH		F	PCT/JP2006/	310571
PO BOX 747		I.A. FILI	NG DATE	PRIORITY DATE
FALLS CHURCH, VA 22040-0747		05/26	5/2006	05/26/2005
				ATION NO. 6965 FANCE LETTER

Date Mailed: 02/25/2009

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>10/31/2007</u> DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS <u>10/31/2007</u> DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** *The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363).* Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Copy of the International Application filed on 10/31/2007
- English Translation of the IA filed on 10/31/2007
- Copy of the International Search Report filed on 10/31/2007
- Preliminary Amendments filed on 10/31/2007
- Information Disclosure Statements filed on 10/31/2007
- Oath or Declaration filed on 10/31/2007
- Request for Immediate Examination filed on 10/31/2007
- U.S. Basic National Fees filed on 10/31/2007
- Assignment filed on 10/31/2007
- Priority Documents filed on 10/31/2007
- Specification filed on 10/31/2007
- Claims filed on 10/31/2007
- Abstracts filed on 10/31/2007
- Drawings filed on 10/31/2007

page 1 of 2

FORM PCT/DO/EO/903 (371 Acceptance Notice)


Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

page 2 of 2

FORM PCT/DO/EO/903 (371 Acceptance Notice)



Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Kazuyuki Fujihara, Osaka-fu, JAPAN;

Power of Attorney: The patent practitioners associated with Customer Number 02292

Domestic Priority data as claimed by applicant This application is a 371 of PCT/JP2006/310571 05/26/2006

Foreign Applications JAPAN 2005-153508 05/26/2005

If Required, Foreign Filing License Granted: 02/23/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 11/919,678**

Projected Publication Date: 06/04/2009

Non-Publication Request: No

Early Publication Request: No

Title

Pharmaceutical composition

Preliminary Class

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier

page 2 of 3

license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

UNITED ST.	ates Patent and Tradema	UNITED STA' United States Address: COMMIS P.O. Box 1	, Virginia 22313-1450	
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	
11/919,678	10/31/2007	Kazuyuki Fujihara	0020-5610PUS1	
			CONFIRMATION NO. 6965	
2292		PUBLICATION NOTICE		
BIRCH STEWART KOLAS PO BOX 747				

Title:Pharmaceutical composition

FALLS CHURCH, VA 22040-0747

Publication No.US-2009-0143404-A1 Publication Date:06/04/2009

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently http://pair.uspto.gov/. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
11/919,678	10/31/2007	Kazuyuki Fujihara	0020-5610PUS1	6965
2292 7590 08/07/2009 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747			EXAMINER	
			PIHONAK, SARAH	
			ART UNIT	PAPER NUMBER
			1617	
			NOTIFICATION DATE	DELIVERY MODE
			08/07/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

	Application No.	Applicant(s)
	Application No.	
Office Action Summary	11/919,678	FUJIHARA, KAZUYUKI
Office Action Summary	Examiner	Art Unit
	SARAH PIHONAK	1617
The MAILING DATE of this communication ap Period for Reply	opears on the cover sheet with	the correspondence address
 A SHORTENED STATUTORY PERIOD FOR REPORT WHICHEVER IS LONGER, FROM THE MAILING I Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). 	DATE OF THIS COMMUNICA .136(a). In no event, however, may a reply d will apply and will expire SIX (6) MONTH te, cause the application to become ABAN	TION. y be timely filed S from the mailing date of this communication. IDONED (35 U.S.C. § 133).
Status		
 1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) Th 3) Since this application is in condition for allow closed in accordance with the practice under 	is action is non-final. ance except for formal matters	
Disposition of Claims		
 4) Claim(s) <u>1-24</u> is/are pending in the applicatio 4a) Of the above claim(s) is/are withdr. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-24</u> are subject to restriction and/or 	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examin		
10) The drawing(s) filed on is/are: a) ac		
Applicant may not request that any objection to the		
Replacement drawing sheet(s) including the corre		
Priority under 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list 	nts have been received. hts have been received in App ority documents have been re au (PCT Rule 17.2(a)).	blication No
Attachment(s)	_	
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date U.S. Patent and Trademark Office 	Paper No(s)/N	nmary (PTO-413) /lail Date rmal Patent Application

PTOL-326 (Rev. 08-06)

Office Action Summary

Part of Paper No./Mail Date 20090710

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4, and 8-24, drawn to an oral preparation comprised of lurasidone. Group II, claim(s) 5-7, drawn to a method of granulation of a powder mixture comprised of lurasidone.

2. As set forth in Rule 13.1 of the Patent Cooperation Treaty (PCT), "the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept." Moreover, as stated in PCT Rule 13.2, "where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features." Furthermore, Rule 13.2 defines "special technical features" as "those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art."

3. The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is an oral preparation comprised of lurasidone, a pregelatinized starch component, and a water-soluble polymer. The oral preparation of claim 1 does not present a contribution over the prior art, as it is disclosed in WO 01/076557 (p. 1, claims 1-3 and 11, English translation; particularly, third line of claim 11, regarding compound SM-13496). Claims 1-3 and 11 of the WO 01/076557 patent application are drawn to an oral composition comprised of SM-13496, which is the hydrochloride salt of lurasidone, as well as a starch component and a water soluble polymer. Therefore, instant claim 1 is not novel over the prior art. As such, Group I does not share a special technical feature with the instant claims of Group II. Therefore, the claims are not so linked within the meaning of PCT Rule 13.2 so as to form a single inventive concept, and unity between Groups I-II is broken.

4. The examiner has required restriction between product and process claims.
Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.
<u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process

claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder**. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached on Monday-Thursday 8:00 AM - 6:30 PM EST, with Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S.P.

/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1617

Par Pharm., Inc. Exhibit 1015 Page 185

Notice of References Cited	Application/Control No. 11/919,678	Applicant(s)/Patent Under Reexamination FUJIHARA, KAZUYUKI	
Notice of References Cheu	Examiner	Art Unit	
	SARAH PIHONAK	1617	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	А	US-			
	В	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	Ι	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 01/76557A1	10-2001	World Intellect	Kobayashi et. al.	
	0					
	Р					
	Q					
	R					
	s					
	т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)					
	U						
	v						
	×						
	x						

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 20090710

Docket No. 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

Application No. 11/919,678

Filed: October 31, 2007

Confirmation No. 6965

Art Unit: 1617

For: PHARMACEUTICAL COMPOSITION Examiner: S. Pihonak

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The following Remarks are submitted in reply to the Restriction Requirement mailed

August 7, 2009.

Remarks begin on page 2 of this paper.

Birch, Stewart, Kolasch & Birch, LLP

REMARKS

The Examiner has required restriction of the present claims to one of Group I, claims 1-4 and 8-24, directed to an oral preparation comprising lurasidone; and

Group II, claims 5-7, directed to a method of making a granulated composition comprising lurasidone.

Applicants hereby elect, without traverse, the claims of Group I, claims 1-4 and 8-24, for prosecution in the present invention.

Applicants submit that, should the claims of Group I be found allowable, the claims of Group II, if commensurate in scope with the allowable claims, should be rejoined to the present application for examination. MPEP 821.04.

The Examiner has asserted that the present invention lacks novelty over WO 01/076557. The Examiner points to claims 1-3 and 11 of the reference.

Applicants note that the present invention is claimed as described as a composition comprising at least "a pregelatinized starch", and that such an ingredient does not appear to be disclosed in WO 01/076557. Accordingly, the present invention is novel of WO 01/076557 for at least this reason.

Favorable action on the merits of the present application is requested.

If allowance of the claims is precluded by some minor issue that can be resolved by telephone discussion, the Examiner is invited to contact the undersigned at the telephone number below to discuss the matter.

2

DRN/kpc

Application No.: 11/919,678

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or to credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Dated: August 24, 2009

Respectfully submitted,

By m/ Dell Mark J. Nuell

Registration No.: 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive, Suite 260 San Diego, California 92130 858 792-8855 Attorney for Applicants

DRN/kpc

Electronic Acl	knowledgement Receipt
EFS ID:	5942202
Application Number:	11919678
International Application Number:	
Confirmation Number:	6965
Title of Invention:	Pharmaceutical composition
First Named Inventor/Applicant Name:	Kazuyuki Fujihara
Customer Number:	02292
Filer:	Mark Jay Nuell
Filer Authorized By:	
Attorney Docket Number:	0020-5610PUS1
Receipt Date:	24-AUG-2009
Filing Date:	31-OCT-2007
Time Stamp:	20:57:42
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment		no	no			
File Listin	g:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1 20090824IDSwSB08.pdf		511363	yes	6		
•		2007002	f34c29a55340058326d770aab05efebad15 15e0e	· ·	Ŭ	

	Multipart Description/PDF files in .zip description							
	Document Des	scription	Start	E	nd			
	Transmittal l	.etter	1		5			
	Information Disclosure Staten	6		6				
Warnings:								
Information								
2	NPL Documents	Chueshov1999.pdf	459306	no	4			
-			5411af6a44268aad8d3624fcddb89e19e63 e202b					
Warnings:								
Information								
3	NPL Documents	Puscian OA ndf	496333	20	7			
5	NPL Documents	RussianOA.pdf	c597cafc72fe74d33fd1fa280d4ae34d334b 0a97	no	/			
Warnings:								
Information								
4	Response to Election / Restriction Filed	20090824RespRestrictReg.pdf	161920	no	3			
		2005002 mesphestnetheq.pu	103c5ab59339c14dc1a9f706b72a5e00521 d66777	no	5			
Warnings :	· · · · · · · · · · · · · · · · · · ·							
Information			-					
		Total Files Size (in bytes)	: 16	28922				
characterize Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 ar national stag <u>New Internat</u> If a new inter an internatic and of the In	ledgement Receipt evidences receip d by the applicant, and including pages described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> lication is being filed and the applica and MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin ge of an International Application un bmission to enter the national stage and other applicable requirements a F ge submission under 35 U.S.C. 371 wi tional Application Filed with the USP rnational application is being filed ar onal filing date (see PCT Article 11 an ternational Filing Date (Form PCT/RC urity, and the date shown on this Ack on.	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Ider 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati Il be issued in addition to the <u>TO as a Receiving Office</u> and the international applicat d MPEP 1810), a Notification D/105) will be issued in due c	It serves as evidence components for a filin course and the date s on is compliant with ng acceptance of the e Filing Receipt, in du ion includes the nece of the International <i>J</i> ourse, subject to pres	of receipt s og date (see hown on th the condition application e course. ssary comp Application scriptions co	similar to a 37 CFR is ons of 35 a as a onents for Number oncerning			

Docket No. 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

Application No. 11/919,678

Filed: October 31, 2007

Confirmation No. 6965

Art Unit: 1617

For: PHARMACEUTICAL COMPOSITION Examiner: S. Pihonak

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Madam:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. <u>COPIES</u>

a.Copies of cited U.S. patents and patent application publications are not included.Copies of foreign patent documents and non-patent literature are included.

b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

Birch, Stewart, Kolasch & Birch, LLP

C. <u>REFERENCES PREVIOUSLY CITED OR SUBMITTED</u> - Pursuant to 37 C.F.R. §1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

a. <u>DOCUMENTS IN THE ENGLISH LANGUAGE</u> – Some or all of the patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

b. <u>DOCUMENTS NOT IN THE ENGLISH LANGUAGE</u> - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows: English translation of Page 10, lines 1-14 and lines 37-43; and of page 11, lines 25-28 of Russian non-Patent Literature reference is provided.

c. <u>ENGLISH LANGUAGE SEARCH REPORT</u> - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. <u>OTHER</u> - The following additional information is provided for the Examiner's consideration: **Russian Official Action with English translation.**

IV. <u>FEES</u> (check one box)

a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

2

b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

C. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*

d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

 \bigcirc f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

3

No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached. or

See the statement below. No fee is required.

 V. <u>STATEMENT UNDER 37 C.F.R. § 1.97(e)</u> (check <u>only</u> one box) The undersigned hereby states that:

a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. <u>PAYMENT OF FEES</u> (check one box)

The required fee is listed on the attached Fee Transmittal.

 \boxtimes No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is

4

Application No. 11/919,678

requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: August 24, 2009

Respectfully submitted,

By my Nell

Mark J Nuell Registration No. 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive, Suite 260 San Diego, California 92130 (703) 205-8000 Attorney for Applicant

Attac	hments:
\boxtimes	PTO/SB/08
\boxtimes	Documents
	Fee Transmittal
	Other:

PTO/SB/08b (06-09) Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449/PTO			Complete if Known		
				Application Number	11/919,678-Conf. #6965	
IP	FORMATION	I DI	SCLOSURE	Filing Date	October 31, 2007	
S	STATEMENT BY APPLICANT			First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	1617	
	(Use as many sheets as necessary)		Examiner Name	S. Pihonak		
Sheet	1	of	1	Attorney Docket Number	0020-5610PUS1	

			U.S. PATI	ENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T6		
	_							
						-		
						-		

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Chueshov, V. I., et al., "Manufacturing Technologies of Drugs," Promyshlennaya Technologiya Lekarstv, Vol 2, pp 10-11 (1999).	part
	СВ	Russian Official Action	part

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (06-09)

Approved for use through 07/31/2009, OMB 0651-10031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	Substitute for form 1449/PTO			Complete if Known		
				Application Number	11/919,678-Conf. #6965	
	NFORMATIO	N DIS	CLOSURE	Filing Date	October 31, 2007	
5	STATEMENT	BY A	PPLICANT	First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	1617	
1	(Use as many sheets as necessary)			Examiner Name	S. PIHONAK	
Sheet	1	of	1	Attorney Docket Number	0020-5610PUS1	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

		FORE	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	BA*	JP-2000-26292-A	01-25-2000			—
	BB	EP-1327440-A1	07-16-2003	Sumitomo Pharma		
	<u> </u>	NON PATEN	IT LITERAT	URE DOCUMENTS		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), titl the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-is number(s), publisher, city and/or country where published.					T ²	
	СА	Makino, T., et al., "Importance of Disintegration Time of Tablets,"				
Examiner Signature			and the second	Date Considered	an a succession of the second s	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Birch, Stewart, Kolasch & Birch, LLP

Electronic Acl	Electronic Acknowledgement Receipt				
EFS ID:	6143364				
Application Number:	11919678				
International Application Number:					
Confirmation Number:	6965				
Title of Invention:	Pharmaceutical composition				
First Named Inventor/Applicant Name:	Kazuyuki Fujihara				
Customer Number:	02292				
Filer:	Mark Jay Nuell/Leila Landa				
Filer Authorized By:	Mark Jay Nuell				
Attorney Docket Number:	0020-5610PUS1				
Receipt Date:	24-SEP-2009				
Filing Date:	31-OCT-2007				
Time Stamp:	22:28:51				
Application Type:	U.S. National Stage under 35 USC 371				

Payment information:

Submitted wi	th Payment	no	no			
File Listing:						
Document Number	Document Description	File Name	Multi Part /.zip	Pages (if appl.)		
1		20090925IDSwSB08.pdf	513755	yes	6	
		200707201201000001pdi	– 04c3a7dc48c13ccb2f59d9ca9e5ea23abedc 2ae7		Ĵ	

	Multipart Description/PDF files in .zip description					
	Document De:	scription	Start	E	nd	
	Transmittal	1		5		
	Information Disclosure Stater	nent (IDS) Filed (SB/08)	6		6	
Warnings:			•			
Information					1	
2	Foreign Reference	EP1327440A1.pdf	1406997	no	32	
_			d764aac5fb347bc4fc2fd3fe155ef1b68ae2a ab5			
Warnings :		· · · · · ·	· · · · ·			
Information						
3	NPL Documents	Makina 1005 ndf	497316	20	3	
5		Makino1995.pdf	dd1ed15daeac6a24dfa6b2a03675839673e 415cc	no	5	
Warnings:			l		1	
Information						
4		EPOSearchReport.pdf	440972	no	6	
4	NPL Documents	Lr OSearchneport.pdf	6a7b4fd3430cde18337cbb5dc58ab1a74d9 2370d	no		
Warnings :			I			
Information			-			
		Total Files Size (in bytes):	28	59040		
characterize Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 ar national stag <u>New Internat</u> If a new inter an internatic and of the In	redgement Receipt evidences receip d by the applicant, and including pages described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> lication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin <u>ge of an International Application ur</u> bmission to enter the national stage nd other applicable requirements a F ge submission under 35 U.S.C. 371 with tional Application Filed with the USP rnational application is being filed an onal filing date (see PCT Article 11 an ternational Filing Date (Form PCT/RG urity, and the date shown on this Ack ion.	ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due of g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati orm PCT/DO/EO/903 indicati ill be issued in addition to the <u>TO as a Receiving Office</u> and the international application d MPEP 1810), a Notification D/105) will be issued in due co	It serves as evidence omponents for a filin course and the date s on is compliant with ng acceptance of the Filing Receipt, in du ion includes the nece of the International <i>J</i> ourse, subject to pres	of receipt s og date (see hown on th the condition application e course. ssary comp Application scriptions co	similar to a 37 CFR his ons of 35 h as a conents for Number oncerning	

Docket No. 0020-5610PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Kazuyuki FUJIHARA

Application No. 11/919,678

Filed: October 31, 2007

Confirmation No. 6965

Art Unit: 1617

For: PHARMACEUTICAL COMPOSITION Examiner: S. Pihonak

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Madam:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. <u>COPIES</u>

a.Copies of cited U.S. patents and patent application publications are not included.Copies of foreign patent documents and non-patent literature are included.

b. Some or all of the documents listed on the PTO-SB08 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

Birch, Stewart, Kolasch & Birch, LLP

C. <u>REFERENCES PREVIOUSLY CITED OR SUBMITTED</u> - Pursuant to 37 C.F.R. \$1.98(d), consideration of information listed on the PTO-SB08 form(s) is requested since any patents, publications, or other information which are listed on the PTO-SB08 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. \$120:

III. <u>CONCISE EXPLANATION OF THE RELEVANCE</u>

(check at least one box)

a. <u>DOCUMENTS IN THE ENGLISH LANGUAGE</u> – Some or all of the patents, publications, or other information listed on the attached PTO SB08 are in the English language and therefore, do not require a statement of relevancy.

b. <u>DOCUMENTS NOT IN THE ENGLISH LANGUAGE</u> - A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. <u>ENGLISH LANGUAGE SEARCH REPORT</u> - An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. <u>OTHER</u> - The following additional information is provided for the Examiner's consideration: European Search Report.

IV. <u>FEES</u> (check one box)

a. This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

b. This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

2

C. This Information Disclosure Statement is being filed within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (*This section is not to be used with RCE's.*)

d. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.

e. This Information Disclosure Statement is being filed concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.

 \bigcirc f. This Information Disclosure Statement is being filed before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).

g. This Information Disclosure Statement is being filed before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached.

or

See the statement below. No fee is required.

V. STATEMENT UNDER 37 C.F.R. § 1.97(e)

(check <u>only</u> one box)

The undersigned hereby states that:

a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or

b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

C. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.

d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. <u>PAYMENT OF FEES</u> (check one box)

The required fee is listed on the attached Fee Transmittal.

 \boxtimes No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is

4

requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: SEP 2 5 2009

Respectfully submitted,

By my Nell

Mark J. Nuel Registration No. 36,623 BIRCH, STEWART, KOLASCH & BIRCH, LLP 12770 High Bluff Drive, Suite 260 San Diego, California 92130 (703) 205-8000 Attorney for Applicant

Attach	ment:
\boxtimes	PTO/SB/08
\boxtimes	Document
\boxtimes	Foreign Search Report
	Fee
	Other:



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
11/919,678	10/31/2007	Kazuyuki Fujihara	0020-5610PUS1	6965
	7590 11/30/200 ART KOLASCH & BI		EXAM	INER
PO BOX 747			PIHONAL	K, SARAH
FALLS CHUR	CH, VA 22040-0747		ART UNIT	PAPER NUMBER
			1627	
			NOTIFICATION DATE	DELIVERY MODE
			11/30/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

	Application No.	Applicant(a)
	Application No.	Applicant(s)
Office Action Summers	11/919,678	FUJIHARA, KAZUYUKI
Office Action Summary	Examiner	Art Unit
	SARAH PIHONAK	1627
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti will apply and will expire SIX (6) MONTHS fron , cause the application to become ABANDON	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on $\underline{17 \text{ S}}$	eptember 2009	
	action is non-final.	
3) Since this application is in condition for allowa		osecution as to the merits is
closed in accordance with the practice under E		
Disposition of Claims		
 4) Claim(s) <u>1-24</u> is/are pending in the application 4a) Of the above claim(s) <u>5-7</u> is/are withdrawn 		
5 Claim(s) is/are allowed.	nom consideration.	
6)⊠ Claim(s) <u>1-4 and 8-24</u> is/are rejected.		
$7) \square Claim(s) _ is/are objected to.$		
	r election requirement	
8) Claim(s) are subject to restriction and/o		
Application Papers		
9) The specification is objected to by the Examine	er.	
10) The drawing(s) filed on is/are: a) acc	epted or b) objected to by the	Examiner.
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correct	tion is required if the drawing(s) is ob	pjected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Ex	caminer. Note the attached Office	e Action or form PTO-152.
Priority under 35 U.S.C. § 119		
	priority upday 25 U.S.C. S. 110/a	
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 		()-(u) of (i).
1. Certified copies of the priority document	a have been reactived	
		tion No.
2. Certified copies of the priority document		
3. Copies of the certified copies of the prio	•	eu in this National Stage
application from the International Burea		od
* See the attached detailed Office action for a list	or the certified copies not receiv	.
Attachment(s)		
1) Notice of References Cited (PTO-892)	4) Interview Summary	
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 	Paper No(s)/Mail D 5)	
Paper No(s)/Mail Date	6) 🔲 Other:	
L <u>10/21/2007</u> 2/17/2008 2/17/2008 8/21/2008 0/21/2000 U.S. Patent and Trademark Office PTOL-326 (Rev. 08-06) Office Av	ction Summary P	art of Paper No./Mail Date 20091113
	r Summary P	an or raper No. Avian Date 20091113

DETAILED ACTION

This application, filed 10/31/2007, is a national stage entry of PCT/JP2006/310571, filed on 5/26/2006.

Priority

This application claims foreign priority to Application No. 2005-153508, filed on 5/26/2005.

Response to Restriction Requirement

- 1. Applicant's election without traverse of the invention of Group I, claims 1-4 and 8-
- 24, in the reply filed on 9/24/2009 is acknowledged.
- 2. Claims 5-7 are withdrawn from further consideration pursuant to 37 CFR 1.142(b)

as being drawn to a nonelected invention, there being no allowable generic or linking

claim. Election was made without traverse in the reply filed on 9/24/2009.

3. Applicant is reminded that, in the event that the claims of Group I are found

allowable, a rejoinder of the withdrawn method claims of Group II will be considered.

- 4. Claims 1-4 and 8-24 were examined.
- 5. Claims 1-4 and 8-24 are rejected.

Claim Rejections-35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

7. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148

USPQ 459 (1966), that are applied for establishing a background for determining

obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

8. Claims 1-4 and 8-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fujihara et. al., EP Patent Publication No. 1327440, in view of Salpekar et. al., US Patent No. 4,600,579. The reference of Fujihara et. al. was submitted by the Applicants in the Information Disclosure Statement.

The claims are drawn to an oral composition comprised of lurasidone,

pregelatinized starch, a water soluble excipient such as mannitol or lactose, and a water soluble polymer binder. The claims are also drawn to the composition in which the pregelatinized starch is present in an amount from 10-50% by weight, and in which the lurasidone is present in an amount from 25 to 45% by weight.

Fujihara et. al. teaches an oral composition comprised of a slightly water soluble active ingredient, such as lurasidone, along with a first disintegrant, a second disintegrant, and a water soluble polymer binder (Abstract; p. 4-5, paragraph [0008]). Fujihara et. al. teaches that the composition provides advantageous dissolution characteristics when ingested (Abstract). It is taught that one of the water soluble excipients includes sugar alcohols such as mannitol or lactose (p. 3, paragraph [0017],

item (18); p. 5, paragraph [0014]). The other disintegrant is taught as including excipients such as microcrystalline cellulose, croscarmellose sodium, among others (p. 5, paragraph [0011]), and the water soluble polymer binder includes polyvinylpyrrolidone, polyvinyl alcohol, and others (p. 5, paragraph [0010]). It is taught that the amount of lurasidone present in the oral composition is 40 mg., which is within the range instantly claimed (p. 5, paragraph [0015]; p. 22, paragraph [0152], Table 28), and that the average particle size of lurasidone is between 0.5 to 5 μ m, which meets the limitations of claim 22 (p. 6, paragraph [0021]). It is taught that for a tablet of a weight of approximately 142 mg., the amount of lurasidone present is 40 mg., which is approximately 28 % of the weight of the composition (p. 29, paragraph [0194], Table 44), which meets the limitations of claims 10 and 11. The amount of the disintegrants present in the composition is taught as ranging from 5 to 300 % by weight of the composition (p. 4, paragraph [0007], item (33)), or up to 1200% by weight (p. 6, paragraph [0029]). It is taught that the oral preparation comprises a granule, which is prepared by granulating the water-soluble polymer binder with the powdery mixture consisting of the active agent (lurasidone), a water soluble excipient, and another disintegrant (p. 3, paragraph [0007], items (11-13); p. 4, paragraph [0007], item (40)). Fujihara et. al. teaches that the preparation can be formulated as pills, granules, fine granules, capsules, tablets, etc. (p. 5, paragraph [0016]).

Fujihara et. al. does not explicitly teach that the composition comprises pregelatinized starch, in an amount from 10 to 50% by weight of the composition.

Salpekar et. al. teaches a composition comprised of a pharmaceutically active ingredient, a lubricant, a disintegrant, and pregelatinized starch allows for high hardness, and short dissolution time when ingested (Abstract). Salpekar et. al. teaches that the composition comprised of the pregelatinized starch is beneficial for preparing oral pharmaceutical formulations such as tablets (column 1, lines 22-29). It is taught that the partially pregelatinized starch, such as the starch commercially known as Starch 1500, acts as a binder to the composition, and provides beneficial disintegrant properties, as well as increasing hardness of the composition and shortening the dissolution and disintegration time (column 3, lines 38-51; column 4, lines 31-37). Salpekar et. al. teaches that the amount of partially pregelatinized starch ranges from 5 or less to 15 or more parts per 100 parts of the composition (column 4, lines 15-17), which is within the amount of pregelatinized starch instantly claimed. It is taught that the amount of pregelatinized starch present is based upon the amount necessary to impart the high hardness and decreased dissolution times to the composition (column 4, lines 3-9); therefore, it would have been obvious to one of ordinary skill in the art that the optimum range of the pregelatinized starch may comprise amounts greater than or less than 5-15 % by weight, as taught. Salpekar et. al. teaches that the percent gelatinization of the pregelatinized starch ranges optimally from 50 to 75% (column 2, lines 33-55), which is within the percent range cited in claim 21. Additionally, it is taught that Starch 1500 has a moisture content between 3 and 5 % (column 3, lines 38-45), which meets the limitations of claim 22.

One of ordinary skill in the art would have been motivated, at the time of the invention, to prepare the oral lurasidone preparation taught by Fujihara et. al. with the pregelatinized starch excipient taught by Salpekar et. al. because Salpekar et. al. teaches that the pregelatinized starch in oral pharmaceutical formulations provides beneficial properties, such as increased hardness of the tablet, decreased dissolution time after ingestion, and short disintegration time. As such, it would have been prima facie obvious for one of ordinary skill in the art to prepare the oral lurasidone composition as taught by Fujihara et. al. with the pregelatinized starch excipient as taught by Salpekar et. al. because both Fujihara et. al. and Salpekar et. al. teach pharmaceutical compositions formulated for oral administration. Therefore, there would have been an expectation of success in utilizing the pregelatinized excipient for the composition comprising lurasidone, because it is taught by Salpekar et. al. that the pregelatinized starch imparts beneficial properties to oral formulations.

Information Disclosure Statements

9. The information disclosure statements (IDS) submitted on 10/31/2007, 3/17/2008, 8/24/2009, and 9/24/2009 were filed. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner.

Conclusion

Par Pharm., Inc. Exhibit 1015 Page 212

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached on Monday-Thursday 8:00 AM - 6:30 PM EST, with Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S.P.

/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1627

Notice of References Cited	Application/Control No. 11/919,678	Applicant(s)/Pater Reexamination FUJIHARA, KAZU	
Notice of Kelerences Offed	Examiner	Art Unit	
	SARAH PIHONAK	1627	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	А	US-4,600,579	07-1986	Salpekar et al.	514/629
	в	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	Ι	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Ν					
	0					
	Р					
	Q					
	R					
	S					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	v	
	w	
	x	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 20091113

	Index of Claims			Application/Control No. 11919678 Examiner				Reexa FUJIH	Applicant(s)/Patent Under Reexamination FUJIHARA, KAZUYUKI Art Unit				
					SARAH PIHONAK				1627				
✓ Re	ejected		-	C	ancelled		N	Non-E	ected		A	Арр	eal
= AI	lowed		÷	R	estricted		I	Interfe	rence		0	Obje	cted
🛛 Claims re	numbered	in the s	ame or	der as	presented by a	pplica	ant	C] СРА		T.D	. 🗆 I	R.1.47
CLAI	М							DATE					
Final	Original	11/13/2	2009										
	1	✓											
	2	✓											
	3	~											
	4	~											
	5	N											
	6	N											
		N											
	-												
	11												
					_								
			1		1 1								
	Original 1 2 3 4 5 6 7 7 8 8 9 9 10												

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

	SEARCHED		
Class	Subclass	Date	Examiner

SEARCH NOTES				
Search Notes	Date	Examiner		
Inventor search in EAST, PALM	11/12/2009	S.P.		
Invention and claims search in EAST, STN	11/12/2009	S.P.		

INTERFERENCE SEARCH				
Subclass	Date	Examiner		
	Subclass	Subclass Date		

/S. P./ Examiner.Art Unit 1627

U.S. Patent and Trademark Office

Part of Paper No.: 20091113



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 6965

SERIAL NUM 11/919,67		FILING or DATI 10/31/2	E		CLASS 514	GR	DUP ART 1627	UNIT		DRNEY DOCKET NO. 20-5610PUS1		
		RULI	E									
	APPLICANTS Kazuyuki Fujihara, Osaka-fu, JAPAN;											
* CONTINUING DATA ***********************************												
	** FOREIGN APPLICATIONS ************************************											
	** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 02/23/2009											
Foreign Priority claime 35 USC 119(a-d) cone		Yes No	Met af Allowa	ter ince	STATE OR COUNTRY		IEETS WINGS	TOT/ CLAII		INDEPENDENT CLAIMS		
	SARAH PI Examiner's		Initials		JAPAN		5 24			5		
ADDRESS												
PO BOX	747 HURCH	1, VA 22040-0 3		l								
TITLE												
Pharmac	eutical o	composition										
							🗅 All Fe	es				
	FFF0.		heese situa				🖵 1.16 F	Fees (Fili	ing)			
I FILINNS FEE I		Authority has to	•		aper EPOSIT ACCOUI	NT	🖵 1.17 F	Fees (Pro	ocessi	ing Ext. of time)		
		for					🖵 1.18 F	⁻ ees (lss	ue)			
							C Other					
							Credit	t				

Ref #	Hits	Search Query	DBs	Defa ult Oper ator	Plurals	Time Stamp
S1	4	"2001076557".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2009/07/17 07:52
S2	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:53
S3	2622	pre-gelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S4	0	S2 and S3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S5	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S6	25	S2 and S5	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:55
S7	234938	oral and pharmaceutical	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S8	10067	S5 and S7	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S9	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01

EAST Search History (Prior Art)

EAST Search History (Prior Art)

S10	446	S9 and oral	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:02
S11	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:17
S12	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S13	1	S11 and S12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S14	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S15	86	S11 and S14	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S16	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:57
S17	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S18	86	S16 and S17	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S19	1	"3607394".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2009/11/12 14:11

EAST Search History (Prior Art)

S20	67	(pregelatin\$4 with starch) same (polymer with binder)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:29
S21	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S22	745	S21 and (starch adj "1500")	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S23	47786	water adj solub\$4 adj polymer	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S24	43	S22 and S23	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S25	99	S21 and (PCS)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:42
S26	5	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2009/11/12 15:05
S27	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2009/11/12 15:07
S28	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S29	1747	S28 and (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S30	202	S28 with (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:15

Used in Lieu of PTO/SB/08A/B (Based on PTO 01-08 version)

	Substitute for form 1449/PTC)		Complete if Known			
				Application Number	11/919,678-Conf. #6965		
	INFORMATIO	N DI	SCLOSURE	Filing Date	October 31, 2007		
	STATEMENT	BY /	APPLICANT	First Named Inventor	Kazuyuki FUJIHARA		
				Art Unit	N/A		
	(Use as many s	sheets as	s necessary)	Examiner Name	Not Yet Assigned		
Shee	et 1	of	1	Attorney Docket Number	0020-5610PUS1		

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					

Examiner Initials*	Cite No.'	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T6
	BA	WO 02/24166 A1	03-28-02			Abs
	BB	WO 2004/078173 A1	10-12-1990			Abs
	BC	JP-08-325146	12-10-1996			Abs
			12-10-1990			

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²						
	CA	Handbook of Pharmaceutical Excipients, 2 nd edition, Vol. 491, The Pharmaceutical Press, 1994							

|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Birch, Stewart, Kolasch & Birch, LLP ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.P./

Used in Lieu of PTO/SB/08A/B (Based on PTO 01-08 version)

SI	ubstitute for form 1449/P	то		Complete if Known		
				Application Number	11/919,678-Conf. #6965	
	NFORMATI	ON DISC	LOSURE	Filing Date	October 31, 2007	
	STATEMEN [®]	T BY AP	PLICANT	First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	N/A	
	(Use as many	y sheets as nec	essary)	Examiner Name	Not Yet Assigned	
Shee	1	of	1	Attorney Docket Number	0020-5610PUS1	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No,1	Document Number Number-Kind Code ² (<i>ii known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,532,372-A	07-02-1996	Saji et al.	

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>it known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
	BA	JP-2000-26292-A	01-25-2000			Abs
	BB	JP-08-325146 A	10-12-1990	//////////////////////////////////////		Abs
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.; Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Handbook of Pharmaceutical Excipients, 2 nd edition, Vol. 491, The Pharmaceutical Press, 1994	

|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Birch, Stewart, Kolasch & Birch, LLP

DRN/kpc

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.P./

Par Pharm., Inc. Exhibit 1015 Page 222

PTO/SB/08b (06-09) Approved for use through 07/31/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449/PTO			Complete if Known		
				Application Number	11/919,678-Conf. #6965	
IP	FORMATION	I DI	SCLOSURE	Filing Date	October 31, 2007	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	1617	
	(Use as many she	eets as	s necessary)	Examiner Name	S. Pihonak	
Sheet	1	of	1	Attorney Docket Number	0020-5610PUS1	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
· · ·								

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ₆				
						_				
	-					L				

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Chueshov, V. I., et al., "Manufacturing Technologies of Drugs," Promyshlennaya Technologiya Lekarstv, Vol 2, pp 10-11 (1999).	part
	СВ	Russian Official Action	part

Signature /Saran Pinonak/ Considered 11/13/2009	Signature / Our an I monate	Date	11/13/2009
---	-----------------------------	------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Birch, Stewart, Kolasch & Birch, LLP

DRN/II

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.P./

Par Pharm., Inc. Exhibit 1015 Page 223

PTO/SB/08b (06-09)

Approved for use through 07/31/2009, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PT	0		Complete if Known		
		-		Application Number	11/919,678-Conf. #6965	
	INFORMATIC	ON DIS	CLOSURE	Filing Date	October 31, 2007	
	STATEMENT	BY A	PPLICANT	First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	1617	
	(Use as many sheets as necessary)			Examiner Name	S. PIHONAK	
Shee	et 1	of	1	Attorney Docket Number	0020-5610PUS1	

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				

		FORE	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T6
	BA*	JP-2000-26292-A	01-25-2000			<u> </u>
	BB	EP-1327440-A1	07-16-2003	Sumitomo Pharma		
		NON PATEN	IT LITEDAT	URE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of				
	СА	Makino, T., et al., "Importance of Disintegration Time of Tablets,"	of Gelatinization	on Degree of Starch Past Bin		
]
Examiner Signature		/Sarah Pihonak/	and the second	Date Considered	11/13/2009	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Birch, Stewart, Kolasch & Birch, LLP

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.P./

TT/919678 IAP05Rec'd PGT 31 OCT 2007

Used in Lieu of PTO/SB/08A/B (Based on PTO 10-07 version)

Su	bstitute for form 1449/PTO			Complete if Known		
				Application Number	NEW	
	NFORMATIO	N DIS	SCLOSURE	Filing Date	October 31, 2007	
5	STATEMENT	BY A	PPLICANT	First Named Inventor	Kazuyuki FUJIHARA	
				Art Unit	N/A	
	(Use as many si	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	0020-5610PUS1	

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where				
Initials*	No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear				
	AA*	US-2004/0028741-A1	02-12-2004	Fujihara					

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document			Pages, Columns, Lines, Where Relevant				
Initials*	No. ¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages Or Relevant Figures Appear	T ⁶			
	BA	WO-02/24166-A1	03-28-2002			ABS			
	BB	WO-2004/078173-A1	09-16-2004			ABS			
	BC	JP-8-325146-A	12-10-1996						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at <u>www.uspto.dov</u> or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the regin of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²						


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sarah Pihonak/	Date Considered	11/13/2009
Birch, Stewart, H	Kolasch & Birch, LLP		DRN//scp

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.P./

FILE 'HCAPLUS' ENTERED AT 13:06:25 ON 12 NOV 2009 L11 S US 20090143404/PN FILE 'REGISTRY' ENTERED AT 13:07:00 ON 12 NOV 2009 1 S 9005-25-8/RN L2 SET NOTICE 1 DISPLAY SET NOTICE LOGIN DISPLAY FILE 'REGISTRY' ENTERED AT 13:07:49 ON 12 NOV 2009 LЗ 1 S 367514-87-2/RN L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN 367514-87-2 REGISTRY RN 4,7-Methano-1H-isoindole-1,3(2H)-dione, CN 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)-(CA INDEX NAME) OTHER NAMES: CN 2-[[(1R,2R)-2-[[4-(1,2-Benzoisothiazol-3-yl)-1piperazinyl]methyl]cyclohexyl]methyl]hexahydro-(3aS,4R,7S,7aR)-4,7-methano-1H-isoindole-1,3(2H)-dione CN Lurasidone FS STEREOSEARCH C28 H36 N4 O2 S MF CI COM SR CA LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL DT.CA CAplus document type: Journal; Patent RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses) RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses) RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses) Absolute stereochemistry.



SET NOTICE 1 DISPLAY SET NOTICE LOGIN DISPLAY

	FILE	'HCAPI	JUS	' H	ENTEF	red <i>i</i>	AT :	13:	08:	:02	ON	12	NOV	2009	
L4		1	S	L2	AND	LЗ									
L5		0	S	L4	NOT	L1									
L6		3195	S	L2	AND	PHA	RMA(CEU	TIC	CAL	TAE	3LE'	IS/II	Г	
L7		227	S	L6	AND	(PY<	<20	05	OR	AY<	<200)5 (OR PI	RY<2005)
L8		9	S	L7	AND	PREC	GEL	ATI	N?						

L8 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN

AB Disclosed are modified release oral tranexamic acid formulations that preferably minimize or eliminate undesirable side effects and methods of treatment therewith. Thus, modified release 650 mg tranexamic acid tablets comprised (in mg/tablet): tranexamic acid 650.0, microcryst. cellulose 44.25, colloidal silicon dioxide 0.75, pregelatinized corn starch 49.50, hypromellose 147.00, povidone 36.00, stearic acid 18.00, magnesium stearate 4.50, purified water 135.00.

purrired water 155.	.00.				
ACCESSION NUMBER:			PLUS	<u>Full-text</u>	
DOCUMENT NUMBER:	151:27	2936			
TITLE:	Tranex	amic acid mo	difi	ed release oral	
formulations					
INVENTOR(S):	Moore	Koith A · H	loagl	ey, Ralph A.; Greiwe	
	110010,		ICUST.	ey, Raiph M., Gieiwe	· /
Jeffrey	~ =				
				Modest, Jason D.	
PATENT ASSIGNEE(S):	Xanody	ne Pharmaceu	itica	ls, Inc., USA	
SOURCE:	U.S. P	at. Appl. Pu	ıbl.,	46pp., Contin-par	t of
U.S.					
	Ser. N	o. 220,241.			
		USXXCO			
DOCUMENT TYPE:	Patent				
LANGUAGE:	Englis	h			
FAMILY ACC. NUM. COUNT:	3				
PATENT INFORMATION:					
PATENT NO.	KIND	DATE	APP	LICATION NO.	DATE
	70 1	222222		0000 100510	
	A1	20090820	US .	2009-433510	
20090430 <					
US 20050245614	A1	20051103	US .	2005-72162	

TI Tranexamic acid modified release oral formulations

20050304 < WO 2006	023000		A1		2006	0302		WO 2	005-	US20	558		
20050613 < W:	AE, AG	, AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,
CA, CH,	CN, CO	, CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,
GB, GD,	GE, GH	, GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KP,
KR, KZ,	LC, LK	, LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
MZ, NA,	NG, NI	, NO,	NZ,	OM,	PG,	PH,	PL,	ΡT,	RO,	RU,	sc,	SD,	SE,
SG, SK,	SL, SM	, SY,	ТJ,	TM,	TN,	TR,	ΤT,	ΤZ,	UA,	UG,	US,	UZ,	VC,
VN, YU,	ZA, ZM			,	,	,	,		,	,	,	,	,
RW: HU, IE,	AT, BE		CH,	CY,	CZ,	DE,	DK,	ΕE,	ES,	FI,	FR,	GB,	GR,
BJ, CF,	IS, IT	, LT,	LU,	MC,	NL,	PL,	ΡT,	RO,	SE,	SI,	SK,	TR,	BF,
GH, GM,	CG, CI	, CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG,	BW,
	KE, LS	, MW,	MZ,	NA,	SD,	SL,	SZ,	ΤZ,	UG,	ZM,	ZW,	AM,	AZ,
BY, KG,	KZ, MD	, RU,		ΤM	2000	0202			005		ECO		
20050613 <			A1		2006			WO 2					DE
W: CA, CH,	AE, AG												
GB, GD,	CN, CO												FΙ,
KR, KZ,	GE, GH	, GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚM,	KP,
MZ, NA,	LC, LK	, LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
SG, SK,	NG, NI	, NO,	ΝΖ,	OM,	PG,	PH,	PL,	ΡT,	RO,	RU,	SC,	SD,	SE,
VN, YU,	SL, SM	, SY,	ΤJ,	ΤM,	ΤN,	TR,	ΤT,	ΤΖ,	UA,	UG,	US,	UZ,	VC,
RW:	ZA, ZM AT, BE		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,
HU, IE,	IS, IT	, LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,
BJ, CF,	CG, CI											ΤG,	BW,
GH, GM,	KE, LS												
BY, KG,	KZ, MD			TM	557	52,	51,	,	00,	,	2,	,	,
JP 2008 20050613	508275	, 100,	т Т		2008	0321		JP 2	007-	5235	55		
JP 2008	508276		Т		2008	0321		JP 2	007-	5235	56		
20050613 < US 2008	0280981		A1		2008	1113		US 2	008-	2202	41		
20080723 < PRIORITY APP 20040304 <	LN. INF	0.:						US 2	004-	5501	13P	:	Ρ

```
US 2004-592885P
                                                                Ρ
20040730 <--
                                            US 2005-72162
                                                                B1
20050304
                                            US 2008-220241
                                                                A2
20080723
                                            WO 2005-US20558
                                                                W
20050613
                                            WO 2005-US20563
                                                                W
20050613
INCL 514561000
    63-6 (Pharmaceuticals)
CC
     Section cross-reference(s): 1
IΤ
     Pharmaceutical tablets
        (coated tablets; tranexamic acid modified release oral
formulations)
    Constipation
ΤТ
     Diarrhea
     Dissolution
     Drug bioavailability
     Drug bioequivalence
     Headache
     Human
     Nausea
     Oral drug delivery systems
     Pharmaceutical capsules
     Pharmaceutical granules
     Pharmaceutical lozenges
     Pharmaceutical pellets
     Pharmaceutical powders
       Pharmaceutical tablets
     Pharmacokinetics
     Vomiting
        (tranexamic acid modified release oral formulations)
ΤТ
     57-11-4, Stearic Acid, biological studies
                                                 557-04-0, Magnesium
Stearate
     7631-86-9, Silicon Dioxide, biological studies
                                                      9003-39-8,
Povidone
                                                9004-65-3, Hypromellose
     9004-34-6, Cellulose, biological studies
     9005-25-8, Starch, biological studies 390816-70-3, Opadry White
     YS 1-7003
     RL: BSU (Biological study, unclassified); THU (Therapeutic use);
BIOL
     (Biological study); USES (Uses)
        (tranexamic acid modified release oral formulations)
     ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
L8
     Controlled release pharmaceutical compositions
ТΤ
     A non-disintegrating, non-eroding, non-bioadhesive and non-
AB
     swelling oral controlled-release pharmaceutical composition and
     process for preparation of such compns. is provided which
     comprises at least one high-dose water-soluble drug, a diluent, a
     binder, and a polymer system comprising of a release-controlling
     polymer wherein the composition formulated into a suitable dosage
     form maintains its geometric shape even after the drug has
     diffused from the dosage form and provides the concns. of active
     ingredient above effective levels for extended periods of time,
```

optionally with other excipients. The compns. preferably comprise antibiotic(s) as active ingredient, more preferably amoxicillin or its salts, hydrates, polymorphs, esters, and derivs. thereof, most preferably amoxicillin sodium, either alone or in combination with other antibiotic(s). Also described are controlled-release compns. which provide an initial burst release of approx. 20-40% of the active ingredient within 1 h for achieving blood levels equivalent to min. inhibitory concentration, while maintaining these levels for an extended period of time. ACCESSION NUMBER: 2009:393268 HCAPLUS Full-text DOCUMENT NUMBER: 150:383031 TITLE: Controlled release pharmaceutical compositions Jain, Rajesh; Jindal, Kour Chand; Singh, INVENTOR(S): Sukhjeet PATENT ASSIGNEE(S): Panacea Biotec Ltd., India SOURCE: U.S. Pat. Appl. Publ., 9pp., Cont.-in-part of Appl. No. PCT/IN2005/000004. CODEN: USXXCO DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 2 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ _____ _____ ____ 20090402 US 20090088415 A1 US 2006-482185 20060706 <--IN 2004DE00023 A 20060210 IN 2004-DE23 20040106 <--WO 2005065641 A2 20050721 WO 2005-IN4 20050105 <--WO 2005065641 A3 20060427 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG A 20081126 ZA 2006-6408 ZA 2006006408 20050105 <--

PRIOF 20040		APPLN. <	INFO.:				2004-DE23	A
20040	0106	<				ΤN	2004-DE28	A
						WO	2005-IN4	A2
20050 INCL CC IT	5141 63-6 Phar Phar Phar ((Pharr maceut maceut larmaceu contro	maceutical ical capsu ical granu itical tak lled-relea	.s) iles iles olets ase; con) e pharmaceutica	l compns.)
IT	RL:	THU (Th	nerapeutic	use);			al study); USES armaceutical co	
L8 TI AB	Vita The of vita with a ta 0.00 mone 1.55 and	invent vitamin amins a h other ablet m 38; pyr ohydrat 2; hydr gelati	2 and foli ion conce B12 with re dissol componen dixture co ridoxine 1 e 7.6; ce rogenated	c acid rns the folic ved in ts and ntained .9; pre llulose castor	preparation acid or anot suitable bin auxiliary ag (kg): folic gelatinized 16.834; gel oil 0.76. Cy	s fo her din ent cor ati	S on STN or oral tablets solid oral com vitamin B comp g agents and th s to form table id 0.228; cyano n starch 7.6; I n 1.52; water S cobalamine, for water prior ado	mbinations ods.; the nen mixed ets. Thus ocobalamine lactose 0.88; talc lic acid
	SSION 4ENT	I NUMBER:	R:	2008:10 148:175 Vitamin	5746		<u>Full-text</u> acid combinati	ons for
SOURC	NT AS CE:	SIGNEE	(S):	Mepha A Patents CODEN:	s e, Max Werner AG, Switz. schrift (Swit SWXXAS		, 9pp.	
LANGU FAMII	JAGE: Ly ac		. COUNT: ION:	Patent German 1				
	PATE	ENT NO.		KIND	DATE	API	PLICATION NO.	DATE
		96870		A5	20080115	СН	2004-1319	
20040 PRIOF 20040 CC	RITY 0809 63-6	APPLN. < (Pharr	INFO.: maceutical oss-refere	•	• 1	СН	2004-1319	
IT	Diss Feta Neur Oral Phar	solution al distr codegene drug c maceuti	n	sease systems les				

Pharmaceutical granules Pharmaceutical solids Pharmaceutical tablets Vascular disease (vitamin B12 and folic acid combinations for oral tablets) 50-99-7, D-Glucose, biological studies 59-30-3, Folic acid, ΤТ biological studies 68-19-9, Vitamin B12 1327-43-1, Magnesium aluminum silicate 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-65-1, Tragant gum 9003-39-8, Polyvinylpyrrolidone 9004-65-3, Hydroxypropylmethylcellulose 9005-25-8, Starch, biological studies 9050-36-6, Maltodextrin 9062-14-0, Hydroxypropylethylcellulose 12001-76-2, Vitamin B RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (vitamin B12 and folic acid combinations for oral tablets) ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN L8 Novel drug delivery systems for amoxicillin ТΤ AB A novel composition is disclosed of oral controlled release formulations of amoxycillin for releasing the drug over a prolonged period of time suitable for ones a day administration in highly absorptive regions of the gastrointestinal tract using dissoln. controlled matrix technol. Thus, tablets contained amoxicillin trihydrate 1148, starch 112, pregelatinized starch 90, hydroxypropyl Me cellulose K4M 120, talc 15, Mg stearate 15, and colloidal silica 7.5 mg/tablet. ACCESSION NUMBER: 2007:179133 HCAPLUS Full-text DOCUMENT NUMBER: 146:365585 TITLE: Novel drug delivery systems for amoxicillin INVENTOR(S): Kesharlal, Biyani Milind; Khushikesh, Jathar Shripad; Simha, Nanda Pratap PATENT ASSIGNEE(S): Ajanta Pharma Ltd., India SOURCE: Indian Pat. Appl., 23pp. CODEN: INXXBQ DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: ALENT NO. KIND DATE DATE PATENT NO. APPLICATION NO. _____ _____ IN 1999BO00836 A 20050318 IN 1999-BO836 19991124 <--PRIORITY APPLN. INFO.: IN 1999-BO836 19991124 <--TC ICM A61K007-00 CC 63-6 (Pharmaceuticals) IT Pharmaceutical tablets (controlled-release; drug delivery systems for amoxicillin) 9003-39-8, Polyvinylpyrrolidone 9004-34-6D, Cellulose, derivs. ΤТ 9004-57-3, Ethyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Starch, biological studies 9005-25-8D,

Starch, derivs. 26787-78-0, Amoxicillin 61336-70-7, Amoxicillin trihydrate RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (drug delivery systems for amoxicillin) ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN T.8 Starch based excipients for pharmaceutical tablets ТΤ Starch and modified starches are safe and well established AB excipients and they can be phys. modified to enhance their properties to improve their performance, and could also be chemical modified to obtain a very wide range of new properties that can play an important role in the formulation of complex delivery systems. Tablets containing regular maize starch easily allow water to penetrate into the tablet, softening it for fast disintegration. Pregelatinized or cold water soluble starches act as strong binders leading to stronger, but also slower, disintegrating tablets. A direct compressible starch that has to be both a binder and a disintegrant needs to possess the correct ratio of both crystalline to amorphous structure. Slow-release tablets involve the encapsulation of an active ingredient in a modified starch matrix like a modified pregelatioized high amylose maize starch. The bioadhesive tablet, containing pregelatinized waxy starch is applied to increase buccal residence time of miconazole. 2002:579348 HCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 138:243111 TITLE: Starch based excipients for pharmaceutical tablets AUTHOR(S): Michaud, Jacques CORPORATE SOURCE: Application Centre Pharma & Chemical, Cerestar, Vilvoorde, Belg. SOURCE: PharmaChem (2002), 1(6), 42-44CODEN: PHARGZ B5 srl PUBLISHER: DOCUMENT TYPE: Journal LANGUAGE: English CC 63-6 (Pharmaceuticals) ΤТ Drug delivery systems (tablets; starch based excipients for pharmaceutical tablets) 9005-25-8, Starch, biological studies ΤТ RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (starch based excipients for pharmaceutical tablets OS.CITING REF COUNT: THERE ARE 1 CAPLUS RECORDS THAT CITE 1 THIS RECORD (1 CITINGS) REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN T-8 ТΤ Sustained-release pharmaceutical tablets containing combination of

piperidinoalkanols and decongestants

A pharmaceutical composition in the form of a bilayer tablet is AB provided comprising, (a) a first discrete zone made with formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of; (i) carnauba wax in an amount of about 59% to about 81% by weight of formulation (A); and (ii) a suitable antiadherent in an amount of about 0.25% to about 2.00% by weight of formulation (A). Wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and (b) a second discrete zone made with formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol, or a pharmaceutically acceptable salt thereof, in an amount of about 15% to about 30% by weight of formulation (B) and a second carrier base material, the second carrier base comprising a mixture of; (i) a cellulose diluent in an amount of about 27% to about 73% by weight of formulation (B); (ii) pregelatinized starch in an amount of about 15% to about 30% by weight of formulation (B); (iii) a suitable disintegrant in an amount of about 0.25% to about 6.00% by weight of formulation (B); and (iv) a suitable lubricant in an amount of about 0.25% to about 2.00% by weight of formulation (B); wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof. A bilayer tablet contained 4[4[4(Hydroxydiphenylmethyl)-1piperdinyl]-1-hydroxybutyl] dimethylbenzeneacetic acid hydrochloride 60.00, microcryst. cellulose 26.00, pregelatinized starch 60.00, microcryst. cellulose (Avicel PH 102) 190.5, croscarmellose sodium 12.00, magnesium stearate 2.633 mg in the immediate-release layer; pseudoephedrine hydrochloride 120.0, carnauba wax 300.0, stearic acid flakes 4.899, colloidal silicon dioxide 1.065, and Opadry YS-17006 23.31 mg in the sustainedrelease layer. ACCESSION NUMBER: 2000:186719 HCAPLUS Full-text DOCUMENT NUMBER: 132:227453 TITLE: Sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants INVENTOR(S): Maclaren, David D.; Lefler, John R.; Minish, Sharon K. PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., USA SOURCE: U.S., 15 pp. CODEN: USXXAM DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: KIND DATE PATENT NO. APPLICATION NO. DATE _____ _____ _____ US 6039974 A 20000321 US 1998-127478 19980731 <--

PRIORITY APPLN. INFO.: 19970826 <--TC ICM A61K009-22 ICS A61K009-24; A61K009-28 INCL 424472000 63-6 (Pharmaceuticals) CC ΤТ Adrenoceptor agonists Decongestants Lubricants (sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants) IΤ Carnauba wax RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants) ΤТ Drug delivery systems (tablets, sustained-release; sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants) ΙT 9005-25-8, Starch, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pregelatinized; sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants) ΤТ 345-78-8, Pseudoephedrine hydrochloride 557-04-0, Magnesium stearate 7631-86-9, Silicon dioxide, biological studies 9004-34-6, Cellulose, biological studies 74811-65-7, Croscarmellose sodium 153439-40 - 8174523-28-5 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants) OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS) REFERENCE COUNT: THERE ARE 53 CITED REFERENCES AVAILABLE 53 FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN T.8 Pharmaceutical tablets containing irbesartan ТΤ AB Pharmaceutical tablets containing irbesartan (I), alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties. Pharmaceutical tablets contained I 50, anhydrous lactose 10.25, pregelatinized starch 15.0, croscarmellose sodium 2.5, poloxamer-188 3.0, microcryst. cellulose 15.0, croscarmellose sodium 2.5, silicon dioxide 0.75, and magnesium stearate 1.0 %. 1997:72239 HCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 126:94807 ORIGINAL REFERENCE NO.: 126:18213a,18216a TITLE: Pharmaceutical tablets containing irbesartan INVENTOR(S): Ku, Cathy C.; Sprockel, Omar L.; Rubitski,

Beth A.; Desai, Divyakant S. PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Sanofi Synthelabo SOURCE: Eur. Pat. Appl., 16 pp. CODEN: EPXXDW DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ ____ EP 747050 A1 19961211 EP 1996-304291 19960607 <--B1 20030903 EP 747050 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE TW 442301 в 20010623 TW 1996-85105820 19960516 <--IL 118309 A 20030624 IL 1996-118309 19960517 <--A 19971128 ZA 9604337 ZA 1996-4337 19960528 <--A1 19961208 CA 2177772 CA 1996-2177772 19960530 <--CA 2177772 С 20070410 CZ 291532 B6 20030312 CZ 1996-1634 19960605 <--A 19961209 NO 1996-2387 NO 9602387 19960606 <--B1 20010716 NO 310495 AU 9654763 A 19961219 AU 1996-54763 19960606 <--B2 19990225 AU 702651 HU 9601564 A2 19980928 HU 1996-1564 19960606 <--A3 20001228 HU 9601564 RU 2181590 C2 20020427 RU 1996-111030 19960606 <--C1 20030820 RU 2210368 RU 2001-130903 19960606 <--A JP 08333253 19961217 JP 1996-145579 19960607 <--B2 20010508 JP 3162626 A 19970312 CN 1144656 CN 1996-106832 19960607 <--С CN 1149083 20040512 A1 20030115 EP 1275391 EP 2002-16237 19960607 <--R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI PL 184893 B1 20030131 PL 1996-314670 19960607 <--

20030915 AT 248594 Т AT 1996-304291 19960607 <--ES 2205000 TЗ 20040501 ES 1996-304291 19960607 <--HK 1002384 20040305 HK 1998-100693 A1 19980127 <--US 5994348 А 19991130 US 1998-81685 19980520 <--NO 2000004743 19961209 NO 2000-4743 А 20000922 <--NO 310393 В1 20010702 20020129 US 2000-686378 US 6342247 В1 20001011 <--PRIORITY APPLN. INFO.: US 1995-472618 А 19950607 <--US 1996-642978 B1 19960506 <--RU 1996-111030 А 19960606 <--EP 1996-304291 A3 19960607 <--US 1998-81685 A3 19980520 <--US 1999-390868 В1 19990907 <--ICM A61K031-415 IC ICS A61K009-00; A61K009-20 CC 63-6 (Pharmaceuticals) Glycerides, biological studies ΤТ RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (C16-18; pharmaceutical tablets containing irbesartan) Diuretics IΤ Surfactants (pharmaceutical tablets containing irbesartan) ΙT Drug delivery systems (tablets; pharmaceutical tablets containing irbesartan) Fats and Glyceridic oils, biological studies ΤТ RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (vegetable, hydrogenated; pharmaceutical tablets containing irbesartan) ΙT 9004-34-6, Cellulose, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (microcryst.; pharmaceutical tablets containing irbesartan) 57-11-4, Stearic acid, biological studies 58-93-5, TΤ Hydrochlorothiazide 58-94-6, Chlorothiazide 63-42-3, Lactose 73-48-3, Bendroflumethiazide 73-49-4, Quinethazone 77-36-1, Chlorthalidone 91-33-8, Benzthiazide 133-67-5, Trichlormethiazide 135-09-1, Hydroflumethiazide 346-18-9, Polythiazide 532-32-1, Sodium benzoate 557-04-0, Magnesium stearate 557-05-1, Zinc stearate 1592-23-0, Calcium stearate 2259-96-3, Cyclothiazide 4070-80-8, Sodium stearyl fumarate 7631-86-9, Silicon

dioxide, biological studies 7757-93-9, Dibasic calcium phosphate 9003-39-8, Povidone 9004-32-4, Carboxymethyl cellulose sodium 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropylmethyl cellulose 9004-67-5, Methyl cellulose 9005-28-8, Starch, biological studies 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 14807-96-6, Talc, biological studies 14987-04-3, Magnesium trisilicate 17560-51-9, Metolazone 25322-68-3, Peg 31566-31-1, Glyceryl monostearate 64044-51-5, Lactose monohydrate 106392-12-5, Poloxamer 138402-11-6, Irbesartan RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical tablets containing irbesartan) 1309-37-1, Ferric oxide, biological studies ΤТ RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (red and yellow; pharmaceutical tablets containing irbesartan) OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS) ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN T.8 ΤI Retarded-release pharmaceuticals containing dihydropyridines as

active agents and having rapid-release cores and slowly dissolving coatings GI

R³0₂C

AB Solid pharmaceutical formulations with a prolonged efficacy contain a dihydropyridinecarboxylate derivative (I; R1 = nitro-, halo-, or CF3-mono- or disubstituted Ph, benzofuran-4-yl, 2-phenyl-4-oxo-4H-1-benzothiopyran-8-yl; R2 = NO2, CO2R6; R3 = optionally alkoxy- or F-substituted alkyl; R4, R5 = optionally OHsubstituted alkyl; R2R5 = CO2CH2; R6 = optionally alkoxy- or halosubstituted alkyl). The pharmaceutical consists of a core which is capable of rapidly releasing ≥ 1 I; the cores are coated with a coating, free of active agent, which only slowly dissolves in aqueous medium. The coating optionally carries a coating which is capable of rapidly releasing an initial dose of dihydropyridine; the diameter of the formulations is 0.5-15 mm. Tablet cores containing microfine nitrendipine 8.0, lactose 8.0, microcryst. cellulose 8.0, crosslinked PVP 16.0, PVP-25 4.0, SDS 0.8, and Mg stearate 0.2 mg each were coated to contain in their coatings

hydroxypropylcellulose (type L) 50.0, hydroxypropylcellulose (type M) 87.5, lactose 110.0, and Mg stearate 1.65 mg each. A lacquer rapid-release coating was applied to these coated tablets which contained nitrendipine 4.0, hydroxypropylmethylcellulose, and PEG. The tablets thus gave a retarded-release effect. ACCESSION NUMBER: 1989:639511 HCAPLUS Full-text DOCUMENT NUMBER: 111:239511 ORIGINAL REFERENCE NO.: 111:39663a,39666a TITLE: Retarded-release pharmaceuticals containing dihydropyridines as active agents and having rapid-release cores and slowly dissolving coatings Ohm, Andreas; Luchtenberg, Helmut; Buecheler, INVENTOR(S): Manfred; Schmoll, Josef; Rupp, Roland; Porges, Eduard; Nishioka, Takaaki PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger. SOURCE: Eur. Pat. Appl., 18 pp. CODEN: EPXXDW DOCUMENT TYPE: Patent LANGUAGE: German FAMILY ACC. NUM. COUNT: 2 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE EP 306699 A1 19890315 EP 1988-112494 19880801 <--R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE DE 3726666 A1 19890223 DE 1987-3726666 19870811 <--A1 19891005 DE 3810350 DE 1988-3810350 19880326 <--PRIORITY APPLN. INFO.: DE 1987-3726666 А 19870811 <--DE 1988-3810350 А 19880326 <--OTHER SOURCE(S): MARPAT 111:239511 IC ICM A61K031-44 ICS A61K009-24; A61K009-54 CC 63-6 (Pharmaceuticals) ΤТ 9005-25-8, Starch, biological studies RL: BIOL (Biological study) (pregelatinized, retarded-release pharmaceuticals containing dihydropyridine-containing rapid-release core and coating of) IΤ 39562-70-4, Nitrendipine RL: BIOL (Biological study) (retarded-release pharmaceutical tablets of, containing rapid-release core and slowly dissolving coating) 9003-39-8, Poly(vinylpyrrolidinone) ΤТ RL: BIOL (Biological study) (retarded-release pharmaceutical tablets with slowly dissolving coating and rapid-release core containing) OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD

(2 CITINGS)

ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN T.8 ΤI Spray-dried ibuprofen-containing powders for direct-impression tabletting applications AB Spray-dried ibuprofen compns. are suitable for direct compression into tablets and consist essentially of spray-dried aqueous dispersions of ibuprofen, preglatinized starch, a disintegrant, and a wetting agent for ibuprofen. In a semiprodn. run, a dry blend containing pregelatinized starch 10.25, croscarmellose Na 3.50, colloidal silica 0.25, povidone 1.00, and ibuprofen 85.00% was used to prepare a 30% aqueous dispersion of solids in 246 gal H2O which was fed into a spray dryer; the spray dryer was operated at an air inlet temperature of 270-275°F and an air outlet temperature of 140°F, the atomizer at 18,639 rotations/min, and a feed rate of 0.77-0.87 gal/min. Tablets contained the spray-dried powder above 236.0 pregelatioized starch 22.5, compressible starch 22.5, croscarmellose Na (type A) 18.0, colloidal silica 0.45, Na lauryl sulfate 0.75, and stearic acid 1.80 mg/tablet. ACCESSION NUMBER: 1989:520917 HCAPLUS Full-text DOCUMENT NUMBER: 111:120917 ORIGINAL REFERENCE NO.: 111:20153a,20156a TITLE: Spray-dried ibuprofen-containing powders for direct-impression tabletting applications Ho, Ying Tien Richard; Blank, Robert George INVENTOR(S): PATENT ASSIGNEE(S): American Home Products Corp., USA Eur. Pat. Appl., 19 pp. SOURCE: CODEN: EPXXDW DOCUMENT TYPE: Patent English LANGUAGE • FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: KIND DATE PATENT NO. APPLICATION NO. DATE _____ ____ _____ _____ ____ ____ EP 298666 A2 19890111 EP 1988-306003 19880701 <--A3 19890517 EP 298666 EP 298666 R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL AT 92752 Т 19930815 AT 1988-306003 19880701 <--ES 2058288 TЗ 19941101 ES 1988-306003 19880701 <--С CA 1319109 19930615 CA 1989-588463 19890117 <--А US 4904477 19900227 US 1989-378480 19890713 <--PRIORITY APPLN. INFO.: US 1987-71116 А 19870708 <--EP 1988-306003 Α 19880701 <--ICM A61K009-20 TC ICS A61K031-19; A61K047-00 CC 63-6 (Pharmaceuticals) IT 15687-27-1, Ibuprofen

RL: BIOL (Biological study) (direct compressed pharmaceutical tablets containing) IT 151-21-3, Sodium lauryl sulfate, biological studies 9003-39-8, Povidone 9005-25-8, Starch, biological studies 9063-38-1, Sodium starch glycolate 74811-65-7, Croscarmellose sodium RL: BIOL (Biological study) (direct compressed pharmaceutical tablets containing ibuprofen and)

PTO/SB/81 (01-09) Approved for use through 11/30/2011. OMB 0651-0035

hippitotod for dae middigh i hadizetti.	01110 0001 0000
U.S. Patent and Trademark Office; U.S. DEPARTMENT	OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OME	control number.

POW	ER OF ATTORNEY	Application Number	11919678
	OR	Filing Date	2007-10-31
REVOCATION	OF POWER OF ATTORNEY	First Named Inventor	Kazuyuki FUJIHARA
	V POWER OF ATTORNEY	Title	Pharmaceutical Composition
	AND	Art Unit	1627
CHANGE OF CO	DRRESPONDENCE ADDRESS	Examiner Name	Pihonak, Sarah
		Attorney Docket Number	7379/98100
hereby revoke all	previous powers of attorney given i	in the above-identified a	pplication
	orney is submitted herewith.	·	
OR hereby appoin	nt Practitioner(s) associated with the following	a Customer	42798
1 ¥ 1	our attorney(s) or agent(s) to prosecute the a		42798
	e, and to transact all business in the United S c Office connected therewith:	States Patent	I
OR	Office connected therewill.		
	nt Practitioner(s) named below as my/our atto		
to transact all b	usiness in the United States Patent and Trac	iemark Utrice connected there	
	Practitioner(s) Name	Re	gistration Number
OR The address as OR OR	sociated with Customer Number:		
Firm or			
Individual Name	<u>;</u>		
Address			
0.4		04.1	1 _ 1
City		State	Zip
Country			
Telephone			
1 M		Email	
	L	Email	
Applicant/Inven	tor.	Email	
Applicant/Inven OR Assignee of rec	ord of the entire interest. See 37 CFR 3.71.		······································
Applicant/Inven OR Assignee of rec	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt	ted herewith or filed on	· ·
Applicant/Inven OR Assignee of rec	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt		1
Applicant/Inven OR Assignee of rec Statement unde	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt	ted herewith or filed on	
Applicant/Inven OR Assignee of rec Statement unde	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt SIGNATURE of App	ted herewith or filed on icant or Assignee of Record Dat	
OR Assignee of rec	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt SIGNATURE of App Masayo TADA	ted herewith or filed on iCant or Assignee of Record Dat	e March 26, 2010
Applicant/Inven OR Assignee of rec Statement under Signature Name Title and Company NOTE: Signatures of all th	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt SIGNATURE of App Masayo TADA President and Representat he inventors or assignees of record of the entire interest.	ted herewith or filed on Frant or Assignee of Record Dat Tel tive Director of D	e March 26, 2010 ephone ainippon Sumitomo Pharma Co.
Applicant/Inven OR Assignee of rec Statement under Signature Name Title and Company NOTE: Signatures of all th	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt SIGNATURE of App Masayo TADA President and Representat he inventors or assignees of record of the entire interest.	ted herewith or filed on Frant or Assignee of Record Dat Tel tive Director of D	e March 26, 2010 ephone ainippon Sumitomo Pharma Co.
Applicant/Inven OR Assignee of rec Statement under Signature Name Title and Company	ord of the entire interest. See 37 CFR 3.71. er 37 CFR 3.73(b) (Form PTO/SB/96) submitt SIGNATURE of App Masayo TADA President and Representat he inventors or assignees of record of the entire interest.	ted herewith or filed on Frant or Assignee of Record Dat Tel tive Director of D	e March 26, 2010 ephone ainippon Sumitomo Pharma Co.
Applicant/Inven OR Assignee of rec Statement under Signature Name Title and Company NOTE: Signatures of all the signature is required, see	And the entire interest. See 37 CFR 3.71. SIGNATOR of App Masayo TADA President and Representat he inventors or assignees of record of the entire int below. forms are submitted.	ted herewith or filed on icant or Assignee of Record Dat Tel tive Director of D terest or their representative(s) ar	e March 26, 2010 ephone ainippon Sumitomo Pharma Co.

In scollection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/96 (07-09) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a vail OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	1					
Applicant/Patent Owner: Kazuyuki FUJIHARA						
Application No./Patent No.: 11919678 Filed/Issue Date: 2007-10-31						
Titled: Pharmaceutical Composition						
Dainippon Sumitomo Pharma Co., Ltd.						
(Name of Assignee) (Type of Assignee, e.g., corporate	tion, partnership, university, government agency, etc.					
states that it is:						
1. X the assignee of the entire right, title, and interest in;						
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or						
3. the assignee of an undivided interest in the entirety of (a complete assignmen	t from one of the joint inventors was made)					
the patent application/patent identified above, by virtue of either:						
A. An assignment from the inventor(s) of the patent application/patent identified a the United States Patent and Trademark Office at Reel 020124, copy therefore is attached.	above. The assignment was recorded in Frame 0821, or for which a					
OR						
B. A chain of title from the inventor(s), of the patent application/patent identified a	above, to the current assignee as follows:					
1. From: To:						
The document was recorded in the United States Patent and Trade						
Reel, or	for which a copy thereof is attached.					
2. From: To:						
The document was recorded in the United States Patent and Trade	mark Office at					
Reel, Frame, or	for which a copy thereof is attached.					
3. From: To:						
The document was recorded in the United States Patent and Trade						
Reel, Frame, or	for which a copy thereof is attached.					
Additional documents in the chain of title are listed on a supplemental sheet(s).					
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of titl or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	le from the original owner to the assignee was					
[NOTE: A separate copy (<i>i.e.</i> , a true copy of the original assignment document(s) accordance with 37 CFR Part 3, to record the assignment in the records of the US						
The undersigned (whose title is supplied below) is authorized to act on behalf of the assig	gnee.					
that fary	March 26, 2010					
Signature	Date					
Masayo TADA	President and Representative Director					
Printed or Typed Name	Title					
This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefi process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 114. This collection is gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon you require to complete this form and/or submatting the completed application form to the USPTO.	is estimated to take 12 minutes to complete, including h the individual case. Any comments on the amount of time					

you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form call 1.800...PTO_9199 and select option 2

s,

Electronic Acl	knowledgement Receipt
EFS ID:	7561094
Application Number:	11919678
International Application Number:	
Confirmation Number:	6965
Title of Invention:	Pharmaceutical composition
First Named Inventor/Applicant Name:	Kazuyuki Fujihara
Customer Number:	02292
Filer:	Kendrew H. Colton
Filer Authorized By:	
Attorney Docket Number:	0020-5610PUS1
Receipt Date:	06-MAY-2010
Filing Date:	31-OCT-2007
Time Stamp:	10:08:46
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment		no	no			
File Listing:						
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1	Power of Attorney	PowerAttorney.pdf	113437	no	1	
	i owel of Actomey	r ower/atomey.par	f3ed5bfdc6b715d06b98db6441b55be4a0f d6a39			
Warnings:						
Information:						

2	2 Power of Attorney Statement.pd	Statement.pdf	97015	no	1
			79ae2cd9937e6f5cf5c7cf01f24659c4d3ad1 6ee		
Warnings:					
Information:					
	Total Files Size (in bytes): 210452				
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for a filing Receipt, in due course.					
an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

UNITED ST	ates Patent and Tradema	UNITED STA' United States Address: COMMI P.O. Box I	a, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
11/919,678	10/31/2007	Kazuyuki Fujihara	7379/98100
			CONFIRMATION NO. 6965
42798		POA ACC	EPTANCE LETTER
FITCH, EVEN, TABIN & F P. O. BOX 18415 WASHINGTON, DC 2003			OC000000041587393*

Date Mailed: 05/13/2010

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 05/06/2010.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/sleutchit/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

UNITED ST	ates Patent and Tradem	UNITED STA United States Address: COMMI P.O. Box I	a, Virginia 22313-1450	
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	
11/919,678	10/31/2007	Kazuyuki Fujihara	0020-5610PUS1	
			CONFIRMATION NO. 6965	
2292		POWER OF ATTORNEY NOTICE		
BIRCH STEWART KOLAS	SCH & BIRCH			
PO BOX 747 FALLS CHURCH, VA 220	40-0747		SC000000041587333*	
			Date Mailed: 05/13/2010	

NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 05/06/2010.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

/sleutchit/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

Attorney Docket No.: 7379/98100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	:
Kazuyuki FUJIHARA	Confirmation No.: 6965
U.S. Application No.: 11/919,678	. Examiner: PIHONAK, SARAH
Filed: October 31, 2007	: Group Art Unit: 1627 :

For: PHARMACEUTICAL COMPOSITION

AMENDMENT

May 24, 2010

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Kindly enter this Amendment and grant the concurrently filed Petition for Extension of Time.

- 1. Amendments to Claims begin on page 2 of this paper.
- 2. Remarks/Arguments begin on page 7 of this paper.


Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 2

Amendments to the Claims:

This listing of claims replaces any and all prior claim lists.

Listing of Claims:

1. (Currently Amended) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

2. (Currently Amended) An oral preparation which is prepared by <u>the process which</u> <u>comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch</u> and a water-soluble excipient by using a solution of a water-soluble polymer binder; <u>wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the</u> <u>pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the</u> <u>weight of the preparation</u>.

3. (Currently Amended) An oral preparation which is prepared by <u>the process which</u> <u>comprises</u> granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble polymer binder;

wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

4. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose.

5. (Withdrawn – Currently Amended) A method-of for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

6. (Withdrawn – Currently Amended) A method-of for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by using a solution or dispersion of lurasidone and a water-soluble polymer binder.

7. (Withdrawn – Currently Amended) The method-of granulation of claim 5 wherein the water-soluble excipient is mannitol or lactose.

8. (Cancelled)

9. (Previously presented) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 4

10. (Cancelled)

11. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

12. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. (Cancelled)

16. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17. (Cancelled)

18. (Cancelled)

19. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount

of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

20. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

21. (Previously Presented) The oral preparation of claim 1 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Previously Presented) The oral preparation of claim 1 wherein an average particle size of lurasidone is 0.1 to 8 μ m.

23. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to 40% (wt/wt) and a content lurasidone per tablet is 20 to 120 mg.

25. (New) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 20 to 45% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

26. (New) The oral preparation of claim 9 wherein the water-soluble excipient is mannitol or lactose.

<u>REMARKS</u>

Applicants courteously solicit favorable reconsideration followed by a Notice of Allowance.

Upon entry of this Amendment claims 1-7, 9, 11-14, 16, and 19-26 will be presented. Claims 8, 15, 16, and 18 have been cancelled with neither prejudice nor disclaimer. Claim 1 includes language drawn from claims 10 and 15. Similarly, claims 2 and 3 have been amended. Amended non-elected claims 5, 6, and 7 find basis in the original application, and attention is respectfully invited to the examples. New claims 25 and 26 are supported, respectively, by the original claims 10 and 24 and original claim 9. The amended and new claims avoid new matter and entry thereof is courteously solicited.

Applicants acknowledge the Office Action at page 2 and respectfully solicit allowance of the group I claims, and rejoinder of the withdrawn method claims 5-7 is also requested. Applicants notes the rejoinder offered in the Office Action, page 2, paragraph 2.

Traversal of Rejection under 35 U.S.C. §103(a)

Applicants respectfully traverse the rejection of claims 1-4 and 8-24 under 35 U.S.C. §103(a) over Fujihara *et al.* (EP Patent Publication No. 1327440) in view of Salpekar *et al.* (U.S. Patent No. 4,600,579).

By way of background, aspects of the present claimed inventions involve an oral preparation that may comprise high contents of a hardly-soluble pharmaceutically active agent (e.g. lurasidone), yet the preparation exhibits a similar dissolution profile as compared to oral preparations having different contents of such pharmaceutically active agent (*see* paragraph [0013]). An aspect of the present invention includes an oral preparation having pregelatinized starch in the amount of 10-50% wt/wt per oral preparation.

The claims would not have been obvious over Fujihara *et al*. in view of Salpekar *et al*.

Although Fujihara discloses an oral composition comprising lurasidone which provides dissolution characteristics, Fujihara's 16.3% (wt/wt) or less of lurasidone is definitely different from the currently claimed invention in the content rates of lurasidone per oral preparation. This difference is one of the distinguishing aspects of the present claimed of the invention.

Fujihara only discloses that tablets comprising 8.13-16.3% (wt/wt) of lurasidone may have advantageous dissolution characteristics, and does not teach that any tablets comprising more than 16.3% (wt/wt) of lurasidone show remarkable dissolution profiles. In this respect, Fujihara's tablets of Comparative Examples 1-3, including a tablet comprising 29% of lurasidone (Comparative Example 3), are significantly inferior to the corresponding FC tablets of Examples 2-28 which comprise 8.13-16.3% (wt/wt) of lurasidone in terms of the dissolution characteristics (see [0185], [0191] and [0197]). Fujihara thus teaches away. Accordingly, Fujihara neither discloses nor suggests the claim 1 oral preparation comprising high amounts (20-45% (wt/wt)) of lurasidone which shows excellent dissolution profiles.

Furthermore, Fujihara's method does not yield (allow) compositions having high contents of lurasidone to show excellent dissolution profiles. As clearly disclosed in Test 1 (Tables 1-5, Figure 2 and Comparative Examples 1 and 2) of the original description, two tablets of Comparative Example 1 and 2 were prepared according to Fujihara's method and comprised lurasidone in the weight of 12.3% and 24.7%, respectively. Test 1 shows that Fujihara's tablet comprising 24.7% of lurasidone (80 mg tablet) clearly shows lower dissolution profile than that comprising 12.3% of lurasidone in 15 minutes (see Figure 2, Table 4, [0039]). In contrast, the present oral preparation has favorable dissolution rates and similar dissolution profiles between tablets (see Test 1, Figure 3,

Tables 1-3, 13). As shown in Figure 3, dissolution rates of three tablets are more than 80% in 15 minutes. Table 4 and Figure 3 show that these tablets have similar dissolution profiles.

Whereas Fujihara does not disclose compositions comprising more than 16.3% (wt/wt) of lurasidone which show advantageous dissolution profiles as it only discloses those comprising 16.3% (wt/wt) or less of lurasidone, the instant invention provides a composition comprising 20% (wt/wt) or more of lurasidone which shows a remarkably advantageous dissolution profile. The advantageous dissolution profiles for the high content rates of lurasidone may result from inclusion of the recited amount of pregelatinized starch, which is not taught or suggested by Fujihara.

Fujihara's shortcomings are not overcome, even if, for the sake of argument it were combined with Salpekar *et al*.

Although Salpekar *et al.* teaches a composition comprised of a pharmaceutically active ingredient and pregelatinized starch, and even if arguendo some of such compositions may allow short dissolution time and shorter the dissolution and disintegration time, as the Examiner postulates, Salpekar *et al.* nonetheless does not provide any motivation towards the claimed inventions.

Specifically, the pharmaceutically active ingredient used by Salpekar *et al.* is N-acetyl-p-aminophenol (Acetaminophen) (see lines 6-14 of column 1). According to DrugBank (http://www.drugbank.ca/drugs/DB00316), the experimental water solubility of acetaminophen is 14 mg/mL (see the attachment). In contrast, the water solubility of lurasidone is 0.224 mg/mL at 20°C which is extremely lower (approximately 1/62.5) than that of acetaminophen.

That means that lurasidone is much more difficult from the solubility standpoint than acetaminophen, and that Salpekar *et al.* just relates to a comparatively soluble agent "acetaminophen," not to a hardly-soluble agent.

In addition, Salpekar *et al.* discloses that a preferred embodiment is a composition comprising 93-83% of acetaminophen (see line 63, column 5 to line 9, column 6). Those skilled in the art cannot apply Salpekar's formulation for comparatively soluble agents including extremely high contents (93-83%) of the active ingredient to tablets comprising a hardly-soluble lurasidone in order to solve the problem of the undesired dissolution profiles of hardly-soluble agents in any conventional compositions. The higher contents of the different material teach away from the claim 1 oral preparation. Therefore, Applicants submit a combination of Salpekar *et al.* with Fujihara is proscribed hindsight.

Even if, for the sake of argument, Salpekar *et al.* were combined with Fujihara, a person skilled in the art cannot arrive at the inventive content rates of pre gelatinized starch (10 to 50% (wt/wt)) as below. Although Salpekar *et al.* teaches that effective amount of PGS (i.e., pregelatinized starch) is from about 5 or less to about 15 or more parts per 100 parts of the composition (see lines 15-17 of column 4), Salpekar's compositions which substantially show significant technical effects are only those supported by Examples (i.e., 4.45-8.85% of PGS), in view of Salpekar's disclosure that the PGS is included in an amount effective for imparting to the composition time (e.g., about 10 minutes or less) and short dissolution time (e.g., about 20 minutes or less for 80% or more of the APAP to dissolve) (see lines 3-9 of column 4).

As seen from Table of column 8 and taken lines 3-9 of column 4 into consideration, Ex.1 tablet (18.0% of PGS) is not acceptable in order to solve Salpekar's problem, since the disintegration time of Ex. 1 tablet is 18.0 minutes which is 3-12 times longer than that of Ex. 2 (6 minutes) or Ex.3 tablet (1.5 minutes). Even Ex.2 tablet comprising 8.85% of PGS is not perfectly acceptable in terms of 4-times longer disintegration time than Ex.3 tablet.

Therefore, those skilled in the art may understand that 4.45-8.85% of PGS is preferable for a tablet having a short disintegration time and a short dissolution time. Accordingly, a person of ordinary skill in the art cannot arrive at pregelatinized starch (10 to 50% (wt/wt)), beyond Salpekar's preferable ranges, which can cause compositions comprising high content rates of the active ingredient with the advantageous dissolution profiles.

Conclusion

Applicant has found that it is possible to provide an oral preparation which includes a high concentration of lurasidone (20 to 45 wt.-%) in combination with 10 to 50 wt.-% pregelatinized starch that provides advantageous dissolution profiles. None of the prior art documents, alone or in combination, would have taught or suggested this combination of features or that the advantages can be achieved therewith.

In view of the above amendment and remarks, Applicant respectfully request favorable reconsideration of the instant application in the form of a Notice of Allowance.

If the Examiner has any questions concerning the application, or perhaps suggestions for further constructively advancing patent prosecution, kindly contact Applicants' undersigned representative.

Applicants hereby request that any concurrent or future reply submitted by Applicants to the U.S. Patent and Trademark Office in connection with the aboveidentified patent application requiring an extension of time under 37 C.F.R. §1.136(a) for its timely submission be treated as incorporating therein a request for an extension of time for the appropriate length of time. In addition, to the extent necessary during prosecution of the present application, Applicants hereby authorize the Commissioner to charge any required fee not otherwise provided for, including application processing, extension, and extra claims fees, to Deposit Account No. 06-1135 with reference to Attorney Docket No. **7379/98100**.

> Respectfully submitted, FITCH, EVEN, TABIN & FLANNERY

> > /Kendrew H. Colton/

Kendrew H. Colton Registration No. 30,368

Please send official correspondence to:

FITCH, EVEN, TABIN & FLANNERY 1120 20th St., NW, Suite 750 South Washington, DC 20036 Tel: (202) 419-7000 Fax: (202) 419-7007 Customer Number 42798

	PTO/SB/22 (07-09)
ved for use t	hrough 07/31/2012. OMB 0651-0031
1 0 10	

Under the p	paperwork Reduction Act of 1995, no persons are rec		Patent and Trademark Office; U.S.	
	FOR EXTENSION OF TIME UNDER FY 2009 pursuant to the Consolidated Appropriations Act,		Docket Number (Optiona 7379/98100	1)
Application N	Number 11/919,678		Filed October 31, 20	07
For Phar	maceutical Composition			
Art Unit 162	27		Examiner Pihonak, S	arah
This is a req application.	uest under the provisions of 37 CFR 1.13	6(a) to extend the p	period for filing a reply in the	above identified
The request	ed extension and fee are as follows (cheo	k time period desire	ed and enter the appropriate	fee below):
		<u>Fee</u>	Small Entity Fee	
	One month (37 CFR 1.17(a)(1))	\$130	\$65	\$
	Two months (37 CFR 1.17(a)(2))	\$490	\$245	\$
~	Three months (37 CFR 1.17(a)(3))	\$1110	\$555	\$ <u>_1110.00</u>
	Four months (37 CFR 1.17(a)(4))	\$1730	\$865	\$
	Five months (37 CFR 1.17(a)(5))	\$2350	\$1175	\$
Applica	nt claims small entity status. See 37 CFR	1.27.		

A check in the amount of the fee is enclosed.

Payment by credit card. Form PTO-2038 is attached.

The Director has already been authorized to charge fees in this application to a Deposit Account.

The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to ~ Deposit Account Number 061135 W, Pr

ARNING: Information on this form may become public. Credit card information should not be included on this form.
ovide credit card information and authorization on PTO-2038.

Kendre	ew H. Colton Typed or printed name	202-419-7000 Telephone Number
	Signature	Date
/Kendre	ew H. Colton/	May 24, 2010
	attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34	
	attorney or agent of record. Registration N	umber <u>30368</u>
	assignee of record of the entire interest. S Statement under 37 CFR 3.73(b) is end	
m the	applicant/inventor.	

than one signature is required, see below. Total of forms are submitted.

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal						
Application Number:	11	919678				
Filing Date:	31-	-Oct-2007				
Title of Invention: Pharmaceutical composition						
First Named Inventor/Applicant Name:	Ka	zuyuki Fujihara				
Filer:	Ke	ndrew H. Colton/Kir	ndra Johnson			
Attorney Docket Number:	73	79/98100				
Filed as Large Entity						
U.S. National Stage under 35 USC 371 Filing	Fee	S				
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Basic Filing:						
Pages:						
Claims:						
Miscellaneous-Filing:						
Petition:						
Patent-Appeals-and-Interference:						
Post-Allowance-and-Post-Issuance:						
Extension-of-Time:						
Extension - 3 months with \$0 paid		1253	1	1110	1110	

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Tot	al in USD	(\$)	1110

Electronic Acl	knowledgement Receipt
EFS ID:	7673443
Application Number:	11919678
International Application Number:	
Confirmation Number:	6965
Title of Invention:	Pharmaceutical composition
First Named Inventor/Applicant Name:	Kazuyuki Fujihara
Customer Number:	42798
Filer:	Kendrew H. Colton/Kindra Johnson
Filer Authorized By:	Kendrew H. Colton
Attorney Docket Number:	7379/98100
Receipt Date:	24-MAY-2010
Filing Date:	31-OCT-2007
Time Stamp:	15:46:52
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1110
RAM confirmation Number	2293
Deposit Account	061135
Authorized User	
The Director of the USPTO is hereby authorized to charg	e indicated fees and credit any overpayment as follows:
Charge any Additional Fees required under 37 C.F.R. Se	ection 1.17 (Patent application and reexamination processing fees)
Charge any Additional Fees required under 37 C.F.R. Se	ection 1.21 (Miscellaneous fees and charges)

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.
1		2010-05-24Amendment.pdf	143086	yes	12
			faede9e0a1f5aede383262fa328360b98f78 258b	,	
	Multip	oart Description/PDF files in .	zip description		
	Document De	scription	Start	Ei	nd
	Amendment/Req. Reconsiderat	ion-After Non-Final Reject	1		1
	Claims	i	2	,	6
	Applicant Arguments/Remarks	Made in an Amendment	7	1	2
Warnings:			·		
Information:					
2	Extension of Time	2010 05 24 EOT ndf	321940	20	n
2	Extension of Time	2010-05-24EOT.pdf	fed9135eb6e22f40cc8c2f8200e40d38d5e9 4316	no	2
Warnings:					
Information:					
3	Fee Worksheet (PTO-875)	fee-info.pdf	29881	no	2
5			367f743de4da03d217487465573410d7928 709c3	110	2
Warnings:					
Information:					
		Total Files Size (in bytes)	49	4907	
Post Card, as de <u>New Applicatio</u> If a new applica 1.53(b)-(d) and Acknowledgem <u>National Stage</u> If a timely subm U.S.C. 371 and c national stage s <u>New Internation</u>	y the applicant, and including pa escribed in MPEP 503. Ins <u>Under 35 U.S.C. 111</u> tion is being filed and the applica MPEP 506), a Filing Receipt (37 Cl ent Receipt will establish the filin of an International Application un ission to enter the national stage other applicable requirements a F submission under 35 U.S.C. 371 w	ation includes the necessary of FR 1.54) will be issued in due og date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicati form PCT/DO/EO/903 indicati ill be issued in addition to the PTO as a Receiving Office	components for a filin course and the date s on is compliant with t ng acceptance of the e Filing Receipt, in du	g date (see hown on th the conditic application e course.	37 CFR is ons of 35 as a
an internationa	tional application is being filed a l filing date (see PCT Article 11 ar national Filing Date (Form PCT/R	d MPEP 1810), a Notification	of the International A	Application	Number

P/	Under the Par ATENT APPL		E DETE	ERMINATION			plication or l	Docket Number 9,678	Fil	ing Date 31/2007	To be Maile
	AF	PPLICATION /	AS FILE (Column 1		Column 2)	-	SMALL		OR		HER THAN
	FOR	N	JMBER FIL	.ED NU	MBER EXTRA		RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)
X	BASIC FEE (37 CFR 1.16(a), (b), (or (c))	N/A		N/A	1 F	N/A			N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), o		N/A		N/A	1	N/A			N/A	
	EXAMINATION FE (37 CFR 1.16(o), (p), (E	N/A		N/A	1	N/A			N/A	
	(37 CFR 1.16(0), (p), (TAL CLAIMS CFR 1.16(i))	or (q))	min	us 20 = *		1	X\$ =		OR	X\$ =	
١D	EPENDENT CLAIM CFR 1.16(h))	s	mi	nus 3 = *		1	X \$ =			X\$ =	
	APPLICATION SIZE 37 CFR 1.16(s))	FEE shee is \$2 addit 35 U	ts of pape 50 (\$125 ional 50 s .S.C. 41(a	ation and drawing er, the applicatio for small entity) sheets or fraction a)(1)(G) and 37	n size fee due for each n thereof. See						
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))						IL	ΤΟΤΑΙ			TOTAL	
lf t	he difference in colu	LICATION AS	,						•		ER THAN
			,		(Column 3) PRESENT EXTRA][SMAL RATE (\$)	L ENTITY ADDITIONAL FEE (\$)	OR		ER THAN LL ENTITY ADDITIONAL FEE (\$)
lft	APPI	(Column 1) CLAIMS REMAINING AFTER	,	Column 2) (Column 2) HIGHEST NUMBER PREVIOUSLY	PRESENT			ADDITIONAL	OR	SMA	LL ENTITY
	APP 05/24/2010 Total (37 CFR	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT	AMEND	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	4	RATE (\$)	ADDITIONAL		SMA RATE (\$)	LL ENTITY
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21	AMEND Minus Minus	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24	PRESENT EXTRA	4	RATE (\$) x \$ =	ADDITIONAL	OR	SMA RATE (\$) X \$ =	LL ENTITY
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 ize Fee (37 CFR 1	AMENE Minus Minus .16(s))	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24	PRESENT EXTRA = =	4	RATE (\$) x \$ =	ADDITIONAL	OR	SMA RATE (\$) X \$ =	LL ENTITY
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 ze Fee (37 CFR 1 station of Multif	AMENE Minus Minus .16(s))	Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24 ***5	PRESENT EXTRA = = R 1.16(j))	4	RATE (\$) x \$ =	ADDITIONAL	OR OR	SMA RATE (\$) X \$ =	LL ENTITY
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 Ize Fee (37 CFR 1 NTATION OF MULTIF	AMENE Minus Minus .16(s))	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24 ***5 DENT CLAIM (37 CFI	PRESENT EXTRA = =	4	RATE (\$) x \$ = x \$ = TOTAL ADD'L	ADDITIONAL	OR OR OR	SMA RATE (\$) X \$ = X \$ = TOTAL ADD'L	LL ENTITY
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 ze Fee (37 CFR 1 station of Multif	AMENE Minus Minus .16(s))	Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24 ***5	PRESENT EXTRA = = R 1.16(j))	4	RATE (\$) x \$ = x \$ = TOTAL ADD'L	ADDITIONAL	OR OR OR	SMA RATE (\$) X \$ = X \$ = TOTAL ADD'L	LL ENTITY
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 ize Fee (37 CFR 1 NTATION OF MULTIF (Column 1) CLAIMS REMAINING AFTER	AMENE Minus Minus .16(s))	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24 ***5 DENT CLAIM (37 CFI (Column 2) HIGHEST NUMBER PREVIOUSLY	PRESENT EXTRA = = R 1.16(j)) (Column 3) PRESENT		RATE (\$) X \$ = X \$ = TOTAL ADD'L FEE	ADDITIONAL FEE (\$)	OR OR OR	SMA RATE (\$) X \$ = X \$ = TOTAL ADD'L FEE	ADDITIONAL FEE (\$)
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 ize Fee (37 CFR 1 NTATION OF MULTIF (Column 1) CLAIMS REMAINING AFTER	AMENE Minus .16(s)) PLE DEPEN	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24 ***5 DENT CLAIM (37 CFI (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA = = R 1.16(j)) (Column 3) PRESENT EXTRA		RATE (\$) x \$ = x \$ = TOTAL ADD'L FEE RATE (\$)	ADDITIONAL FEE (\$)	OR OR OR	SMA RATE (\$) X \$ = X \$ = TOTAL ADD'L FEE RATE (\$)	ADDITIONAL FEE (\$)
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 IZE Fee (37 CFR 1 ITATION OF MULTIF (Column 1) CLAIMS REMAINING AFTER AMENDMENT *	AMENE Minus 16(s)) PLE DEPEN	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24 ***5 DENT CLAIM (37 CFI (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR **	PRESENT EXTRA = = R 1.16(j)) (Column 3) PRESENT EXTRA =		RATE (\$) x \$ = x \$ = TOTAL ADD'L FEE RATE (\$) x \$ =	ADDITIONAL FEE (\$)	OR OR OR OR OR	SMA RATE (\$) x \$ = x \$ = x \$ = ADD'L FEE RATE (\$) x \$ =	ADDITIONAL FEE (\$)
	APP	LICATION AS (Column 1) CLAIMS REMAINING AFTER AMENDMENT * 21 * 3 IZE Fee (37 CFR 1 ITATION OF MULTIF (Column 1) CLAIMS REMAINING AFTER AMENDMENT * * X ZE Fee (37 CFR 1	AMENE Minus .16(s)) PLE DEPEN Minus .16(s))	ED – PART II (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR ** 24 ***5 DENT CLAIM (37 CFI (Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR **	PRESENT EXTRA = = R 1.16(j)) (Column 3) PRESENT EXTRA = =		RATE (\$) x \$ = x \$ = TOTAL ADD'L FEE RATE (\$) x \$ =	ADDITIONAL FEE (\$)	OR OR OR OR	SMA RATE (\$) x \$ = x \$ = x \$ = ADD'L FEE RATE (\$) x \$ =	ADDITIONAL FEE (\$)

The ingrest value Previously Paid For (Fourier Integretient) is the ingrest number value in the appropriate box in contine 1. This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
11/919,678	10/31/2007	Kazuyuki Fujihara	7379/98100	6965
	7590 07/27/201 , TABIN & FLANNER	EXAM	INER	
P. O. BOX 184	15	-	PIHONAR	K, SARAH
WASHINGTO	N, DC 20036		ART UNIT	PAPER NUMBER
			1627	
			MAIL DATE	DELIVERY MODE
			07/27/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
Office Action Summary	11/919,678	FUJIHARA, KAZUYUKI
Onice Action Summary	Examiner	Art Unit
	SARAH PIHONAK	
The MAILING DATE of this communication ap Period for Reply	opears on the cover sheet v	nth the correspondence address
 A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING I Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailif earned patent term adjustment. See 37 CFR 1.704(b). 	DATE OF THIS COMMUN .136(a). In no event, however, may a d will apply and will expire SIX (6) MC te, cause the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
Status		
 1) Responsive to communication(s) filed on <u>24 /</u> 2a) This action is FINAL. 3) Since this application is in condition for allows closed in accordance with the practice under 	is action is non-final. ance except for formal ma	-
Disposition of Claims		
 4) Claim(s) <u>1-7,9,11-14,16 and 19-26</u> is/are pen 4a) Of the above claim(s) <u>5-7</u> is/are withdrawn 5) Claim(s) is/are allowed. 6) Claim(s) <u>1-4,9,11-14,16 and 19-26</u> is/are reje 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/ 	n from consideration.	
Application Papers		
 9) The specification is objected to by the Examination 10) The drawing(s) filed on is/are: a) action and a construction and a con	cepted or b) dbjected to e drawing(s) be held in abeya ction is required if the drawin	nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list 	nts have been received. hts have been received in , ority documents have bee au (PCT Rule 17.2(a)).	Application No n received in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date U.S. Patent and Trademark Office PTOL-326 (Rev. 08-06) Office J	Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application Part of Paper No./Mail Date 20100715

DETAILED ACTION

This application, filed 10/31/2007, is a national stage entry of PCT/JP2006/310571, filed on 5/26/2006.

Priority

This application claims foreign priority to Application No. 2005-153508, filed on 5/26/2005.

Response to Remarks

1. Claims 8, 10, 15, 17-18 have been cancelled by the Applicants in the amendments filed on 5/24/2010; therefore, all rejections regarding these claims are rendered moot. Claims 5-7 were previously withdrawn from consideration, as being directed to a non-elected invention. New claims 25-26 have been added by the Applicants, and have been examined in this office action.

2. Applicant's arguments filed 5/24/2010 have been fully considered but they are not persuasive. The Applicants have argued that the claims would not have been prima facie obvious to one of ordinary skill in the art, at the time of the invention, over Fujihara et. al. in view of Salpekar et. al., because Fujihara et. al. does not teach that oral compositions comprised of 20-45% of lurasidone have improved dissolution profiles. The Applicants have asserted that Fujihara et. al. shows that a tablet comprised of 24.7% lurasidone has a lower dissolution profile than a tablet comprising 12.3% of lurasidone, and as such, one of ordinary skill in the art would not have been motivated to prepare the claimed oral preparation comprising 20 to 45% lurasidone. The examiner

respectfully disagrees. Fujihara et. al. teaches an oral composition comprised of lurasidone, in an amount up to 28% of the weight of the composition, along with disintegrants and a water soluble polymer binder. While Fujihara et. al. does not teach that the composition comprises pregelatinized starch, Salpekar et. al. teaches that pregelatinized starch is beneficial in oral pharmaceutical preparations for decreasing the dissolution and disintegration times, and imparting hardness to tablets. Therefore, as lurasidone is taught as a slightly water soluble active agent, and pregelatinized starch is taught to decrease the dissolution and disintegration times of oral formulations, one of ordinary skill in the art, at the time of the invention, would have been motivated to add pregelatinized starch to the composition comprised of lurasidone, within the weight percent range as claimed, to decrease the dissolution and disintegration profiles of lurasidone. The Applicants have asserted that Fujihara et. al. teaches that tablets comprised of higher amounts of lurasidone (24 %) have poorer dissolution profiles in comparison to formulations with lower amounts of lurasidone (12.3%), one of ordinary skill in the art would not have been motivated to prepare an oral formulation with lurasidone in the amount range as claimed. This argument is not found persuasive, as Fujihara et. al. teaches oral compositions comprised of lurasidone in amounts up to 28% of the composition. While it is acknowledged that the formulation of lurasidone in an amount of 24.7% has a poorer dissolution profile in comparison to tablets comprising lower amounts of the drug, Salpekar et. al. teaches that pregelatinized starch improves the dissolution profiles of oral formulations. As such, it would have been prima facie

obvious to add pregelatinized starch to tablets comprising up to 28% of lurasidone to improve the dissolution and disintegration times.

The Applicants have asserted it would not have been prima facie obvious to combine the teachings of Salpekar with the teachings of Fujihara et. al., because the drug present in the oral formulation taught by Salpekar et. al. is more water soluble than lurasidone, as well as the amount of active drug in the composition taught by Salpekar et. al. is considerably greater than the amount of lurasidone instantly claimed. The examiner respectfully disagrees. Fujihara et. al. teaches that oral formulations of lurasidone up to 28% by weight can be prepared; Salpekar et. al. teaches that pregelatinized starch, in amounts ranging from 5 or less to 15 or more parts per 100 parts of the composition, improves dissolution and disintegration times. Therefore, as it is taught by Salpekar et. al. that pregelatinized starch can be used to improve the dissolution profile of an oral formulation comprised of a pharmaceutical agent, one of ordinary skill in the art would have been motivated to add pregelatinized starch, in the amount range as taught, to improve the dissolution profile of oral formulations comprised of other pharmaceutical agents, such as lurasidone. As Salpekar et. al. teaches that pregelatinized starch, within the weight percent range as claimed, improves the dissolution and disintegration properties of oral pharmaceutical formulations, one of ordinary skill in the art would have expected that the addition of pregelatinized starch to oral formulations comprised of lurasidone would also have resulted in improved dissolution and disintegration profiles. The rejection under 35 USC 103(a) was proper and is maintained, for reasons of record. For Applicants'

convenience, this rejection will be reiterated below, with slight modification due to new

claims 25 and 26. Accordingly, this action is made FINAL.

- 3. Claims 1-4, 9, 11-14, 16, and 19-26 were examined.
- 4. Claims 1-4, 9, 11-14, 16, and 19-26 are rejected.

Claim Rejections-35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all

obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

6. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148

USPQ 459 (1966), that are applied for establishing a background for determining

obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 7. Claims 1-4, 9, 11-14, 16, and 19-26 are rejected under 35 U.S.C. 103(a) as being

unpatentable over Fujihara et. al., EP Patent Publication No. 1327440, in view of

Salpekar et. al., US Patent No. 4,600,579 (both of previous record).

The claims are drawn to an oral composition comprised of lurasidone,

pregelatinized starch, a water soluble excipient such as mannitol or lactose, and a water

soluble polymer binder. The claims are also drawn to the composition in which the

pregelatinized starch is present in an amount from 10-50% by weight, and in which the lurasidone is present in an amount from 25 to 45% by weight.

Fujihara et. al. teaches an oral composition comprised of a slightly water soluble active ingredient, such as lurasidone, along with a first disintegrant, a second disintegrant, and a water soluble polymer binder (Abstract; p. 4-5, paragraph [0008]). Fujihara et. al. teaches that the composition provides advantageous dissolution characteristics when ingested (Abstract). It is taught that one of the water soluble excipients includes sugar alcohols such as mannitol or lactose (p. 3, paragraph [0017], item (18); p. 5, paragraph [0014]). The other disintegrant is taught as including excipients such as microcrystalline cellulose, croscarmellose sodium, among others (p. 5, paragraph [0011]), and the water soluble polymer binder includes polyvinylpyrrolidone, polyvinyl alcohol, and others (p. 5, paragraph [0010]). It is taught that the amount of lurasidone present in the oral composition is 40 mg., which is within the range instantly claimed (p. 5, paragraph [0015]; p. 22, paragraph [0152], Table 28), and that the average particle size of lurasidone is between 0.5 to 5 µm (p. 6, paragraph [0021]). It is taught that for a tablet of a weight of approximately 142 mg., the amount of lurasidone present is 40 mg., which is approximately 28 % of the weight of the composition (p. 29, paragraph [0194], Table 44). The amount of the disintegrants present in the composition is taught as ranging from 5 to 300 % by weight of the composition (p. 4, paragraph [0007], item (33)), or up to 1200% by weight (p. 6, paragraph [0029]). It is taught that the oral preparation comprises a granule, which is prepared by granulating the water-soluble polymer binder with the powdery mixture

consisting of the active agent (lurasidone), a water soluble excipient, and another disintegrant (p. 3, paragraph [0007], items (11-13); p. 4, paragraph [0007], item (40)). Fujihara et. al. teaches that the preparation can be formulated as pills, granules, fine granules, capsules, tablets, etc. (p. 5, paragraph [0016]).

Fujihara et. al. does not explicitly teach that the composition comprises pregelatinized starch, in an amount from 10 to 50% by weight of the composition.

Salpekar et. al. teaches a composition comprised of a pharmaceutically active ingredient, a lubricant, a disintegrant, and pregelatinized starch allows for high hardness, and short dissolution time when ingested (Abstract). Salpekar et. al. teaches that the composition comprised of the pregelatinized starch is beneficial for preparing oral pharmaceutical formulations such as tablets (column 1, lines 22-29). It is taught that the partially pregelatinized starch, such as the starch commercially known as Starch 1500, acts as a binder to the composition, and provides beneficial disintegrant properties, as well as increasing hardness of the composition and shortening the dissolution and disintegration time (column 3, lines 38-51; column 4, lines 31-37). Salpekar et. al. teaches that the amount of partially pregelatinized starch ranges from 5 or less to 15 or more parts per 100 parts of the composition (column 4, lines 15-17), which is within the amount of pregelatinized starch instantly claimed. It is taught that the amount of pregelatinized starch present is based upon the amount necessary to impart the high hardness and decreased dissolution times to the composition (column 4, lines 3-9); therefore, it would have been obvious to one of ordinary skill in the art that the optimum range of the pregelatinized starch may comprise amounts greater than or less

than 5-15 % by weight, as taught. Salpekar et. al. teaches that the percent gelatinization of the pregelatinized starch ranges optimally from 50 to 75% (column 2, lines 33-55). Additionally, it is taught that Starch 1500 has a moisture content between 3 and 5 % (column 3, lines 38-45).

One of ordinary skill in the art would have been motivated, at the time of the invention, to prepare the oral lurasidone preparation taught by Fujihara et. al. with the pregelatinized starch excipient taught by Salpekar et. al. because Salpekar et. al. teaches that the pregelatinized starch in oral pharmaceutical formulations provides beneficial properties, such as increased hardness of the tablet, decreased dissolution time after ingestion, and short disintegration time. As such, it would have been prima facie obvious for one of ordinary skill in the art to prepare the oral lurasidone composition as taught by Fujihara et. al. with the pregelatinized starch excipient as taught by Salpekar et. al. because both Fujihara et. al. and Salpekar et. al. teach pharmaceutical compositions formulated for oral administration. Therefore, there would have been an expectation of success in utilizing the pregelatinized excipient for the composition comprising lurasidone, because it is taught by Salpekar et. al. that the pregelatinized starch is tauch the pregelatinized starch is tauch the pregelatinized starch oral formulations.

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached on Monday-Thursday 8:00 AM - 6:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S.P.

/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1627

Par Pharm., Inc. Exhibit 1015 Page 277

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

	SEARCHED		
Class	Subclass	Date	Examiner

SEARCH NOTES							
Search Notes	Date	Examiner					
Inventor search in EAST, PALM	11/12/2009	S.P.					
Invention and claims search in EAST, STN	11/12/2009	S.P.					
Inventor search in EAST, PALM	7/12/2010	S.P.					
Invention and claims search in EAST, STN	7/12/2010	S.P.					

INTERFERENCE SEARCH							
Class	Subclass	Date	Examiner				

/S. P./ Examiner.Art Unit 1627	

U.S. Patent and Trademark Office

Part of Paper No.: 20100715

Index of Claims				Application/Control No.				Applicant(s)/Patent Under Reexamination FUJIHARA, KAZUYUKI				ler			
						Examin	er				Art Unit				
						SARAH	PIHONA	K			1627				
✓	R	ejected		-	C	ancelle	ed	N	Non-I	Ele	cted		Α	Αμ	peal
=	A	llowed		÷	R	estricte	ed	I	Interf	ere	ence		0	Obj	ected
	Claims r	enumbered	in the s	ame	order as	presented	d by applic	ant			СРА	Ľ] т.с	D. 🗆	R.1.47
	CLA	M							DATE						
F	inal	Original	11/13/2	2009	07/20/20)10									
		1	✓		\checkmark										
		2	✓		\checkmark										
		3	✓		~										
		4	√		\checkmark										
		5	N		Ν										
		6	N		N										
		7	N		N										
		8	~		-										
		9	~		√										_
		10	✓		-										
		11	✓		✓										_
<u> </u>		12	✓		✓										
		13	✓		✓					-					
<u> </u>		14	✓ ✓		~					-					_
<u> </u>		15	✓ ✓		-					-					
		16	✓ ✓							-					
		17 18	v v		-					-					
			✓ ✓		- ✓					-					
		19	✓ ✓		 ✓					-					
<u> </u>		20 21	v √		 ✓					-					
<u> </u>		21	▼ ▼		 ✓					-					
<u> </u>		22	▼ ▼		 ✓					-					
<u> </u>		23 24	v v		 ✓					-					
		24 25	+ · ·		 ✓					-					
		25			· ✓					-					

Part of Paper No.: 20100715

[1		1	1
Ref #	Hits	Search Query	DBs	Defa ult Oper ator	Plurals	Time Stamp
L1	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2010/07/20 12:22
L2	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:23
L3	84	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:24
L4	15801	pregelatin\$5 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
L5	31	13 and 14	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
L6	23548	accugel or absorbo or actobody or alphajel or allbond or alstar or amaizo or amalean or amerikor or amicoa or amidex or amigel or amilofax or amilys or amisol or amycol or amylex or amylogel or amylogum or amylomaize or amylon or amylose	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:27
L7	0	13 and 16	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:28
S1	4	"2001076557".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2009/07/17 07:52
S2	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:53
S3	2622	pre-gelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54

EAST Search History (Prior Art)

EAST Search History (Prior Art)

S4	0	S2 and S3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S5	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S6	25	S2 and S5	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:55
S7	234938	oral and pharmaceutical	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S8	10067	S5 and S7	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S9	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S10	446	S9 and oral	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:02
S11	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:17
S12	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S13	1	S11 and S12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18

Par Pharm., Inc. Exhibit 1015 Page 281

		-	(•		
S14	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S15	86	S11 and S14	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S16	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:57
S17	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S18	86	S16 and S17	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S19	1	"3607394".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2009/11/12 14:11
S20	67	(pregelatin\$4 with starch) same (polymer with binder)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:29
S21	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S22	745	S21 and (starch adj "1500")	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S23	47786	water adj solub\$4 adj polymer	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40

EAST Search History (Prior Art)

EAST Search History	(Prior Art)
----------------------------	-------------


S24	43	S22 and S23	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S25	99	S21 and (PCS)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:42
S26	5	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2009/11/12 15:05
S27	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2009/11/12 15:07
S28	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S29	1747	S28 and (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S30	202	S28 with (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:15

E LURASIDONE/CN

```
ANSWER 1 OF 2 REGISTRY COPYRIGHT 2010 ACS on STN
L1
RN
     367514-88-3 REGISTRY
     Entered STN: 07 Nov 2001
ΕD
CN
     4,7-Methano-1H-isoindole-1,3(2H)-dione,
     2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-
     piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride
(1:1),
     (3aR, 4S, 7R, 7aS) - (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN
     4,7-Methano-1H-isoindole-1,3(2H)-dione,
     2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-
     piperazinyl]methyl]cyclohexyl]methyl]hexahydro-,
monohydrochloride,
     (3aR,4S,7R,7aS)- (9CI)
OTHER NAMES:
    Lurasidone hydrochloride
CN
CN
     SM 13496
FS
     STEREOSEARCH
DR
     441351-20-8
     C28 H36 N4 O2 S . C1 H
MF
SR
     CA
     STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS,
LC
EMBASE,
       IMSRESEARCH, IPA, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
    (367514 - 87 - 2)
CRN
```

```
Absolute stereochemistry.
```

L1



```
🕒 HCl
```

SET EXPAND CONTINUOUS 2 S E3-E4

FILE 'CAPLUS' ENTERED AT 12:31:30 ON 20 JUL 2010

29 S L1 L2 3 S L2 AND (STARCH OR ?PRE!GELATIN? OR ACCUGEL? OR L3 ABSORBO? OR AC 3 S L3 AND (PY<=2005 OR AY<=2005 OR PRY<=2005) L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN L4A preparation for oral administration comprises a pregelatinized AB starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1piperazinyl]-(2R,3R)-2,3- tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3- bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone hydrochloride) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, where the preparation exhibits an invariant level of elution behavior even when the content of its active ingredient is varied. For example, tablets were formulated containing lurasidone 80, mannitol 144, pregelatinized starch 80, croscarmellose sodium 4, hydroxypropyl Me cellulose 8, and Mg stearate 4 mg per tablet and film coated with a composition containing hydroxypropyl Me cellulose, titania, polyethylene glycol, and carnauba wax. ACCESSION NUMBER: 2006:1252571 CAPLUS Full-text DOCUMENT NUMBER: 146:13212 TITLE: Oral pharmaceutical compositions of lurasidone INVENTOR(S): Fujihara, Kazuyuki PATENT ASSIGNEE(S): Dainippon Sumitomo Pharma Co., Ltd., Japan SOURCE: PCT Int. Appl., 42pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ _____ _____ WO 2006126681 20061130 WO 2006-JP310571 A1 20060526 <--W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2006250340 A1 20061130 AU 2006-250340 20060526 <--20061130 CA 2606510 Α1 CA 2006-2606510 20060526 <--EP 1884242 A1 20080206 EP 2006-746900 20060526 <--R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR 20090604 US 20090143404 A1 US 2007-919678 20071031 <--KR 2008012306 А 20080211 KR 2007-727270 20071123 <--20080215 MX 2007-14872 MX 2007014872 А 20071123 <--20080125 IN 2007-CN5369 IN 2007CN05369 А 20071126 <--CN 101184489 20080521 CN 2006-80018223 А 20071126 <--PRIORITY APPLN. INFO.: JP 2005-153508 Α 20050526 <--WO 2006-JP10571 W 20060526 WO 2006-JP310571 W 20060526 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT IPCI A61K0031-496 [I,A]; A61K0009-20 [I,A]; A61K0047-10 [I,A]; A61K0047-26 [I,A]; A61K0047-38 [I,A]; C07D0417-12 [I,A]; C07D0417-00 [I,C*] IPCR A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0009-20 [I,C]; A61K0009-20 [I,A]; A61K0047-10 [I,C]; A61K0047-10 [I,A]; A61K0047-26 [I,C]; A61K0047-26 [I,A]; A61K0047-38 [I,C]; A61K0047-38 [I,A]; C07D0417-0.0 [I,C]; C07D0417-12 [I,A] CC 63-6 (Pharmaceuticals) ΤТ 63-42-3, Lactose 69-65-8, D-Mannitol 9005-25-8D, Starch, pregelatinized 367514-87-2, Lurasidone 367514-88-3 , Lurasidone hydrochloride RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns. of lurasidone with improved dissoln. profile) Pharmaceutical tablets ΤТ (coated tablets; oral compns. of lurasidone with improved dissoln. profile) Dissolution ΤТ Particle size Pharmaceutical granules Pharmaceutical tablets (oral compns. of lurasidone with improved dissoln. profile) 63-42-3, Lactose 69-65-8, D-Mannitol 9005-25-8D, Starch, ΤТ 367514-87-2, Lurasidone 367514-88-3 pregelatinized , Lurasidone hydrochloride RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns. of lurasidone with improved dissoln. profile)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS) REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

Disclosed are oral compns. containing a hardly water-soluble AB active ingredient and having favorable disintegration characteristics which comprise a molded solid article (for example, granules) obtained by mixing the hardly water-soluble active ingredient, a first disintegrating agent and a watersoluble filler with the use of a water-soluble polymer binder and then mixing this molded solid article with a second disintegrating agent, or a molded solid article obtained by mixing the hardly water-soluble active ingredient, a disintegrating agent and a sugar alc. with the use of a water-soluble polymer binder. When orally administered, these prepns. show excellent elution of the active ingredient in the digestive tract. Moreover, these prepns. can show the same elution behavior at different contents of the active ingredient and thus enable the selection of the most suitable drug for each patient, which makes these prepns. highly useful in clin. medicine. A film-coated tablet was prepared form granules containing N-[4-[4-(1,2-benzisothiazole-3-yl)-1piperazinyl]-(2R,3R)-2,3- tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3- bicyclo[2,2,1]heptanedicarboxyimide hydrochloride 10, lactose 50, sodium croscarmellose 6 mg, and polyvinyl alc. 1.2 mg, calcium hydrogen phosphate anhydride 35, crystalline cellulose 17, and magnesium stearate 0.8 mg, and a coating material containing hydroxypropyl Me cellulose 1.95, titanium oxide 0.6, concentrate glycerin 0.45 mg, and carnauba wax g.s. ACCESSION NUMBER: 2002:240535 CAPLUS Full-text DOCUMENT NUMBER: 136:268164 TITLE: Oral compositions with favorable disintegration characteristics PATENT ASSIGNEE(S): INVENTOR(S): Fujihara, Kazuyuki Sumitomo Pharmaceuticals Company, Limited, Japan SOURCE: PCT Int. Appl., 49 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: KIND DATE APPLICATION NO. DATE PATENT NO. _____ _____ _____ ____ ____ WO 2002024166 A1 20020328 WO 2001-JP7983 20010914 <--W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2001086237 20020402 AU 2001-86237 А 20010914 <--CA 2424001 Α1 20030320 CA 2001-2424001 20010914 <--20030716 EP 2001-965637 EP 1327440 A1 20010914 <--EP 1327440 20090513 В1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR EP 1974724 A2 20081001 EP 2008-156778 20010914 <--EP 1974724 A3 20081112 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR AT 431136 20090515 AT 2001-965637 т 20010914 <---ES 2325764 Т3 20090916 ES 2001-965637 20010914 <--TW 289062 20071101 TW 2001-90123036 В 20010919 <--TW 289063 В 20071101 TW 2005-94103731 20010919 <--US 20040028741 A1 20040212 US 2003-381036 20030321 <--US 7727553 B2 20100601 PRIORITY APPLN. INFO.: JP 2000-288234 Α 20000922 <--EP 2001-965637 A3 20010914 <--WO 2001-JP7983 W 20010914 <--ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT IPCI A61K0009-16 [ICM, 7]; A61K0009-20 [ICS, 7]; A61K0009-30 [ICS, 7]; A61K0031-496 [ICS,7]; A61K0045-00 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-26 [ICS,7]; A61K0047-30 [ICS,7] IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-16 [I,C*]; A61K0009-16 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-30 [I,C*]; A61K0009-30 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A] CC 63-6 (Pharmaceuticals) IΤ 63-42-3, Lactose 69-65-8, D-Mannitol 557-04-0, Magnesium stearate 7757-93-9, Calcium hydrogen phosphate 9002-89-5, Polyvinyl

alcohol 9003-39-8, Polyvinyl pyrrolidone 9004-34-6, Crystalline cellulose, biological studies 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Corn starch, biological studies 74811-65-7, Sodium croscarmellose 367514-88-3 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients) ΤТ Alditols RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients) ΤТ Drug delivery systems (solids, oral; oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients) Drug delivery systems ΤТ (tablets, coated; oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients) Drug delivery systems IΤ (tablets; oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients) Polymers, biological studies ΤТ RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (water-soluble; oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients) 69-65-8, D-Mannitol ΤТ 63-42-3, Lactose 557-04-0, Magnesium stearate 7757-93-9, Calcium hydrogen phosphate 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinyl pyrrolidone 9004-34-6, Crystalline cellulose, biological studies 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Corn starch, biological studies 74811-65-7, Sodium 367514-88-3 croscarmellose RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients) OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS) REFERENCE COUNT: THERE ARE 6 CITED REFERENCES AVAILABLE 6 FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN τ.4

AB Disclosed are pH-independent sustained release prepns. capable of releasing a drug independently from the pH value in the gastric tract. These sustained release prepns. are characterized in that a

drug-containing core is coated with (1) a first layer made of a water-insol. polymer, and (2) a second layer made of an enteric polymer and a water-soluble polymer. Core granules were prepared containing perospirone HCl, crystalline cellulose, PVP, starch and silica. The granules were coated with a first composition containing Et cellulose, talc, tri-Et citrate, ethanol, and water, and then a second composition containing methacrylate copolymer, PVP, sucrose ester, Macrogol 6000, and water. ACCESSION NUMBER: 2001:762782 CAPLUS Full-text DOCUMENT NUMBER: 135:322722 TITLE: Coating agents for sustained-release oral preparations containing basic drugs INVENTOR(S): Nishii, Hiroyuki; Kobayashi, Hirohisa; Otoda, Kazuya Sumitomo Pharmaceuticals Co., Ltd., Japan PATENT ASSIGNEE(S): PCT Int. Appl., 20 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ _____ WO 2001076557 A1 20011018 WO 2001-JP3024 20010409 <--W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: JP 2000-107671 20000410 <--IPCI A61K0009-14 [ICM, 7]; A61K0009-16 [ICS, 7]; A61K0009-36 [ICS, 7]; A61K0009-30 [ICS,7,C*]; A61K0047-32 [ICS,7]; A61K0047-38 [ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C*]; A61K0031-496 [ICS,7]; A61K0031-506 [ICS,7]; A61K0031-5377 [ICS,7]; A61K0031-5375 [ICS,7,C*] IPCR A61K0009-28 [I,C*]; A61K0009-28 [I,A]; A61K0009-30 [I,C*]; A61K0009-36 [I,A]; A61K0009-50 [I,C*]; A61K0009-50 [I,A] CC 63-6 (Pharmaceuticals)

9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinylpyrrolidone ΤT 9004-35-7, Cellulose acetate 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 21829-25-4, Nifedipine 25086-15-1, Methacrylic acid-methyl methacrylate 25212-88-8, Ethyl acrylate-methacrylic acid copolymer copolymer 37205-99-5, Carboxymethyl ethyl cellulose 68377-91-3, Arotinolol 71138-97-1, Hydroxypropyl hydrochloride 68377-92-4, Arotinolol methyl cellulose acetate succinate 87760-53-0, Tandospirone 100986-85-4, 112457-95-1, Tandospirone citrate Levofloxacin 129273-38-7 150915-41-6, Perospirone 367514-87-2 367514-88-3 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polymeric coating agents for sustained-release oral prepns. containing basic drugs) Drug delivery systems TΤ (granules, sustained release; polymeric coating agents for sustained-release oral prepns. containing basic drugs) Drug delivery systems IT (microgranules, sustained-release; polymeric coating agents for sustained-release oral prepns. containing basic drugs) IΤ Dissolution rate (polymeric coating agents for sustained-release oral prepns. containing basic drugs) ΤT Drug delivery systems (tablets, sustained-release; polymeric coating agents for sustained-release oral prepns. containing basic drugs) 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinylpyrrolidone IΤ 9004-35-7, Cellulose acetate 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 25086-15-1, Methacrylic acid-methyl 21829-25-4, Nifedipine methacrylate 25212-88-8, Ethyl acrylate-methacrylic acid copolymer copolymer 37205-99-5, Carboxymethyl ethyl cellulose 68377-91-3, Arotinolol 68377-92-4, Arotinolol 71138-97-1, Hydroxypropyl hydrochloride methyl 87760-53-0, Tandospirone cellulose acetate succinate 100986-85-4, 112457-95-1, Tandospirone citrate 129273-38-7 Levofloxacin 150915-41-6, Perospirone 367514-87-2 367514-88-3 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polymeric coating agents for sustained-release oral prepns. containing basic drugs)

PTO/SB/30 (06-09) Approved for use through 06/30/2009. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requi	red to respond to a collection of int	rmation unless it contains a v	alid OMB control number.
Request	Application Number	11/919,678	
for Continued Examination (RCE)	Filing Date	October 31, 2007	
Transmittal	First Named Inventor	Kazuyuki FUJIHARA	
Address to: Mail Stop RCE	Art Unit	1627	
Commissioner for Patents	Examiner Name	Sarah Pihonak	
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket Numb	er 7379/98100	
This is a Request for Continued Examination (RCE) of Request for Continued Examination (RCE) practice under 37 C 1995, or to any design application. See Instruction Sheet for RC	FR 1.114 does not apply to an	utility or plant application	
 Submission required under 37 CFR 1.114 No amendments enclosed with the RCE will be entered in th applicant does not wish to have any previously filed uner amendment(s). Previously submitted. If a final Office action is 	e order in which they were file tered amendment(s) entered, outstanding, any amendments	unless applicant instructs applicant must request not	s otherwise. If n-entry of such
considered as a submission even if this box is	not checked.		
i. Consider the arguments in the Appeal B		ed on	
liOther b. ☑ Enclosed			
b.	iji. Inform	tion Disclosure Statement	
ii. Affidavit(s)/ Declaration(s)		. ,	
2. Miscellaneous			
a Suspension of action on the above-identified period of months. (Period of suspens b Other	sion shall not exceed 3 months; Fe		:d)
 Fees The RCE fee under 37 CFR 1.17(e) is require The Director is hereby authorized to charge the Deposit Account No. <u>06-1135</u> 	he following fees, any underpa		y overpayments, to
i. 🗹 RCE fee required under 37 CFR 1.17(e))		
ii. 🗹 Extension of time fee (37 CFR 1.136 and 1	l.17)		
iii Other			
b Check in the amount of \$	enclos	d	
c. Payment by credit card (Form PTO-2038 enclos WARNING: Information on this form may become public. C card information and authorization on PTO-2038.		I not be included on this	form. Provide credit
SIGNATURE OF ARPLICA	ANT, ATTORNEY, OR AGEN	REQUIRED	
Signature Princhent H			y 21, 2011
	F MAILING OR TRANSMISS		
I hereby certify that this correspondence is being deposited with the Unit addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 145 Office on the date shown below.	ed States Postal Service with suffi	ient postage as first class ma	
Signature	r- <u>-</u>		
Name (Print/Type) This collection of information is required by 37 CFR 1.114. The informat		ate benefit by the public which is	to file (and by the USPTO
to process) an application. Confidentiality is governed by 35 U.S.C. 12: including gathering, preparing, and submitting the completed application the amount of time you require to complete this form and/or suggestion:	2 and 37 CFR 1.11 and 1.14. This form to the USPTO. Time will var	collection is estimated to take depending upon the individua	e 12 minutes to complete, al case. Any comments on

the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SE ND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.: 7379/98100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

:		
:	Confirmation No.:	6965
:	Examiner:	PIHONAK, SARAH
• : •	Group Art Unit:	1627
	· : : :	: Confirmation No.:

For: PHARMACEUTICAL COMPOSITION

AMENDMENT

January 21, 2011

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Kindly enter this Amendment and grant the concurrently filed Petition for Extension of Time.


- 1. Amendments to Claims begin on page 2 of this paper.
- 2. Remarks/Arguments begin on page 8 of this paper.

Amendments to the Claims:

This listing of claims replaces any and all prior claim lists.

Listing of Claims:

1. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

2. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

3. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble polymer binder;

wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

4. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose.

5. (Withdrawn) A method for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

6. (Withdrawn) A method for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by using a solution or dispersion of lurasidone and a water-soluble polymer binder.

7. (Withdrawn) The method of claim 5 wherein the water-soluble excipient is mannitol or lactose.

8. (Canceled)

9. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10. (Canceled)

11. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

12. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. (Canceled)

16. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17-18. (Canceled)

19. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

20. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

21. (Previously Presented) The oral preparation of claim 1 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Previously Presented) The oral preparation of claim 1 wherein an average particle size of lurasidone is 0.1 to 8 μ m.

23. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to 40% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

25. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 20 to 45% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

26. (Previously Presented) The oral preparation of claim 9 wherein the water-soluble excipient is mannitol or lactose.

27. (New) The oral preparation of claim 1 wherein a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt).

28. (New) The oral preparation of claim 1 wherein the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose.

29. (New) The oral preparation of claim 1 wherein a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

30. (New) The oral preparation of claim 1, further comprising a disintegrant wherein a content of the disintegrant per tablet is 0.5 to 5% (wt/wt).

31. (New) The oral preparation of claim 1, further comprising a disintegrant wherein a content of the disintegrant per tablet is 0.5 to 5% (wt/wt);

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation;

a content of lurasidone per tablet is 40 to 120 mg;

a pregelatinizing ratio of the pregelatinized starch is 50 to 95%;

an average particle size of lurasidone is 0.1 to 8 µm;

the pregelatinized starch contains water soluble matter of 30% or less;

a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt);

the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose; and

a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

32. (New) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 160 mg.

33. (New) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 80 to 160 mg.

34. (New) The oral preparation of either one of claim 1 or 31, wherein a similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg.

35. (New) A method for treating psychosis, comprising administering the oral preparation of claim 1 to a patient suffering from psychosis.

36. (New) A method for treating schizophrenia, comprising administering the oral preparation of claim 1 to a patient suffering from schizophrenia.

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 8

REMARKS

Applicants courteously solicit favorable reconsideration followed by a Notice of Allowance.

Upon entry of this Amendment claims 1-7, 9, 11-14, 16, 19-36 will be presented. New claims 27-36 find basis in the original specification. Paragraph [0017] supports new claim 27. Paragraph [0018] supports new claims 28 and 29. Paragraph [0020] supports new claim 30. New claim 31 reflects a combination of various claims, such as claims 1, 9, 14, 21-23, and 27-30. Paragraph [0015] supports new claim 32. Results of Tests 2-5 provide support for new claim 33. New claim 34 is supported by the similar dissolution profile shown in Tests 9 and 13, Figure 3 and the similarity factor f2 can be calculated by paragraphs [0029] and[0030]. Paragraph [0015] supports new claims 35 and 36. The new claims avoid new matter and entry thereof is courteously solicited.

Applicants acknowledge the previous Office Action at page 2 and respectfully solicit allowance of the group I claims, and rejoinder of the withdrawn method claims 5-7 is also requested. Applicants notes the rejoinder offered in the previous Office Action, page 2, paragraph 2.

Traversal of Rejection under 35 U.S.C. §103(a)

Applicants respectfully traverse the rejection of claims 1-4 and 8-24 under 35 U.S.C. §103(a) over Fujihara *et al.* (EP Patent Publication No. 1327440) in view of Salpekar *et al.* (U.S. Patent No. 4,600,579).

By way of background, aspects of the present claimed inventions involve an oral preparation that may comprise high contents of a hardly-soluble pharmaceutically active agent (e.g. lurasidone), yet the preparation exhibits a similar dissolution profile as compared to oral preparations having different contents of such pharmaceutically active agent (*see* paragraph [0013]). An aspect of the present invention includes an oral

preparation having pregelatinized starch in the amount of 10-50% wt/wt per oral preparation.

The claims would not have been obvious over Fujihara *et al.* in view of Salpekar *et al.*

- Fujihara does not teach the higher wt/wt amounts of lurasidone.

Although Fujihara discloses an oral composition comprising lurasidone which provides dissolution characteristics, Fujihara's 16.3% (wt/wt) or less of lurasidone is definitely different from the currently claimed invention in the content rates of lurasidone per oral preparation. This difference is one of the distinguishing aspects of the present claimed of the invention.

Fujihara only discloses that tablets comprising 8.13-16.3% (wt/wt) of lurasidone may have advantageous dissolution characteristics, and does not teach that any tablets comprising more than 16.3% (wt/wt) of lurasidone show remarkable dissolution profiles. In this respect, Fujihara's tablets of Comparative Examples 1-3, including a tablet comprising 29% of lurasidone (Comparative Example 3), are significantly inferior to the corresponding FC tablets of Examples 2-28 which comprise 8.13-16.3% (wt/wt) of lurasidone in terms of the dissolution characteristics (see [0185], [0191] and [0197]). Fujihara thus teaches away. Accordingly, Fujihara neither discloses nor suggests the claim 1 oral preparation comprising high amounts (20-45% (wt/wt)) of lurasidone which shows excellent dissolution profiles.

Furthermore, Fujihara's method does not yield (allow) compositions having high contents of lurasidone to show excellent dissolution profiles. As clearly disclosed in Test 1 (Tables 1-5, Figure 2 and Comparative Examples 1 and 2) of the original description, two tablets of Comparative Example 1 and 2 were prepared according to Fujihara's method and comprised lurasidone in the weight of 12.3% and 24.7%, respectively. Test 1 shows that Fujihara's tablet comprising 24.7% of lurasidone (80 mg tablet) clearly

shows lower dissolution profile than that comprising 12.3% of lurasidone in 15 minutes (see Figure 2, Table 4, [0039]). In contrast, the present oral preparation has favorable dissolution rates and similar dissolution profiles between tablets (see Test 1, Figure 3, Tables 1-3, 13). As shown in Figure 3, dissolution rates of three tablets are more than 80% in 15 minutes. Table 4 and Figure 3 show that these tablets have similar dissolution profiles.

Whereas Fujihara does not disclose compositions comprising more than 16.3% (wt/wt) of lurasidone which show advantageous dissolution profiles as it only discloses those comprising 16.3% (wt/wt) or less of lurasidone, the instant invention provides a composition comprising 20% (wt/wt) or more of lurasidone which shows a remarkably advantageous dissolution profile. The advantageous dissolution profiles for the high content rates of lurasidone may result from inclusion of the recited amount of pregelatinized starch, which is not taught or suggested by Fujihara.

- Fujihara's shortcomings are not overcome, even if, for the sake of argument it were combined with Salpekar *et al.*

Although Salpekar *et al.* teaches a composition comprised of a pharmaceutically active ingredient and pregelatinized starch, and even if *arguendo* some of such compositions with other additives and amounts may allow a shorter dissolution time and may shorten the dissolution and disintegration time, as the Examiner apparently postulates, Salpekar *et al.* nonetheless does not provide any motivation towards the claimed inventions.

- No expectation of Applicant's success and an element of teaching away.

There is a teaching away element to Salpekar *et al.* and a lack of an expectation of the success achieved in utilizing the pregelatinized starch within the range of recited in the claims.

Salpekar *et al.*'s Examples 1-3 are relevant, and suggest Salpekar *et al* apparently does not teach what is asserted in the Office Action. The disintegration time of the Example 1 tablet (18.0% pregelatinized starch, "PGS") is 18.0 minutes, which is 2 to 12 (200% to 1200%) times longer than the Example 2 tablet (6 minutes) and the Example 3 tablet (1.5 minutes). Salpekar *et al.* explains at column 8, lines 44-49 that "As indicated in these examples, Example 1 contains neither auxiliary binder nor auxiliary disintegrating agent; Example 2 includes an auxiliary binder but no auxiliary disintegrating agent; and Example 3 includes both an auxiliary binder and an auxiliary disintegrating agent."

Salpekar et al.'s Examples and related disclosures show that too large amounts of PGS, such as the 18.0% in Example 1, do not improve the disintegration time as well as the dissolution profile of the tablet.

Sepekar et al. teaches, however, that only a combination of small amounts of pregelatinzed starch ("PGS"), such as 8.85 % or 6.4%, <u>and</u> at least an auxiliary binder disclosed can improve disintegration time.

On the other hand, claim 1 recites "the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation," which is far from Sepekar *et al.*'s disclosed value of 8.85%.

Sepekar et al. uses a much more water soluble active ingredient than lurasidone. The former would not predict results obtained with the latter.

Specifically, the pharmaceutically active ingredient used by Salpekar *et al.* is N-acetyl-p-aminophenol (Acetaminophen) (see lines 6-14 of column 1). According to DrugBank (http://www.drugbank.ca/drugs/DB00316), the experimental water solubility of acetaminophen is 14 mg/mL (see the attachment). In contrast, the water solubility of lurasidone is 0.224 mg/mL at 20°C which is extremely lower (approximately 1/62.5) than that of acetaminophen.

That means that lurasidone is much more difficult from the solubility standpoint than acetaminophen, and that Salpekar *et al.* just relates to a comparatively soluble agent "acetaminophen," not to a hardly-soluble agent.

Therefore, the improvement in disintegration time in Salpekar *et al.* must be caused by the good water solubility for acetaminophen. It would have been <u>un</u>reasonable to expect Salpekar *et al.*'s disclosure regarding good water soluble agents to be appropriate for the hardly soluble lurasidone.

Salpekar *et al.* discloses that a preferred embodiment is a composition comprising 93-83% of acetaminophen (see line 63, column 5 to line 9, column 6). Those skilled in the art cannot apply Salpekar's formulation for comparatively soluble agents including extremely high contents (93-83%) of the active ingredient to tablets comprising a hardly-soluble lurasidone in order to solve the problem of the undesired dissolution profiles of hardly-soluble agents in any conventional compositions. The higher contents of the different material in Salpekar teach away from the claim 1 oral preparation.

Even if, for the sake of argument, Salpekar *et al.* were combined with Fujihara, a person skilled in the art cannot arrive at the pregelatinized starch (10 to 50% (wt/wt)) in the claims. Although Salpekar *et al.* teaches that effective amount of PGS (i.e., pregelatinized starch) is from about 5 or less to about 15 or more parts per 100 parts of the composition (see lines 15-17 of column 4), Salpekar's compositions which substantially show significant technical effects are only those supported by Examples (i.e., 4.45-8.85% of PGS), in view of Salpekar's disclosure that the PGS is included in an amount effective for imparting to the composition the capability of being formed into tablets having high hardness, short disintegration time (e.g., about 10 minutes or less) and short dissolution time (e.g., about 20 minutes or less for 80% or more of the APAP to dissolve) (see lines 3-9 of column 4).

As discussed previously, from Table of column 8 and taking lines 3-9 of column 4 into consideration, the Example 1 tablet (18.0% of PGS) is not acceptable in order to

solve Salpekar's problem, since the disintegration time of Example 1 tablet is 18.0 minutes which is 3-12 (300% to 1200%) times longer than that of Example 2 (6 minutes) or Example 3 tablet (1.5 minutes). Even the Example 2 tablet comprising 8.85% of PGS is not perfectly acceptable in terms of it having a 4 (400%) times longer disintegration time than Example 3 tablet.

Therefore, those skilled in the art may understand that 4.45-8.85% of PGS is preferable for a tablet having a short disintegration time and a short dissolution time. Accordingly, a person of ordinary skill in the art cannot arrive at pregelatinized starch (10 to 50% (wt/wt)), beyond Salpekar's preferable ranges, which can cause compositions comprising high content rates of the active ingredient with the advantageous dissolution profiles.

Conclusion

Applicant has found that it is possible to provide an oral preparation which includes a high concentration of lurasidone (20 to 45 wt./wt.%) in combination with 10 to 50 wt./wt.% pregelatinized starch that provides advantageous dissolution profiles. None of the prior art documents, alone or in combination, would have taught or suggested this combination of features or that the advantages can be achieved therewith.

In view of the above amendment and remarks, Applicant respectfully request favorable reconsideration of the instant application in the form of a Notice of Allowance.

The Examiner is encouraged to telephone the undersigned with any comments, suggestions or questions concerning the application for further constructively advancing patent prosecution.

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 14

Applicants hereby request that any concurrent or future reply submitted by Applicants to the U.S. Patent and Trademark Office in connection with the aboveidentified patent application requiring an extension of time under 37 C.F.R. §1.136(a) for its timely submission be treated as incorporating therein a request for an extension of time for the appropriate length of time. In addition, to the extent necessary during prosecution of the present application, Applicants hereby authorize the Commissioner to charge any required fee not otherwise provided for, including application processing, extension, and extra claims fees, to Deposit Account No. 06-1135 with reference to Attorney Docket No. **7379/98100**.

> Respectfully submitted, FITCH, EVEN, TABIN & FLANNERY

> > /Kendrew H. Colton/

Kendrew H. Colton Registration No. 30,368

Please send official correspondence to: **Customer Number 42798**

FITCH, EVEN, TABIN & FLANNERY 1120 20th St., NW, Suite 750 South Washington, DC 20036 Tel: (202) 419-7000 Fax: (202) 419-7007

PTO/SB/22 (06-09) Approved for use through 06/30/2009. OMB 0651-0031 IIS Datent

U.S. Patent and Trademark Office; U.S. DEPARMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)	Docket Number (Optional)
FY 2009 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)	7379/98100
Application Number 11/919,678	Filed October 31, 2007
For PHARAMACEUTICAL COMPOSITION	_
Art Unit 1627	Examiner Sarah Pihonak
This is a request under the provisions of 37 CFR 1.136(a) to extend the per application.	eriod for filing a reply in the above identified
The requested extension and fee are as follows (check time period desired	d and enter the appropriate fee below):
<u>Fee</u>	Small Entity Fee
One month (37 CFR 1.17(a)(1)) \$130	\$65 \$
Two months (37 CFR 1.17(a)(2)) \$490	\$245 \$
✓ Three months (37 CFR 1.17(a)(3)) \$1110	\$555 \$ <u>1110.00</u>
Four months (37 CFR 1.17(a)(4)) \$1730	\$865 \$
Five months (37 CFR 1.17(a)(5)) \$2350	\$1175 \$
Applicant claims small entity status. See 37 CFR 1.27.	
A check in the amount of the fee is enclosed.	
Payment by credit card. Form PTO-2038 is attached.	
The Director has already been authorized to charge fees in this	is application to a Deposit Account.
The Director is hereby authorized to charge any fees which ma Deposit Account Number 06-1135	ay be required, or credit any overpayment, to
WARNING: Information on this form may become public. Credit card info Provide credit card information and authorization on PTO-2038.	ormation should not be included on this form.
I am the applicant/inventor.	
assignee of record of the entire interest. See 37	
Statement under 37 CFR 3.73(b) is enclosed attorney or agent of record. Registration Numbe	· ·
attorney or agent under 37 CFR 1.34.	
Registration number if acting under 37 CFR 1.34	January 21, 2011
Signature	Date
Kendrew H. Colton	(202) 419-7000
Typed or printed name	Telephone Number
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their repre signature is required, see below.	esentative(s) are required. Submit multiple forms if more than one
Total of <u>1</u> forms are submitted.	
This collection of information is required by 37 CFR 1.136(a). The information is required to obtai USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1. complete, including gathering, preparing, and submitting the completed application form to the U comments on the amount of time you require to complete this form and/or suggestions for reduci U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 , <i>J</i>	11 and 1.14. This collection is estimated to take 6 minutes to JSPTO. Time will vary depending upon the individual case. Any ing this burden, should be sent to the Chief Information Officer, VA 22313-1450. DO NOT SEND FEES OR COMPLETED

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Patent Application Fee Transmittal								
Application Number:	11	919678						
Filing Date:	31	Oct-2007						
Title of Invention:	Pharmaceutical composition							
First Named Inventor/Applicant Name:	Kazuyuki Fujihara							
Filer:	Kendrew H. Colton/Lois Ford							
Attorney Docket Number:	7379/98100							
Filed as Large Entity								
U.S. National Stage under 35 USC 371 Filing	Fee	s						
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)			
Basic Filing:								
Pages:								
Claims:								
Miscellaneous-Filing:								
Petition:								
Patent-Appeals-and-Interference:								
Post-Allowance-and-Post-Issuance:								
Extension-of-Time:								
Extension - 3 months with \$0 paid		1253	1	1110	1110			

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Miscellaneous:					
Request for continued examination	1801	1	810	810	
	Total in USD (\$)			1920	

Electronic Acl	knowledgement Receipt
EFS ID:	9279145
Application Number:	11919678
International Application Number:	
Confirmation Number:	6965
Title of Invention:	Pharmaceutical composition
First Named Inventor/Applicant Name:	Kazuyuki Fujihara
Customer Number:	42798
Filer:	Kendrew H. Colton/Lois Ford
Filer Authorized By:	Kendrew H. Colton
Attorney Docket Number:	7379/98100
Receipt Date:	21-JAN-2011
Filing Date:	31-OCT-2007
Time Stamp:	13:34:26
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes						
Payment Type	Deposit Account						
Payment was successfully received in RAM	\$1920						
RAM confirmation Number	10625						
Deposit Account	061135						
Authorized User							
The Director of the USPTO is hereby authorized to charge	e indicated fees and credit any overpayment as follows:						
Charge any Additional Fees required under 37 C.F.R. Se	Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)						
Charge any Additional Fees required under 37 C.F.R. Se	ction 1.20 (Post Issuance fees)						

Charge	any Additional Fees required under 37 C.F.	R. Section 1.21 (Miscellaneous fee	s and charges)					
File Listin	g:							
Document Number	Document Description	File Name	Iame File Size(Bytes)/ Message Digest P ary21.pdf 70608 0b3424efbb9a304eb12d72c2508819bbc/2 bc068 January21.pdf 513405 January21.pdf 237247b58059b7ba2a55c59918c93511 cea2a JPDF files in .zip description A/RCE 1 A/RCE 2 Gment 8 EOT.pdf 59903 31897 31897		Pages (if appl.)			
1	Request for Continued Examination (RCE)	RCE-January21.pdf	0b3424efbb9a304eb12df2e2508819bbcf2	no	1			
Warnings:		I	11					
This is not a US	PTO supplied RCE SB30 form.							
Information:								
2		Amendment-January21.pdf	513405	yes	14			
		· · · · · · · · · · · · · · · · · · ·		,				
Multipart Description/PDF files in .zip description								
	Document De	Start	E	nd				
	Amendment Submitted/Entere	1		1				
	Claims	2	7					
	Applicant Arguments/Remarks	Made in an Amendment	8	14				
Warnings:								
Information:		r	· · · · · · · · · · · · · · · · · · ·					
3	Extension of Time	Petition-EOT.pdf	59903	no	1			
Warnings:								
Information:		Γ						
4	Fee Worksheet (PTO-875)	fee-info.pdf	31897	no	2			
			7e6101b790087c1271c7dd61f32937683da 1165d					
Warnings:								
Information:			1					
		Total Files Size (in bytes)	67	75813				

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

P/	ATENT APPL		FEE DETE for Form P		N RECORD	Application or Docket Number 11/919,678			Filing Date 10/31/2007 To be		
	A	PLICATIO	N AS FILE	D – PART I						OTH	HER THAN
			(Column 1) (1	Column 2)	SMA	LL E	ENTITY	OR	SMA	LL ENTITY
	FOR		NUMBER FIL	.ED NUM	MBER EXTRA	RATE (S	\$)	FEE (\$)		RATE (\$)	FEE (\$)
	BASIC FEE (37 CFR 1.16(a), (b),	or (c))	N/A		N/A	N/A				N/A	
]	SEARCH FEE (37 CFR 1.16(k), (i), (or (m))	N/A		N/A	N/A				N/A	
]	EXAMINATION FE (37 CFR 1.16(o), (p),		N/A		N/A	N/A				N/A	
	TAL CLAIMS CFR 1.16(i))		min	us 20 = *		X \$	=		OR	X \$ =	
	EPENDENT CLAIM CFR 1.16(h))	S	mi	nus 3 = *		X \$	=			X \$ =	
	APPLICATION SIZE (37 CFR 1.16(s)) MULTIPLE DEPEN	FEE is ad 35	\$250 (\$125 Iditional 50 s 5 U.S.C. 41(a	er, the applicatio for small entity) sheets or fractior a)(1)(G) and 37 (7 CFR 1.16(j))	for each 1 thereof. See						
ft	the difference in colu	umn 1 is less th	an zero, ente	r "0" in column 2.		TOTAL	. 1			TOTAL	
	01/21/2011	(Column 1) CLAIMS REMAINING		(Column 2) HIGHEST NUMBER	(Column 3)	SN RATE (S			OR		ADDITIONA
		AFTER AMENDMEN	ІТ	PREVIOUSLY PAID FOR	EXTRA		• /	FEE (\$)			FEE (\$)
	Total (37 CFR 1.16(i))	* 21	Minus	** 24	= 0	X \$	=		OR	X \$52=	0
	Independent (37 CFR 1.16(h))	* 3	Minus	***5	= 0	X \$	-		OR	X \$220=	0
	Application Si	ze Fee (37 CFF	R 1.16(s))				-				
	FIRST PRESEN	ITATION OF MUL	TIPLE DEPENI	DENT CLAIM (37 CFF	R 1.16(j))				OR		
						TOTAL ADD'L FEE			OR	TOTAL ADD'L FEE	0
		(Column 1)		(Column 2)	(Column 3)				•	•	
		CLAIMS REMAINING AFTER AMENDMEN		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (S	\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONA FEE (\$)
	Total (37 CFR 1.16(i))	*	Minus	**	=	X \$	=		OR	X \$ =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$	=		OR	X \$ =	
	Application Si	ze Fee (37 CFI	R 1.16(s))								
		ITATION OF MUL	TIPLE DEPEN	DENT CLAIM (37 CFF	R 1.16(j))				OR		
						TOTAL ADD'L FEE	Ī		OR	TOTAL ADD'L FEE	
lf	the entry in column the "Highest Numbe f the "Highest Numb	er Previously Pa per Previously F	aid For" IN TH Paid For" IN T	IIS SPACE is less	than 20, enter "20' s than 3, enter "3".	· /TIFF		istrument Ex NY n. TABB/	amin	er:	

The Highest Number Previously Fail For (Your of Independent) is the highest number round in the appropriate box in column 1. This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** If you need assistance in completion the form. *cell 1-800-FTO-9199 and select option 2*

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Par Pharm., Inc. Exhibit 1015 Page 313

PTO/SB/06 (07-06)

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE	Application Number		11919678		
	Filing Date		2007-10-31		
	First Named Inventor	Kazuy	yuki Fujihara		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1627		
	Examiner Name	Sara I	Pihonak		
	Attorney Docket Number		7379/98100		

					U.S.F	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Document		t Pages,Columns,Lines v Relevant Passages or F Figures Appear		
	1									
If you wisl	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUBL			Remove	
Examiner Initial*	Cite No		Publica Date	tion	Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1									
If you wisl	h to ad	d additional U.S. Publi	shed Ap	plication	citatior	n information p	lease click the Add	d butto	on. Add	
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*			Country Code ²		Kind Code⁴	Publication Date Name of Patented Applicant of cited Document		e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T 5
	1									
If you wis	h to ad	d additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	buttor	Add	
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seria	al, sympo	osium, (catalog, etc), c				T⁵

	Application Number		11919678
	Filing Date		2007-10-31
INFORMATION DISCLOSURE	First Named Inventor	Kazuy	yuki Fujihara
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1627
	Examiner Name	Sara I	Pihonak
	Attorney Docket Numb	er	7379/98100

	1 EPO Communication dated Feb. 1, 2012, with enclosed Supplemental Search Report, in EPO Appln. 11181100.6							
	2 Kibbe, Handbook of Pharmaceutical Excipients, Chapter 7, pages 528-530 (2000)							
If you wis	h to ao	dd add	ditional non-patent literature document citation information p	lease click the Add I	button Add			
			EXAMINER SIGNATURE					
Examiner	Examiner Signature Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
Standard S	T.3) . ³ F	citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁵ Applicant is to place a check mark here if						

English language translation is attached.

	Application Number		11919678
	Filing Date		2007-10-31
INFORMATION DISCLOSURE	First Named Inventor	Kazuy	/uki Fujihara
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1627
	Examiner Name	Sara I	Pihonak
	Attorney Docket Numb	er	7379/98100

CERTIFICATION STATEME	NT
-----------------------	----

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
 from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

 \square

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Kendrew H. Colton/	Date (YYYY-MM-DD)	2012-03-07
Name/Print	Kendrew H. Colton	Registration Number	30368

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt				
EFS ID:	12241196			
Application Number:	11919678			
International Application Number:				
Confirmation Number:	6965			
Title of Invention:	Pharmaceutical composition			
First Named Inventor/Applicant Name:	Kazuyuki Fujihara			
Customer Number:	42798			
Filer:	Kendrew H. Colton			
Filer Authorized By:				
Attorney Docket Number:	7379/98100			
Receipt Date:	07-MAR-2012			
Filing Date:	31-OCT-2007			
Time Stamp:	09:11:42			
Application Type:	U.S. National Stage under 35 USC 371			

Payment information:

Submitted wit	Submitted with Payment no				
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Non Patent Literature	D3.pdf	160553	no	3
		55.pai	c21ed8321d4fc247b0a16fae0ff38cea79dc1 2c0	110	5
Warnings:					
Information:					

	Non Patent Literature	EESR.pdf -	419625	no	10	
2	Nonrachtenerature	Lonpar	bc62e2fd262baef9192d2fa8eb5b17a81859 ef8c		10	
Warnings:					·	
Information:						
3	Information Disclosure Statement (IDS) Form (SB08)	updated_IDS7March2012.pdf	611842	no	4	
			765fd8f661c71d28956340d5c5eebc96234 676d9			
Warnings:						
Information:						
you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.						
	Total Files Size (in bytes): 1192020					
	ledgement Receipt evidences receip	t on the noted date by the U	SPTO of the indicated	l document	-	
characterized Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) an	ledgement Receipt evidences receip d by the applicant, and including pag described in MPEP 503. tions Under 35 U.S.C. 111 ication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin	t on the noted date by the U ge counts, where applicable. tion includes the necessary o R 1.54) will be issued in due	SPTO of the indicated It serves as evidence components for a filir	d document of receipt : ng date (see	similar to a 37 CFR	
characterized Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) an Acknowledg <u>National Star</u> If a timely su U.S.C. 371 an	d by the applicant, and including page described in MPEP 503. <u>tions Under 35 U.S.C. 111</u> ication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF	t on the noted date by the U ge counts, where applicable. tion includes the necessary of R 1.54) will be issued in due g date of the application. <u>Inder 35 U.S.C. 371</u> of an international applicat orm PCT/DO/EO/903 indicat	SPTO of the indicated It serves as evidence components for a filir course and the date s ion is compliant with ng acceptance of the	document of receipt : ng date (see shown on th the condition	similar to a 37 CFR nis ons of 35	



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
11/919,678	10/31/2007	Kazuyuki Fujihara	7379/98100	6965		
	7590 03/13/201 TABIN & FLANNER	-	EXAM	IINER		
P. O. BOX 184	FITCH, EVEN, TABIN & FLANNERY, LLP P. O. BOX 18415			PIHONAK, SARAH		
WASHINGTON, DC 20036		ART UNIT PAPER NUMBER				
		1627				
			MAIL DATE	DELIVERY MODE		
			03/13/2012	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	11/919,678	FUJIHARA, KAZUYUKI				
Office Action Summary	Examiner	Art Unit				
	SARAH PIHONAK	1627				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
 A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 13). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 						
Status						
 1) Responsive to communication(s) filed on <u>21 Ja</u> 2a) This action is FINAL. 2b) This 3) An election was made by the applicant in responsive to requirement and election 4) Since this application is in condition for allowant closed in accordance with the practice under E 	action is non-final. onse to a restriction requirement have been incorporated into this ice except for formal matters, pr	s action. osecution as to the merits is				
Disposition of Claims						
 5) Claim(s) <u>1-7,9,11-14,16 and 19-36</u> is/are pendi 5a) Of the above claim(s) <u>5-7,35 and 36</u> is/are w 6) Claim(s) is/are allowed. 7) Claim(s) <u>1-4,9,11-14,16 and 19-34</u> is/are reject 8) Claim(s) is/are objected to. 9) Claim(s) are subject to restriction and/or 	vithdrawn from consideration. ed.					
Application Papers						
 Application Papers 10) The specification is objected to by the Examiner. 11) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 12) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 						
Priority under 35 U.S.C. § 119						
 13) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of 	s have been received. have been received in Applicat ity documents have been receive (PCT Rule 17.2(a)).	ion No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>3/7/2012</u> . U.S. Patent and Trademark Office PTOL-326 (Rev. 03-11) Office Action	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	ate				

Application/Control Number: 11/919,678 Art Unit: 1627

DETAILED ACTION

This application, filed 10/31/2007, is a national stage entry of PCT/JP2006/310571, filed on 5/26/2006.

Priority

This application claims foreign priority to Application No. 2005-153508, filed on 5/26/2005.

Request for Continued Examination

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/21/2011 has been entered.

Response to Remarks

2. Claims 1-7, 9, 11-14, 16, 19-36 are pending as of the amendments filed on 1/21/2011. Claims 5-7 were previously withdrawn from consideration, due to the restriction requirement.

Application/Control Number: 11/919,678 Art Unit: 1627

3. Newly submitted claims 35-36 are directed to an invention that is independent or distinct from the invention originally elected for examination for the following reasons: claims 35-36 are directed to a method of treating psychosis and schizophrenia, while the elected claims of 1-4, 9, 11-14, and 19-34 are directed to an oral preparation comprised of lurasidone HCI, pregelatinized starch, and a water soluble excipient. The inventions are related as a product and a process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the elected invention of a product comprised of an oral preparation comprised of lurasidone, pregelatinized starch, and a water soluble excipient can be used for purposes other than the methods as cited in claims 35 and 36, such as in toxicology testing assays.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 35-36 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Applicant's arguments over the rejection under 35 USC 103(a) as being unpatentable over Fujihara, EP 1327440, in view of Salpekar et. al., US Patent No. 4,600,579, have been fully considered but are not found persuasive. The Applicant has argued that the claimed oral composition comprised of lurasidone

Application/Control Number: 11/919,678 Art Unit: 1627

HCl, a pregelatinized starch, and a water-soluble excipient would not have been prima facie obvious to one of ordinary skill in the art, because Fujihara discloses that only tablets comprised of 8.13 to 16.3% of lurasidone have advantageous dissolution profiles, and that the tablet comprised of 29% lurasidone has a significantly inferior dissolution profile. The Applicant asserts that one of ordinary skill in the art would not have looked to Fujihara to have prepared an oral composition comprised of 20 to 45% by weight lurasidone. The examiner respectfully disagrees, because while the Applicant asserts that Fujihara only discloses beneficial dissolution profiles for tablets having 16.3% or less of lurasidone, the examiner maintains that Fujihara explicitly teaches that oral compositions comprised of up to 40 mg. lurasidone have good disintegration, and equivalent dissolution profiles to tablets comprised of lower amounts of lurasidone (see Fujihara, p. 2, paragraphs [0001] and [0004-0005]; p. 5, paragraph [0015]). A reference is interpreted for the teachings as a whole, and not only for working examples and preferred embodiments. See MPEP 2123; Merck & Co. v. Biocraft Laboratories, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.). Furthermore, Applicant's direct comparison of the claimed composition to the composition taught by Fujihara is not found to be persuasive, as the rejection was based upon the combination of Fujihara and Salpekar et. al., and it was acknowledged in the office action dated 7/27/2010 that Fujihara does not explicitly teach the incorporation of a pregelatinized starch. Salpekar et. al. teaches the benefits of incorporating a pregelatinized starch into an oral composition, such as imparting improved disintegration and dissolution profiles.

Fujihara teaches lurasidone HCl as only slightly water soluble, thus one of ordinary skill in the art would have been motivated to have incorporated a pregelatinized starch into the composition, with the expectation of improving the dissolution and thus bioavailability of lurasidone HCl.

The Applicant has argued that Salpekar et. al. does not provide any motivation towards the claimed invention and teaches away from the claimed composition. The Applicant cites examples 1-3 from Salpekar as teaching away from the claimed composition, asserting that the examples and disclosure of Salpekar show that too large amounts of pregelatinized starch do not improve the disintegration time or dissolution profile of the tablet. The Applicant has argued that Salpekar et. al. teaches only the combination of a small amount of pregelatinized starch, such as 8.85% and 6.4%, along with an auxiliary binder improve the disintegration time. The examiner respectfully disagrees, because as discussed above, a reference is to be relied upon for all of its teachings, and not only exemplifications or preferred embodiments. The examiner maintains that Salpekar et. al. teaches a pregelatinized starch, such as Starch 1500, for decreasing disintegration and dissolution times for tablets (see column 3, lines 46-51; column 4, lines 31-37). Salpekar et. al. also explicitly teaches an effective amount of pregelatinized starch to range from about 5 or less to about 15 parts of more per 100 parts of the composition (column 4, lines 15-17); thus, one of ordinary skill in the art would not have limited the amount of pregelatinized starch in the oral tablet to comprise 8.85% and 6.4%, or less than these amounts. The Applicant has argued that the active agent present in the composition taught by

Salpekar et. al. is acetaminophen, which is much more water soluble than lurasidone HCI. The Applicant asserts that due to the differences in water solubility between the active agents, one of ordinary skill in the art could not have reasonably utilized the teachings of Salpekar et. al. to predict the claimed composition. The Applicant has also pointed out that the composition taught by Salpekar employs a high percentage of acetaminophen, which teaches away from the claimed composition. The examiner respectfully disagrees, as Salpekar et. al. explicitly teaches the incorporation of a pregelatinized starch for improving dissolution and disintegration times. Additionally, Salpekar's teachings are not limited to tablets comprised of high amounts of acetominophen (see Abstract). While the examiner has considered Applicant's argument that the water solubilities of acetaminophen and lurasidone HCI differ, the examiner maintains that one of ordinary skill in the art, in consideration of Salpekar's teachings of improving dissolution times by incorporation of a pregelatinized starch, would have been motivated to have incorporated a pregelatinized starch into an oral composition comprised of an active agent with low water solubility, for the purpose of improving the dissolution of the active drug. The rejection under 35 USC 103(a) as being unpatentable over Fujihara, in view of Salpekar et. al., was proper and is maintained, for reasons of record. A modified rejection under 103(a) over Fujihara in view of Salpekar et. al. has been made, in consideration of the new claims, which will be discussed in the office action. A new rejection for obviousness type double patenting has been made, which will be discussed in the office action.

- 4. Claims 1-4, 9, 11-14, 16, and 19-34 were examined.
- 5. Claims 1-4, 9, 11-14, 16, and 19-34 are rejected.

Claim Rejections-35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for

all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

7. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1,

148 USPQ 459 (1966), that are applied for establishing a background for

determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 8. Claims 1-4, 9, 11-14, 16, and 19-34 are rejected under 35 U.S.C. 103(a)

as being unpatentable over Fujihara et. al., EP Patent Publication No. 1327440,

in view of Salpekar et. al., US Patent No. 4,600,579 (both of previous record).

The claims are drawn to an oral composition comprised of lurasidone,

pregelatinized starch, a water soluble excipient such as mannitol or lactose, and

a water soluble polymer binder. The claims are also drawn to the composition in which the pregelatinized starch is present in an amount from 10-50% by weight, and in which the lurasidone is present in an amount from 25 to 45% by weight.

Fujihara et. al. teaches an oral composition comprised of a slightly water soluble active ingredient, such as lurasidone, along with a first disintegrant, a second disintegrant, and a water soluble polymer binder (Abstract; p. 4-5, paragraph [0008]). Fujihara et. al. teaches that the composition provides advantageous dissolution characteristics when ingested (Abstract). Corn starch is taught and exemplified as a first disintegrant (p. 4, lines 6-9; p. 5, paragraph [0011]; p. 22, paragraph [0152], Ex. 28). It is taught that one of the water soluble excipients includes sugar alcohols such as mannitol or lactose (p. 3, paragraph [0017], item (18); p. 5, paragraph [0014]). The other disintegrant is taught as including excipients such as microcrystalline cellulose, croscarmellose sodium, among others (p. 5, paragraph [0011]), and the water soluble polymer binder includes polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl methylcellulose, and others (p. 4, lines 10-12; p. 5, paragraph [0010]). It is taught that the amount of lurasidone present in the oral composition is 40 mg., which is within the range instantly claimed (p. 5, paragraph [0015]; p. 22, paragraph [0152], Table 28), and that the average particle size of lurasidone is between 0.5 to 5 μ m (p. 6, paragraph [0021]). It is taught that for a tablet of a weight of approximately 142 mg., the amount of lurasidone present is 40 mg., which is approximately 28 % of the weight of the composition (p. 29, paragraph [0194], Table 44). The water soluble polymer binder is taught to comprise from about 1 to 10% by weight of

the preparation (p. 4, lines 39-40), and water soluble excipients such as mannitol or lactose are taught to comprise from 200 to 2000 % by weight to the weight of lurasidone (p. 9, paragraph [0066]), however, Fujihara et. al. provides an example wherein mannitol is present in an amount of 94 mg., and lurasidone present in an amount of 20 mg. (p. 20, Table 24, paragraph [0145]), in addition to another example wherein lurasidone comprises 40 mg. of the tablet, while mannitol comprises 132 mg., of a total mass of 250 mg. for the tablet (p. 23, paragraph [0159], Table 32, Ex. 24). Thus, Fujihara teaches a water soluble excipient such as D-mannitol or lactose to comprise about 53% of the tablet (p. 23, paragraph [0159], Ex. 24 of Table 32; 132 mg./250 mg. is about 53%), which is within the amount range of water soluble excipient cited in the claimed composition. Fujihara provides an example formulation wherein the amount of the disintegrant crosscarmellose sodium is 4.8 % of the tablet weight (12 mg. for a 250 mg. tablet; p. 23, paragraph [0159], Table 32); therefore, the limitation of claim 30 is met. It is taught that the oral preparation comprises a granule, which is prepared by granulating the water-soluble polymer binder with the powdery mixture consisting of the active agent (lurasidone), a water soluble excipient, and another disintegrant (p. 3, paragraph [0007], items (11-13); p. 4, paragraph [0007], item (40)). Fujihara et. al. teaches that the preparation can be formulated as pills, granules, fine granules, capsules, tablets, etc. (p. 5, paragraph [0016]).

Fujihara et. al. does not explicitly teach that the composition comprises pregelatinized starch, in an amount from 10 to 50% by weight of the composition. It is not explicitly taught that the composition comprises 80 mg. of lurasidone.

Salpekar et. al. teaches that a composition comprised of a pharmaceutically active ingredient, a lubricant, a disintegrant, and pregelatinized starch allows for high hardness, and short dissolution time when ingested (Abstract). Salpekar et. al. teaches that the composition comprised of the pregelatinized starch is beneficial for preparing oral pharmaceutical formulations such as tablets (column 1, lines 22-29). It is taught that the partially pregelatinized starch, such as the starch commercially known as Starch 1500, acts as a binder to the composition, and provides beneficial disintegrant properties, as well as increasing hardness of the composition and shortening the dissolution and disintegration time (column 3, lines 38-51; column 4, lines 31-37). Salpekar et. al. teaches that the amount of partially pregelatinized starch ranges from 5 or less to 15 or more parts per 100 parts of the composition (column 4, lines 15-17), which is within the amount of pregelatinized starch instantly claimed. It is taught that the amount of pregelatinized starch present is based upon the amount necessary to impart the high hardness and decreased dissolution times to the composition (column 4, lines 3-9); therefore, it would have been obvious to one of ordinary skill in the art that the optimum range of the pregelatinized starch may comprise amounts greater than or less than 5-15 % by weight, as taught. Salpekar et. al. teaches that the percent gelatinization of the pregelatinized starch ranges optimally from 50 to 75% (column 2, lines 33-55). Additionally, it is taught that Starch 1500 has a moisture content between 3 and 5 % (column 3, lines 38-45).

One of ordinary skill in the art would have been motivated, at the time of the invention, to have prepared the oral lurasidone preparation taught by Fujihara et. al. with incorporation of the pregelatinized starch excipient taught by Salpekar et. al. because Salpekar et. al. teaches that the pregelatinized starch in oral pharmaceutical formulations provides beneficial properties, such as increased hardness of the tablet, decreased dissolution time after ingestion, and short disintegration time. As such, it would have been prima facie obvious for one of ordinary skill in the art to have prepared the oral lurasidone composition as taught by Fujihara et. al. with the pregelatinized starch excipient as taught by Salpekar et. al. because both Fujihara et. al. and Salpekar et. al. teach pharmaceutical compositions formulated for oral administration, and Salpekar teaches the addition of a pregelatinized starch for improving the dissolution time of the active agent. One of ordinary skill in the art would have been motivated to have incorporated pregelatinized starch, within the amount range as claimed, with a reasonable expectation that the dissolution and solubility of lurasidone HCI would have been improved. Properties associated with a composition are not patentably separable from the composition itself; see MPEP 2141.02, In re Papesch, 315 F.2d 381, 391, 137 USPQ 43, 51 (CCPA 1963). Therefore, as it would have been prima facie obvious to have prepared an oral composition comprised of lurasidone HCI, pregelatinized starch, within the amount ranges as cited, in addition to a water-soluble excipient, it would have been prima facie obvious that properties associated with the composition, such as the similarity factor f2, which is cited as being in the range of $50 \le f2 \le 100$ when a content of

lurasidone per tablet changes over a range of 20 mg. to 120 mg., would also have been present. Fujihara explicitly teaches oral preparations comprised of lurasidone HCI up to 40 mg.; however, one of ordinary skill in the art would have expected success in incorporating a greater amount of lurasidone HCI in the preparation, as the pregelatinized starch taught by Salpekar et. al. improves the solubility and dissolution of the drug. It would have been obvious as such to have incorporated 80 mg. to 160 mg. of lurasidone HCI into the oral preparation, with the expectation that the presence of the pregelatinized starch, as taught by Salpekar, would have allowed for effective solubility and dissolution of the drug. Therefore, there would have been an expectation of success in utilizing the pregelatinized excipient for the composition comprising lurasidone, because it is taught by Salpekar et. al. that the pregelatinized starch imparts beneficial properties such as improvement of dissolution and disintegration to oral formulations.

Claim Rejections-Obviousness Type Double Patenting

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application

Par Pharm., Inc. Exhibit 1015 Page 332

claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

10. Claims 1-4, 9, 11-14, 16, and 19-34 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8 of copending Application No. 12/997779. Although the conflicting claims are not identical, they are not patentably distinct from each other because: the co-pending claims and the instant claims are directed to compositions which overlap considerably in scope. The instantly claimed composition is directed to

an oral composition comprised of lurasidone HCl in an amount between 20% to 45% by weight, a pregelatinized starch in an amount from about 10% to about 50% by weight, and a water soluble excipient; the co-pending claims are directed to a tablet comprised of an active ingredient in an amount not less than 25% by weight, mannitol, a pregelatinized starch, and a disintegrant. The claimed composition also comprises the ingredients cited in the co-pending claims, and as such the claims are not patentably separable.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Information Disclosure Statement

11. The information disclosure statement (IDS) submitted on 3/7/2012 was filed after the mailing date of the final office action on 7/27/2010. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner.

Conclusion

12. No claim is currently found allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached on Monday-Thursday 7:00 AM - 5:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (tollfree). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S.P.

/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1627


				4	Application/Control No.					Applicant(s)/Patent Under Reexamination					
	Ind	lex of C	Claim	IS	1	11919678					FUJIHARA, KAZUYUKI				
					E	Examiner					Art Unit				
					S	SARAH PIHONAK					1627				
✓	✓ Rejected -			Са	Cancelled N Non-Elec			cted		Α	Ар	peal			
=	A	llowed		÷	Re	stricted		Ι	Interfe	ere	nce		0	Obj	ected
	Claims r	enumbered	in the s	ame oro	der as p	presented by a	oplic	ant	[СРА	C] т.с). 🗆	R.1.47
	CLA	IM							DATE						
Fi	inal	Original	11/13/2	2009 07	/20/201	0 03/08/2012									
		1	~		\checkmark	✓									
		2	~		~	√									
		3	~		\checkmark	√									
		4	✓		√	✓									
		5	N		Ν	N									
		6	N		Ν	N									
		7	N		Ν	N									
		8	 ✓ 		-	-									
		9	 ✓ 		~	✓									
		10	✓ ✓		-	-									
		11 12	v √		v √	✓ ✓									
		13	· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·									
		13	· ·		· ✓	· · ·									
		15			-										
		16	√		√	✓									
		17	√		-										
		18	√		-	-									
		19	~		~	✓									
		20	✓		\checkmark	√									
		21	√		\checkmark	√									
		22	~		\checkmark	√									
		23	~		\checkmark	~									
		24	~		~	✓									
		25			✓	✓									
L		26			~	✓									
<u> </u>		27				✓									
		28				✓ ✓									
		29				✓ ✓									
		30 31				v √									+
<u> </u>		31				✓ ✓									+
<u> </u>		33				· · · · · · · · · · · · · · · · · · ·									
<u> </u>		34				· · ·									
		35				N									1
<u> </u>		36				N									

U.S. Patent and Trademark Office

Part of Paper No. : 20111102

L11 S US 20090143404/PN FILE 'REGISTRY' ENTERED AT 12:25:41 ON 08 MAR 2012 L2 1 S 9005-25-8/RN SET NOTICE 1 DISPLAY SET NOTICE OFF DISPLAY FILE 'REGISTRY' ENTERED AT 12:26:29 ON 08 MAR 2012 LЗ 1 S 367514-87-2/RN SET NOTICE 1 DISPLAY SET NOTICE OFF DISPLAY FILE 'REGISTRY' ENTERED AT 12:26:55 ON 08 MAR 2012 L41 S 367514-88-3/RN ANSWER 1 OF 1 REGISTRY COPYRIGHT 2012 ACS on STN L4 367514-88-3 REGISTRY RN CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS) - (CA INDEX NAME) OTHER CA INDEX NAMES: CN 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, monohydrochloride, (3aR,4S,7R,7aS) - (9CI) OTHER NAMES: Lurasidone hydrochloride CN CN SM 13496 FS STEREOSEARCH DR 441351-20-8 MF C28 H36 N4 O2 S . C1 H SR CA LCSTN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, TOXCENTER, USAN, USPAT2, USPATFULL (*File contains numerically searchable property data) DT.CA CAplus document type: Journal; Patent Roles from patents: BIOL (Biological study); PREP (Preparation); PROC RL.P (Process); USES (Uses) RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses) Roles from non-patents: BIOL (Biological study); PREP (Preparation); RL.NP USES (Uses) CRN (367514-87-2)

Absolute stereochemistry.



HC1

SET NOTICE 1 DISPLAY SET NOTICE OFF DISPLAY

- FILE 'CAPLUS' ENTERED AT 12:27:13 ON 08 MAR 2012 E PHARMACEUTICAL TABLETS/CT SET EXPAND CONTINUOUS E E3+ALL/CT L5 52184 S E22-E23,E29-E30,E32 E DISSOLUTION/CT E E44+ALL/CT L6 113293 S E55-E56,E73 E E47+ALL/CT L7 62485 S E79-E80 L8 2 S L2 AND (L3 OR L4)
- L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2012 ACS on STN
- AB Disclosed are oral compns. containing a hardly water-soluble active ingredient and having favorable disintegration characteristics which comprise a molded solid article (for example, granules) obtained by mixing the hardly water-soluble active ingredient, a first disintegrating agent and a water-soluble filler with the use of a watersoluble polymer binder and then mixing this molded solid article with a second disintegrating agent, or a molded solid article obtained by mixing the hardly water-soluble active ingredient, a disintegrating agent and a sugar alc. with the use of a water-soluble polymer binder. When orally administered, these prepns. show excellent elution of the active ingredient in the digestive tract. Moreover, these prepns. can show the same elution behavior at different contents of the active ingredient and thus enable the selection of the most suitable drug for each patient, which makes these prepns. highly useful in clin. medicine. A film-coated tablet was prepared form granules containing N-[4-[4-(1,2benzisothiazole-3-yl)-1-piperazinyl]-(2R,3R)-2,3- tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3- bicyclo[2,2,1]heptanedicarboxyimide hydrochloride 10, lactose 50, sodium croscarmellose 6 mg, and polyvinyl alc. 1.2 mg, calcium hydrogen phosphate anhydride 35, crystalline cellulose 17, and magnesium stearate 0.8 mg, and a coating material containing hydroxypropyl Me cellulose 1.95, titanium oxide 0.6, concentrate glycerin 0.45 mg, and carnauba wax q.s. ACCESSION NUMBER: 2002:240535 CAPLUS Full-text

DOCUMENT NUMBER: 136:268164 TITLE: Oral compositions with favorable disintegration characteristics INVENTOR(S): Fujihara, Kazuyuki PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan SOURCE : PCT Int. Appl., 49 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent. Japanese LANGUAGE: FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: KIND DATE APPLICATION NO. PATENT NO. DATE
 WO 2002024166
 A1
 20020328
 WO 2001-JP7983
 20010914
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU2001086237A20020402AU2001-86237CA2424001A120030320CA2001-2424001EP1327440A120030716EP2001-965637EP1327440B12009051320090513 20010914 20010914 20010914 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR EP 1974724 A2 20081001 EP 2008-156778 20010914 A3 20081112 EP 1974724 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR AT 431136 Т 20090515 AT 2001-965637 20010914 ES 2325764 20010914 JP 4868695 20010914 20010919 TW 289062 TW 289063 20010919 US 20040028741 A1 20040212 US 2003-381036 US 7727553 B2 20100601 20030321 B2 20100601 US 7727553 JP2000-288234A20000922EP2001-965637A320010914WO2001-JP7983W20010914 PRIORITY APPLN. INFO.: ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT IPCI A61K0009-16 [ICM,7]; A61K0009-20 [ICS,7]; A61K0009-30 [ICS,7]; A61K0031-496 [ICS,7]; A61K0045-00 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-26 [ICS,7]; A61K0047-30 [ICS,7] IPCR A61K0009-00 [I,A]; A61K0009-16 [I,A]; A61K0009-20 [I,A]; A61K0009-30 [I,A]; A61K0031-496 [I,A] СС 63-6 (Pharmaceuticals) 63-42-3, Lactose 69-65-8, D-Mannitol 557-04-0, Magnesium stearate ΤТ 7757-93-9, Calcium hydrogen phosphate 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinyl pyrrolidone 9004-34-6, Crystalline cellulose, biological studies 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Corn starch, biological studies 74811-65-7, Sodium croscarmellose 367514-88-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns. with favorable disintegration characteristics containing hardly water-soluble active ingredients)
IT 9005-25-8, Corn starch, biological studies 367514-88-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. with favorable disintegration characteristics
containing
hardly water-soluble active ingredients)
L9 6709 S L2 AND L5
L10 0 S L2 (L) L5
L11 1513 S L9 AND L6
L12 412 S L11 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)
L13 152795 S (IMPROV? OR INCREASE?)(S)(DISSOL? OR SOLUB?)
L14 193 S L11 AND L13
L15 39 S L14 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)
FILE 'CAPLUS' ENTERED AT 14:05:51 ON 08 MAR 2012
FILE 'CAPLUS' ENTERED AT 14:06:04 ON 08 MAR 2012 L16 61 S L3 OR L4
L17 21 S L16 AND (AY<=2006 OR PRY<=2006 OR PY<=2006)

Doc code: IDS

PTO/SB/08a (01-10)

Doc description: Information Disclosure Statement (IDS) Filed

mation Disclosure Statement (IDS) Filed U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		11919678
	Filing Date		2007-10-31
INFORMATION DISCLOSURE	First Named Inventor	Kazuy	yuki Fujihara
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1627
	Examiner Name	Sara	Pihonak
	Attorney Docket Number		7379/98100

					U.S.F	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines w Relevant Passages or R Figures Appear			
	1										
If you wis	h to ado	d additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
	U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite N	o Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		nt Pages,Columns,Lines v Relevant Passages or I Figures Appear			
	1										
If you wis	h to ado	d additional U.S. Publ	ished Ap	plication	citatior	n information p	lease click the Add	d butto	n. Add		
				FOREIG	EN PA T	ENT DOCUM	ENTS		Remove		
Examiner Initial*		Foreign Document Number ³	Country Code ²		Kind Code⁴	Publication Date Name of Patente Applicant of cited Document		e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5	
	1										
If you wis	h to add	d additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	buttor	Add		
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item										

	Application Number		11919678	
	Filing Date		2007-10-31	
INFORMATION DISCLOSURE	First Named Inventor	Kazuyuki Fujihara		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1627	
	Examiner Name	Sara I	Pihonak	
	Attorney Docket Number		7379/98100	

	1 EPO Communication dated Feb. 1, 2012, with enclosed Supplemental Search Report, in EPO Appln. 11181100.6							
	2	Kibbe	e, Handbook of Pharmaceutical Excipients, Chapter 7, pages 528-3	530 (2000)				
If you wis	h to ao	dd add	litional non-patent literature document citation information p	lease click the Add I	outton Add			
			EXAMINER SIGNATURE					
Examiner	Signa	ture	/Sarah Pihonak/	Date Considered	03/08/2012			
			reference considered, whether or not citation is in conforma rmance and not considered. Include copy of this form with r					
Standard S ⁻ ⁴ Kind of do	T.3). ³ F cument	For Japa by the a	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office anese patent documents, the indication of the year of the reign of the Emper appropriate symbols as indicated on the document under WIPO Standard S in is attached.	eror must precede the set	rial number of the patent doc	ument.		

Ref #	Hits	Search Query	DBs	Defa ult Oper ator	Plurals	Time Stamp
L1	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2012/03/08 16:19
L2	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 16:19
L3	3215	dainippon.as.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:20
L4	232	((pregelatinize\$1 or pregelatinise\$1) with starch).ab.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:21
L5	1	I3 and I4	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:21
L6	1	I1 and I4	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:22
S1	4	"2001076557".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2009/07/17 07:52
S2	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:53
S3	2622	pre-gelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S4	0	S2 and S3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S5	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S6	25	S2 and S5	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:55

EAST Search History	(Prior Art)
---------------------	-------------

S7	234938	oral and pharmaceutical	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S8	10067	S5 and S7	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S9	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S10	446	S9 and oral	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:02
S11	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:17
S12	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S13	1	S11 and S12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S14	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S15	86	S11 and S14	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S16	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:57

				1	1	1
S17	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S18	86	S16 and S17	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S19	1	"3607394".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2009/11/12 14:11
S20	67	(pregelatin\$4 with starch) same (polymer with binder)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:29
S21	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S22	745	S21 and (starch adj "1500")	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S23	47786	water adj solub\$4 adj polymer	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S24	43	S22 and S23	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S25	99	S21 and (PCS)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:42
S26	5	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2009/11/12 15:05
S27	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2009/11/12 15:07

S28	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S29	1747	S28 and (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S30	202	S28 with (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:15
S31	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2010/07/20 12:22
S32	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2010/07/20 12:23
\$33	84	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:24
S34	15801	pregelatin\$5 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
S35	31	S33 and S34	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
S36	23548	accugel or absorbo or actobody or alphajel or allbond or alstar or amaizo or amalean or amerikor or amicoa or amidex or amigel or amilofax or amilys or amisol or amycol or amylex or amylogel or amylogum or amylomaize or amylon or amylose	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:27
S37	0	S33 and S36	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:28
S38	1	"4600579".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2011/11/02 11:19

S39	2	"20040028741".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2012/03/08 12:35
S40	1936	(corn adj starch) with (pregelatinized adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 13:13
S41	1138	(corn adj starch) adj5 (pregelatinized adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 13:13
S42	4	"2002053140".pn.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 14:12
S43	4	"2003066039".pn.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 14:13
S44	6	"2005009999".pn.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 14:15
S45	2389	((pregelatinize\$1 or pregelatinise\$1) adj4 starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:50
S46	16953	((improve\$4 or increas\$4) adj4 (solubility or soluble)).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:51
S47	41	S45 and S46	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:51

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

	SEARCHED		
Class	Subclass	Date	Examiner

SEARCH NOTES					
Search Notes	Date	Examiner			
Inventor search in EAST, PALM	11/12/2009	S.P.			
Invention and claims search in EAST, STN	11/12/2009	S.P.			
Inventor search in EAST, PALM	7/12/2010	S.P.			
Invention and claims search in EAST, STN	7/12/2010	S.P.			
invention and claims search updated in EAST, STN	3/8/2012	S.P.			
updated inventor and assignee search in EAST, PALM	3/8/2012	S.P.			

	INTERFERENCE SEA	NRCH	
Class	Subclass	Date	Examiner

/S. P./ Examiner.Art Unit 1627	

U.S. Patent and Trademark Office

Part of Paper No. : 20111102

PTO/SB/22 (09-11) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Option	Docket Number (Optional)	
		7379/98100		
Application	Number 11/919,678		Filed October 31, 2	007
For PHA	RMACEUTICAL COMPOSITION			
Art Unit 16	27		Examiner Sarah Pih	onak
This is a req application.	uest under the provisions of 37 CFR 1.136(a) to extend the period	od for filing a reply in the	e above identified
The request	ed extension and fee are as follows (check	time period desired a	and enter the appropriate	e fee below):
_		<u>Fee</u>	Small Entity Fee	
	One month (37 CFR 1.17(a)(1))	\$150	\$75	\$
	Two months (37 CFR 1.17(a)(2))	\$560	\$280	\$
	Three months (37 CFR 1.17(a)(3))	\$1270	\$635	\$ <u>1270</u>
	Four months (37 CFR 1.17(a)(4))	\$1980	\$990	\$
	Five months (37 CFR 1.17(a)(5))	\$2690	\$1345	\$
Applica	nt claims small entity status. See 37 CFR 1	.27.		
A chec	k in the amount of the fee is enclosed.			
Payme	ent by credit card. Form PTO-2038 is at	tached.		
🔲 The Di	rector has already been authorized to c	harge fees in this a	application to a Depos	sit Account.
	rector is hereby authorized to charge a it Account Number <u>06-1135</u>	ny fees which may	be required, or credit	any overpayment, to
	NG: Information on this form may become pul credit card information and authorization on		nation should not be inclu	uded on this form.
I am the	applicant/inventor.			
	assignee of record of the entire Statement under 37 CFR 3.7			
	attorney or agent of record. Rec	gistration Number	30,368	
	attorney or agent under 37 CFF Registration number if acting under			
/Kend	rew H. Colton/		13 Septembe	r 2012
Signature			Date	
Kendrew H. Colton		(202) 419-700	00	
	Typed or printed name		Telepho	one Number
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.				
	Total of _1 forms are submitted.			
USPTO to proces complete, includi	information is required by 37 CFR 1.136(a). The inform ss) an application. Confidentiality is governed by 35 U.S. ng gathering, preparing, and submitting the completed a s amount of time you require to complete this form and/c	S.C. 122 and 37 CFR 1.11 application form to the USP	and 1.14. This collection is es TO. Time will vary depending	timated to take 6 minutes to upon the individual case. Any

U.S. Patern and Tadamark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Patent Application Fee Transmittal					
Application Number:	11	919678			
Filing Date:	31-	-Oct-2007			
Title of Invention:	Pharmaceutical composition				
First Named Inventor/Applicant Name:	Kazuyuki Fujihara				
Filer:	Kendrew H. Colton/Lois Ford				
Attorney Docket Number:	73	79/98100			
Filed as Large Entity					
U.S. National Stage under 35 USC 371 Filing	Fee	S			
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Extension-of-Time:					
Extension - 3 months with \$0 paid		1253	1	1270	1270

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Tot	al in USD	(\$)	1270

Electronic Acknowledgement Receipt				
EFS ID:	13734662			
Application Number:	11919678			
International Application Number:				
Confirmation Number:	6965			
Title of Invention:	Pharmaceutical composition			
First Named Inventor/Applicant Name:	Kazuyuki Fujihara			
Customer Number:	42798			
Filer:	Kendrew H. Colton/Lois Ford			
Filer Authorized By:	Kendrew H. Colton			
Attorney Docket Number:	7379/98100			
Receipt Date:	13-SEP-2012			
Filing Date:	31-OCT-2007			
Time Stamp:	14:14:41			
Application Type:	U.S. National Stage under 35 USC 371			

Payment information:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
File Listing:					
Authorized U	Authorized User				
Deposit Acco	unt	061135	061135		
RAM confirma	ation Number	424			
Payment was	successfully received in RAM	\$1270			
Payment Type	2	Deposit Account			
Submitted wi	th Payment	yes			

		Total Files Size (in bytes):	8	5254	
Information					
Warnings:					
-			43b033c20da766766020707e2b46725d6d 2cedaa		
2	Fee Worksheet (SB06)	fee-info.pdf	29902	no	2
Information		11			
Warnings:					
'			cf83572627e78201ebde01583e963743aa2 b14a7		1
1	Extension of Time	PetitionEOT-13Sept2012.pdf	55352	no	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:		
Kazuyuki FUJIHARA	Confirmation No.:	6965
U.S. Application No.: 11/919,678	Examiner:	PIHONAK, SARAH
Filed: October 31, 2007	Group Art Unit:	1627
: For: PHARMACEUTICAL COMPOSITION	Attorney Docket N	o.: 7379/98100

AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Kindly enter this Amendment and grant the concurrently filed Petition for Extension of Time. This Amendment should be considered together with the concurrently filed Appendix.

TABLE OF CONTENTS


1.	Amendments to Claims	2
2.	Remarks/Arguments	9

Amendments to the Claims:

This listing of claims replaces any and all prior claim lists.

Listing of Claims:

1. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

2. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

3. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble polymer binder;

wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

4. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose.

5. (Withdrawn) A method for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

6. (Withdrawn) A method for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by using a solution or dispersion of lurasidone and a water-soluble polymer binder.

7. (Withdrawn) The method of claim 5 wherein the water-soluble excipient is mannitol or lactose.

8. (Canceled)

9. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10. (Canceled)

Par Pharm., Inc. Exhibit 1015 Page 357 11. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

12. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. (Canceled)

16. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17-18. (Canceled)

19. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

20. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

21. (Previously Presented) The oral preparation of claim 1 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Currently amended) The oral preparation of claim 1 wherein an average <u>a 50% by</u> volume particle size of lurasidone is 0.1 to 8 μ m.

23. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to 40% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

25. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 20 to 45% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

26. (Previously Presented) The oral preparation of claim 9 wherein the water-soluble excipient is mannitol or lactose.

27. (Previously submitted) The oral preparation of claim 1 wherein a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt).

28. (Previously submitted) The oral preparation of claim 1 wherein the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose.

29. (Previously submitted) The oral preparation of claim 1 wherein a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

30. (Previously submitted) The oral preparation of claim 1, further comprising a disintegrant wherein a content of the disintegrant per tablet is 0.5 to 5% (wt/wt).

31. (Currently amended) The oral preparation of claim 1, further comprising a disintegrant wherein

a content of the disintegrant per tablet is 0.5 to 5% (wt/wt);

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation;

a content of lurasidone per tablet is 40 to 120 mg;

a pregelatinizing ratio of the pregelatinized starch is 50 to 95%;

an average <u>50% by volume</u> article size of lurasidone is 0.1 to 8 µm;

the pregelatinized starch contains water soluble matter of 30% or less;

a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt);

the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose; and

a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

32. (Previously submitted) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 160 mg.

33. (Previously submitted) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 80 to 160 mg.


34. (Previously submitted) The oral preparation of either one of claim 1 or 31, wherein a similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg.

35. (Withdrawn) A method for treating psychosis, comprising administering the oral preparation of claim 1 to a patient suffering from psychosis.

36. (Withdrawn) A method for treating schizophrenia, comprising administering the oral preparation of claim 1 to a patient suffering from schizophrenia.

37. (New) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 8



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder,

wherein the oral preparation contains 20 to 45% (wt/wt) of lurasidone, the oral preparation contains 20 mg to 120 mg of lurasidone, the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the oral preparation, and the oral preparation exhibits an equivalent dissolution profile across the range of lurasidone per oral preparation.

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 9

REMARKS

Applicant courteously solicits favorable reconsideration upon entry of this Amendment and consideration of the concurrently filed Appendix (evidence).

Claims Presented

Upon entry of this Amendment claims 1-7, 9, 11-14, 16, and 19-37 are presented. Claims 5-7 and 35-36 are withdrawn.

Amended claims 22 and 31 are supported by the original specification, including page 8 at the bottom (see paragraph [0015]). New claim 37 find basis in the original specification, including original claim 1 and elsewhere in the original specification, such as in paragraphs [0001], [0008], [0009] and [0013], to mention examples. The new and amended claims avoid new matter and entry thereof is courteously solicited.

Rejoinder is requested.

Applicant respectfully solicits rejoinder of the withdrawn claims 5-7 and 35-36.

Claims 1-4, 9, 11-14, 16 and 19-34 define unobvious inventions <u>over Fujihara and Salepakar.</u>

Applicants respectfully traverse the rejection of claims 1-4, 9, 11-14, 16, and 19-34 under 35 U.S.C. §103(a) over Fujihara *et al.* (EP Patent Publication No. 1327440) in view of Salpekar *et al.* (U.S. Patent No. 4,600,579).

Aspects of the claims inventions verus the references.

Aspects of the present claimed inventions involve an oral preparation that can comprise higher contents of a hardly-soluble pharmaceutically active agent (e.g. lurasidone), yet the preparation exhibits a similar dissolution profile as compared to oral preparations having different contents of such pharmaceutically active agent (*see, e.g.,* specification, paragraphs [0001], [0008]-[0009] and [0013]; the examples and FIG. 3.).

More particularly, characteristics of the present invention include:

1) the oral preparation of the present invention includes a high lurasidone content per tablet, particularly high content ratio (%) of 20 to 45% (wt/wt) of lurasidone as recited in claim 1^1 - which allows the employment of relatively high total amounts of lurasidone in a tablet of relatively small size – while, at the same time, the oral preparation exhibits beneficial dissolution properties (*see, e.g.*, paragraph [0106]);

2) the oral preparation of the present invention incorporates pregelatinized starch in a range of 10 to 50% (wt/wt) based on the weight of the preparation; and

3) the preparation of the present invention has beneficial dissolution properties, that is, it shows equivalent dissolution profiles as between oral preparations having different contents of lurasidone, as reflected by a similarity factor (f2) of $\geq 50^2$, and furthermore exhibits <u>rapid dissolution</u> (*e.g.*, a dissolution of at least 85% of the initially present lurasidone within 30 minutes).

In short, an oral preparation provides a high content ratio of lurasidone (which allows employing comparatively higher amounts of lurasidone in relatively small tablets) that, at the same time, exhibiting rapid dissolution. Equivalent dissolution profiles ($f2 \ge 50$) as between the oral preparations having different lurasidone contents is an advantage. This combination of advantageous properties results from the presence of pregelatinized starch in the claimed oral preparation in an amount of 10 to 50% (wt/wt) based on the weight of the preparation, as can be seen from the data shown in the as discussed in this Amendment.

¹ The Office Action mistakenly refers to the amounts as 25 to 45% at page 8, line 3. That amount is in dependent claims, but not independent claims 1, 2, 3 or 37.

² Dependent claim 34 provides an oral preparation according to claim 1 or 31 has a similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg.

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 11

As demonstrated below, Fujihara (the primary reference) does not teach or suggest an oral preparation which contains lurasidone in a content ratio of lurasidone of 20 to 45% (wt/wt)) (claims 1, 2 and 3) that can include, for instance, 20 mg to 120 mg lurasidone per oral preparation (dependent claim 13, independent claim 37), is completely silent on the use of pregelatinized starch, does not teach or disclose a pregelainized starch in an amount of 10 to 50% (wt/wt) based on the weight of the preparation (independent claims 1, 2, 3, and 37), and does not disclose or teach an oral preparation, such as equivalent dissolution properties obtainable with a present oral preparation, such as equivalent dissolution profiles at different contents of lurasidone³ (*see, e.g.,* claim 37), as reflected by a similarity factor (f2) of \geq 50 (note dependent claim 34), and also rapid dissolution (*e.g.,* a dissolution of at least 85% of the initially present lurasidone within 30 minutes).

As also demonstrated below, these and other shortcomings of Fujihara would not have been overcome even if, for the sake of argument, Salpekar were additionally considered, which combination would not have been made in any event.

Fujihara does not motivate towards the higher % wt/wt amounts of lurasidone.

In one of its aspects, the present invention is an oral preparation which comprises lurasidone, "wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt)" as recited in claims 1, 2, and 3, for example.

Fujihara neither discloses nor suggests the claim 1 oral preparation having a content of lurasidone in the preparation of 20 to 45% (wt/wt) and that such an oral preparation exhibits excellent dissolution profiles.

Rather, as discussed below Fujihara would have focused a person of ordinary skill on an oral composition comprising lesser amounts of lurasidone which provides dissolution characteristics.

³ In re Papesch, 137 U.S.P.Q 143 (CCPA 1963).

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 12

Based on the data shown in Figure 1 attached to the original specification and the data from original Tables 26 to 28 in the original specification, data is summarized and presented for convenience in the following Table 1. The 30-minutes dissolution values are provided as a courtesy and were calculated based on the data shown in the original specification.

Table 1
Comparative formulations which do not contain pregelatinized starch
based on Fujihara et al. formulations*

	Α	В
(mg/tablet)	10 mg tablet	40 mg tablet
	Fig. 1, Tables	Fig. 1, Tables 26-28 (Comp.
	26-28	Ex.1)
Lurasidone	10	40
Mannitol	47	188
Croscarmellose Na	4	16
Hydroxypropyl Methylcellulose	2.5	10
Lactose	15.5	62
Magnesium Stearate	1	4
f2	77	
	(A vs. B)	
Lurasidone Content Ratio (%)	12.5%	12.5%
(in core tablet)		
Lurasidone Content Ratio (%)(in FC tablet)	12.2%	12.3%
30-minute dissolution values	91%	92%

* Tablets in Table 1 were manufactured according to Fujihara as the Examiner will see from Test 7 in the original specification. Fujihara (as cited by the Examiner) is the same as the patent document 2 in the original specification.

The data in Table 1 make the case that in formulations "A" and "B," the smaller content ratio of lurasidone such as 12.2% and 12.3%, falls outside of the range of 20 to 45% (wt/wt) in independent claims 1, 2, 3 and 37, as well as the "25 to 40%" in dependent claims 11, 16, 19, 24, 25, which additionally means the amount lurasidone in milligrams (mg) in formulations A and B must be distinct from the range recited in dependent claims 12-14 and 31-34 as well as independent claim 37.

Furthermore, the Fujihara preparations have a considerably smaller content ratio of lurasidone per oral preparation than the presently claimed formulations. The Fujihara preparations would make it necessary to prepare comparatively larger-sized tablets or to administer several tablets in order to treat patients in need of higher doses of lurasidone as compared to an oral preparation of the present invention. *See, e.g.,* specification at paragraph [0005].

Fujihara teaches against higher amounts of lurasidone in an oral preparation.

Fujihara discloses that tablets comprising 8.13-16.3% (wt/wt) of lurasidone may have advantageous dissolution characteristics, but does not disclose a tablet comprising more than 16.3% (wt/wt) of lurasidone showing remarkable dissolution profiles. The Fujihara preparations with the low content of luradisone per preparation may show similar dissolution profiles (f2-value of 77) and rapid dissolution (30-minute dissolution ratio values of 91% and 92%, respectively).

The same may not be said for an oral preparation of Fujihara having a higher lurasidone content.

This is clearly seen from Fujihara's tablets in Comparative Examples 1-3, including a tablet comprising 29% of lurasidone (Comparative Example 3), as they are significantly *inferior* to the corresponding FC tablets of Examples 2-28 which comprise 8.13-16.3% (wt/wt) of lurasidone in terms of the dissolution characteristics (see [0185], [0191] and [0197]). The person of ordinary skill in the art would have focused on opportunity for positive results, and thus focused on the tablets with 8.13-16.3% (wt/wt) of lurasidone as in Fujihara's Examples 2-28

This is borne out in Test 1 (Tables 1-5, Figure 2 and Comparative Examples 1 and 2) of the original description, two tablets of Comparative Example 1 and 2 were prepared according to Fujihara's method and comprised lurasidone in the weight of 12.3% and 24.7%, respectively. According to Test 1, Fujihara's tablet comprising 24.7%

of lurasidone (80 mg tablet) clearly shows *lower* dissolution profile than that comprising 12.3% of lurasidone in 15 minutes (see Figure 2, Table 4, [0039]).

The data reported support the proposition that teaches away from independent claims 1, 2, 3 and 37, as well as the claims dependent from claim 1.

Contrary to Fujihara, oral preparations of the present invention exhibited consistent 30 minute dissolution profiles as between for oral preparations <u>containing different amounts of lurasidone in the claimed range.</u>

Based on the data disclosed in Examples 1 to 3 as well as in Table 4 in the original description, data are summarized and presented in the following Table 2 for convenience. The 30-minutes dissolution values are provided as a courtesy and were calculated based on the data shown in the original specification.

	E	G	F	G	
(mg/tablet)	Ex.3	Ex.1	Ex.2	Ex.1	
	Table 4	Table 4	Table 4	Table 4	
Lurasidone	20	80	40	80	
Mannitol	36	144	72	144	
Pregelatinized starch	20	80	40	80	
Croscarmellose Na	1	4	2	4	
Hydroxypropyl Methylcellulose	2	8	4	8	
Magnesium Stearate	1	4	2	4	
f2	97		97 88		
	(E vs. G)		(E vs. G) (F vs. 4		vs. G)
Lurasidone Content Ratio (%) (in core tablet)	25%	25%	25%	25%	
Lurasidone Content Ratio (%) (in FC tablet)	24.4%	24.6%	24.5%	24.6%	
30-minute dissolution values	<u>89%</u>	<u>89%</u>	<u>91%</u>	89%	

Table 2Formulations according to the presently claimed invention which containpregelatinized starch

As can be seen from Table 2, the formulations of Examples 1 to 3 according to the claimed invention – with different mg contents of lurasidone and a content of lurasidone in the preparation within the range of "20 to 45% (wt/wt), show 30-minutes dissolution ratio values of 89% (Example 1/formulation "G"), 91% (Example 2/formulation "F") and 89% (Example 3/formulation "E"), respectively. The formulations of Examples 1 to 3 can thus be considered to show <u>rapid dissolution</u>, in accordance with the U.S. FDA reference document "Guidance for Industry" which is enclosed. The latter document explains that "*an IR* [*i.e., immediate-release*] *drug product is considered rapidly dissolving when no less than 85% of the labeled amount of the drug substance dissolves within 30 minutes (...).*" *See* the concurrently filed Appendix, at 1 (Guidance for Industry, paragraph bridging pages 2 and 3, entitled "C. Dissolution").

A present oral preparation has favorable dissolution rates and similar dissolution profiles between tablets (see Test 1, Figure 3, the specification at Tables 1-3, 13). As shown in Figure 3, dissolution rates of three tablets are more than 80% in 15 minutes. Table 4 and Figure 3 show that these tablets have similar dissolution profiles even at a lurasidone content greater than disclosed in Fujihara.

Whereas Fujihara does not disclose compositions comprising more than 16.3% (wt/wt) of lurasidone which show advantageous dissolution profiles as it only discloses those comprising 16.3% (wt/wt) or less of lurasidone, the instant invention provides an oral preparation having "a content of lurasidone of 20% to 45% (wt/wt)," which shows a remarkably advantageous dissolution profile even at when the lurasidone content is greater than disclosed in Fujihara.

In short, oral preparations of the present invention are superior to the known preparations according to Fujihara that contain smaller ratio content (amount) of lurasidone per preparation as illustrated by comparing the data for formulations "A" and "B" in Table 1 hereinabove with the data for the formulations "E" to "G" in Table 2 hereinabove.

Oral preparations of the present invention advantageously mean a smallersized oral preparation for a given lurasidone content. A smaller sized oral preparation for a given lurasidone content would be more advantageous than an oral preparation having a like lurasidone content according to Fujihara.

Oral preparations of the present invention, such as seen from formulations "E", "F" and "G", are advantageous as compared to comparative formulations "A" and "B" according to Fujihara. The present oral preparations have a greater content ratio of lurasidone and thus a higher total amount of lurasidone per tablet of a given size as compared to Fujihara.

This can be conveniently illustrated by reference to the total weights and sizes required for tablets having a lurasidone content of, *e.g.*, 80 mg/tablet, 120 mg/tablet or 160 mg/tablet, which are prepared from either a comparative formulation (i.e. formulation "B"; Comparative Example 1, having a lurasidone content ratio of 12.3%) or formulation "G" (i.e. Example 1 according to the invention, having a lurasidone content ratio of 24.6%).

Large tablets are difficult to swallow, which places increased burden on the patients and can therefore be expected to prejudice patient compliance. *See, e.g.,* specification, paragraphs [0005] and [0013]. This is germane because if tablets containing a high total amount of lurasidone are prepared on the basis of the comparative formulation B of Fujihara, the total weight of the resulting tablets would amount to 648 mg (80 mg lurasidone/tablet), 972 mg (120 mg lurasidone/tablet) and 1296 mg (160 mg lurasidone/tablet), respectively, with sizes of 12.5 mm, 14.5 mm and 16 mm in diameter as conventional round tablets. Such large sized round tablets prepared according to the comparative formulation B of Fujihara would be expected to present issues with patient compliance.

On the other hand, an oral preparation according to an aspect of the present invention can have a higher content of lurasidone per oral preparation, in a smallersized oral preparation (such as a round tablet) as compared to Fujihara, whereby prospects of patient non-compliance due to oral preparation size would be reduced. This is illustrated when considering tablet sizes for larger dosages of lurasidone in a tablet prepared according to formulation G. Thus, if tablets having a lurasidone content of 80 mg/tablet, 120 mg/tablet or 160 mg/tablet are prepared using formulation "G" (*i.e.*, Example 1 according to the invention), resulting tablets would have total weights of only 325 mg (80 mg lurasidone/tablet), 487.5 mg (120 mg lurasidone/tablet) and 650 mg (160 mg lurasidone/tablet) and, in the case of conventional round tablets, diameters of 10 mm, 11.5 mm and 12.5 mm, respectively. In perspective, an oral preparation formed into a conventional round tablet having 180 mg of lurasidone would be about the same size as a round tablet having 80 mg of lurasidone prepared according to a tablet having 180 mg of lurasidone prepared according to a tablet having 180 mg of lurasidone prepared to prepared tablet having 1

From another perspective, if similarly sized round tablets are considered, with an oral preparation of the present invention the number of tablets to be administered to a patient to dose a given amount of lurasidone, especially if a high amount of lurasidone needs to be administered to a patient, can be reduced compared to the number of tablets required with a similarly sized conventional tablet with a lurasidone content according to Fujihara.

Furthermore, the relevancy of an increased content ratio of lurasidone is emphasized from as seen from the News Release at page 1, first and third paragraphs, where new recommended dosage ranges are expanded to 120 mg/day and 160 mg/day, and an approval for a new tablet having 120 mg lurasidone. *See* concurrently filed Appendix at item 3.

Present oral compositions having PGS versus an oral preparation without PGS show results supporting patentability.

The data shown in the following Table 3 are summarized from the data of Example 4 in the original description and a comparative formulation (prepared in the same manner as in Example 4 except the pregelatinized starch was used 0(zero) % and instead the amount of sodium croscarmellose was increased).

Components	Example 4 of the original specification		Comparative formulation	
	mg	wt/wt%	mg	wt/wt%
Lurasidone	80	25	80	25
Mannitol	176	55	176	55
PGS (pregelatinized starch)	40	12.5	0	0
Ac-Di-Sol (Croscarmellose Na)	8	2.5	48	15
HPMC (Hypromellose, Hydroxypropyl methylcellulose)	12	3.75	12	3.75
Magnesium stearate	4	1.25	4	1.25
Total	320	100	320	100
30-minute dissolution values	86%		^m 86% 70%	

Table 3

As can be seen from Table 3, the 30-minute dissolution value of the tablet according to the present invention is 86% which is significantly better than the value of 70% which is achieved by the comparative formulation which does not contain pregelatinized starch. This comparative formulation did not satisfy the explanation of an immediate-release drug product in the Guidance for Industry. *See* concurrently filed Appendix, at item 1, and the paragraph bridging pages 2 and 3, entitled "C. Dissolution."

Applicant respectfully submits the evidence shows that good dissolution can be achieved by the claimed selection of pregelatized starch compared to croscarmellose.

Fujihara does not teach or suggest the pregelatinzed starch in the claims.

Claim 1 refers to an oral preparation containing "a pregelatinized starch, ...wherein ... the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation." *See also* independent claims 2, 3 and 37.

Dependent claim 9 refers to an oral preparation wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation. *See also* dependent claims 19, 20, 24, 25, and 31.

Fujihara is completely silent on the use of pregelatinized starch or on the advantages to an oral preparation having the pregelatinized startch incorporated in an amount of 10 to 50% (wt/wt).

Accordingly, the advantageous dissolution profiles for a present oral preparation having a higher content ratio of lurasidone, with the recited amount of pregelatinized starch, is neither taught nor suggested by Fujihara.

Fujihara's shortcomings are not overcome, even if, for the sake of argument it were combined with Salpekar, which is a combination that would *not* have been made by a person of ordinary skill in the art.

Fujihara in view of Salpekar nonetheless would not have provided motivation towards the claimed inventions.

As demonstrated below, this follows since Salpekar *et al.* teaches a specific composition comprising acetaminophen as the pharmaceutically active ingredient and pregelatinized starch, which is significantly more water soluble compared to the relatively water insoluble lurasidone, and even if *arguendo* some of Salpekar's

acetaminophen-containing compositions having other additives and amounts may allow a shorter dissolution time and may shorten the dissolution and disintegration time.

Selpekar teaches away from the pregelatinized starch in an <u>amount of 10 to 50% (wt/wt) based on the weight of the preparation.</u>

Claim 1 recites "the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation."

Salpekar effectively teaches away from this feature in claim 1 and other claims 2, 3, and 37 as examples.

<u>First</u>, Sepekar teaches that only a combination of small amounts of pregelatinzed starch ("PGS"), such as 8.85 % or 6.4%, <u>and</u> at least an auxiliary binder disclosed can improve disintegration time in the acetaminophen tablets. Sepekar's disclosed value of 8.85% or 6.4% would not have suggested an oral composition containing lurasidone and pregelatinized starch incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

<u>Second</u>, Salpekar's Examples and related disclosures show that larger amounts of pregelatinized starch, such as the 18.0% in Example 1, do not improve the disintegration time and the dissolution profile of the acetaminophen-containing tablet.

The poorer results reported with 18% pregelatinized starch would have led away from claim 1. More particularly, Salpekar's Examples 1-3 are teach away from the amount of pregelatinized starch in the present claims.⁴ From the Table in column 8 and taking col. 4, lines 3-9 into consideration, the Example 1 tablet (18.0% of PGS) is not acceptable in order to solve Salpekar's problem, since the disintegration time of Example 1 tablet is 18.0 minutes which is 300% times longer than that the Example 2 tablet (6 minutes) and

⁴ Salpekar explains at column 8, lines 44-49 that "As indicated in these examples, Example 1 contains neither auxiliary binder nor auxiliary disintegrating agent; Example 2 includes an auxiliary binder but no auxiliary disintegrating agent; and Example 3 includes both an auxiliary binder and an auxiliary disintegrating agent."

1200% times longer than the Example 3 tablet (1.5 minutes). Even the Example 2 tablet comprising 8.85% of PGS is more disadvantageous since it shows a 400% times longer disintegration time than exhibited by a tablet according to Salpekar's Example 3.

Thus, a present oral preparation having pregelatinized starch incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation would <u>not</u> have been suggested by the poorer results reported for Sepekar's Example 3 (18% of PGS) (*e.g.*, an increased disintegration time for the acetaminophen containing composition). Increasing the amount of pregelatinized starch would have suggested longer, not shorter disintegration times in an acetominophen tablet, but longer disintegration times would have been contrary to Salpekar's stated objective for disintegration times (col. 4, lines 3-9).

<u>Third</u>, even if, for the sake of argument, Salpekar *et al.* were combined with Fujihara, a person skilled in the art would not have arrived at the pregelatinized starch (10 to 50% (wt/wt)) in the independent claims. Those skilled in the art would have understood from Salpekar that 4.45-8.85% of pregelatinized starch is preferable for an acetaminophen tablet having a short disintegration time and a short dissolution time. Although Salpekar might be said to teach an effective amount of pregelatinized starch (PGS) is from about 5 or less to about 15 or more parts per 100 parts of the acetaminophen composition (see, col. 4, lines 15-17), Salpekar's acetaminophen compositions that show technical effects are only those supported by Examples 2 and 3 (*i.e.*, 4.45-8.85% of pregelatinized starch). This follows from Salpekar's disclosure that the pregelatized starch is included in an amount effective for imparting to the acetaminophen composition the capability of being formed into tablets having high hardness, short disintegration time (e.g., about 10 minutes or less) and short dissolution time (e.g., about 20 minutes or less). See, col. 4, lines 3-9. In other words, Fujihara + Salpekar, even if the combination were made, which is not conceded, a person of ordinary skill in the art would have been led away from the claimed oral preparations.

Literature reports pregelatinized starch (PGS) in amounts that would have taught away from the claimed oral preparation having 10 to 50% (wt/wt) of pregelatinized starch. The literature reports typically 10% or less of PGS as <u>does Salpekar</u>.

As reported in the present specification, pregelatinized starch "is often used, typically, in 10% <u>or less</u> of contents as described in Non-patent Document 1." See, e.g., specification, paragraph s [0006] and [0007] (emphasis added). See also, concurrently filed Appendix at item 2.

This supports the point that typically (conventionally) *less* than 10% (wt/wt) pregelatinized starch would have been used, which is consistent with the results Selpaker disclosed for the acetaminophen compositions.

This conventional teaching would have led away from the present oral preparations.

Sepekar discloses acetaminophen. It is markedly much more water soluble than the comparatively water insoluble lurasidone. Sepekar's results with only acetaminophen would not have led one to expect the present results obtained with the comparatively highly water *in*soluble ingredient (lurasidone), nor led to combining it with Fujihara.

Salpekar exclusively focuses on the comparatively water soluble acetaminophen⁵ would not have motivated a person of ordinary skill in the art would towards an oral preparation having 10 to 50% (wt/wt) of pregelatinized starch and the comparatively water <u>in</u>soluble lurasidone as recited in the claims.

There is no evidence cited in the Office Action to suggest relating acetaminophen with lurasidone, nor evidence suggesting Sepekar's results with the former would have

⁵ Salpekar specifically and only focuses on the requirements for an acetaminophen composition. Selpekar "relates to an N-acetyl-p-amino-phenol composition" (col. 1, lines 6-7) in which "N-acetyl-p-aminophenol [is] ... hereinafter referred to sometimes as acetaminophen..."). Selpekar, col. 1, lines 11-12.

been the candidate of choice selected in discovering an oral preparation as claimed. The compounds are different. Their properties are different.

The Examiner, however, cites passages in Salpekar at col. 3, lines 46-51 and col. 4, lines 31-37, see, e.g., Office Action, page 5, lines 6-9 from the bottom, as if these passages were generic, which they are not.

Contrary to the Office Action, the actual passages in Salpekar specifically only relate to "<u>the</u> composition," which must contain acetaminophen. *See, e.g.*, Selpekar, Abstract, col. 1, lines 6-29, col. 1, lines 38 and 63, col. 2, line 21, col. 5, line 48, col. 6, (Tables), and the Examples.

Since Salpekar relates only to a comparatively soluble agent "acetaminophen," <u>not</u> to the hardly-soluble agent (lurasidone) in the claimed oral preparations, it would have been <u>um</u>reasonable to expect Salpekar's disclosure regarding an acetaminophen composition to be appropriate for an oral preparation having a "content of [the comparatively hardly soluble] lurasidone ... [of] 20 to 45% (wt/wt)," as claimed herein.

In other words, on the present factual record, there would have been no basis to have expected Selpekar's results with acetaminophen, which is a comparatively more water soluble agent would even have made Salpekar the candidate of choice for, let alone applicable, to a lurasidone composition as in Fujihara since lurasidone is comparatively significantly more water *in*soluble because it is 1/62.5 as soluble as acetaminophen.⁶

⁶ <u>Acetaminophen</u> has an experimental water solubility of <u>14 mg/mL</u> (DrugBank (http://www.drugbank.ca/drugs/DB00316), see the attachment to prior Amendment).

<u>Lurasidone</u>, however, has a water solubility of only <u>0.224 mg/mL</u> at 20°C, which more than an order of magnitude less than that for acetaminophen.

Salpekar teaches amounts of a water soluble active ingredient that would not have suggested the amounts of relatively water insoluble active ingredient (lurasidone) in the present oral compositions.

The higher contents of the different material in Salpekar teach away from the claim 1 oral preparation with an oral preparation having "a content of lurasidone in the preparation [of] 20 to 45% (wt/wt)" as in claim 1, as an example.

Salpekar discloses a preferred embodiment is a composition comprising 93-83% of acetaminophen (see line 63, column 5 to line 9, column 6). Those skilled in the art would have had no expectation or motivation to apply Salpekar's formulation for acetaminophen with extremely high contents (93-83%) of that active ingredient to tablets comprising the comparatively water <u>insoluble</u> lurasidone in order to solve the problem of the undesired dissolution profiles of lurasidone in a conventional composition.

Applicant traverses the common law obviousness type double patenting rejection. Applicant requests reconsideration and withdrawal of same.

Applicant respectfully requests the Examiner to reconsider the non-statutory rejection of claims 1-4, 9, 11-14, and 19-34 over commonly owned U.S. application 12/997779 and claims 1-8 therein. This application is the earlier filed application (series "11" application) and the common law rejection over claims in a later filed application seems misplaced, and besides, such claims might be canceled or amended, or other action taken. Withdrawal of this non-statutory rejection seems appropriate and is respectfully requested.

Conclusion

Applicant respectfully solicits reconsideration and a Notice of Allowance.

Applicant has found that it is possible to provide an oral preparation having a lurasidone content in the preparation of 20 to 45% (wt/wt.) in combination with 10 to 50% (wt/wt) pregelatinized starch that provides advantageous dissolution profiles.

None of the prior art documents applied against the claims would have taught or suggested this oral preparation or its advantages.

Fujihara does not disclose or suggest a lurasidone formulation incorporated with a comparatively large amount (10 to 50% (wt/wt) based on the preparation) of a pregelatinized starch which can exhibit excellent dissolution properties, such equivalent dissolution profiles at different contents of lurasidone (as reflected by a similar factor (f2) of \geq 50) and rapid dissolution (e.g. a dissolution of at least 85% of the initially present lurasidone within 30 minutes).

Salpekar's acetomimophen compositions are not apposite to the present oral preparations or to Fujihara, do not teach or even suggest any lurasidone oral preparation, and when fairly considered teach away the incorporation of the comparatively larger amount of the pregelatinized starch into an oral preparation because of undesirable disintegration times.

Even if Fujihara were combined with Salpekar et al., which is a point not conceded, the present claimed oral preparations with their advantages would have been *un*foreseen or *un*expected by a person skilled in the art.

The Examiner is cordially invited to telephone the undersigned with any comments, suggestions or questions, or to schedule an interview.

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 26

Applicant hereby requests that any concurrent or future reply submitted by Applicants to the U.S. Patent and Trademark Office in connection with the aboveidentified patent application requiring an extension of time under 37 C.F.R. §1.136(a) for its timely submission be treated as incorporating therein a request for an extension of time for the appropriate length of time. In addition, to the extent necessary during prosecution of the present application, Applicant hereby authorizes the Commissioner to charge any required fee not otherwise provided for, including application processing, extension, and extra claims fees, to Deposit Account No. 06-1135 with reference to Attorney Docket No. **7379/98100**.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

/Kendrew H. Colton/

Kendrew H. Colton Registration No. 30,368

Please send official correspondence to: **Customer Number 42798**

FITCH, EVEN, TABIN & FLANNERY 1120 20th St., NW, Suite 750 South Washington, DC 20036 Tel: (202) 419-7000 Fax: (202) 419-7007

Attorney Docket No.: 7379/98100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	:	
Kazuyuki FUJIHARA	: Confirmation No.:	6965
U.S. Application No.: 11/919,678	: Examiner:	PIHONAK, SARAH
Filed: October 31, 2007	: Group Art Unit:	1627

For: PHARMACEUTICAL COMPOSITION

APPENDIX

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Kindly enter this APPENDIX (evidence) and consider same with the Amendment filed on even date herewith.

CONTENTS

- 1. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System, U.S. D.H.S., FDA, pp. 1-13 (August 2000)
- 2. Pregelatinized Starch, Handbook of Pharmaceutical Excipients, 2nd Ed., pp. 491-493 (1994)
- 3. News Release from Sunovion Pharmaceuticals Inc. (May 2012)

The Examiner is cordially invited to telephone the undersigned with any comments, suggestions or questions concerning the application.

Applicant hereby requests that any concurrent or future reply submitted by Applicants to the U.S. Patent and Trademark Office in connection with the aboveidentified patent application requiring an extension of time under 37 C.F.R. §1.136(a) for its timely submission be treated as incorporating therein a request for an extension of time for the appropriate length of time. In addition, to the extent necessary during prosecution of the present application, Applicants hereby authorize the Commissioner to charge any required fee not otherwise provided for, including application processing, extension, and extra claims fees, to Deposit Account No. 06-1135 with reference to Attorney Docket No. **7379/98100**.

> Respectfully submitted, FITCH, EVEN, TABIN & FLANNERY

> > /Kendrew H. Colton/

Kendrew H. Colton Registration No. 30,368

Please send official correspondence to: **Customer Number 42798**

FITCH, EVEN, TABIN & FLANNERY 1120 20th St., NW, Suite 750 South Washington, DC 20036 Tel: (202) 419-7000 Fax: (202) 419-7007

Guidance for Industry

Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) August 2000 BP

C:\Documents and Settings\STAUFFERP\Desktop\3618FNL.DOC 02/03/05

Guidance for Industry

Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System

Additional copies are available from:

Office of Training and Communications Division of Communications Management Drug Information Branch, HFD-210 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573

(Internet) http://www.fda.gov/cder/guidance/index.htm

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) August 2000 BP

TABLE OF CONTENTS

I.	INTRODUCTION 1
II.	THE BIOPHARMACEUTICS CLASSIFICATION SYSTEM 1
A B C	PERMEABILITY
ПІ.	METHODOLOGY FOR CLASSIFYING A DRUG SUBSTANCE AND FOR DETERMINING THE DISSOLUTION CHARACTERISTICS OF A DRUG PRODUCT 3
A B C	
IV.	ADDITIONAL CONSIDERATIONS FOR REQUESTING A BIOWAIVER 8
A B C	Prodrugs
v.	REGULATORY APPLICATIONS OF THE BCS
A B C	ANDAS
VI.	DATA TO SUPPORT A REQUEST FOR BIOWAIVERS 10
A B C D	DATA SUPPORTING HIGH PERMEABILITY
AT?	ACHMENT A

.

GUIDANCE FOR INDUSTRY¹

Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System

I. INTRODUCTION

This guidance provides recommendations for sponsors of investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplements to these applications who wish to request a waiver of in vivo bioavailability (BA) and/or bioequivalence (BE) studies for immediate release (IR) solid oral dosage forms. These waivers are intended to apply to (1) subsequent in vivo BA or BE studies of formulations after the initial establishment of the in vivo BA of IR dosage forms during the IND period, and (2) in vivo BE studies of IR dosage forms in ANDAs. Regulations at 21 CFR part 320 address the requirements for bioavailability (BA) and BE data for approval of drug applications and supplemental applications. Provision for waivers of in vivo BA/BE studies (biowaivers) under certain conditions is provided at 21 CFR 320.22. This guidance explains when biowaivers can be requested for IR solid oral dosage forms based on an approach termed the Biopharmaceutics Classification System (BCS).

II. THE BIOPHARMACEUTICS CLASSIFICATION SYSTEM

The BCS is a scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability. When combined with the dissolution of the drug product, the BCS takes into account three major factors that govern the rate and extent of drug absorption from IR solid oral dosage forms: dissolution, solubility, and intestinal permeability.² According to the BCS, drug substances are classified as follows:

Class 1:	High Solubility – High Permeability
Class 2:	Low Solubility – High Permeability
Class 3:	High Solubility – Low Permeability

¹ This guidance has been prepared by the Biopharmaceutics Classification System Working Group of the Biopharmaceutics Coordinating Committee in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). This guidance represents the Agency's current thinking on the topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such an approach satisfies the requirements of the applicable statutes, regulations, or both.

²Amidon, G. L., H. Lennernäs, V. P. Shah, and J. R. Crison, IA Theoretical Basis For a Biopharmaceutics Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability, *I Pharmaceutical Research*, 12: 413-420 (1995).

Class 4: Low Solubility – Low Permeability

In addition, IR solid oral dosage forms are categorized as having rapid or slow dissolution. Within this framework, when certain criteria are met, the BCS can be used as a drug development tool to help sponsors justify requests for biowaivers.

Observed in vivo differences in the rate and extent of absorption of a drug from two pharmaceutically equivalent solid oral products may be due to differences in drug dissolution in vivo.² However, when the in vivo dissolution of an IR solid oral dosage form is rapid in relation to gastric emptying and the drug has high permeability, the rate and extent of drug absorption is unlikely to be dependent on drug dissolution and/or gastrointestinal transit time. Under such circumstances, demonstration of in vivo BA or BE may not be necessary for drug products containing Class 1 drug substances, as long as the inactive ingredients. The BCS approach outlined in this guidance can be used to justify biowaivers for *highly soluble* and *highly permeable* drug substances (i.e., Class 1) in IR solid oral dosage forms that exhibit *rapid in vitro dissolution* using the recommended test methods (21 CFR 320.22(e)). The recommended methods for determining solubility, permeability, and in vitro dissolution are discussed below.

A. Solubility

The solubility class boundary is based on the highest dose strength of an IR product that is the subject of a biowaiver request. A drug substance is considered *highly soluble* when the highest dose strength is soluble in 250 ml or less of aqueous media over the pH range of 1-7.5. The volume estimate of 250 ml is derived from typical BE study protocols that prescribe administration of a drug product to fasting human volunteers with a glass (about 8 ounces) of water.

B. Permeability

The permeability class boundary is based indirectly on the extent of absorption (fraction of dose absorbed, not systemic BA) of a drug substance in humans and directly on measurements of the rate of mass transfer across human intestinal membrane. Alternatively, nonhuman systems capable of predicting the extent of drug absorption in humans can be used (e.g., in vitro epithelial cell culture methods). In the absence of evidence suggesting instability in the gastrointestinal tract, a drug substance is considered to be *highly permeable* when the extent of absorption in humans is determined to be 90% or more of an administered dose based on a mass balance determination or in comparison to an intravenous reference dose.

C. Dissolution

In this guidance, an IR drug product is considered *rapidly dissolving* when no less than 85% of the labeled amount of the drug substance dissolves within 30

minutes, using U.S. Pharmacopeia (USP) Apparatus I at 100 rpm (or Apparatus II at 50 rpm) in a volume of 900 ml or less in each of the following media: (1) 0.1 N HCl or Simulated Gastric Fluid USP without enzymes; (2) a pH 4.5 buffer; and (3) a pH 6.8 buffer or Simulated Intestinal Fluid USP without enzymes.

III. METHODOLOGY FOR CLASSIFYING A DRUG SUBSTANCE AND FOR DETERMINING THE DISSOLUTION CHARACTERISTICS OF A DRUG PRODUCT

The following approaches are recommended for classifying a drug substance and determining the dissolution characteristics of an IR drug product according to the BCS:

A. Determining Drug Substance Solubility Class

An objective of the BCS approach is to determine the equilibrium solubility of a drug substance under physiological pH conditions. The pH-solubility profile of the test drug substance should be determined at $37 \pm 1^{\circ}$ C in aqueous media with a pH in the range of 1-7.5. A sufficient number of pH conditions should be evaluated to accurately define the pH-solubility profile. The number of pH conditions for a solubility determination can be based on the ionization characteristics of the test drug substance. For example, when the pKa of a drug is in the range of 3-5, solubility should be determined at pH = pKa, pH = pKa + 1, pH = pKa-1, and at pH = 1 and 7.5. A minimum of three replicate determinations of solubility in each pH condition is recommended. Depending on study variability, additional replication may be necessary to provide a reliable estimate of solubility. Standard buffer solutions described in the USP are considered appropriate for use in solubility studies. If these buffers are not suitable for physical or chemical reasons, other buffer solutions can be used. Solution pH should be verified after addition of the drug substance to a buffer. Methods other than the traditional shake-flask method, such as acid or base titration methods, can also be used with justification to support the ability of such methods to predict equilibrium solubility of the test drug substance. Concentration of the drug substance in selected buffers (or pH conditions) should be determined using a validated stability-indicating assay that can distinguish the drug substance from its degradation products.³ If degradation of the drug substance is observed as a function of buffer composition and/or pH, it should be reported along with other stability data recommended in section III.B.3.

The solubility class should be determined by calculating the volume of an aqueous medium sufficient to dissolve the highest dose strength in the pH range of 1-7.5. A drug substance should be classified as highly soluble when the highest dose strength is soluble in ≤ 250 ml of aqueous media over the pH range of 1-7.5.

³ See the FDA guidance for industry on *Submitting Documentation for the Stability of Human Drugs and Biologics* (February 1987), posted at http://www.fda.gov/guidance/index.htm.

B. Determining Drug Substance Permeability Class

The permeability class of a drug substance can be determined in human subjects using mass balance, absolute BA, or intestinal perfusion approaches. Recommended methods not involving human subjects include in vivo or in situ intestinal perfusion in a suitable animal model (e.g., rats), and/or in vitro permeability methods using excised intestinal tissues, or monolayers of suitable epithelial cells. In many cases, a single method may be sufficient (e.g., when the absolute BA is 90% or more, or when 90% or more of the administered drug is recovered in urine). When a single method fails to conclusively demonstrate a permeability classification, two different methods may be advisable. Chemical structure and/or certain physicochemical attributes of a drug substance (e.g., partition coefficient in suitable systems) can provide useful information about its permeability characteristics. Sponsors may wish to consider use of such information to further support a classification.

1. Pharmacokinetic Studies in Humans

a. Mass Balance Studies

Pharmacokinetic mass balance studies using unlabeled, stable isotopes or a radiolabeled drug substance can be used to document the extent of absorption of a drug. Depending on the variability of the studies, a sufficient number of subjects should be enrolled to provide a reliable estimate of extent of absorption. Because this method can provide highly variable estimates of drug absorption for many drugs, other methods described below may be preferable.

b. Absolute Bioavailability Studies

Oral BA determination using intravenous administration as a reference can be used. Depending on the variability of the studies, a sufficient number of subjects should be enrolled in a study to provide a reliable estimate of the extent of absorption. When the absolute BA of a drug is shown to be 90% or more, additional data to document drug stability in the gastrointestinal fluid is not necessary.

2. Intestinal Permeability Methods

The following methods can be used to determine the permeability of a drug substance from the gastrointestinal tract: (1) in vivo intestinal perfusion studies in humans; (2) in vivo or in situ intestinal perfusion studies using suitable animal models; (3) in vitro permeation studies using excised human or animal intestinal tissues; or (4) in vitro permeation studies across a monolayer of cultured epithelial cells.

In vivo or in situ animal models and in vitro methods, such as those using cultured monolayers of animal or human epithelial cells, are considered appropriate for passively transported drugs. The observed low permeability of some drug substances in humans could be caused by efflux of drugs via membrane transporters such as P-glycoprotein (P-gp). When the efflux transporters are absent in these models, or their degree of expression is low compared to that in humans, there may be a greater likelihood of misclassification of permeability class for a drug subject to efflux compared to a drug transported passively. Expression of known transporters in selected study systems should be characterized. Functional expression of efflux systems (e.g., P-gp) can be demonstrated with techniques such as bidirectional transport studies, demonstrating a higher rate of transport in the basolateral-to-apical direction as compared to apical-to-basolateral direction using selected model drugs or chemicals at concentrations that do not saturate the efflux system (e.g., cyclosporin A, vinblastine, rhodamine 123). An acceptance criterion for intestinal efflux that should be present in a test system cannot be set at this time. Instead, this guidance recommends limiting the use of nonhuman permeability test methods for drug substances that are transported by passive mechanisms. Pharmacokinetic studies on dose linearity or proportionality may provide useful information for evaluating the relevance of observed in vitro efflux of a drug. For example, there may be fewer concerns associated with the use of in vitro methods for a drug that has a higher rate of transport in the basolateral-to-apical direction at low drug concentrations but exhibits linear pharmacokinetics in humans.

For application of the BCS, an apparent passive transport mechanism can be assumed when one of the following conditions is satisfied:

- A linear (pharmacokinetic) relationship between the dose (e.g., relevant clinical dose range) and measures of BA (area under the concentration-time curve) of a drug is demonstrated in humans
- Lack of dependence of the measured in vivo or in situ permeability is demonstrated in an animal model on initial drug concentration (e.g., 0.01, 0.1, and 1 times the highest dose strength dissolved in 250 ml) in the perfusion fluid
- Lack of dependence of the measured in vitro permeability on initial drug concentration (e.g., 0.01, 0.1, and 1 times the highest dose strength dissolved in 250 ml) is demonstrated in donor fluid and transport direction (e.g., no statistically significant difference in the rate of transport between the apical-to-basolateral and basolateral-to-apical direction for the drug concentrations selected) using a suitable in vitro cell culture method that has been shown to express known efflux transporters (e.g., P-gp)

To demonstrate suitability of a permeability method intended for application of the BCS, a rank-order relationship between test permeability values and the extent of drug absorption data in human subjects should be established using a sufficient number of model drugs. For in vivo intestinal perfusion studies in humans, six model drugs are recommended. For in vivo or in situ intestinal perfusion studies in animals and for in vitro cell culture methods, twenty model drugs are recommended. Depending on study variability, a sufficient number of subjects, animals, excised tissue samples, or cell monolayers should be used in a study to provide a reliable estimate of drug permeability. This relationship should allow precise differentiation between drug substances of low and high intestinal permeability attributes.

For demonstration of suitability of a method, model drugs should represent a range of low (e.g., < 50%), moderate (e.g., 50 - 89%), and high ($\ge 90\%$) absorption. Sponsors may select compounds from the list of drugs and/or chemicals provided in Attachment A or they may choose to select other drugs for which there is information available on mechanism of absorption and reliable estimates of the extent of drug absorption in humans.

After demonstrating suitability of a method and maintaining the same study protocol, it is not necessary to retest all selected model drugs for subsequent studies intended to classify a drug substance. Instead, a low and a high permeability model drug should be used as internal standards (i.e., included in the perfusion fluid or donor fluid along with the test drug substance). These two internal standards are in addition to the fluid volume marker (or a zero permeability compound such as PEG 4000) that is included in certain types of perfusion techniques (e.g., closed loop techniques). The choice of internal standards should be based on compatibility with the test drug substance (i.e., they should not exhibit any significant physical, chemical, or permeation interactions). When it is not feasible to follow this protocol, the permeability of internal standards should be determined in the same subjects, animals, tissues, or monolayers, following evaluation of the test drug substance. The permeability values of the two internal standards should not differ significantly between different tests, including those conducted to demonstrate suitability of the method. At the end of an in situ or in vitro test, the amount of drug in the membrane should be determined.

For a given test method with set conditions, selection of a high permeability internal standard with permeability in close proximity to the low/high permeability class boundary may facilitate classification of a test drug substance. For instance, a test drug substance may be determined to be highly permeable when its permeability value is equal to or greater than that of the selected internal standard with high permeability.

3. Instability in the Gastrointestinal Tract

Determining the extent of absorption in humans based on mass balance studies using total radioactivity in urine does not take into consideration the extent of degradation of a drug in the gastrointestinal fluid prior to intestinal membrane permeation. In addition, some methods for determining permeability could be based on loss or clearance of a drug from fluids perfused into the human and/or animal gastrointestinal tract either in vivo or in situ. Documenting the fact that drug loss from the gastrointestinal tract arises from intestinal membrane permeation, rather than a degradation process, will help establish permeability. Stability in the gastrointestinal tract may be documented using gastric and intestinal fluids obtained from human subjects. Drug solutions in these fluids should be incubated at 37°C for a period that is representative of in vivo drug contact with these fluids; for example, 1 hour in gastric fluid and 3 hours in intestinal fluid. Drug concentrations should then be determined using a validated stability-indicating assay method. Significant degradation (>5%) of a drug in this protocol could suggest potential instability. Obtaining gastrointestinal fluids from human subjects requires intubation and may be difficult in some cases. Use of gastrointestinal fluids from suitable animal models and/or simulated fluids such as Gastric and Intestinal Fluids USP can be substituted when properly justified.

C. Determining Drug Product Dissolution Characteristics and Dissolution Profile Similarity⁴

Dissolution testing should be carried out in USP Apparatus I at 100 rpm or Apparatus II at 50 rpm using 900 ml of the following dissolution media: (1) 0.1 N HCl or Simulated Gastric Fluid USP without enzymes; (2) a pH 4.5 buffer; and (3) a pH 6.8 buffer or Simulated Intestinal Fluid USP without enzymes. For capsules and tablets with gelatin coating, Simulated Gastric and Intestinal Fluids USP (with enzymes) can be used.

Dissolution testing apparatus used in this evaluation should conform to the requirements in USP (<711> Dissolution). Selection of the dissolution testing apparatus (USP Apparatus I or II) during drug development should be based on a comparison of in vitro dissolution and in vivo pharmacokinetic data available for the product. The USP Apparatus I (*basket method*) is generally preferred for capsules and products that tend to float, and USP Apparatus II (*paddle method*) is generally preferred for tablets. For some tablet dosage forms, in vitro (but not in vivo) dissolution may be slow due to the manner in which the disintegrated product settles at the bottom of a dissolution vessel. In such situations, USP Apparatus I may be preferred over Apparatus II. If the testing conditions need to be modified to better reflect rapid in vivo dissolution (e.g., use of a different rotating speed), such modifications can be justified by comparing in vitro

⁴ See the FDA guidance for industry on *Dissolution Testing of Immediate Release Solid Oral Dosage Forms* (August 1997).

dissolution with in vivo absorption data (e.g., a relative BA study using a simple aqueous solution as the reference product).

A minimum of 12 dosage units of a drug product should be evaluated to support a biowaiver request. Samples should be collected at a sufficient number of intervals to characterize the dissolution profile of the drug product (e.g., 10, 15, 20, and 30 minutes).

When comparing the test and reference products, dissolution profiles should be compared using a similarity factor (f_2) . The similarity factor is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) of dissolution between the two curves.

$$f_2 = 50 \bullet \log \{ [1 + (1/n) \sum_{t=1}^{n} (R_t - T_t)^2]^{-0.5} \bullet 100 \}$$

Two dissolution profiles are considered similar when the f_2 value is ≥ 50 . To allow the use of mean data, the coefficient of variation should not be more than 20% at the earlier time points (e.g., 10 minutes), and should not be more than 10% at other time points. Note that when both test and reference products dissolve 85% or more of the label amount of the drug in ≤ 15 minutes using all three dissolution media recommended above, the profile comparison with an f_2 test is unnecessary.

IV. ADDITIONAL CONSIDERATIONS FOR REQUESTING A BIOWAIVER

When requesting a BCS-based waiver for in vivo BA/BE studies for IR solid oral dosage forms, applicants should note that the following factors can affect their request or the documentation of their request:

A. Excipients

Excipients can sometimes affect the rate and extent of drug absorption. In general, using excipients that are currently in FDA-approved IR solid oral dosage forms will not affect the rate or extent of absorption of a highly soluble and highly permeable drug substance that is formulated in a rapidly dissolving IR product. To support a biowaiver request, the quantity of excipients in the IR drug product should be consistent with the intended function (e.g., lubricant). When new excipients or atypically large amounts of commonly used excipients are included in an IR solid dosage form, additional information documenting the absence of an impact on BA of the drug may be requested by the Agency. Such information can be provided with a relative BA study using a simple aqueous solution as the reference product. Large quantities of certain excipients, such as surfactants (e.g., polysorbate 80) and sweeteners (e.g., mannitol or sorbitol) may be problematic, and sponsors are encouraged to contact the review division when this is a factor.

B. Prodrugs

Permeability of prodrugs will depend on the mechanism and (anatomical) site of conversion to the drug substance. When the prodrug-to-drug conversion is shown to occur predominantly after intestinal membrane permeation, the permeability of the prodrug should be measured. When this conversion occurs prior to intestinal permeation, the permeability of the drug should be determined. Dissolution and pH-solubility data on both prodrug and drug can be relevant. Sponsors may wish to consult with appropriate review staff before applying the BCS approach to IR products containing prodrugs.

C. Exceptions

BCS-based biowaivers are not applicable for the following:

1. Narrow Therapeutic Range Drugs⁵

This guidance defines narrow therapeutic range drug products as those containing certain drug substances that are subject to therapeutic drug concentration or pharmacodynamic monitoring, and/or where product labeling indicates a narrow therapeutic range designation. Examples include digoxin, lithium, phenytoin, theophylline, and warfarin. Because not all drugs subject to therapeutic drug concentration or pharmacodynamic monitoring are narrow therapeutic range drugs, sponsors should contact the appropriate review division to determine whether a drug should be considered to have a narrow therapeutic range.

2. Products Designed to be Absorbed in the Oral Cavity

A request for a waiver of in vivo BA/BE studies based on the BCS is not appropriate for dosage forms intended for absorption in the oral cavity (e.g., sublingual or buccal tablets).

V. REGULATORY APPLICATIONS OF THE BCS

A. INDs/NDAs

Evidence demonstrating in vivo BA or information to permit FDA to waive this evidence must be included in NDAs (21 CFR 320.21(a)). A specific objective is to establish in vivo performance of the dosage form used in the clinical studies that provided primary evidence of efficacy and safety. The sponsor may wish to determine the relative BA of an IR solid oral dosage form by comparison with an

⁵ This guidance uses the term *narrow therapeutic range* instead of *narrow therapeutic index*, although the latter is more commonly used.

oral solution, suspension, or intravenous injection (21 CFR 320.25 (d)(2) and 320.25 (d)(3)). The BA of the clinical trial dosage form should be optimized during the IND period.

Once the in vivo BA of a formulation is established during the IND period, waivers of subsequent in vivo BE studies, following major changes in components, composition, and/or method of manufacture (e.g., similar to SUPAC-IR Level 3 changes⁶) may be possible using the BCS. BCS-based biowaivers are applicable to the to-be-marketed formulation when changes in components, composition, and/or method of manufacture occur to the clinical trial formulation, as long as the dosage forms have rapid and similar in vitro dissolution profiles (see sections II and III). This approach is useful only when the drug substance is highly soluble and highly permeable (BCS Class 1), and the formulations pre- and postchange are *pharmaceutical equivalents* (under the definition at 21 CFR 320.1 (c)). BCS-based biowaivers are intended only for BE studies.

B. ANDAs

BCS-based biowaivers can be requested for rapidly dissolving IR test products containing highly soluble and highly permeable drug substances, provided that the reference listed drug product is also rapidly dissolving and the test product exhibits similar dissolution profiles to the reference listed drug product (see sections II and III). This approach is useful when the test and reference dosage forms are pharmaceutical equivalents. The choice of dissolution apparatus (USP Apparatus I or II) should be the same as that established for the reference listed drug product.

C. Postapproval Changes

BCS-based biowaivers can be requested for significant postapproval changes (e.g., Level 3 changes in components and composition) to a rapidly dissolving IR product containing a highly soluble, highly permeable drug substance, provided that dissolution remains rapid for the postchange product and both pre- and postchange products exhibit similar dissolution profiles (see sections II and III). This approach is useful only when the drug products pre- and postchange are pharmaceutical equivalents.

VI. DATA TO SUPPORT A REQUEST FOR BIOWAIVERS

The drug substance for which a waiver is being requested should be highly soluble and highly permeable. Sponsors requesting biowaivers based on the BCS should submit the following information to the Agency for review by the Office of Clinical Pharmacology

⁶ See the FDA guidance for industry on *Immediate Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes* (November 1995).

and Biopharmaceutics (for NDAs) or Office of Generic Drugs, Division of Bioequivalence (for ANDAs):

A. Data Supporting High Solubility

Data supporting high solubility of the test drug substance should be developed (see section III.A). The following information should be included in the application:

- A description of test methods, including information on analytical method and composition of the buffer solutions
- Information on chemical structure, molecular weight, nature of the drug substance (acid, base, amphoteric, or neutral), and dissociation constants (pKa(s))
- Test results (mean, standard deviation, and coefficient of variation) summarized in a table under solution pH, drug solubility (e.g., mg/ml), and volume of media required to dissolve the highest dose strength
- A graphic representation of mean pH-solubility profile

B. Data Supporting High Permeability

Data supporting high permeability of the test drug substance should be developed (see section III.B). The following information should be included in the application:

- For human pharmacokinetic studies, information on study design and methods used along with the pharmacokinetic data
- For direct permeability methods, information supporting the suitability of a selected method that encompasses a description of the study method, criteria for selection of human subjects, animals, or epithelial cell line, drug concentrations in the donor fluid, description of the analytical method, method used to calculate extent of absorption or permeability, and where appropriate, information on efflux potential (e.g., bidirectional transport data)
- A list of selected model drugs along with data on extent of absorption in humans (mean, standard deviation, coefficient of variation) used to establish suitability of a method, permeability values for each model drug (mean, standard deviation, coefficient of variation), permeability class of each model drug, and a plot of the extent of absorption as a function of permeability (mean ± standard deviation or 95% confidence interval) with identification of the low/high permeability

class boundary and selected internal standard. Information to support high permeability of a test drug substance should include permeability data on the test drug substance, the internal standards (mean, standard deviation, coefficient of variation), stability information, data supporting passive transport mechanism where appropriate, and methods used to establish high permeability of the test drug substance.

C. Data Supporting Rapid and Similar Dissolution

For submission of a biowaiver request, an IR product should be rapidly dissolving. Data supporting rapid dissolution attributes of the test and reference products should be developed (see section III.C). The following information should be included in the application:

- A brief description of the IR products used for dissolution testing, including information on batch or lot number, expiry date, dimensions, strength, and weight
- Dissolution data obtained with 12 individual units of the test and reference products using recommended test methods in section III.C. The percentage of labeled claim dissolved at each specified testing interval should be reported for each individual dosage unit. The mean percent dissolved, range (highest and lowest) of dissolution, and coefficient of variation (relative standard deviation) should be tabulated. A graphic representation of the mean dissolution profiles for the test and reference products in the three media should also be included.
- Data supporting similarity in dissolution profiles between the test and reference products in each of the three media, using the f_2 metric

D. Additional Information

The manufacturing process used to make the test product should be described briefly to provide information on the method of manufacture (e.g., wet granulation vs. direct compression). A list of excipients used, the amount used, and their intended functions should be provided. Excipients used in the test product should have been used previously in FDA-approved IR solid oral dosage forms.

ATTACHMENT A

This attachment includes model drugs suggested for use in establishing suitability of a permeability method as described in section III. The permeability of these compounds was determined based on data available to the FDA. Potential *internal standards* (IS) and *efflux pump substrates* (ES) are also identified.

Drug	Permeability Class
Antipyrine	High (Potential IS candidate)
Caffeine	High
Carbamazepine	High
Fluvastatin	High
Ketoprofen	High
Metoprolol	High (Potential IS candidate)
Naproxen	High
Propranolol	High
Theophylline	High
Verapamil	High (Potential ES candidate)
Amoxicillin	Low
Atenolol	Low
Furosemide	Low
Hydrochlorthiazide	Low
Mannitol	Low (Potential IS candidate)
α -Methyldopa	Low
Polyethylene glycol (400)	Low
Polyethylene glycol (1000)	Low
Polyethylene glycol (4000)	Low (Zero permeability marker)
Ranitidine	Low

Handbook of Pharmaceutical Excipients, 2nd edition, 491, 1994

Pregelatinized Starch

1. Nonproprietary Names

BP: Pregelatinised maize starch USPNF: Pregelatinized starch

2. Synonyms

Compressible starch; Instastarch; Lycatab PGS; National 78-1551; Pharma-Gel; Prejel; Sepistab ST 200; Starch 1500; Sta-Rx 1500.

3. Chemical Name and CAS Registry Number Pregelatinized starch [9005-25-8]

4. Empirical Formula Molecular Weight

 $(C_6H_{10}O_5)_n$ Where n = 300-1000.

Pregelatinized starch is a starch that has been chemically and mechanically processed to rupture all or part of the starch granules and so render the starch flowable and directly compressible. Partially pregelatinized grades are also commercially available. Typically, pregelatinized starch contains 5% of free amylose, 15% of free amylopeciin and 80% unmodified starch. The USPNF XVII does not specify the botanical origin of the original starch but the BP 1993 specifies that corn (maize) starch should be used. See also Starch and Section 13.

5. Structural Formula

See Starch

6. Functional Category

Tablet and capsule dilucit; tablet and capsule disintegrant; tablet binder

7. Applications in Pharmaceutical Formulation or

Pregelatinized starch is a modified starch used in oral capsule and tablet formulations as a binder, diluent⁽¹⁾ and disintegrant.⁽²⁾

In comparison to starch, grades of pregelatinized starch may be produced with enhanced flow and compression charactertablet binder in dry compression processes.⁽³⁻¹¹⁾ In such processes, pregelatinized starch is self-lubricating. However, when used with other excipients it may be necessary to add a lubricant to a formulation. Although magnesium stearate 0.25% w/w is commonly used for this purpose, concentrations greater than this may have adverse effects on tablet strength and dissolution. Therefore, stearie acid is generally the preferred lubricant with pregelatinized starch.⁽¹²⁾

Pregelatinized starch may also be used in wet granulation processes.⁽¹³⁾

2

Use Concentration (%) Diluent (hard gelatin capsules) 5-75 Tublet binder (direct compression) 5-20 Tablet binder (wet granulation) 5-10 Tablet disintegrant 5-10

Pregelatinized Starch 491

8. Description

Pregelatinized starch occurs as a moderately coarse to fine. white to off-white colored powder. It is odorless and has a slight characteristic taste.

Examination of fully pregelatinized starch as a slurry in cold water, under a polarizing microscope, reveals no significant ungelatinized granules. Examination of samples suspended in glycerin show characteristic forms depending upon the method of drying used during manufacture, e.g. either irregular chunks from drum drying or thin plates.

9. Pharmacopeial Specifications

Test	BP 1993	USPNF XVII (Suppl 5)
Identification	+	+
pH (10% w/v slurry)	4.5-7.0	4.5-7.0
Iron		≤ 0.002%
Oxidizing substances		+
Sulfur dioxide		≪ 0.008%
Microbial limits	+	+
Loss on drying	≤ 15.0%	≤ 14.0%
Residue on ignition		≤ 0.5%
Sulfated ash	≤ 0.5%	-10-m
Protein	≤ 0.5%	

10. Typical Properties

Acidity/alkalinity: pH = 4.5-7.0 for a 10% w/v aqueous dispersion.

Angle of repose: 40.7°(6)

Flowability: 18-23% (Carr compressibility index)(14) Moisture content: pregelatinized maize starch is hygro-scopic,^(1,15,16) see HPE Data.

Particle size distribution: 30-150 μ m, median diameter 52 μ m. For partially pregelatinized starch, greater than 90% through

a US #100 mesh (149 μ m), and less than 0.5% retained on a US #40 mesh (420 µm). Solubility: practically insoluble in organic solvents. Slightly

soluble to soluble in cold water, depending upon the degree of pregelatinization. Fully pregelatinized starch conforms to the completeness of solution test in the USP XXII. Pastes can be prepared by sifting the pregelatinized starch into stirred, cold water. Cold water soluble matter for partially pregelatinized starch is 10-20%.

Specific surface area: 0.21-0.22 m²/g

Viscosity (dynamic): 8-10 mPa s (8-10 cP) for a 2% w/v aqueous dispersion at 25°C.

492 Pregelatinized Starch

	HPE Labo	ratory Proj	ect Data
	Method	Lab #	Results
Bulk/tap density			
Starch 1500	BTD-7	14	B: 0.650 g/cm ^{3 (a)}
			T: 0.820 g/cm ³
Moisture content	MC-22	2	7.0% ^(b)
	MC-15	34	8.94% ^(b)
	EMC-1	2	See Fig. 1, (b)
Starch 1500	MC-15	34	11.12% (*)
Starch 1500	MC-15	14	11.30% (*)
Starch 1500	SDI-I	14	See Fig. 2. (2)
Wheat (Paygel 90)	MC-15	14	6.60% ^(c)
Wheat (Paygel 90)	SDI-1	14	See Fig. 2. (c)
Particle size	PSD-2	5	68 µm ^(b)
Starch 1500	PSD-2	5	80 μm ^(a)

Supplier: a. Colorcon Ltd; b. National Starch & Chemicals Ltd; c. Henkel Corp.

* Note that results are for pregelatinized corn starch unless otherwise indicated.

11. Stability and Storage Conditions

Pregelatinized starch is a stable, though hygroscopic material, which should be stored in a well-closed container in a cool, dry, place.

12. Incompatibilities

13. Method of Manufacture

Fully pregelativized starch is prepared by heating an aqueous slurry containing up to 42% w/w of starch at $62-72^{\circ}C$. Chemical additives which may be included in the slurry are




Fig. 1: Equilibrium moisture content of corn starch and pregelatinized starch.

○ Corn starch (National Starch & Chemicals Ltd; Lot #421).
△ Pregelatinized corn starch (National Starch & Chemicals Ltd; Lot #HJW 103).




Fig. 2: Sorption-desorption isotherms of pregelatinized corn starch and pregelatinized wheat starch.

• Pregelatinized corn starch, Sla-Rx 1500 (AE Staley Mfg Co; Lot #977912).

▲ Pregelatinized wheat starch, Paygel 90 (Henkel Corp; Lot #289D).

♥Pregelatinized corn starch, Starch 1500 (Colorcon Ltd; Lot #904014)

gelatinization aids (salts or bases) and surfactants, added to control rehydration or minimize stickiness during drying. After heating, the slurry may be spray-dried, roll-dried, extruded or drum-dried. In the latter case, the dried material may be processed to produce a desired particle size range. Partially pregelatinized starch is prepared by spreading an aqueous suspension of ungelatinized starch on hot drums where partial gelatinization and subsequent drying takes place.

14. Safety

Pregelatinized starch, and starch, are widely used in oral solid dosage formulations. Pregelatinized starch is generally regarded as a nontoxic and nonirritant excipient. However, oral consumption of massive amounts of pregelatinized starch may be harmful.

See Starch for further information.

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye protection and a dustmask are recommended. Excessive dust generation should be avoided to minimize the risks of explosions.

In the UK, the long-term (8-hour TWA) occupational exposure limits for starch are, 10 mg/m³ for total inhalable dust and 5 mg/m³ for respirable dust.⁽⁷⁷⁾</sup>

16. Regulatory Status

Included in the FDA Inactive Ingredients Guide (oral capsules, suspensions and tablets). Included in nonparenteral medicines licensed in the UK.

Pregelatinized Starch 493

17. Pharmacopeias

Br and USPNF.

18. Related Substances Starch; Sterilizable Maize Starch.

19. Comments

A low moisture grade of pregelatinized starch. Starch 1500 L.M. (Colorcon Ltd), containing less than 7% of water, is commercially available specifically intended for use as a diluent in capsule formulations.

20. Specific References

- Small LE, Augsburger LL. Aspects of the lubrication requirements for an automatic capsule filling machine. Drug Dev Ind Pharm 1978; 4: 345-372.
- Rudnic EM, Rhodes CT, Welch S, Bernardo P. Evaluations of the mechanism of disintegrant action. Drug Dev Ind Pharm 1982; 8: 87-109.
- Manudhane KS, Contractor AM, Kim HY, Shangraw RF. Tableting properties of a directly compressible starch. J Pharm Sci 1969, 58: 616-620.
- Underwood TW, Cadwallader DE, Influence of various starches on dissolution rate of salicylic acid from tablets. J Pharm Sci 1972; 61: 239-243.
- Bolhuis GK, Lerk CF. Comparative evaluation of excipients for direct compression. Pharm Weekbl 1973; 108: 469-481
- direct compression. Pharm Weekbl 1973; 108: 469-481.
 6. Sakr AM, Elsabbagh HM, Ernara KM. Sta-Rx 1500 starch: a new vehicle for the direct compression of tablets. Arch Pharm Chemi (Sci) 1974; 2: 14-24.
- Schwartz JB, Martin ET, Dehner EJ. Intragranular starch: comparison of starch USP and modified cornstarch. J Pharm Sci 1975; 64: 328-332.
- Rees JE, Rue PJ. Work required to cause failure of tablets in diametral compression. Drug Dev Ind Pharm 1978; 4: 131-156.

- Shangraw RF, Wallace JW. Bowers FM. Morphology and functionality in tablet excipients for direct compression: part II. Pharmaceut Technol 1981; 5(10): 44-60.
- Chilamkurti RW, Rhodes CT, Schwartz JB. Some studies on compression properties of tablet matrices using a computerized instrumental press. Drug Dev Ind Pharm 1982; 8: 63-86.
- Malamataris S, Goidas P, Dimitriou A. Moisture sorption and tensile strength of some tableted direct compression excipients. Int J Pharmaceutics 1991; 68: 51-60.
- 12. Colorcon Ltd. Technical literature: Starch 1500, 1993.
- Jaiyeoba KT, Spring MS. The granulation of ternary mixtures: the effect of the stability of the excipients. J Pharm Pharmacol 1980; 32: 1-5.
- Carr RL. Particle behaviour storage and flow. Br Chem Eng 1970; 15: 1541-1549.
- Callahan JC, Cleary GW, Elefant M, Kaplan G, Kensler T, Nash RA. Equilibrium moisture content of pharmaceutical excipients. Drug Dev Ind Pharm 1982; 8: 355-369.
- Wurster DE, Peck GE, Kiklsig DO. A comparison of the moisture adsorption-desorption properties of corn starch, U.S.P., and directly compressible starch. Drug Dev Ind Pharm 1982; 8: 343-354.
- Health and Safety Executive. EH40/93: occupational exposure limits 1993. London: HMSO, 1993.

21. General References

- Roquette Frères. Technical literature: Lycatab PGS excipient for wet granulation, 1992.
- Sanghvi PP, Collins CC, Shukla AJ. Evaluation of Preflo modified starchies as new direct compression excipients I: tabletting characteristics. Pharm Res 1993; 10: 1597-1603.

22. Authors USA: NG Lordi,



Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700

News Release

Contact: Susan Alesina Vice President, Corporate Communications Sunovion Pharmaceuticals Inc. 508-481-6700 susan.alesina@sunovion.com

Latuda[®] (lurasidone HCI) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients with Schizophrenia

Mariborough, Mass., May 5, 2012 – Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dose range for LATUDA in the treatment of adult patients with schizophrenia. The FDA decision followed a review of the supplemental New Drug Application (sNDA), which was submitted in June 2011.

The maximum recommended dose of LATUDA was increased from 80 mg/day to 160 mg/day based in part on data from a 6-week placebo and active-controlled trial (N=482) involving two fixed doses of LATUDA (80 mg/day or 160 mg/day) and an active control (quetiapine XR 600 mg/day). In this study¹, both LATUDA doses demonstrated statistically significant improvement at the Week 6 study endpoint compared to placebo in change from baseline in Positive and Negative Syndrome Scale total score (PANSS, primary efficacy endpoint) and the Clinical Global Impression-Severity scale (CGI-S, key secondary efficacy endpoint). The active control (quetiapine XR) also separated from placebo on the PANSS total and CGI-S scale at study endpoint. The LATUDA safety profile in this study was consistent with prior studies in patients with schizophrenia: no new safety concerns were identified.

The newly expanded recommended dose range for LATUDA (40-160 mg/day) includes approval of the 120 mg/day and 160 mg/day doses, as well as a new 120 mg tablet. This dose range reflects positive results from five short-term studies that evaluated the safety and efficacy of LATUDA where doses of 40 mg/day, 80 mg/day, 120 mg/day and 160 mg/day were shown to be safe and effective.

"Schizophrenia is a complex disorder that requires a careful assessment of each patient. Having added dosing flexibility for LATUDA will allow physicians to better tailor treatment to the individual needs of patients with schizophrenia," said Antony Loebel, M.D., Executive Vice President and Chief Medical Officer of Sunovion Pharmaceuticals Inc.

www.sunovion.com

Page 1 of 5

¹ PEARL 3 (Program to Evaluate the Antipsychotic Response to Lurasidone) was a six-week, double-blind, placebo-controlled study to evaluate the efficacy of LATUDA in adult patients with schizophrenia. The double-blind extension study followed a core six-week, double-blind, placebo-controlled study (PEARL 3) where patients were randomized to treatment with one of the following: LATUDA 80 mg/day, LATUDA 160 mg/day, quetiapine XR 600 mg/day or placebo.

The sNDA summarized safety information derived from a clinical study database consisting of 2,905 patients with schizophrenia who were exposed to at least one dose of LATUDA. Of these patients, 1,508 participated in short-term, placebo-controlled schizophrenia studies with doses of 20 mg, 40 mg, 80 mg, 120 mg or 160 mg once daily. The most common adverse reactions (incidence \geq 5% and at least twice the rate of placebo) in patients treated with LATUDA were somnolence, akathisia, nausea and parkinsonism. There were no dose-related adverse reactions observed in patients treated with LATUDA across the 20 mg to 160 mg/day dose range compared to placebo. The frequency of akathisia increased with the dosage strength up to 120 mg/day (5.6% for LATUDA 20 mg/day, 10.7% for LATUDA 40 mg/day, 12.3% for LATUDA 80 mg/day, 22.0% for LATUDA 120 mg/day, 7.4% for LATUDA 160 mg/day and 3.0% for patients receiving placebo).

LATUDA initially received FDA approval for the treatment of schizophrenia on October 28, 2010 and is available in pharmacies across the United States and Puerto Rico.

About LATUDA

LATUDA is an atypical antipsychotic indicated for the treatment of patients with schizophrenia. Efficacy was established in five 6-week controlled studies of adult patients with schizophrenia. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

The recommended starting dose for LATUDA is 40 mg once daily taken with food (at least 350 calories) with no initial dose titration required. LATUDA has been shown to be effective in a dose range of 40 mg/day to 160 mg/day. The maximum recommended dose is 160 mg/day. For patients with moderate and severe renal or hepatic impairment, the recommended starting dose of LATUDA is 20 mg/day. The maximum recommended dose is 80 mg/day in patients with moderate hepatic impairment and 40 mg/day in patients with severe hepatic impairment. The recommended starting dose of LATUDA is 20 mg/day with a maximum recommended dose of 80 mg/day. The recommended starting dose of LATUDA is 20 mg/day with a maximum recommended dose of 80 mg/day. LATUDA should not be administered with strong CYP3A4 inhibitors such as ketoconazole or strong CYP3A4 inducers such as rifampin.

Please see Important Safety Information, including **Boxed Warning** below, and full Prescribing Information at <u>www.LATUDA.com</u>.

IMPORTANT SAFETY INFORMATION FOR LATUDA

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- LATUDA is not approved for the treatment of patients with dementiarelated psychosis.

CONTRAINDICATIONS

LATUDA is contraindicated in the following:

www.surievion.com

Page 2 of 5

- Any patient with a known hypersensitivity to lurasidone HCI or any components in the formulation. Angioedema has been observed with lurasidone.
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole)
- Concomitant use with strong CYP3A4 inducers (e.g., rifampin).

WARNINGS AND PRECAUTIONS

Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.

Tardive Dyskinesia (TD): TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of TD. If signs and symptoms appear in a patient on LATUDA, drug discontinuation should be considered.

Metabolic Changes

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

www.sunovion.com

Page 3 of 5

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. In short-term, placebo-controlled studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was -0.2 ng/mL and was 0.5 ng/mL for males. The proportion of female patients with prolactin elevations ≥5x ULN was 5.7% for LATUDA-treated patients versus 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations > 5x ULN was 1.6% versus 0.6% for placebo-treated male patients.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Patients with a preexisting low white blood cell count (WBC) or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy, and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: LATUDA may cause orthostatic hypotension. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension and in patients with known cardiovascular disease or cerebrovascular disease.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold (e.g., Alzheimer's dementia).

Potential for Cognitive and Motor Impairment: In short-term, placebo-controlled trials, somnolence was reported in 17.0% (256/1508) of patients treated with LATUDA compared to 7.1% (50/708) of placebo patients, respectively. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. **Suicide:** The possibility of suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

ADVERSE REACTIONS

Commonly Observed Adverse Reactions: (incidence \geq 5% and at least twice the rate of placebo) in patients treated with LATUDA were somnolence, akathisia, nausea and parkinsonism.

Before prescribing LATUDA, please read the full Prescribing Information, including **Boxed Warning** at <u>www.LATUDA.com</u>.

www.sunovion.com

Page 4 of 5

About Schizophrenia

Schizophrenia is a chronic, disabling and serious brain disorder that affects approximately 2.4 million American adults or 1 in 100 people. Schizophrenia is characterized by symptoms such as hallucinations, delusions, disorganized thinking, lack of emotion, lack of energy, as well as problems with memory, attention and the ability to plan, organize and make decisions.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system (CNS) and respiratory disease areas and improve the lives of patients and their families. Sunovion's drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products including LATUDA[®] (lurasidone HCI) tablets, LUNESTA[®] (eszopiclone) tablets, XOPENEX[®] (levalbuterol HCI) inhalation solution, XOPENEX HFA[®] (levalbuterol tartrate) inhalation aerosol, BROVANA[®] (aformoterol tartrate) inhalation solution, OMNARIS[®] (ciclesonide) nasal spray and ALVESCO[®] (ciclesonide) HFA inhalation aerosol.

Sunovion, an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at <u>www.sunovion.com</u>.

About Dainippon Sumitomo Pharma Co., Ltd. (DSP)

DSP is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP aims to produce innovative pharmaceutical products in the CNS field, which has been designated as the key therapeutic area and will also focus in on other specialty disease categories with significant unmet medical needs, which are designated as frontier therapeutic areas. DSP is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd. and Sumitomo Pharmaceuticals Co., Ltd. Today, DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at <u>www.ds-pharma.com.</u>

LATUDA is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd. LUNESTA, XOPENEX, XOPENEX HFA and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc. OMNARIS and ALVESCO are registered trademarks of Nycomed GmbH.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd.[©] 2012 Sunovion Pharmaceuticals Inc.

For a copy of this release visit Sunovion's web site at www.sunovion.com

###

www.sunovion.com

Page 5 of 5

Electronic Acl	knowledgement Receipt
EFS ID:	13739305
Application Number:	11919678
International Application Number:	
Confirmation Number:	6965
Title of Invention:	Pharmaceutical composition
First Named Inventor/Applicant Name:	Kazuyuki Fujihara
Customer Number:	42798
Filer:	Kendrew H. Colton/Lois Ford
Filer Authorized By:	Kendrew H. Colton
Attorney Docket Number:	7379/98100
Receipt Date:	13-SEP-2012
Filing Date:	31-OCT-2007
Time Stamp:	17:07:38
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted wi	th Payment	no	no				
File Listin	g:						
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1		Amendment-13Sept2012.pdf	1070515	yes	26		
			490760be45e5c4be5e9c2dbb6379ce3cd93 66692	,	20		

	Multip	oart Description/PDF files in	.zip description				
	Document De	scription	Start	En	d		
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1			
	Claims	2	8				
	Applicant Arguments/Remarks	Made in an Amendment	9	26	õ		
Warnings:							
Information							
2	Appendix to the Specification	Appendix-13Sept2012.pdf	1252587	no	26		
2	Appendix to the specification				20		
Warnings:							
Information							
		Total Files Size (in bytes)	23	23102			
characterize Post Card, as <u>New Applica</u> If a new appl	This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR						
	nd MPEP 506), a Filing Receipt (37 CF ement Receipt will establish the filin		course and the date s	nown on this	5		
National Sta	ge of an International Application ur	der 35 S C 371					
If a timely su	bmission to enter the national stage	of an international applicat					
U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.							
If a new inter an internation and of the In	tional Application Filed with the USP rnational application is being filed an onal filing date (see PCT Article 11 an ternational Filing Date (Form PCT/RG urity, and the date shown on this Ack ion.	nd the international applicat d MPEP 1810), a Notificatior D/105) will be issued in due o	of the International <i>I</i> ourse, subject to pres	Application N scriptions co	Number ncerning		

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						Application or Docket Number 11/919,678 1			ing Date 31/2007	To be Maile	
	AF	PLICATION	AS FILE	D – PART I						OTI	HER THAN
			(Column ·) (1	Column 2)		SMALL	ENTITY	OR	SMA	ALL ENTITY
	FOR	١	NUMBER FIL	.ED NUM	MBER EXTRA	R.	ATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)
\triangleleft	BASIC FEE (37 CFR 1.16(a), (b), o	or (c))	N/A		N/A		N/A			N/A	310
	SEARCH FEE (37 CFR 1.16(k), (i), c	or (m))	N/A		N/A		N/A			N/A	
]	EXAMINATION FE (37 CFR 1.16(o), (p), (c)	E	N/A		N/A		N/A		1	N/A	
	CFR 1.16(i))	(4)/	mir	us 20 = *		×	\$ =		OR	X \$ =	
ID	EPENDENT CLAIM CFR 1.16(h))	S	m	inus 3 = *		×	\$ =		1	X \$ =	
	APPLICATION SIZE (37 CFR 1.16(s)) MULTIPLE DEPEN the difference in colu	FEE shee is \$2 add 35 U	ets of pap 250 (\$125 itional 50 J.S.C. 41(RESENT (3	677	n size fee due for each 1 thereof. See		FOTAL			TOTAL	310
	APPI	(Column 1)	S AMENL	ED — PART II (Column 2)	(Column 3)		SMAL	L ENTITY	OR		ER THAN
	01/21/2012	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	R.	ATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONA FEE (\$)
	Total (37 CFR 1.16(i))	* 31	Minus	** 24	= 7	х	\$ =		OR	X \$60=	420
	Independent (37 CFR 1.16(h))	* 3	Minus	***5	= 0	х	\$ =		OR	X \$250=	0
	Application Si	ze Fee (37 CFR	1.16(s))								
	FIRST PRESEN	ITATION OF MULT	IPLE DEPEN	DENT CLAIM (37 CFF	R 1.16(j))				OR		
						AI	DTAL DD'L EE		OR	TOTAL ADD'L FEE	420
		(Column 1)		(Column 2)	(Column 3)					-	-
	09/13/2012	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	R	ATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONA FEE (\$)
	Total (37 CFR 1.16(i))	* 32	Minus	31	= 1	х	\$ =		OR	X \$60 =	60
	Independent (37 CFR 1.16(h))	* 4	Minus	*** 5	= 0	х	\$ =		OR	X \$250 =	0
	Application Si	ze Fee (37 CFR	1.16(s))								
		ITATION OF MULT	IPLE DEPEN	DENT CLAIM (37 CFF	R 1.16(j))				OR		
						A	DTAL DD'L EE		OR	TOTAL ADD'L FEE	60
lf	the entry in column the "Highest Numbe	er Previously Pai	d For" IN Th		than 20, enter "20'			nstrument Ex A ALLEN-JEN			

PTO/SB/06 (07-06) Approved for use through 1/31/2007. OMB 0651-0032

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Par Pharm., Inc. Exhibit 1015 Page 409 Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 09/14/2012

FALLEN SALE #00000002 Mailroom Dt: 09/13/2012 061135 11919678 01 FC : 1202 60.00 DA

> Par Pharm., Inc. Exhibit 1015 Page 410



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
11/919,678	10/31/2007	Kazuyuki Fujihara	7379/98100	6965	
	7590 12/11/201 , TABIN & FLANNER	EXAM	INER		
P. O. BOX 184	15	PIHONAK	S, SARAH		
WASHINGTO.	WASHINGTON, DC 20036		n, DC 20036	ART UNIT	PAPER NUMBER
			1627		
			MAIL DATE	DELIVERY MODE	
			12/11/2012	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	11/919,678	FUJIHARA, KAZUYUKI				
Office Action Summary	Examiner	Art Unit				
	SARAH PIHONAK	1627				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
 A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 						
Status						
1) Responsive to communication(s) filed on <u>13 Sec</u>	eptember 2012.					
	action is non-final.					
3) An election was made by the applicant in respo	onse to a restriction requirement	set forth during the interview on				
; the restriction requirement and election	have been incorporated into this	action.				
4) Since this application is in condition for allowar	nce except for formal matters, pro	secution as to the merits is				
closed in accordance with the practice under E	<i>x parte Quayle</i> , 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims						
5)X Claim(s) <u>1-7,9,11-14,16 and 19-37</u> is/are pend	ing in the application					
5a) Of the above claim(s) <u>5-7,35 and 36</u> is/are	•					
6) Claim(s) is/are allowed.						
7)⊠ Claim(s) <u>1-4,9,11-14,16,19-34 and 37</u> is/are re	iected.					
8) Claim(s) is/are objected to.						
9) Claim(s) are subject to restriction and/or	r election requirement.					
* If any claims have been determined <u>allowable</u> , you may program at a participating intellectual property office for t <u>http://www.uspto.gov/patents/init_events/pph/index.jsp</u> of	v be eligible to benefit from the P a he corresponding application. Fo	r more information, please see				
Application Papers						
10) The specification is objected to by the Examine	r.					
	epted or b) 🗌 objected to by the I	Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. & 119(a)	-(d) or (f)				
a) \square All b) \square Some * c) \square None of:						
1. Certified copies of the priority documents	s have been received.					
2. Certified copies of the priority documents have been received.						
3.∑ Copies of the certified copies of the priority documents have been received in his National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 3) Interview Summary (PTO-413)						
2) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 4)	are				
U.S. Patent and Trademark Office						

DETAILED ACTION

This application, filed 10/31/2007, is a national stage entry of PCT/JP2006/310571, filed on 5/26/2006.

Priority

This application claims foreign priority to Application No. 2005-153508, filed on 5/26/2005.

Response to Remarks

1. Claims 1-7, 9, 11-14, 16, and 19-37 are pending as of the reply and amendments filed on 9/13/2012. Claims 5-7 and 35-36 were previously withdrawn from consideration, due to the restriction requirement.

Claims 1-4, 9, 11-14, 16, and 19-34 were previously rejected under 35 USC 103(a) as being unpatentable over Fujihara et. al., in view of Salpekar et. al. The Applicant has traversed this rejection with the argument that the claimed oral preparation would not have been prima facie obvious to one of ordinary skill in the art in consideration of the prior art, because Fujihara et. al. does not teach or suggest an oral preparation which contains a content ratio of lurasidone from 20 to 45 wt%, is silent to the use of pregelatinized starch, and does not teach the rapid dissolution properties of the instantly claimed oral preparation. The Applicant has submitted that the oral preparation taught by Fujihara et. al. has a considerably smaller content ratio of lurasidone per oral preparation than the

instantly claimed composition. The Applicant has argued that Fujihara et. al. provides a formulation tablet comprised of 29% lurasidone which is significantly inferior with regards to dissolution in comparison to tablets comprising from 8.13-16.3% of lurasidone, and thus one of ordinary skill in the art would have focused on lurasidone tablets comprised of 8.13-16.3% of lurasidone, rather than 20-45% by weight lurasidone, as instantly claimed. The Applicant has compared formulations of lurasidone tablets comprising 12.3% and 24.7% lurasidone, respectively, according to the Fujihara et. al. method, with the 24.7% lurasidone tablet having a lower dissolution profile in comparison to the 12.3% lurasidone tablet. The Applicant has further maintained that contrary to the teachings of Fujihara et. al., the claimed oral preparations containing different amounts of lurasidone within the claimed range exhibited consistent 30 minute dissolution profiles, as shown in Table 2. The Applicant has submitted that the claimed oral preparations comprised of a greater ratio content of lurasidone than that shown by Fujihara et. al. are superior to the oral preparations taught by Fujihara et. al.

The examiner has fully considered Applicant's arguments and the comparison data provided in the discussion tables as well as the appendix, but does not find them fully persuasive to overcome the rejection for obviousness over Fujihara et. al., in view of Salpekar et. al. While the Applicant has argued that the oral preparations taught by Fujihara et. al. have a poorer dissolution profile in comparison to the instantly claimed oral preparation, the examiner notes that the preparation taught by Fujihara et. al. does not comprise pregelatinized starch, which the Applicant has pointed out is important to provide

the desired dissolution profile. The Applicant has argued that the composition comprised of 29% by weight lurasidone as taught by Fujihara et. al. has a slower dissolution profile in comparison to tablets comprised of 8.13-16.3% of lurasidone, and therefore one of ordinary skill in the art would not have been motivated to have formulated an oral lurasidone preparation comprising greater than 8.13-16.3% lurasidone. The examiner does not find this argument persuasive, because Fujihara et. al. explicitly teaches a tablet comprised of 40 mg. lurasidone, or 28% of the total weight of the formulation. One of ordinary skill in the art would therefore have had a reasonable expectation of success in preparing a tablet comprised of 40 mg., or 28% by weight of the composition. Additionally, the rejection under 35 USC 103(a) was made over a combination of references, and not only the Fujihara et. al. reference. Salpekar et. al. teaches pregelatinized starch for increasing the hardness of an oral composition and shortening the dissolution and disintegration time. While the Applicant has argued that the Fujihara et. al. preparation comprised of 29% by weight lurasidone has slower dissolution time in comparison to the tablets comprised of 8.13-16.3% lurasidone, one of ordinary skill in the art would have found it prima facie obvious to have incorporated pregelatinized starch into the tablet formulation taught by Fujihara et. al. for the purpose of improving the dissolution and disintegration time. Salpekar et. al. teaches that the amount of partially pregelatinized starch ranges from 5 or less to 15 or more parts per 100 parts of the composition. The examiner maintains that one of ordinary skill in the art would have been motivated to have incorporated pregelatinized starch in an

amount taught by Salpekar et. al., which includes the cited range of pregelatinized starch in the instantly claimed preparation, with a reasonable expectation that the dissolution time of the tablet would have been shortened.

The Applicant has further argued that the instantly claimed oral preparation, exemplified in formulations "E", "F", and "G", have better dissolution properties in comparison to formulations "A" and "B" as taught by Fujihara et. al. The Applicant has argued that the tablets prepared according to Fujihara et. al. would be required to be larger than the instantly claimed oral preparations, which would introduce issues with patient compliance, as the new recommended dosages of lurasidone have been expanded to 120 mg/day and 160 mg/day, as shown in Appendix at item 3. The Applicant has compared the dissolution profile of an oral preparation comprised of 80 mg. lurasidone and 12.5% pregelatinized starch with an oral preparation comprised of 80 mg. lurasidone which does not comprise pregelatinized starch but rather contains a greater amount of sodium croscarmellose to make up the difference in weight. The Applicant has submitted that as the 30 minute dissolution profile of the lurasidone + pregelatinized starch formulation is clearly greater than the formulation which does not comprise pregelatinized starch, the instantly claimed composition is allowable.

The examiner has fully considered the comparison dissolution profiles presented by the Applicant along with the discussion points, but notes that the comparisons of formulations "E", "F", and "G" with the Fujihara et. al. formulations "A" and "B" are not equivalent, as the instantly claimed formulations comprise pregelatinized starch, which the Applicant has submitted is important to the

improved dissolution profiles, while the formulations taught by Fujihara et. al. do not comprise pregelatinized starch. Similarly, while the Applicant has shown that the preparation comprised of 80 mg. lurasidone and 12.5% pregelatinized starch has an improved 30 minute dissolution profile in comparison to the formulation without the pregelatinized starch, the examiner maintains that this result would not have been unexpected, as Salpekar et. al. teaches the incorporation of pregelatinized starch into an oral preparation for improving the disintegration and dissolution profiles. One of ordinary skill in the art, in consideration of the combined teachings of Fujihara et. al. and Salpekar et. al., would have reasonably expected that the addition of pregelatinized starch within the amount cited in the instantly claimed preparation would have improved the dissolution time of the lurasidone oral preparation.

The Applicant has argued that Salpekar et. al. would not have rendered the claimed oral preparation prima facie obvious and in fact teaches away from the claimed invention, as Salpekar teaches a specific oral preparation comprised of acetaminophen which is significantly more water soluble in comparison to lurasidone, and additionally teaches only a combination of small amounts of pregelatinized starch and at least an auxiliary binder to improve disintegration time. The Applicant has further submitted that Salpekar et. al. teaches an example formulation comprised of 18% pregelatinized starch which does not have an improved dissolution and disintegration time over the formulations have less pregelatinized starch. It has also been argued by the Applicant that in consideration of the poorer dissolution time of the 18% pregelatinized starch oral

preparation taught by Salpekar et. al., and the preferable dissolution times of the 4.45-8.85% pregelatinized starch compositions taught by Salpekar, one of ordinary skill in the art would have been motivated to have incorporated less than 18% pregelatinized starch into an oral preparation. The Applicant has also argued several additional points, namely that Salpekar's teaching of PGS from about 5 to about 15 parts or more per 100 parts of the composition applies only to the acetaminophen composition; and that Salpekar discloses a preferred embodiment wherein the composition comprises 83-93% acetaminophen, which one of ordinary skill in the art would not have been motivated to have applied to a lurasidone preparation.

The examiner has fully considered Applicant's arguments, but they are not found fully persuasive. While the Applicant has argued that Salpekar et. al. teaches a particular composition comprised of acetaminophen, which the Applicants have submitted is considerably more water soluble than lurasidone, the examiner submits that the lurasidone preparation and preparation taught by Salpekar et. al. are both oral formulations. Salpekar et. al. teaches incorporation of pregelatinized starch in an amount of about 5 parts or less up to 15 parts or more per 100 parts of the oral composition for imparting high hardness, short disintegration, and short dissolution times. The lurasidone composition taught by Fujihara et. al. is also for oral administration. Therefore, as Salpekar et. al. teaches pregelatinized starch as an adjuvant for improving the disintegration and dissolution times of an oral preparation, one of ordinary skill in the art would have been motivated to have incorporated pregelatinized starch into another oral

preparation, such as the lurasidone preparation taught by Fujihara et. al., for the purpose of improving the disintegration and dissolution times. While the Applicant has argued that lurasidone is considerably less water soluble than acetaminophen, the examiner maintains that one of ordinary skill in the art nonetheless would have been motivated to have added pregelatinized starch within the amount range taught by Salpekar et. al. to an oral lurasidone preparation, particularly if the active agent is known to be poorly water soluble and therefore have slower dissolution, for the purpose of improving the dissolution profile. While the Applicant has argued that Salpekar et. al. implies that oral preparations comprised of 4.45-8.85% pregelatinized starch have better dissolution times in comparison to the composition comprised of 18% pregelatinized starch and thus one of ordinary skill in the art would not have been motivated to have added pregelatinized starch within the amount range cited in the instant claims, the examiner notes that the disintegration profile comparison of the examples referred to by Salpekar et. al. shows the difference in the compositions with and without an auxiliary binder and auxiliary disintegration agent. The instantly claimed oral preparation does not exclude auxiliary binders or disintegrants; thus, Salpekar's teaching of these excipients along with pregelatinized starch would not have rendered the claimed preparation unobvious. Furthermore, a prior art reference is not limited to only specific examples and preferred embodiments; see MPEP 2123. Particularly, the MPEP 2123 states that, "A reference may be relied upon for all that it would have reasonably suggested to one having ordinary skill in the art, including

nonpreferred embodiments"; see *Merck & Co. v. Biocraft Laboratories*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989). Salpekar et. al. teaches an oral preparation which is comprised of pregelatinized starch in an amount of about 5 parts or less to 15 parts or more, per 100 parts of the composition, for improving hardness, dissolution, and disintegration times. The examiner maintains that it would have been prima facie obvious to one of ordinary skill in the art to have incorporated pregelatinized starch into another oral preparation, such as the lurasidone preparation taught by Fujihara et. al., within the amount taught by Salpekar et. al., for the purpose of improving the dissolution time. The rejection under 35 USC 103(a) as being unpatentable over Fujihara et. al., in view of Salpekar et. al., was proper and is maintained for reasons of record. This rejection will be reiterated in the office action, for Applicant's convenience.

Applicants have requested that the rejection for obviousness type double patenting over the claims of co-pending application 12/997779 be withdrawn, as the instant application is earlier filed. The rejection for obviousness type double patenting is maintained for reasons of record, and will be reiterated in the office action. Accordingly, this action is made FINAL.

- 2. Claims 1-4, 9, 11-14, 16, 19-34, and 37 were examined.
- 3. Claims 1-4, 9, 11-14, 16, 19-34, and 37 are rejected.

Claim Rejections-35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for

all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1,

148 USPQ 459 (1966), that are applied for establishing a background for

determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

6. Claims 1-4, 9, 11-14, 16, 19-34, and 37 are rejected under 35 U.S.C.

103(a) as being unpatentable over Fujihara et. al., EP Patent Publication No.

1327440, in view of Salpekar et. al., US Patent No. 4,600,579 (both of previous

record).

The claims are drawn to an oral composition comprised of lurasidone,

pregelatinized starch, a water soluble excipient such as mannitol or lactose, and a water soluble polymer binder. The claims are also drawn to the composition in which the pregelatinized starch is present in an amount from 10-50% by weight, and in which the lurasidone is present in an amount from 25 to 45% by weight.

Fujihara et. al. teaches an oral composition comprised of a slightly water soluble active ingredient, such as lurasidone, along with a first disintegrant, a

second disintegrant, and a water soluble polymer binder (Abstract; p. 4-5, paragraph [0008]). Fujihara et. al. teaches that the composition provides advantageous dissolution characteristics when ingested (Abstract). Corn starch is taught and exemplified as a first disintegrant (p. 4, lines 6-9; p. 5, paragraph [0011]; p. 22, paragraph [0152], Ex. 28). It is taught that one of the water soluble excipients includes sugar alcohols such as mannitol or lactose (p. 3, paragraph [0017], item (18); p. 5, paragraph [0014]). The other disintegrant is taught as including excipients such as microcrystalline cellulose, croscarmellose sodium, among others (p. 5, paragraph [0011]), and the water soluble polymer binder includes polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl methylcellulose, and others (p. 4, lines 10-12; p. 5, paragraph [0010]). It is taught that the amount of lurasidone present in the oral composition is 40 mg., which is within the range instantly claimed (p. 5, paragraph [0015]; p. 22, paragraph [0152], Table 28), and that the average particle size of lurasidone is between 0.5 to 5 μ m (p. 6, paragraph [0021]). It is taught that for a tablet of a weight of approximately 142 mg., the amount of lurasidone present is 40 mg., which is approximately 28 % of the weight of the composition (p. 29, paragraph [0194], Table 44). The water soluble polymer binder is taught to comprise from about 1 to 10% by weight of the preparation (p. 4, lines 39-40), and water soluble excipients such as mannitol or lactose are taught to comprise from 200 to 2000 % by weight to the weight of lurasidone (p. 9, paragraph [0066]), however, Fujihara et. al. provides an example wherein mannitol is present in an amount of 94 mg., and lurasidone present in an amount of 20 mg. (p. 20, Table 24, paragraph [0145]), in addition to

another example wherein lurasidone comprises 40 mg. of the tablet, while mannitol comprises 132 mg., of a total mass of 250 mg. for the tablet (p. 23, paragraph [0159], Table 32, Ex. 24). Thus, Fujihara teaches a water soluble excipient such as D-mannitol or lactose to comprise about 53% of the tablet (p. 23, paragraph [0159], Ex. 24 of Table 32; 132 mg./250 mg. is about 53%), which is within the amount range of water soluble excipient cited in the claimed composition. Fujihara provides an example formulation wherein the amount of the disintegrant crosscarmellose sodium is 4.8 % of the tablet weight (12 mg. for a 250 mg. tablet; p. 23, paragraph [0159], Table 32); therefore, the limitation of claim 30 is met. It is taught that the oral preparation comprises a granule, which is prepared by granulating the water-soluble polymer binder with the powdery mixture consisting of the active agent (lurasidone), a water soluble excipient, and another disintegrant (p. 3, paragraph [0007], items (11-13); p. 4, paragraph [0007], item (40)). Fujihara et. al. teaches that the preparation can be formulated as pills, granules, fine granules, capsules, tablets, etc. (p. 5, paragraph [0016]).

Fujihara et. al. does not explicitly teach that the composition comprises pregelatinized starch, in an amount from 10 to 50% by weight of the composition. It is not explicitly taught that the composition comprises 80 mg. of lurasidone.

Salpekar et. al. teaches that a composition comprised of a pharmaceutically active ingredient, a lubricant, a disintegrant, and pregelatinized starch allows for high hardness, and short dissolution time when ingested (Abstract). Salpekar et. al. teaches that the composition comprised of the pregelatinized starch is beneficial for preparing oral pharmaceutical formulations

such as tablets (column 1, lines 22-29). It is taught that the partially pregelatinized starch, such as the starch commercially known as Starch 1500, acts as a binder to the composition, and provides beneficial disintegrant properties, as well as increasing hardness of the composition and shortening the dissolution and disintegration time (column 3, lines 38-51; column 4, lines 31-37). Salpekar et. al. teaches that the amount of partially pregelatinized starch ranges from 5 or less to 15 or more parts per 100 parts of the composition (column 4, lines 15-17), which is within the amount of pregelatinized starch instantly claimed. It is taught that the amount of pregelatinized starch present is based upon the amount necessary to impart the high hardness and decreased dissolution times to the composition (column 4, lines 3-9); therefore, it would have been obvious to one of ordinary skill in the art that the optimum range of the pregelatinized starch may comprise amounts greater than or less than 5-15 % by weight, as taught. Salpekar et. al. teaches that the percent gelatinization of the pregelatinized starch ranges optimally from 50 to 75% (column 2, lines 33-55). Additionally, it is taught that Starch 1500 has a moisture content between 3 and 5 % (column 3, lines 38-45).

One of ordinary skill in the art would have been motivated, at the time of the invention, to have prepared the oral lurasidone preparation taught by Fujihara et. al. with incorporation of the pregelatinized starch excipient taught by Salpekar et. al. because Salpekar et. al. teaches that the pregelatinized starch in oral pharmaceutical formulations provides beneficial properties, such as increased hardness of the tablet, decreased dissolution time after ingestion, and short

disintegration time. As such, it would have been prima facie obvious for one of ordinary skill in the art to have prepared the oral lurasidone composition as taught by Fujihara et. al. with the pregelatinized starch excipient as taught by Salpekar et. al. because both Fujihara et. al. and Salpekar et. al. teach pharmaceutical compositions formulated for oral administration, and Salpekar teaches the addition of a pregelatinized starch for improving the dissolution time of the active agent. One of ordinary skill in the art would have been motivated to have incorporated pregelatinized starch, within the amount range as claimed, with a reasonable expectation that the dissolution and solubility of lurasidone HCI would have been improved. Properties associated with a composition are not patentably separable from the composition itself; see MPEP 2141.02, In re Papesch, 315 F.2d 381, 391, 137 USPQ 43, 51 (CCPA 1963). Therefore, as it would have been prima facie obvious to have prepared an oral composition comprised of lurasidone HCl, pregelatinized starch, within the amount ranges as cited, in addition to a water-soluble excipient, it would have been prima facie obvious that properties associated with the composition, such as the similarity factor f2, which is cited as being in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 mg. to 120 mg., a 50% by volume particle size of lurasidone of 0.1 to 8 µm, and an equivalent dissolution profile across the range of lurasidone per oral preparation, would also have been present. Fujihara explicitly teaches oral preparations comprised of lurasidone HCI up to 40 mg.; however, one of ordinary skill in the art would have expected success in incorporating a greater amount of lurasidone HCI in the preparation,

as the pregelatinized starch taught by Salpekar et. al. improves the solubility and dissolution of the drug. It would have been obvious as such to have incorporated 80 mg. to 160 mg. of lurasidone HCl into the oral preparation, with the expectation that the presence of the pregelatinized starch, as taught by Salpekar, would have allowed for effective solubility and dissolution of the drug. Therefore, there would have been an expectation of success in utilizing the pregelatinized excipient for the composition comprising lurasidone, because it is taught by Salpekar et. al. that the pregelatinized starch imparts beneficial properties such as improvement of dissolution and disintegration to oral formulations.

Claim Rejections-Obviousness Type Double Patenting

7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686

F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

8. Claims 1-4, 9, 11-14, 16, 19-34, and 37 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7 of copending Application No. 12/997779. Although the conflicting claims are not identical, they are not patentably distinct from each other because: the co-pending claims and the instant claims are directed to compositions which overlap considerably in scope. The instantly claimed composition is directed to an oral composition comprised of lurasidone HCl in an amount between 20% to 45% by weight, a pregelatinized starch in an amount from about 10% to about 50% by weight, and a water soluble excipient; the co-pending claims are directed to a tablet comprised of an active ingredient in an amount not less than 25% by weight, mannitol, a pregelatinized starch, and a disintegrant. The claimed

composition also comprises the ingredients cited in the co-pending claims, and as such the claims are not patentably separable.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

9. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Conclusion

10. Claims 1-4, 9, 11-14, 16, 19-34, and 37 are rejected.

Page 17

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached on Monday-Thursday 7:00 AM - 5:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (tollfree). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/SARAH PIHONAK/ Examiner, Art Unit 1627

/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1627

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Defa ult Oper ator	Plurals	Time Stamp
L1	22381	(pregelatin\$6 or (pre-gelatin\$6)) adj6 starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:31
L2	3343	((pregelatin\$6 or (pre-gelatin\$6)) adj6 starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:32
L3	942420	(solubility or dissolution or \$4availability or soluble or \$4available).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33
L4	1105	I2 and I3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33
L5	195	lurasidone or latuda	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33
L6	3	14 and 15	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33
L7	1572986	(drug or pharmaceutical or medicine or medicament or active).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:34
L8	719	14 and 17	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:35
L9	64608	(schizophren\$2 or psychosis or psychotic or neurological or psychiatric or mental or cognit\$3).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:40

L10	37	18 and 19	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:40
L11	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:04
L12	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2012/11/26 11:04
L13	3294	dainippon.as.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:05
L14	1	I2 and I13	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:05
L15	39	I1 and I13	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:05
S1	4	"2001076557".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2009/07/17 07:52
S2	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:53
83	2622	pre-gelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S4	0	S2 and S3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S5	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S6	25	S2 and S5	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:55

EAST Search History (Prior Art)

EAST Search History	(Prior Art)
---------------------	-------------

S7	234938	oral and pharmaceutical	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S8	10067	S5 and S7	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S9	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S10	446	S9 and oral	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:02
S11	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:17
S12	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S13	1	S11 and S12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S14	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S15	86	S11 and S14	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S16	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:57

S17	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	OFF	2009/11/12 14:09
S18	86	S16 and S17	DERWENT US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S19	1	"3607394".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2009/11/12 14:11
S20	67	(pregelatin\$4 with starch) same (polymer with binder)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:29
S21	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S22	745	S21 and (starch adj "1500")	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S23	47786	water adj solub\$4 adj polymer	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S24	43	S22 and S23	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S25	99	S21 and (PCS)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:42
S26	5	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2009/11/12 15:05
S27	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; JPO; DERWENT	OR	OFF	2009/11/12 15:07

S28	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S29	1747	S28 and (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
\$30	202	S28 with (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:15
S31	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2010/07/20 12:22
S32	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2010/07/20 12:23
\$33	84	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:24
S34	15801	pregelatin\$5 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
\$35	31	S33 and S34	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
S36	23548	accugel or absorbo or actobody or alphajel or allbond or alstar or amaizo or amalean or amerikor or amicoa or amidex or amigel or amilofax or amilys or amisol or amycol or amylex or amylogel or amylogum or amylomaize or amylon or amylose	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:27
\$37	0	S33 and S36	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:28
S38	1	"4600579".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2011/11/02 11:19

S39	2	"20040028741".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2012/03/08 12:35
S40	1936	(corn adj starch) with (pregelatinized adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 13:13
S41	1138	(corn adj starch) adj5 (pregelatinized adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 13:13
S42	4	"2002053140".pn.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 14:12
S43	4	"2003066039".pn.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 14:13
S44	6	"2005009999".pn.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 14:15
S45	2389	((pregelatinize\$1 or pregelatinise\$1) adj4 starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:50
S46	16953	((improve\$4 or increas\$4) adj4 (solubility or soluble)).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:51
S47	41	S45 and S46	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:51
S48	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2012/03/08 16:19
S49	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 16:19
S50	3215	dainippon.as.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:20
S51	232	((pregelatinize\$1 or pregelatinise\$1) with starch).ab.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:21
S52	1	S50 and S51	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:21

S53	1	S48 and S51	US-PGPUB;	OR	OFF	2012/03/08 16:22
			USPAT;			
			USOCR			

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

	SEARCHED		
Class	Subclass	Date	Examiner

SEARCH NOTES	6	
Search Notes	Date	Examiner
Inventor search in EAST, PALM	11/12/2009	S.P.
Invention and claims search in EAST, STN	11/12/2009	S.P.
Inventor search in EAST, PALM	7/12/2010	S.P.
Invention and claims search in EAST, STN	7/12/2010	S.P.
invention and claims search updated in EAST, STN	3/8/2012	S.P.
updated inventor and assignee search in EAST, PALM	3/8/2012	S.P.
updated inventor and assignee search in EAST, PALM	11/26/2012	S.P.
updated invention and claims search in EAST, STN	11/26/2012	S.P.
STIC search	11/30/2012	S.P.

	INTERFERENCE SEARCH		
Class	Subclass	Date	Examiner

/S. P./ Examiner.Art Unit 1627	


U.S. Patent and Trademark Office

Part of Paper No.: 20121205

L11 S US 20090143404/PN FILE 'REGISTRY' ENTERED AT 10:18:20 ON 26 NOV 2012 L2 1 S 9005-25-8/RN ANSWER 1 OF 1 REGISTRY COPYRIGHT 2012 ACS on STN L2 9005-25-8 REGISTRY RN CN Starch (CA INDEX NAME) OTHER NAMES: CN $\alpha ext{-Starch}$ CN 75A CN 75A (polysaccharide) CN Absorbo HP CN AccuGel CN Ace P 320 CN Actobody TP 2 ADM Clineo 716 CN CN Aeromyl 115 CN Agglofroid 009 Agglofroid 313E CN CN Allbond 200 Alphajel KS 37 CN CN Alstar B CN Alstar E CN Alstar H CN Amaizo 100 Amaizo 213 CN Amaizo 310 CN Amaizo 5 CN Amaizo 71 CN Amaizo 710 CN Amaizo W 13 CN CN Amalean I-A 2131 CN Amalean I-A 7081 CN Amerikor 818 CN Amicoa Amidex 3001 CN CN Amidex 3005 CN Amidex 4001 Amido-STA 1500 CN CN Amidomax 4800 CN Amigel Amigel 12014 CN CN Amigel 30076 CN Amijel VA 160 CN Amilofaks CN Amilofax 00 Amilys 100 CN CN Amisol 3408 Amycol HF CN CN Amycol K CN Amycol W

CN Amylex 20/20 Amylogel CN CN Amylogel 03001 CN Amylogel 03003 CN Amylogel HB 450 CN Amylogum CN Amylomaize starch SET NOTICE 1 DISPLAY SET NOTICE OFF DISPLAY FILE 'REGISTRY' ENTERED AT 10:18:44 ON 26 NOV 2012 E LURASIDONE/CN ANSWER 1 OF 1 REGISTRY COPYRIGHT 2012 ACS on STN L3 RN 367514-87-2 REGISTRY ΕD Entered STN: 07 Nov 2001 4,7-Methano-1H-isoindole-1,3(2H)-dione, CN 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, (3aR,4S,7R,7aS)- (CA INDEX NAME) OTHER NAMES: (3AR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)piperazin-1-CN yl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-2H-isoindole-1,3-dione 2-[[(1R,2R)-2-[[4-(1,2-Benzoisothiazol-3-yl)-1-CN piperazinyl]methyl]cyclohexyl]methyl]hexahydro-(3aS,4R,7S,7aR)-4,7methano-1H-isoindole-1,3(2H)-dione Latuda CN CN Lurasidone STEREOSEARCH FS MF C28 H36 N4 O2 S CI СОМ SR CA ADISINSIGHT, ANABSTR, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, LCSTN Files: CHEMLIST, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, TOXCENTER, USAN, USPAT2, USPATFULL (*File contains numerically searchable property data)

Absolute stereochemistry.



SET EXPAND CONTINUOUS

L3 1 S E3

FILE 'CAPLUS' ENTERED AT 10:19:16 ON 26 NOV 2012

- L4 138787 S L2
- L5 77 S L3
- L6 2 S L4 AND L5
- L7 1 S L6 NOT L1
- L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2012 ACS on STN
- AB The invention discloses to a lurasidone coating tablet which contains 0.1-8mm lurasidone hydrochloride(structural formula provided on page 2) 10-50, cellulose derivative(low substituted HPC) 15-50, sugar alc. 5-50, filler 5-50, adjuvants(binder, lubricant, or glidant) 1-20 weight%. The sugar alc. is mannitol, lactose, sorbierite, sucrose, fructose preferably mannitol or lactose; the filler is starch, dextrin, microcryst. cellulose, or modified starch; the binder is water-soluble polymer; the lubricant is Mg stearate, stearic acid, Zn stearate, liquid paraffin, PEG, and/or hydrogenated vegetable oil; the glidant is SiO2, colloidal silicon dioxide, silica gel micropowder, and/or talc powder. The preparation process comprises uniformly mixing lurasidone hydrochloride, sugar alc. and part or whole of low substituted HPC, wet granulating using water or $<\!40\,\%$ ethanol as wetting agent or using binder solution, drying, adding residual low substituted HPC(if presence), optional lubricant and glidant, mixing uniformly, tableting, and optionally coating to obtain the lurasidone coating tablet. The content of lurasidone in coating tablet is 10-160mg per tablet. The lurasidone coating tablet has good drug release performance and good mech. property.

propercy.	
ACCESSION NUMBER:	2012:1419908 CAPLUS <u>Full-text</u>
DOCUMENT NUMBER:	157:558467
TITLE:	Lurasidone coating tablet and preparation method
	thereof
INVENTOR(S):	Li, Xinghui
PATENT ASSIGNEE(S):	Peop. Rep. China
SOURCE:	Faming Zhuanli Shenqing, 10pp.
	CODEN: CNXXEV
DOCUMENT TYPE:	Patent
LANGUAGE:	Chinese
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 102688209	А	20120926	CN 2012-10206844	20120621
PRIORITY APPLN. INFO.:			CN 2012-10206844	20120621

		Е	PHARMACEUTICAL TABLETS/CT
		Ε	E15+ALL/CT
L8	73330	S	E34-E35,E41-E42,E44,E53
		Е	DISSOLUTION/CT
		Е	E56+ALL/CT
L9	68521	S	E67-E68
L10	8592	S	L4 AND L8
L11	3243	S	L4 AND L9
L12	0	S	L4 (L) L9
L13	3243	S	L4 (S) L9
L14	0	S	L4 (L) L8
L15	9098	S	L8 AND L9
L16	1864	S	L4 AND L15
L17	62093	S	(?ENHANC? OR ?IMPROV? OR ?INCREAS?)(S)(?DISSOL?)
L18	253	S	L16 AND L17
L19	39	S	L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)
L20	38	S	L19 NOT L1
L21	38	S	L20 NOT L7

			A	oplication/0	Control	No.	Applica Reexam	nt(s)/P ninatior	atent Undei n				
In	Index of Claims				11919678				FUJIHARA, KAZUYUKI Art Unit				
				Examiner				t					
		SA	SARAH PIHONAK				1627						
✓ F	Rejected	Car	celled	N	Non-El	ected	Α	Арр	eal				
= Allowed ÷			Res	Restricted		Interfer	rence	0	Obje	Objected			
Claims	renumbered	in the same	order as pr	esented by a	pplicant		СРА	пτ	.D. 🗆 F	R.1.47			
CL	AIM					DATE							
Final	Original	11/13/2009	07/20/2010	03/08/2012	12/06/2012	2							
	1	 ✓ 	\checkmark	√	\checkmark								
	2	 ✓ 	✓	✓	✓								
	3	~	~	 ✓ 	~								
	4	 ✓ 	✓	✓	~								
	5	N	N	N	N								
	6	N	N	N	N								
	7	N √	N	N	N	-							
	8	✓ ✓	-	-	-								
	10	v √	-	-	-								
	11	· · · · · · · · · · · · · · · · · · ·	~	- -	- -								
	12	✓	~	\checkmark	~								
	13	✓	✓	✓	✓								
	14	✓	~	✓	~								
	15	 ✓ 	-	-	-								
	16	✓	~	√	~								
	17	✓	-	-	-								
	18	 ✓ 	-	-	-								
	19	~	✓	~	~								
	20	✓	✓	✓	✓								
	21	 ✓ 	✓	✓	✓								
	22	✓ ✓	✓ ✓	✓ ✓	✓ ✓	┥───┤							
	23	✓ ✓	 ✓	✓ ✓	 ✓	+							
	24		 ✓	v √	 ✓	+							
	26		· ✓	· ·	· •				+				
	27			✓	~								
	28			~	~								
	29			 ✓ 	~								
	30			✓	\checkmark								
	31			 ✓ 	~								
	32			~	~								
	33			✓	<u>√</u>								
	34			✓ 	✓ 								
	35			N	N	+							
	36			N	Ν				1				

U.S. Patent and Trademark Office

Part of Paper No. : 20121205

							Applicant(s)/Patent Under Reexamination							
Index of Claims					11919678			FUJIHARA, KAZUYUKI						
					Examiner			Art Unit						
				SARAH PIHONAK			1627							
~	R	ejected	d - (Cancelled		Ν	Non-Ele	ected		A	Ар	peal
=	= Allowed ÷ F		Re	Restricted		Interference			0	Obje	ected			
☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47														
CLAIM DATE														
Fi	Final Original 11/13/2009 07/20		07/20/20	10 03/08/2012										
37						V	/							

Part of Paper No. : 20121205

Par Pharm., Inc. Exhibit 1015 Page 443

	RE	QUEST FC		D EXAMINATIC d Only via EFS	N(RCE)TRANSMITTA	L	 -
Application Number	11919678	Filing Date	2007-10-31	Docket Number (if applicable)	7379/98100	Art Unit	1627
First Named Inventor	Kazuyuki FU.	IIHARA		Examiner Name	Sarah PIHONAK	_1	I
Request for C	ontinued Exar	nination (RCE)		R 1.114 does not a	above-identified application. oply to any utility or plant applic WWW.USPTO.GOV		t prior to June 8,
		S	UBMISSION REQ	UIRED UNDER 37	CFR 1.114		
in which they	were filed unle	ss applicant ins		applicant does not wi	nents enclosed with the RCE w sh to have any previously filed		
		a final Office ac		any amendments file	d after the final Office action m	ay be con	sidered as a
□ Co	nsider the arg	uments in the A	Appeal Brief or Reply	Brief previously filed	on		
🗌 Otl	ner						
Enclosed							
🖂 An	nendment/Rep	ly					
🔲 Info	ormation Discl	osure Statemer	nt (IDS)				
Aff	idavit(s)/ Decla	aration(s)					
🛛 Ot	her <u>Petition</u>	For Extension	of Time				
			MIS	CELLANEOUS			
			ntified application is d 3 months; Fee und		CFR 1.103(c) for a period of m quired)	onths	
Other							
				FEES			
🛛 🛛 The Dire			s required by 37 CF harge any underpay		RCE is filed. it any overpayments, to		
		SIGNATUF	RE OF APPLICAN	T, ATTORNEY, OF	AGENT REQUIRED		
	Practitioner S ant Signature	gnature					

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner						
Signature	/Kendrew H. Colton/	· · ·		Date (YYYY-MM-DD)	2013-06-11	
Name	Kendrew H. Colton	, <i>House</i>	· · · · · · · · · · · · · · · · · · ·	Registration Number	30368	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:		
Kazuyuki FUJIHARA	Confirmation No.:	6965
U.S. Application No.: 11/919,678	Examiner:	PIHONAK, SARAH
Filed: October 31, 2007	Group Art Unit:	1627
For: PHARMACEUTICAL COMPOSITION	Attorney Docket N	o.: 7379/98100

AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Kindly enter this Amendment and grant the concurrently filed Petition for Extension of Time. This Amendment should be considered together with the concurrently filed Appendix.

TABLE OF CONTENTS

....

1.	Amendments to Claims	2
2.	Remarks/Arguments	11
	A. Claims Presented	11
	B. Rejoinder is Requested	11
	C. Claims 1-4, 9, 11-14, 16, 19-34 and 37 define unobvious inventions over Fujihara and Salepakar. Even if combined, the references would not have suggested these claimed inventions.	11
	D. Introducing the claims inventions versus the references.	11
	Ŭ	
	E. Fujihara does not teach or suggest the pregelatinzed starch in the claims.	14
	F. Fujihara's shortcomings are not overcome, even if, for the sake of argument it were combined with Salpekar, which is a combination that would <i>not</i> have been made by a person of ordinary skill in the art.	14
	G. Selpekar teaches away from the pregelatinized starch in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.	15
	H. Contrary to the Office Action, Salpekar actually teaches away from the present claimed inventions.	17
	 I. Literature reports pregelatinized starch (PGS) in amounts that would have taught away from the claimed oral preparation having 10 to 50% (wt/wt) of pregelatinized starch. The literature reports typically 10% or less of PGS as does Salpekar. 	19

Atty. Docket No. 7398/88063 Application 10/569,740

Amendment

3.

. . .

J. The Office Action has not adduced evidence relating the comparatively water soluble acetoaminophen to the comparatively water insoluble lurasidone. Sepekar discloses acetaminophen. It is markedly much more water soluble than the comparatively water insoluble lurasidone. Therefore, Sepekar's results	
with only acetaminophen would not have led	
one to expect the present results obtained	
with the comparatively water <i>in</i> soluble ingredient	
(lurasidone), nor led to combining Fujihara and	
Sepekar.	20
K. Salpekar teaches amounts of a water soluble active ingredient that would not have suggested the amounts of relatively water insoluble active ingredient (lurasidone) in the present oral compositions.	21
L. Commercial success favors patentability	
for the present claimed inventions.	22
M. Applicant traverses the common law obviousness type double patenting rejection. Applicant requests	
reconsideration and withdrawal of same.	22
N. Conclusion	23
Appendix	25

....


Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 4

Amendments to the Claims:

This listing of claims replaces any and all prior claim lists.

Listing of Claims:

(Previously Presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

2. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

3. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble polymer binder;

wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

4. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose.

5. (Withdrawn) A method for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder.

6. (Withdrawn) A method for preparing the oral preparation of claim 1 wherein the method comprises granulation of a powder mixture which comprises granulating a powder mixture comprising a pregelatinized starch and a water-soluble excipient by using a solution or dispersion of lurasidone and a water-soluble polymer binder.

7. (Withdrawn) The method of claim 5 wherein the water-soluble excipient is mannitol or lactose.

8. (Canceled)

9. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10. (Canceled)

11. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

. . .

12. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. (Canceled)

16. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17-18. (Canceled)

19. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

20. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

21. (Previously Presented) The oral preparation of claim 1 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Previously presented) The oral preparation of claim 1 wherein a 50% by volume particle size of lurasidone is 0.1 to 8 μ m.

23. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to 40% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

25. (Previously Presented) The oral preparation of claim 1 wherein the water-soluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 20 to 45% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

26. (Previously Presented) The oral preparation of claim 9 wherein the water-soluble excipient is mannitol or lactose.

27. (Previously submitted) The oral preparation of claim 1 wherein a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt).

28. (Previously submitted) The oral preparation of claim 1 wherein the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose.

29. (Previously submitted) The oral preparation of claim 1 wherein a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

30. (Previously submitted) The oral preparation of claim 1, further comprising a disintegrant wherein a content of the disintegrant per tablet is 0.5 to 5% (wt/wt).

31. (Currently amended) The oral preparation of claim 1, further comprising a disintegrant wherein

a content of the disintegrant per tablet is 0.5 to 5% (wt/wt);

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation;

a content of lurasidone per tablet is 40 to 120 mg;

a pregelatinizing ratio of the pregelatinized starch is 50 to 95%;

50% by volume particle size of lurasidone is 0.1 to 8 µm;

the pregelatinized starch contains water soluble matter of 30% or less;

a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt);

the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose; and

. . .

a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

32. (Previously submitted) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 160 mg.

33. (Previously submitted) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 80 to 160 mg.


34. (Previously submitted) The oral preparation of either one of claim 1 or 31, wherein a similarity factor f2 of each preparation is in the range of 50≤f2≤100 when a content of lurasidone per tablet changes over a range of 20 to 120 mg.

35. (Withdrawn) A method for treating psychosis, comprising administering the oral preparation of claim 1 to a patient suffering from psychosis.

36. (Withdrawn) A method for treating schizophrenia, comprising administering the oral preparation of claim 1 to a patient suffering from schizophrenia.

37. (Previously presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 10



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder, wherein the oral preparation contains 20 to 45% (wt/wt) of lurasidone, the oral preparation contains 20 mg to 120 mg of lurasidone, the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the oral preparation, and the oral preparation exhibits an equivalent dissolution profile across the range of lurasidone per oral preparation.

38. (New) The oral preparation of either one of claim 1 or 31, wherein the water-soluble excipient is one or more selected from the group consisting of mannitol, lactose, saccharose, sorbitol, D-sorbitol, erythritol and xylitol.

39. (New) The oral preparation of either one of claim 30 or 31, wherein the disintegrant is one or more selected from the group consisting of corn starch, crystalline cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium and crospovidone.

REMARKS

Applicant courteously solicits favorable reconsideration upon entry of this Amendment and consideration of the concurrently filed Appendix (evidence).

Claims Presented

Upon entry of this Amendment claims 1-7, 9, 11-14, 16, and 19-39 are presented. Claims 5-7 and 35-36 are withdrawn.

The new and amended claims avoid new matter and entry thereof is courteously solicited. Claim 31 is amended to correct "article" to "particle." New claims 38 and 39 find basis in the original specification at paragraphs [0017] and [0020], respectively.

Rejoinder is requested.

Applicant respectfully solicits rejoinder of the withdrawn claims 5-7 and 35-36.

Claims 1-4, 9, 11-14, 16, 19-34 and 37 define unobvious inventions over Fujihara and Salepakar. Even if combined, the references would not have suggested these claimed inventions.

Applicants respectfully traverse the rejection of claims 1-4, 9, 11-14, 16, 19-34 and 37 under 35 U.S.C. §103(a) over Fujihara *et al.* (EP Patent Publication No. 1327440) in view of Salpekar *et al.* (U.S. Patent No. 4,600,579).

Introducing the claims inventions versus the references.

Aspects of the present claimed inventions involve an oral preparation that can comprise higher contents of a hardly-soluble pharmaceutically active agent (e.g. lurasidone), yet the preparation exhibits a similar dissolution profile as compared to oral preparations having different contents of such pharmaceutically active agent (*see*, *e.g.*, specification, paragraphs [0001], [0008]-[0009] and [0013]; the examples and FIG. 3.).

Applicant has found that it is possible to provide an oral preparation having a lurasidone content in the preparation of 20 to 45% (wt/wt.) in combination with 10 to 50% (wt/wt) pregelatinized starch that provides advantageous dissolution profiles.

More particularly, characteristics of the present invention include:

1) the oral preparation of the present invention includes a high lurasidone content per tablet, particularly high content ratio (%) of 20 to 45% (wt/wt) of lurasidone as recited in claim 1 - which allows the employment of relatively high total amounts of lurasidone in a tablet of relatively small size – while, at the same time, the oral preparation exhibits beneficial dissolution properties (*see, e.g.*, paragraph [0106]);

2) the oral preparation of the present invention incorporates pregelatinized starch in a range of 10 to 50% (wt/wt) based on the weight of the preparation; and

3) the preparation of the present invention has beneficial dissolution properties, that is, it shows equivalent dissolution profiles as between oral preparations having different contents of lurasidone, as reflected by a similarity factor (f2) of $\geq 50^{1}$, and furthermore exhibits <u>rapid dissolution</u> (*e.g.*, a dissolution of at least 85% of the initially present lurasidone within 30 minutes).

In short, an oral preparation provides a high content ratio of lurasidone (which allows employing comparatively higher amounts of lurasidone in relatively small tablets) that, at the same time, exhibiting rapid dissolution. Oral preparations having different lurasidone contents exhibit equivalent dissolution profiles ($f2 \ge 50$). This is a distinct advantage. This combination of advantageous properties results from the presence of pregelatinized starch in the claimed oral preparation in an amount of 10 to 50% (wt/wt) based on the weight of the preparation, as can be seen from the data shown in the as discussed in this Amendment.

¹ Dependent claim 34 provides an oral preparation according to claim 1 or 31 has a similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg. *Neither* cited reference describes or suggests claim 34.

None of the prior art documents applied against the claims would have taught or suggested this oral preparation or its advantages.

As demonstrated below, Fujihara (the primary reference) does not teach or suggest an oral preparation which contains lurasidone in a content ratio of lurasidone of 20 to 45% (wt/wt)) (claims 1, 2 and 3) that can include, for instance, 20 mg to 120 mg lurasidone per oral preparation (dependent claim 13, independent claim 37), is completely silent on the use of pregelatinized starch, does not teach or disclose a pregelainized starch in an amount of 10 to 50% (wt/wt) based on the weight of the preparation (independent claims 1, 2, 3, and 37), and does not disclose or teach an oral preparation with the superior dissolution properties obtainable with a present oral preparation, such as equivalent dissolution profiles at different contents of lurasidone² (*see, e.g.,* claim 37), as reflected by a similarity factor (f2) of \geq 50 (note dependent claim 34), and also rapid dissolution (*e.g.,* a dissolution of at least 85% of the initially present lurasidone within 30 minutes).

As also demonstrated below, these and other shortcomings of Fujihara would not have been overcome even if, for the sake of argument, Fujihara is additionally combined with Salpekar, which combination would not have been made in any event.

<u>Salpekar's compositions</u> containing the <u>comparatively water soluble</u> <u>acetomimophen are not apposite to</u> the present <u>oral preparations containing the</u> <u>comparatively water insoluble lurasidone</u>, are not relatable except with hindsight to Fujihara, do not teach or even suggest any lurasidone oral preparation, <u>and</u> when fairly considered <u>teach away</u> the incorporation of the comparatively larger amount of the pregelatinized starch into an oral preparation because of undesirable disintegration times. In other words, there would have been no expectation of achieving the present claimed oral preparations and their advantages.

² In re Papesch, 137 U.S.P.Q 143 (CCPA 1963).

Therefore, *even if* Fujihara were combined with Salpekar, which is a point not conceded, the present claimed oral preparations with their advantages would have been *un*foreseen and *un*expected by a person skilled in the art.

. . .

Fujihara does not teach or suggest the pregelatinzed starch in the claims.

Claim 1 refers to an oral preparation containing "a pregelatinized starch, ...wherein ... the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation." *See also* independent claims 2, 3 and 37.

Dependent claim 9 refers to an oral preparation wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation. *See also* dependent claims 19, 20, 24, 25, and 31.

Fujihara is completely silent on the use of pregelatinized starch or on the advantages to an oral preparation having the pregelatinized startch incorporated in an amount of 10 to 50% (wt/wt).

Accordingly, the advantageous dissolution profiles for a present oral preparation having a higher content ratio of lurasidone (*see, e.g.,* Applicant's prior Amendment) with the recited amount of pregelatinized starch, is neither taught nor suggested by Fujihara.

Fujihara's shortcomings are not overcome, even if, for the sake of argument it were combined with Salpekar, which is a combination that would *not* have been made by a person of ordinary skill in the art.

Fujihara in view of Salpekar nonetheless would not have provided motivation towards the claimed inventions.

As demonstrated below, this follows since Salpekar teaches a specific composition comprising acetaminophen as the pharmaceutically active ingredient and pregelatinized starch, which is significantly more water soluble compared to the chemically different and relatively water insoluble lurasidone, and even if *arguendo* some of Salpekar's acetaminophen-containing compositions having other additives and amounts may allow a shorter dissolution time and may shorten the dissolution and disintegration time.

None-the-less, the Examiner has alleged that Salpekar teaches that the amount of pregelatinized starch ranges from 5 or less to 15 or more parts per 100 parts of the composition (e.g. Office Action, page 4 lines 20-22). Applicant respectfully disagrees and requests reconsideration.

Even if, for the sake of argument, the Examiner's acknowledgement might be correct, which is a point not conceded, and even if the two references would have been combined, which is another point not conceded, in order to arrive at the present claimed invention, a person of ordinary skill in the art would have been required to combine Fujihara disclosing lurasidone oral preparations, while ignoring Salpekar's teachings to use acetaminophen, with Salpekar disclosing pregelatinized starch, and further, adopt the amount of pregelatinized starch (i.e. 20 to 30% (wt/wt)) which is beyond the range of 5 to 15 parts disclosed in Salpekar and beyond 18.0% in Example 1 which is unfavorable in view of the disintegration time.

Selpekar teaches away from the pregelatinized starch in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

Claim 1 recites "the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation."

Salpekar effectively teaches away from this feature in claim 1 and other claims 2, 3, and 37 as examples.

<u>First</u>, Sepekar teaches that only a combination of small amounts of pregelatinzed starch ("PGS"), such as 8.85 % or 6.4%, <u>and</u> at least an auxiliary binder disclosed can improve disintegration time in the acetaminophen tablets. Sepekar's disclosed value of 8.85% or 6.4% would not have suggested an oral composition containing lurasidone and

pregelatinized starch incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

<u>Second</u>, Salpekar's Examples and related disclosures show that larger amounts of pregelatinized starch, such as the 18.0% in Example 1, do not improve the disintegration time and the dissolution profile of the acetaminophen-containing tablet.

The poorer results reported with 18% pregelatinized starch would have led away from claim 1. More particularly, Salpekar's Examples 1-3 are teach away from the amount of pregelatinized starch in the present claims.³ From the Table in column 8 and taking col. 4, lines 3-9 into consideration, the Example 1 tablet (18.0% of PGS) is not acceptable in order to solve Salpekar's problem, since the disintegration time of Example 1 tablet is 18.0 minutes which is 300% times longer than that the Example 2 tablet (6 minutes) and 1200% times longer than the Example 3 tablet (1.5 minutes). Even the Example 2 tablet comprising 8.85% of PGS is more disadvantageous since it shows a 400% times longer disintegration time than exhibited by a tablet according to Salpekar's Example 3.

Thus, a present oral preparation having pregelatinized starch incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation would <u>not</u> have been suggested by the poorer results reported for Sepekar's Example 3 (18% of PGS) (*e.g.*, an increased disintegration time for the acetaminophen containing composition). Increasing the amount of pregelatinized starch would have suggested longer, not shorter disintegration times in an acetominophen tablet, but longer disintegration times would have been contrary to Salpekar's stated objective for disintegration times (col. 4, lines 3-9).

<u>Third</u>, even if, for the sake of argument, Salpekar *et al*. were combined with Fujihara, a person skilled in the art would not have arrived at the pregelatinized starch

³ Salpekar explains at column 8, lines 44-49 that "As indicated in these examples, Example 1 contains neither auxiliary binder nor auxiliary disintegrating agent; Example 2 includes an auxiliary binder but no auxiliary disintegrating agent; and Example 3 includes both an auxiliary binder and an auxiliary disintegrating agent."

(10 to 50% (wt/wt)) in the independent claims. Those skilled in the art would have understood from Salpekar that 4.45-8.85% of pregelatinized starch is preferable for an acetaminophen tablet having a short disintegration time and a short dissolution time. Although Salpekar might be said to teach an effective amount of pregelatinized starch (PGS) is from about 5 or less to about 15 or more parts per 100 parts of the <u>acetaminophen</u> composition (*see*, col. 4, lines 15-17), Salpekar's acetaminophen compositions that show technical effects are only those supported by Examples 2 and 3 (*i.e.*, 4.45-8.85% of pregelatinized starch). This follows from Salpekar's disclosure that the pregelatized starch is included in an amount effective for imparting to the acetaminophen composition the capability of being formed into tablets having high hardness, short disintegration time (*e.g.*, about 10 minutes or less) and short dissolution time (e.g., about 20 minutes or less). *See*, col. 4, lines 3-9. In other words, Fujihara + Salpekar, even if the combination were made, which is not conceded, a person of ordinary skill in the art would have been led away from the claimed oral preparations.

Contrary to the Office Action, Salpekar actually teaches away from the present <u>claimed inventions</u>.

In response to Applicant's previous argument against Salpekar regarding a comparison of Examples 1 and 2, the Examiner asserts that the disintegration profile comparison of the examples referred to by Salpekar shows the differences in the compositions with and without an auxiliary binder and auxiliary disintegration agent. See, Office Action, page 8 lines 14-17.

In this respect, although Applicant argued that Example 1 of Salpekar which includes 18.0% of pregelatinized starch should not be preferable in view of longer disintegration time of 18.0 minutes in Example 1 compared to shorter disintegration time of 6 or 1.5 minutes in Example 2 or 3, which constitutes a "teaching-away" factor for high content ratios of pregelatinized starch comprised in a composition such as 18.0% in Example 1 of Salpekar, the Examiner asserts that Salpekar teaches that the

composition comprised of the pregelatinized starch is beneficial for preparing oral pharmaceutical formulations with high hardness and short dissolution time. See Office Action, page 12 line 19 to page 13 line 5, etc.

However, Applicant disagrees with the Examiner's acknowledgement.

As evident, Salpekar discloses that an additional binding agent (referred to as a "compressibility-promoting agent") such as PVP may be included in the composition in order to increase the obtainable hardness of tablets. See, Salpekar, column 4 line 67 to column 5 line 3. An additional disintegration agent (referred to as a "disintegration-promoting material"), such as XL-PVP, may be included in the acetaminophen composition to decrease the obtainable disintegration time of tablets. See, Salpekar column 5 lines 24 to 29.

Specifically, Salpekar's Example 1 discloses its composition comprises neither an additional binding agent nor an additional disintegration agent, whereas Salpekar's Example 2 does not comprise XL-PVP as the additional disintegration agent but comprises PVP as the additional binding agent. Consequently, when the compositions of Examples 1 and 2 are compared, a person of ordinary skill in the art would expect the composition of Example 2 comprising the additional binding agent to increase the hardness of tablets, and Example 2 actually shows 13 kp of hardness which is higher than Example 1 (9.3 kp).

Typically, in the art it has been believed that a binding agent makes a disintegration time of composition longer in view of the increase of hardness. Nevertheless, Example 2 shows 6 minutes of the disintegration time which is one-third of the disintegration time of Example 1 (18.0 minutes). Then, a skilled person would consider that the reason why Example 2 - even comprising the binding agent - could achieve a shorter disintegration time is to reduce the amount of pregelatinized starch by more than half in Example 2 (i.e. from 18.0% of Example 1 to 8.85% of Example 2),

which is the only difference between Examples 1 and 2 except for the inclusion of the binding agent in Example 2.

.....

As seen in abstract, the Salpekar acetaminophen composition should achieve a tablet having both (1) high hardness, and (2) short disintegration time and short dissolution time, where the property (1) and the property (2) are clearly an opposite property each other. In view of this technical goal in Salpekar and the above comparison between Examples 1 and 2, Example 1 could not meet the two properties since the disintegration time of Example 1 was 18.0 minutes which is apparently longer than "short disintegration time" (i.e. 10 minutes or less). See, Salpekar, col. 4 lines 3-9.

As mentioned above, the only difference between Examples 1 and 2 is that Example 2 comprises only less than half of pregelatinized starch in Example 1 except for the inclusion of PVP in Example 2 which basically increases the hardness, then is expected to extend the disintegration time. That means that Salpekar discloses that only 4.45 to 8.85% of pregelatinized starch could work for achieving the tablet having the desired above two properties, and a high content ratio of pregelatinized starch such as 18.0% could not achieve the desired tablet.

In short, Salpekar clearly teaches away from Applicant's lurasidone composition having a high content ratio of pregelatinized starch, and certainly teaches away from one having 18.0%.

Literature reports pregelatinized starch (PGS) in amounts that would have taught away from the claimed oral preparation having 10 to 50% (wt/wt) of pregelatinized starch. The literature reports typically 10% or less of PGS as <u>does Salpekar</u>.

The conventional teachings would have led away from the present oral preparations. As reported in the present specification, pregelatinized starch "is often used, typically, in 10% <u>or less</u> of contents as described in Non-patent Document 1." *See, e.g.*, specification, paragraph s [0006] and [0007] (emphasis added). *See also*, Applicant's *previously* filed Appendix at item 2. This supports the point that typically

(conventionally) *less* than 10% (wt/wt) pregelatinized starch would have been used, which is consistent with the results Selpaker disclosed for the acetaminophen compositions.

. . .

The Office Action has not adduced evidence relating the comparatively water soluble acetoaminophen to the comparatively water insoluble lurasidone. Sepekar discloses acetaminophen. It is markedly much more water soluble than the comparatively water insoluble lurasidone. Therefore, Sepekar's results with only acetaminophen would not have led one to expect the present results obtained with the comparatively water *in*soluble ingredient (lurasidone), nor led to combining Fujihara with Sepekar.

Salpekar exclusively focuses on the comparatively water soluble acetaminophen⁴ would not have motivated a person of ordinary skill in the art would towards an oral preparation having 10 to 50% (wt/wt) of pregelatinized starch and the comparatively water <u>in</u>soluble lurasidone as recited in the claims.

There is no evidence cited in the Office Action to show a person of ordinary skill in the art would have related acetaminophen with lurasidone, nor is there evidence cited to suggest Sepekar's results with the former would have led to a candidate of choice to be selected in discovering an oral preparation as claimed. The compounds are different. Their properties are different.

The Examiner, however, isolates and cites passages in Salpekar at col. 3, lines 46-51 and col. 4, lines 31-37, see, e.g., Office Action, page 5, lines 6-9 from the bottom, as if these passages were generic, which they are not. See, *In re Wesslau*, 147 USPQ 391, 393 (CCPA 1965) ("It is impermissible within the framework of section 103 to pick and choose from any one reference only so much of it as will support a given position, to the

⁴ Contrary to the Office Action, Salpekar specifically and only focuses on the requirements for an acetaminophen composition. Selpekar "relates to an N-acetyl-p-amino-phenol composition" (col. 1, lines 6-7) in which "N-acetyl-p-aminophenol [is] ... hereinafter referred to sometimes as acetaminophen..."). Selpekar, col. 1, lines 11-12.

exclusion of other parts necessary to the full appreciation of what such reference fairly suggests to one of ordinary skill in the art.")

. . .

Contrary to the Office Action, the actual passages in Salpekar specifically only relate to "<u>the</u> composition," which must contain acetaminophen. *See, e.g.,* Selpekar, Abstract, col. 1, lines 6-29, col. 1, lines 38 and 63, col. 2, line 21, col. 5, line 48, col. 6, (Tables), and the Examples.

Since Salpekar relates only to a comparatively soluble agent "acetaminophen," <u>not</u> to the hardly-soluble agent (lurasidone) in the claimed oral preparations, it would have been <u>un</u>reasonable to expect Salpekar's disclosure regarding an acetaminophen composition to be appropriate for an oral preparation having a "content of [the comparatively hardly soluble] lurasidone ... [of] 20 to 45% (wt/wt)," as claimed herein.

In other words, on the present factual record, there would have been no basis to have expected Selpekar's results with acetaminophen, which is a comparatively more water soluble agent would even have made Salpekar the candidate of choice for, let alone applicable, to a lurasidone composition as in Fujihara since lurasidone is comparatively significantly more water *in*soluble because it is 1/62.5 as soluble as acetaminophen.⁵

Salpekar teaches amounts of a water soluble active ingredient that would not have suggested the amounts of a relatively water *in*soluble active ingredient (lurasidone) in the present oral compositions.

The higher contents of the different material in Salpekar teach away from the claim 1 oral preparation with an oral preparation having "a content of lurasidone in the preparation [of] 20 to 45% (wt/wt)" as in claim 1, as an example.

⁵ <u>Acetaminophen</u> has an experimental water solubility of <u>14 mg/mL</u> (DrugBank (http://www.drugbank.ca/drugs/DB00316), see the attachment to prior Amendment).

<u>Lurasidone</u>, however, has a water solubility of only <u>0.224 mg/mL</u> at 20°C, which more than an order of magnitude less than that for acetaminophen.

Salpekar discloses a preferred embodiment is a composition comprising 93-83% of acetaminophen (see line 63, column 5 to line 9, column 6). Those skilled in the art would have had no expectation or motivation to apply Salpekar's formulation for acetaminophen with extremely high contents (93-83%) of that active ingredient to tablets comprising the comparatively water <u>insoluble</u> lurasidone in order to solve the problem of the undesired dissolution profiles of lurasidone in a conventional composition.

Commercial success favors patentability for the present claimed inventions.

Applicant respectfully invites the Examiner to peruse the Appendix hereto.

Applicant respectfully submits the great commercial success achieved by the attainment of the oral preparation. This evidence supports unobviousness. The oral preparation comprises high content ratios of lurasidone as the active ingredient and shows a prominent dissolution profile.

The oral lurasidone preparation was approved as LATUDA® in October 2010 by the FDA and in June 2012 by Health Canada, and is currently available for sale as one of therapeutic agents for schizophrenia (tablet) in the U.S. and Canada.

Applicant encloses a News Release of Sunovion (page 3, 5th paragraph), http://www.ds-pharma.com/pdf_view.php?id=299. The Examiner is invited to peruse businesswire. See http://www.businesswire.com/news/home/20130520006314/en.

The Examiner is advised that sales of lurasidone (for present purposes, the above mentioned LATUDA® brand product) in North America reached about \$202 million in fiscal year 2012 (from April 2012 to March 2013). Applicant encloses an extract from the Financial Results for FY2012 (5th slide), although the Examiner may wish to peruse http://www.ds-pharma.com/pdf_view.php?id=296.

Applicant traverses the common law obviousness type double patenting rejection. Applicant requests reconsideration and withdrawal of same.

Applicant respectfully requests the Examiner to reconsider the non-statutory rejection of claims 1-4, 9, 11-14, and 19-34 over commonly owned U.S. application 12/997779 and claims 1-8 therein. This application is the earlier filed application (series "11" application) and the common law rejection over claims in a later filed application seems misplaced, and besides, such claims might be canceled or amended, or other action taken. Withdrawal of this non-statutory rejection seems appropriate and is respectfully requested.

Conclusion

Applicant respectfully submits claims 1-4, 9, 11-14, 16, 19-34, 37, and new claims 38-39 are in allowable form. Applicant courteously solicits a Notice of Allowance for these claims.

Applicant respectfully solicits rejoinder for the non-elected claims. If not rejoined, the Examiner is invited to telephone the undersigned regarding disposition of such claims upon allowability for the elected claims.

The Examiner is cordially invited to telephone the undersigned with any comments, suggestions or questions, or to schedule an interview.

Applicant hereby requests that any concurrent or future reply submitted by Applicants to the U.S. Patent and Trademark Office in connection with the aboveidentified patent application requiring an extension of time under 37 C.F.R. §1.136(a) for its timely submission be treated as incorporating therein a request for an extension of time for the appropriate length of time. In addition, to the extent necessary during prosecution of the present application, Applicant hereby authorizes the Commissioner to charge any required fee not otherwise provided for, including application processing, extension, and extra claims fees, to Deposit Account No. 06-1135 with reference to Attorney Docket No. **7379/98100**.

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 24

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

/Kendrew H. Colton/

Kendrew H. Colton Registration No. 30,368 Tel: (202) 419-7000 Fax: (202) 419-7007

Please send official correspondence to: **Customer Number 42798**

FITCH, EVEN, TABIN & FLANNERY 1120 20th St., NW, Suite 750 South Washington, DC 20036

Attorney Docket No.: 7379/98100 U.S. Application No. 11/919,678 Page 25

APPENDIX



Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700

News Release

Contact: Patricia Moriarty Senior Director, Corporate Communications Sunovion Pharmaceuticals Inc. 508-787-4279 patricia.moriarty@sunovion.com

Sunovion Pharmaceuticals Inc. Announces Data Showing Latuda[®] (lurasidone HCI) was Associated with Low Rates of Weight and Metabolic Changes in Patients with Depressive Episodes Associated with Bipolar I Disorder

A Similar Pattern of Metabolic Changes was Observed in Patients Who Received LATUDA as Monotherapy or as Adjunctive Therapy to Mood Stabilizers

Marlborough, Mass., May 20, 2013 – Sunovion Pharmaceuticals Inc. today announced it will present 18 research posters on Latuda[®] (lurasidone HCI), an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia, at the 166th Annual Meeting of the American Psychiatric Association (APA) in San Francisco. The presentation includes results from analyses of two pivotal studies in patients with depressive episodes associated with bipolar I disorder (bipolar depression). These new data showed that LATUDA in the treatment of bipolar depression, either as monotherapy or added to ongoing treatment with lithium or valproate, was associated with low rates of change in weight, body mass index (BMI), lipid parameters and measures of glycemic control.

The two pivotal studies evaluated the efficacy and safety of LATUDA as monotherapy (PREVAIL 2) or adjunctive therapy (PREVAIL 1) for the treatment of bipolar depression, and supported two supplemental New Drug Applications (sNDAs) that were accepted by the U.S. Food and Drug Administration (FDA) on October 30, 2012.

"Sunovion is pleased to present data from two extensive research programs that studied LATUDA in patients with schizophrenia and bipolar depression," said Antony Loebel, M.D., Executive Vice President and Chief Medical Officer of Sunovion Pharmaceuticals Inc. "We are proud of the contributions we are making to improved understanding of these disorders where high unmet clinical needs remain."

Effects of LATUDA on Metabolic Indices in Bipolar Depression

The LATUDA monotherapy (PREVAIL 2) and adjunctive therapy studies (PREVAIL 1) were six-week, randomized, double-blind, placebo-controlled clinical trials that evaluated the efficacy and safety of LATUDA as monotherapy (20-60 mg/day or 80-120 mg/day vs. placebo, N=505) or adjunctive therapy (20-120 mg/day, N=348) to lithium or valproate in patients with bipolar depression, with or without rapid cycling (DSM-IV-TR). Changes from baseline to Week 6 in metabolic parameters [lipids, glucose, weight,

insulin and homeostatic model assessment of insulin resistance (HOMA-IR)] were assessed [using rank ANCOVA (LOCF) controlling for the baseline values of these metabolic parameters]. Results from the studies were as follows:

PREVAIL 2 (Monotherapy)

- Mean weight change from baseline for LATUDA vs. placebo was 0.64 vs. -0.09 lbs. (p=not significant).
- Weight gain from baseline (≥ 7%) occurred in 2.4% of patients treated with LATUDA vs. 0.7% of patients treated with placebo.
- Mean changes from baseline in metabolic laboratory parameters were: cholesterol -1.7 vs. -3.2 mg/dL, LDL -2.7 vs. -3.5 mg/dL, triglycerides 3.0 vs. 6.0 mg/dL, glucose 0.5 vs. 1.8 mg/dL, insulin 3.56 vs. 2.95 mU/L and HOMA-IR 1.08 vs. 1.19, for LATUDA vs. placebo, respectively (p=not significant for all comparisons).

PREVAIL 1 (Adjunctive Therapy)

- Mean weight change from baseline for LATUDA vs. placebo was 0.51 vs. 0.31 lbs. (p= not significant).
- Weight gain from baseline (≥ 7%) occurred in 3.1% of patients treated with LATUDA vs. 0.7% of patients treated with placebo.
- Mean changes from baseline in metabolic laboratory parameters were: cholesterol -3.0 vs. -3.8 mg/dL, LDL -3.2 vs. -2.0 mg/dL, triglycerides 9.0 vs. -6.2 mg/dL, glucose 0.9 vs. -0.3 mg/dL, insulin 1.66 vs. -0.16 mU/L and HOMA-IR 0.26 vs. -0.07, for LATUDA vs. placebo, respectively (p=not significant for all comparisons).

Using the National Cholesterol Education Program (NCEP) adult treatment panel criteria for metabolic syndrome, approximately 15% of patients met criteria for metabolic syndrome (MetS) at study baseline, which is associated with risk for diabetes and cardiovascular disease.

"Prior research has shown that patients with bipolar disorder are already at high risk for metabolic syndrome," said Loebel. "As such, it is critically important that we continue to evaluate the effect of LATUDA on these key measures of metabolic health, in both short and longer-term treatment."

In PREVAIL 1, the most frequently reported adverse events were nausea, somnolence, tremor, akathisia and insomnia. Discontinuation rates due to adverse events were 6% for LATUDA and 7.9% for placebo. In PREVAIL 2, the most frequently reported adverse events were nausea, headache, akathisia, somnolence and sedation. Discontinuation rates due to adverse events were 6% for LATUDA (either dose group) and 6% for placebo.

About Bipolar I Disorder and Bipolar Depression

Bipolar disorder, a mental illness characterized by debilitating mood swings, affects approximately 10.4 million American adults.^{1.2} Bipolar depression refers to the depressive phase of bipolar disorder.³ Symptoms of bipolar depression include: extreme sadness, anxiety, fatigue, inactivity and disinterest in usual activities, disruptions to sleeping patterns and hopelessness.^{1.4} When symptomatic, most people with bipolar disorder tend to be depressed, rather than manic.³ Bipolar disorder can also double a person's risk of early death from a range of medical conditions, including obesity, diabetes and

Page 2 of 7

cardiovascular disease.^{5,6,7} Bipolar disorder is the sixth leading cause of disability worldwide⁸ and is among the top 10 leading causes of disability in the United States (U.S.).⁹

About LATUDA

LATUDA is an atypical antipsychotic agent indicated for the treatment of patients with schizophrenia. Efficacy was established in five six-week controlled studies of adult patients with schizophrenia. The effectiveness of LATUDA for longer-term use, that is, for more than six weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

The recommended starting dose for LATUDA for the treatment of patients with schizophrenia is 40 mg once daily taken with food (at least 350 calories) with no initial dose titration required. LATUDA has been shown to be effective in a dose range of 40 mg/day to 160 mg/day. The maximum recommended dose is 160 mg/day. For patients with moderate and severe renal or hepatic impairment, the recommended starting dose of LATUDA is 20 mg/day. The maximum recommended dose is 80 mg/day in patients with moderate hepatic impairment and 40 mg/day in patients with severe hepatic impairment. The recommended starting dose of LATUDA in patients taking a moderate CYP3A4 inhibitor such as diltiazem is 20 mg/day with a maximum recommended dose of 80 mg/day. LATUDA should not be administered with strong CYP3A4 inhibitors such as ketoconazole or strong CYP3A4 inducers such as rifampin.

Please see Important Safety Information, including **Boxed Warning** below, and full Prescribing Information at <u>www.LATUDA.com</u>.

LATUDA received FDA approval for the treatment of adult patients with schizophrenia on October 28, 2010 and is available in the U.S. and Canada. On October 30, 2012, the FDA accepted two supplemental New Drug Applications (sNDAs) for the use of LATUDA as monotherapy and adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

IMPORTANT SAFETY INFORMATION FOR LATUDA

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- LATUDA is not approved for the treatment of patients with dementia-related psychosis.

CONTRAINDICATIONS

LATUDA is contraindicated in the following:

- Any patient with a known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone.
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole)

Page 3 of 7

• Concomitant use with strong CYP3A4 inducers (e.g., rifampin).

WARNINGS AND PRECAUTIONS

Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.

Tardive Dyskinesia (TD): TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of TD. If signs and symptoms appear in a patient on LATUDA, drug discontinuation should be considered.

Metabolic Changes

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

www.sunovion.com

Page 4 of 7

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. In short-term, placebo-controlled studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was -0.2 ng/mL and was 0.5 ng/mL for males. The proportion of female patients with prolactin elevations ≥5x ULN was 5.7% for LATUDA-treated patients versus 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations > 5x ULN was 1.6% versus 0.6% for placebo-treated male patients.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Patients with a preexisting low white blood cell count (WBC) or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy, and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: LATUDA may cause orthostatic hypotension. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension and in patients with known cardiovascular disease or cerebrovascular disease.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold (e.g., Alzheimer's dementia).

Potential for Cognitive and Motor Impairment: In short-term, placebo-controlled trials, somnolence was reported in 17.0% (256/1508) of patients treated with LATUDA compared to 7.1% (50/708) of placebo patients, respectively. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Suicide: The possibility of suicide attempt is inherent in psychotic illness and close supervision of highrisk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

www.sunovion.com

Page 5 of 7

ADVERSE REACTIONS

Commonly Observed Adverse Reactions: (incidence \geq 5% and at least twice the rate of placebo) in patients treated with LATUDA were somnolence, akathisia, nausea and parkinsonism.

Before prescribing LATUDA, please read the full Prescribing Information, including **Boxed Warning** at <u>www.LATUDA.com</u>.

About Sunovion

About Sunovion Pharmaceuticals Inc. (Sunovion) is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry & Neurology and Respiratory disease areas and improve the lives of patients and their families. Sunovion's drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products including LATUDA[®] (lurasidone HCI) tablets, LUNESTA[®] (eszopiclone) tablets, XOPENEX[®] (levalbuterol HCI) inhalation solution, XOPENEX HFA[®] (levalbuterol tartrate) inhalation aerosol, BROVANA[®] (arformoterol tartrate) inhalation solution, OMNARIS[®] (ciclesonide) nasal spray, ZETONNA[®] (ciclesonide) nasal aerosol and ALVESCO[®] (ciclesonide) inhalation aerosol.

Sunovion, an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at www.sunovion.com.

About Dainippon Sumitomo Pharma Co., Ltd. (DSP)

Dainippon Sumitomo Pharma Co., Ltd. (DSP) is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP aims to produce innovative pharmaceutical products in the Psychiatry & Neurology field, which has been designated as one of the two key therapeutic areas. DSP is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at www.ds-pharma.com.

LATUDA is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd. LUNESTA, XOPENEX, XOPENEX HFA and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc. OMNARIS and ALVESCO are registered trademarks of Nycomed GmbH, used with permission.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. [©] 2013 Sunovion Pharmaceuticals Inc.

For a copy of this release, visit Sunovion Pharmaceutical Inc.'s web site at www.sunovion.com

####

Page 6 of 7

¹ National Institute of Mental Health. Bipolar Disorder. [Internet] Available from: <u>http://www.nimh.nih.gov/health/publications/bipolar-disorder/nimh-bipolar-adults.pdf</u>. Accessed July 26, 2012.

² Bipolar Disorder." Decision Resources. Table 2-1: Number of Total Prevalent Cases of Bipolar Disorder in the Major Pharmaceutical Markets, by Subtype, 2008-2018. Waltham, MA. December 2009. ³ The Depression and Bipolar Support Alliance. Mood Disorders and Different Kinds of Depression. [Internet]. Available from:

http://www.dbsalliance.org/site/DocServer/DBSA_Uni_Bipolar.v3.pdf?docID=2901. Accessed March 7,

2012. ⁴ The Journal of the American Medical Association. Bipolar Disorder Patient Page. [Internet]. Available from: http://jama.ama-assn.org/cgi/reprint/301/5/564.pdf. Accessed June 22, 2012. ⁵ Roshanaei-Moghaddam, B, Katon, W. Premature Mortality from General Medical Illnesses among

Persons with Bipolar Disorder: A Review. Psychiatric Services. 2009; 60(2):147-156.

⁶ Fagiolini A et al. Bipolar Disorder and the Metabolic Syndrome: Causal Factors, Psychiatric Outcomes and Economic Burden. *CNS Drugs.* 2008; 22(8):655-669. ⁷ Mcintyre R. et al. Bipolar Disorder and Diabetes Mellitus: Epidemiology, Etiology, and Treatment

Implications. Annals of Clinical Psychiatry. 2005; (17) 2:83-93.

⁸ National Alliance on Mental Illness. The Impact and Cost of Mental Illness: The Case of Bipolar Disorder. [Internet]. Available from: http://www.nami.org. Accessed March 29, 2013 (To Access: Communities, Living With, Bipolar Disorder).

National Alliance on Mental Illness. A Primer on Depressive, Bipolar and Anxiety Illnesses: Facts for Policymakers. [Internet]. Available from: http://www.nami.org. Accessed March 29, 2013 (To Access: Inform Yourself, About Public Policy, Policy Research Institute, Policymakers Toolkit).



May 20, 2013 03:10 PM Eastern Daylight Time

Sunovion Pharmaceuticals Inc. Announces Data Showing Latuda[®] (lurasidone HCI) was Associated with Low Rates of Weight and Metabolic Changes in Patients with Depressive Episodes Associated with Bipolar I Disorder

A Similar Pattern of Metabolic Changes was Observed in Patients Who Received LATUDA as Monotherapy or as Adjunctive Therapy to Mood Stabilizers

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced it will present 18 research posters on Latuda[®] (lurasidone HCI), an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia, at the 166th Annual Meeting of the American Psychiatric Association (APA) in San Francisco. The presentation includes results from analyses of two pivotal studies in patients with depressive episodes associated with bipolar I disorder (bipolar depression). These new data showed that LATUDA in the treatment of bipolar depression, either as monotherapy or added to ongoing treatment with lithium or valproate, was associated with low rates of change in weight, body mass index (BMI), lipid parameters and measures of glycemic control.

The two pivotal studies evaluated the efficacy and safety of LATUDA as monotherapy (PREVAIL 2) or adjunctive therapy (PREVAIL 1) for the treatment of bipolar depression, and supported two supplemental New Drug Applications (sNDAs) that were accepted by the U.S. Food and Drug Administration (FDA) on October 30, 2012.

"Sunovion is pleased to present data from two extensive research programs that studied LATUDA in patients with schizophrenia and bipolar depression," said Antony Loebel, M.D., Executive Vice President and Chief Medical Officer of Sunovion Pharmaceuticals Inc. "We are proud of the contributions we are making to improved understanding of these disorders where high unmet clinical needs remain."

"As such, it is critically important that we continue to evaluate the effect of LATUDA on these key measures of metabolic health, in both short and longer-term treatment."

Effects of LATUDA on Metabolic Indices in Bipolar Depression

The LATUDA monotherapy (PREVAIL 2) and adjunctive therapy studies (PREVAIL 1) were six-week, randomized, double-blind, placebo-controlled clinical trials that evaluated the efficacy and safety of LATUDA as monotherapy (20-60 mg/day or 80-120 mg/day vs. placebo, N=505) or adjunctive therapy (20-120 mg/day, N=348) to lithium or valproate in patients with bipolar depression, with or without rapid cycling (DSM-IV-TR). Changes from baseline to Week 6 in metabolic parameters [lipids, glucose, weight, insulin and homeostatic model assessment of insulin resistance (HOMA-IR)] were assessed [using rank ANCOVA

(LOCF) controlling for the baseline values of these metabolic parameters]. Results from the studies were as follows:

....

PREVAIL 2 (Monotherapy)

- Mean weight change from baseline for LATUDA vs. placebo was 0.64 vs. -0.09 lbs. (p=not significant).
- Weight gain from baseline (≥ 7%) occurred in 2.4% of patients treated with LATUDA vs. 0.7% of patients treated with placebo.
- Mean changes from baseline in metabolic laboratory parameters were: cholesterol -1.7 vs. -3.2 mg/dL, LDL -2.7 vs. -3.5 mg/dL, triglycerides 3.0 vs. 6.0 mg/dL, glucose 0.5 vs. 1.8 mg/dL, insulin 3.56 vs. 2.95 mU/L and HOMA-IR 1.08 vs. 1.19, for LATUDA vs. placebo, respectively (p=not significant for all comparisons).

PREVAIL 1 (Adjunctive Therapy)

- Mean weight change from baseline for LATUDA vs. placebo was 0.51 vs. 0.31 lbs. (p= not significant).
- Weight gain from baseline (≥ 7%) occurred in 3.1% of patients treated with LATUDA vs. 0.7% of patients treated with placebo.
- Mean changes from baseline in metabolic laboratory parameters were: cholesterol -3.0 vs. -3.8 mg/dL, LDL -3.2 vs. -2.0 mg/dL, triglycerides 9.0 vs. -6.2 mg/dL, glucose 0.9 vs. -0.3 mg/dL, insulin 1.66 vs. -0.16 mU/L and HOMA-IR 0.26 vs. -0.07, for LATUDA vs. placebo, respectively (p=not significant for all comparisons).

Using the National Cholesterol Education Program (NCEP) adult treatment panel criteria for metabolic syndrome, approximately 15% of patients met criteria for metabolic syndrome (MetS) at study baseline, which is associated with risk for diabetes and cardiovascular disease.

"Prior research has shown that patients with bipolar disorder are already at high risk for metabolic syndrome," said Loebel. "As such, it is critically important that we continue to evaluate the effect of LATUDA on these key measures of metabolic health, in both short and longer-term treatment."

In PREVAIL 1, the most frequently reported adverse events were nausea, somnolence, tremor, akathisia and insomnia. Discontinuation rates due to adverse events were 6% for LATUDA and 7.9% for placebo. In PREVAIL 2, the most frequently reported adverse events were nausea, headache, akathisia, somnolence and sedation. Discontinuation rates due to adverse events were 6% for LATUDA (either dose group) and 6% for placebo.

About Bipolar I Disorder and Bipolar Depression

Bipolar disorder, a mental illness characterized by debilitating mood swings, affects approximately 10.4 million American adults.^{1,2} Bipolar depression refers to the depressive phase of bipolar disorder.³ Symptoms of bipolar depression include: extreme sadness, anxiety, fatigue, inactivity and disinterest in usual activities, disruptions to sleeping patterns and hopelessness.^{1,4} When symptomatic, most people with bipolar disorder tend to be depressed, rather than manic.³ Bipolar disorder can also double a person's risk of early death from a range of medical conditions, including obesity, diabetes and cardiovascular disease.^{5,6,7} Bipolar disorder is the sixth leading cause of disability worldwide⁸ and is among the top 10 leading causes of disability in the United States (U.S.).⁹

About LATUDA

LATUDA is an atypical antipsychotic agent indicated for the treatment of patients with schizophrenia. Efficacy was established in five síx-week controlled studies of adult patients with schizophrenia. The effectiveness of LATUDA for longer-term use, that is, for more than six weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

The recommended starting dose for LATUDA for the treatment of patients with schizophrenia is 40 mg once daily taken with food (at least 350 calories) with no initial dose titration required. LATUDA has been shown to be effective in a dose range of 40 mg/day to 160 mg/day. The maximum recommended dose is 160 mg/day. For patients with moderate and severe renal or hepatic impairment, the recommended starting dose of LATUDA is 20 mg/day. The maximum recommended dose is 80 mg/day in patients with moderate hepatic impairment and 40 mg/day in patients with severe hepatic impairment. The recommended starting dose of LATUDA in patients taking a moderate CYP3A4 inhibitor such as diltiazem is 20 mg/day with a maximum recommended dose of 80 mg/day. LATUDA should not be administered with strong CYP3A4 inhibitors such as ketoconazole or strong CYP3A4 inducers such as rifampin.

Please see Important Safety Information, including **Boxed Warning** below, and full Prescribing Information at www.LATUDA.com.

LATUDA received FDA approval for the treatment of adult patients with schizophrenia on October 28, 2010 and is available in the U.S. and Canada. On October 30, 2012, the FDA accepted two supplemental New Drug Applications (sNDAs) for the use of LATUDA as monotherapy and adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

IMPORTANT SAFETY INFORMATION FOR LATUDA

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- LATUDA is not approved for the treatment of patients with dementia-related psychosis.

CONTRAINDICATIONS

LATUDA is contraindicated in the following:

- Any patient with a known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone.
- · Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole)
- Concomitant use with strong CYP3A4 inducers (e.g., rifampin).

WARNINGS AND PRECAUTIONS

Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.

Tardive Dyskinesia (TD): TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of TD. If signs and symptoms appear in a patient on LATUDA, drug discontinuation should be considered.

Metabolic Changes

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. In short-term, placebo-controlled studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was -0.2 ng/mL and was 0.5 ng/mL for males. The proportion of female patients with prolactin elevations ≥5x ULN was 5.7% for LATUDA-treated patients versus 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations > 5x ULN was 1.6% versus 0.6% for placebo-treated male patients.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Patients with a preexisting low white blood cell count (WBC) or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy, and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: LATUDA may cause orthostatic hypotension. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension and in patients with known cardiovascular disease or cerebrovascular disease.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold (e.g., Alzheimer's dementia).

Potential for Cognitive and Motor Impairment: In short-term, placebo-controlled trials, somnolence was reported in 17.0% (256/1508) of patients treated with LATUDA compared to 7.1% (50/708) of placebo patients, respectively. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Suicide: The possibility of suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

ADVERSE REACTIONS

Commonly Observed Adverse Reactions: (incidence \geq 5% and at least twice the rate of placebo) in patients treated with LATUDA were somnolence, akathisia, nausea and parkinsonism.

Before prescribing LATUDA, please read the full Prescribing Information, including **Boxed Warning** at www.LATUDA.com.

About Sunovion

About Sunovion Pharmaceuticals Inc. (Sunovion) is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry & Neurology and Respiratory disease areas and improve the lives of patients and their families. Sunovion's drug development program, together with its corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products including LATUDA[®] (lurasidone HCI) tablets, LUNESTA[®] (eszopiclone) tablets, XOPENEX[®] (levalbuterol HCI) inhalation solution, XOPENEX HFA[®] (levalbuterol tartrate) inhalation aerosol, BROVANA[®] (arformoterol tartrate) inhalation solution, OMNARIS[®]

(ciclesonide) nasal spray, ZETONNA[®] (ciclesonide) nasal aerosol and ALVESCO[®] (ciclesonide) inhalation aerosol.

Sunovion, an indirect, wholly-owned subsidiary of Dainippon Sümitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at www.sunovion.com.

About Dainippon Sumitomo Pharma Co., Ltd. (DSP)

Dainippon Sumitomo Pharma Co., Ltd. (DSP) is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP aims to produce innovative pharmaceutical products in the Psychiatry & Neurology field, which has been designated as one of the two key therapeutic areas. DSP is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at www.ds-pharma.com.

LATUDA is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd. LUNESTA, XOPENEX, XOPENEX HFA and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc. OMNARIS and ALVESCO are registered trademarks of Nycomed GmbH, used with permission.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. [©] 2013 Sunovion Pharmaceuticals Inc.

For a copy of this release, visit Sunovion Pharmaceutical Inc.'s web site at www.sunovion.com

¹ National Institute of Mental Health. Bipolar Disorder. [Internet] Available from:

http://www.nimh.nih.gov/health/publications/bipolar-disorder/nimh-bipolar-adults.pdf. Accessed July 26, 2012.

² Bipolar Disorder." Decision Resources. Table 2-1: Number of Total Prevalent Cases of Bipolar Disorder in the Major Pharmaceutical Markets, by Subtype, 2008-2018. Waltham, MA. December 2009.

³ The Depression and Bipolar Support Alliance. Mood Disorders and Different Kinds of Depression. [Internet]. Available from: http://www.dbsalliance.org/site/DocServer/DBSA_Uni_Bipolar.v3.pdf? docID=2901. Accessed March 7, 2012.

⁴ *The Journal of the American Medical Association.* Bipolar Disorder Patient Page. [Internet]. Available from: http://jama.ama-assn.org/cgi/reprint/301/5/564.pdf. Accessed June 22, 2012.

⁵ Roshanaei-Moghaddam, B, Katon, W. Premature Mortality from General Medical Illnesses among Persons with Bipolar Disorder: A Review. Psychiatric Services. 2009; 60(2):147-156.

⁶ Fagiolini A et al. Bipolar Disorder and the Metabolic Syndrome: Causal Factors, Psychiatric Outcomes and Economic Burden. *CNS Drugs*. 2008; 22(8):655-669.

⁷ Mcintyre R. et al. Bipolar Disorder and Diabetes Mellitus: Epidemiology, Etiology, and Treatment Implications. *Annals of Clinical Psychiatry*. 2005; (17) 2:83-93.

⁸ National Alliance on Mental Illness. The Impact and Cost of Mental Illness: The Case of Bipolar Disorder. [Internet]. Available from: http://www.nami.org. Accessed March 29, 2013 (To Access: Communities, Living With, Bipolar Disorder).

⁹ National Alliance on Mental Illness. A Primer on Depressive, Bipolar and Anxiety Illnesses: Facts for Policymakers. [Internet]. Available from: http://www.nami.org. Accessed March 29, 2013 (To Access: Inform Yourself, About Public Policy, Policy Research Institute, Policymakers Toolkit). Contacts

Sunovion Pharmaceuticals Inc. Patricia Moriarty, 508-787-4279 Senior Director, Corporate Communications patricia moriarty@sunovion.com





 More from Business Wire:
 Blog
 Apps
 Canada
 UK/Ireland
 Deutschland
 France
 Italy
 Japan

 EON:
 Enhanced Online News
 Tradeshownews.com
 PYMNTS.com
 Voltage
 Contact Us
 Privacy Statement
 Terms of Use
 ©2013 Business Wire
 Voltage
 Voltage

Par Pharm., Inc. Exhibit 1015 Page 484



Financial Results for FY2012 (The year ended March 31, 2013)

May 10, 2013 Masayo Tada, President and CEO Dainippon Sumitomo Pharma Co., Ltd.

Par Pharm., Inc. Exhibit 1015 Page 485

Sales by Product in North America and China Segments

	FY2011 Results	FY2012 Results	Change	FY2011 Results	FY2012 Results	Change		
North America	(Million \$)				(Billion yen)			
LATUDA®	86	202	116	6.9	16.1	9.2		
LUNESTA®	528	561	34	42.1	44.8	2.7		
XOPENEX®	419	317	- 102	33.4	25.3	- 8.1		
BROVANA®	127	160	32	10.2	12.7	2.6		
ALVESCO®	35	38	3	2.8	3.1	0.3		
OMNARIS®	64	24	- 41	5.1	1.9	- 3.2		
ZETONNA®		5	5		0.4	0.4		
Industrial property revenues	72	98	26	5.8	7.8	2.0		
Others	27	46	19	2.1	3.7	1.5		
Total	1,359	1,451	92	108.4	115.8	7.4		
China		(Million RMB)		(Billion yen)				
MEROPEN®	447	494	47	5.5	6.3	0.7		
Others	83	110	27	1.0	1.4	0.4		
Total	529	603	74	6.5	7.6	1.1		

Exchange Rate:

FY2011: 1US\$ = ¥79.8, 1RMB = ¥12.4 FY2012: 1US\$ = ¥79.8, 1RMB = ¥12.7 ⁵

Electronic Patent Application Fee Transmittal							
Application Number:	11919678						
Filing Date:	31-	31-Oct-2007					
Title of Invention:	Pharmaceutical composition						
First Named Inventor/Applicant Name:	Kazuyuki Fujihara						
Filer:	Kendrew H. Colton/Lois Ford						
Attorney Docket Number:	7379/98100						
Filed as Large Entity							
U.S. National Stage under 35 USC 371 Filing	Fee	s					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)		
Basic Filing:							
Pages:							
Claims:							
Miscellaneous-Filing:							
Petition:	Petition:						
Patent-Appeals-and-Interference:							
Post-Allowance-and-Post-Issuance:							
Extension-of-Time:							
Extension - 3 months with \$0 paid 1253 1 1400 140							

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Submission After Final Rejection	1809	1	840	840
	Tot	al in USD	(\$)	2240

Electronic Acknowledgement Receipt					
EFS ID:	16006881				
Application Number:	11919678				
International Application Number:					
Confirmation Number:	6965				
Title of Invention:	Pharmaceutical composition				
First Named Inventor/Applicant Name:	Kazuyuki Fujihara				
Customer Number:	42798				
Filer:	Kendrew H. Colton/Lois Ford				
Filer Authorized By:	Kendrew H. Colton				
Attorney Docket Number:	7379/98100				
Receipt Date:	11-JUN-2013				
Filing Date:	31-OCT-2007				
Time Stamp:	15:14:57				
Application Type:	U.S. National Stage under 35 USC 371				

Payment information:

Submitted wit	h Payment	yes	yes					
Payment Type		Deposit Account	Deposit Account					
Payment was	successfully received in RAM	\$2240	\$2240					
RAM confirma	tion Number	1795	1795					
Deposit Accou	int	061135	061135					
Authorized Us	er							
File Listing	j :							
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)			

1	Extension of Time	Petition-EOT.pdf	59199	no	1
			24388a06955becc9688b39ac19d6ce08b8a 26fa7	ne	
Warnings:		·	· · · · · ·		
Information:					
2	Request for Continued Examination	RCE.pdf	68997	no	2
	(RCE)		b770648ce44782ad2d1647443eb8593113 dc4d23		
Warnings:		1			1
This is not a US	PTO supplied RCE SB30 form.				
Information:					
3		Amendment-11June2013.pdf	1880971	yes	41
5			4f987b93e3dfd9d388c753a60fd860f6e6bd f83c	,	
	Multip	bart Description/PDF files in .	zip description		1
	Document De	Start	E	nd	
	Amendment Submitted/Entere	1	3		
·	Claims	4	10		
	Applicant Arguments/Remarks	11	24		
·	Appendix to the S	25	41		
Warnings:			11		
Information:					
4 Fee Worksheet (SB06)		fee-info.pdf	32070	P 0	2
4	Fee Worksheet (SB06)	lee-into.put	b74c51b5d0aaa2a4b1d0fa9b96e8d39aef7 1faf5	no	2
Warnings:					
Information:					
		Total Files Size (in bytes)	20	41237	
			1		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Under the Paperwork Reduction Act of 1995,			nt and Trademark Office	PTO/SB/22 (03 se through 3/31/2013. OMB 0651-0 ; U.S. DEPARTMENT OF COMMEN it displays a valid OMB control pure
Under the Paperwork Neduction Act of 1950,	no persons are req			et Number (Optional)
PETITION FOR EXTENSION	OF TIME U	INDER 37 CFR	1.136(a) ₇₃₇₉	9/98100
Application Number 11/919678 Filed October 31, 2			ber 31, 200)7
^{or} PHARMACEUTICAL	. COMPC			
Art Unit 1627		Examiner Sa	rah PIHON	AK
his is a request under the provisions of 37 C	CFR 1.136(a) to e	xtend the period for filing	a reply in the above-	identified application.
he requested extension and fee are as follo	ws (check time pe	eriod desired and enter t	he appropriate fee bel	ow):
	Fee	Small Entity Fee	Micro Entity Fee	
One month (37 CFR 1.17(a)(1))	\$200	\$100	\$50	\$
Two months (37 CFR 1.17(a)(2))	\$600	\$300	\$150	\$
Three months (37 CFR 1.17(a)(3))	\$1,400	\$700	\$350	<u>\$</u> 1400
Four months (37 CFR 1.17(a)(4))	\$2,200	\$1,100	\$550	\$
Five months (37 CFR 1.17(a)(5))	\$3,000	\$1,500	\$750	\$
Applicant asserts small entity status			•••••	•
Applicant certifies micro entity statu Form PTO/SB/15A or B or equivalent mu A check in the amount of the fee is	st either be enclose		reviously.	
Payment by credit card. Form PTO-	2038 is attached.			
The Director has already been auth	orized to charge f	ees in this application to	a Deposit Account.	
✓ The Director is hereby authorized to Deposit Account Number 061135	charge any fees	which may be required,	or credit any overpay	ment, to
Payment made via EFS-Web.				
VARNING: Information on this form may redit card information and authorization am the		Credit card information	n should not be inclu	uded on this form. Provide
applicant/inventor.			0.70%	
			Satement is	enclosed (Form PTO/SB/96).
✓ attorney or agent of record			<u> </u>	
attorney or agent acting u	Inder 37 CFR 1.34	-		·
/Kendrew H. Colton/		11 June		
Signature Kendrew H. Colton		(202) 42	Dat 19-7000	
Typed or printed name	e		Telephone	Number
<u>OTE:</u> This form must be signed in accorda ultiple forms if more than one signature is r	nce with 37 CFR			
✓ * Total of 1 forms	s are submitted.			
his collection of information is required by 37 CFR SPTO to process) an application. Confidentiality i	s governed by 35 U.	S.C. 122 and 37 CFR 1.11	and 1.14. This collection	is estimated to take 6 minutes to

complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/06 (09-11) Approved for use through 1/31/2014. OMB 0651-0032 ademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trade

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application or Docket Numbe PATENT APPLICATION FEE DETERMINATION RECORD Filing Date 11/919.678 10/31/2007 To be Mailed Substitute for Form PTO-875 ENTITY: **APPLICATION AS FILED – PART I** (Column 1) (Column 2) FEE (\$) NUMBER FILED NUMBER EXTRA RATE (\$) FOR BASIC FEE N/A N/A N/A 37 CFB 1.16(a), (b), or (c) SEARCH FEE N/A N/A N/A 37 CFR 1.16(k), (i), or (m) EXAMINATION FEE N/A N/A N/A (37 CFR 1.16(o), (p), or (q)) TOTAL CLAIMS minus 20 = X \$ _ (37 CFR 1.16(i)) INDEPENDENT CLAIMS minus 3 = X \$ = (37 CFR 1.16(h)) If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 APPLICATION SIZE FEE for small entity) for each additional 50 sheets or (37 CFR 1.16(s)) fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CEB 1 16(s) MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j)) * If the difference in column 1 is less than zero, enter "0" in column 2. TOTAL **APPLICATION AS AMENDED – PART II** (Column 1) (Column 2) (Column 3) CLAIMS HIGHES REMAINING NUMBER 06/11/2013 PRESENT EXTRA RATE (\$) ADDITIONAL FEE (\$) PREVIOUSLY AFTER AMENDMEN AMENDMENT PAID FOR Total (37 CFR * 37 Minus ** 31 = 6 x \$80 = 480 Independen * 4 Minus ***5 = 0 x \$420 = 0 37 CFR 1.16(h) Application Size Fee (37 CFR 1.16(s)) 780 FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j)) TOTAL ADD'L FEE 1260 (Column 1) (Column 2) (Column 3) CLAIMS HIGHEST REMAINING NUMBER PRESENT EXTRA RATE (\$) ADDITIONAL FEE (\$) AFTER PREVIOUSLY AMENDMENT PAID FOR Total (37 CFR ΞN. Minus _ X \$ = ≥ Independent (37 CFR 1.16(h)) *** Minus X \$ END Application Size Fee (37 CFR 1.16(s)) FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j)) TOTAL ADD'L FEE * If the entry in column 1 is less than the entry in column 2, write "0" in column 3. LIE ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". /MOLIKI MAY/ *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1 This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 06/12/2013

MMAY22 SALE #00000002 Mailroom Dt: 06/11/2013 061135 11919678 01 FC : 1801 1,200.00 DA Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 06/12/2013

MMAY22	SALE	#00000	0003	Mailroom Dt:	06/11/2013	061135	11919678
		01	FC :	1202	480.00 DA		
		02	FC :	1203	780.00 DA		

Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 06/13/2013

 MMAY22
 ADJ #00000001
 Mailroom Dt: 06/11/2013

 Seq No:
 1795
 Sales Acctg Dt: 06/12/2013
 061135
 11919678

 02
 FC : 1809
 840.00
 CR

PATENT Attorney Docket No. 05273.0147-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

)

In re Application of:

Kazuyuki FUJIHARA

Application No.: 11/919,678

Filed: October 31, 2007

For: PHARMACEUTICAL COMPOSITION

Commissioner for Patents

Group Art Unit: 1627

Examiner: Sarah Pihonak

Confirmation No.: 6965

VIA EFS-WEB

P.O. Box 1450 Alexandria, VA 22313-1450

Commissioner:

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114

Further to the June 11, 2013, Amendment filed in this application, Applicant

submits this Supplemental Amendment Under 37 C.F.R. § 1.114 along with a

Certification and Request for Prioritized Examination under 37 C.F.R. § 1.102(e).

Please amend this application as follows:


Amendments to the Claims being at page 2 of this paper.

Remarks/Arguments follow the amendment section.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

2. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising lurasidone, a pregelatinized starch and a water-soluble excipient by using a solution of a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

3. (Previously Presented) An oral preparation which is prepared by the process which comprises granulating a powder mixture comprising a pregelatinized starch and a

Application No.: 11/919,678 Attorney Docket No.: 05723.0147-00

water-soluble excipient by a solution or dispersion of lurasidone and a water-soluble polymer binder;

wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

4. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose.

5-8. (Canceled).

9. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10. (Canceled).

11. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone in the preparation is 25 to 40% (wt/wt).

12. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. (Canceled).

16. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17-18. (Canceled)

19. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

20. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

21. (Previously Presented) The oral preparation of claim 1 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Previously presented) The oral preparation of claim 1 wherein a 50% by volume particle size of lurasidone is 0.1 to 8 μ m.

23. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 25 to 40% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg. 25. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content of lurasidone in the preparation is 20 to 45% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

26. (Previously Presented) The oral preparation of claim 9 wherein the watersoluble excipient is mannitol or lactose.

27. (Previously Presented) The oral preparation of claim 1 wherein a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt).

28. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose.

29. (Previously Presented) The oral preparation of claim 1 wherein a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

30. (Previously Presented) The oral preparation of claim 1, further comprising a disintegrant wherein a content of the disintegrant per tablet is 0.5 to 5% (wt/wt).

31. (Previously Presented) The oral preparation of claim 1, further comprising a disintegrant wherein

a content of the disintegrant per tablet is 0.5 to 5% (wt/wt);

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation;

a content of lurasidone per tablet is 40 to 120 mg;

a pregelatinizing ratio of the pregelatinized starch is 50 to 95%;

50% by volume particle size of lurasidone is 0.1 to 8 µm;

the pregelatinized starch contains water soluble matter of 30% or less;

a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt);

the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose; and

a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).


32. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 160 mg.

33. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 80 to 160 mg.

34. (Currently Amended) The oral preparation of either one of claim 1 or 31 <u>claim 1</u>, wherein a similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg.

35-36. (Canceled).

37. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder, wherein the oral preparation contains 20 to 45% (wt/wt) of lurasidone, the oral

-6-

preparation contains 20 mg to 120 mg of lurasidone, the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the oral preparation, and the oral preparation exhibits an equivalent dissolution profile across the range of lurasidone per oral preparation.

38. (Currently Amended) The oral preparation of either one of claim 1 or 31_ <u>claim 1</u>, wherein the water-soluble excipient is one or more selected from the group consisting of mannitol, lactose, saccharose, sorbitol, D-sorbitol, erythritol and xylitol.

39. (Currently Amended) The oral preparation of either one of claim 30 or 31 claim 30, wherein the disintegrant is one or more selected from the group consisting of com starch, crystalline cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium and crospovidone.

REMARKS

Following entry of the Amendment, claims 1-4, 9, 11-14, 16, 19-34, and 37-39 (4 independent claims and 29 total claims) will be pending. The claims have been amended to remove all multiple dependencies. Specifically, claims 34 and 38 have been amended to depend from claim 1 and claim 39 has been amended to depend from claim 30. In addition, claims 5-7, 35, and 36, which are withdrawn by the Office as being directed to a non-elected invention, are cancelled without prejudice or disclaimer. The specification provides written description support for the amended claims. Accordingly, no new matter is added by the amendments provided herein. Their entry is respectfully requested.

If there is any fee due in connection with the filing of this Supplemental Amendment, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: December 6, 2013

Charles E.Van Hom Bv:

Charles E. Van Horn Reg. No. 40,266 (202) 408-4000

PATENT

Attorney Docket No. 05273.____-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	pplication of:)	κ.
Kazuy	uki FUJIHARA)))	Group Art Unit: 1627
Applic	ation No.: 11/919,678)	Examiner: Sarah Pihonak
Filed:	October 31, 2007)	Confirmation No.: 6965
For:	PHARMACEUTICAL COMPOSITION)	
	COMPOSITION)	VIA EFS-WEB

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Commissioner:

REVOCATION OF POWER OF ATTORNEY STATEMENT UNDER 37 C.F.R. § 3.73(b) AND GRANT OF NEW POWER OF ATTORNEY

The undersigned, a representative authorized to sign on behalf of the assignee owning all of the interest in this patent application, hereby revokes all previous powers of attorney or authorization of agent granted in this application before the date of execution hereof.

As required by 37 C.F.R. § 3.73(b), the undersigned verifies that DAINIPPON SUMITOMO PHARMA CO., LTD., is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from the inventor recorded in the U.S. Patent and Trademark Office (USPTO) at Reel 020124, Frame 0821. A corrective assignment was recorded in the USPTO at Reel 021008,

Frame 0209, to correct the address of the assignee.

The undersigned representative of the Assignee hereby grants its power of attorney to the patent practitioners associated with FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Customer No. 22,852, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patent.

Please send all future correspondence concerning this application to Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., Customer No. 22,852.

Dated: December 4, 2013

By: Masayo TADA

Representative Director, President and Chief Executive Officer of Dainippon Sumitomo Pharma Co., Ltd.

Electronic Patent Application Fee Transmittal					
Application Number:	11919678				
Filing Date:	31.	-Oct-2007			
Title of Invention:	Pharmaceutical composition				
First Named Inventor/Applicant Name:	Ka:	zuyuki Fujihara			
Filer:	Ch	arles E. Van Horn/Cl	narlene Woods		
Attorney Docket Number: 7379/98100					
Filed as Large Entity					
U.S. National Stage under 35 USC 371 Filing	Fee	s			
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Request for Prioritized Examination		1817	1	4000	4000
Pages:					
Claims:					
Miscellaneous-Filing:					
PROCESSING FEE, EXCEPT PROV. APPLS.		1830	1	140	140
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
	Tot	al in USD) (\$)	4140

Electronic Acknowledgement Receipt		
EFS ID:	17593939	
Application Number:	11919678	
International Application Number:		
Confirmation Number:	6965	
Title of Invention:	Pharmaceutical composition	
First Named Inventor/Applicant Name:	Kazuyuki Fujihara	
Customer Number:	42798	
Filer:	Charles E. Van Horn/Charlene Woods	
Filer Authorized By:	Charles E. Van Horn	
Attorney Docket Number:	7379/98100	
Receipt Date:	06-DEC-2013	
Filing Date:	31-OCT-2007	
Time Stamp:	17:46:28	
Application Type:	U.S. National Stage under 35 USC 371	

Payment information:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
File Listing:							
Authorized Us	er						
Deposit Account							
RAM confirmation Number		5259	5259				
Payment was successfully received in RAM		\$4140	\$4140				
Payment Type		Credit Card	Credit Card				
Submitted with Payment		yes	yes				

1	TrackOne Request	est Certification_and_Request_fo _Prioritized_Exam.pdf	86388	no	1
		_Prioritized_Exam.pdf	919cb7dafc620e97a4204b960f7d22a648fa 3942		
Warnings:		·	· · · ·		
Information:					
2		Supplemental_Amendment.	337905	yes	8
		pdf	2534e6313ef538e48c07acb5dd914b25d35 514d9		
	Multi	part Description/PDF files in .	zip description		
	Document De	escription	Start	E	nd
	Supplemental Response or Supplemental Amendment		1		1
	Claims		2	7	
	Applicant Arguments/Remarks Made in an Amendment		8	8	
Warnings:					
Information:					
3	Power of Attorney	Revocation_of_POA-	76597	no	2
-	· · · · · · · · · · · · · · · · · · ·	Grant_of_New_POA.pdf	72adaac9fd396f60147b9d474cdf648df05a 4e76		
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	32173	no	2
			320c2791ec37f179ea0d270e030c242de95 193eb		-
Warnings:			· · · · · · · · · · · · · · · · · · ·		
Information:					
		Total Files Size (in bytes)	53.	3063	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

CERTIF		ST FOR PRIORITIZED EXAMINATION 37 CFR 1.102(e)		
First Named Inventor	Kazuyuki FUJIHARA	Nonprovisional Application 11/919,678 Number (if known):		
Title of Invention	PHARMACEUTICAL COMP			
Attorney Docket Number	05273.0147-00			
	BY CERTIFIES THE FOLL DENTIFIED APPLICATION	OWING AND REQUEST PRIORITIZED EXAMINATION		
1.17(c), and the request.	if not already paid, the publi The basic filing fee, search	.17(i), the prioritized examination fee set forth in 37 CFR cation fee set forth in 37 CFR 1.18(d) have been filed with fee, examination fee, and any required excess claims and quest or have already been paid.		
	on contains or is amended t irty total claims, and no mul	o contain no more than four independent claims and no tiple dependent claims.		
3. The applicab	le box is checked below:			
I. □Origin	al Application (Track One)	- Prioritized Examination under 1.102(e)(1)		
		risional utility application filed under 35 U.S.C. 111(a). d with the utility application via EFS-Web. OR		
		risional plant application filed under 35 U.S.C. 111(a). Id with the plant application in paper.		
ii. An executed	oath or declaration under 3	7 CFR 1.63 is filed with the application		
II. 🛛 <u>Req</u> ı	iest for Continued Examin	ation - Prioritized Examination under 1.102(e)(2)		
i. A request for	continued examination has	been filed with, or prior to, this form.		
ii. If the applica	tion is a utility application, th	is certification and request is being filed via EFS-Web.		
	The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is a national stage entry under 35 U.S.C. 371.			
	tion and request is being file or continued examination.	d prior to the mailing of a first Office Action responsive to		
v. No prior requ 37 CFR 1.10		on has been granted prioritized examination status under		
	s hereby authorized to char ck 1 requirements, to Depos	ge any additional filing fees, including any fees necessary it Account No. 06-0916.		
*********	E.Van thom	~~~		
Charles E. Van Horn Reg. No.: 40,266				
FINNEGAN, HENDER 202-408-4000	SON, FARABOW, GARRETT	& DUNNER, LLP		

PTO/SB/06 (09-11) Approved for use through 1/31/2014. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application or Docket Number PATENT APPLICATION FEE DETERMINATION RECORD Filing Date 11/919.678 10/31/2007 To be Mailed Substitute for Form PTO-875 X LARGE SMALL MICRO ENTITY: **APPLICATION AS FILED – PART I** (Column 1) (Column 2) FEE (\$) NUMBER FILED NUMBER EXTRA FOR RATE (\$) BASIC FEE N/A N/A N/A (37 CEB 1.16(a), (b), or (c)) SEARCH FEE N/A N/A N/A 37 CFR 1.16(k), (i), or (m) EXAMINATION FEE N/A N/A N/A (37 CFR 1.16(o), (p), or (q)) TOTAL CLAIMS minus 20 = X \$ _ (37 CFR 1.16(i)) INDEPENDENT CLAIMS minus 3 = X \$ = (37 CFR 1.16(h)) If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 APPLICATION SIZE FEE for small entity) for each additional 50 sheets or (37 CFR 1.16(s)) fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s) MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j)) * If the difference in column 1 is less than zero, enter "0" in column 2. TOTAL **APPLICATION AS AMENDED – PART II** (Column 1) (Column 2) (Column 3) CLAIMS HIGHES' REMAINING NUMBER 12/06/2013 PRESENT EXTRA RATE (\$) ADDITIONAL FEE (\$) PREVIOUSI Y AFTER AMENDMEN⁻ AMENDMENT PAID FOR Total (37 CFR * 29 Minus ** 37 = 0 x \$80 = 0 Independent (37 CFR 1.16(h * 4 Minus ***5 = 0 x \$420 = 0 Application Size Fee (37 CFR 1.16(s)) FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j)) TOTAL ADD'L FEE 0 (Column 1) (Column 2) (Column 3) CLAIMS HIGHEST REMAINING NUMBER PRESENT EXTRA RATE (\$) ADDITIONAL FEE (\$) AFTER PREVIOUSLY AMENDMENT PAID FOR Total (37 CFR Minus _ X \$ = ш 1 16/ ENDM Independent (37 CFR 1.16(h) *** Minus X \$ = Application Size Fee (37 CFR 1.16(s)) ₹ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j)) TOTAL ADD'L FEE * If the entry in column 1 is less than the entry in column 2, write "0" in column 3. LIE ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". /TAMMY L. ACREE/ *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1 This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 12/30/2013

CKHLOK SALE #00000017 Mailroom Dt: 12/16/2013 061135 11919678 01 FC : 1504 300.00 DA

UNITED ST	ates Patent and Tradema	UNITED STA United State: Address: COMMI P.O. Box	a, Virginia 22313-1450		
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE		
11/919,678	10/31/2007	Kazuyuki Fujihara	05273-00		
			CONFIRMATION NO. 6965		
22852	22852 POA ACCEPTANCE LETTER				
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413					

Date Mailed: 12/19/2013

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 12/06/2013.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/afessehaye/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

UNITED STA	ates Patent and Tradem	UNITED STA United State: Addres: COMMI P.O. Box	a, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
11/919,678	10/31/2007	Kazuyuki Fujihara	7379/98100
42798 FITCH, EVEN, TABIN & F One Lafayette Center 1120 20th Street, NW, Sui WASHINGTON, DC 20036	te 750 South		CONFIRMATION NO. 6965 OF ATTORNEY NOTICE

Date Mailed: 12/19/2013

NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 12/06/2013.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

/afessehaye/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
, www.uspto.gov

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER	in T
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW	IM.
901 NEW YORK AVENUE, NW	UVU
WASHINGTON DC 20001-4413	



Doc Code: TRACK1.GRANT

	Decision Granting Request for Prioritized Examination (Track I or After RCE)		Application No.: 11/919,678		
1.	THE REQUEST FILED <u>December 6, 2013</u> IS GRANTED.				
	The above-identified application has met the requirements for prioritized examination A. for an original nonprovisional application (Track I). B. X for an application undergoing continued examination (RCE).				
2.	2. The above-identified application will undergo prioritized examination. The application will be accorded special status throughout its entire course of prosecution until one of the following occurs:				
	Α.	filing a petition for extension of	f time to extend the time period for filing a reply;		
	В.	filing an <u>amendment to amend</u>	the application to contain more than four independent		
	claims, more than thirty total claims, or a multiple dependent claim;				
	C.	filing a request for continued examination ;			
	D.	D. filing a notice of appeal;			
	E. filing a request for suspension of action;				
	F. mailing of a notice of allowance;				
	G.	mailing of a final Office action;			
	Н.	completion of examination as de	fined in 37 CFR 41.102; or		
	I. abandonment of the application.				
	Telephone inquiries with regard to this decision should be directed to <u>JoAnne Burke</u> at <u>571-272-4584</u> . In his/her absence, calls may be directed to <u>Brian Brown, 571-272-5338</u> .				
<u> IoAnne Burke</u> [Signature]			Paralegal Specialist, Office of Petitions (Title)		

U.S. Patent and Trademark Office PTO-2298 (Rev. 02-2012)

PATENT Attorney Docket No. 05273.0147-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kazuyuki FUJIHARA

Application No.: 11/919,678

Filed: October 31, 2007

For: PHARMACEUTICAL COMPOSITION Group Art Unit: 1627 Examiner: Sarah Pihonak

Confirmation No.: 6965

) VIA EFS-WEB

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Commissioner:

SECOND SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114

Further to the December 6, 2013, Supplemental Amendment filed in this

application, Applicant submits this Second Supplemental Amendment under

37 C.F.R. § 1.114.

Please amend this application as follows:


Amendments to the Claims being at page 2 of this paper.

Remarks/Arguments follow the amendment section.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the preparation.

2. (Canceled).

3. (Canceled).

4. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose.

5-8. (Canceled).

9. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10-11. (Canceled).

12. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. (Canceled).

16. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17-19. (Canceled).

20. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

21. (Previously Presented) The oral preparation of claim 1 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Previously presented) The oral preparation of claim 1 wherein a 50% by volume particle size of lurasidone is 0.1 to 8 μ m.

23. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Canceled).

25. (Currently Amended) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, a content oflurasidone in the preparation is 20 to 45% (wt/wt) and a content of lurasidone per tablet is 20 to 120 mg.

26. (Previously Presented) The oral preparation of claim 9 wherein the watersoluble excipient is mannitol or lactose.

27. (Previously Presented) The oral preparation of claim 1 wherein a content of the water-soluble excipient per tablet is 30 to 80% (wt/wt).

28. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol,

polyvinylpyrrolidone or hydroxypropylcellulose.

29. (Previously Presented) The oral preparation of claim 1 wherein a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

30. (Previously Presented) The oral preparation of claim 1, further comprising a disintegrant wherein a content of the disintegrant per tablet is 0.5 to 5% (wt/wt).

31. (Currently Amended) The oral preparation of claim 1, further comprising a disintegrant wherein

a content of the disintegrant per tablet is 0.5 to 5% (wt/wt);

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation;

a content of lurasidone per tablet is 40 to 120 mg;

a pregelatinizing ratio of the pregelatinized starch is 50 to 95%;

50% by volume particle size of lurasidone is 0.1 to 8 µm;

the pregelatinized starch contains water soluble matter of 30% or less;

the water-soluble excipient is mannitol or lactose, and a content of the watersoluble excipient per tablet is 30 to 80% (wt/wt);

the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose; and

a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).


32. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 160 mg.

33. (Canceled).

34. (Previously Presented) The oral preparation of claim 1, wherein a similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg.

35-36. (Canceled).

37. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder, wherein the oral preparation contains 20 to 45% (wt/wt) of lurasidone, the oral

-5-

Application No.: 11/919,678 Attorney Docket No.: 05273.0147-00

preparation contains 20 mg to 120 mg of lurasidone, the pregelatinized starch is incorporated in an amount of 10 to 50% (wt/wt) based on the weight of the oral preparation, and the oral preparation exhibits an equivalent dissolution profile across the range of lurasidone per oral preparation.

38. (Currently Amended) The oral preparation of claim 1, wherein the watersoluble excipient is one or more selected from the group consisting of mannitol, lactose, saccharose, sorbitol, D-sorbitol, erythritol and xylitol.

39. (Currently Amended) The oral preparation of claim 30, wherein the disintegrant is one or more selected from the group consisting of com starch, crystalline cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium and crospovidone.

40. (New) The oral preparation of claim 1, further comprising a lubricant, wherein a content of the lubricant per tablet is 1.0% (wt/wt) to 1.43% (wt/wt).

41. (New) The oral preparation of claim 40, wherein the lubricant is selected from the group of magnesium stearate, talc, polyethylene glycol, silica and hydrogenated vegetable oil.

42. (New) The oral preparation of claim 1, wherein the oral preparation is a tablet.

43. (New) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone), a pregelatinized starch,

-6-

a water-soluble excipient and a water-soluble polymer binder, wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt),

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation,

the water-soluble excipient is mannitol or lactose, and

the water-soluble polymer binder is one or more agents selected from the group of hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

44. (New) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-

bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone), a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder, and further comprises a disintegrant and a lubricant, wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt),

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation,

the water-soluble excipient is mannitol,

the water-soluble polymer binder is hydroxypropylmethylcellulose, and

the oral preparation is a tablet.

45. (New) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 50% (wt/wt) based on the weight of the preparation.

<u>REMARKS</u>

I. Status of Claims

Following entry of the Amendment, claims 1, 4, 9, 12-14, 16, 20-23, 25-32, 34, and 37-45 (4 independent claims and 29 total claims) will be pending. Claims 25, 31, 38, and 39 are amended, claims 2, 3, 11, 19, 24, and 33 are canceled, and claims 40-45 are added herein. The specification, e.g., "[[0022], [0023], [0044], [0047], and [0149] (formulations RP-03320 and RP-03322) of U.S. Patent Application Publication No. 2009/0143404 A1 ("the '404 publication"), which is the publication of the present application, and original claim 9, provide written description support for the amended claims. Specifically, the lower limit, i.e. 1.0%, of new claim 40 is calculated from formulation RP-03322 in Table 36 in paragraph [0149] of the '404 publication, where the formulation contains 2 mg of magnesium stearate and the total amount of the formulation is 200 mg (2 mg/200 mg x 100 = 1.0%); similarly, the upper limit, i.e. 1.43%of new claim 40, is calculated from formulation RP-03320 in Table 36 in paragraph [0149] of the '404 publication, where the formulation contains 4 mg of magnesium stearate and the total amount of the formulation is 280 mg (4 mg/280 mg x 100 = 1.43%). Accordingly, no new matter is added by the amendments provided herein. Entry of the amendments is respectfully requested.

II. Rejection over EP Patent Publication No. 1 327 440 A1 to Fujihara et al. ("Fujihara") in view of U.S. Patent No. 4,600,579 to Salpekar et al. ("Salpekar")

Claims 1-4, 9, 11-14, 16, 19-34, and 37 are rejected under 35 U.S.C. § 103(a) as allegedly unpatentable over Fujihara in view of Salpekar. Final Office Action dated

-8-

December 11, 2012, at p. 10. Applicant traverses the rejection for at least the following reasons.

A. <u>Claims 1, 4, 12-14, 16, 21-23, 26-30, 32, 34, and 37-42</u> (claims 2, 3, 11, 19, 24, and 33 have been canceled)

As previously pointed out, the characteristics of the present invention include:

1) the oral preparation of the present invention includes a high lurasidone content per tablet, particularly high content ratio (%) of 20 to 45% (wt/wt) of lurasidone as recited in claims 1 and 37 - which allows for the employment of relatively high total amounts of lurasidone in a relatively small sized tablet, while, at the same time, the oral preparation exhibits beneficial dissolution properties (*see*, *e.g.*, paragraph [0149] of the '404 publication).

 the oral preparation of the present invention incorporates pregelatinized starch in a range of 10 to 50% (wt/wt) based on the weight of the preparation; and

3) the preparation of the present invention has beneficial dissolution properties; that is, the preparation shows equivalent dissolution profiles as between oral preparations having different contents of lurasidone, as reflected by a similarity factor (f2) of $50 \le f2 \le 100^1$, and furthermore exhibits rapid dissolution (*e.g.*, a dissolution of at least 85% of the initially present lurasidone within 30 minutes).

Neither Fujihara or Salpekar teach or suggest the claimed oral preparation or its

advantages.

1. Fujihara teaches away from higher amounts of lurasidone in an oral preparation.

The Fujihara preparations with a low content of luradisone (e.g., the film-coated formulations disclosed in Table 28 at \P [0128] of the '404 publication, which contain

¹ Dependent claim 34 is directed to an oral preparation according to claim 1, wherein the similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg. Neither Fujihara or Salpekar teaches or suggests claim 34.

12.2% and 12.3% of lurasidone in the film-coated tablets²) show similar dissolution profiles (f2-value of 77) and rapid dissolution (30-minute dissolution ratio values of 91% and 92%, respectively). See the '404 publication at Figure 1 and Tables 26-28 at 11 [0126]-[0128] of the specification (Patent Document 2 is identified as WO 2002/024166 (Fujihara) at ¶ [0008] of the '404 publication). Fujihara, however, teaches that tablets comprising 16.3% (wt/wt) or more of lurasidone have inferior dissolution profiles as compared with tablets comprising lesser amounts of lurasidone. This is seen from the tablets prepared in Comparative Examples 1-3 in Fujihara, which include tablets comprising 16.3% (wt/wt), 17.1% (wt/wt), 29.0% (wt/wt) of lurasidone, respectively.³ See Fujihara at pages 27-30, paragraphs [0180] to [198]. According to Fujihara, the tablets of Comparative Examples 1-3 are significantly inferior in terms of the dissolution characteristics to the corresponding tablets of Examples 2-28 which comprise 8.13-16.3% (wt/wt) of lurasidone (see ¶¶ [0185], [0191], [0197] and [0198]). Specifically, Fujihara teaches that the dissolution percentage of tablet in Comparative Example 3 was merely 74% at 15 minutes, and only 84% after 30 minutes, while the dissolution percentage for the tablets of Examples 20-28 was over 84% at 15 minutes and in almost all instances over 90% after 30 minutes (Ex. No. 23 has a dissolution of

² The percent of lurasidone in each of the film-coated tablets in Table 28 was calculated by dividing the amount of lurasidone in each tablet (10 mg and 40 mg, respectively) by the total weight of the film-coated formulation (82.006 mg and 324.01 mg, respectively). For example, 10 mg/82.006 mg x 100 = 12.2% and 40 mg/324.01 mg x 100 = 12.3%.

³ The percent of lurasidone in each of the film-coated tablets in Comparative Examples 1-3 in Fujihara was calculated by dividing the amount of lurasidone in each tablet (20 mg, 20 mg, and 40 mg, respectively) by the total weight of the film-coated formulation (123 mg, 117 mg, and 137.7 mg, respectively). For example, 20 mg/123 mg x 100 = 16.3%, 20 mg/117 mg x 100 = 17.1% and 40 mg/137.7 mg x 100 = 29.0%. Applicants note that Table 42 indicates that the content of the uncoated tablet of (a) is 120 mg, but the sum of the content of the ingredients of the uncoated tablet listed in Table 41 is actually 114 mg, not 120 mg.

87% at 30 min.). See *id.* at ¶ [0197].⁴ Similarly, data provided in Test 1 (Tables 1-5, Figure 2 and Comparative Examples 1 and 2) of Applicant's specification also supports Fujihara's proposition that tablets comprising 16.3% (wt/wt) or more of lurasidone have inferior dissolution profiles as compared with tablets comprising lesser amounts of lurasidone.

In Comparative Examples 1 and 2 of Test 1, two tablets comprising 40 mg (12.3% (wt/wt)), and 80 mg, (24.7% (wt/wt)) respectively, of lurasidone per tablet were manufactured on the basis of the formulation disclosed in Fujihara. See ¶¶ [0089]-[0098] of the '404 publication.⁵ According to Test 1, Fujihara's tablet comprising 24.7% (wt/wt) of lurasidone (80 mg tablet, Comparative Example No. 2) clearly shows a lower dissolution profile than a tablet comprising 12.3% (wt/wt) of lurasidone (40 mg tablet, Comparative Example No. 1). See Applicant's specification at Figure 2. Based on these teachings in Fujihara, one of ordinary skill in the art would have focused on preparing tablets with 8.13-16.3% (wt/wt) of lurasidone as in Fujihara's Examples 2-28, and would have been led away from preparing oral preparations with higher amounts of

⁴ The U.S. FDA reference document, "Guidance for Industry," which was submitted with the Amendment filed September 13, 2012, explains that "an IR [i.e., immediate release] drug product is considered rapidly dissolving when no less than 85% of the labeled amount of the drug substance dissolves within 30 minutes (…)."

⁵ The percent of lurasidone in Comparative Examples 1 and 2 in Test 1 was calculated by dividing the content of lurasidone in each formulation by the total amount of the film-coated tablet formulation. For example, the percentage of lurasidone in Comparative Example 1 was calculated by dividing 40 mg, the amount of lurasidone in Comparative Example 1, by the total weight of the film-coated formulation provided in Table 3 in paragraph [0094] of the '404 publication (40 mg/324.01 mg x 100 = 12.3%); similarly, the percent of lurasidone in Comparative Example 2 was calculated by dividing 80 mg, the amount of lurasidone in Comparative Example 2, by the total weight of the film-coated formulation provided by dividing 80 mg, the amount of lurasidone in Comparative Example 2, by the total weight of the film-coated formulation provided in Table 3 of paragraph [0094] of the '404 publication (80 mg/324.01 mg x 100 = 24.7%).

lurasidone, *e.g.*, 20 to 45% (wt/wt), as in claims 1, 4, 9, 12-14, 16, 21-23, 26-30, 32, 34, and 37-42 of the present application.

2. Oral preparations comprising PGS in accordance with the present claims are unexpectedly superior as compared with oral preparations without PGS and would not be predicted based on the teachings of the prior art.

The data shown in Table 3 below compares a preparation of Example 4 of Applicant's specification to a Comparative formulation prepared in the same manner as Example 4 except that 0 (zero) percent (%) of pregelatinized starch was used and the amount of sodium croscarmellose was increased.

Components	Example 4 of the original specification		Comparative formulation	
	mg	wt/wt%	mg	wt/wt%
Lurasidone	80	25	80	25
Mannitol	176	55	176	55
PGS (pregelatinized starch)	40	12.5	0	0
Ac-Di-Sol (Croscarmellose Na)	8	2.5	48	15
HPMC (Hypromellose, Hydroxypropyl methylcellulose)	12	3.75	12	3.75
Magnesium stearate	4	1.25	4	1.25
Total	320	100	320	100
30-minute dissolution values	86%		70%	

Table 3

As can be seen from Table 3, the 30-minute dissolution value for the tablet according to the claimed invention is 86%. This is significantly better than the value of

70% which is achieved by the Comparative formulation which does not contain pregelatinized starch.⁶ Applicant respectfully submits that the evidence in Table 3 above shows that the claimed oral preparation has superior dissolution values as compared with the Comparative formulation. These results would <u>not</u> be expected by one of ordinary skill in the art or predicted from the teachings of the prior art including Fujihara and Salpekar.

While Applicant does not concede that the Office has established a *prima facie* case of obviousness based on the cited references, Applicant submits that the evidence in Table 3 above is sufficient to rebut any *prima facie* case of obviousness that has been established.

3. One of ordinary skill in the art would not be able to predict the results obtained with a highly water insoluble ingredient such as lurasidone based on the teachings of Salpekar.

Salpekar discloses that "PGS is included in an amount effective for imparting to the composition the capability of being formed into tablets having high hardness . . ., short disintegration time (e.g., about 10 minutes or less), and short dissolution time (e.g., about 20 minutes or less for 80% or more of the APAP to dissolve)". Salpekar at col. 4, lines 3-9. Salpekar does not provide any data showing that adding PGS to a composition shortens dissolution times. On the contrary, as shown in Examples 1-3 of Salpekar, increasing PGS (Ex. 2 (8.85% PGS) vs. Ex. 1 (18.0% PGS)) actually

⁶ As the Office will notice, the Comparative formulation in Table 3 above includes 48 mg of Croscarmellose Na, which is six times the amount of Croscarmellose Na in Example 4 of the original specification. But, this would not alter the conclusion drawn from the comparison provided in Table 3. Croscarmellose Na is a typical disintegrant and one of ordinary skill in the art would expect Croscarmellose Na to increase dissolution values (or shorten dissolution times); however, as shown in Table 3, the dissolution value of Comparative formulation is lower (or the dissolution time is more prolonged) than Example 4 in the original specification.

prolonged rather than shortened the disintegration time of the compositions. Moreover, there was no need to improve dissolution in Salpekar because the active ingredient being used therein, N-acetyl-p-aminophenol (also referred to as APAP or acetaminophen), is already highly water soluble.

The compositions disclosed in Salpekar exclusively focus on water soluble acetaminophen.⁷ In contrast, lurasidone is water insoluble.⁸ There is no reason based on the teachings of Salpekar that a person of ordinary skill in the art would have been directed towards using PGS with a water insoluble ingredient such as lurasidone. Further, one of ordinary skill in the art could not predict or expect the superior dissolution values achieved when combining lurasidone and PGS. PGS is known to be a binder and improve tablet crushing strength, and binder effectiveness is known to be related to optimization of tablet properties, especially crushing strength, which is the most strongly affected tablet property. See Becker et al., "Effectiveness of Binders in Wet Granulation: A Comparison Using Model Formulations of Different Tabletability," Drug Development and Industrial Pharmacy, 23(8), pp. 791-808 ("Becker"), p. 791, abstract at lines 1-3 ("Based on an analysis of model granulates and tablets, a comparison was made of the binders, ... Lycatab PGS, "), and p. 806, left-column at lines 16-17 ("The main effect of Lycatab PGS [a pregelatinized maize starch] is the improvement of tablet crushing strength."); see also Becker at p. 802, right-column at lines 11-17 ("Binder effectiveness refers to the degree to which the lowest possible

⁷ Acetaminophen has an experimental water solubility of 14 mg/mL. See DrugBank (http://www.drugbank.ca/drugs/DB00316, previously submitted.

⁸ Lurasidone has a water solubility of 0.224 mg/ml at 20°C, which is more than an order of magnitude less than that for acetaminophen.

concentration of a binder can contribute to the optimization of *all* granulate and tablet properties.... The tablet property most strongly affected is crushing strength.") Since a PGS formulation was demonstrated to improve tablet crushing strength, and thus shown to act as an effective binder, one of skill in the art would not expect the addition of PGS to a composition to shorten (improve) the dissolution time but rather would expect to actually prolong or lengthen the dissolution time; however, as shown in Table 3 above, the testing comparing the claimed oral preparation (comprising, *inter alia*, lurasidone and PGS) to the closest prior art, a comparative formulation outperformed the Comparative formulation by a substantial margin. These results would <u>not</u> be expected by one of ordinary skill in the art or predicted from the teachings of the prior art including Fujihara and Salpekar.

B. Claims 9, 20, 25, 31, and 43-45

Fujihara and Salpekar fail to teach or suggest the amount of pregelatinized starch recited in claims 9, 20, 25, 31, and 43-45.

New independent claims 43 and 44 are directed to oral preparations comprising, *inter alia*, pregelatinized starch in an amount of 20 to 30% (wt/wt) based on the weight of the preparation. Dependent claims 9, 20, 25, and 31 also recite that the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation. New dependent claim 45 is directed to an oral preparation of claim 1 wherein the pregelatinized starch is incorporated is incorporated in an amount of 20 to 50% (wt/wt) based on the weight of the pregelatinized starch is incorporated in an amount of 20 to 50% (wt/wt) based on the weight of the pregelatinized starch is incorporated in an amount of 20 to 50% (wt/wt) based on the weight of the preparation. Fujihara is completely silent regarding the use of pregelatinized starch, which the Office acknowledges on page 12 of the Final

Office Action dated December 11, 2012. The Office relies on Salpekar to cure this deficiency in Fujihara.

As mentioned above, Salpekar is directed to compositions comprising acetaminophen. See Salpekar at col. 1, lines 6-10. Salpekar teaches that "PGS is included in an amount effective for imparting to the composition the capability of being formed into tablets having high hardness . . ., short disintegration time . . . and short dissolution time" See id. at col. 4, lines 3-9. Specifically, Salpekar teaches that an effective amount of PGS is from about 5 or less to about 15 or more parts per 100 parts of the composition or about 5% to about 15% PGS. See id. at col. 4, lines 15-17. The range of PGS disclosed in Salpekar is clearly outside the range of 20 to 30% (wt/wt) as recited in new independent claims 43 and 44 and dependent claims 9, 20, 25, and 31, and is also clearly outside the range of 20 to 50% (wt/wt) as recited in new dependent claims 45. Further, there is nothing in Salpekar or Fujihara that would teach or suggest using higher amounts of PGS. In fact, Salpekar teaches away from using more than 15% (wt/wt) of PGS in its compositions.

Examples 1-3 in Salpekar provide a comparison of three compositions with differing amounts of PGS, an auxiliary binder, and an auxiliary disintegrating agent. *See* Salpekar at col. 8, lines 17-50. Example 1 in Salpekar includes 18.0 % of PGS, Example 2 includes 8.85% of PGS and 1.0% of PVP (aux. binder). The disintegration time of Example 1 is 18 minutes, which is 300% longer than the disintegration time for the composition of Composition 2 (6 minutes). The poorer disintegration results reported with Example 1, which includes 18% pregelatinized starch, would have led away from using 20 to 30% (wt/wt) of PGS as recited in independent claims 43 and 44

-16-

and dependent claims 9, 20, 25, and 31 or higher amounts of PGS such as 20 to 50% (wt/wt) of PGS as recited in dependent claim 45. Indeed, based on the Examples in Salpekar, increasing the amount of PGS would have suggested longer, not shorter disintegration times in an acetaminophen tablet, and longer disintegration times would have been contrary to Salpekar's stated objective. See Salpekar at col. 4, lines 3-9 (PGS is included in an amount effective for imparting a composition the capability of being formed into tablets having high hardness (e.g., about 8 kp or more), [and] short disintegration time (e.g., about 10 minutes or less)).

A prior art reference must be considered in its entirety, i.e., as a <u>whole</u>, including portions that would lead away from the claimed invention. See M.P.E.P. § 2141.02(VI). Indeed, the totality of the prior art must be considered, and proceeding contrary to accepted wisdom in the art is "strong evidence of unobviousness." *In re Hedges*, 783 F.2d 1038, 1041, 228 U.S.P.Q. 685, 687 (Fed. Cir. 1986). When the disclosure of Salpekar is considered in its entirety, as required, see M.P.E.P. § 2141.02(VI), a person would have been directed away from using higher amounts of PGS such as 20 to 30% (wt/wt) or 50% (wt/wt) of PGS. For at least this reason, Applicant submits that independent claims 43 and 44 and dependent claims 9, 20, 25, 31, and 45 would not have been obvious over Fujihara and Salpekar.

Applicants appreciate that Example 2 includes an auxiliary binder, PVP, in addition to PGS, but Applicant submits that PVP is known to delay (lengthen) rather than shorten disintegration. See Becker at p. 802, right-column at lines 4-6 (1997). Thus, the shortened disintegration time observed in Example 2 in Salpekar is a result of the reduced amount of PGS, not the inclusion of PVP.

-17-

For at least the foregoing reasons, Applicant respectfully requests that the Office reconsider and withdraw the rejection.

III. Rejection over claims of co-pending U.S. Application No. 12/997,779

Claims 1-4, 9, 11-14, 16, 19-34, and 37 are provisionally rejected on the ground of non-statutory obviousness-type double patenting as allegedly being unpatentable over claims 1-7 of co-pending U.S. Application No. 12/997,779. Office Action at p. 16.

A proper rejection under the doctrine of non-statutory obviousness-type double patenting requires an analysis that "parallels the guidelines for a 35 U.S.C. 103(a) rejection," see M.P.E.P. § 804(II)(B)(1), including for example, ascertaining "the differences between the claimed invention and the prior art." See M.P.E.P. § 2141(II).

Claims 1-7 of U.S. Application No. 12/997,779 ("the '779 application") have been amended to recite a tablet comprising, *inter alia*, an active ingredient selected from a group of droxidopa, levodopa, ethenzamide, ibuprofen, indomethacin, amoxicillin, cephalexin, erythromycin and clarithromycin. Lurasidone, the active ingredient recited in present claims 1, 4, 9, 12-14, 16, 20-23, 25-32, 34, and 37-45, is not listed as an active ingredient in the claims of the '779 application. Thus, claims 1-7 of the '779 application fail to teach or suggest every element of present claims 1, 4, 9, 12-14, 16, 20-23, 25-32, 34, and 37-45. For at least this reason, the provisional rejection of claims 1, 4, 9, 12-14, 16, 20-23, 25-32, 34, and 37 under the doctrine of non-statutory obviousness-type double patenting should be withdrawn, and Applicants respectfully request withdrawal of the same.

Application No.: 11/919,678 Attorney Docket No.: 05273.0147-00

IV. Conclusion

In view of the foregoing amendments and remarks, Applicant respectfully requests reconsideration of this application and the timely allowance of the pending claims.

If there is any fee due in connection with the filing of this Supplemental Amendment, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: January 17, 2014

horles E Nan Horn By:

Charles E. Van Horn Reg. No. 40,266 (202) 408-4000 RESEARCH PAPER

Effectiveness of Binders in Wet Granulation: A Comparison Using Model Formulations of Different Tabletability

D. Becker,¹ T. Rigassi,¹ and A. Bauer-Brandl²

¹Novartis, Inc., Building K-401.2.65, CH-4002 Basel, Switzerland ²Universität Freiburg, Pharmazeutische Technologie, Hermann-Herder-Str. 9, D-79104 Freiburg, Germany

ABSTRACT

Based on an analysis of model granulates and tablets, a comparison was made of the effectiveness of the binders PVP K30 PH, Cellulose HP-M 603, Lycatab DSH, Lycatab PGS, and L-HPC (type LH 11). A high shear mixer was used to prepare two model granulates (placebo and paracetamol) under processing conditions which were, as far as possible, comparable. The binders were added as proportions of 2%, 6%, and 10%. Water was used as the granulating liquid. The properties of the placebo granulates (particle size distribution, bulk and tapped density, granule strength, flow properties), and those of the tablets (crushing strength, friability) prepared from these granulates under different compaction forces, were generally good. However, with PVP, Cellulose HP-M603, and Lycatab, the disintegration time of the tablets did not meet pharmacopoeial requirements even though a "disintegrant" was used in the "outer phase." The paracetamol formulations were prime examples of high-dose drug substances with particularly poor granulating and tabletting properties, well suited to reveal differences between the binders. The paracetamol granulates were of higher friability and less flowability than the placebo granulates. The tablets tended to cap, friability was (with few exceptions) high, and disintegration times were long. In the preparation of model tablets containing paracetamol, PVP K30 PH (6%), and Cellulose HP-M 603 (6%) turn out to be the binders of choice with respect to crushing strength, but the disintegration times are too long. Lycatab PGS, Lycatab DSH, and L-HPC-LH 11 could not be used to produce paracetamol tablets that met the requirements.

791

Copyright © 1997 by Marcel Dekker, Inc.

Par Pharm., Inc. Exhibit 1015 Page 537 An assessment method involving calculation of averages for all granulates is used to evaluate the effectiveness of the binders. Key Words: Wet granulation; High shear mixer; Binder; Tablet; Hydroxypropylmethylcellulose; Polyvinylpyrrolidone; Lycatab; L-HPC.

INTRODUCTION

The properties of wet granulates, and of the tablets into which they are processed, are decisively influenced by binders. Not only are the type and amount of binder important, but also the processing procedure, e.g. the initial and then thorough wetting of the tablet mass (1). A standard method for wet granulation in a high shear mixer involves the dry addition of binder, followed by mixing, and then the addition of water. In this method a good correlation was found between granulate particle size and binder concentration (2), and in addition, this method does not require the preparation of a binder solvent.

The aim of the present study is to compare the effectiveness of different binders when used for wet granulation in a high shear mixer.

Commercial formulations of the binders polyvinylpyrrolidone (PVP K30 PH) and hydroxypropylmethylcellulose (Cellulose HP-M 603) are widely used (3) and serve here as a reference. Lycatab PGS^{TM} (a pregelatinised maize starch), Lycatab DSH^{TM} (a maltodextrin), and L-HPC, type LH 11TM (a low-substituted hydroxypropylcellulose) are used less frequently or are new.

Two models, a placebo formulation and a drug formulation, were assessed. The latter was given a very high content of paracetamol so that its tableting properties would be particularly unfavorable. The influence of different types and amounts of binders both on granulate properties (particle size distribution, bulk, and tapped density, granule strength, flow properties) and on tablet quality (crushing strength, friability, disintegration time) was investigated.

The degree to which wetting affects the particle size of the agglomerates depends to a large extent on the adhesion properties between binder and powder (4,5). Powder wettability is particularly important for binder distribution in the granules (6) and for the mechanical properties of the tablets (7). For this reason, it was not possible in the present study to go to the literature for data on the reference substances. However, since particle enlargement is for the most part unrelated to the the particular machines used (4,8), these observations can be applied to other manufacturing situations.

MATERIALS AND METHODS

Preparation of the Granulates

The raw materials used in the preparation of the granulates are listed in Table 1. Of the 1800 g in each granulate, 89.3% of the final mixture was the "inner" phase and 10.7% was the "outer" phase. Table 2 summarizes the compositions of the formulations.

The manufacturing steps for the granulates are listed in Table 3.

Properties of the Granulates

Particle size distribution of the granulates was determined twice in each case, on 50 g portions of granulate, using a laboratory VE 1000/s sieving machine (Kurt Retsch GmbH & Co. KG, 42781 Haan, Germany) set to run for 10 minutes at an amplitude of 1.5 mm. The stack consisted of analytical-grade screens conforming to DIN/ISO 3310/1, with mesh sizes of 1000, 710, 630, 500, 315, 250, 200, and 100 μ m.

The *bulk and tapped density* of the granulates were assessed in accordance with the Germany pharmacopoeia (DAB 1966) using a JEL tamped volume measuring apparatus (STAV 2003, J. Engelsmann AG, 6700 Ludwigshafen, Germany). V_{250} is the result reported.

The granule strength was determined by testing friability using the "Roche" oscillating friability testing machine. The testing drum, equipped with two steel rollers, alternately rolls 50 times to the left and right, rotating 170° each time. 10 g of granulate from the 250-800 μ m sieve fraction was used for the test of granule strength. After the drum movement stopped, the granulate was sieved for 2 min through a 250 μ m sieve, with an air throughput of (48-58) m³/hr, using the Alpine 200 LS air-jet sieving machine (Alpine AG, 8900 Augsburg, Germany), and the residue remaining on the sieve was weighed. The granule strength was calculated using the following formula: Effecti

(Eı

Par Pharm., Inc. Exhibit 1015 Page 538

Effectiveness of Binders in Wet Granulation

Materials				
Name	Manufacturer	Batch E8213		
Lycatab PGS	Roquette Fréres, F-Lille			
Lycatab DSH	Roquette Fréres, F-Lille	E5810		
L-HPC Typ: LH-11	ShinEtsu Chemicals, J-Tokio	501019		
Cellulose HP-M 603	DOW Chemical USA, Midland, MI, USA	JJ15012N23		
PVP K 30 PH	I.S.P., Guildford, U.K.	TX51028		
Lactose, ground	De Melkindustrie Holland, NL-Veghel	024448		
Avicel PH 102	FMC, Philadelphia, PA, USA	Y541		
PVP XL	I.S.P., Guildford, U.K.	\$50529		
Aerosil 200	CABOT Corp., Tuscola, IL, USA			
Magnesium stearate	FACI Italien ??	MGS-30159		
Paracetamol	Hou Zhou Syn. Pharm. Fact.	9512082(M)		
	-	9512105		

Table 1

granule strength $=\frac{\text{final weight of sieve residue * 100}}{\text{weight of sample}}$

The *flow properties* of the granulates were assessed using a Flowtester FT 300 from Sotax (Sotax AG, 4123 Allschwil, Switzerland). A single sample of 350 g of granulate was used for each of the 6 measurements (with differing funnel vibrations). The flow angle quotient is reported in each case as the result. According to Sotax (9), values in excess of 0.8 indicate that flow is good, while those below 0.6 indicate that it is poor.

Pressing Into Tablets

An EKO laboratory model eccentric tablet press (Emil Korsch, Berlin, Germany) was used to press 400 mg tablets, 10 mm in diameter and with bevelled edges, at a rate of 52 tablets per min.

The compaction forces and tolerances used in the preparation of batches of 100 tablets were: (5.0 ± 0.25) kN, (7.5 ± 0.35) kN, (10.0 ± 0.50) kN, (12.5 ± 0.60) kN, (15.0 ± 0.75) kN, (17.5 ± 0.90) kN, (20.0 ± 1.20) kN, (25.0 ± 1.80) kN, and (35.0 ± 2.00) kN.

Tablet Properties

Tablet friability was determined by placing 20 tablets each time into a "Roche" friability testing machine and then setting the machine for 500 revolutions. The friability of the tablets was calculated using the following formula:

Composition of Finished Blends					
		Placebo	Paracetamol		
	Material	Proportion [M/M]	Proportion [M/M]		
Inner phase	1 paracetamol	0%	75%		
	2 lactose/Avicel 2.45 : 1	ad 100%	ad 100%		
	4 binder	0%, 2.0%,	0%, 2.0%,		
		6.0%, 10%	6.0%. 10%		
Outer phase	б Avicel	5.0%	5.0%		
	7 PVP XL	5.0%	5.0%		
	8 Aerosil 200	0.2%	0.2%		
	9 magnesium stearate	0.5%	0.5%		

Table 2

Par Pharm., Inc. Exhibit 1015 Page 539

Becker, Rigassi, and Bauer-Brand]

Preparation of the "Inner" Phase Machines **Process** Parameter Processing Step 1. dry mixing high shear mixer Diosna P10^a 2 min impeller: 167 U min⁻¹ chopper: 3000 U min-1 30 sec; then scaping, addition of 2. wetting and kneading high shear mixer Diosna P10^a water, kneading impeller: 167 U min-1 chopper: 3000 U min-1 3. deagglomeration 3 mm manual screen 60°C 25-50 min as required fluidized bed dryer Strea 1b 4. drying 5, moisture content Mettler infrared dryer LP 16° 10 g samples, 30 min, 105°C 6. dry sieving classifying screening machine oszillating mode, screen: 1.25 mm Frewitt MGL^d mesh size; diameter of wire 0.8 mm 7. finished blend Turbula blender T10B° 42 U min⁻¹ in 3 1 lidded drum; outer phase added via 0.8 mm manual screen, blending for 10 min.; then magnesium stearate via 0.8 mm manual screen, blending for 5 min

1 apie	3	

Dierks & Söhne, D-Osnabrück.

^bAeromatik AG, CH-Bubendorf.

*Mettler Instrumente AG, CH-8606 Nänikon-Uster.

^dFrewitt AG, CH-Fribourg. ^oW. A. Bachofen Maschinenfabrik, CH Basel.

friability = $\frac{\text{weight of sample - final weight}}{\text{weight of sample}} \times 100$

The *crushing strength* of 10 tablets from each lot was determined using a Schleuniger 6 D tablet tester (Dr. Schleuniger & Co., 4501, Solothurn, Switzerland).

The disintegration time for 6 tablets in each case was tested in accordance with DAB 1996 using the DT 3 testing apparatus (Sotax AG, 4123 Allschwil, Switzerland).

RESULTS AND DISCUSSION

Preparation of the Granulates

The time required for kneading and drying the placebo granulates is summarized in Table 4. The paracetamol granulates required markedly less granulating fluid than did the placebo granulate. The kneading and drying times are not directly comparable.

A higher content of binder would be expected to accelerate formation of the granulate, thereby necessitating shorter kneading times, and this is precisely when happens during granulation in the high shear mixer with most of the binders tested (Table 4), the only exception being L-HPC. L-HPC presumably differs in this regard due to the high swelling capacity (10) which causes it to absorb a large amount of water, thereby delaying the wetting of the particle surfaces of other substances. In addition, the particles of binder increase in volume as swelling progresses, physically separating the particles to be bound.

The drying time in the fluid-bed dryer also depends on the amount of binder used (Figure 1). In the case of PVP, HP-M, and Lycatab DSH, the higher the binder concentration, the shorter the drying time. On the other hand, the drying time remains constant or even increases slightly when the amount of Lycatab PGS or L-HPC is increased. In both of these cases, this is also due to the large water-absorbing capacity of the binders, which precludes a rapid drying time. As a kinetic factor, drying time is nevertheless also highly dependent on particle size distribution and other particle properties (porosity, particle shape, and surface properties).

Properties of the Granulates

Particle Size Distribution

Figure 2 (below) shows the particle size distribution of the placebo granulates. The values reported for total

Γĉ

51

 \mathbf{v}_i

S.

Ef

Bi

		Placebo				Paraceta	umol	
Binder	Proportion of Binder	Kneading Time (s)	Drying Time (min)	Water Content (%)	Amount of Water (%)	Kneading Time (s)	Water Content (%)	Drying Time (min)
Without binder		240	49.0	2.5	29.5	30	0.3	32
PVP K30 PH	2%	240	37.0	2.5	26.7	30	0.5	30
	6%	90	34.5	2.5	24.4	20	0.9	30
	10%	30	24.0	3,1	11.1	210	1.6	17
Cellulose HP-M 603	2%	180	32.0	2.0	18.1	360	0.4	28
	6%	90	25.0	1.8	16.7	150	0.6	23
	10%	60	25.0	2.6	16.7	90	0,5	23
Lycatab PGS	2%	240	38.0	2.1	18.1	150	0.5	29
•	6%	120	37.0	2.5	18.1	150	0.8	29
	10%	90	39.0	3.2	18,1	150	1,4	37
Lycatab DSH	2%	240	45.0	2,4	13.9	120	0.5	24
•	6%	90	42.0	2,5	13.9	120	0.8	23
	10%	30	40.0	2.8	13.9	120	0.8	25
L-HPC Type: LH11	2%	170	44.0	2.1	16.7	90	0.4	27
**	6%	150	40.0	2.9	16.7	90	0.7	33
	10%	180	42.0	3.2	16.7	90	0.9	33

Table 4

residues are 16% (oversize particles), the median (R 50%), and the percentage of fine particles (R 84%). The values shown are the mean in each case for sieve analy-

ses carried out in duplicate. They can be compared, in

Figure 3, with the corresponding figures for sieve analysis of the paracetamol granulates.

A rise in binder concentration would lead one to expect an increase in particle size, and a large upturn




Figure 1. Drying time of placebo granulates.

Par Pharm., Inc. Exhibit 1015 Page 541






Figure 3. Particle size distributions of paracetamol granulates.

in the mean particle size (R 50%) of the placebo granulate can in fact be seen with the binders PVP K30 PH, Cellulose HP-M 603, and Lycatab DSH at concentrations of up to 6% (Figure 2). Particle size cannot be increased further when the concentration of these binders is raised (to 10%), which suggests that the binding mechanism changes above a certain critical concentration limit.

Use of L-HPC leads to a reduction in granulate particle size. This tendency continues as concentrations increase due to the small mean particle size (about 50 μ m (11)) and poor binding properties of L-HPC.

The particles of paracetamol granulate are more irregular in size (Figure 3) and more oversized, but show characteristics similar to those noted for the placebo granulate.

Granule Strength

100

Strong granulates are advantageous for subsequent steps in the production process, such as final mixing and transport because powdery, friable granulate has a detrimental effect on flow properties and can cause demixing. For both types of granulate, and for all binder concentrations tested, the highest granule strengths were achieved using the tried and trusted binders PVP K30 PH and Cellulose HP-M 603 (Figure 4).

The binders Lycatab PGS and Lycatab DSH showed different effects in the placebo and paracetamol formulations. The granule strength of the paracetamol granulate remained constant for all 3 concentrations of Lycatab PGS but rose in the placebo granulate as concentrations of Lycatab PGS increased. However, even at a binder concentration of 10%, granule strength was lower than in granulate prepared without a binder. The maximum granule strength for paracetamol granulate is achieved with Lycatab DSH at a concentration of 10%. Granule strength is very dependent on the binder used. However, the granule strength of the placebo granulate is largely unaffected by the concentration of Lycatab DSH.

t 90 80 Strength of Granulates [%] 70 60 50 40 30 no binder 63% 950 6% %O 3% 6% 80 3% 6% %O 2% % PVP K30 PH 2% Cell. HP-M 603 2% % Lycalab PGS Lycatab D.S.H. LIHU-JHPC-LHU - - Paracetamol -- Placebo

Figure 4. Strengths of placebo- and paracetamol granulates.

Par Pharm., Inc. Exhibit 1015 Page 543

Becker, Rigassi, and Bauer-Brandl

Granulate prepared using L-HPC shows low granule strength, in many cases even lower than that achieved when no binder is used.

Flow Properties

The flow capacity (expressed as flow angle quotients) observed in the analysis of granulate flow are shown in Figure 5. The placebo granulates proved to have very good flow characteristics with most binders. However, use of increasing concentrations of L-HPC leads to an increasing inhibition of flow, presumably due to a rise in the quantity of fine particles (Figure 2).

The relationship between flow characteristics and binder is even clearer with the paracetamol granulates. The flow characteristics of the granulate are poor without binder, but improve when even small amounts (2%) of PVP K30 PH or Cellulose HP-M 603 are added. The flow characteristics are not affected by further increases in the concentrations of these binders. Similarly good flow characteristics are achieved with Lycatab DSH at concentrations above 6%. The optimum binder concentration for Lycatab PGS is 2%, with all further additions leading to a rise in the amount of fine particles (Figure 3) and thus to reduced flow capacity. Paracetamol granulates prepared using L-HPC all flow poorly, particularly when the concentration of binder is high (compare also particle sizes in Figures 2 and 3).

Bulk and Tapped Densities

Figure 6 shows the bulk and tapped densities for the placebo granulates after 1250 taps. Figure 7 shows the corresponding results for the paracetamol granulates. Bulk and tapped densities of both sorts of granulates tend to fall as binder concentrations rise (Figures 6 and 7). This is explained by the fact that, generally speaking, larger agglomerates form. What is unusual in the




Figure 5. Flow properties of granulates (placebo and paracetamol).

798






Figure 6. Bulk/tapped densities and Hausner factor of placebo granulates.

case of the L-HPC-paracetamol granulates is that all of them, despite increasing looseness as binder concentrations increase, show about the same final tapped density. This is probably related to their low granule strength (Figure 4).

The Hausner factor (the quotient of bulk density and tapped density) expresses the relative mechanical compression of the granulate (which can occur during transport or as a result of vibrations in the tablet press). It thus allows us to make inferences regarding the uniformity of particle size, shape, and crushing strength. With the help of the Hausner factor, attempts can be made at predicting both the extent of compression, and the flow problems which may occur during tabletting. With the exception of granulates containing high concentrations of L-HPC, the granulates tested had a Hausner factor

lower than 1.2, and were thus within a range in which no problems were to be expected.

Tablet Properties

Crushing Strength

Figures 8 and 9 show profiles for compaction force and tablet crushing strength in relation to the binder used.

Even placebo granulate without binder could be processed into tablets with a good relationship between compaction force and crushing strength (Figure 8). Above a compaction force of 7.5 kN, an adequate crushing strength of 50 N is achieved for tablets with the selected diameters. The addition of binders did not necessarily lead to an increase in crushing strength. For

> Par Pharm., Inc. Exhibit 1015 Page 545

L, η




Figure 7. Bulk/tapped densities and Hausner factor of paracetamol granulates.

example, use of low concentrations of the binders PVP K30 PH, Cellulose HP-M 603, and Lycatab DSH (2% and, in the case of PVP K30 PH, 6% as well) led to a reduction in crushing strength. Use of Lycatab PGS at a concentration of 2% and Lycatab DSH at a concentration of 6% yielded crushing strength comparable to that of a granulate lacking a binder (cf. similar results in (12)). Only L-HPC at a low concentration improved crushing strength (by about 30%) as compared with the binder-free placebo formulation. PVP K30 PH does not bring about a similar rise in crushing strength until the concentration is 10%.

Cellulose HP-M 603 (6% and 10%), Lycatab DSH (10%), and Lycatab PGS (6%) can be characterised as

differing very little from each other. These binders increase crushing strength by an average of 45%. The largest rise in crushing strength, approximately 75%, is achieved with a 10% concentration of the binder Lycatab PGS, which is also the concentration recommended by the manufacturer for raising crushing strength (13).

The *paracetamol tablets* without binder (Figure 9) show poor crushing strength and also are prone to capping, regardless of the compaction force applied. They are improved by the addition of binders (except for 2% L-HPC). As expected, differences relating to the type and concentration of binder are greater in this problematic formulation than in placebo. Cellulose HP-M 603 and PVP K30 PH are best here. Adequate crushing

Effectiveness of Binders in Wet Granulation




Figure 8. Compression force vs. crushing strength profile of placebo tablets.

strength is achieved with these binders even at a concentration as low as 6%, and when tablets are produced using a low compaction force.

30

38

íX.

3-

3đ

3.

9)

p-

¢3

\$

98

33-

03

88

The binders Lycatab PGS and Lycatab DSH have nearly equal binding capacity in concentrations up to 6%. At higher concentrations, Lycatab PGS shows better binding capacity. The minimum concentrations of either of these binders should not be less than 10% in the paracetamol formulation discussed here. This recommendation is based on the large amount of drug substance and poor tableting properties (capping) of the paracetamol tablets. With other model formulations based on mixtures of lactose and starch, which have fewer problematic properties, there is reason to believe that an increase in binder content above the maximum of 6% investigated here could make possible further improvement in crushing strength (14). A binder concentration of 5% has been described as adequate for tablets containing a filler of anhydrous lactose and a 10% formulation of drug substance (hydrochlorothiazide) (15).

Improvement in tablet crushing strength was comparable for L-HPC, at concentrations of 6% and 10%, Lycatab PGS (6%), and Lycatab DSH (6%).

Friability

Another important mechanical property of tablets is friability (see Figures 10 and 11). When regarding the figures, keep in mind that the scale for compaction force

> Par Pharm., Inc. Exhibit 1015 Page 547

801




Figure 9. Compression force vs. crushing strength profile of paracetamol tablets.

begins at the rear of the graph and moves forward. To enhance the intelligibility of the chart, no bars were drawn in for friability in excess of 2% (a degree of friability which would no longer be acceptable in practice).

For all placebo formulations, friability was low when compaction force was 7.5 kN or higher, but the friability of the paracetamol tablets was often high. Sufficiently abrasion-resistant tablets (usually understood to mean tablets with a friability of no more than 1%) could only be prepared using PVP and HP-M 603.

Disintegration Times

The disintegration time of the tablets is of critical importance of their efficacy. Although an effective "disintegrant" is added to the outer phase before tableting, there are considerable differences in disintegration times. Figure 12 compares the disintegration times of placebo tablets produced under different compaction forces, while Figure 13 provides similar information on paracetamol tablets. It can be seen that it is in fact the tried and trusted binders (PVP and HP-M 603) which delay disintegration. Lycatab DSH has the same effect.

Binder Effectiveness

Binder effectiveness refers to the degree to which the lowest possible concentration of a binder can contribute to the optimization of *all* granulate and tablet properties. For granulates, these properties include in particular flow characteristics, crushing strength, and mean particle size. The tablet property most strongly affected is crushing strength.

Par Pharm., Inc. Exhibit 1015 Page 548





Figure 11. Friability of paracetamol tablets.






Figure 13. Disintegration time of paracetamol tablets.

Par Pharm., Inc. Exhibit 1015 Page 551

Ef

Table 5

Effect of Binder on Some Properties of Granulates and Tablets: Binder Effectiveness Particle Tablet Proportion Size Flow-Granulate Crushing of Binder (R 50%) Strength Binder ability Strength PVP K30 PH 33% 56% 2% 166% 13%6% 221% 33% 65% 65% 10% 221% 35% 62 % 121% Cellulose HP-M 603 2% 117% 35% 68% 33% 120% 6% 191% 34% 68% 10% 33% 68% 163% 183% Lycatab PGS 2% 20% 28% 27% 11% 6% 9% 25% 34% 46%10% 16% 11% 40% 83% Lycatab DSH 2% 33% 16% 12%-6% 6% 90% 32% 53% 26% 10% 174% 36% 78% 54% L-HPC Typ: LH11 2% -34% -5% -4% 11% 6% -57% -20% -24% 35% 10% -58% -23% -20% 37%

The present assessment has been restricted to these features in order to allow conclusions about binder effectiveness in different formulations to be drawn more easily.

For the graphs, the results obtained with binder-free placebo and drug preparations were taken as reference values and set at zero. The percentage deviations of the properties of the other granulates and tablets were always calculated in relation to these reference values. The arithmetic mean of the values obtained was then calculated for both the placebo and paracetamol granulates (Table 5) and plotted (Figure 14).

PVP K30 PH and Cellulose HP-M 603 show the greatest binder effectiveness. A 10% concentration of Lycatab DSH can be used as an alternative.

The main effect of Lycatab PGS is the improvement of tablet crushing strength. Although L-HPC worsens granulate properties, it nevertheless improves tablet crushing strength to some extent.

CONCLUSIONS

Use of the standard binders PVP and Cellulose HP-M 603 makes possible the manufacture of tablets with the best mechanical properties but the worst disintegration times. Hydroxypropylmethylcellulose in particular is used in granulate formulations to achieve delayed release (16). Lycatab PGS has fewer soluble components than other pre-gelatinized maize starches currently on the market (17) and is therefore expected to have a relatively good disintegrating effect (18). This has been confirmed in the present study.


Lycatab DSH is spray-dried maltodextrin and dissolves completely in water. According to the manufacturer, it is not supposed to interfere with disintegration and dissolution at recommended concentrations of 2-10%, and it is supposed to promote good flow in granulates and hardness in tablets. This claim was not necessarily confirmed, particularly because the disintegration time of the placebo tablets was markedly increased. And the advantage of a lactose-starch formulation over PVP in improving the relationship between crushing strength and disintegration, noted by Delacourte et al. (19), could not be verified here over the entire range of binder concentration and compaction force, either for placebo or for paracetamol. At a 10% concentration, however, Lycatab DSH can be substituted for PVP or HP-M 603.

When L-HPC is used as a dry binder, its small particle size makes it particularly suitable for the manufacture of hard tablets. Thanks to its high swelling capacity (greater that of PVP XL, which is used as a

Par Pharm., Inc.

Exhibit 1015 Page 552

Effectiveness of Binders in Wet Granulation 250% Average change compared to formulation without binder 200% 150% 100% 50% 0% -80% -100% \$6.01 \$0.0% 29% % 01 10% % (H 6%6 20% 200 Lycatab POS 2% 6% Lycateb D.S.H. 2% 88 L-RPC-URIJ 2% 8 H4 0EX 4A4 Cell, HP-M 603



disintegrant (20)), it reduces the disintegration time of tablets even after wet granulation. However, it shows little binding efficacy in granulates.

ACKNOWLEDGMENTS

Our thanks to Markus Gottschling for his conscientious performance of the tests and to Robert E. Kenyon for translation into proper English.

REFERENCES

 E. Horisawa, A. Komura, K. Danjo, and A. Otsuka, Chem. Pharm. Bull, 41, 1428–1433 (1993).

- G. D. D'Alonzo, R. E. O'Connor, and J. B. Schwartz, Drug Dev. Ind. Pharm. 16, 1931–1944 (1990).
- Rote Liste 1996, published by Bundesverband der Pharmazeutischen Industrie BPI, Frankfurt a.M., Germany.
- H. G. Kristensen, P. Hom, T. Schaefer, Powder Technol., 44, 239 (1985).
- T. Cutt, J. T. Fell, P. J. Rue, M. S. Spring, Int. J. Pharmaceutics, 33, 81–87 (1986).
- L. Zajie, G. Buckton, Int. J. Pharmacentics, 59, 155-164 (1990).
- M. Wikberg, G. Alderborn, Pharm. Research, 10, 88– 94 (1993).
- K. Held, U. Kopp, I. Kilchmann-Bohli, and H. Sucker, Pharm. Ind. 55, 171-175 (1993).

Becker, Rigassi, and Bauer-Brandl

- 9. Documentation from Sotax. Flowtest FT 300, p. 4.
- Brochure from ShinEtsu, Low-Substituted Hydroxypropyl Cellulose, p. 7, Fig. 4, and p. 13, Fig. 13.
- 11. Brochure from ShinEtsu, Low-Substituted Hydroxypropyl Cellulose, p. 5, Table 3.
- Documentation from Roquette Fréres, Lille, France: LycatabTM DSH, p. 5.
- Documentation from Roquette Fréres, Lille, France: Lycatab^m PGS, Bindemittel f
 ür die Feuchtgranulierung, p. 3.
- P. Soyeux, A. Delacourte, B. Delie, B. Boniface, S.T.P. Pharma Sciences, 4, 324-328 (1994).
- 15. C. W. Symecko, A. J. Romero, and C. T. Rhodes,

Drug Dev. Ind. Pharm., 19, 1131-1141 (1993).

- R. Acquier, H. Hamandi, H. Maillols, and H. Delonca, Pharm. Acta Helv., 67, 315–320 (1992).
- C. W. Symercko, C. T. Rhodes, Binding Performance of Pregelatinized Starches, Proc. 1st World Meeting APGI/APV, Budapest, 9-11 May 1995, 145-146.
- Documentation from Roquette Fréres, Lille, France: Lycatab^m PGS, Bindemittel für die Feuchtgranulierung, p. 6.
- A. Delacourte, J. F. Saint-Pol, J. C. Guyot, H. Dupas, and B. Delie, Pharm. Acta Helv., 67, 308-314 (1992).
- 20. Brochure from ShinEtsu, Low-Substituted Hydroxypropyl Cellulose, p. 7, Fig. 3 and Fig. 4.

PATENT Attorney Docket No. 05273.0147-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kazuyuki FUJIHARA

Application No.: 11/919,678

Filed: October 31, 2007

For: PHARMACEUTICAL COMPOSITION Group Art Unit: 1627

Examiner: Sarah Pihonak

Confirmation No.: 6965

) VIA EFS-WEB

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Commissioner:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the listed documents on the attached IDS Form ("Form"). This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination in the above-referenced application.

Copies of the listed non-patent literature documents are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

Application No.: 11/919,678 Attorney Docket No.: 05723.0147-00

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the U.S. Patent and Trademark Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: January 17, 2014

de te Van Horn By:

Charles E. Van Horn Reg. No. 40,266 (202) 408-4000

		Co	mplete if Known
		Application Number	11/919,678
INFORMATION DISCLOSURE	~	Filing Date	October 31, 2007
STATEMENT BY APPLICANT		First Named Inventor	Kazuyuki FUJIHARA
		Art Unit	1627
(Use as many sheets as necessary)		Examiner Name	Sarah PIHONAK
Sheet 1 of	1	Attorney Docket Number	05273.0147-00000

	U.S. PATENTS					
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (# known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Cite No. ¹	Foreign Patent Document Country Code ³ Rumber ⁴ Kind Code ⁵ (#known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation®	
	No.1	Cite No. ¹ Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>il known</i>)	Cite Publication Date	Cite No.1 Foreign Patent Document Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁶ (If known) Image: Country Code ³ Number ⁴ Kind Code ⁴ (Image: Code ⁴ Number ⁴ Kind Code ⁴ Number ⁴ Kind Code ⁴ (Image: Code ⁴ Kind Code ⁴ (Image: Code ⁴ Kind Code ⁴ Kind Code ⁴ (Image: Code ⁴ Kind Code ⁴ (Image: Code	Cite No.1 Foreign Patent Document Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages or Relevant Passages or Relevant Figures Appear	

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Request for Invalidation from invalidity proceedings in corresponding Chinese Application No. 200680018223.4 (original Chinese version and English-language translation), August 5, 2012.	Yes
		Bi Dianzhou, Pharmaceutics, Edition 4, Beijing: People's Medical Publishing House, February 2003.	Yes
		"Application and Effect of Pregelatinized Starch in Tablets," Chinese Pharmaceutical Information, Vol.16, Issue 7, 2000, published in 2000	Yes
		"Use of Pregelatinized Starch in Tablet Manufacturing," Chinese Pharmaceutical Journal, Vol. 29, Issue 4, April 1994, published in April 1994.	Yes
		"Application of the Pregelatinized Starch in Capsules," Chinese Journal of Modern Applied Pharmacy, Vol. 8, Issue 1, February 1991, published in February 1991	Yes
		"In Vitro Dissolution and Bioavailability of Acyclovir Capsules Formulated with Pregelatinized Starch," Chinese Journal of Pharmaceuticals, 1998, 29(5), published on May 20, 1998.	Yes
		Dissolution of Drug Solid Preparation, "Factors Influencing Dissolution Rates," Wu Guangchen, Yue Zhiwei, People's Medical Publishing House, published in October 1994.	Yes
		Reply Brief from invalidity proceedings in corresponding Chinese Application No. 200680018223.4 (original Chinese version and English-language translation), October 25, 2012.	Yes
		Examination Decision on the Request for Invalidation in corresponding Chinese Application No. 200680018223.4 (original Chinese version and English-language translation), April 26, 2013.	Yes

Examiner	Date	
Signature	Considered	
200000000000000000000000000000000000000	***************************************	***************************************

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Electronic Acl	knowledgement Receipt
EFS ID:	17947872
Application Number:	11919678
International Application Number:	
Confirmation Number:	6965
Title of Invention:	Pharmaceutical composition
First Named Inventor/Applicant Name:	Kazuyuki Fujihara
Customer Number:	22852
Filer:	Charles E. Van Horn/Charlene Woods
Filer Authorized By:	Charles E. Van Horn
Attorney Docket Number:	05273.0147-00000
Receipt Date:	17-JAN-2014
Filing Date:	31-OCT-2007
Time Stamp:	15:11:31
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment		no	no				
File Listin	g:						
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1		Second Supp Amendment.pdf	961339	yes	19		
			8f72aa74058075764d1169adf2deafdd8410 dc95	, i			

Information: Applicant Arguments/Remarks Made in an Amendment Becker,pdf S009161 headers116/addition/s0044451313377 no 18 Warnings: Information: 192414 distribution sources/additionation additionation of additionation additionationation additionation addition addition additionation additeddition additionation ad		Multip	oart Description/PDF files in .	zip description		
$\begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c c } \hline \begin{tabular}{ c c c } \hline \begin{tabular}{ c c } \hline \hline $				Start		
Image: set of the set				1		
Marnings: Information: 2 Applicant Arguments/Remarks Made in an Amendment Becker.pdf 5009101 beckmonts/sector/main/sector/		Claims		2		7
Information: Applicant Arguments/Remarks Made in an Amendment Becker,pdf S009161 headers116/addition/s0044451313377 no 18 Warnings: Information: 192414 distribution sources/additionation additionation of additionation additionationation additionation addition addition additionation additeddition additionation ad		Applicant Arguments/Remarks	Made in an Amendment	8	1	19
Applicant Arguments/Remarks Made in an Amendment Becker.pdf 5009161 bootstatistical Model Militaria no 18 Warnings: Information: 192414 yes 3 3 Supp_IDS.pdf 192414 yes 3 Multipart Description/PDF files in .zip description yes 3 Multipart Description/PDF files in .zip description Start End Information Disclosure Statement (IDS) Form (SB08) 3 3 Warnings: Information Disclosure Statement (IDS) Form (SB08) 3 3 4 Non Patent Literature RequestForInvalidation-CN.pdf 16484384 and and and and and and and and and and	Warnings:			1		
2 Applicant Arguments/Remarks Made in an Amendment Becker,pdf no 18 Warnings: Information: Information: Information: Information: 3 3 Supp_IDS.pdf 192414 yes 3 4 Multipart Description Start End 1 1 2 1 Information: Information: 3 Multipart Description/PDF files in .zip description Start End 1 1 2 Information: Information: Information: 4 Non Patent Literature RequestForInvalidation-CN.pdf 16484384 no 157 3 Non Patent Literature RequestForInvalidation-CN.pdf 7808906 no 157 3 Non Patent Literature RequestForInvalidation-CN.pdf 7808906 no 26 4 Non Patent Literature RequestForInvalidation-CN.pdf 7808906 no 26 4 Non Patent Literature RequestForInvalidation-CN.pdf 7808906 no 26 4 Non Patent Literature RequestForInvalidation-CN.pdf 7808906 no 26 3 Non Patent Literature RequestForInvalidation-CN.pdf 7808906 no 26 <td>Information:</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Information:					
Marnings: Information: 3 Supp_IDS.pdf 192414 yes 3 3 Multipart Description/PDF files in .zip description yes 3 Multipart Description/PDF files in .zip description Start End 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2		Becker.pdf	5009161	no	18
Information: Supp_IDS.pdf 192414 192414 distance concentration of the state of		an Amendment				
3 Image: Supp_IDS,pdf 192414 yes 3 4 Multipart Description/PDF files in .zip description Start End 1 2 1 2 1 2 1 3 3 3 <td>Warnings:</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Warnings:					
3 Supp_IDS.pdf yes 3 Multipart Description/PDF files in ip description File 1 1 Importantion Disclosure Statement (IDS) Form (SB08) 3 3 Warnings: Imformation Disclosure Statement (IDS) Form (SB08) 3 3 Warnings: Imformation Disclosure Statement (IDS) Form (SB08) 3 3 4 Non Patent Literature RequestForInvalidation-CN.pdf Info484384 (Multipart Disclosure Statement (IDS) Form (SB08) 10 5 Non Patent Literature RequestForInvalidation-CN.pdf Info484384 (Multipart Disclosure Statement (IDS) Form (SB08) no 157 Warnings: Information: Information: Non Patent Literature Info484384 no 5 Non Patent Literature RequestForInvalidation-CN.pdf Info484384 no 26 Warnings: Information: Information: Info 26 6 Non Patent Literature RequestForInvalidation-CN.pdf Info Info 26 Warnings: Information: Information: Info 26 Info 26 Warnings: Information: Information: Info Info 26	Information:					
Image: state	3		Supp IDS.pdf	192414	ves	3
Document Description Start End Transmittal Letter 1 2 Information Disclosure Statement (IDS) Form (SB08) 3 3 Warnings: Information Information Information 4 Non Patent Literature RequestForInvalidation-CN.pdf 16484384 (Masked08bb/bd0112/0000000000000000000000000000000000					,	
$\frac{1}{1} 2$ $\frac{1}$		Multip	part Description/PDF files in .	zip description		
Information Disclosure Statement (IDS) Form (SB08) 3 Warnings: Information: 4 Non Patent Literature A Non Patent Literature Barnings: Information-CN.pdf 3 16484384 0 157 Warnings: Information-CN.pdf 1 16484384 0 157 Warnings: Information-CN.pdf 5 Non Patent Literature 5 Non Patent Literature 6 Non Patent Literature 1 NOTICEOfAcceptanceOfReques 3 3		Document Des	scription	Start	End	
Warnings: Information: 4 Non Patent Literature RequestForInvalidation-CN.pdf 16484384 (MBS4e600b)dd9124086649002002202 (MBS4e600b)dd91240866490020022022 (MBS4e600b)dd912408664900020022022 (MBS4e600b)dd91240866490002002202 (MBS4e600b)dd912408664900020022002 (MBS4e600b)dd912408664900020022002 (MBS4e600b)dd912408664900020022002 (MBS4e600b)dd912408664900020022002 (MBS4e600b)dd912408664900020022002 (MBS4e600b)dd912408649002002200240 (MBS4e600b)dd91240864900020024002400240024002400240002400240		Transmittal Letter		1	2	
Information: A Non Patent Literature RequestForInvalidation-CN.pdf 16484384 no 157 Warnings:		Information Disclosure Statement (IDS) Form (SB08)		3	3	
4Non Patent LiteratureRequestForInvalidation-CN.pdf16484384 De54edb005id913a2008-0acde900022732no157Warnings:Information:5Non Patent LiteratureRequestForInvalidation- EnglText.pdf7808906 e0d1cce5750450741288ba2097ce29672d abad5no26Warnings:Information:6Non Patent LiteratureNOTICEOFAcceptanceOfReques tForInvalidation.pdf340727 e0d45sdba0bb4020bbabba6s7e7/32b opt109no2	Warnings:			1		
$ \begin{array}{c c c c c c c } \hline 4 & Non Patent Literature & RequestForInvalidation-CN.pdf & no & 157 \\ \hline 1854e600tb.3db91a2d08c9ac6e900b2ff32 & No & 26 \\ \hline 1854e600tb.3db91a2d08ba66f7e7a2b & No & 26 \\ \hline 1854e600tb.3db91a2d08ba66f7e7a2b & No & 26 \\ \hline 1854e600tb.3db91a2d08ba66f7e7a2b & 0 \\ \hline 1854e600tb.3db91a2d08ba6f7e7a2b & 0 \\ \hline 1854e600tb.3db91a2d08ba6f7e7a2b & 0 \\ \hline 1854e60tb.3db91a2d08ba6f7e7a2b & 0 \\ \hline 1854e60tb.3db91a2d08b$	Information:					
Information:5Non Patent LiteratureRequest ForInvalidation- EnglText.pdf7808906 eod1cce5759450741288ba2097cc29672d a3ea5no26Warnings:Information:6Non Patent LiteratureNOTICEOfAcceptanceOfReques tForInvalidation.pdf340727 dod458dba0bc050bbd20bbd209bd520b	4	Non Patont Litoraturo	PoquestEorInvalidation-CN pdf		20	157
Information: 5 Non Patent Literature RequestForInvalidation- EnglText.pdf 7808906 no 26 Warnings: e0d1cce5759450741288ba2097cc29672d no 26 Information: Information: 1 1 6 Non Patent Literature NOTICEOfAcceptanceOfReques tForInvalidation.pdf 340727 40d458dba00bc0990b0420bbab8e67e7a2b 69cid9 no 2	7	Non ratent Elteratore	Requesti onivalidation-ch.pdf	0a854e6b0fb3da91a2d08c9ac6e900b2ff32	110	137
5Non Patent LiteratureRequestForInvalidation- EnglText.pdf7808906no26Warnings:Information:6Non Patent LiteratureNOTICEOfAcceptanceOfReques tForInvalidation.pdf340727 du458dba00bc090b0420bbab8e67e7a2b e9c1d9no2	Warnings:			· · ·		
5Non Patent LiteratureRequestForInvalidation- EnglText.pdfno26Warnings:Information:6Non Patent LiteratureNOTICEOfAcceptanceOfReques tForInvalidation.pdf340727 dot458dba00bc090b0420bbab8e67e7a2b o9c1d9no2	Information:					
Engllext.pdf evd1cce5759450741288ba2097ce29672d a3ea5 Warnings: Information: 6 Non Patent Literature NOTICEOfAcceptanceOfReques tForInvalidation.pdf 340727 dod458dba00bc090b0420bbab8e67e7a2b 69c1d9 no 2	5	Non Patent Literature		7808906	no	26
Information: 6 Non Patent Literature NOTICEOfAcceptanceOfReques tForInvalidation.pdf 340727 	-		EnglText.pdf			23
6 Non Patent Literature NOTICEOfAcceptanceOfReques tForInvalidation.pdf <u>340727</u> no 2	Warnings:					
6 Non Patent Literature NOTICEOfAcceptanceOfReques tForInvalidation.pdf dod458dba00bc090b0420bbab8e67e7a2b 69c1d9 no 2	Information:					
tForInvalidation.pdf dot458dba00bc090b0420bbab8e67e7a2b 69c1d9	6	Non Patent Literature	NOTICEOfAcceptanceOfReques	340727	no	2
Warnings:	-		tForInvalidation.pdf		-	
	Warnings:					

7	Non Patent Literature	Exhibit-D2.pdf	2312593 d07f19876a03332d0f11820a3a83a2cc9c3b	no	9
			d0/1198/6a03332d011820a3a83a2cc9c3b 7fcc		
Warnings:					
Information:					
8	Non Patent Literature	Exhibit-D3.pdf	810770	no	3
			25fcd875444c49e21e6a2d0a9e222c1641f1 0d7d		
Warnings:		1	1 1		
Information:					
			1516546		_
9	Non Patent Literature	Exhibit-D4.pdf	626f164dd7d58c47c67fa5f8f1b0bc90c17ce	no	5
Warnings:			ced		
Information:					
			2682798		
10	Non Patent Literature	Exhibit-D5.pdf	9982238e3b8d0637f43c5b6b840be0af549	no	9
			6f586		<u> </u>
Warnings: Information:					
Information:					
11	Non Patent Literature	Exhibit-D6.pdf	2127221	no	7
			fdd41a9cb7dc3b8c38fcb94740ef6343c659 eb13		
Warnings:					
Information:		1			
10	Non Datant Literatura	Exhibit-D8.pdf	5725962	no	-1
12	Non Patent Literature		dc4b63ed360d593fc508f096d2b3f0cb6415 3efa		21
Warnings:			544		
Information:					
			1676870		
13	Non Patent Literature	ReplyBrief-CN.pdf	445c8906510406ad6fa846f221ebd39dc67	no	20
Warnings:			39290		
Information:					
			6205777		
14	Non Patent Literature	ReplyBrief-EnglText.pdf		no	20
			c322afa53b372dc912047f0b2f6ac55e2878 9d93		
Warnings:					
Information:		1			
15	Non Patent Literature	DECISIONForm_130426.pdf	204998	no	1
			68b337d1b4f7957469a2ac0779a33979054 5e8e5		
347 *		•			-
Warnings:					

		Total Files Size (in bytes):	600	060974	
Information					
Warnings:					
			37e4fb49368209ced3a9f023d0ca1c06bcab 68b7		
17	Non Patent Literature	TextOfTheDecision 130426.pdf	4804487	no	27
Information					
Warnings:					
	CN_130426.pdf	b78103970a7f69f5b55388cd9f0a304b2de3 5f8c	no	13	
16	Non Patent Literature	DECISIONInvalidity-	1196021	no	13

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Kazuyuki FUJIHARA) Group Art Unit: 1627
Application No.: 11/919,678) Examiner: Sarah Pihonak
Filed: October 31, 2007))) Confirmation No.: 6065
For: PHARMACEUTICAL COMPOSITION)Confirmation No.: 6965)
) VIA EFS-WEB

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Commissioner:

THIRD SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114

Further to the December 6, 2013, Supplemental Amendment, and

January 17, 2014, Second Supplemental Amendment filed in this application, Applicant

submits this Third Supplemental Amendment under 37 C.F.R. § 1.114.

Please amend this application as follows:


Amendments to the Claims being at page 2 of this paper.

Remarks/Arguments follow the amendment section.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder; wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt), and the pregelatinized starch is incorporated in an amount of 40 <u>20</u> to 50% (wt/wt) based on the weight of the preparation.

2. (Canceled).

3. (Canceled).

4. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose.

5-8. (Canceled).

9. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation.

10-11. (Canceled).

12. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 10 to 160 mg.

13. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 120 mg.

14. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 40 to 120 mg.

15. (Canceled).

16. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose and a content of lurasidone in the preparation is 25 to 40% (wt/wt).

17-19. (Canceled).

20. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation and a content of lurasidone per tablet is 40 to 120 mg.

21. (Previously Presented) The oral preparation of claim 1 wherein a pregelatinizing ratio of the pregelatinized starch is 50 to 95%.

22. (Previously presented) The oral preparation of claim 1 wherein a 50% by volume particle size of lurasidone is 0.1 to 8 μ m.

23. (Previously Presented) The oral preparation of claim 1 wherein the pregelatinized starch contains water soluble matter of 30% or less.

24. (Canceled).

-3-

25. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble excipient is mannitol or lactose, the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation, and a content of lurasidone per tablet is 20 to 120 mg.

26. (Previously Presented) The oral preparation of claim 9 wherein the watersoluble excipient is mannitol or lactose.

27. (Canceled).

28. (Previously Presented) The oral preparation of claim 1 wherein the watersoluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol,

polyvinylpyrrolidone or hydroxypropylcellulose.

29. (Previously Presented) The oral preparation of claim 1 wherein a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).

30. (Previously Presented) The oral preparation of claim 1, further comprising a disintegrant wherein a content of the disintegrant per tablet is 0.5 to 5% (wt/wt).

31. (Currently Amended) The oral preparation of claim 1, further comprising a disintegrant wherein

a content of the disintegrant per tablet is 0.5 to 5% (wt/wt);

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation;

a content of lurasidone per tablet is 40 to 120 mg;

a pregelatinizing ratio of the pregelatinized starch is 50 to 95%;

50% by volume particle size of lurasidone is 0.1 to 8 µm;

the pregelatinized starch contains water soluble matter of 30% or less;

the water-soluble excipient is mannitol or lactose, and a content of the watersoluble excipient per tablet is 30 to 80% (wt/wt);

the water-soluble polymer binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone or hydroxypropylcellulose; and

a content of the water-soluble polymer binder per tablet is 0.5 to 10% (wt/wt).


32. (Previously Presented) The oral preparation of claim 1 wherein a content of lurasidone per tablet is 20 to 160 mg.

33. (Canceled).

34. (Previously Presented) The oral preparation of claim 1, wherein a similarity factor f2 of each preparation is in the range of $50 \le f2 \le 100$ when a content of lurasidone per tablet changes over a range of 20 to 120 mg.

35-36. (Canceled).

37. (Currently Amended) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone) of the formula (1):



a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder, wherein the oral preparation contains 20 to 45% (wt/wt) of lurasidone, the oral preparation contains 20 mg to 120 mg of lurasidone, the pregelatinized starch is incorporated in an amount of 40 <u>20</u> to 50% (wt/wt) based on the weight of the oral

preparation, and the oral preparation exhibits an equivalent dissolution profile across the range of lurasidone per oral preparation.

38. (Previously Presented) The oral preparation of claim 1, wherein the watersoluble excipient is one or more selected from the group of mannitol, lactose, saccharose, sorbitol, D-sorbitol, erythritol and xylitol.

39. (Previously Presented) The oral preparation of claim 30, wherein the disintegrant is one or more selected from the group of com starch, crystalline cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium and crospovidone.

40. (Previously Presented) The oral preparation of claim 1, further comprising a lubricant, wherein a content of the lubricant per tablet is 1.0% (wt/wt) to 1.43% (wt/wt).

41. (Previously Presented) The oral preparation of claim 40, wherein the lubricant is selected from the group of magnesium stearate, talc, polyethylene glycol, silica and hydrogenated vegetable oil.

42. (Previously Presented) The oral preparation of claim 1, wherein the oral preparation is a tablet.

43. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone), a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder, wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt),

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation,

-6-

the water-soluble excipient is mannitol or lactose, and

the water-soluble polymer binder is one or more agents selected from the group of hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

44. (Previously Presented) An oral preparation which comprises N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone), a pregelatinized starch, a water-soluble excipient and a water-soluble polymer binder, and further comprises a disintegrant and a lubricant, wherein a content of lurasidone in the preparation is 20 to 45% (wt/wt),

the pregelatinized starch is incorporated in an amount of 20 to 30% (wt/wt) based on the weight of the preparation,

the water-soluble excipient is mannitol,

the water-soluble polymer binder is hydroxypropylmethylcellulose, and the oral preparation is a tablet.

45. (Canceled).

<u>REMARKS</u>

I. Status of Claims

Following entry of the Amendment, claims 1, 4, 9, 12-14, 16, 20-23, 25, 26, 28-32, 34, and 37-44 (4 independent claims and 27 total claims) will be pending. The Examiner telephoned Applicant's representative on January 22, 2014, proposing that Applicant change the lower limit of the pregelatinized starch in claims 1 and 37 from 10% (wt/wt) to 20% (wt/wt), delete the recitation regarding the amount of water-soluble excipient from claim 31, and cancel claims 27 and 45 in order to place the aboveidentified application in condition for allowance. To comply with the Examiner's proposals and solely for the purpose of placing this application in condition for allowance, claims 1, 31, and 37 are amended, and claims 27 and 45 are canceled herein. Applicant is not disclaiming any subject matter by the amendments provided herein, and reserves the right to file a continuation application with claims that include the canceled subject matter.

The specification, *e.g.*, **¶¶**[0022], [0023] of U.S. Patent Application Publication No. 2009/0143404 A1 ("the '404 publication"), which is the publication of the present application, provides written description support for the amended claims. Accordingly, no new matter is added by the amendments provided herein. Entry of the amendments is respectfully requested.

II. Conclusion

In view of the foregoing amendments and remarks, Applicant respectfully requests reconsideration of this application and the timely allowance of the pending claims.

-8-

Application No.: 11/919,678 Attorney Docket No.: 05273.0147-00

If there is any fee due in connection with the filing of this Supplemental Amendment, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: January 24, 2014

By: Charles E. Van Horn

Charles E. Van Horn Reg. No. 40,266 (202) 408-4000

Electronic Acknowledgement Receipt			
EFS ID:	18022499		
Application Number:	11919678		
International Application Number:			
Confirmation Number:	6965		
Title of Invention:	Pharmaceutical composition		
First Named Inventor/Applicant Name:	Kazuyuki Fujihara		
Customer Number:	22852		
Filer:	Charles E. Van Horn/Charlene Woods		
Filer Authorized By:	Charles E. Van Horn		
Attorney Docket Number:	05273.0147-00000		
Receipt Date:	24-JAN-2014		
Filing Date:	31-OCT-2007		
Time Stamp:	17:39:21		
Application Type:	U.S. National Stage under 35 USC 371		

Payment information:

Submitted wi	th Payment	no	no				
File Listin	g:						
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1		Third_Supplemental_Amendm	359999	yes	9		
		ent.pdf	d0fada65a1e152cc2f89c343a9277aeb7590 aedb	yes	5		

	Multipart Description/PDF files in .zip description				
	Document Description	Start	End		
	Supplemental Response or Supplemental Amendment	1	1		
	Claims	2	7		
	Applicant Arguments/Remarks Made in an Amendment	8	9		
Warnings:		I			

Information:

Total Files Size (in bytes):

359999

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



UNITED STATES PATENT AND TRADEMARK OFFICE

NITED STATES DEPARTMENT OF COMMERCE nited States Patent and Trademark Office	
dress: COMMISSIONER FOR PATENTS	
P.O. Box 1450	
Alexandria, Virginia 22313-1450	
www.uspto.gov	

NOTICE OF ALLOWANCE AND FEE(S) DUE

22852 7590 02/03/2014 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413

EXAMINER	
PIHONAK, SARAH	

ART UNIT PAPER NUMBER

1627

U U Ā

DATE MAILED: 02/03/2014

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
11/919,678	10/31/2007	Kazuyuki Fujihara	05273.0147-00000	6965
TITLE OF INVENTION: PHARMACEUTICAL COMPOSITION				

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	05/05/2014

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: <u>Mail</u> Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450

Alexandria,	Virginia	22313-1450
-------------	----------	------------

or <u>Fax</u> (571)-273-2885

appropriate. All further con	respondence including the below or directed otherwise	smitting the ISSUE FEE and PUBLI Patent, advance orders and notification in Block 1, by (a) specifying a new	n of maintenance fees v	will be mailed to the current	t correspondence address as
CURRENT CORRESPONDENC	E ADDRESS (Note: Use Block 1 for	any change of address)	Fee(s) Transmittal. The papers. Each additional	mailing can only be used for is certificate cannot be used al paper, such as an assignme of mailing or transmission.	for any other accompanying
		30W, GARRETT & DUNN	I hereby certify that th ERates Postal Service v addressed to the Mail	rtificate of Mailing or Trans nis Fee(s) Transmittal is bein with sufficient postage for fin 1 Stop ISSUE FEE address TO (571) 273-2885, on the d	g deposited with the United st class mail in an envelope above, or being facsimile
WASHINGTON, I	-)				(Depositor's name)
					(Signature)
					(Date)
ADDI ICATION NO	EILING DATE	EIDST NAMED INVE	NTOP	ATTORNEY DOCKET NO	CONFIRMATION NO

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.			
11/919,678	10/31/2007	Kazuyuki Fujihara	05273.0147-00000	6965			

TITLE OF INVENTION: PHARMACEUTICAL COMPOSITION

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	05/05/2014
EXAM	IINER	ART UNIT	CLASS-SUBCLASS			
PIHONAR	K, SARAH	1627	514-254020			
 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 		or agents OR, alternativ (2) The name of a single registered attorney or a	3 registered patent attorn vely, e firm (having as a memb igent) and the names of up rnevs or agents. If no nam	er a 2		

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE

Please check the appropriate assignee category or categories (will not be printed on the patent): 🗖 Individual 🗖 Corporation or other private group entity 📮 Government

 4a. The following fee(s) are submitted: Issue Fee Publication Fee (No small entity discount permitted) Advance Order - # of Copies	 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) A check is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number (enclose an extra copy of this form). 			
5. Change in Entity Status (from status indicated above)				
Applicant certifying micro entity status. See 37 CFR 1.29	<u>NOTE:</u> Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.			
Applicant asserting small entity status. See 37 CFR 1.27	<u>NOTE:</u> If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.			
Applicant changing to regular undiscounted fee status.	<u>NOTE:</u> Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.			
NOTE: This form must be signed in accordance with 37 CFR 1.31 and	d 1.33. See 37 CFR 1.4 for signature requirements and certifications.			
<u>_</u>				
Authorized Signature	Date			
Typed or printed name	Registration No			
Page 2 of 3				

PTOL-85 Part B (10-13) Approved for use through 10/31/2013.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE OMB 0651-0033



UNITED STATES PATENT AND TRADEMARK OFFICE

			UNITED STATES DEPART United States Patent and T Address: COMMISSIONER FC P.O. Box 1450 Alexandria, Virginia 223 www.uspto.gov	F rademark Office DR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
11/919,678	10/31/2007	Kazuyuki Fujihara	05273.0147-00000	6965
²²⁸⁵² 7590 02/03/2014 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			EXAMINER	
			PIHONAK, SARAH	
			ART UNIT	PAPER NUMBER
			1627	
		DATE MAILED: 02/03/2014		

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 276 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 276 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

	Application No.	Applicant(s)
Examiner-Initiated Interview Summary	11/919,678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627
All participants (applicant, applicant's representative, PTO	personnel):	
(1) <u>SARAH PIHONAK</u> .	(3)	
(2) <u>JENNIFER GUPTA</u> .	(4)	
Date of Interview: 27 January 2014.		
Type: 🛛 Telephonic 🗌 Video Conference 🗌 Personal [copy given to: 🗌 applicant	applicant's representative]	
Exhibit shown or demonstration conducted: Yes	🛛 No.	
Issues Discussed 101 112 102 103 Oth (For each of the checked box(es) above, please describe below the issue and detail		
Claim(s) discussed: <u>1,4,9,12-14,16,20-23,25,26,28-32,34 a</u>	<u>nd 37-44</u> .	
Identification of prior art discussed: <i>Fujihara et. al. & Salpe</i>	<u>kar et. al.</u> .	
Substance of Interview (For each issue discussed, provide a detailed description and indicate if agreement reference or a portion thereof, claim interpretation, proposed amendments, argument		identification or clarification of a
<u>A proposed examiner's amendment was discussed. Applic</u> <u>1/24/14. Claims 1, 4, 9, 12-14, 16, 20-23, 25-26, 28-32, 34,</u>		
Applicant recordation instructions: It is not necessary for applicant to p	provide a separate record of the subst	ance of interview.
Examiner recordation instructions : Examiners must summarize the sub the substance of an interview should include the items listed in MPEP 713 general thrust of each argument or issue discussed, a general indication o general results or outcome of the interview, to include an indication as to v	.04 for complete and proper recordation f any other pertinent matters discusse	on including the identification of the d regarding patentability and the
Attachment		
/SARAH PIHONAK/ Examiner, Art Unit 1627		
U.S. Patent and Trademark Office		

Notice of Allowability Examiner SARAH PIHONAK Art Unit 1927 Art Pint Investor to Page Status No The MALING DATE of this communication appears on the cover sheet with the correspondence address All dams being allowable, PROSECUTION ON THE MENTS IS (CR REMAINS) CLOSED in this application. If not included herewith for previously mailed), a Notice of Allowance (PTCL-40) or other appopriate communication is address to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.13G and MPEP 1008. 1.3 This communication is represente to 1242014.	Application No.Applicant(s)11/919,678FUJIHARA, KAZUYUH									
The MALLING DATE of this communication appears on the cover sheet with the correspondence address- Address being allowable. PROSECUTION ON THE MERITS IS (COR REMINS) (COEDS in this application. If not included herewith for previously mailed), a Notice of Allowance (PTCI-48) or other appropriate communication is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.130(b) was/were filed on	Notice of Allowability	Examiner	Art Unit	AIA (First Inventor to						
All claims being allowable, PROSECUTION ON THE MENTS is (OR REMANS) CLOSED in this application. Into included herewith or proviously malled is, a local or Allowable or other appropriate communication will be mailed in due course. THS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MEEP 1308. 1. This communication is responsive to <i>124/2014</i> . A declaration(s)/affidavit(s) under 37 CFR 1.300(b) was/were filed on 2. A nelection was made by the applicants in response to a restriction requirement set forth during the interview on; the restriction requirement and election have been incorporated into this action. 3. 3. 3. 3. 3. 3. 4. 4. B allowable distribution and the course of the protony down and the protony office for the corresponding application. For more information, please see http://www.uspto.gov/patentis/int_wents/patindex/lag.org or send an inquiry to http://www.uspto.gov/patentis/int_wents/patindex/lag.org or send an inquiry to http://www.uspto.gov/patentis/int_wents/patindex/lag.org or send an inquiry to http://www.uspto.gov/patentis/int_wents/patindex/lag.org (C Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). <a a="" communication="" complying="" date"="" file="" href="http://www.uspto.gov/patentis/int_wents/patindex/lag.org/lag.</td><td></td><td>SARAH PIHONAK</td><td>1627</td><td></td></tr><tr><th> A declaration(s)/affidavit(s) under 37 CFR 1.130(b) was/were filed on</th><th>All claims being allowable, PROSECUTION ON THE MERITS IS
herewith (or previously mailed), a Notice of Allowance (PTOL-85
NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R</th><th>(OR REMAINS) CLOSED in this a
) or other appropriate communication
IGHTS. This application is subject</th><th>pplication. If no</th><th>t included
I in due course. THIS</th></tr><tr><td>requirement and election have been incorporated into this action. 3. Image: The allowed claim(s) is/are 1_4.8.12-14.16.20:23.25.66.28:32.37-44. As a result of the allowed claim(s), you may be eligible to benefit from the Patent Prosecution Highway program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/poh/index.jsp or send an inquiry to PPHtechack@uspto.gov. 4. Image: Anowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). Certified copies: a) Image: anowledgment is made of a claim for foreign priority documents have been received. 2. Image: Certified copies of the priority documents have been received in Application No</td><td></td><td>s/were filed on</td><td></td><td></td></tr><tr><td>benefit from the Patent Prosecution Highway program at a participating intellectual property office for the corresponding application.
For more information, please see http://www.usplo.gov/patents/init_events/aph/index.lsp or send an inquiry to
PPH-leedback@usplo.gov. 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
Certified copies: a) All b) Some 'c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. © Copies of the certified copies of the priority documents have been received in this national stage application from the
International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE " mailing="" of="" reply="" requirements<br="" the="" this="" to="" with="">noted below. Failure to timely comply will result in ABANDON/MENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			the interview or	n; the restriction						
Certified copies: a) Ø All b) ⊆ Some *c) ⊆ None of the: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. Ø Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. □ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date	3. ☑ The allowed claim(s) is/are <u>1,4,9,12-14,16,20-23,25-26,28-32,34,37-44</u> . As a result of the allowed claim(s), you may be eligible to benefit from the Patent Prosecution Highway program at a participating intellectual property office for the corresponding application For more information, please see <u>http://www.uspto.gov/patents/init_events/pph/index.isp</u> or send an inquiry to									
 a)	4. 🛛 Acknowledgment is made of a claim for foreign priority under	er 35 U.S.C. § 119(a)-(d) or (f).								
1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. ⊠ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. □ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be twritten on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be tabeled as such in the header according to 37 CFR 1.121(d). 6. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL. Attachment(s) 1. □ Notice of References Cited (PTO-892) 2. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date Summer's Comment Regarding Requirement for Deposit of Biological Material 4. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 1/27/2014 . (SARAH PIHONAK/ Examiner's Comment Regarding Requirement for Deposit of Biological Material 4. □ Interview Summary (PTO-413), Paper No./Mail Date 1/27/2014 . (SARAH PIHONAK/ Examiner, Art Unit 1627	-									
1		a been received								
3.										
International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5 CORRECTED DRAWINGS (as "replacement sheets") must be submitted including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL Attachment(s) 1 Notice of References Cited (PTO-892) 2 Linformation Disclosure Statements (PTO/SB/08), Paper No./Mail Date 3 Examiner's Comment Regarding Requirement for Deposit of Biological Material 4 Interview Summary (PTO-413), Paper No./Mail Date /SARAH PIHONAK/ Examiner, Art Unit 1627 US Patent and Trademark Office US Patent and Trademark Office				application from the						
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date										
noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. □ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. □ Notice of References Cited (PTO-892) 5. □ Examiner's Amendment/Comment 2. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	* Certified copies not received:									
□ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 5. Examiner's Amendment/Comment 1. Notice of References Cited (PTO-892) 5. Examiner's Amendment/Comment 2. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 6. Examiner's Statement of Reasons for Allowance 9. Examiner's Comment Regarding Requirement for Deposit of Biological Material 7. Other	noted below. Failure to timely comply will result in ABANDONN		y complying with	n the requirements						
Paper No./Mail Date	5. CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.								
each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. □ Notice of References Cited (PTO-892) 5. □ Examiner's Amendment/Comment 2. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date		's Amendment / Comment or in the	Office action of							
attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. □ Notice of References Cited (PTO-892) 5. □ Examiner's Amendment/Comment 2. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	each sheet. Replacement sheet(s) should be labeled as such in	the header according to 37 CFR 1.12	l (d).							
1. □ Notice of References Cited (PTO-892) 5. □ Examiner's Amendment/Comment 2. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 6. ☑ Examiner's Statement of Reasons for Allowance 3. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 7. □ Other 4. ☑ Interview Summary (PTO-413), Paper No./Mail Date <u>1/27/2014</u> . 7. □ Other /SARAH PIHONAK/ Examiner, Art Unit 1627 Us. Patent and Trademark Office				the						
U.S. Patent and Trademark Office	 Notice of References Cited (PTO-892) Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date Examiner's Comment Regarding Requirement for Deposit of Biological Material Interview Summary (PTO-413), Paper No./Mail Date <u>1/27/2014</u>. 	6. 🛛 Examiner's Stater								
PTOL-37 (Rev. 08-13) Notice of Allowability Part of Paper No./Mail Date 20140128-A	Examiner, Art Unit 1627	tice of Allowability	Dat of Down							

1. The present application is being examined under the pre-AIA first to invent provisions.

DETAILED ACTION

This application, filed 10/31/2007, is a national stage entry of PCT/JP2006/310571, filed on 5/26/2006.

Request for Continued Examination

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/11/2013 has been entered.

Response to Remarks

3. Claims 1, 4, 9, 12-14, 16, 20-23, 25-26, 28-32, 34, and 37-44 are currently pending as of the supplemental reply and amendments filed on 1/24/2014. A track one request has been granted for this application.

Claims 1-4, 9, 11-14, 16, 19-34, and 37 were previously rejected under 35 USC 103(a) as being unpatentable over Fujihara et. al., EP 1327440, in view of Salpekar et. al., USP 4.600,579. The Applicants have traversed this rejection and have argued that neither Fujihara nor Salpekar teach or suggest the claimed oral preparation, as Fujihara teaches that tablets comprising 16.3% or more of lurasidone have inferior dissolution profiles in comparison to tablets having lesser amounts of lurasidone. The Applicants have submitted that Fujihara does not teach the lurasidone tablets as comprising pregelatinized starch, and that the dissolution profiles presented in Fujihara show that a lurasidone tablet comprising 29.0% of lurasidone had a percent dissolution of only 84% at 30 minutes, while tablets having less than 16.3% of lurasidone had over 90% dissolution after 30 minutes. The Applicants have argued that a skilled person would not have incorporated lurasidone in a tablet preparation at an amount of 20-45% from the teachings of Fujihara, based upon the poorer dissolution profiles of tablets comprising more than 16.3% lurasidone. The Applicants have submitted that Salpekar does not provide any data showing that adding pregelatinized starch shortens dissolution time, and in fact Salpekar shows that by increasing pregelatinized starch in a tablet formulation, such as that shown in Ex. 1 of Salpekar (18.0% PGS), the disintegration time is prolonged (18 minutes) in comparison to the disintegration time for tablet formulation comprising 8.85% PGS (6 minutes). The Applicants have additionally argued that Salpekar teaches a tablet composition which comprises water soluble acetaminophen, while the instantly claimed preparation comprises water insoluble lurasidone. It has been maintained by the Applicants that a person of ordinary skill in the

art would not have looked to using PGS with a water insoluble ingredient such as lurasidone based upon the teachings of Salpekar. The Applicants have argued that the instantly claimed oral preparation has unexpected properties over the prior art, and have provided comparison data for the 30-minute dissolution values for the instantly claimed oral preparation which comprises pregelatinized starch and lurasidone and the oral preparation taught by Fujihara which comprises the same amount of lurasidone and the disintegrant croscarmellose sodium but without pregelatinized starch. The Applicants have argued that the 30-minute dissolution value of 86% for the instantly claimed preparation is significantly better than the preparation taught by Fujihara, which has a 30-minute dissolution value of 70%.

The examiner has fully considered Applicants' arguments and the supplemental claim amendments, and they are found persuasive. The rejection of claims 1-4, 9, 11-14, 16, 19-34, and 37 were previously rejected under 35 USC 103(a) as being unpatentable over Fujihara et. al., in view of Salpekar et. al., is withdrawn.

Claims 1-4, 9, 11-14, 16, 19-34, and 37 were previously rejected for obviousness type double patenting over claim 1-7 of co-pending appl. 12/997779. The claims in the co-pending application have been amended to recite specific active ingredients in the formulation which excludes lurasidone. The rejection for provisional obviousness type double patenting over the claims of 12/997779 is withdrawn in consideration of the amendments to the claims of the co-pending application.

4. Claims 1, 4, 9, 12-14, 16, 20-23, 25-26, 28-32, 34, and 37-44 are free of the prior art. A statement of reasons for allowance is disclosed below.

Reasons for Allowance

5. The following is an examiner's statement of reasons for allowance: there is no prior art which teaches or suggests the instantly claimed oral preparation which comprises from 20-45% (wt/wt) lurasidone; and from 20-50% (wt/wt) pregelatinized starch. The closest prior art is Fujihara et. al., EP 1327440; and Salpekar et. al., USP 4,600,579 (both of previous record). Fujihara et. al. teaches a tablet composition which comprises lurasidone; water soluble excipients such as mannitol or lactose; and corn starch as a disintegrant. However, Fujihara et. al. does not teach pregelatinized starch. Salpekar teaches an oral acetaminophen composition which comprises partially gelatinized starch in an amount from 5 or less to 15 or more parts per 100 parts of the composition. Salpekar does not teach the composition as comprising lurasidone. Salpekar shows comparison data for a tablet which comprises acetaminophen and about 18.0% partially gelatinized starch, having a disintegration time of 18 minutes, to a tablet which comprises acetaminophen and 8.85% partially gelatinized starch that exhibits a disintegration time of about 6 minutes. The Applicants have shown in the specification that a composition comprising 80 mg. lurasidone without pregelatinized starch as prepared according to Fujihara et. al. showed reduced percent dissolution over a period of 45 minutes in comparison to 2-40 mg. lurasidone tablets not containing pregelatinized starch, and have submitted that doubling the content of lurasidone in a tablet without pregelatinized starch results in a poorer dissolution profile (see paragraph

[0089] and Fig. 2). The Applicants have also shown that tablets comprising lurasidone (80 mg.) and pregelatinized starch in an amount of 25% wt/wt have nearly the same dissolution profile as tablets comprising lesser amounts of lurasidone (40 and 20 mg.) and 25% wt/wt pregelatinized starch (see paragraphs [0031-0035], and Fig. 3); therefore, doubling the amount of lurasidone in a tablet (from 40 mg. to 80 mg.) did not decrease the percent dissolution. The claimed oral preparation is therefore novel and non-obvious over the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Information Disclosure Statement

6. The information disclosure statement (IDS) submitted on 1/17/2014 was filed after the mailing date of the final office action on 12/11/2012. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner.

Conclusion

7. Claims 1, 4, 9, 12-14, 16, 20-23, 25-26, 28-32, 34, and 37-44 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached on Monday-Thursday 8:00 AM - 6:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/SARAH PIHONAK/ Examiner, Art Unit 1627

	Application No.	Applicant(s)
Examiner-Initiated Interview Summary	11/919,678	FUJIHARA, KAZUYUKI
Examiner-initiated interview Summary	Examiner	Art Unit
	SARAH PIHONAK	1627
All participants (applicant, applicant's representative, PTO	personnel):	
(1) <u>SARAH PIHONAK</u> .	(3)	
(2) <u>JENNIFER GUPTA</u> .	(4)	
Date of Interview: 27 January 2014.		
Type: 🛛 Telephonic 🗌 Video Conference 🗋 Personal [copy given to: 🗋 applicant [applicant's representative]	
Exhibit shown or demonstration conducted: Yes I If Yes, brief description:	🖾 No.	
Issues Discussed 101 112 102 103 Othe (For each of the checked box(es) above, please describe below the issue and detail		
Claim(s) discussed: <u>1,4,9,12-14,16,20-23,25,26,28-32,34 a</u>	<u>nd 37-44</u> .	
Identification of prior art discussed: Fujihara et. al. & Salpe	<u>kar et. al.</u> .	
Substance of Interview (For each issue discussed, provide a detailed description and indicate if agreement reference or a portion thereof, claim interpretation, proposed amendments, argume		dentification or clarification of a
A proposed examiner's amendment was discussed. Applica 1/24/14. Claims 1, 4, 9, 12-14, 16, 20-23, 25-26, 28-32, 34,	ants submitted supplemental c and 37-44 as amended on 1/2	elaim amendments on 24/14, are allowed.
Applicant recordation instructions: It is not necessary for applicant to p	rovide a separate record of the substa	ance of interview.
Examiner recordation instructions: Examiners must summarize the sub-	stance of any interview of record. A co	omplete and proper recordation of
the substance of an interview should include the items listed in MPEP 713, general thrust of each argument or issue discussed, a general indication of general results or outcome of the interview, to include an indication as to w	04 for complete and proper recordation f any other pertinent matters discusse	on including the identification of the definition of the definitio
Attachment		
/SARAH PIHONAK/ Examiner, Art Unit 1627		
U.S. Patent and Trademark Office		

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

CPC								
Symbol	Symbol							

CPC Combination Sets											
Symbol			Туре	Set	Ranking	Version					

/S.P./ Examiner.Art Unit 1627	01/28/2014	Total Claims Allowed:						
(Assistant Examiner)	(Date)	27						
/SARAH PIHONAK/ Examiner.Art Unit 1627	01/28/2014	O.G. Print Claim(s)	O.G. Print Figure					
(Primary Examiner)	(Date)	1	None					
U.S. Patent and Trademark Office	ent and Trademark Office Part of Paper No. 2014012							

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

	US ORIGINAL CLASSIFICATION					INTERNATIONAL CLASSIFICATION								
	CLASS			SUBCLASS					С	LAIMED			NO	N-CLAIMED
514	514 254.02					А	6	1	к	31 / 497 (2006.01.01)				
	CROSS REFERENCE(S)				С	0	7	D	413 / 00 (2006.01.01)					
Choos herenence(s)					С	0	7	D	417 / 00 (2006.01.01)					
CLASS	SUB	CLASS (ONE	E SUBCLAS	S PER BLC	CK)	С	0	7	D	419 / 00 (2006.01.01)				
544	368													
						<u> </u>								
						-								

/S.P./ Examiner.Art Unit 1627	01/28/2014	Total Claims Allowed:					
(Assistant Examiner)	(Date)	27					
/SARAH PIHONAK/ Examiner.Art Unit 1627	01/28/2014	O.G. Print Claim(s)	O.G. Print Figure				
(Primary Examiner)	(Date)	1	None				
U.S. Patent and Trademark Office Part of Paper No. 2014012							

Par Pharm., Inc. Exhibit 1015 Page 587

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Issue Classification	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

	Claims renumbered in the same order as presented by applicant								СР] T.D.	[] R.1.4	47	
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
1	1		17		33										
	2		18	19	34										
	3		19		35										
2	4	8	20		36										
	5	9	21	20	37										
	6	10	22	21	38										
	7	11	23	22	39										
	8		24	23	40										
3	9	12	25	24	41										
	10	13	26	25	42										
	11		27	26	43										
4	12	14	28	27	44										
5	13	15	29		45										
6	14	16	30												
	15	17	31												
7	16	18	32												

/S.P./ Examiner.Art Unit 1627	01/28/2014	Total Claims Allowed:			
(Assistant Examiner)	(Date)	27			
/SARAH PIHONAK/ Examiner.Art Unit 1627	01/28/2014	O.G. Print Claim(s)	O.G. Print Figure		
(Primary Examiner)	(Date)	1	None		
U.S. Patent and Trademark Office Part of Paper No. 20140128					

Par Pharm., Inc. Exhibit 1015 Page 588

	Index of Oleime			Application/Control No.			Applicant(s)/Patent Under Reexamination			
Index of Claims				11919678			FUJIHARA	, KAZ	UYUKI	
			Examiner			Art Unit				
				SARAH PIHONA	K		1627			
✓	Rejected	-	C	Cancelled	Ν	Non-Ele	ected	A	Appeal	

=	Allowed		- Res	tricted	Ι	Interf	erence	0	Ot	ojected
Claims	renumbered	in the same	e order as pi	esented by	applicant		СРА	Τ	.D. [] R.1.47
CL	AIM					DATE				
Final	Original	11/13/2009	07/20/2010	03/08/2012	12/06/2012	01/28/2014				
1	1	√	√	√	1	=				
	2	√	√	√	~	-				
	3	✓	√	√	~	-				
2	4	√	√	√	√	=				
	5	N	N	N	N	-				
	6	N	N	N	N	-				
	7	N	Ν	N	N	-				
	8	√	-	-	-	-				
3	9	√	√	√	~	=				
	10	√	-	-	-	-				
	11	√	√	√	✓	-				
4	12	~	~	✓	~	=				
5	13	✓	√	√	~	=				
6	14	√	~	√	~	=				
	15	√	-	-	-	-				
7	16	√	~	√	~	=				
	17	√	-	-	-	-				

-

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

√

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

Ν

Ν

-

-

=

=

=

=

-

=

=

-

=

=

=

=

=

-

=

-

-

U.S. Patent and Trademark Office

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

8

9

10

11

12

13

14

15

16

17

18

19

 \checkmark

~

 \checkmark

 \checkmark

 \checkmark

 \checkmark

√

-

 \checkmark

√

 \checkmark

√

 \checkmark

√

 \checkmark

 \checkmark

-

 \checkmark

√

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

 \checkmark

✓

 \checkmark

√

 \checkmark

 \checkmark

 \checkmark

 \checkmark

Ν

Ν

Part of Paper No. : 20140128-A

Index of Claims			11 E)	11919678 Examiner			Reexa	Applicant(s)/Patent Under Reexamination FUJIHARA, KAZUYUKI Art Unit				
Image:			SARAH PIHONAK Cancelled N Non-Ele		lected]	A		Appeal			
=	Allowed	-	- Res	tricted	ed I Interferen		erence		0	0	bjected	
Claims	renumbered	in the sam	e order as pr	esented by	applica	ant	l	СРА	C] T.D.	.	R.1.47
CL	AIM						DATE					
Final	Original	11/13/2009	07/20/2010	03/08/2012	12/06/	2012	01/28/2014					
20	37				√	·	=					
21	38						=					
22	39						=					
23	40						=					
24	41						=					
25	42						=					
26	43						=					
27	44						=					
	45						-					

Ref #	Hits	Search Query	DBs	Defa ult Oper ator	Plurals	Time Stamp
L1	1	"20040028741".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2014/01/22 11:16
L2	297	lurasidone or latuda	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:19
L3	22732	starch with (pregelatin\$6)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:19
L4	4808	starch with (pre-gelatin\$6)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:19
L5	167535	starch with (gelatin\$6)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:20
L6	176381	13 or 14 or 15	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:20
L7	143	I2 and I6	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:20
L8	10012	starch adj12 (pregelatin\$6)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:20
L9	3034	starch adj12 (pre-gelatin\$6)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:20
L10	91735	starch adj12 (gelatin\$6)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/01/22 11:20

L11 81 I2 and (I8 or I9 or I10) US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT OR OFF 2014/01/2 L12 1202 514/254.02.ccls. US-PGPUB; USPAT; USOCR OR OFF 2014/01/2 L13 991 544/368.ccls. US-PGPUB; USPAT; USOCR OR OFF 2014/01/2	22 11:28
L13 991 544/368.ccls. US-PGPUB; OR OFF 2014/01/2 USOCR USPAT; USOCR	22 11:29
USPAT; USOCR	
	22 11:29
L14 1914 I12 or I13 US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR II2 or I13 US-PGPUB; OR OFF 2014/01/2	
L15 477 I14 and (I8 or I9 or I10) US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR; EPO; JPO; DERWENT OF OFF 2014/01/2	2 11:29
L16 9371 starch adj6 (pregelatin\$6) US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR; EPO; JPO; DERWENT OR OFF 2014/01/2	2 11:31
L17 2950 starch adj6 (pre-gelatin\$6) US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT OFF 2014/01/2	2 11:31
L18 78571 starch adj6 (gelatin\$6) US-PGPUB; US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT OFF 2014/01/2	2 11:31
L19 447 I14 and (I16 or I17 or I18) US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR; EPO; JPO; DERWENT OR OFF 2014/01/2	2 11:31
L20 6 ((KAZUYUKI) near2 (FUJIHARA)).INV. US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR	2 11:37
L21 3436 dainippon.as. US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR OFF 2014/01/2	2 11:37
L22 11 I14 and I21 US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR OFF 2014/01/2	2 11:38
L23 11 I22 not I20 US-PGPUB; OR OFF 2014/01/2 USPAT; USOCR OFF 2014/01/2	2 11:38

1/22/2014 11:43:37 AM C:\Users\spihonak\Documents\EAST\Workspaces\11919678.wsp Page 2

			•			
L24	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2014/01/22 11:41
S1	4	" 2001076557".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2009/07/17 07:52
S2	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:53
83	2622	pre-gelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S4	0	S2 and S3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S5	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:54
S6	25	S2 and S5	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 12:55
S7	234938	oral and pharmaceutical	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S8	10067	S5 and S7	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S9	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:01
S10	446	S9 and oral	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:02

011	4000			00		0000/11/10 10 17
S11	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:17
S12	68	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S13	1	S11 and S12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S14	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S15	86	S11 and S14	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:18
S16	1916	(pregelatin\$4 with starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 13:57
S17	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S18	86	S16 and S17	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:09
S19	1	"3607394".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2009/11/12 14:11
S20	67	(pregelatin\$4 with starch) same (polymer with binder)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:29

S21	14534	pregelatin\$4 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S22	745	S21 and (starch adj "1500")	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:39
S23	47786	water adj solub\$4 adj polymer	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S24	43	S22 and S23	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:40
S25	99	S21 and (PCS)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/12 14:42
S26	5	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2009/11/12 15:05
S27	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2009/11/12 15:07
S28	1803	starch adj "1500"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
S29	1747	S28 and (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:14
\$30	202	S28 with (water or moisture)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2009/11/13 14:15
S31	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2010/07/20 12:22
S32	4	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2010/07/20 12:23

\$33	84	lurasidone	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:24
S34	15801	pregelatin\$5 with starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
S35	31	S33 and S34	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:25
S36	23548	accugel or absorbo or actobody or alphajel or allbond or alstar or amaizo or amalean or amerikor or amicoa or amidex or amigel or amilofax or amilys or amisol or amycol or amylex or amylogel or amylogum or amylomaize or amylon or amylose	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:27
S37	0	S33 and S36	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2010/07/20 12:28
S38	1	"4600579".pn.	US-PGPUB; USPAT; USOCR	OR	OFF	2011/11/02 11:19
S39	2	"20040028741".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2012/03/08 12:35
S40	1936	(corn adj starch) with (pregelatinized adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 13:13
S41	1138	(corn adj starch) adj5 (pregelatinized adj starch)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 13:13
S42	4	"2002053140".pn.	EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:12
S43	4	"2003066039".pn.	EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:13
S44	6	"2005009999".pn.	EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:15

S45	2389	((pregelatinize\$1 or pregelatinise\$1) adj4 starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:50
S46	16953	((improve\$4 or increas\$4) adj4 (solubility or soluble)).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:51
S47	41	S45 and S46	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/03/08 14:51
S48	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT	OR	OFF	2012/03/08 16:19
S49	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2012/03/08 16:19
S50	3215	dainippon.as.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:20
S51	232	((pregelatinize\$1 or pregelatinise\$1) with starch).ab.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:21
S52	1	S50 and S51	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:21
S53	1	S48 and S51	US-PGPUB; USPAT; USOCR	OR	OFF	2012/03/08 16:22
S54	22381	(pregelatin\$6 or (pre-gelatin\$6)) adj6 starch	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:31
S55	3343	((pregelatin\$6 or (pre-gelatin\$6)) adj6 starch).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:32
S56	942420	(solubility or dissolution or \$4availability or soluble or \$4available).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33
S57	1105	S55 and S56	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33

	,				1	
S58	195	lurasidone or latuda	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33
S59	3	S57 and S58	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:33
S60	1572986	(drug or pharmaceutical or medicine or medicament or active).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:34
S61	719	S57 and S60	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:35
S62	64608	(schizophren\$2 or psychosis or psychotic or neurological or psychiatric or mental or cognit\$3).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:40
S63	37	S61 and S62	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2012/11/26 10:40
S64	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:04
S65	6	((KAZUYUKI) near2 (FUJIHARA)).INV.	EPO; J PO ; DERWENT	OR	OFF	2012/11/26 11:04
S66	3294	dainippon.as.	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:05
S67	1	S55 and S66	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:05
S68	39	S54 and S66	US-PGPUB; USPAT; USOCR	OR	OFF	2012/11/26 11:05


SET EXPAND CONTINUOUS E B3+ALL/CT 12 80620 \$ E14-E15 FILE 'REGISTRY' ENTERED AT 09:46:57 ON 22 JAN 2014 E STARCH, PREGELATINIZED/CN FILE 'REGISTRY' ENTERED AT 09:47:33 ON 22 JAN 2014 L3 1 \$ 9005-25-6/RM SET NOTICE 1 DISPLAY SET NOTICE 1 DISPLAY SET NOTICE 0F DISPLAY SET STACH, PRECELATINIZED/CN E PRECELATINIZED SETACH, PRECELATINIZED/CN E DIAL 12 13 14	L1	1 S US 20090143404/PN E DISSOLUTION/CT
L2 80620 S E14-E15 FILE 'REGISTRY' ENTERED AT 09:46:57 ON 22 JAN 2014 E STARCH, PREGLATINIZED/CN E STARCH, PREGLATINIZED/CN FILE 'REGISTRY' ENTERED AT 09:47:33 ON 22 JAN 2014 L3 1 S 9005-25-8/RN SET NOTICE 1 DISPLAY SET NOTICE 0FF DISPLAY SET NOTICE 0FF DISPLAY SET STARCH/CN L4 1 S E64 L5 3627 S 9005-25-8/CRN E 9005-25-80/RN E 9005-25-80/RN E 9005-25-80/RN E 9005-25-80/RN E 9005-25-80/RN E 9005-25-80/RN E 9005-25-80/RN E 9005-25-80/RN E 9005-25-80/RN E 9105-25-80/RN E 9105-2007 E 91100 11 2524 S (PREGELATIN1/S) (S (PSTARCH?) E 9136-ALL/CT E 91		
$ \begin{array}{c} \mbox{File} \ 'REGISTRY' ENTERED AT 09:46:57 ON 22 JAN 2014 \\ \mbox{E} \ STARCH, PRECELATINIZED/CN \\ \mbox{File} \ 'REGISTRY' ENTERED AT 09:47:33 ON 22 JAN 2014 \\ \mbox{I3} \ 1 \ S \ 9005-25-8/RN \\ \mbox{SET NOTICE 1 DISPLAY } \\ \mbox{SET NOTICE 0 OF DISPLAY } \\ \mbox{SET NOTICE 0 TDISPLAY } \\ \mbox{SET NOTICE 0 FF DISPLAY } \\ \mbox{SET NOTICE 0 FF DISPLAY } \\ \mbox{SET NOTICE 0 OFT DISPLAY } \\ \mbox{SET NOTICE 0 FF DISPLAY } \\ \mbox{SET NOTICE 0 FF DISPLAY } \\ \mbox{SET NOTICE 0 OFT DISPLAY } \\ \mbox{SET NOTICE 0 FF DISPLAY } \\ \mbox{SET NOTICAL TABLETS/CT } \\ \mbox{SET NOTICAL TABLETS/CT } \\ \mbox{SET NOTICAL TABLETS/CT } \\ \mbox{SE DISPLAY } \\ SET NOTICAL TABLE$		
<pre>E STARCH, PREGELATINIZED/CN E STARCH, PREGELATINIZED/CN FILE 'REGISTRY' ENTERED AT 09:47:33 ON 22 JAN 2014 L3 1 \$ 9005-25-8/RN SET NOTICE 1 DISPLAY SET NOTICE 0 FF DISPLAY SET NOTICE 0 FF DISPLAY SET EXPAND CONTINUOUS E STARCH/CN L4 1 \$ E64 L5 3627 \$ 9005-25-8/CRN L6 0 \$ 9005-25-8/CRN E 9005-25-8/RN E 9005-25-8/RN E 9005-25-8/RN E 9005-25-8/RN E 9005-25-8/RN E 9005-25-8/RN E 9005-25-8/RN E 9005-25-8/CRN L6 0 \$ STARCH, PREGELATINIZED STARCH/CN L8 0 \$ STARCH, PREGELATINIZED/CN E UTARSIDONE/CN E UTARSIDONE/CN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 \$ (PREGELATINI?) (\$) (7STARCH?) L12 16134 \$ (7GELATIN?) (\$) (7STARCH?) L12 16134 \$ (7GELATIN?) (\$) (7STARCH?) L12 16134 \$ L11 OR L12 L13 71281 \$ E155-E156, E162-E163, E165 L14 16134 \$ L11 OR L12 L15 171 \$ L9 OR L10 L16 2 \$ L14 AND L15 L17 1 \$ L16 NOT L1 L18 1280 \$ L13 AND L14 L19 385 \$ L2 AND L18 L20 36 \$ L19 AND (PY<=2006 OR PY<=2006 OR PY<=2006) L21 35 \$ L20 NOT L1 L22 267 \$ L18 AND (PY<=2006 OR PY<=2006 OR AY<=2006) L23 266 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ L23 NOT L21 L26 66 \$ L23 NOT L21 L27 66 \$ L33 NOT L21 L37 66 \$ L37 AND (</pre>	L2	80620 S E14-E15
L3 1 S 9005-25-8/RN SET NOTICE 1 DISPLAY SET EXPAND CONTINUOUS E STARCH/CN L4 1 S E64 L5 3627 S 9005-25-8/CN L6 0 S 9005-25-8/DR E 9005-25-8/DR E 9005-25-8/DR E 9005-25-8/DR E 975 L7 1 S E88 E PREGELATINIZED STARCH/CN L8 0 S STARCH, PREGELATINIZED/CN E STARCH, PREGELATINIZED/CN E STARCH, PREGELATINIZED/CN E STARCH, PREGELATINIZED/CN E STARCH, PREGELATINIZED/CN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 S (PREGELATIN?) (S) (2STARCH?) L2 16134 S (7CELATIN?) (S) (2STARCH?) E PHARMACEUTICAL TABLETS/CT E PHARMACEUTICAL TABLETS/CT E PHARMACEUTICAL TABLETS/CT E PHARMACEUTICAL TABLETS/CT E PHARMACEUTICAL TABLETS/CT E 13 71281 S E155-E156, E162-E163, E165 L14 16134 S L11 OR L12 L15 171 S L10 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L14 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 100 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		E STARCH, PREGELATINIZED/CN
$ \begin{array}{c} \text{SET NOTICE 1 DISPLAY} \\ \text{SET NOTICE OFF DISPLAY} \\ \text{SET EXPAND CONTINUOUS} \\ \text{E STARCH/CN} \\ \begin{array}{c} \text{I4} & 1 \text{ S E64} \\ \\ \begin{array}{c} \text{I5} & 3627 \text{ S } 9005-25-8/\text{CRN} \\ \text{I6} & 0 \text{ S } 9005-25-8/\text{CRN} \\ \text{I7} & \text{I7} \text{ S E88} \\ \text{E PREGELATINIZED STARCH/CN} \\ \begin{array}{c} \text{I8} \text{I8} \text{ S STARCH, PREGELATINIZED/CN} \\ \text{E STARCH, PREGELATINIZED/CN} \\ \text{E STARCH, PREGELATINIZED/CN} \\ \text{E STARCH, PREGELATINIZED/CN} \\ \text{I9} & 1 \text{ S } \text{ E124} \\ \\ \begin{array}{c} \text{I10} & 3 \text{ S } 367514-87-2/\text{CRN} \\ \end{array} \end{array} \end{array}$		FILE 'REGISTRY' ENTERED AT 09:47:33 ON 22 JAN 2014
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	L3	
L4 1 S E64 L5 3627 S 9005-25-8/CRN L6 0 S 9005-25-8/D/RN E 9005-25-8D/RN E 275 L7 1 S E88 E PRECELATINIZED STARCH/CN L8 0 S STARCH, PREGELATINIZED/CN E UIRASIDONE/CN L9 1 S E124 L10 3 S 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 S (PREGELATIN?) (S) (2STARCH?) L12 16134 S (2GELATIN?) (S) (2STARCH?) E 136+ALL/CT L13 71281 S E155-E156, E162-E163, E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PR<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PR<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S L2 AND L14 L27 669 S L2 AND (PY<=2006 OR PR<=2006)		
L5 3627 S 9005-25-8/CRN L6 0 S 9005-25-8/CRN E 9005-25-8/CRN E 9005-25-8/CRN E 275 L7 1 S E88 E PREGELATINIZED STARCH/CN L8 0 S STARCH, PREGELATINIZED/CN E STARCH, PREGELATINIZED/CN E ULRASIDONE/CN L9 1 S E124 L10 3 S 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 S (PREGELATIN?) (S) (?STARCH?) L12 16134 S (?GELATIN?) (S) (?STARCH?) E PHARMACCUTICAL TABLETS/CT E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 10 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)	T A	
L6 0 S 9005-25-8D/RN E 9005-25-8D/RN E E75 L7 1 S E88 E PREGELATINIZED STARCH/CN E STARCH, PREGELATINIZED/CN E STARCH, PREGELATINIZED/CN E LURASIDONE/CN L9 1 S E124 L10 3 S 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 S (PREGELATIN?) (S) (2STARCH?) L12 16134 S (?GELATIN?) (S) (2STARCH?) E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L50 CR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR PTY<=2006 OR PTY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PTY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PTY<=2006 OR AY<=2006)		
E 9005-25-8D/RN $E E75$ L7 1 S E88 $E PREGELATINIZED STARCH/CN$ L8 0 S STARCH, PREGELATINIZED/CN $E STARCH, PREGELATINIZED/CN$ $E UURASIDONE/CN$ L9 1 S E124 L10 3 S 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 S (PREGELATIN?) (S) (?STARCH?) L12 16134 S (?GELATIN?) (S) (?STARCH?) L12 16134 S (?GELATIN?) (S) (?STARCH?) L12 16134 S (?GELATIN?) (S) (?STARCH?) E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 A669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 A669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L2 L3 L3 L3 L3 L4		
$ \begin{array}{c} {\rm E} \ {\rm E75} \\ {\rm L7} & {\rm I} \ {\rm S} \ {\rm E88} \\ & {\rm E} \ {\rm PREGELATINIZED \ {\rm STARCH/CN}} \\ {\rm L8} & {\rm 0} \ {\rm S} \ {\rm STARCH, \ {\rm PREGELATINIZED/CN}} \\ & {\rm E} \ {\rm STARCH, \ {\rm PREGELATINIZED/CN}} \\ & {\rm E} \ {\rm STARCH, \ {\rm PREGELATINIZED/CN}} \\ & {\rm E} \ {\rm STARCH, \ {\rm PREGELATINIZED/CN}} \\ & {\rm E} \ {\rm LURASIDONE/CN} \\ {\rm L9} & {\rm I} \ {\rm S} \ {\rm E124} \\ {\rm L10} & {\rm 3} \ {\rm S} \ {\rm 367514-87-2/CRN} \\ \end{array} \\ \hline {\rm FILE} \ {\rm 'CAPLUS'} \ {\rm ENTERED \ {\rm AT} \ 09:50:56 \ {\rm ON} \ 22 \ {\rm JAN} \ 2014} \\ {\rm L11} & {\rm 2524 \ {\rm S} \ ({\rm PREGELATIN?) \ ({\rm S}) \ ({\rm 2STARCH?})} \\ & {\rm E} \ {\rm PHARMACEUTICAL \ TABLETS/CT} \\ & {\rm E} \ {\rm E136+ALL/CT} \\ {\rm L13} \ \ 71281 \ {\rm S} \ {\rm E155-E156, E162-E163, E165} \\ {\rm L14} \ \ 16134 \ {\rm S} \ {\rm L10} \ {\rm OR} \ {\rm L12} \\ \\ {\rm L15} \ \ 171 \ {\rm S} \ {\rm L9 \ OR} \ {\rm L10} \\ \\ {\rm L16} \ \ 2 \ {\rm S} \ {\rm L14 \ AND \ L15} \\ \\ {\rm L17} \ \ 1 \ {\rm S} \ {\rm L16 \ NOT \ L1} \\ \\ {\rm L18} \ \ 1280 \ {\rm S} \ {\rm L13 \ AND \ L14} \\ \\ {\rm L19} \ \ 385 \ {\rm L2 \ AND \ L14} \\ \\ {\rm L20} \ \ 36 \ {\rm S} \ \ {\rm L19 \ AND \ L14} \\ \\ {\rm L20} \ \ 36 \ {\rm S} \ {\rm L19 \ AND \ L14} \\ \\ {\rm L20} \ \ 36 \ {\rm S} \ {\rm L10 \ AND \ L14} \\ \\ {\rm L22} \ \ 266 \ {\rm S} \ {\rm L22 \ NOT \ L1} \\ \\ {\rm L24} \ \ 231 \ {\rm S} \ {\rm L23 \ NOT \ L21} \\ \\ {\rm L24} \ \ 231 \ {\rm S} \ {\rm L23 \ NOT \ L21} \\ \\ {\rm L25} \ \ 66 \ {\rm S} \ ({\rm DISSOLUTION? \ OR \ DISSOLV? \ OR \ SOLUB? \ OR \ {\rm AV<=2006} \\ \\ {\rm L24} \ \ 206 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L26} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L27} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L26} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L27} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L26} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L27} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L26} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L27} \ \ 669 \ {\rm S} \ {\rm L2 \ AND \ L14} \\ \\ {\rm L27} \ \ 669 \ {\rm S} \ {\rm L27 \ AND \ (PY<=2006 \ OR \ PRY<=2006 \ OR \ AY<=2006)} \\ \\ {\rm L28} \ \ {\rm L27 \ AND \ (PY<=2006 \ OR \ PRY<=2006 \ OR \ AY<=2006)} \\ \\ \ {\rm L28} \ \$	ЦО	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	L7	1 S E88
E STARCH, PREGELATINIZED/CN E LURASIDONE/CN L9 1 \$ E124 L10 3 \$ 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 \$ (PREGELATIN?) (\$) (?STARCH?) L12 16134 \$ (?GELATIN?) (\$) (?STARCH?) E PHARMACEUTICAL TABLETS/CT E E1364ALL/CT L13 71281 \$ E155-E156,E162-E163,E165 L14 16134 \$ L11 OR L12 L15 171 \$ L9 OR L10 L16 2 \$ L14 AND L15 L17 1 \$ L16 NOT L1 L18 1280 \$ L13 AND L14 L19 385 \$ L2 AND L18 L20 36 \$ L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 \$ L20 NOT L1 L22 266 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L24 231 \$ L23 NOT L21 L25 66 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 \$ L2 AND L14 L27 669 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 \$ L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
E LURASIDONE/CN L9 1 S E124 L10 3 S 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 S (PREGELATIN?) (S) (?STARCH?) L12 16134 S (?GELATIN?) (S) (?STARCH?) E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)	L8	·
L9 1 S E124 L10 3 S 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 S (PREGELATIN?) (S) (?STARCH?) L12 16134 S (?GELATIN?) (S) (?STARCH?) E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
<pre>L10 3 \$ 367514-87-2/CRN FILE 'CAPLUS' ENTERED AT 09:50:56 ON 22 JAN 2014 L11 2524 \$ (PREGELATIN?) (\$) (?STARCH?) L12 16134 \$ (?GELATIN?) (\$) (?STARCH?) E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 \$ E155-E156,E162-E163,E165 L14 16134 \$ L11 OR L12 L15 171 \$ L9 OR L10 L16 2 \$ L14 AND L15 L17 1 \$ L16 NOT L1 L18 1280 \$ L13 AND L14 L19 385 \$ L2 AND L14 L19 385 \$ L2 AND L14 L22 267 \$ L18 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L23 266 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 \$ L2 AND L14 L27 669 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 100 \$ L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 200 \$ L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 201 \$ L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 201 \$ L27 AND L24 L26 L27 AND L24 L26 L28 L27 AND L26 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L27 AND L24 L26 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L25 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L27 AND L24 L26 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L27 AND L24 L26 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L25 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L25 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L24 L25 L28 L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)</pre>	т,9	
L11 2524 \$ (PREGELATIN?) (\$) (?STARCH?) L12 16134 \$ (?GELATIN?) (\$) (?STARCH?) E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 \$ E155-E156,E162-E163,E165 L14 16134 \$ L11 OR L12 L15 171 \$ L9 OR L10 L16 2 \$ L14 AND L15 L17 1 \$ L16 NOT L1 L18 1280 \$ L13 AND L14 L19 385 \$ L2 AND L18 L20 36 \$ L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 \$ L20 NOT L1 L22 267 \$ L18 AND (PY<=2006 OR PRY<=2006) L23 266 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 \$ L2 AND L14 L27 669 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 107 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		3 S 367514-87-2/CRN
L11 2524 \$ (PREGELATIN?) (\$) (?STARCH?) L12 16134 \$ (?GELATIN?) (\$) (?STARCH?) E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 \$ E155-E156,E162-E163,E165 L14 16134 \$ L11 OR L12 L15 171 \$ L9 OR L10 L16 2 \$ L14 AND L15 L17 1 \$ L16 NOT L1 L18 1280 \$ L13 AND L14 L19 385 \$ L2 AND L18 L20 36 \$ L19 AND (PY<=2006 OR AY<=2006 OR AY<=2006) L21 35 \$ L20 NOT L1 L22 267 \$ L18 AND (PY<=2006 OR PRY<=2006) L23 266 \$ L22 NOT L1 L24 231 \$ L23 NOT L21 L25 66 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 \$ L2 AND L14 L27 669 \$ (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 107 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L12 16134 S (?GELATIN?) (S) (?STARCH?) E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 127 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)	T 1 1	
<pre>E PHARMACEUTICAL TABLETS/CT E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)</pre>		
E E136+ALL/CT L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006) L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006) L23 266 S L22 NOT L1 L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L13 71281 S E155-E156,E162-E163,E165 L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006)		
L14 16134 S L11 OR L12 L15 171 S L9 OR L10 L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006)	L13	
L16 2 S L14 AND L15 L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006)	L14	
L17 1 S L16 NOT L1 L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006)		
L18 1280 S L13 AND L14 L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006)		
L19 385 S L2 AND L18 L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006)		
L20 36 S L19 AND (PY<=2006 OR AY<=2006 OR PRY<=2006)		
L21 35 S L20 NOT L1 L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L22 267 S L18 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L24 231 S L23 NOT L21 L25 66 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24 L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L2566 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L24L26669 S L2 AND L14L27669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26L28180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L26 669 S L2 AND L14 L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L27 669 S (DISSOLUTION? OR DISSOLV? OR SOLUB? OR ?AVAILAB?) AND L26 L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		
L28 180 S L27 AND (PY<=2006 OR PRY<=2006 OR AY<=2006)		

STRUCTURE UPLOADED

L1 STRUCTURE UPLOADED

=> d l1 L1 HAS NO ANSWERS L1 STR

L1



L2 2 S L1 SSS SAM LЗ 82 S L1 SSS FULL E STARCH, PREGELATINIZED/CN SET EXPAND CONTINUOUS E STARCH/CN L41 S E15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2014 ACS on STN L4 9005-25-8 REGISTRY RN ΕD Entered STN: 16 Nov 1984 CN Starch (CA INDEX NAME) OTHER NAMES: CN α -Starch CN 75A CN 75A (polysaccharide) A 1FB004215 CN CN Absorbo HP CN AccuGel Ace P 320 CN Actobody TP 2 CN ADM Clineo 716 CN Aeromyl 115 CN Agglofroid 009 CN Agglofroid 313E CN Allbond 200 CN CN Alphajel KS 37 CN Alstar B CN Alstar E CN Alstar H CN Amaizo 100 Amaizo 213 CN Amaizo 310 CN Amaizo 5 CN CN Amaizo 71 CN Amaizo 710 Amaizo W 13 CN

```
CN
    Amalean I-A 2131
     Amalean I-A 7081
CN
CN
     Amerikor 818
CN
    Amicoa
    Amidex 3001
CN
CN
    Amidex 3005
    Amidex 4001
CN
    Amido-STA 1500
CN
    Amidomax 4800
CN
CN
    Amigel
CN
    Amigel 12014
CN
    Amigel 30076
    Amijel VA 160
CN
CN
    Amilofaks
CN
    Amilofax 00
CN
    Amilys 100
    Amisol 3408
CN
    Amycol HF
CN
CN
    Amycol K
    Amycol W
CN
CN
    Amylex 20/20
CN
    Amylogel
CN
    Amylogel 03001
CN
    Amylogel 03003
CN
     Amylogel HB 450
CN
     Amylogum
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
     DISPLAY
DEF A high-polymeric carbohydrate material primarily composed of amylopectin
     and amylose. It is usually derived from cereal grains such as corn,
wheat
     and sorghum, and from roots and tubers such as potatoes and tapioca. It
     includes starch which has been pregelatinized by heating in the presence
    of water.
DR
     9057-05-0, 42616-76-2, 53112-52-0, 53262-79-6, 60496-95-9, 67674-80-0,
     75138-75-9, 75398-82-2, 85746-25-4, 118550-61-1, 131800-97-0, 152987-55-
8,
    154636-77-8, 730985-55-4, 730985-56-5, 730985-57-6, 955949-61-8,
     1374255-25-0
MF
    Unspecified
CT
     PMS, COM, MAN
PCT Manual registration, Polyother, Polyother only
SR
     CA
LC
                ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS,
     STN Files:
       CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSNB, DDFU, DRUGU, EMBASE,
       IFIALL, IPA, MEDLINE, MSDS-OHS, NAPRALERT, PIRA, RTECS*, TOXCENTER,
       USAN, USPAT2, USPATFULL, USPATOLD
         (*File contains numerically searchable property data)
     Other Sources: DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
              0 S 9005-25-8D/RN
L5
                E 9005-25-8D/RN
                E 9005-25-8D/CRN
```

L6 3627 S E38

FILE 'CAPLUS' ENTERED AT 09:28:34 ON 28 JAN 2014 L7 181 S L3 L8 24610 S L6 Гð 3 S L7 AND L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2014 ACS on STN T.9 This invention relates to pharmaceutical compns. comprising one or more AB weakly basic antipsychotic drugs, and methods of making and using such compns. Controlled release compns. comprise a plurality of controlled release particles comprising and acid core, a first coating of water insol. polymer, a second coating containing an antipsychotic drug and a third coating comprising a water insol. polymer. ACCESSION NUMBER: 2011:880401 CAPLUS Full-text DOCUMENT NUMBER: 155:222666 TITLE: Controlled release pharmaceutical comprising antipsychotic drugs Venkatesh, Gopi M.; Lai, Jin-Wang; Papp, Michelle INVENTOR(S): PATENT ASSIGNEE(S): Eurand, Inc., USA PCT Int. Appl., 73pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ _____ _____ WO 2011085188 WO 2011-US20505 20110107 A1 20110714 W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZWRW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM P 20100107 PRIORITY APPLN. INFO.: US 2010-61293067

L10	15990 S (STARCH?) (S) (?PREGELATIN? OR ?GELATIN?)
L11	18340 S (STARCH?) (L) (?PREGELATIN? OR ?GELATIN?)
L12	6365 S (STARCH?) (A) (?PREGELATIN? OR ?GELATIN?)
L13	15990 S (STARCH?) (XA) (?PREGELATIN? OR ?GELATIN?)
L14	18340 S L10 OR L11 OR L12 OR L13
L15	2 S L7 AND L14


L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2014 ACS on STN

AB A preparation for oral administration comprises a pregelatioized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3bicyclo[2,2,1]heptanedicarboxyimide hydrochloride (lurasidone hydrochloride) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, where the preparation exhibits an invariant level of elution behavior even when the content of its active ingredient is varied. For example, tablets were formulated containing lurasidone 80, mannitol 144, pregelatinized starch 80, croscarmellose sodium 4, hydroxypropyl Me cellulose 8, and Mg stearate 4 mg per tablet and film coated with a composition containing hydroxypropyl Me cellulose, titania, polyethylene glycol, and carnauba wax. ACCESSION NUMBER: 2006:1252571 CAPLUS Full-text DOCUMENT NUMBER: 146:13212 TITLE: Oral pharmaceutical compositions of lurasidone INVENTOR(S): Fujihara, Kazuyuki PATENT ASSIGNEE(S): Dainippon Sumitomo Pharma Co., Ltd., Japan SOURCE: PCT Int. Appl., 42pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PAT	TENT	NO.			KIN		ATE		A	PPLI	CATI	ON N	0.		D	ATE	
WO	2006	1266	81		A1	2	0061	130	W	20 S	 06-J	P310	571		2	0060	526
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑΖ,	ΒA,	ΒB,	BG,	BR,	BW,	ΒY,	ΒZ,	CA,	CH,
		CN,	сο,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	ΕE,	ΕG,	ΕS,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	ΚM,	KN,	KP,	KR,
		KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
		ΜZ,	NA,	NG,	NI,	NO,	ΝZ,	OM,	PG,	PH,	PL,	ΡT,	RO,	RU,	SC,	SD,	SE,
		SG,	SK,	SL,	SM,	SY,	ΤJ,	ΤM,	ΤN,	TR,	ΤT,	ΤZ,	UA,	UG,	US,	UΖ,	VC,
		VN,	YU,	ZA,	ZM,	$\mathbb{Z}\mathbb{W}$											
	RW:	ΑT,	BE,	ΒG,	CH,	CY,	CZ,	DE,	DK,	ΕE,	ΕS,	FI,	FR,	GB,	GR,	HU,	IE,
		IS,	IΤ,	LT,	LU,	LV,	MC,	NL,	PL,	ΡT,	RO,	SE,	SI,	SK,	ΤR,	BF,	ΒJ,
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	ΤD,	ΤG,	BW,	GH,
		GM,	KE,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SΖ,	ΤZ,	UG,	ZM,	ZW,	AM,	ΑZ,	ΒY,
		KG,	KΖ,	MD,	RU,	ΤJ,	ΤM										
AU	2006	2503	40		A1	2	0061	130	A	U 20	06-2	5034	0		2	0060	526
AU	2006	2503	40		В2	2	0120	209									
CA	2606	510			A1	2	0061	130			06-2				2	0060	526
ΕP	1884	242			A1	2	0800	206	Ε	P 20	06-7	4690	0		2	0060	526
ΕP	1884	242			В1	2	0130	417									
	R:	ΑT,	BE,	ΒG,	CH,	CY,	CZ,	DE,	DK,	ΕE,	ΕS,	FΙ,	FR,	GB,	GR,	HU,	IΕ,
		IS,	IΤ,	LI,	LT,												
KR	2008	0123			А		0080	211									
	1011				Α			521	C	N 20	06-8	0018	223		2	0060	526
	1011						0110										
	2398				C2		0100				-						
	2006				A2		0101									0060	
-	1020				Α		0110	-	C	N 20	10-1	0564	784		2	0060	526
	1020				В		0131										
	4733						0110										
ΕP	2422					_	0120						-		_	0060	
	R:	AT, IS,			CH, LT,												IE,

PT 1884242 ES 2408687 KR 2013122019 TW 359020 US 20090143404 MX 2007014872 IN 2007CN05369 HK 1108379 JP 2011126915 JP 5285105	E T3 A B A1 A A1 A B2	20130521 20130621 20131106 20120301 20090604 20080215 20080125 20130726 20110630 20130911	ES KR TW US MX IN HK	2006-746900 2006-746900 2013-7027051 2006-121223 2007-919678 2007-14872 2007-CN5369 2008-102367 2011-61211	20060526 20060526 20060526 20060614 20071031 20071123 20071126 20080303 20110318
PRIORITY APPLN. INFO.:			JP	2005-153508	A 20050526
				2006-80018223	A3 20060526
				2006-746900	A3 20060526
				2007-517921	
				2007-7027270 2006-JP310571	
ASSIGNMENT HISTORY FOR U		NT AVATLARIE			
IPCI A61K0031-496 [I]; A					
A61K0047-38 [I]; C0			1110	01/ 10 [1] / Holico	, , , , , , , , , , , , , , , , , , , ,
IPCR A61K0031-496 [I]; A			1K0	047-10 [I]; A61K00)47-26 [I];
A61K0047-38 [I]; C0					
CC 63-6 (Pharmaceutica	ls)				
IT 63-42-3, Lactose				9005-25-8D, Stard	sh,
pregelatinized 36					
367514-88-3, Lurasi					
RL: THU (Therapeuti					
IT 367514-87-2, Lurasi				oved dissoln. prof	ile)
hydrochloride	done	20/014-00-0	, т	urasidone	
RL: THU (Therapeuti	c use)	BIOL (Biol	oqi	cal study): USES ((Uses)
				oved dissoln. prof	
RN 367514-87-2 CAPLUS			-	1	,
CN 4,7-Methano-1H-isoi	ndole-	-1,3(2H)-dion	e,		
2-[[(1R,2R)-2-[[4-(
piperazinyl]methyl] INDEX NAME)	cycloł	nexyl]methyl]	hex	ahydro-, (3aR,4S,7	7R,7aS)- (CA


Absolute stereochemistry.



- RN
- 367514-88-3 CAPLUS 4,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[(1R,2R)-2-[[4-(1,2-benzisothiazol-3-yl)-1-CN

piperazinyl]methyl]cyclohexyl]methyl]hexahydro-, hydrochloride (1:1), (3aR,4S,7R,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



• HCl

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	11919678	FUJIHARA, KAZUYUKI
	Examiner	Art Unit
	SARAH PIHONAK	1627

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED					
Symbol	Date	Examiner			

US CLASSIFICATION SEARCHED							
Class	Subclass	Date	Examiner				
514	254.02	1/21/2014	S.P.				
544	368	1/21/2014	S.P.				

SEARCH NOTES						
Search Notes	Date	Examiner				
Inventor search in EAST, PALM	11/12/2009	S.P.				
Invention and claims search in EAST, STN	11/12/2009	S.P.				
Inventor search in EAST, PALM	7/12/2010	S.P.				
Invention and claims search in EAST, STN	7/12/2010	S.P.				
invention and claims search updated in EAST, STN	3/8/2012	S.P.				
updated inventor and assignee search in EAST, PALM	3/8/2012	S.P.				
updated inventor and assignee search in EAST, PALM	11/26/2012	S.P.				
updated invention and claims search in EAST, STN	11/26/2012	S.P.				
STIC search	11/30/2012	S.P.				
updated invention and claims search in STN, EAST	1/21/2014	S.P.				
updated inventor and assignee search in EAST, PALM	1/21/2014	S.P.				

	INTERFERENCE SEARCH	4	
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

/S. P./ Examiner.Art Unit 1627	

U.S. Patent and Trademark Office

Part of Paper No. : 20140128-A

INTERFERENCE SEARCH							
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner				
514	254.02	1/21/2014	S.P.				
544	368	1/21/2014	S.P.				

/S. P./ Examiner.Art Unit 1627

U.S. Patent and Trademark Office

Part of Paper No. : 20140128-A

				Complete if Known			
				Application Number	11/919,678		
INFC	RMATION D	ISCLOSU	RE	Filing Date	October 31, 2007		
STATEMENT BY APPLICANT				First Named Inventor	Kazuyuki FUJIHARA		
OIMICINI DI MITLIOMNI			79.88	Art Unit	1627		
(Use as many sheets as necessary)				Examiner Name	Sarah PIHONAK		
Sheet	1 of		1	Attorney Docket Number	05273.0147-00000		

	U.S. PATENTS								
Examiner Initials	Cite	Document Number Number-Kind Code ² (it known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		US-							
		US-							
		US-							

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Tr Where Relevant Passages or Relevant Figures Appear	ranslation ⁶			
				3					

		NONPATENT LITERATURE DOCUMENTS			
Examiner Cite Initials No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/S.P./		Request for Invalidation from invalidity proceedings in corresponding Chinese Application No. 200680018223.4 (original Chinese version and English-language translation), August 5, 2012.	Yes		
/S.P./		Bi Dianzhou, Pharmaceutics, Edition 4, Beijing: People's Medical Publishing House, February 2003.	Yes		
/S.P./		"Application and Effect of Pregelatinized Starch in Tablets," Chinese Pharmaceutical Information, Vol.16, Issue 7, 2000, published in 2000	Yes		
/S.P./		"Use of Pregelatinized Starch in Tablet Manufacturing," Chinese Pharmaceutical Journal, Vol. 29, Issue 4, April 1994, published in April 1994.	Yes		
/S.P./		"Application of the Pregelatinized Starch in Capsules," Chinese Journal of Modern Applied Pharmacy, Vol. 8, Issue 1, February 1991, published in February 1991	Yes		
/S.P./		"In Vitro Dissolution and Bioavailability of Acyclovir Capsules Formulated with Pregelatinized Starch," Chinese Journal of Pharmaceuticals, 1998, 29(5), published on May 20, 1998.	Yes		
/S.P./		Dissolution of Drug Solid Preparation, "Factors Influencing Dissolution Rates," Wu Guangchen, Yue Zhiwei, People's Medical Publishing House, published in October 1994.	Yes		
/S.P./		Reply Brief from invalidity proceedings in corresponding Chinese Application No. 200680018223.4 (original Chinese version and English-language translation), October 25, 2012.	Yes		
/S.P./		Examination Decision on the Request for Invalidation in corresponding Chinese Application No. 200680018223.4 (original Chinese version and English-language translation), April 26, 2013.	Yes		

Examiner	1 Data	j – j – j
Literinier /Openale Dilegenale/	{ Date	1 0.100.00.1
Signature 1 / Salah Fihohak/	Considered	1 (11/22/2014
- Cognitiation	1 00000000	} 01/200/00017
	************************************	, your and a second sec

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.P./

PART B - FEE(S) TRANSMITTAL

** ** ** ** ** * / * * 0.7

Complete and st	na mis iorm, (oge	вег with аррисари		Mail Stop 18808. F Commissioner for P.O. Box 1450 Alexandria, Virgin (571)-273-2885	Patents			
INSTRUCTIONS: This appropriate, All further indicated indexs correct maintenance for notific	correspondence includi and below or directed of	for transmitting the ISS ng the Patent, advance o herwise in Block 1, by (rders and notification a) specifying a new c	of maintenance fees wil orrespondence address; a	d). Blocks I through 3 sho be mailed to the current ec nd/or (b) indicating a separa	prespondence address as te "PEE ADDRESS" for		
CURRENT CORRESPOND	DENCE ADDRESS (Note: Use B	lock i for any change of address)		Note: A certificate of m Fee(s) Transmittal. This (papers. Each additional p have its own certificate of	ailing can only be used for a cortificate cannot be used for reper, such as an assignment f mailing or transmission.	lomestic mailings of the any other accompanying or formal drawing, must		
L/L/L	7590 02/0 HENDERSON, FA	V2014 ARABOW, GARR	ETT & DUNNE	hereby certify that this Rates Postal Service with addressed to the Mail 8	icate of Mailing or Transmi Fee(s) Transmittal is being d h sufficient postage for first o hop ISSUE FEE address ab) (571) 273-2885, on the date	eposited with the United lass mail in an envelope evel or being facsimile		
	V, DC 20001-4413					(Depositor's name)		
	1:					(Signature)		
						(Dere)		
APPLICATION NO.	FILING DATE	······	FIRST NAMED INVEN	TOR	TTORNEY DOCKET NO.	CONFIRMATION NO.		
11/919,678	10/31/2007		Kazuyuki Fujihar	·····	05273.0147-00000	6965		
TITLE OF INVENTION	S: PHARMACEUTICAL	COMPOSITION						
APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE D	UE PREV. PAID ISSUE F	BE TOTAL FEE(S) DUE	DATE DUE		
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	05/05/2014		
EXAN	INER	ARTUNIT	CLASS-SUBCLASS					
PIHONAI	K, SARAH	1627	514-254020	~~~~~				
1. Change of correspond	ence address or indicatio	n of "Fee Address" (37		he patent front page, list	s Ed ana a a an			
CFR 1.363). Change of corresp	oondence address (or Cha B/122) attached.	inge of Correspondence	(1) The names of up to 3 registered patent attorneys i Finnegan, Henderson or agents OR, alternatively,					
"Fee Address" ind	lication (or "Fee Address D2 or more recent) attach	" Indication form	(2) The finance of a single firm (having as a member a registered atterney or agent) and the names of up to 2 registered patent atterneys or agents. If no name is histed, no name will be printed.					
PLEASE NOTE: Un recordation as set for (A) NAME OF ASSI	less an assignee is ident h in 37 CFR 3.11. Com		data will appear on d T a substitute for filing (B) RESIDENCE: (C		is identified below, the doct UNTRY)	iment has been filed for		
					oration or other private group	entity Decoverament		
4a. The following fee(s)					previously paid issue fee shu			
Issue Fee		. <i></i>	A check is enclosed.					
	to small entity discount p f of Copies		 Payment by credit card. Porm PTO-2038 is attached. The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 06-0916 (enclose an extra copy of this form) 					
			overpayment, to E	Deposit Account Number	06-0916 (énclose an e	xtra copy of this form).		
 Change in Entity Sta Applicant certifying 	tus (from status indicate ng micro entity status. Se	,	<u>NOTE:</u> Absent a vali	d certification of Micro E icro entity amount will no	ntity Status (see forms PTO/S it be accepted at the risk of ap	B/15A and 15B), issue plication abandonment.		
Applicant assertin	g small ontity status. See	37 CFR 1.27	NOTE; If the applica		r micro entity status, checking			
	ig to regular undiscounte		entity status, as appli	cable.	notification of loss of entitle	ment to small or micro		
NOTE: This form must b	se signed in accordance v	vith 37 CFR 1.31 and 1.3	3. See 37 CFR 1.4 for :	signature requirements an	d cortifications.			
Authorized Signature	<u>Charle</u>	$\underline{t} = Va_{\underline{t}} \underline{t}$		Date April	9, 2014	<u></u>		
Typed or printed nam	e Charles	E. Van Horn		Registration No.	40,266	<u></u>		

Page 2 of 3

11 C. Darant and Perdomont, Office 11 C. INDER DISSURPLACE CONSIMURATE

PATENT Customer No. 22,582 Attorney Docket No. 05273.0147-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	opplication of:)	
Kazuyuki FUJIHARA			Group Art Unit: 1627
Application No.: 11/919,678			Examiner: Sarah Pihonak
Filed:	October 31, 2007)	Confirmation No.: 6965
For:	PHARMACEUTICAL COMPOSITION)	Commation No.: 0805
)	VIA EFS-WEB

Mail Stop Issue Fee

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

Applicant thanks the Examiner for the Notice of Allowance mailed February 3, 2014. Without withdrawing the allowed claims from issue, Applicant submits these comments for the record.

In the Notice of Allowance, the Examiner provided detailed remarks and a statement of reasons for allowance. Although Applicant agrees with the Examiner's ultimate conclusion that the claims are patentable, Applicant does not necessarily agree with each and every characterization and assertion contained in the Examiner's statement.

Application No. 11/919,678 Attorney Docket No. 05273.0147-00

Please charge any fee due in connection with the filing of these Comments, to

Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: April 9, 2014

Charles EVan Horn Bv⊜

Charles E. Van Horn Reg. No. 40,266 (202) 408-4000

Electronic Patent Application Fee Transmittal							
Application Number:	11919678						
Filing Date:	31	31-Oct-2007					
Title of Invention:	PHARMACEUTICAL COMPOSITION						
First Named Inventor/Applicant Name:	Ka	zuyuki Fujihara					
Filer: Charles E. Van Horn/Charlene Woods							
Attorney Docket Number:	05	273.0147-00000					
Filed as Large Entity							
U.S. National Stage under 35 USC 371 Filing	Fee	s					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)		
Basic Filing:							
Pages:							
Claims:							
Miscellaneous-Filing:							
Petition:							
Patent-Appeals-and-Interference:							
Post-Allowance-and-Post-Issuance:							
Utility Appl Issue Fee 1501 1 960 960							
Extension-of-Time:							

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Total in USD (\$)			960

Electronic Acl	Electronic Acknowledgement Receipt					
EFS ID:	18722092					
Application Number:	11919678					
International Application Number:						
Confirmation Number:	6965					
Title of Invention:	PHARMACEUTICAL COMPOSITION					
First Named Inventor/Applicant Name:	Kazuyuki Fujihara					
Customer Number:	22852					
Filer:	Charles E. Van Horn/Charlene Woods					
Filer Authorized By:	Charles E. Van Horn					
Attorney Docket Number:	05273.0147-00000					
Receipt Date:	09-APR-2014					
Filing Date:	31-OCT-2007					
Time Stamp:	20:52:32					
Application Type:	U.S. National Stage under 35 USC 371					

Submitted with Payment		yes	yes				
Payment Type I		Deposit Account	Deposit Account				
Payment was successfully received in RAM		\$960	\$960				
RAM confirmation Number		8177	8177				
Deposit Account		060916	060916				
Authorized Use	er						
File Listing:							
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		

1	Issue Fee Payment (PTO-85B)	lssue Fee.pdf	130914	no	1		
	issue ree rayment (rro osb)		390a0df43528d1628b6e791c0cbea154083 fd7ff				
Warnings:							
Information:							
2	Post Allowance Communication - Incoming	Comments_on- Statement_of_Reasons_for_All	57653	no	2		
	incoming	owance.pdf	dc69ecef8d5b5ec9d16ea70a7418e54a29a b1150				
Warnings:							
Information							
3	Fee Worksheet (SB06)	fee-info.pdf	30467	no	2		
_			22d852b6eed7b635081237648796a58021 19479b				
Warnings:							
Information:			i				
		Total Files Size (in bytes)	2	19034			
characterize	ledgement Receipt evidences receip d by the applicant, and including page described in MPEP 503.						
	tions Under 35 U.S.C. 111						
1.53(b)-(d) a	ication is being filed and the applica nd MPEP 506), a Filing Receipt (37 CF	R 1.54) will be issued in due					
Acknowledg	ement Receipt will establish the filin	g date of the application.					
	ge of an International Application ur			_			
U.S.C. 371 an	bmission to enter the national stage od other applicable requirements a F ge submission under 35 U.S.C. 371 wi	orm PCT/DO/EO/903 indicati	ng acceptance of the	application			
<u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.							

Used in Lieu of PTO/SB/08A/B (Based on PTO 01-08 version)

Abs

Subst	itute for	form 1449/PTO							Complete if F	(nown	
						Application Number 11/9		11/919,67	8-Conf. #6965		
INFORMATION DISCLOSU				RE	Filin	g Date	October 31, 2007				
ST			BY A	APF	PLICA	NT	First	Named Inventor	Kazuyuki I	UJIHARA	
							Art U	nit	N/A		
l	(L	lse as many sh	eets as	s nece	essary)		Exan	niner Name	Not Yet As	signed	
Sheet	heet 1 of 1			1		Attor	ney Docket Number	0020-5610	PUS1		
Examiner Initials*	Cite No. ¹	Document I Number-Kind Coc	_		U.S. PATEN Publication Date MM-DD-YYYY		Aŗ	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Whe Relevant Passages or Releva Figures Appear	
								······			
	r				FOREI	<u>GN P/</u>	ATENT	DOCUMENTS			
Examiner	Foreign Patent Document		Publication Name of Pa		itentee or ed Document	Pages, Columns, Lines, Where Relevant	T ₆				
Initials*	No.1	Country Code ³ -N	umber ⁴ -k	ind Co	de ⁵ (if known)					Passages Or Relevant Figures Appear	-
	BA	WO 02/2416	6 A1			03-28	3-02				Abs
	BB	WO 2004/07	8173	A1		40-42	2-1990	2004-09	•		Abs

12-10-1996

Change(s) applied to document, /D.D./ 3/7/2014

BC

Examiner

Signature

Signature

JP-08-325146

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not "EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application teapplication (s) which are marked with an single asterisk () next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Date

Considered

Considered

		NON PATENT LITE	RATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAl the item (book, magazine, journal, seria number(s), publishe			T ²	
	CA Handbook of Pharmaceutical Excipients, 2 nd edition, Vol. 491, The Pharmaceutical Press, 1994					
Examiner Signature		/Sarah Pihonak/	Date Considered	11/13/2009		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
11/919,678 05/20/2014		8729085	05273.0147-00000	6965
22852 7	590 04/30/2014			

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Kazuyuki Fujihara, Osaka-fu, JAPAN;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit <u>SelectUSA.gov</u>.

Customer Number 22,852 Attorney Docket No. 05273.0147

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Kazuyuki FUJIHARA

Application No.: 11/919,678

U.S. Patent No: 8,729,085 B2

For: PHARMACEUTICAL COMPOSITION) Group Art Unit: 1627

Examiner: Sarah Pihonak

Confirmation No.: 6965

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

FEE ADDRESS FOR MAINTENANCE FEE PURPOSES IN ACCORDANCE WITH 37 C.F.R. 1.363

In accordance with the provisions of 37 C.F.R. 1.363, the fee address set forth below is being supplied for purposes of receiving notices, receipts, and other correspondence relating to the payment of maintenance fees:

AOYAMA & PARTNERS Osaka North P.O. Box 16 Osaka, 530-8691 JAPAN

Customer/Payor No.: 95780

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: 20 June 2014

Charle E Van Hon By:

Charles E. Van Horn Reg. No. 40,266

Electronic Acl	Electronic Acknowledgement Receipt					
EFS ID:	19368610					
Application Number:	11919678					
International Application Number:						
Confirmation Number:	6965					
Title of Invention:	PHARMACEUTICAL COMPOSITION					
First Named Inventor/Applicant Name:	Kazuyuki Fujihara					
Customer Number:	22852					
Filer:	Charles E. Van Horn/Peter Nerenstone					
Filer Authorized By:	Charles E. Van Horn					
Attorney Docket Number:	05273.0147-00000					
Receipt Date:	20-JUN-2014					
Filing Date:	31-OCT-2007					
Time Stamp:	16:09:01					
Application Type:	U.S. National Stage under 35 USC 371					

Submitted with Payment			no					
File Listing:								
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1	Maintenance Fee Address Change	Ma	MaintenanceFeeAddressChang e.pdf	49124	no	1		
				12eeebdd69db3a60d47b6c42f408dc1e3f1 60b00				
Warnings:								
Information:								

Total	Files	Sizal	(in l	hyter	۱.
ισιαι	LIIE2	JIZE	(nytes	1

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PATENT Customer No. 22,852 Attorney Docket No. 05273.0147

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 8,729,085 B2

Inventor: Kazuyuki FUJIHARA

Confirmation No.: 6965

Issue Date .: May 20, 2014

For: PHARMACEUTICAL COMPOSITION <u>VIA EFS WEB</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. 254 and 37 C.F.R. 1.322, this is a request for the issuance of a Certificate of Correction in the above-identified patent. A copy of PTO Form 1050 is appended herewith. The complete Certificate of Correction involves one (1) page.

The mistakes identified in the attached form occurred through the fault of the Patent Office, as clearly disclosed by the records of the application which matured into this patent. Issuance of the Certificate of Correction containing the correction is earnestly requested.

If it should be determined that any of the mistakes resulted from an error made in good faith by the applicants, then, pursuant to 35 U.S.C. 255 and 37 C.F.R. 1.323, it is requested that a Certificate of Correction be issued correcting such mistakes. Under such circumstances, it is requested that the fee set forth in 37 C.F.R. 1.20(a) and any

additional fees needed be charged to our Deposit Account No. 06-0916, for which authorization is hereby given.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP

Dated: January 5, 2015

Charles EVa Hom By:__

Charles E. Van Horn Reg. No. 40,266

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. 8,729,085 B2

DATED: KAZUYUKI FUJIHARA

INVENTORS: PHARMACEUTICAL COMPOSITION

It is hereby certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In claim 1, column 27, lines 14-17,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

In claim 10, column 27, line 57,

"50 by volume" should read -- 50% by volume--.

In claim 20, column 28, lines 33-36,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

In claim 26, column 29, lines 9-12,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

In claim 27, column 30, lines 5-8,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, D.C. 20001-4413 Patent No. 8,729,085 B2

No. of additional copies @ 50¢ per page

> Par Pharm., Inc. Exhibit 1015 Page 623

Electronic Acl	Electronic Acknowledgement Receipt					
EFS ID:	21132918					
Application Number:	11919678					
International Application Number:						
Confirmation Number:	6965					
Title of Invention:	PHARMACEUTICAL COMPOSITION					
First Named Inventor/Applicant Name:	Kazuyuki Fujihara					
Customer Number:	22852					
Filer:	Ernest F. Chapman/veronica bayne					
Filer Authorized By:	Ernest F. Chapman					
Attorney Docket Number:	05273.0147-00000					
Receipt Date:	06-JAN-2015					
Filing Date:	31-OCT-2007					
Time Stamp:	15:50:58					
Application Type:	U.S. National Stage under 35 USC 371					

Submitted with Payment			no					
File Listing:								
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
1	Request for Certificate of Correction	05	05273_0147_PTO_REQUEST_C	124803	no	3		
			OC.pdf	5fa270f4ff92fe38e57edf172d780e1ff17284 36				
Warnings:								
Information:								

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

 PATENT NO.
 : 8,729,085 B2

 APPLICATION NO.
 : 11/919678

 DATED
 : May 20, 2014

 INVENTOR(S)
 : Fujihara

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE CLAIMS:

In claim 1, column 27, lines 14-17,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

In claim 10, column 27, line 57,

"50 by volume" should read --50% by volume--.

In claim 20, column 28, lines 33-36,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

In claim 26, column 29, lines 9-12,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

In claim 27, column 30, lines 5-8,

"N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide" should read --N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxyimide--.

> Signed and Sealed this Thirty-first Day of March, 2015

Michelle K. Lee

Michelle K. Lee Director of the United States Patent and Trademark Office

Par Pharm., Inc. Exhibit 1015 Page 626

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

<u>NOTE</u>: This form is to be submitted with the Power of Attorney by Applicant form to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5. If the Power of Attorney by Applicant form is not accompanied by this transmittal form or an equivalent, the Power of Attorney will not be recognized in the application.

Application Number	11/919,678			
Patent Number	8,729,085			
Filing Date	October 31, 2007			
Issue Date	May 20, 2014			
First Named Inventor	Kazuyuki FUJIHARA			
Title	PHARMACEUTICAL COMPOSITION			
Art Unit	1627			
Examiner Name	PIHONAK, SARAH			
Attorney Docket Number	472659US40PCT			
SIG	GNATURE of Applicant or Patent Prac	titioner		
Signature	/Yuki Onoe/	Date	07/21/16	
Name	Yuki Onoe	Telephone	703-413-3000	
Registration Number	68,563		L	
NOTE: This form must be requirements and certificat	signed in accordance with 37 CFR 1.33. S ions.	See 37 CFR 1	.4(d) for signature	

***** Total of $\underline{1}$ forms are submitted.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

Attorney Docket Number: 472659US40PCT

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(c).

I hereby appoint:

Practitioners associated with the Customer Number:

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO), in connection with any and all patent applications assigned <u>only</u> to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(c).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(c) to:

The address associated with Customer Number:

22850

22850

Assignee Name and Address: Sumitomo Dainippon Pharma Co., Ltd. 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8524 Japan

A copy of this form, together with a statement under 37 CFR 3.73(c) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(c) may be completed by one of the practitioners appointed in this form, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature	Witashi Fujita	Date July 12, 2016
Name	Hitoshi FUJITA	Telephone
	Director	
Title	Intellectual Property	

STATEMENT UNDER 37 CFR 3.7	<u>73(c)</u>
Applicant/Patent Owner: SUMITOMO DAINIPPON PHARMA CO., LTD.	
Application No./Patent No.: 8,729,085	Filed/Issue Date: May 20, 2014
Entitled: PHARMACEUTICAL COMPOSITION	
SUMITOMO DAINIPPON PHARMA CO., LTD. corporation (Name of Assignee) (Type of Assignee, e.g.)	g., corporation, partnership, government agency, etc.)
States that it is:	
1. The assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title and interest.	
The extent (by, percentage) of its ownership interest is%	
in the patent application/patent identified above by virtue of:	
A chain of title from the inventor(s), of the patent application/patent ident follows:	tified above, to the current assignee as
1. From: Kazuyuki Fujihara To: Dainippon Sumitomo Pharma Co., Ltr	<u>d.</u>
The document was recorded in the United States Patent and T	rademark Office at
Reel 020124, Frame 0821, or for which a copy therefore is atta	ached.
2. From: Dainippon Sumitomo Pharma Co., Ltd. To: SUMITOMO DA	INIPPON PHARMA CO., LTD.
The document was recorded in the United States Patent and T	rademark Office at
Reel 033905, Frame 0778, or for which a copy therefore is atta	ached.
3. From: To:	
The document was recorded in the United States Patent and T	rademark Office at
Reel, Frame, or for which a copy therefore is atta	ached.
As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the classignee was, or concurrently is being, submitted for recordation pursua	
The undersigned (whose title is supplied below) is authorized to act on behalf	f of the assignee.
/Yuki Onoe/	
	07/21/16
Signature	Date
Yuki Once	703-413-3000
Printed or Typed Name - Attorney of Record	Telephone Number
68,563	
Registration Number	

Electronic Acknowledgement Receipt				
EFS ID:	26417678			
Application Number:	11919678			
International Application Number:				
Confirmation Number:	6965			
Title of Invention:	PHARMACEUTICAL COMPOSITION			
First Named Inventor/Applicant Name:	Kazuyuki Fujihara			
Customer Number:	22852			
Filer:	Bradley Davis Lytle/Ellen Murabito			
Filer Authorized By:	Bradley Davis Lytle			
Attorney Docket Number:	05273.0147-00000			
Receipt Date:	21-JUL-2016			
Filing Date:	31-OCT-2007			
Time Stamp:	14:59:26			
Application Type:	U.S. National Stage under 35 USC 371			

Submitted with Payment no						
File Listin	g:					
Document Number	Document Description		File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
				1031162		
1	472659US-F.pdf		fbe82fb49ecf0465aec1f567764aa42bf2887 3ad	yes	3	

	Multipart Description/PDF files in .zip description			
	Document Description	Start	End	
	Power of Attorney	1	2	
	Assignee showing of ownership per 37 CFR 3.73	3	3	
Warnings:			1	
Information				
	Total Files Size (in bytes):	1(031162	

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMER United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Vignin 22313-1450 www.usplo.gov			
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
11/919,678	10/31/2007	Kazuyuki Fujihara	472659US40PCT
			CONFIRMATION NO. 6965
22850 OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET ALEXANDRIA, VA 22314		POA ACCI	EPTANCE LETTER
		CC00000084622229	
,			Date Mailed: 07/27/2016

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 07/21/2016.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at (571) 272-4000 or (571) 272-4200 or 1-888-786-0101.

/rmturner myles/

page 1 of 1

UNITED ST	ATES PATENT AND TRADEMA	UNITED STA United State Address: COMMI P.O. Box	ia, Virginia 22313-1450	
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	
11/919,678	10/31/2007	Kazuyuki Fujihara	472659US40PCT	
			CONFIRMATION NO. 6965	
22852 POWER OF ATTORNEY NOTICE				
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413				

Date Mailed: 07/27/2016

NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 07/21/2016.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at (571) 272-4000 or (571) 272-4200 or 1-888-786-0101.

/rmturner myles/